id	sid	tid	token	lemma	pos
ihlr-20834	1	1	the	the	DET
ihlr-20834	1	2	supreme	supreme	PROPN
ihlr-20834	1	3	court	court	PROPN
ihlr-20834	1	4	’s	’s	PART
ihlr-20834	1	5	overreaching	overreach	VERB
ihlr-20834	1	6	preemption	preemption	NOUN
ihlr-20834	1	7	interpretation	interpretation	NOUN
ihlr-20834	1	8	and	and	CCONJ
ihlr-20834	1	9	its	its	PRON
ihlr-20834	1	10	consequences	consequence	NOUN
ihlr-20834	1	11	:	:	PUNCT
ihlr-20834	1	12	granting	grant	VERB
ihlr-20834	1	13	generic	generic	ADJ
ihlr-20834	1	14	drug	drug	NOUN
ihlr-20834	1	15	manufacturers	manufacturer	NOUN
ihlr-20834	1	16	legal	legal	ADJ
ihlr-20834	1	17	immunity	immunity	NOUN
ihlr-20834	1	18	through	through	ADP
ihlr-20834	1	19	“	"	PUNCT
ihlr-20834	1	20	the	the	DET
ihlr-20834	1	21	duty	duty	NOUN
ihlr-20834	1	22	of	of	ADP
ihlr-20834	1	23	sameness	sameness	NOUN
ihlr-20834	1	24	”	"	PUNCT
ihlr-20834	1	25	in	in	ADP
ihlr-20834	1	26	mutual	mutual	ADJ
ihlr-20834	1	27	pharmaceutical	pharmaceutical	PROPN
ihlr-20834	1	28	co.	co.	PROPN
ihlr-20834	1	29	v.	v.	ADP
ihlr-20834	1	30	bartlett	bartlett	PROPN
ihlr-20834	1	31	and	and	CCONJ
ihlr-20834	1	32	pliva	pliva	PROPN
ihlr-20834	1	33	v.	v.	CCONJ
ihlr-20834	1	34	mensing	mense	VERB
ihlr-20834	1	35	tyler	tyler	PROPN
ihlr-20834	1	36	w.	w.	PROPN
ihlr-20834	1	37	olson	olson	PROPN
ihlr-20834	1	38	*	*	PROPN
ihlr-20834	1	39	i.	i.	PROPN
ihlr-20834	1	40	introduction	introduction	NOUN
ihlr-20834	1	41	.................................................................	.................................................................	PUNCT
ihlr-20834	1	42	770	770	NUM
ihlr-20834	1	43	a.	a.	NOUN
ihlr-20834	1	44	issue	issue	NOUN
ihlr-20834	1	45	...........................................................................	...........................................................................	PUNCT
ihlr-20834	1	46	772	772	NUM
ihlr-20834	1	47	b.	b.	PROPN
ihlr-20834	1	48	roadmap	roadmap	PROPN
ihlr-20834	1	49	.....................................................................	.....................................................................	PUNCT
ihlr-20834	1	50	773	773	NUM
ihlr-20834	1	51	ii	ii	NOUN
ihlr-20834	1	52	.	.	PUNCT
ihlr-20834	2	1	the	the	DET
ihlr-20834	2	2	law	law	NOUN
ihlr-20834	2	3	and	and	CCONJ
ihlr-20834	2	4	regulatory	regulatory	ADJ
ihlr-20834	2	5	rules	rule	NOUN
ihlr-20834	2	6	of	of	ADP
ihlr-20834	2	7	the	the	DET
ihlr-20834	2	8	pharmaceutical	pharmaceutical	ADJ
ihlr-20834	2	9	industry	industry	NOUN
ihlr-20834	2	10	...............................................	...............................................	PUNCT
ihlr-20834	2	11	774	774	NUM
ihlr-20834	2	12	a.	a.	NOUN
ihlr-20834	2	13	historical	historical	ADJ
ihlr-20834	2	14	background	background	NOUN
ihlr-20834	2	15	...............................................	...............................................	PUNCT
ihlr-20834	2	16	774	774	NUM
ihlr-20834	2	17	1	1	NUM
ihlr-20834	2	18	.	.	PUNCT
ihlr-20834	2	19	patent	patent	NOUN
ihlr-20834	2	20	law	law	NOUN
ihlr-20834	2	21	..............................................................	..............................................................	PUNCT
ihlr-20834	2	22	774	774	NUM
ihlr-20834	2	23	2	2	NUM
ihlr-20834	2	24	.	.	PUNCT
ihlr-20834	3	1	the	the	DET
ihlr-20834	3	2	federal	federal	ADJ
ihlr-20834	3	3	food	food	NOUN
ihlr-20834	3	4	and	and	CCONJ
ihlr-20834	3	5	drugs	drug	NOUN
ihlr-20834	3	6	act	act	PROPN
ihlr-20834	3	7	,	,	PUNCT
ihlr-20834	3	8	the	the	DET
ihlr-20834	3	9	food	food	NOUN
ihlr-20834	3	10	drug	drug	NOUN
ihlr-20834	3	11	and	and	CCONJ
ihlr-20834	3	12	cosmetics	cosmetic	NOUN
ihlr-20834	3	13	act	act	NOUN
ihlr-20834	3	14	,	,	PUNCT
ihlr-20834	3	15	and	and	CCONJ
ihlr-20834	3	16	hatch	hatch	NOUN
ihlr-20834	3	17	-	-	PUNCT
ihlr-20834	3	18	waxman	waxman	PROPN
ihlr-20834	3	19	act	act	NOUN
ihlr-20834	3	20	....................	....................	PUNCT
ihlr-20834	4	1	777	777	NUM
ihlr-20834	4	2	b.	b.	PROPN
ihlr-20834	4	3	current	current	ADJ
ihlr-20834	4	4	regulatory	regulatory	ADJ
ihlr-20834	4	5	laws	law	NOUN
ihlr-20834	4	6	affecting	affect	VERB
ihlr-20834	4	7	pharmaceutical	pharmaceutical	ADJ
ihlr-20834	4	8	drugs	drug	NOUN
ihlr-20834	4	9	...............................................................................	...............................................................................	PUNCT
ihlr-20834	4	10	781	781	NUM
ihlr-20834	4	11	iii	iii	NOUN
ihlr-20834	4	12	.	.	PROPN
ihlr-20834	4	13	preemption	preemption	PROPN
ihlr-20834	4	14	doctrine	doctrine	VERB
ihlr-20834	4	15	analysis	analysis	NOUN
ihlr-20834	4	16	................................	................................	PUNCT
ihlr-20834	4	17	783	783	NUM
ihlr-20834	4	18	a.	a.	NOUN
ihlr-20834	4	19	preemption	preemption	NOUN
ihlr-20834	4	20	doctrine	doctrine	NOUN
ihlr-20834	4	21	..................................................	..................................................	PUNCT
ihlr-20834	4	22	783	783	NUM
ihlr-20834	4	23	iv	iv	NOUN
ihlr-20834	4	24	.	.	PUNCT
ihlr-20834	4	25	case	case	NOUN
ihlr-20834	4	26	law	law	NOUN
ihlr-20834	4	27	,	,	PUNCT
ihlr-20834	4	28	indiana	indiana	PROPN
ihlr-20834	4	29	statutory	statutory	ADJ
ihlr-20834	4	30	dissemination	dissemination	NOUN
ihlr-20834	4	31	,	,	PUNCT
ihlr-20834	4	32	and	and	CCONJ
ihlr-20834	4	33	recourse	recourse	VERB
ihlr-20834	4	34	available	available	ADJ
ihlr-20834	4	35	for	for	ADP
ihlr-20834	4	36	generic	generic	ADJ
ihlr-20834	4	37	drug	drug	NOUN
ihlr-20834	4	38	consumers	consumer	NOUN
ihlr-20834	4	39	....	....	PUNCT
ihlr-20834	5	1	786	786	NUM
ihlr-20834	5	2	a.	a.	NOUN
ihlr-20834	5	3	wyeth	wyeth	PROPN
ihlr-20834	5	4	,	,	PUNCT
ihlr-20834	5	5	pliva	pliva	NOUN
ihlr-20834	5	6	and	and	CCONJ
ihlr-20834	5	7	bartlett	bartlett	PROPN
ihlr-20834	5	8	.........................................	.........................................	PUNCT
ihlr-20834	5	9	786	786	NUM
ihlr-20834	5	10	1	1	NUM
ihlr-20834	5	11	.	.	PUNCT
ihlr-20834	5	12	wyeth	wyeth	PROPN
ihlr-20834	5	13	–	–	PUNCT
ihlr-20834	5	14	no	no	DET
ihlr-20834	5	15	state	state	NOUN
ihlr-20834	5	16	tort	tort	NOUN
ihlr-20834	5	17	law	law	NOUN
ihlr-20834	5	18	preemption	preemption	NOUN
ihlr-20834	5	19	from	from	ADP
ihlr-20834	5	20	fda	fda	PROPN
ihlr-20834	5	21	’s	’s	PART
ihlr-20834	5	22	brand	brand	NOUN
ihlr-20834	5	23	-	-	PUNCT
ihlr-20834	5	24	name	name	NOUN
ihlr-20834	5	25	drug	drug	NOUN
ihlr-20834	5	26	regulations	regulation	NOUN
ihlr-20834	5	27	..................................	..................................	PUNCT
ihlr-20834	5	28	786	786	NUM
ihlr-20834	5	29	2	2	NUM
ihlr-20834	5	30	.	.	X
ihlr-20834	5	31	pliva	pliva	NOUN
ihlr-20834	5	32	–	–	PUNCT
ihlr-20834	5	33	state	state	NOUN
ihlr-20834	5	34	tort	tort	NOUN
ihlr-20834	5	35	law	law	NOUN
ihlr-20834	5	36	preemption	preemption	NOUN
ihlr-20834	5	37	for	for	ADP
ihlr-20834	5	38	failure	failure	NOUN
ihlr-20834	5	39	-	-	PUNCT
ihlr-20834	5	40	towarn	towarn	NOUN
ihlr-20834	5	41	claims	claim	NOUN
ihlr-20834	5	42	against	against	ADP
ihlr-20834	5	43	generic	generic	ADJ
ihlr-20834	5	44	manufacturers	manufacturer	NOUN
ihlr-20834	5	45	..........	..........	PUNCT
ihlr-20834	5	46	788	788	NUM
ihlr-20834	5	47	3	3	NUM
ihlr-20834	5	48	.	.	PUNCT
ihlr-20834	5	49	bartlett	bartlett	PROPN
ihlr-20834	5	50	state	state	PROPN
ihlr-20834	5	51	tort	tort	PROPN
ihlr-20834	5	52	law	law	NOUN
ihlr-20834	5	53	preemption	preemption	NOUN
ihlr-20834	5	54	for	for	ADP
ihlr-20834	5	55	design	design	NOUN
ihlr-20834	5	56	defect	defect	NOUN
ihlr-20834	5	57	claims	claim	NOUN
ihlr-20834	5	58	against	against	ADP
ihlr-20834	5	59	generic	generic	ADJ
ihlr-20834	5	60	manufacturers	manufacturer	NOUN
ihlr-20834	5	61	.........	.........	PUNCT
ihlr-20834	5	62	792	792	NUM
ihlr-20834	5	63	b.	b.	PROPN
ihlr-20834	5	64	indiana	indiana	PROPN
ihlr-20834	5	65	’s	’s	PART
ihlr-20834	5	66	statutory	statutory	ADJ
ihlr-20834	5	67	analysis	analysis	NOUN
ihlr-20834	5	68	and	and	CCONJ
ihlr-20834	5	69	the	the	DET
ihlr-20834	5	70	importance	importance	NOUN
ihlr-20834	5	71	of	of	ADP
ihlr-20834	5	72	state	state	NOUN
ihlr-20834	5	73	law	law	NOUN
ihlr-20834	5	74	........................................................................	........................................................................	PUNCT
ihlr-20834	5	75	795	795	NUM
ihlr-20834	5	76	c.	c.	NOUN
ihlr-20834	5	77	recourse	recourse	NOUN
ihlr-20834	5	78	available	available	ADJ
ihlr-20834	5	79	to	to	ADP
ihlr-20834	5	80	generic	generic	ADJ
ihlr-20834	5	81	drug	drug	NOUN
ihlr-20834	5	82	consumers	consumer	NOUN
ihlr-20834	5	83	......	......	PUNCT
ihlr-20834	5	84	800	800	NUM
ihlr-20834	5	85	1	1	NUM
ihlr-20834	5	86	.	.	PUNCT
ihlr-20834	5	87	option	option	NOUN
ihlr-20834	5	88	one	one	NUM
ihlr-20834	5	89	suing	sue	VERB
ihlr-20834	5	90	the	the	DET
ihlr-20834	5	91	name	name	NOUN
ihlr-20834	5	92	brand	brand	NOUN
ihlr-20834	5	93	manufacturer	manufacturer	NOUN
ihlr-20834	5	94	.....................................................................................	.....................................................................................	PUNCT
ihlr-20834	5	95	801	801	NUM
ihlr-20834	5	96	*	*	PUNCT
ihlr-20834	5	97	j.d	j.d	PROPN
ihlr-20834	5	98	.	.	PROPN
ihlr-20834	5	99	candidate	candidate	NOUN
ihlr-20834	5	100	,	,	PUNCT
ihlr-20834	5	101	2015	2015	NUM
ihlr-20834	5	102	,	,	PUNCT
ihlr-20834	5	103	indiana	indiana	PROPN
ihlr-20834	5	104	university	university	PROPN
ihlr-20834	5	105	robert	robert	PROPN
ihlr-20834	5	106	h.	h.	PROPN
ihlr-20834	5	107	mckinney	mckinney	PROPN
ihlr-20834	5	108	school	school	PROPN
ihlr-20834	5	109	of	of	ADP
ihlr-20834	5	110	law	law	NOUN
ihlr-20834	5	111	;	;	PUNCT
ihlr-20834	5	112	b.a	b.a	PROPN
ihlr-20834	5	113	.	.	PROPN
ihlr-20834	5	114	,	,	PUNCT
ihlr-20834	5	115	2011	2011	NUM
ihlr-20834	5	116	,	,	PUNCT
ihlr-20834	5	117	ohio	ohio	PROPN
ihlr-20834	5	118	state	state	PROPN
ihlr-20834	5	119	university	university	PROPN
ihlr-20834	5	120	.	.	PUNCT
ihlr-20834	6	1	http://dx.doi.org/10.18060/3911.0008	http://dx.doi.org/10.18060/3911.0008	NOUN
ihlr-20834	6	2	770	770	NUM
ihlr-20834	6	3	indiana	indiana	PROPN
ihlr-20834	6	4	health	health	PROPN
ihlr-20834	6	5	law	law	PROPN
ihlr-20834	6	6	review	review	NOUN
ihlr-20834	6	7	vol	vol	NOUN
ihlr-20834	6	8	.	.	PUNCT
ihlr-20834	7	1	12:2	12:2	NUM
ihlr-20834	7	2	2	2	NUM
ihlr-20834	7	3	.	.	PUNCT
ihlr-20834	7	4	option	option	NOUN
ihlr-20834	7	5	two	two	NUM
ihlr-20834	7	6	–	–	PUNCT
ihlr-20834	7	7	suing	sue	VERB
ihlr-20834	7	8	the	the	DET
ihlr-20834	7	9	generic	generic	ADJ
ihlr-20834	7	10	drug	drug	NOUN
ihlr-20834	7	11	manufacturer	manufacturer	NOUN
ihlr-20834	7	12	for	for	ADP
ihlr-20834	7	13	misbranding	misbrande	VERB
ihlr-20834	7	14	...........................................................	...........................................................	PUNCT
ihlr-20834	7	15	804	804	NUM
ihlr-20834	7	16	3	3	NUM
ihlr-20834	7	17	.	.	PUNCT
ihlr-20834	7	18	option	option	NOUN
ihlr-20834	7	19	three	three	NUM
ihlr-20834	7	20	–	–	PUNCT
ihlr-20834	7	21	paying	pay	VERB
ihlr-20834	7	22	for	for	ADP
ihlr-20834	7	23	protection	protection	NOUN
ihlr-20834	7	24	through	through	ADP
ihlr-20834	7	25	brand	brand	NOUN
ihlr-20834	7	26	name	name	NOUN
ihlr-20834	7	27	drugs	drug	NOUN
ihlr-20834	7	28	................................................................	................................................................	PUNCT
ihlr-20834	7	29	805	805	NUM
ihlr-20834	7	30	4	4	NUM
ihlr-20834	7	31	.	.	PUNCT
ihlr-20834	8	1	option	option	NOUN
ihlr-20834	8	2	four	four	NUM
ihlr-20834	8	3	legislative	legislative	ADJ
ihlr-20834	8	4	amendment	amendment	NOUN
ihlr-20834	8	5	..................	..................	PUNCT
ihlr-20834	9	1	806	806	NUM
ihlr-20834	9	2	v.	v.	ADP
ihlr-20834	9	3	conclusion	conclusion	NOUN
ihlr-20834	9	4	...................................................................	...................................................................	PUNCT
ihlr-20834	9	5	809	809	NUM
ihlr-20834	9	6	i.	i.	NOUN
ihlr-20834	9	7	introduction	introduction	PROPN
ihlr-20834	9	8	national	national	PROPN
ihlr-20834	9	9	health	health	NOUN
ihlr-20834	9	10	expenditures	expenditure	NOUN
ihlr-20834	9	11	in	in	ADP
ihlr-20834	9	12	the	the	DET
ihlr-20834	9	13	united	united	PROPN
ihlr-20834	9	14	states	states	PROPN
ihlr-20834	9	15	are	be	AUX
ihlr-20834	9	16	projected	project	VERB
ihlr-20834	9	17	to	to	PART
ihlr-20834	9	18	exceed	exceed	VERB
ihlr-20834	9	19	$	$	SYM
ihlr-20834	9	20	3.093	3.093	NUM
ihlr-20834	9	21	trillion	trillion	NUM
ihlr-20834	9	22	in	in	ADP
ihlr-20834	9	23	2014.1	2014.1	NUM
ihlr-20834	9	24	prescription	prescription	NOUN
ihlr-20834	9	25	drug	drug	NOUN
ihlr-20834	9	26	sales	sale	NOUN
ihlr-20834	9	27	accounted	account	VERB
ihlr-20834	9	28	for	for	ADP
ihlr-20834	9	29	8.9	8.9	NUM
ihlr-20834	9	30	%	%	NOUN
ihlr-20834	9	31	of	of	ADP
ihlr-20834	9	32	all	all	DET
ihlr-20834	9	33	national	national	ADJ
ihlr-20834	9	34	health	health	NOUN
ihlr-20834	9	35	expenditures	expenditure	NOUN
ihlr-20834	9	36	in	in	ADP
ihlr-20834	9	37	2013	2013	NUM
ihlr-20834	9	38	.	.	PUNCT
ihlr-20834	10	1	2	2	NUM
ihlr-20834	10	2	in	in	ADP
ihlr-20834	10	3	2014	2014	NUM
ihlr-20834	10	4	,	,	PUNCT
ihlr-20834	10	5	these	these	DET
ihlr-20834	10	6	drug	drug	NOUN
ihlr-20834	10	7	sales	sale	NOUN
ihlr-20834	10	8	are	be	AUX
ihlr-20834	10	9	projected	project	VERB
ihlr-20834	10	10	to	to	PART
ihlr-20834	10	11	exceed	exceed	VERB
ihlr-20834	10	12	$	$	SYM
ihlr-20834	10	13	275.9	275.9	NUM
ihlr-20834	10	14	billion	billion	NUM
ihlr-20834	10	15	of	of	ADP
ihlr-20834	10	16	national	national	ADJ
ihlr-20834	10	17	health	health	NOUN
ihlr-20834	10	18	expenditures.3	expenditures.3	PROPN
ihlr-20834	10	19	the	the	DET
ihlr-20834	10	20	significant	significant	ADJ
ihlr-20834	10	21	pharmaceutical	pharmaceutical	ADJ
ihlr-20834	10	22	drug	drug	NOUN
ihlr-20834	10	23	sales	sale	NOUN
ihlr-20834	10	24	are	be	AUX
ihlr-20834	10	25	due	due	ADJ
ihlr-20834	10	26	,	,	PUNCT
ihlr-20834	10	27	in	in	ADP
ihlr-20834	10	28	large	large	ADJ
ihlr-20834	10	29	part	part	NOUN
ihlr-20834	10	30	,	,	PUNCT
ihlr-20834	10	31	to	to	ADP
ihlr-20834	10	32	the	the	DET
ihlr-20834	10	33	increasing	increase	VERB
ihlr-20834	10	34	commonality	commonality	NOUN
ihlr-20834	10	35	of	of	ADP
ihlr-20834	10	36	treatment	treatment	NOUN
ihlr-20834	10	37	;	;	PUNCT
ihlr-20834	10	38	in	in	ADP
ihlr-20834	10	39	2013	2013	NUM
ihlr-20834	10	40	,	,	PUNCT
ihlr-20834	10	41	nearly	nearly	ADV
ihlr-20834	10	42	seven	seven	NUM
ihlr-20834	10	43	in	in	ADP
ihlr-20834	10	44	ten	ten	NUM
ihlr-20834	10	45	americans	americans	PROPN
ihlr-20834	10	46	took	take	VERB
ihlr-20834	10	47	prescription	prescription	NOUN
ihlr-20834	10	48	drugs	drug	NOUN
ihlr-20834	10	49	for	for	ADP
ihlr-20834	10	50	treatment.4	treatment.4	NUM
ihlr-20834	10	51	most	most	ADJ
ihlr-20834	10	52	pharmaceutical	pharmaceutical	ADJ
ihlr-20834	10	53	drugs	drug	NOUN
ihlr-20834	10	54	brought	bring	VERB
ihlr-20834	10	55	to	to	ADP
ihlr-20834	10	56	market	market	NOUN
ihlr-20834	10	57	are	be	AUX
ihlr-20834	10	58	subject	subject	ADJ
ihlr-20834	10	59	to	to	ADP
ihlr-20834	10	60	patent	patent	NOUN
ihlr-20834	10	61	protection	protection	NOUN
ihlr-20834	10	62	.	.	PUNCT
ihlr-20834	11	1	this	this	DET
ihlr-20834	11	2	limited	limited	ADJ
ihlr-20834	11	3	protection	protection	NOUN
ihlr-20834	11	4	provides	provide	VERB
ihlr-20834	11	5	incentives	incentive	NOUN
ihlr-20834	11	6	for	for	ADP
ihlr-20834	11	7	drug	drug	NOUN
ihlr-20834	11	8	development	development	NOUN
ihlr-20834	11	9	and	and	CCONJ
ihlr-20834	11	10	research	research	NOUN
ihlr-20834	11	11	.	.	PUNCT
ihlr-20834	12	1	however	however	ADV
ihlr-20834	12	2	,	,	PUNCT
ihlr-20834	12	3	following	follow	VERB
ihlr-20834	12	4	patent	patent	NOUN
ihlr-20834	12	5	expiration	expiration	NOUN
ihlr-20834	12	6	it	it	PRON
ihlr-20834	12	7	is	be	AUX
ihlr-20834	12	8	common	common	ADJ
ihlr-20834	12	9	that	that	SCONJ
ihlr-20834	12	10	brand	brand	NOUN
ihlr-20834	12	11	-	-	PUNCT
ihlr-20834	12	12	name	name	NOUN
ihlr-20834	12	13	drugs	drug	NOUN
ihlr-20834	12	14	lose	lose	VERB
ihlr-20834	12	15	their	their	PRON
ihlr-20834	12	16	market	market	NOUN
ihlr-20834	12	17	share	share	NOUN
ihlr-20834	12	18	to	to	ADP
ihlr-20834	12	19	generic	generic	ADJ
ihlr-20834	12	20	alternatives.5	alternatives.5	PROPN
ihlr-20834	12	21	these	these	DET
ihlr-20834	12	22	generic	generic	ADJ
ihlr-20834	12	23	drugs	drug	NOUN
ihlr-20834	12	24	provide	provide	VERB
ihlr-20834	12	25	more	more	ADJ
ihlr-20834	12	26	affordable	affordable	ADJ
ihlr-20834	12	27	1	1	NUM
ihlr-20834	12	28	national	national	ADJ
ihlr-20834	12	29	health	health	NOUN
ihlr-20834	12	30	expenditure	expenditure	NOUN
ihlr-20834	12	31	projections	projection	NOUN
ihlr-20834	12	32	2012	2012	NUM
ihlr-20834	12	33	-	-	SYM
ihlr-20834	12	34	2022	2022	NUM
ihlr-20834	12	35	,	,	PUNCT
ihlr-20834	12	36	center	center	NOUN
ihlr-20834	12	37	for	for	ADP
ihlr-20834	12	38	medicare	medicare	PROPN
ihlr-20834	12	39	&	&	CCONJ
ihlr-20834	12	40	medicaid	medicaid	PROPN
ihlr-20834	12	41	services	services	PROPN
ihlr-20834	12	42	,	,	PUNCT
ihlr-20834	12	43	http://www.cms.gov/researchstatistics-data-and-systems/statistics-trends-andreports/nationalhealthexpenddata/downloads/proj2012.pdf	http://www.cms.gov/researchstatistics-data-and-systems/statistics-trends-andreports/nationalhealthexpenddata/downloads/proj2012.pdf	PROPN
ihlr-20834	12	44	(	(	PUNCT
ihlr-20834	12	45	last	last	ADV
ihlr-20834	12	46	visited	visit	VERB
ihlr-20834	12	47	mar	mar	PROPN
ihlr-20834	12	48	.	.	PROPN
ihlr-20834	12	49	16	16	NUM
ihlr-20834	12	50	,	,	PUNCT
ihlr-20834	12	51	2015	2015	NUM
ihlr-20834	12	52	)	)	PUNCT
ihlr-20834	12	53	.	.	PUNCT
ihlr-20834	13	1	2	2	NUM
ihlr-20834	14	1	i	i	PRON
ihlr-20834	14	2	d.	d.	NOUN
ihlr-20834	14	3	3	3	NUM
ihlr-20834	14	4	i	i	PROPN
ihlr-20834	14	5	d.	d.	PROPN
ihlr-20834	14	6	4	4	NUM
ihlr-20834	14	7	the	the	DET
ihlr-20834	14	8	most	most	ADV
ihlr-20834	14	9	common	common	ADJ
ihlr-20834	14	10	prescription	prescription	NOUN
ihlr-20834	14	11	drugs	drug	NOUN
ihlr-20834	14	12	taken	take	VERB
ihlr-20834	14	13	were	be	AUX
ihlr-20834	14	14	antibiotics	antibiotic	NOUN
ihlr-20834	14	15	,	,	PUNCT
ihlr-20834	14	16	antiasthmas	antiasthma	NOUN
ihlr-20834	14	17	,	,	PUNCT
ihlr-20834	14	18	painkillers	painkiller	NOUN
ihlr-20834	14	19	,	,	PUNCT
ihlr-20834	14	20	and	and	CCONJ
ihlr-20834	14	21	antidepressants	antidepressant	NOUN
ihlr-20834	14	22	.	.	PUNCT
ihlr-20834	15	1	nearly	nearly	ADV
ihlr-20834	15	2	7	7	NUM
ihlr-20834	15	3	in	in	ADP
ihlr-20834	15	4	10	10	NUM
ihlr-20834	15	5	americans	americans	PROPN
ihlr-20834	15	6	take	take	VERB
ihlr-20834	15	7	prescription	prescription	NOUN
ihlr-20834	15	8	drugs	drug	NOUN
ihlr-20834	15	9	,	,	PUNCT
ihlr-20834	15	10	mayo	mayo	NOUN
ihlr-20834	15	11	clinic	clinic	PROPN
ihlr-20834	15	12	,	,	PUNCT
ihlr-20834	15	13	olmstead	olmstead	PROPN
ihlr-20834	15	14	medical	medical	ADJ
ihlr-20834	15	15	center	center	NOUN
ihlr-20834	15	16	find	find	VERB
ihlr-20834	15	17	,	,	PUNCT
ihlr-20834	15	18	mayo	mayo	NOUN
ihlr-20834	15	19	clinic	clinic	PROPN
ihlr-20834	15	20	(	(	PUNCT
ihlr-20834	15	21	june	june	PROPN
ihlr-20834	15	22	19	19	NUM
ihlr-20834	15	23	,	,	PUNCT
ihlr-20834	15	24	2013	2013	NUM
ihlr-20834	15	25	)	)	PUNCT
ihlr-20834	15	26	,	,	PUNCT
ihlr-20834	15	27	http://newsnetwork.mayoclinic.org/	http://newsnetwork.mayoclinic.org/	NOUN
ihlr-20834	15	28	discussion	discussion	NOUN
ihlr-20834	15	29	/	/	SYM
ihlr-20834	15	30	nearly-7	nearly-7	NOUN
ihlr-20834	15	31	-	-	PUNCT
ihlr-20834	15	32	in-10	in-10	DET
ihlr-20834	15	33	-	-	PUNCT
ihlr-20834	15	34	americans	americans	PROPN
ihlr-20834	15	35	-	-	PUNCT
ihlr-20834	15	36	take	take	ADJ
ihlr-20834	15	37	-	-	PUNCT
ihlr-20834	15	38	prescription	prescription	NOUN
ihlr-20834	15	39	-	-	PUNCT
ihlr-20834	15	40	drugs	drug	NOUN
ihlr-20834	15	41	-	-	PUNCT
ihlr-20834	15	42	mayoclinic	mayoclinic	ADJ
ihlr-20834	15	43	-	-	PUNCT
ihlr-20834	15	44	olmsted	olmste	VERB
ihlr-20834	15	45	-	-	PUNCT
ihlr-20834	15	46	medical	medical	ADJ
ihlr-20834	15	47	-	-	PUNCT
ihlr-20834	15	48	center	center	NOUN
ihlr-20834	15	49	-	-	PUNCT
ihlr-20834	15	50	find	find	NOUN
ihlr-20834	15	51	[	[	PUNCT
ihlr-20834	15	52	hereinafter	hereinafter	NOUN
ihlr-20834	15	53	nearly	nearly	ADV
ihlr-20834	15	54	7	7	NUM
ihlr-20834	15	55	in	in	ADP
ihlr-20834	15	56	10	10	NUM
ihlr-20834	15	57	americans	americans	PROPN
ihlr-20834	15	58	]	]	PUNCT
ihlr-20834	15	59	.	.	PUNCT
ihlr-20834	16	1	5	5	NUM
ihlr-20834	16	2	a	a	DET
ihlr-20834	16	3	“	"	PUNCT
ihlr-20834	16	4	generic	generic	ADJ
ihlr-20834	16	5	”	"	PUNCT
ihlr-20834	16	6	drug	drug	NOUN
ihlr-20834	16	7	in	in	ADP
ihlr-20834	16	8	this	this	DET
ihlr-20834	16	9	note	note	NOUN
ihlr-20834	16	10	refers	refer	VERB
ihlr-20834	16	11	to	to	ADP
ihlr-20834	16	12	pharmaceutical	pharmaceutical	ADJ
ihlr-20834	16	13	equivalents	equivalent	NOUN
ihlr-20834	16	14	of	of	ADP
ihlr-20834	16	15	brand	brand	NOUN
ihlr-20834	16	16	-	-	PUNCT
ihlr-20834	16	17	name	name	NOUN
ihlr-20834	16	18	fda	fda	PROPN
ihlr-20834	16	19	approved	approve	VERB
ihlr-20834	16	20	drugs	drug	NOUN
ihlr-20834	16	21	that	that	PRON
ihlr-20834	16	22	exist	exist	VERB
ihlr-20834	16	23	post	post	NOUN
ihlr-20834	16	24	patent	patent	NOUN
ihlr-20834	16	25	-	-	PUNCT
ihlr-20834	16	26	expiration	expiration	NOUN
ihlr-20834	16	27	.	.	PUNCT
ihlr-20834	17	1	for	for	ADP
ihlr-20834	17	2	a	a	DET
ihlr-20834	17	3	full	full	ADJ
ihlr-20834	17	4	list	list	NOUN
ihlr-20834	17	5	of	of	ADP
ihlr-20834	17	6	approved	approve	VERB
ihlr-20834	17	7	drugs	drug	NOUN
ihlr-20834	17	8	with	with	ADP
ihlr-20834	17	9	equivalence	equivalence	NOUN
ihlr-20834	17	10	evaluations	evaluation	NOUN
ihlr-20834	17	11	,	,	PUNCT
ihlr-20834	17	12	see	see	VERB
ihlr-20834	17	13	2015	2015	NUM
ihlr-20834	17	14	771	771	NUM
ihlr-20834	17	15	the	the	DET
ihlr-20834	17	16	supreme	supreme	PROPN
ihlr-20834	17	17	court	court	PROPN
ihlr-20834	17	18	’s	’s	PART
ihlr-20834	17	19	overreaching	overreach	VERB
ihlr-20834	17	20	preemption	preemption	NOUN
ihlr-20834	17	21	interpretation	interpretation	NOUN
ihlr-20834	17	22	and	and	CCONJ
ihlr-20834	17	23	it	it	PRON
ihlr-20834	17	24	’s	’	VERB
ihlr-20834	17	25	consequences	consequence	VERB
ihlr-20834	17	26	treatment	treatment	NOUN
ihlr-20834	17	27	options	option	NOUN
ihlr-20834	17	28	versus	versus	ADP
ihlr-20834	17	29	their	their	PRON
ihlr-20834	17	30	brand	brand	NOUN
ihlr-20834	17	31	-	-	PUNCT
ihlr-20834	17	32	name	name	NOUN
ihlr-20834	17	33	counterparts.6	counterparts.6	NOUN
ihlr-20834	17	34	the	the	DET
ihlr-20834	17	35	savings	saving	NOUN
ihlr-20834	17	36	of	of	ADP
ihlr-20834	17	37	switching	switch	VERB
ihlr-20834	17	38	to	to	ADP
ihlr-20834	17	39	generic	generic	ADJ
ihlr-20834	17	40	drugs	drug	NOUN
ihlr-20834	17	41	can	can	AUX
ihlr-20834	17	42	be	be	AUX
ihlr-20834	17	43	significant	significant	ADJ
ihlr-20834	17	44	;	;	PUNCT
ihlr-20834	17	45	for	for	ADP
ihlr-20834	17	46	example	example	NOUN
ihlr-20834	17	47	,	,	PUNCT
ihlr-20834	17	48	opting	opt	VERB
ihlr-20834	17	49	for	for	ADP
ihlr-20834	17	50	generic	generic	ADJ
ihlr-20834	17	51	drugs	drug	NOUN
ihlr-20834	17	52	versus	versus	ADP
ihlr-20834	17	53	their	their	PRON
ihlr-20834	17	54	brandname	brandname	NOUN
ihlr-20834	17	55	counterparts	counterpart	NOUN
ihlr-20834	17	56	saved	save	VERB
ihlr-20834	17	57	consumers	consumer	NOUN
ihlr-20834	17	58	an	an	DET
ihlr-20834	17	59	estimated	estimate	VERB
ihlr-20834	17	60	$	$	SYM
ihlr-20834	17	61	33	33	NUM
ihlr-20834	17	62	billion	billion	NUM
ihlr-20834	17	63	in	in	ADP
ihlr-20834	17	64	2013	2013	NUM
ihlr-20834	17	65	.	.	PUNCT
ihlr-20834	18	1	7	7	NUM
ihlr-20834	18	2	external	external	ADJ
ihlr-20834	18	3	forces	force	NOUN
ihlr-20834	18	4	are	be	AUX
ihlr-20834	18	5	known	know	VERB
ihlr-20834	18	6	to	to	PART
ihlr-20834	18	7	influence	influence	VERB
ihlr-20834	18	8	consumer	consumer	NOUN
ihlr-20834	18	9	choices	choice	NOUN
ihlr-20834	18	10	for	for	ADP
ihlr-20834	18	11	prescription	prescription	NOUN
ihlr-20834	18	12	filing8	filing8	NOUN
ihlr-20834	18	13	and	and	CCONJ
ihlr-20834	18	14	an	an	DET
ihlr-20834	18	15	estimated	estimate	VERB
ihlr-20834	18	16	90	90	NUM
ihlr-20834	18	17	%	%	NOUN
ihlr-20834	18	18	of	of	ADP
ihlr-20834	18	19	prescription	prescription	NOUN
ihlr-20834	18	20	drugs	drug	NOUN
ihlr-20834	18	21	written	write	VERB
ihlr-20834	18	22	in	in	ADP
ihlr-20834	18	23	2007	2007	NUM
ihlr-20834	18	24	were	be	AUX
ihlr-20834	18	25	generic.9	generic.9	NOUN
ihlr-20834	18	26	the	the	DET
ihlr-20834	18	27	u.s	u.s	PROPN
ihlr-20834	18	28	.	.	PROPN
ihlr-20834	18	29	constitution	constitution	PROPN
ihlr-20834	18	30	plays	play	VERB
ihlr-20834	18	31	an	an	DET
ihlr-20834	18	32	important	important	ADJ
ihlr-20834	18	33	role	role	NOUN
ihlr-20834	18	34	of	of	ADP
ihlr-20834	18	35	safeguarding	safeguard	VERB
ihlr-20834	18	36	fundamental	fundamental	ADJ
ihlr-20834	18	37	interests	interest	NOUN
ihlr-20834	18	38	of	of	ADP
ihlr-20834	18	39	citizens	citizen	NOUN
ihlr-20834	18	40	.	.	PUNCT
ihlr-20834	19	1	it	it	PRON
ihlr-20834	19	2	establishes	establish	VERB
ihlr-20834	19	3	“	"	PUNCT
ihlr-20834	19	4	a	a	DET
ihlr-20834	19	5	system	system	NOUN
ihlr-20834	19	6	of	of	ADP
ihlr-20834	19	7	dual	dual	ADJ
ihlr-20834	19	8	sovereignty	sovereignty	NOUN
ihlr-20834	19	9	between	between	ADP
ihlr-20834	19	10	the	the	DET
ihlr-20834	19	11	states	state	NOUN
ihlr-20834	19	12	and	and	CCONJ
ihlr-20834	19	13	the	the	DET
ihlr-20834	19	14	federal	federal	ADJ
ihlr-20834	19	15	government	government	NOUN
ihlr-20834	19	16	.	.	PUNCT
ihlr-20834	20	1	”10	”10	NOUN
ihlr-20834	20	2	as	as	SCONJ
ihlr-20834	20	3	it	it	PRON
ihlr-20834	20	4	relates	relate	VERB
ihlr-20834	20	5	to	to	ADP
ihlr-20834	20	6	the	the	DET
ihlr-20834	20	7	pharmaceutical	pharmaceutical	ADJ
ihlr-20834	20	8	industry	industry	NOUN
ihlr-20834	20	9	,	,	PUNCT
ihlr-20834	20	10	this	this	DET
ihlr-20834	20	11	dual	dual	ADJ
ihlr-20834	20	12	sovereignty	sovereignty	NOUN
ihlr-20834	20	13	allows	allow	VERB
ihlr-20834	20	14	the	the	DET
ihlr-20834	20	15	federal	federal	ADJ
ihlr-20834	20	16	and	and	CCONJ
ihlr-20834	20	17	state	state	NOUN
ihlr-20834	20	18	government	government	NOUN
ihlr-20834	20	19	the	the	DET
ihlr-20834	20	20	ability	ability	NOUN
ihlr-20834	20	21	to	to	PART
ihlr-20834	20	22	enact	enact	VERB
ihlr-20834	20	23	protection	protection	NOUN
ihlr-20834	20	24	laws	law	NOUN
ihlr-20834	20	25	for	for	ADP
ihlr-20834	20	26	its	its	PRON
ihlr-20834	20	27	citizens	citizen	NOUN
ihlr-20834	20	28	.	.	PUNCT
ihlr-20834	21	1	thus	thus	ADV
ihlr-20834	21	2	,	,	PUNCT
ihlr-20834	21	3	the	the	DET
ihlr-20834	21	4	constitution	constitution	NOUN
ihlr-20834	21	5	grants	grant	VERB
ihlr-20834	21	6	states	state	VERB
ihlr-20834	21	7	the	the	DET
ihlr-20834	21	8	power	power	NOUN
ihlr-20834	21	9	to	to	PART
ihlr-20834	21	10	enact	enact	VERB
ihlr-20834	21	11	laws	law	NOUN
ihlr-20834	21	12	subject	subject	ADJ
ihlr-20834	21	13	to	to	ADP
ihlr-20834	21	14	the	the	DET
ihlr-20834	21	15	supremacy	supremacy	NOUN
ihlr-20834	21	16	clause	clause	NOUN
ihlr-20834	21	17	..	..	PUNCT
ihlr-20834	21	18	11	11	NUM
ihlr-20834	21	19	states	state	NOUN
ihlr-20834	21	20	have	have	AUX
ihlr-20834	21	21	enacted	enact	VERB
ihlr-20834	21	22	tort	tort	NOUN
ihlr-20834	21	23	laws	law	NOUN
ihlr-20834	21	24	that	that	PRON
ihlr-20834	21	25	provide	provide	VERB
ihlr-20834	21	26	protection	protection	NOUN
ihlr-20834	21	27	to	to	ADP
ihlr-20834	21	28	its	its	PRON
ihlr-20834	21	29	citizens	citizen	NOUN
ihlr-20834	21	30	.	.	PUNCT
ihlr-20834	22	1	in	in	ADP
ihlr-20834	22	2	the	the	DET
ihlr-20834	22	3	pharmaceutical	pharmaceutical	NOUN
ihlr-20834	22	4	industry	industry	NOUN
ihlr-20834	22	5	,	,	PUNCT
ihlr-20834	22	6	state	state	NOUN
ihlr-20834	22	7	tort	tort	NOUN
ihlr-20834	22	8	laws	law	NOUN
ihlr-20834	22	9	“	"	PUNCT
ihlr-20834	22	10	uncover	uncover	VERB
ihlr-20834	22	11	unknown	unknown	ADJ
ihlr-20834	22	12	drug	drug	NOUN
ihlr-20834	22	13	hazards	hazard	NOUN
ihlr-20834	22	14	and	and	CCONJ
ihlr-20834	22	15	provide	provide	VERB
ihlr-20834	22	16	incentives	incentive	NOUN
ihlr-20834	22	17	for	for	SCONJ
ihlr-20834	22	18	drug	drug	NOUN
ihlr-20834	22	19	manufacturers	manufacturer	NOUN
ihlr-20834	22	20	to	to	PART
ihlr-20834	22	21	disclose	disclose	VERB
ihlr-20834	22	22	safety	safety	NOUN
ihlr-20834	22	23	risks	risk	NOUN
ihlr-20834	22	24	promptly	promptly	ADV
ihlr-20834	22	25	.	.	PUNCT
ihlr-20834	22	26	”	"	PUNCT
ihlr-20834	23	1	12	12	NUM
ihlr-20834	23	2	orange	orange	PROPN
ihlr-20834	23	3	book	book	NOUN
ihlr-20834	23	4	,	,	PUNCT
ihlr-20834	23	5	approved	approve	VERB
ihlr-20834	23	6	drug	drug	NOUN
ihlr-20834	23	7	products	product	NOUN
ihlr-20834	23	8	with	with	ADP
ihlr-20834	23	9	therapeutic	therapeutic	ADJ
ihlr-20834	23	10	equivalence	equivalence	NOUN
ihlr-20834	23	11	evaluations	evaluation	NOUN
ihlr-20834	23	12	,	,	PUNCT
ihlr-20834	23	13	u.s	u.s	PROPN
ihlr-20834	23	14	.	.	PROPN
ihlr-20834	23	15	food	food	PROPN
ihlr-20834	23	16	&	&	CCONJ
ihlr-20834	23	17	drug	drug	PROPN
ihlr-20834	23	18	admin	admin	PROPN
ihlr-20834	23	19	,	,	PUNCT
ihlr-20834	23	20	http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm	http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm	PUNCT
ihlr-20834	23	21	(	(	PUNCT
ihlr-20834	23	22	last	last	ADV
ihlr-20834	23	23	visited	visit	VERB
ihlr-20834	23	24	mar	mar	PROPN
ihlr-20834	23	25	.	.	PROPN
ihlr-20834	23	26	16	16	NUM
ihlr-20834	23	27	,	,	PUNCT
ihlr-20834	23	28	2015	2015	NUM
ihlr-20834	23	29	)	)	PUNCT
ihlr-20834	23	30	.	.	PUNCT
ihlr-20834	24	1	6	6	NUM
ihlr-20834	24	2	tod	tod	X
ihlr-20834	24	3	cooperman	cooperman	NOUN
ihlr-20834	24	4	,	,	PUNCT
ihlr-20834	24	5	what	what	PRON
ihlr-20834	24	6	you	you	PRON
ihlr-20834	24	7	need	need	VERB
ihlr-20834	24	8	to	to	PART
ihlr-20834	24	9	know	know	VERB
ihlr-20834	24	10	about	about	ADP
ihlr-20834	24	11	generic	generic	ADJ
ihlr-20834	24	12	drugs	drug	NOUN
ihlr-20834	24	13	(	(	PUNCT
ihlr-20834	24	14	apr	apr	NOUN
ihlr-20834	24	15	.	.	PROPN
ihlr-20834	24	16	8	8	NUM
ihlr-20834	24	17	,	,	PUNCT
ihlr-20834	24	18	2013	2013	NUM
ihlr-20834	24	19	)	)	PUNCT
ihlr-20834	24	20	,	,	PUNCT
ihlr-20834	24	21	http://www.doctoroz.com/videos/what-you-need-knowabout-generic-drugs	http://www.doctoroz.com/videos/what-you-need-knowabout-generic-drug	NOUN
ihlr-20834	24	22	.	.	PROPN
ihlr-20834	24	23	7	7	NUM
ihlr-20834	24	24	danielle	danielle	PROPN
ihlr-20834	24	25	l.	l.	PROPN
ihlr-20834	24	26	steele	steele	PROPN
ihlr-20834	24	27	,	,	PUNCT
ihlr-20834	24	28	the	the	DET
ihlr-20834	24	29	“	"	PUNCT
ihlr-20834	24	30	duty	duty	NOUN
ihlr-20834	24	31	of	of	ADP
ihlr-20834	24	32	sameness	sameness	NOUN
ihlr-20834	24	33	”	"	PUNCT
ihlr-20834	24	34	as	as	ADP
ihlr-20834	24	35	a	a	DET
ihlr-20834	24	36	shield	shield	NOUN
ihlr-20834	24	37	--	--	PUNCT
ihlr-20834	24	38	generic	generic	ADJ
ihlr-20834	24	39	drug	drug	NOUN
ihlr-20834	24	40	manufacturers	manufacturer	NOUN
ihlr-20834	24	41	’	’	PART
ihlr-20834	24	42	tort	tort	NOUN
ihlr-20834	24	43	liability	liability	NOUN
ihlr-20834	24	44	and	and	CCONJ
ihlr-20834	24	45	the	the	DET
ihlr-20834	24	46	need	need	NOUN
ihlr-20834	24	47	for	for	ADP
ihlr-20834	24	48	label	label	NOUN
ihlr-20834	24	49	independence	independence	NOUN
ihlr-20834	24	50	after	after	ADP
ihlr-20834	24	51	pliva	pliva	PROPN
ihlr-20834	24	52	,	,	PUNCT
ihlr-20834	24	53	inc	inc	PROPN
ihlr-20834	24	54	.	.	PROPN
ihlr-20834	25	1	v.	v.	CCONJ
ihlr-20834	25	2	mensing	mense	VERB
ihlr-20834	25	3	,	,	PUNCT
ihlr-20834	25	4	43	43	NUM
ihlr-20834	25	5	seton	seton	PROPN
ihlr-20834	25	6	hall	hall	PROPN
ihlr-20834	25	7	l.	l.	PROPN
ihlr-20834	25	8	rev	rev	PROPN
ihlr-20834	25	9	441	441	NUM
ihlr-20834	25	10	,	,	PUNCT
ihlr-20834	25	11	442	442	NUM
ihlr-20834	25	12	-	-	SYM
ihlr-20834	25	13	43	43	NUM
ihlr-20834	25	14	(	(	PUNCT
ihlr-20834	25	15	2013	2013	NUM
ihlr-20834	25	16	)	)	PUNCT
ihlr-20834	25	17	(	(	PUNCT
ihlr-20834	25	18	citing	cite	VERB
ihlr-20834	25	19	effects	effect	NOUN
ihlr-20834	25	20	of	of	ADP
ihlr-20834	25	21	using	use	VERB
ihlr-20834	25	22	generic	generic	ADJ
ihlr-20834	25	23	drugs	drug	NOUN
ihlr-20834	25	24	on	on	ADP
ihlr-20834	25	25	medicare	medicare	PROPN
ihlr-20834	25	26	’s	’s	PART
ihlr-20834	25	27	prescription	prescription	NOUN
ihlr-20834	25	28	drug	drug	NOUN
ihlr-20834	25	29	spending	spending	NOUN
ihlr-20834	25	30	cong	cong	NOUN
ihlr-20834	25	31	.	.	PUNCT
ihlr-20834	26	1	budget	budget	NOUN
ihlr-20834	26	2	off	off	ADP
ihlr-20834	26	3	.	.	PUNCT
ihlr-20834	27	1	(	(	PUNCT
ihlr-20834	27	2	sept	sept	PROPN
ihlr-20834	27	3	.	.	PROPN
ihlr-20834	27	4	15	15	NUM
ihlr-20834	27	5	,	,	PUNCT
ihlr-20834	27	6	2010	2010	NUM
ihlr-20834	27	7	)	)	PUNCT
ihlr-20834	27	8	,	,	PUNCT
ihlr-20834	27	9	http://www.cbo.gov/sites/	http://www.cbo.gov/sites/	NOUN
ihlr-20834	27	10	default	default	NOUN
ihlr-20834	27	11	/	/	SYM
ihlr-20834	27	12	files	file	NOUN
ihlr-20834	27	13	/	/	SYM
ihlr-20834	27	14	cbofiles	cbofile	NOUN
ihlr-20834	27	15	/	/	SYM
ihlr-20834	27	16	ftpdocs/118xx	ftpdocs/118xx	NOUN
ihlr-20834	27	17	/	/	SYM
ihlr-20834	27	18	doc11838/09	doc11838/09	ADJ
ihlr-20834	27	19	-	-	PUNCT
ihlr-20834	27	20	15prescriptiondrugs.pdf	15prescriptiondrugs.pdf	NUM
ihlr-20834	27	21	)	)	PUNCT
ihlr-20834	27	22	.	.	PUNCT
ihlr-20834	28	1	8	8	NUM
ihlr-20834	28	2	see	see	VERB
ihlr-20834	28	3	i	i	PRON
ihlr-20834	28	4	d.	d.	PROPN
ihlr-20834	28	5	at	at	ADP
ihlr-20834	28	6	443	443	NUM
ihlr-20834	28	7	(	(	PUNCT
ihlr-20834	28	8	stating	state	VERB
ihlr-20834	28	9	that	that	SCONJ
ihlr-20834	28	10	“	"	PUNCT
ihlr-20834	28	11	[	[	X
ihlr-20834	28	12	private	private	ADJ
ihlr-20834	28	13	pharmaceutical	pharmaceutical	ADJ
ihlr-20834	28	14	benefit	benefit	NOUN
ihlr-20834	28	15	management	management	NOUN
ihlr-20834	28	16	companies	company	NOUN
ihlr-20834	28	17	]	]	PUNCT
ihlr-20834	28	18	strategically	strategically	ADV
ihlr-20834	28	19	manipulate	manipulate	VERB
ihlr-20834	28	20	pricing	pricing	NOUN
ihlr-20834	28	21	and	and	CCONJ
ihlr-20834	28	22	coverage	coverage	NOUN
ihlr-20834	28	23	in	in	ADP
ihlr-20834	28	24	order	order	NOUN
ihlr-20834	28	25	to	to	PART
ihlr-20834	28	26	influence	influence	VERB
ihlr-20834	28	27	patient	patient	ADJ
ihlr-20834	28	28	behavior	behavior	NOUN
ihlr-20834	28	29	in	in	ADP
ihlr-20834	28	30	prescription	prescription	NOUN
ihlr-20834	28	31	fulfillment	fulfillment	NOUN
ihlr-20834	28	32	.	.	PUNCT
ihlr-20834	28	33	”	"	PUNCT
ihlr-20834	29	1	(	(	PUNCT
ihlr-20834	29	2	citations	citation	NOUN
ihlr-20834	29	3	omitted	omit	VERB
ihlr-20834	29	4	)	)	PUNCT
ihlr-20834	29	5	)	)	PUNCT
ihlr-20834	29	6	.	.	PUNCT
ihlr-20834	30	1	9	9	NUM
ihlr-20834	30	2	i	i	PRON
ihlr-20834	30	3	d.	d.	PROPN
ihlr-20834	30	4	at	at	ADP
ihlr-20834	30	5	442	442	NUM
ihlr-20834	30	6	.	.	PUNCT
ihlr-20834	31	1	10	10	NUM
ihlr-20834	31	2	gregory	gregory	PROPN
ihlr-20834	31	3	v.	v.	PROPN
ihlr-20834	31	4	ashcroft	ashcroft	PROPN
ihlr-20834	31	5	,	,	PUNCT
ihlr-20834	31	6	501	501	NUM
ihlr-20834	31	7	u.s	u.s	PROPN
ihlr-20834	31	8	.	.	PROPN
ihlr-20834	31	9	452	452	NUM
ihlr-20834	31	10	,	,	PUNCT
ihlr-20834	31	11	457	457	NUM
ihlr-20834	31	12	(	(	PUNCT
ihlr-20834	31	13	1991	1991	NUM
ihlr-20834	31	14	)	)	PUNCT
ihlr-20834	31	15	.	.	PUNCT
ihlr-20834	32	1	11	11	NUM
ihlr-20834	32	2	u.s	u.s	PROPN
ihlr-20834	32	3	.	.	PROPN
ihlr-20834	32	4	const	const	PROPN
ihlr-20834	32	5	.	.	PUNCT
ihlr-20834	32	6	art	art	NOUN
ihlr-20834	32	7	.	.	PUNCT
ihlr-20834	33	1	vi	vi	NOUN
ihlr-20834	33	2	cl	cl	NOUN
ihlr-20834	33	3	.	.	PUNCT
ihlr-20834	34	1	2	2	NUM
ihlr-20834	34	2	.	.	NOUN
ihlr-20834	34	3	12	12	NUM
ihlr-20834	34	4	wyeth	wyeth	PROPN
ihlr-20834	34	5	v.	v.	PROPN
ihlr-20834	34	6	levine	levine	PROPN
ihlr-20834	34	7	,	,	PUNCT
ihlr-20834	34	8	555	555	NUM
ihlr-20834	34	9	u.s	u.s	PROPN
ihlr-20834	34	10	.	.	PROPN
ihlr-20834	34	11	555	555	NUM
ihlr-20834	34	12	,	,	PUNCT
ihlr-20834	34	13	579	579	NUM
ihlr-20834	34	14	(	(	PUNCT
ihlr-20834	34	15	2009	2009	NUM
ihlr-20834	34	16	)	)	PUNCT
ihlr-20834	34	17	.	.	PUNCT
ihlr-20834	35	1	772	772	NUM
ihlr-20834	35	2	indiana	indiana	PROPN
ihlr-20834	35	3	health	health	PROPN
ihlr-20834	35	4	law	law	PROPN
ihlr-20834	35	5	review	review	NOUN
ihlr-20834	35	6	vol	vol	NOUN
ihlr-20834	35	7	.	.	PUNCT
ihlr-20834	36	1	12:2	12:2	NUM
ihlr-20834	36	2	these	these	DET
ihlr-20834	36	3	state	state	NOUN
ihlr-20834	36	4	tort	tort	NOUN
ihlr-20834	36	5	laws	law	NOUN
ihlr-20834	36	6	also	also	ADV
ihlr-20834	36	7	provide	provide	VERB
ihlr-20834	36	8	(	(	PUNCT
ihlr-20834	36	9	sometimes	sometimes	ADV
ihlr-20834	36	10	limited	limited	ADJ
ihlr-20834	36	11	)	)	PUNCT
ihlr-20834	36	12	compensation	compensation	NOUN
ihlr-20834	36	13	to	to	ADP
ihlr-20834	36	14	injured	injure	VERB
ihlr-20834	36	15	parties	party	NOUN
ihlr-20834	36	16	in	in	ADP
ihlr-20834	36	17	an	an	DET
ihlr-20834	36	18	attempt	attempt	NOUN
ihlr-20834	36	19	to	to	PART
ihlr-20834	36	20	redress	redress	VERB
ihlr-20834	36	21	injuries.13	injuries.13	NOUN
ihlr-20834	36	22	additionally	additionally	ADV
ihlr-20834	36	23	,	,	PUNCT
ihlr-20834	36	24	these	these	DET
ihlr-20834	36	25	tort	tort	NOUN
ihlr-20834	36	26	laws	law	NOUN
ihlr-20834	36	27	help	help	VERB
ihlr-20834	36	28	to	to	PART
ihlr-20834	36	29	supplement	supplement	VERB
ihlr-20834	36	30	gaps	gap	NOUN
ihlr-20834	36	31	present	present	ADJ
ihlr-20834	36	32	in	in	ADP
ihlr-20834	36	33	federal	federal	ADJ
ihlr-20834	36	34	law	law	NOUN
ihlr-20834	36	35	,	,	PUNCT
ihlr-20834	36	36	such	such	ADJ
ihlr-20834	36	37	as	as	ADP
ihlr-20834	36	38	the	the	DET
ihlr-20834	36	39	lack	lack	NOUN
ihlr-20834	36	40	of	of	ADP
ihlr-20834	36	41	a	a	DET
ihlr-20834	36	42	private	private	ADJ
ihlr-20834	36	43	cause	cause	NOUN
ihlr-20834	36	44	of	of	ADP
ihlr-20834	36	45	action	action	NOUN
ihlr-20834	36	46	in	in	ADP
ihlr-20834	36	47	the	the	DET
ihlr-20834	36	48	food	food	NOUN
ihlr-20834	36	49	,	,	PUNCT
ihlr-20834	36	50	drug	drug	NOUN
ihlr-20834	36	51	,	,	PUNCT
ihlr-20834	36	52	and	and	CCONJ
ihlr-20834	36	53	cosmetic	cosmetic	ADJ
ihlr-20834	36	54	act	act	NOUN
ihlr-20834	36	55	(	(	PUNCT
ihlr-20834	36	56	“	"	PUNCT
ihlr-20834	36	57	fdca”).14	fdca”).14	X
ihlr-20834	36	58	the	the	DET
ihlr-20834	36	59	long	long	ADV
ihlr-20834	36	60	held	hold	VERB
ihlr-20834	36	61	constitutional	constitutional	ADJ
ihlr-20834	36	62	right	right	NOUN
ihlr-20834	36	63	of	of	ADP
ihlr-20834	36	64	permitting	permit	VERB
ihlr-20834	36	65	tort	tort	NOUN
ihlr-20834	36	66	law	law	NOUN
ihlr-20834	36	67	causes	cause	NOUN
ihlr-20834	36	68	of	of	ADP
ihlr-20834	36	69	action	action	NOUN
ihlr-20834	36	70	for	for	ADP
ihlr-20834	36	71	injured	injured	ADJ
ihlr-20834	36	72	parties	party	NOUN
ihlr-20834	36	73	might	might	AUX
ihlr-20834	36	74	no	no	ADV
ihlr-20834	36	75	longer	long	ADV
ihlr-20834	36	76	be	be	AUX
ihlr-20834	36	77	available	available	ADJ
ihlr-20834	36	78	to	to	ADP
ihlr-20834	36	79	generic	generic	ADJ
ihlr-20834	36	80	drug	drug	NOUN
ihlr-20834	36	81	consumers	consumer	NOUN
ihlr-20834	36	82	.	.	PUNCT
ihlr-20834	37	1	two	two	NUM
ihlr-20834	37	2	recently	recently	ADV
ihlr-20834	37	3	decided	decide	VERB
ihlr-20834	37	4	supreme	supreme	PROPN
ihlr-20834	37	5	court	court	PROPN
ihlr-20834	37	6	cases	case	NOUN
ihlr-20834	37	7	have	have	AUX
ihlr-20834	37	8	established	establish	VERB
ihlr-20834	37	9	precedent	precedent	NOUN
ihlr-20834	37	10	holding	hold	VERB
ihlr-20834	37	11	that	that	SCONJ
ihlr-20834	37	12	while	while	SCONJ
ihlr-20834	37	13	brand	brand	NOUN
ihlr-20834	37	14	name	name	NOUN
ihlr-20834	37	15	drug	drug	NOUN
ihlr-20834	37	16	manufacturers	manufacturer	NOUN
ihlr-20834	37	17	face	face	VERB
ihlr-20834	37	18	liability	liability	NOUN
ihlr-20834	37	19	for	for	ADP
ihlr-20834	37	20	failure	failure	NOUN
ihlr-20834	37	21	-	-	PUNCT
ihlr-20834	37	22	to	to	PART
ihlr-20834	37	23	-	-	PUNCT
ihlr-20834	37	24	warn	warn	VERB
ihlr-20834	37	25	and	and	CCONJ
ihlr-20834	37	26	product	product	NOUN
ihlr-20834	37	27	liability	liability	NOUN
ihlr-20834	37	28	claims	claim	NOUN
ihlr-20834	37	29	,	,	PUNCT
ihlr-20834	37	30	generic	generic	ADJ
ihlr-20834	37	31	drug	drug	NOUN
ihlr-20834	37	32	manufacturers	manufacturer	NOUN
ihlr-20834	37	33	will	will	AUX
ihlr-20834	37	34	not	not	PART
ihlr-20834	37	35	face	face	VERB
ihlr-20834	37	36	liability	liability	NOUN
ihlr-20834	37	37	so	so	ADV
ihlr-20834	37	38	long	long	ADV
ihlr-20834	37	39	as	as	SCONJ
ihlr-20834	37	40	it	it	PRON
ihlr-20834	37	41	complies	comply	VERB
ihlr-20834	37	42	with	with	ADP
ihlr-20834	37	43	the	the	DET
ihlr-20834	37	44	duty	duty	NOUN
ihlr-20834	37	45	of	of	ADP
ihlr-20834	37	46	sameness	sameness	NOUN
ihlr-20834	37	47	as	as	SCONJ
ihlr-20834	37	48	defined	define	VERB
ihlr-20834	37	49	in	in	ADP
ihlr-20834	37	50	the	the	DET
ihlr-20834	37	51	fdca.15	fdca.15	NOUN
ihlr-20834	37	52	this	this	DET
ihlr-20834	37	53	precedent	precedent	NOUN
ihlr-20834	37	54	is	be	AUX
ihlr-20834	37	55	preventing	prevent	VERB
ihlr-20834	37	56	innocently	innocently	ADV
ihlr-20834	37	57	injured	injure	VERB
ihlr-20834	37	58	consumers	consumer	NOUN
ihlr-20834	37	59	from	from	ADP
ihlr-20834	37	60	being	be	AUX
ihlr-20834	37	61	able	able	ADJ
ihlr-20834	37	62	to	to	PART
ihlr-20834	37	63	seek	seek	VERB
ihlr-20834	37	64	legal	legal	ADJ
ihlr-20834	37	65	recourse	recourse	NOUN
ihlr-20834	37	66	against	against	ADP
ihlr-20834	37	67	liable	liable	ADJ
ihlr-20834	37	68	generic	generic	ADJ
ihlr-20834	37	69	drug	drug	NOUN
ihlr-20834	37	70	manufacturers	manufacturer	NOUN
ihlr-20834	37	71	.	.	PUNCT
ihlr-20834	38	1	addressing	address	VERB
ihlr-20834	38	2	this	this	DET
ihlr-20834	38	3	issue	issue	NOUN
ihlr-20834	38	4	or	or	CCONJ
ihlr-20834	38	5	providing	provide	VERB
ihlr-20834	38	6	alternative	alternative	ADJ
ihlr-20834	38	7	legal	legal	ADJ
ihlr-20834	38	8	courses	course	NOUN
ihlr-20834	38	9	remains	remain	VERB
ihlr-20834	38	10	paramount	paramount	ADJ
ihlr-20834	38	11	to	to	PART
ihlr-20834	38	12	protect	protect	VERB
ihlr-20834	38	13	consumer	consumer	NOUN
ihlr-20834	38	14	needs	need	NOUN
ihlr-20834	38	15	.	.	PUNCT
ihlr-20834	39	1	a.	a.	NOUN
ihlr-20834	39	2	issue	issue	NOUN
ihlr-20834	39	3	the	the	DET
ihlr-20834	39	4	two	two	NUM
ihlr-20834	39	5	decisions	decision	NOUN
ihlr-20834	39	6	issued	issue	VERB
ihlr-20834	39	7	by	by	ADP
ihlr-20834	39	8	the	the	DET
ihlr-20834	39	9	supreme	supreme	PROPN
ihlr-20834	39	10	court	court	PROPN
ihlr-20834	39	11	will	will	AUX
ihlr-20834	39	12	have	have	VERB
ihlr-20834	39	13	debilitating	debilitate	VERB
ihlr-20834	39	14	effects	effect	NOUN
ihlr-20834	39	15	on	on	ADP
ihlr-20834	39	16	generic	generic	ADJ
ihlr-20834	39	17	drug	drug	NOUN
ihlr-20834	39	18	consumers	consumer	NOUN
ihlr-20834	39	19	in	in	ADP
ihlr-20834	39	20	the	the	DET
ihlr-20834	39	21	u.s	u.s	PROPN
ihlr-20834	39	22	.	.	PROPN
ihlr-20834	39	23	marketplace	marketplace	NOUN
ihlr-20834	39	24	.	.	PUNCT
ihlr-20834	40	1	this	this	DET
ihlr-20834	40	2	precedent	precedent	NOUN
ihlr-20834	40	3	is	be	AUX
ihlr-20834	40	4	likely	likely	ADJ
ihlr-20834	40	5	to	to	PART
ihlr-20834	40	6	result	result	VERB
ihlr-20834	40	7	in	in	ADP
ihlr-20834	40	8	denying	deny	VERB
ihlr-20834	40	9	individuals	individual	NOUN
ihlr-20834	40	10	who	who	PRON
ihlr-20834	40	11	take	take	VERB
ihlr-20834	40	12	generic	generic	ADJ
ihlr-20834	40	13	drugs	drug	NOUN
ihlr-20834	40	14	the	the	DET
ihlr-20834	40	15	ability	ability	NOUN
ihlr-20834	40	16	to	to	PART
ihlr-20834	40	17	legally	legally	ADV
ihlr-20834	40	18	redress	redress	VERB
ihlr-20834	40	19	their	their	PRON
ihlr-20834	40	20	injuries	injury	NOUN
ihlr-20834	40	21	.	.	PUNCT
ihlr-20834	41	1	this	this	PRON
ihlr-20834	41	2	is	be	AUX
ihlr-20834	41	3	significant	significant	ADJ
ihlr-20834	41	4	because	because	SCONJ
ihlr-20834	41	5	an	an	DET
ihlr-20834	41	6	estimated	estimate	VERB
ihlr-20834	41	7	80	80	NUM
ihlr-20834	41	8	%	%	NOUN
ihlr-20834	41	9	of	of	ADP
ihlr-20834	41	10	consumers	consumer	NOUN
ihlr-20834	41	11	opt	opt	VERB
ihlr-20834	41	12	for	for	ADP
ihlr-20834	41	13	generic	generic	ADJ
ihlr-20834	41	14	drug	drug	NOUN
ihlr-20834	41	15	treatment	treatment	NOUN
ihlr-20834	41	16	.	.	PUNCT
ihlr-20834	42	1	in	in	ADP
ihlr-20834	42	2	pliva	pliva	PROPN
ihlr-20834	42	3	v.	v.	CCONJ
ihlr-20834	42	4	mensing	mensing	PROPN
ihlr-20834	42	5	,	,	PUNCT
ihlr-20834	42	6	the	the	DET
ihlr-20834	42	7	court	court	NOUN
ihlr-20834	42	8	expanded	expand	VERB
ihlr-20834	42	9	the	the	DET
ihlr-20834	42	10	scope	scope	NOUN
ihlr-20834	42	11	of	of	ADP
ihlr-20834	42	12	the	the	DET
ihlr-20834	42	13	impossibility	impossibility	NOUN
ihlr-20834	42	14	preemption	preemption	NOUN
ihlr-20834	42	15	.	.	PUNCT
ihlr-20834	43	1	16	16	NUM
ihlr-20834	44	1	this	this	DET
ihlr-20834	44	2	expansion	expansion	NOUN
ihlr-20834	44	3	granted	grant	VERB
ihlr-20834	44	4	immunity	immunity	NOUN
ihlr-20834	44	5	to	to	ADP
ihlr-20834	44	6	generic	generic	ADJ
ihlr-20834	44	7	drug	drug	NOUN
ihlr-20834	44	8	manufacturers	manufacturer	NOUN
ihlr-20834	44	9	from	from	ADP
ihlr-20834	44	10	state	state	NOUN
ihlr-20834	44	11	law	law	NOUN
ihlr-20834	44	12	failure	failure	NOUN
ihlr-20834	44	13	-	-	PUNCT
ihlr-20834	44	14	to	to	PART
ihlr-20834	44	15	-	-	PUNCT
ihlr-20834	44	16	warn	warn	VERB
ihlr-20834	44	17	claims.17	claims.17	PROPN
ihlr-20834	44	18	in	in	ADP
ihlr-20834	44	19	pliva	pliva	NOUN
ihlr-20834	44	20	,	,	PUNCT
ihlr-20834	44	21	two	two	NUM
ihlr-20834	44	22	individuals	individual	NOUN
ihlr-20834	44	23	that	that	PRON
ihlr-20834	44	24	had	have	AUX
ihlr-20834	44	25	developed	develop	VERB
ihlr-20834	44	26	tardive	tardive	ADJ
ihlr-20834	44	27	dyskinesia	dyskinesia	NOUN
ihlr-20834	44	28	,	,	PUNCT
ihlr-20834	44	29	a	a	DET
ihlr-20834	44	30	severe	severe	ADJ
ihlr-20834	44	31	abnormal	abnormal	ADJ
ihlr-20834	44	32	and	and	CCONJ
ihlr-20834	44	33	13	13	NUM
ihlr-20834	44	34	i	i	NOUN
ihlr-20834	44	35	d.	d.	PROPN
ihlr-20834	44	36	14	14	NUM
ihlr-20834	44	37	see	see	VERB
ihlr-20834	44	38	merrell	merrell	PROPN
ihlr-20834	44	39	dow	dow	PROPN
ihlr-20834	44	40	pharm	pharm	PROPN
ihlr-20834	44	41	.	.	PUNCT
ihlr-20834	45	1	inc	inc	PROPN
ihlr-20834	45	2	.	.	PROPN
ihlr-20834	46	1	v.	v.	ADP
ihlr-20834	46	2	thompson	thompson	PROPN
ihlr-20834	46	3	,	,	PUNCT
ihlr-20834	46	4	478	478	NUM
ihlr-20834	46	5	u.s	u.s	AUX
ihlr-20834	46	6	.	.	PROPN
ihlr-20834	46	7	804	804	NUM
ihlr-20834	46	8	(	(	PUNCT
ihlr-20834	46	9	1986	1986	NUM
ihlr-20834	46	10	)	)	PUNCT
ihlr-20834	46	11	(	(	PUNCT
ihlr-20834	46	12	reasoning	reason	VERB
ihlr-20834	46	13	that	that	SCONJ
ihlr-20834	46	14	fdca	fdca	ADJ
ihlr-20834	46	15	violations	violation	NOUN
ihlr-20834	46	16	provide	provide	VERB
ihlr-20834	46	17	no	no	DET
ihlr-20834	46	18	federal	federal	ADJ
ihlr-20834	46	19	cause	cause	NOUN
ihlr-20834	46	20	of	of	ADP
ihlr-20834	46	21	action	action	NOUN
ihlr-20834	46	22	)	)	PUNCT
ihlr-20834	46	23	.	.	PUNCT
ihlr-20834	47	1	15	15	NUM
ihlr-20834	47	2	21	21	NUM
ihlr-20834	47	3	u.s.c	u.s.c	NOUN
ihlr-20834	47	4	.	.	PUNCT
ihlr-20834	48	1	§	§	PROPN
ihlr-20834	48	2	§	§	PROPN
ihlr-20834	48	3	355(j)(2)(a)(ii)-(iii	355(j)(2)(a)(ii)-(iii	NUM
ihlr-20834	48	4	)	)	PUNCT
ihlr-20834	48	5	(	(	PUNCT
ihlr-20834	48	6	2015	2015	NUM
ihlr-20834	48	7	)	)	PUNCT
ihlr-20834	48	8	.	.	PUNCT
ihlr-20834	49	1	16	16	NUM
ihlr-20834	49	2	pliva	pliva	PROPN
ihlr-20834	49	3	,	,	PUNCT
ihlr-20834	49	4	inc	inc	PROPN
ihlr-20834	49	5	.	.	PROPN
ihlr-20834	50	1	v.	v.	CCONJ
ihlr-20834	50	2	mensing	mense	VERB
ihlr-20834	50	3	,	,	PUNCT
ihlr-20834	50	4	131	131	NUM
ihlr-20834	50	5	s.ct	s.ct	NOUN
ihlr-20834	50	6	.	.	PROPN
ihlr-20834	50	7	2567	2567	NUM
ihlr-20834	50	8	(	(	PUNCT
ihlr-20834	50	9	2011	2011	NUM
ihlr-20834	50	10	)	)	PUNCT
ihlr-20834	50	11	.	.	PUNCT
ihlr-20834	51	1	17	17	NUM
ihlr-20834	52	1	i	i	PRON
ihlr-20834	52	2	d.	d.	PROPN
ihlr-20834	52	3	at	at	ADP
ihlr-20834	52	4	2569	2569	NUM
ihlr-20834	52	5	.	.	PUNCT
ihlr-20834	53	1	2015	2015	NUM
ihlr-20834	53	2	773	773	NUM
ihlr-20834	53	3	the	the	DET
ihlr-20834	53	4	supreme	supreme	PROPN
ihlr-20834	53	5	court	court	PROPN
ihlr-20834	53	6	’s	’s	PART
ihlr-20834	53	7	overreaching	overreach	VERB
ihlr-20834	53	8	preemption	preemption	NOUN
ihlr-20834	53	9	interpretation	interpretation	NOUN
ihlr-20834	53	10	and	and	CCONJ
ihlr-20834	53	11	it	it	PRON
ihlr-20834	53	12	’s	’	VERB
ihlr-20834	53	13	consequences	consequence	VERB
ihlr-20834	53	14	uncontrollable	uncontrollable	ADJ
ihlr-20834	53	15	face	face	NOUN
ihlr-20834	53	16	movement	movement	NOUN
ihlr-20834	53	17	disorder,18	disorder,18	NOUN
ihlr-20834	53	18	were	be	AUX
ihlr-20834	53	19	left	leave	VERB
ihlr-20834	53	20	without	without	ADP
ihlr-20834	53	21	legal	legal	ADJ
ihlr-20834	53	22	recourse.19	recourse.19	NOUN
ihlr-20834	53	23	in	in	ADP
ihlr-20834	53	24	mutual	mutual	PROPN
ihlr-20834	53	25	co.	co.	PROPN
ihlr-20834	53	26	pharmaceutical	pharmaceutical	PROPN
ihlr-20834	53	27	v.	v.	ADP
ihlr-20834	53	28	bartlett	bartlett	PROPN
ihlr-20834	53	29	,	,	PUNCT
ihlr-20834	53	30	the	the	DET
ihlr-20834	53	31	court	court	NOUN
ihlr-20834	53	32	unnecessarily	unnecessarily	ADV
ihlr-20834	53	33	expanded	expand	VERB
ihlr-20834	53	34	the	the	DET
ihlr-20834	53	35	reach	reach	NOUN
ihlr-20834	53	36	of	of	ADP
ihlr-20834	53	37	the	the	DET
ihlr-20834	53	38	preemption	preemption	NOUN
ihlr-20834	53	39	doctrine.20	doctrine.20	PROPN
ihlr-20834	53	40	the	the	DET
ihlr-20834	53	41	injured	injure	VERB
ihlr-20834	53	42	plaintiff	plaintiff	NOUN
ihlr-20834	53	43	purchased	purchase	VERB
ihlr-20834	53	44	an	an	DET
ihlr-20834	53	45	affordable	affordable	ADJ
ihlr-20834	53	46	generic	generic	ADJ
ihlr-20834	53	47	drug	drug	NOUN
ihlr-20834	53	48	to	to	PART
ihlr-20834	53	49	treat	treat	VERB
ihlr-20834	53	50	her	her	PRON
ihlr-20834	53	51	life	life	NOUN
ihlr-20834	53	52	threatening	threaten	VERB
ihlr-20834	53	53	dermatologic	dermatologic	ADJ
ihlr-20834	53	54	disorder	disorder	NOUN
ihlr-20834	53	55	.	.	PUNCT
ihlr-20834	54	1	however	however	ADV
ihlr-20834	54	2	,	,	PUNCT
ihlr-20834	54	3	as	as	ADP
ihlr-20834	54	4	a	a	DET
ihlr-20834	54	5	result	result	NOUN
ihlr-20834	54	6	of	of	ADP
ihlr-20834	54	7	the	the	DET
ihlr-20834	54	8	court	court	NOUN
ihlr-20834	54	9	’s	’s	PART
ihlr-20834	54	10	preemption	preemption	NOUN
ihlr-20834	54	11	interpretation	interpretation	NOUN
ihlr-20834	54	12	,	,	PUNCT
ihlr-20834	54	13	she	she	PRON
ihlr-20834	54	14	was	be	AUX
ihlr-20834	54	15	left	leave	VERB
ihlr-20834	54	16	without	without	ADP
ihlr-20834	54	17	legal	legal	ADJ
ihlr-20834	54	18	recourse	recourse	NOUN
ihlr-20834	54	19	to	to	PART
ihlr-20834	54	20	address	address	VERB
ihlr-20834	54	21	her	her	PRON
ihlr-20834	54	22	debilitating	debilitate	VERB
ihlr-20834	54	23	injuries.21	injuries.21	NOUN
ihlr-20834	54	24	these	these	DET
ihlr-20834	54	25	recent	recent	ADJ
ihlr-20834	54	26	supreme	supreme	PROPN
ihlr-20834	54	27	court	court	NOUN
ihlr-20834	54	28	decisions	decision	NOUN
ihlr-20834	54	29	raise	raise	VERB
ihlr-20834	54	30	the	the	DET
ihlr-20834	54	31	need	need	NOUN
ihlr-20834	54	32	for	for	ADP
ihlr-20834	54	33	legislative	legislative	ADJ
ihlr-20834	54	34	action	action	NOUN
ihlr-20834	54	35	and/or	and/or	CCONJ
ihlr-20834	54	36	statutory	statutory	ADJ
ihlr-20834	54	37	amendment	amendment	NOUN
ihlr-20834	54	38	.	.	PUNCT
ihlr-20834	55	1	the	the	DET
ihlr-20834	55	2	food	food	NOUN
ihlr-20834	55	3	and	and	CCONJ
ihlr-20834	55	4	drug	drug	PROPN
ihlr-20834	55	5	administration	administration	NOUN
ihlr-20834	55	6	(	(	PUNCT
ihlr-20834	55	7	“	"	PUNCT
ihlr-20834	55	8	fda	fda	PROPN
ihlr-20834	55	9	”	"	PUNCT
ihlr-20834	55	10	)	)	PUNCT
ihlr-20834	55	11	acts	act	VERB
ihlr-20834	55	12	as	as	ADP
ihlr-20834	55	13	a	a	DET
ihlr-20834	55	14	gatekeeper	gatekeeper	NOUN
ihlr-20834	55	15	in	in	ADP
ihlr-20834	55	16	“	"	PUNCT
ihlr-20834	55	17	protect[ing	protect[e	VERB
ihlr-20834	55	18	]	]	PUNCT
ihlr-20834	55	19	the	the	DET
ihlr-20834	55	20	public	public	ADJ
ihlr-20834	55	21	health	health	NOUN
ihlr-20834	55	22	by	by	ADP
ihlr-20834	55	23	assuring	assure	VERB
ihlr-20834	55	24	the	the	DET
ihlr-20834	55	25	safety	safety	NOUN
ihlr-20834	55	26	,	,	PUNCT
ihlr-20834	55	27	efficacy	efficacy	NOUN
ihlr-20834	55	28	,	,	PUNCT
ihlr-20834	55	29	and	and	CCONJ
ihlr-20834	55	30	security	security	NOUN
ihlr-20834	55	31	of	of	ADP
ihlr-20834	55	32	human	human	ADJ
ihlr-20834	55	33	and	and	CCONJ
ihlr-20834	55	34	veterinary	veterinary	ADJ
ihlr-20834	55	35	drugs	drug	NOUN
ihlr-20834	55	36	.	.	PUNCT
ihlr-20834	55	37	.	.	PUNCT
ihlr-20834	55	38	.	.	PUNCT
ihlr-20834	56	1	.”22	.”22	PUNCT
ihlr-20834	57	1	the	the	DET
ihlr-20834	57	2	fda	fda	PROPN
ihlr-20834	57	3	remains	remain	VERB
ihlr-20834	57	4	responsible	responsible	ADJ
ihlr-20834	57	5	“	"	PUNCT
ihlr-20834	57	6	helping	help	VERB
ihlr-20834	57	7	to	to	PART
ihlr-20834	57	8	speed	speed	VERB
ihlr-20834	57	9	innovations	innovation	NOUN
ihlr-20834	57	10	that	that	PRON
ihlr-20834	57	11	make	make	VERB
ihlr-20834	57	12	medicines	medicine	NOUN
ihlr-20834	57	13	more	more	ADV
ihlr-20834	57	14	effective	effective	ADJ
ihlr-20834	57	15	,	,	PUNCT
ihlr-20834	57	16	safer	safe	ADJ
ihlr-20834	57	17	,	,	PUNCT
ihlr-20834	57	18	and	and	CCONJ
ihlr-20834	57	19	more	more	ADV
ihlr-20834	57	20	affordable	affordable	ADJ
ihlr-20834	57	21	.	.	PUNCT
ihlr-20834	57	22	.	.	PUNCT
ihlr-20834	57	23	.	.	PUNCT
ihlr-20834	58	1	.”23	.”23	NOUN
ihlr-20834	59	1	as	as	ADP
ihlr-20834	59	2	a	a	DET
ihlr-20834	59	3	result	result	NOUN
ihlr-20834	59	4	of	of	ADP
ihlr-20834	59	5	these	these	DET
ihlr-20834	59	6	two	two	NUM
ihlr-20834	59	7	recent	recent	ADJ
ihlr-20834	59	8	decisions	decision	NOUN
ihlr-20834	59	9	,	,	PUNCT
ihlr-20834	59	10	the	the	DET
ihlr-20834	59	11	fda	fda	PROPN
ihlr-20834	59	12	’s	’s	PART
ihlr-20834	59	13	responsibility	responsibility	NOUN
ihlr-20834	59	14	is	be	AUX
ihlr-20834	59	15	subject	subject	ADJ
ihlr-20834	59	16	to	to	ADP
ihlr-20834	59	17	this	this	DET
ihlr-20834	59	18	large	large	ADJ
ihlr-20834	59	19	gap	gap	NOUN
ihlr-20834	59	20	that	that	PRON
ihlr-20834	59	21	is	be	AUX
ihlr-20834	59	22	preventing	prevent	VERB
ihlr-20834	59	23	innocent	innocent	ADJ
ihlr-20834	59	24	generic	generic	ADJ
ihlr-20834	59	25	drug	drug	NOUN
ihlr-20834	59	26	consumers	consumer	NOUN
ihlr-20834	59	27	from	from	ADP
ihlr-20834	59	28	seeking	seek	VERB
ihlr-20834	59	29	legal	legal	ADJ
ihlr-20834	59	30	recourse	recourse	NOUN
ihlr-20834	59	31	to	to	PART
ihlr-20834	59	32	address	address	VERB
ihlr-20834	59	33	their	their	PRON
ihlr-20834	59	34	injuries.24	injuries.24	PROPN
ihlr-20834	59	35	b.	b.	PROPN
ihlr-20834	59	36	roadmap	roadmap	PROPN
ihlr-20834	59	37	this	this	DET
ihlr-20834	59	38	note	note	NOUN
ihlr-20834	59	39	discusses	discuss	VERB
ihlr-20834	59	40	the	the	DET
ihlr-20834	59	41	ramifications	ramification	NOUN
ihlr-20834	59	42	of	of	ADP
ihlr-20834	59	43	three	three	NUM
ihlr-20834	59	44	recently	recently	ADV
ihlr-20834	59	45	decided	decide	VERB
ihlr-20834	59	46	supreme	supreme	PROPN
ihlr-20834	59	47	court	court	PROPN
ihlr-20834	59	48	cases	case	NOUN
ihlr-20834	59	49	dealing	deal	VERB
ihlr-20834	59	50	with	with	ADP
ihlr-20834	59	51	federal	federal	ADJ
ihlr-20834	59	52	preemption	preemption	NOUN
ihlr-20834	59	53	in	in	ADP
ihlr-20834	59	54	the	the	DET
ihlr-20834	59	55	prescription	prescription	NOUN
ihlr-20834	59	56	drug	drug	NOUN
ihlr-20834	59	57	marketplace	marketplace	NOUN
ihlr-20834	59	58	:	:	PUNCT
ihlr-20834	59	59	wyeth	wyeth	PROPN
ihlr-20834	59	60	v.	v.	PROPN
ihlr-20834	59	61	18	18	NUM
ihlr-20834	59	62	see	see	VERB
ihlr-20834	59	63	tardive	tardive	ADJ
ihlr-20834	59	64	dyskinesia	dyskinesia	NOUN
ihlr-20834	59	65	,	,	PUNCT
ihlr-20834	59	66	medlineplus	medlineplus	CCONJ
ihlr-20834	59	67	,	,	PUNCT
ihlr-20834	59	68	http://www.nlm.nih.gov/	http://www.nlm.nih.gov/	PROPN
ihlr-20834	59	69	medlineplus	medlineplus	ADJ
ihlr-20834	59	70	/	/	SYM
ihlr-20834	59	71	ency	ency	NOUN
ihlr-20834	59	72	/	/	SYM
ihlr-20834	59	73	article/000685.htm	article/000685.htm	PROPN
ihlr-20834	60	1	(	(	PUNCT
ihlr-20834	60	2	last	last	ADJ
ihlr-20834	60	3	visited	visit	VERB
ihlr-20834	60	4	mar	mar	PROPN
ihlr-20834	60	5	.	.	PROPN
ihlr-20834	60	6	6	6	NUM
ihlr-20834	60	7	,	,	PUNCT
ihlr-20834	60	8	2015	2015	NUM
ihlr-20834	60	9	)	)	PUNCT
ihlr-20834	60	10	(	(	PUNCT
ihlr-20834	60	11	“	"	PUNCT
ihlr-20834	60	12	tardive	tardive	ADJ
ihlr-20834	60	13	dyskinesia	dyskinesia	NOUN
ihlr-20834	60	14	is	be	AUX
ihlr-20834	60	15	a	a	DET
ihlr-20834	60	16	disorder	disorder	NOUN
ihlr-20834	60	17	that	that	PRON
ihlr-20834	60	18	involves	involve	VERB
ihlr-20834	60	19	involuntary	involuntary	ADJ
ihlr-20834	60	20	movements	movement	NOUN
ihlr-20834	60	21	.	.	PUNCT
ihlr-20834	60	22	.	.	PUNCT
ihlr-20834	61	1	.	.	PUNCT
ihlr-20834	62	1	,	,	PUNCT
ihlr-20834	63	1	[	[	X
ihlr-20834	63	2	especially	especially	ADV
ihlr-20834	63	3	of	of	ADP
ihlr-20834	63	4	]	]	PUNCT
ihlr-20834	63	5	the	the	DET
ihlr-20834	63	6	lower	low	ADJ
ihlr-20834	63	7	face	face	NOUN
ihlr-20834	63	8	.	.	PUNCT
ihlr-20834	64	1	tardive	tardive	ADJ
ihlr-20834	64	2	means	mean	NOUN
ihlr-20834	64	3	delayed	delay	VERB
ihlr-20834	64	4	and	and	CCONJ
ihlr-20834	64	5	dyskinesia	dyskinesia	NOUN
ihlr-20834	64	6	means	mean	VERB
ihlr-20834	64	7	abnormal	abnormal	ADJ
ihlr-20834	64	8	movement	movement	NOUN
ihlr-20834	64	9	.	.	PUNCT
ihlr-20834	64	10	”	"	PUNCT
ihlr-20834	64	11	)	)	PUNCT
ihlr-20834	64	12	)	)	PUNCT
ihlr-20834	64	13	.	.	PUNCT
ihlr-20834	65	1	19	19	NUM
ihlr-20834	65	2	pliva	pliva	PROPN
ihlr-20834	65	3	,	,	PUNCT
ihlr-20834	65	4	inc	inc	PROPN
ihlr-20834	65	5	.	.	PROPN
ihlr-20834	65	6	,	,	PUNCT
ihlr-20834	65	7	131	131	NUM
ihlr-20834	65	8	s.ct	s.ct	NOUN
ihlr-20834	65	9	.	.	PUNCT
ihlr-20834	66	1	at	at	ADP
ihlr-20834	66	2	2569	2569	NUM
ihlr-20834	66	3	.	.	PUNCT
ihlr-20834	67	1	20	20	NUM
ihlr-20834	67	2	mut	mut	NOUN
ihlr-20834	67	3	.	.	PUNCT
ihlr-20834	68	1	pharm	pharm	PROPN
ihlr-20834	68	2	.	.	PUNCT
ihlr-20834	69	1	co.	co.	PROPN
ihlr-20834	69	2	,	,	PUNCT
ihlr-20834	69	3	inc	inc	PROPN
ihlr-20834	69	4	.	.	PROPN
ihlr-20834	70	1	v.	v.	ADP
ihlr-20834	70	2	bartlett	bartlett	PROPN
ihlr-20834	70	3	,	,	PUNCT
ihlr-20834	70	4	133	133	NUM
ihlr-20834	70	5	s.ct	s.ct	NOUN
ihlr-20834	70	6	.	.	PROPN
ihlr-20834	70	7	2466	2466	NUM
ihlr-20834	70	8	,	,	PUNCT
ihlr-20834	70	9	2472	2472	NUM
ihlr-20834	70	10	(	(	PUNCT
ihlr-20834	70	11	2013	2013	NUM
ihlr-20834	70	12	)	)	PUNCT
ihlr-20834	70	13	(	(	PUNCT
ihlr-20834	70	14	the	the	DET
ihlr-20834	70	15	victim	victim	NOUN
ihlr-20834	70	16	developed	develop	VERB
ihlr-20834	70	17	epidermal	epidermal	ADJ
ihlr-20834	70	18	necrolysis	necrolysis	NOUN
ihlr-20834	70	19	,	,	PUNCT
ihlr-20834	70	20	a	a	DET
ihlr-20834	70	21	skin	skin	NOUN
ihlr-20834	70	22	eating	eat	VERB
ihlr-20834	70	23	bacteria	bacteria	NOUN
ihlr-20834	70	24	)	)	PUNCT
ihlr-20834	70	25	.	.	PUNCT
ihlr-20834	71	1	21	21	NUM
ihlr-20834	72	1	i	i	PRON
ihlr-20834	72	2	d.	d.	PROPN
ihlr-20834	72	3	22	22	NUM
ihlr-20834	72	4	about	about	ADP
ihlr-20834	72	5	fda	fda	PROPN
ihlr-20834	72	6	:	:	PUNCT
ihlr-20834	72	7	what	what	PRON
ihlr-20834	72	8	we	we	PRON
ihlr-20834	72	9	do	do	VERB
ihlr-20834	72	10	,	,	PUNCT
ihlr-20834	72	11	u.s	u.s	PROPN
ihlr-20834	72	12	.	.	PROPN
ihlr-20834	72	13	food	food	PROPN
ihlr-20834	72	14	&	&	CCONJ
ihlr-20834	72	15	drug	drug	PROPN
ihlr-20834	72	16	admin	admin	PROPN
ihlr-20834	72	17	.	.	PROPN
ihlr-20834	72	18	,	,	PUNCT
ihlr-20834	72	19	http://www.fda.gov/aboutfda/whatwedo/	http://www.fda.gov/aboutfda/whatwedo/	PROPN
ihlr-20834	72	20	(	(	PUNCT
ihlr-20834	72	21	last	last	ADJ
ihlr-20834	72	22	updated	update	VERB
ihlr-20834	72	23	aug	aug	PROPN
ihlr-20834	72	24	.	.	PROPN
ihlr-20834	72	25	5	5	NUM
ihlr-20834	72	26	,	,	PUNCT
ihlr-20834	72	27	2014	2014	NUM
ihlr-20834	72	28	)	)	PUNCT
ihlr-20834	72	29	.	.	PUNCT
ihlr-20834	73	1	23	23	NUM
ihlr-20834	74	1	i	i	PRON
ihlr-20834	74	2	d.	d.	PROPN
ihlr-20834	74	3	24	24	NUM
ihlr-20834	74	4	see	see	VERB
ihlr-20834	74	5	therapeutic	therapeutic	ADJ
ihlr-20834	74	6	drug	drug	NOUN
ihlr-20834	74	7	use	use	NOUN
ihlr-20834	74	8	,	,	PUNCT
ihlr-20834	74	9	center	center	NOUN
ihlr-20834	74	10	for	for	ADP
ihlr-20834	74	11	disease	disease	NOUN
ihlr-20834	74	12	control	control	PROPN
ihlr-20834	74	13	&	&	CCONJ
ihlr-20834	74	14	prevention	prevention	PROPN
ihlr-20834	74	15	,	,	PUNCT
ihlr-20834	74	16	http://www.cdc.gov/nchs/fastats/drug-use-therapeutic.htm	http://www.cdc.gov/nchs/fastats/drug-use-therapeutic.htm	PROPN
ihlr-20834	74	17	(	(	PUNCT
ihlr-20834	74	18	last	last	ADV
ihlr-20834	74	19	visited	visit	VERB
ihlr-20834	74	20	mar	mar	PROPN
ihlr-20834	74	21	.	.	PROPN
ihlr-20834	74	22	16	16	NUM
ihlr-20834	74	23	,	,	PUNCT
ihlr-20834	74	24	2015	2015	NUM
ihlr-20834	74	25	)	)	PUNCT
ihlr-20834	74	26	(	(	PUNCT
ihlr-20834	74	27	in	in	ADP
ihlr-20834	74	28	2007	2007	NUM
ihlr-20834	74	29	,	,	PUNCT
ihlr-20834	74	30	48.5	48.5	NUM
ihlr-20834	74	31	%	%	NOUN
ihlr-20834	74	32	of	of	ADP
ihlr-20834	74	33	persons	person	NOUN
ihlr-20834	74	34	in	in	ADP
ihlr-20834	74	35	the	the	DET
ihlr-20834	74	36	u.s	u.s	PROPN
ihlr-20834	74	37	.	.	PROPN
ihlr-20834	74	38	reported	report	VERB
ihlr-20834	74	39	using	use	VERB
ihlr-20834	74	40	least	least	ADJ
ihlr-20834	74	41	one	one	NUM
ihlr-20834	74	42	prescription	prescription	NOUN
ihlr-20834	74	43	drug	drug	NOUN
ihlr-20834	74	44	in	in	ADP
ihlr-20834	74	45	the	the	DET
ihlr-20834	74	46	past	past	ADJ
ihlr-20834	74	47	thirty	thirty	NUM
ihlr-20834	74	48	days	day	NOUN
ihlr-20834	74	49	)	)	PUNCT
ihlr-20834	74	50	.	.	PUNCT
ihlr-20834	75	1	774	774	NUM
ihlr-20834	75	2	indiana	indiana	PROPN
ihlr-20834	75	3	health	health	PROPN
ihlr-20834	75	4	law	law	PROPN
ihlr-20834	75	5	review	review	NOUN
ihlr-20834	75	6	vol	vol	NOUN
ihlr-20834	75	7	.	.	PROPN
ihlr-20834	75	8	12:2	12:2	NUM
ihlr-20834	75	9	levine,25	levine,25	ADJ
ihlr-20834	75	10	pliva	pliva	NOUN
ihlr-20834	75	11	v.	v.	ADP
ihlr-20834	75	12	mensing,26	mensing,26	NOUN
ihlr-20834	75	13	and	and	CCONJ
ihlr-20834	75	14	mutual	mutual	PROPN
ihlr-20834	75	15	co.	co.	PROPN
ihlr-20834	75	16	pharm	pharm	PROPN
ihlr-20834	75	17	.	.	PUNCT
ihlr-20834	76	1	v.	v.	ADP
ihlr-20834	76	2	bartlett	bartlett	PROPN
ihlr-20834	76	3	.	.	PUNCT
ihlr-20834	76	4	27	27	NUM
ihlr-20834	76	5	to	to	PART
ihlr-20834	76	6	facilitate	facilitate	VERB
ihlr-20834	76	7	an	an	DET
ihlr-20834	76	8	understanding	understanding	NOUN
ihlr-20834	76	9	of	of	ADP
ihlr-20834	76	10	the	the	DET
ihlr-20834	76	11	issue	issue	NOUN
ihlr-20834	76	12	discussed	discuss	VERB
ihlr-20834	76	13	,	,	PUNCT
ihlr-20834	76	14	section	section	NOUN
ihlr-20834	76	15	ii	ii	PROPN
ihlr-20834	76	16	explains	explain	VERB
ihlr-20834	76	17	the	the	DET
ihlr-20834	76	18	statutory	statutory	ADJ
ihlr-20834	76	19	history	history	NOUN
ihlr-20834	76	20	of	of	ADP
ihlr-20834	76	21	both	both	DET
ihlr-20834	76	22	patent	patent	NOUN
ihlr-20834	76	23	law	law	NOUN
ihlr-20834	76	24	and	and	CCONJ
ihlr-20834	76	25	federal	federal	ADJ
ihlr-20834	76	26	regulations	regulation	NOUN
ihlr-20834	76	27	applicable	applicable	ADJ
ihlr-20834	76	28	to	to	ADP
ihlr-20834	76	29	generic	generic	ADJ
ihlr-20834	76	30	and	and	CCONJ
ihlr-20834	76	31	brand	brand	NOUN
ihlr-20834	76	32	name	name	NOUN
ihlr-20834	76	33	pharmaceutical	pharmaceutical	NOUN
ihlr-20834	76	34	manufacturers	manufacturer	NOUN
ihlr-20834	76	35	.	.	PUNCT
ihlr-20834	77	1	section	section	NOUN
ihlr-20834	77	2	ii	ii	PROPN
ihlr-20834	77	3	will	will	AUX
ihlr-20834	77	4	also	also	ADV
ihlr-20834	77	5	discuss	discuss	VERB
ihlr-20834	77	6	the	the	DET
ihlr-20834	77	7	procedural	procedural	ADJ
ihlr-20834	77	8	and	and	CCONJ
ihlr-20834	77	9	regulatory	regulatory	ADJ
ihlr-20834	77	10	thresholds	threshold	NOUN
ihlr-20834	77	11	that	that	SCONJ
ihlr-20834	77	12	generic	generic	ADJ
ihlr-20834	77	13	drug	drug	NOUN
ihlr-20834	77	14	manufacturers	manufacturer	NOUN
ihlr-20834	77	15	are	be	AUX
ihlr-20834	77	16	required	require	VERB
ihlr-20834	77	17	to	to	PART
ihlr-20834	77	18	satisfy	satisfy	VERB
ihlr-20834	77	19	to	to	PART
ihlr-20834	77	20	bring	bring	VERB
ihlr-20834	77	21	its	its	PRON
ihlr-20834	77	22	drugs	drug	NOUN
ihlr-20834	77	23	to	to	ADP
ihlr-20834	77	24	market	market	NOUN
ihlr-20834	77	25	.	.	PUNCT
ihlr-20834	78	1	section	section	NOUN
ihlr-20834	78	2	iii	iii	PROPN
ihlr-20834	78	3	will	will	AUX
ihlr-20834	78	4	explore	explore	VERB
ihlr-20834	78	5	the	the	DET
ihlr-20834	78	6	preemption	preemption	NOUN
ihlr-20834	78	7	doctrine	doctrine	NOUN
ihlr-20834	78	8	,	,	PUNCT
ihlr-20834	78	9	delving	delve	VERB
ihlr-20834	78	10	into	into	ADP
ihlr-20834	78	11	potential	potential	ADJ
ihlr-20834	78	12	preemption	preemption	NOUN
ihlr-20834	78	13	scenarios	scenario	NOUN
ihlr-20834	78	14	that	that	PRON
ihlr-20834	78	15	may	may	AUX
ihlr-20834	78	16	arise	arise	VERB
ihlr-20834	78	17	as	as	ADP
ihlr-20834	78	18	a	a	DET
ihlr-20834	78	19	legal	legal	ADJ
ihlr-20834	78	20	argument	argument	NOUN
ihlr-20834	78	21	.	.	PUNCT
ihlr-20834	79	1	section	section	NOUN
ihlr-20834	79	2	iv	iv	NUM
ihlr-20834	79	3	will	will	AUX
ihlr-20834	79	4	analyze	analyze	VERB
ihlr-20834	79	5	these	these	DET
ihlr-20834	79	6	three	three	NUM
ihlr-20834	79	7	supreme	supreme	ADJ
ihlr-20834	79	8	court	court	NOUN
ihlr-20834	79	9	cases	case	NOUN
ihlr-20834	79	10	and	and	CCONJ
ihlr-20834	79	11	it	it	PRON
ihlr-20834	79	12	will	will	AUX
ihlr-20834	79	13	apply	apply	VERB
ihlr-20834	79	14	this	this	DET
ihlr-20834	79	15	flawed	flawed	ADJ
ihlr-20834	79	16	precedent	precedent	NOUN
ihlr-20834	79	17	to	to	ADP
ihlr-20834	79	18	indiana	indiana	NOUN
ihlr-20834	79	19	by	by	ADP
ihlr-20834	79	20	applying	apply	VERB
ihlr-20834	79	21	this	this	DET
ihlr-20834	79	22	precedent	precedent	NOUN
ihlr-20834	79	23	to	to	PART
ihlr-20834	79	24	previously	previously	ADV
ihlr-20834	79	25	decided	decide	VERB
ihlr-20834	79	26	indiana	indiana	PROPN
ihlr-20834	79	27	cases	case	NOUN
ihlr-20834	79	28	.	.	PUNCT
ihlr-20834	80	1	finally	finally	ADV
ihlr-20834	80	2	,	,	PUNCT
ihlr-20834	80	3	section	section	NOUN
ihlr-20834	80	4	iv	iv	NUM
ihlr-20834	80	5	will	will	AUX
ihlr-20834	80	6	explore	explore	VERB
ihlr-20834	80	7	possible	possible	ADJ
ihlr-20834	80	8	options	option	NOUN
ihlr-20834	80	9	available	available	ADJ
ihlr-20834	80	10	to	to	ADP
ihlr-20834	80	11	injured	injure	VERB
ihlr-20834	80	12	generic	generic	ADJ
ihlr-20834	80	13	drug	drug	NOUN
ihlr-20834	80	14	consumers	consumer	NOUN
ihlr-20834	80	15	.	.	PUNCT
ihlr-20834	81	1	ii	ii	PROPN
ihlr-20834	81	2	.	.	PUNCT
ihlr-20834	82	1	the	the	DET
ihlr-20834	82	2	law	law	NOUN
ihlr-20834	82	3	and	and	CCONJ
ihlr-20834	82	4	regulatory	regulatory	ADJ
ihlr-20834	82	5	rules	rule	NOUN
ihlr-20834	82	6	of	of	ADP
ihlr-20834	82	7	the	the	DET
ihlr-20834	82	8	pharmaceutical	pharmaceutical	ADJ
ihlr-20834	82	9	industry	industry	NOUN
ihlr-20834	82	10	to	to	PART
ihlr-20834	82	11	understand	understand	VERB
ihlr-20834	82	12	the	the	DET
ihlr-20834	82	13	statutory	statutory	ADJ
ihlr-20834	82	14	structure	structure	NOUN
ihlr-20834	82	15	of	of	ADP
ihlr-20834	82	16	pharmaceutical	pharmaceutical	ADJ
ihlr-20834	82	17	law	law	NOUN
ihlr-20834	82	18	and	and	CCONJ
ihlr-20834	82	19	market	market	NOUN
ihlr-20834	82	20	entry	entry	NOUN
ihlr-20834	82	21	barriers	barrier	NOUN
ihlr-20834	82	22	pharmaceutical	pharmaceutical	ADJ
ihlr-20834	82	23	drugs	drug	NOUN
ihlr-20834	82	24	face	face	VERB
ihlr-20834	82	25	,	,	PUNCT
ihlr-20834	82	26	it	it	PRON
ihlr-20834	82	27	is	be	AUX
ihlr-20834	82	28	important	important	ADJ
ihlr-20834	82	29	to	to	PART
ihlr-20834	82	30	understand	understand	VERB
ihlr-20834	82	31	the	the	DET
ihlr-20834	82	32	reasoning	reasoning	NOUN
ihlr-20834	82	33	underlying	underlie	VERB
ihlr-20834	82	34	the	the	DET
ihlr-20834	82	35	creation	creation	NOUN
ihlr-20834	82	36	of	of	ADP
ihlr-20834	82	37	the	the	DET
ihlr-20834	82	38	acts	act	NOUN
ihlr-20834	82	39	themselves	themselves	PRON
ihlr-20834	82	40	.	.	PUNCT
ihlr-20834	83	1	this	this	DET
ihlr-20834	83	2	section	section	NOUN
ihlr-20834	83	3	briefly	briefly	NOUN
ihlr-20834	83	4	explores	explore	VERB
ihlr-20834	83	5	u.s	u.s	PROPN
ihlr-20834	83	6	.	.	PROPN
ihlr-20834	83	7	patent	patent	NOUN
ihlr-20834	83	8	law	law	NOUN
ihlr-20834	83	9	as	as	SCONJ
ihlr-20834	83	10	it	it	PRON
ihlr-20834	83	11	relates	relate	VERB
ihlr-20834	83	12	to	to	ADP
ihlr-20834	83	13	generic	generic	ADJ
ihlr-20834	83	14	and	and	CCONJ
ihlr-20834	83	15	brand	brand	NOUN
ihlr-20834	83	16	name	name	NOUN
ihlr-20834	83	17	drugs	drug	NOUN
ihlr-20834	83	18	,	,	PUNCT
ihlr-20834	83	19	it	it	PRON
ihlr-20834	83	20	provides	provide	VERB
ihlr-20834	83	21	a	a	DET
ihlr-20834	83	22	brief	brief	ADJ
ihlr-20834	83	23	history	history	NOUN
ihlr-20834	83	24	of	of	ADP
ihlr-20834	83	25	acts	act	NOUN
ihlr-20834	83	26	relevant	relevant	ADJ
ihlr-20834	83	27	to	to	ADP
ihlr-20834	83	28	the	the	DET
ihlr-20834	83	29	pharmaceutical	pharmaceutical	ADJ
ihlr-20834	83	30	industry	industry	NOUN
ihlr-20834	83	31	,	,	PUNCT
ihlr-20834	83	32	and	and	CCONJ
ihlr-20834	83	33	it	it	PRON
ihlr-20834	83	34	explores	explore	VERB
ihlr-20834	83	35	the	the	DET
ihlr-20834	83	36	barriers	barrier	NOUN
ihlr-20834	83	37	to	to	ADP
ihlr-20834	83	38	entry	entry	NOUN
ihlr-20834	83	39	applicable	applicable	ADJ
ihlr-20834	83	40	to	to	ADP
ihlr-20834	83	41	brand	brand	NOUN
ihlr-20834	83	42	name	name	NOUN
ihlr-20834	83	43	and	and	CCONJ
ihlr-20834	83	44	generic	generic	ADJ
ihlr-20834	83	45	drug	drug	NOUN
ihlr-20834	83	46	manufacturers	manufacturer	NOUN
ihlr-20834	83	47	.	.	PUNCT
ihlr-20834	84	1	a.	a.	PROPN
ihlr-20834	84	2	historical	historical	ADJ
ihlr-20834	84	3	background	background	NOUN
ihlr-20834	84	4	1	1	NUM
ihlr-20834	84	5	.	.	PUNCT
ihlr-20834	84	6	patent	patent	NOUN
ihlr-20834	84	7	law	law	NOUN
ihlr-20834	84	8	the	the	DET
ihlr-20834	84	9	original	original	ADJ
ihlr-20834	84	10	article	article	NOUN
ihlr-20834	84	11	of	of	ADP
ihlr-20834	84	12	the	the	DET
ihlr-20834	84	13	constitution	constitution	NOUN
ihlr-20834	84	14	provides	provide	VERB
ihlr-20834	84	15	the	the	DET
ihlr-20834	84	16	origin	origin	NOUN
ihlr-20834	84	17	of	of	ADP
ihlr-20834	84	18	patent	patent	NOUN
ihlr-20834	84	19	protection.28	protection.28	NOUN
ihlr-20834	84	20	patents	patent	NOUN
ihlr-20834	84	21	play	play	VERB
ihlr-20834	84	22	a	a	DET
ihlr-20834	84	23	central	central	ADJ
ihlr-20834	84	24	role	role	NOUN
ihlr-20834	84	25	in	in	ADP
ihlr-20834	84	26	25	25	NUM
ihlr-20834	84	27	wyeth	wyeth	PROPN
ihlr-20834	84	28	v.	v.	PROPN
ihlr-20834	84	29	levine	levine	PROPN
ihlr-20834	84	30	,	,	PUNCT
ihlr-20834	84	31	555	555	NUM
ihlr-20834	84	32	u.s	u.s	PROPN
ihlr-20834	84	33	.	.	PROPN
ihlr-20834	84	34	555	555	NUM
ihlr-20834	84	35	(	(	PUNCT
ihlr-20834	84	36	2009	2009	NUM
ihlr-20834	84	37	)	)	PUNCT
ihlr-20834	84	38	.	.	PUNCT
ihlr-20834	85	1	26	26	NUM
ihlr-20834	85	2	pliva	pliva	PROPN
ihlr-20834	85	3	,	,	PUNCT
ihlr-20834	85	4	inc	inc	PROPN
ihlr-20834	85	5	.	.	PROPN
ihlr-20834	86	1	v.	v.	CCONJ
ihlr-20834	86	2	mensing	mense	VERB
ihlr-20834	86	3	,	,	PUNCT
ihlr-20834	86	4	131	131	NUM
ihlr-20834	86	5	s.ct	s.ct	NOUN
ihlr-20834	86	6	.	.	PROPN
ihlr-20834	86	7	2567	2567	NUM
ihlr-20834	86	8	,	,	PUNCT
ihlr-20834	86	9	2570	2570	NUM
ihlr-20834	86	10	(	(	PUNCT
ihlr-20834	86	11	2011	2011	NUM
ihlr-20834	86	12	)	)	PUNCT
ihlr-20834	86	13	.	.	PUNCT
ihlr-20834	87	1	27	27	NUM
ihlr-20834	87	2	mut	mut	NOUN
ihlr-20834	87	3	.	.	PUNCT
ihlr-20834	88	1	pharm	pharm	PROPN
ihlr-20834	88	2	.	.	PUNCT
ihlr-20834	88	3	co.	co.	PROPN
ihlr-20834	88	4	inc	inc	PROPN
ihlr-20834	88	5	.	.	PROPN
ihlr-20834	88	6	,	,	PUNCT
ihlr-20834	89	1	v.	v.	PROPN
ihlr-20834	89	2	bartlett	bartlett	PROPN
ihlr-20834	89	3	,	,	PUNCT
ihlr-20834	89	4	133	133	NUM
ihlr-20834	89	5	s.ct	s.ct	NOUN
ihlr-20834	89	6	.	.	PROPN
ihlr-20834	89	7	2466	2466	NUM
ihlr-20834	89	8	(	(	PUNCT
ihlr-20834	89	9	2013	2013	NUM
ihlr-20834	89	10	)	)	PUNCT
ihlr-20834	89	11	.	.	PUNCT
ihlr-20834	90	1	28	28	NUM
ihlr-20834	91	1	u.s	u.s	PROPN
ihlr-20834	91	2	.	.	PROPN
ihlr-20834	91	3	const	const	PROPN
ihlr-20834	91	4	.	.	PUNCT
ihlr-20834	92	1	art	art	NOUN
ihlr-20834	92	2	.	.	PUNCT
ihlr-20834	93	1	i	i	PRON
ihlr-20834	93	2	,	,	PUNCT
ihlr-20834	93	3	§	§	PROPN
ihlr-20834	93	4	8	8	NUM
ihlr-20834	93	5	,	,	PUNCT
ihlr-20834	93	6	cl	cl	NOUN
ihlr-20834	93	7	.	.	NOUN
ihlr-20834	93	8	8	8	NUM
ihlr-20834	93	9	.	.	X
ihlr-20834	93	10	2015	2015	NUM
ihlr-20834	93	11	775	775	NUM
ihlr-20834	93	12	the	the	DET
ihlr-20834	93	13	supreme	supreme	PROPN
ihlr-20834	93	14	court	court	PROPN
ihlr-20834	93	15	’s	’s	PART
ihlr-20834	93	16	overreaching	overreach	VERB
ihlr-20834	93	17	preemption	preemption	NOUN
ihlr-20834	93	18	interpretation	interpretation	NOUN
ihlr-20834	93	19	and	and	CCONJ
ihlr-20834	93	20	it	it	PRON
ihlr-20834	93	21	’s	’	VERB
ihlr-20834	93	22	consequences	consequence	VERB
ihlr-20834	93	23	the	the	DET
ihlr-20834	93	24	creation	creation	NOUN
ihlr-20834	93	25	and	and	CCONJ
ihlr-20834	93	26	development	development	NOUN
ihlr-20834	93	27	of	of	ADP
ihlr-20834	93	28	pharmaceutical	pharmaceutical	ADJ
ihlr-20834	93	29	drugs	drug	NOUN
ihlr-20834	93	30	.	.	PUNCT
ihlr-20834	94	1	29	29	NUM
ihlr-20834	94	2	by	by	ADP
ihlr-20834	94	3	granting	grant	VERB
ihlr-20834	94	4	limited	limited	ADJ
ihlr-20834	94	5	monopoly	monopoly	NOUN
ihlr-20834	94	6	powers	power	NOUN
ihlr-20834	94	7	,	,	PUNCT
ihlr-20834	94	8	these	these	DET
ihlr-20834	94	9	patents	patent	NOUN
ihlr-20834	94	10	provide	provide	VERB
ihlr-20834	94	11	monetary	monetary	ADJ
ihlr-20834	94	12	incentives	incentive	NOUN
ihlr-20834	94	13	for	for	SCONJ
ihlr-20834	94	14	companies	company	NOUN
ihlr-20834	94	15	to	to	PART
ihlr-20834	94	16	invest	invest	VERB
ihlr-20834	94	17	in	in	ADP
ihlr-20834	94	18	researching	research	VERB
ihlr-20834	94	19	and	and	CCONJ
ihlr-20834	94	20	developing	develop	VERB
ihlr-20834	94	21	new	new	ADJ
ihlr-20834	94	22	drugs	drug	NOUN
ihlr-20834	94	23	to	to	PART
ihlr-20834	94	24	bring	bring	VERB
ihlr-20834	94	25	to	to	ADP
ihlr-20834	94	26	market	market	NOUN
ihlr-20834	94	27	.	.	PUNCT
ihlr-20834	95	1	30	30	NUM
ihlr-20834	95	2	this	this	DET
ihlr-20834	95	3	limited	limited	ADJ
ihlr-20834	95	4	monopoly	monopoly	NOUN
ihlr-20834	95	5	is	be	AUX
ihlr-20834	95	6	important	important	ADJ
ihlr-20834	95	7	in	in	ADP
ihlr-20834	95	8	helping	help	VERB
ihlr-20834	95	9	brand	brand	NOUN
ihlr-20834	95	10	name	name	NOUN
ihlr-20834	95	11	drug	drug	NOUN
ihlr-20834	95	12	manufacturers	manufacturer	NOUN
ihlr-20834	95	13	recoup	recoup	VERB
ihlr-20834	95	14	the	the	DET
ihlr-20834	95	15	research	research	NOUN
ihlr-20834	95	16	and	and	CCONJ
ihlr-20834	95	17	development	development	NOUN
ihlr-20834	95	18	costs	cost	NOUN
ihlr-20834	95	19	of	of	ADP
ihlr-20834	95	20	new	new	ADJ
ihlr-20834	95	21	drugs	drug	NOUN
ihlr-20834	95	22	which	which	PRON
ihlr-20834	95	23	may	may	AUX
ihlr-20834	95	24	exceed	exceed	VERB
ihlr-20834	95	25	$	$	SYM
ihlr-20834	95	26	2.5	2.5	NUM
ihlr-20834	95	27	billion	billion	NUM
ihlr-20834	95	28	.	.	PUNCT
ihlr-20834	96	1	31	31	NUM
ihlr-20834	97	1	it	it	PRON
ihlr-20834	97	2	is	be	AUX
ihlr-20834	97	3	important	important	ADJ
ihlr-20834	97	4	to	to	PART
ihlr-20834	97	5	note	note	VERB
ihlr-20834	97	6	,	,	PUNCT
ihlr-20834	97	7	however	however	ADV
ihlr-20834	97	8	,	,	PUNCT
ihlr-20834	97	9	that	that	SCONJ
ihlr-20834	97	10	this	this	DET
ihlr-20834	97	11	patent	patent	NOUN
ihlr-20834	97	12	protection	protection	NOUN
ihlr-20834	97	13	is	be	AUX
ihlr-20834	97	14	with	with	ADP
ihlr-20834	97	15	limits	limit	NOUN
ihlr-20834	97	16	.	.	PUNCT
ihlr-20834	98	1	for	for	ADP
ihlr-20834	98	2	example	example	NOUN
ihlr-20834	98	3	,	,	PUNCT
ihlr-20834	98	4	the	the	DET
ihlr-20834	98	5	bolar	bolar	PROPN
ihlr-20834	98	6	exemption	exemption	NOUN
ihlr-20834	98	7	allows	allow	VERB
ihlr-20834	98	8	a	a	DET
ihlr-20834	98	9	generic	generic	ADJ
ihlr-20834	98	10	drug	drug	NOUN
ihlr-20834	98	11	manufacturer	manufacturer	NOUN
ihlr-20834	98	12	to	to	PART
ihlr-20834	98	13	start	start	VERB
ihlr-20834	98	14	researching	research	VERB
ihlr-20834	98	15	and	and	CCONJ
ihlr-20834	98	16	testing	testing	NOUN
ihlr-20834	98	17	for	for	ADP
ihlr-20834	98	18	drug	drug	NOUN
ihlr-20834	98	19	approval	approval	NOUN
ihlr-20834	98	20	pre	pre	ADJ
ihlr-20834	98	21	-	-	ADJ
ihlr-20834	98	22	patent	patent	ADJ
ihlr-20834	98	23	expiration.32	expiration.32	NOUN
ihlr-20834	98	24	patent	patent	NOUN
ihlr-20834	98	25	protection	protection	NOUN
ihlr-20834	98	26	is	be	AUX
ihlr-20834	98	27	authorized	authorize	VERB
ihlr-20834	98	28	by	by	ADP
ihlr-20834	98	29	article	article	NOUN
ihlr-20834	98	30	1	1	NUM
ihlr-20834	98	31	,	,	PUNCT
ihlr-20834	98	32	section	section	NOUN
ihlr-20834	98	33	8	8	NUM
ihlr-20834	98	34	,	,	PUNCT
ihlr-20834	98	35	clause	clause	NOUN
ihlr-20834	98	36	8	8	NUM
ihlr-20834	98	37	of	of	ADP
ihlr-20834	98	38	the	the	DET
ihlr-20834	98	39	u.s	u.s	PROPN
ihlr-20834	98	40	.	.	PROPN
ihlr-20834	98	41	constitution	constitution	PROPN
ihlr-20834	98	42	,	,	PUNCT
ihlr-20834	98	43	which	which	PRON
ihlr-20834	98	44	states	state	VERB
ihlr-20834	98	45	in	in	ADP
ihlr-20834	98	46	part	part	NOUN
ihlr-20834	98	47	,	,	PUNCT
ihlr-20834	98	48	“	"	PUNCT
ihlr-20834	98	49	[	[	X
ihlr-20834	98	50	t]o	t]o	NOUN
ihlr-20834	98	51	promote	promote	VERB
ihlr-20834	98	52	the	the	DET
ihlr-20834	98	53	progress	progress	NOUN
ihlr-20834	98	54	of	of	ADP
ihlr-20834	98	55	science	science	NOUN
ihlr-20834	98	56	and	and	CCONJ
ihlr-20834	98	57	useful	useful	ADJ
ihlr-20834	98	58	arts	art	NOUN
ihlr-20834	98	59	,	,	PUNCT
ihlr-20834	98	60	by	by	ADP
ihlr-20834	98	61	securing	secure	VERB
ihlr-20834	98	62	for	for	ADP
ihlr-20834	98	63	limited	limited	ADJ
ihlr-20834	98	64	times	time	NOUN
ihlr-20834	98	65	.	.	PUNCT
ihlr-20834	98	66	.	.	PUNCT
ihlr-20834	98	67	.	.	PUNCT
ihlr-20834	99	1	the	the	DET
ihlr-20834	99	2	exclusive	exclusive	ADJ
ihlr-20834	99	3	right	right	NOUN
ihlr-20834	99	4	to	to	ADP
ihlr-20834	99	5	their	their	PRON
ihlr-20834	99	6	respective	respective	ADJ
ihlr-20834	99	7	writings	writing	NOUN
ihlr-20834	99	8	and	and	CCONJ
ihlr-20834	99	9	discoveries	discovery	NOUN
ihlr-20834	99	10	.	.	PUNCT
ihlr-20834	100	1	”33	”33	VERB
ihlr-20834	100	2	a	a	DET
ihlr-20834	100	3	patent	patent	NOUN
ihlr-20834	100	4	is	be	AUX
ihlr-20834	100	5	a	a	DET
ihlr-20834	100	6	property	property	NOUN
ihlr-20834	100	7	right	right	NOUN
ihlr-20834	100	8	29	29	NUM
ihlr-20834	100	9	patent	patent	NOUN
ihlr-20834	100	10	faqs	faq	NOUN
ihlr-20834	100	11	,	,	PUNCT
ihlr-20834	100	12	u.s	u.s	PROPN
ihlr-20834	100	13	.	.	PROPN
ihlr-20834	100	14	pat	pat	PROPN
ihlr-20834	100	15	.	.	PROPN
ihlr-20834	100	16	&	&	CCONJ
ihlr-20834	100	17	trademark	trademark	PROPN
ihlr-20834	100	18	off	off	ADP
ihlr-20834	100	19	.	.	PUNCT
ihlr-20834	100	20	,	,	PUNCT
ihlr-20834	101	1	http://www.uspto.gov/inventors/patents.jsp	http://www.uspto.gov/inventors/patents.jsp	PROPN
ihlr-20834	101	2	(	(	PUNCT
ihlr-20834	101	3	last	last	ADJ
ihlr-20834	101	4	visited	visit	VERB
ihlr-20834	101	5	mar	mar	PROPN
ihlr-20834	101	6	.	.	PROPN
ihlr-20834	101	7	16	16	NUM
ihlr-20834	101	8	,	,	PUNCT
ihlr-20834	101	9	2015	2015	NUM
ihlr-20834	101	10	)	)	PUNCT
ihlr-20834	101	11	(	(	PUNCT
ihlr-20834	101	12	patents	patent	NOUN
ihlr-20834	101	13	provide	provide	VERB
ihlr-20834	101	14	security	security	NOUN
ihlr-20834	101	15	on	on	ADP
ihlr-20834	101	16	the	the	DET
ihlr-20834	101	17	idea	idea	NOUN
ihlr-20834	101	18	for	for	ADP
ihlr-20834	101	19	a	a	DET
ihlr-20834	101	20	limited	limited	ADJ
ihlr-20834	101	21	duration	duration	NOUN
ihlr-20834	101	22	)	)	PUNCT
ihlr-20834	101	23	.	.	PUNCT
ihlr-20834	102	1	30	30	NUM
ihlr-20834	102	2	35	35	NUM
ihlr-20834	102	3	u.s.c	u.s.c	NOUN
ihlr-20834	102	4	.	.	PUNCT
ihlr-20834	103	1	§	§	PROPN
ihlr-20834	103	2	154(a)(2	154(a)(2	NUM
ihlr-20834	103	3	)	)	PUNCT
ihlr-20834	103	4	(	(	PUNCT
ihlr-20834	103	5	2015	2015	NUM
ihlr-20834	103	6	)	)	PUNCT
ihlr-20834	103	7	(	(	PUNCT
ihlr-20834	103	8	the	the	DET
ihlr-20834	103	9	patent	patent	NOUN
ihlr-20834	103	10	term	term	NOUN
ihlr-20834	103	11	is	be	AUX
ihlr-20834	103	12	20	20	NUM
ihlr-20834	103	13	years	year	NOUN
ihlr-20834	103	14	from	from	ADP
ihlr-20834	103	15	the	the	DET
ihlr-20834	103	16	filing	filing	NOUN
ihlr-20834	103	17	date	date	NOUN
ihlr-20834	103	18	)	)	PUNCT
ihlr-20834	103	19	.	.	PUNCT
ihlr-20834	104	1	31	31	NUM
ihlr-20834	104	2	pr	pr	NOUN
ihlr-20834	104	3	tufts	tuft	NOUN
ihlr-20834	104	4	csdd	csdd	ADJ
ihlr-20834	104	5	2014	2014	NUM
ihlr-20834	104	6	cost	cost	NOUN
ihlr-20834	104	7	study	study	NOUN
ihlr-20834	104	8	,	,	PUNCT
ihlr-20834	104	9	tufts	tuft	NOUN
ihlr-20834	104	10	csdd	csdd	ADJ
ihlr-20834	104	11	,	,	PUNCT
ihlr-20834	104	12	http://csdd.tufts.edu/news/complete_story/pr_tufts_csdd_2014_cost_stud	http://csdd.tufts.edu/news/complete_story/pr_tufts_csdd_2014_cost_stud	ADJ
ihlr-20834	104	13	y	y	PROPN
ihlr-20834	104	14	(	(	PUNCT
ihlr-20834	104	15	last	last	ADV
ihlr-20834	104	16	visited	visit	VERB
ihlr-20834	104	17	mar	mar	PROPN
ihlr-20834	104	18	.	.	PROPN
ihlr-20834	104	19	30	30	NUM
ihlr-20834	104	20	,	,	PUNCT
ihlr-20834	104	21	2015	2015	NUM
ihlr-20834	104	22	)	)	PUNCT
ihlr-20834	104	23	.	.	PUNCT
ihlr-20834	105	1	32	32	NUM
ihlr-20834	105	2	see	see	VERB
ihlr-20834	105	3	roche	roche	PROPN
ihlr-20834	105	4	prods	prod	VERB
ihlr-20834	105	5	.	.	PROPN
ihlr-20834	105	6	,	,	PUNCT
ihlr-20834	105	7	inc	inc	PROPN
ihlr-20834	105	8	.	.	PROPN
ihlr-20834	105	9	v.	v.	ADP
ihlr-20834	105	10	bolar	bolar	PROPN
ihlr-20834	105	11	pharm	pharm	PROPN
ihlr-20834	105	12	.	.	PUNCT
ihlr-20834	106	1	co.	co.	PROPN
ihlr-20834	106	2	,	,	PUNCT
ihlr-20834	106	3	inc	inc	PROPN
ihlr-20834	106	4	.	.	PROPN
ihlr-20834	106	5	,	,	PUNCT
ihlr-20834	106	6	733	733	NUM
ihlr-20834	106	7	f.2d	f.2d	ADP
ihlr-20834	106	8	858	858	NUM
ihlr-20834	106	9	(	(	PUNCT
ihlr-20834	106	10	fed	fed	PROPN
ihlr-20834	106	11	.	.	PUNCT
ihlr-20834	106	12	cir	cir	PROPN
ihlr-20834	106	13	.	.	PUNCT
ihlr-20834	106	14	1984	1984	NUM
ihlr-20834	106	15	)	)	PUNCT
ihlr-20834	106	16	,	,	PUNCT
ihlr-20834	106	17	superseded	supersede	VERB
ihlr-20834	106	18	by	by	ADP
ihlr-20834	106	19	statute	statute	NOUN
ihlr-20834	106	20	as	as	SCONJ
ihlr-20834	106	21	stated	state	VERB
ihlr-20834	106	22	in	in	ADP
ihlr-20834	106	23	warner	warner	PROPN
ihlr-20834	106	24	-	-	PUNCT
ihlr-20834	106	25	lambert	lambert	PROPN
ihlr-20834	106	26	co.	co.	PROPN
ihlr-20834	106	27	v.	v.	ADP
ihlr-20834	106	28	apotex	apotex	PROPN
ihlr-20834	106	29	corp	corp	PROPN
ihlr-20834	106	30	.	.	PROPN
ihlr-20834	106	31	316	316	NUM
ihlr-20834	106	32	f.3d	f.3d	NUM
ihlr-20834	106	33	1348	1348	NUM
ihlr-20834	106	34	(	(	PUNCT
ihlr-20834	106	35	fed	fed	PROPN
ihlr-20834	106	36	.	.	PUNCT
ihlr-20834	106	37	cir	cir	PROPN
ihlr-20834	106	38	.	.	PROPN
ihlr-20834	106	39	2003	2003	NUM
ihlr-20834	106	40	)	)	PUNCT
ihlr-20834	107	1	(	(	PUNCT
ihlr-20834	107	2	the	the	DET
ihlr-20834	107	3	bolar	bolar	PROPN
ihlr-20834	107	4	exemption	exemption	NOUN
ihlr-20834	107	5	also	also	ADV
ihlr-20834	107	6	allows	allow	VERB
ihlr-20834	107	7	generic	generic	ADJ
ihlr-20834	107	8	drug	drug	NOUN
ihlr-20834	107	9	manufacturers	manufacturer	NOUN
ihlr-20834	107	10	to	to	PART
ihlr-20834	107	11	perform	perform	VERB
ihlr-20834	107	12	research	research	NOUN
ihlr-20834	107	13	and	and	CCONJ
ihlr-20834	107	14	tests	test	NOUN
ihlr-20834	107	15	in	in	ADP
ihlr-20834	107	16	preparation	preparation	NOUN
ihlr-20834	107	17	for	for	ADP
ihlr-20834	107	18	regulatory	regulatory	ADJ
ihlr-20834	107	19	approval	approval	NOUN
ihlr-20834	107	20	prior	prior	ADV
ihlr-20834	107	21	to	to	ADP
ihlr-20834	107	22	patent	patent	NOUN
ihlr-20834	107	23	expiration	expiration	NOUN
ihlr-20834	107	24	,	,	PUNCT
ihlr-20834	107	25	and	and	CCONJ
ihlr-20834	107	26	this	this	DET
ihlr-20834	107	27	exemption	exemption	NOUN
ihlr-20834	107	28	immunizes	immunize	VERB
ihlr-20834	107	29	the	the	DET
ihlr-20834	107	30	generic	generic	ADJ
ihlr-20834	107	31	manufacturers	manufacturer	NOUN
ihlr-20834	107	32	against	against	ADP
ihlr-20834	107	33	patent	patent	NOUN
ihlr-20834	107	34	infringement	infringement	NOUN
ihlr-20834	107	35	suits	suit	NOUN
ihlr-20834	107	36	.	.	PUNCT
ihlr-20834	108	1	the	the	DET
ihlr-20834	108	2	rationale	rationale	NOUN
ihlr-20834	108	3	is	be	AUX
ihlr-20834	108	4	for	for	SCONJ
ihlr-20834	108	5	the	the	DET
ihlr-20834	108	6	bolar	bolar	PROPN
ihlr-20834	108	7	exemption	exemption	NOUN
ihlr-20834	108	8	is	be	AUX
ihlr-20834	108	9	to	to	PART
ihlr-20834	108	10	allow	allow	VERB
ihlr-20834	108	11	generic	generic	ADJ
ihlr-20834	108	12	drug	drug	NOUN
ihlr-20834	108	13	manufacturers	manufacturer	NOUN
ihlr-20834	108	14	the	the	DET
ihlr-20834	108	15	opportunity	opportunity	NOUN
ihlr-20834	108	16	to	to	PART
ihlr-20834	108	17	conduct	conduct	VERB
ihlr-20834	108	18	clinical	clinical	ADJ
ihlr-20834	108	19	trials	trial	NOUN
ihlr-20834	108	20	on	on	ADP
ihlr-20834	108	21	patented	patented	ADJ
ihlr-20834	108	22	products	product	NOUN
ihlr-20834	108	23	before	before	SCONJ
ihlr-20834	108	24	the	the	DET
ihlr-20834	108	25	products	product	NOUN
ihlr-20834	108	26	patent	patent	NOUN
ihlr-20834	108	27	has	have	AUX
ihlr-20834	108	28	expired	expire	VERB
ihlr-20834	108	29	)	)	PUNCT
ihlr-20834	108	30	.	.	PUNCT
ihlr-20834	109	1	there	there	PRON
ihlr-20834	109	2	are	be	VERB
ihlr-20834	109	3	other	other	ADJ
ihlr-20834	109	4	exceptions	exception	NOUN
ihlr-20834	109	5	and	and	CCONJ
ihlr-20834	109	6	protections	protection	NOUN
ihlr-20834	109	7	granted	grant	VERB
ihlr-20834	109	8	to	to	ADP
ihlr-20834	109	9	generic	generic	ADJ
ihlr-20834	109	10	drug	drug	NOUN
ihlr-20834	109	11	manufacturers	manufacturer	NOUN
ihlr-20834	109	12	.	.	PUNCT
ihlr-20834	110	1	for	for	ADP
ihlr-20834	110	2	example	example	NOUN
ihlr-20834	110	3	,	,	PUNCT
ihlr-20834	110	4	a	a	DET
ihlr-20834	110	5	paragraph	paragraph	NOUN
ihlr-20834	110	6	4	4	NUM
ihlr-20834	110	7	(	(	PUNCT
ihlr-20834	110	8	often	often	ADV
ihlr-20834	110	9	referred	refer	VERB
ihlr-20834	110	10	to	to	ADP
ihlr-20834	110	11	as	as	SCONJ
ihlr-20834	110	12	p4	p4	ADJ
ihlr-20834	110	13	)	)	PUNCT
ihlr-20834	110	14	certification	certification	NOUN
ihlr-20834	110	15	is	be	AUX
ihlr-20834	110	16	a	a	DET
ihlr-20834	110	17	form	form	NOUN
ihlr-20834	110	18	that	that	PRON
ihlr-20834	110	19	generic	generic	ADJ
ihlr-20834	110	20	firms	firm	NOUN
ihlr-20834	110	21	can	can	AUX
ihlr-20834	110	22	use	use	VERB
ihlr-20834	110	23	to	to	PART
ihlr-20834	110	24	challenge	challenge	VERB
ihlr-20834	110	25	current	current	ADJ
ihlr-20834	110	26	patents	patent	NOUN
ihlr-20834	110	27	.	.	PUNCT
ihlr-20834	111	1	if	if	SCONJ
ihlr-20834	111	2	the	the	DET
ihlr-20834	111	3	brand	brand	NOUN
ihlr-20834	111	4	-	-	PUNCT
ihlr-20834	111	5	name	name	NOUN
ihlr-20834	111	6	manufacturer	manufacturer	NOUN
ihlr-20834	111	7	sues	sue	VERB
ihlr-20834	111	8	the	the	DET
ihlr-20834	111	9	generic	generic	ADJ
ihlr-20834	111	10	filing	filing	NOUN
ihlr-20834	111	11	p4	p4	ADJ
ihlr-20834	111	12	party	party	NOUN
ihlr-20834	111	13	,	,	PUNCT
ihlr-20834	111	14	and	and	CCONJ
ihlr-20834	111	15	it	it	PRON
ihlr-20834	111	16	is	be	AUX
ihlr-20834	111	17	determined	determine	VERB
ihlr-20834	111	18	that	that	SCONJ
ihlr-20834	111	19	the	the	DET
ihlr-20834	111	20	patent	patent	NOUN
ihlr-20834	111	21	is	be	AUX
ihlr-20834	111	22	indeed	indeed	ADV
ihlr-20834	111	23	invalid	invalid	ADJ
ihlr-20834	111	24	,	,	PUNCT
ihlr-20834	111	25	the	the	DET
ihlr-20834	111	26	generic	generic	ADJ
ihlr-20834	111	27	manufacturer	manufacturer	NOUN
ihlr-20834	111	28	is	be	AUX
ihlr-20834	111	29	rewarded	reward	VERB
ihlr-20834	111	30	with	with	ADP
ihlr-20834	111	31	a	a	DET
ihlr-20834	111	32	valuable	valuable	ADJ
ihlr-20834	111	33	180	180	NUM
ihlr-20834	111	34	-	-	PUNCT
ihlr-20834	111	35	day	day	NOUN
ihlr-20834	111	36	marketing	marketing	NOUN
ihlr-20834	111	37	exclusivity	exclusivity	NOUN
ihlr-20834	111	38	period	period	NOUN
ihlr-20834	111	39	.	.	PUNCT
ihlr-20834	112	1	the	the	DET
ihlr-20834	112	2	p4	p4	PROPN
ihlr-20834	112	3	’s	’s	PART
ihlr-20834	112	4	origin	origin	NOUN
ihlr-20834	112	5	traces	trace	VERB
ihlr-20834	112	6	back	back	ADV
ihlr-20834	112	7	to	to	ADP
ihlr-20834	112	8	the	the	DET
ihlr-20834	112	9	hatch	hatch	NOUN
ihlr-20834	112	10	-	-	PUNCT
ihlr-20834	112	11	waxman	waxman	PROPN
ihlr-20834	112	12	act	act	PROPN
ihlr-20834	112	13	.	.	PUNCT
ihlr-20834	113	1	33	33	NUM
ihlr-20834	113	2	u.s	u.s	PROPN
ihlr-20834	113	3	.	.	PROPN
ihlr-20834	113	4	const	const	PROPN
ihlr-20834	113	5	.	.	PUNCT
ihlr-20834	113	6	art	art	NOUN
ihlr-20834	113	7	.	.	PUNCT
ihlr-20834	114	1	i	i	PRON
ihlr-20834	114	2	,	,	PUNCT
ihlr-20834	114	3	§	§	PROPN
ihlr-20834	114	4	8	8	NUM
ihlr-20834	114	5	,	,	PUNCT
ihlr-20834	114	6	cl	cl	NOUN
ihlr-20834	114	7	.	.	NOUN
ihlr-20834	114	8	8	8	NUM
ihlr-20834	114	9	(	(	PUNCT
ihlr-20834	114	10	congress	congress	PROPN
ihlr-20834	114	11	shall	shall	AUX
ihlr-20834	114	12	have	have	AUX
ihlr-20834	114	13	power	power	NOUN
ihlr-20834	114	14	“	"	PUNCT
ihlr-20834	114	15	[	[	X
ihlr-20834	114	16	t]o	t]o	NOUN
ihlr-20834	114	17	promote	promote	VERB
ihlr-20834	114	18	the	the	DET
ihlr-20834	114	19	progress	progress	NOUN
ihlr-20834	114	20	of	of	ADP
ihlr-20834	114	21	science	science	NOUN
ihlr-20834	114	22	and	and	CCONJ
ihlr-20834	114	23	useful	useful	ADJ
ihlr-20834	114	24	arts	art	NOUN
ihlr-20834	114	25	,	,	PUNCT
ihlr-20834	114	26	by	by	ADP
ihlr-20834	114	27	securing	secure	VERB
ihlr-20834	114	28	for	for	ADP
ihlr-20834	114	29	limited	limited	ADJ
ihlr-20834	114	30	times	time	NOUN
ihlr-20834	114	31	to	to	ADP
ihlr-20834	114	32	authors	author	NOUN
ihlr-20834	114	33	and	and	CCONJ
ihlr-20834	114	34	inventors	inventor	NOUN
ihlr-20834	114	35	the	the	DET
ihlr-20834	114	36	exclusive	exclusive	ADJ
ihlr-20834	114	37	right	right	NOUN
ihlr-20834	114	38	to	to	ADP
ihlr-20834	114	39	their	their	PRON
ihlr-20834	114	40	respective	respective	ADJ
ihlr-20834	114	41	776	776	NUM
ihlr-20834	114	42	indiana	indiana	PROPN
ihlr-20834	114	43	health	health	PROPN
ihlr-20834	114	44	law	law	PROPN
ihlr-20834	114	45	review	review	NOUN
ihlr-20834	114	46	vol	vol	NOUN
ihlr-20834	114	47	.	.	PUNCT
ihlr-20834	114	48	12:2	12:2	NUM
ihlr-20834	114	49	granted	grant	VERB
ihlr-20834	114	50	by	by	ADP
ihlr-20834	114	51	the	the	DET
ihlr-20834	114	52	u.s	u.s	PROPN
ihlr-20834	114	53	.	.	PROPN
ihlr-20834	114	54	to	to	ADP
ihlr-20834	114	55	an	an	DET
ihlr-20834	114	56	inventor	inventor	NOUN
ihlr-20834	114	57	“	"	PUNCT
ihlr-20834	114	58	to	to	PART
ihlr-20834	114	59	exclude	exclude	VERB
ihlr-20834	114	60	others	other	NOUN
ihlr-20834	114	61	from	from	ADP
ihlr-20834	114	62	making	make	VERB
ihlr-20834	114	63	,	,	PUNCT
ihlr-20834	114	64	using	use	VERB
ihlr-20834	114	65	,	,	PUNCT
ihlr-20834	114	66	offering	offer	VERB
ihlr-20834	114	67	for	for	ADP
ihlr-20834	114	68	sale	sale	NOUN
ihlr-20834	114	69	,	,	PUNCT
ihlr-20834	114	70	or	or	CCONJ
ihlr-20834	114	71	selling	sell	VERB
ihlr-20834	114	72	the	the	DET
ihlr-20834	114	73	invention	invention	NOUN
ihlr-20834	114	74	throughout	throughout	ADP
ihlr-20834	114	75	the	the	DET
ihlr-20834	114	76	[	[	X
ihlr-20834	114	77	u.s	u.s	PROPN
ihlr-20834	114	78	.	.	PROPN
ihlr-20834	114	79	]	]	PUNCT
ihlr-20834	115	1	or	or	CCONJ
ihlr-20834	115	2	importing	import	VERB
ihlr-20834	115	3	the	the	DET
ihlr-20834	115	4	invention	invention	NOUN
ihlr-20834	115	5	to	to	ADP
ihlr-20834	115	6	the	the	DET
ihlr-20834	115	7	[	[	X
ihlr-20834	115	8	u.s	u.s	PROPN
ihlr-20834	115	9	.	.	PROPN
ihlr-20834	115	10	]	]	X
ihlr-20834	115	11	”	"	PUNCT
ihlr-20834	115	12	for	for	ADP
ihlr-20834	115	13	a	a	DET
ihlr-20834	115	14	limited	limited	ADJ
ihlr-20834	115	15	time.34	time.34	NOUN
ihlr-20834	115	16	for	for	ADP
ihlr-20834	115	17	a	a	DET
ihlr-20834	115	18	patent	patent	NOUN
ihlr-20834	115	19	to	to	PART
ihlr-20834	115	20	be	be	AUX
ihlr-20834	115	21	held	hold	VERB
ihlr-20834	115	22	valid	valid	ADJ
ihlr-20834	115	23	,	,	PUNCT
ihlr-20834	115	24	there	there	PRON
ihlr-20834	115	25	are	be	VERB
ihlr-20834	115	26	many	many	ADJ
ihlr-20834	115	27	requirements	requirement	NOUN
ihlr-20834	115	28	.	.	PUNCT
ihlr-20834	116	1	generally	generally	ADV
ihlr-20834	116	2	,	,	PUNCT
ihlr-20834	116	3	the	the	DET
ihlr-20834	116	4	patent	patent	NOUN
ihlr-20834	116	5	must	must	AUX
ihlr-20834	116	6	be	be	AUX
ihlr-20834	116	7	novel	novel	ADJ
ihlr-20834	116	8	,	,	PUNCT
ihlr-20834	116	9	useful	useful	ADJ
ihlr-20834	116	10	,	,	PUNCT
ihlr-20834	116	11	and	and	CCONJ
ihlr-20834	116	12	non	non	ADJ
ihlr-20834	116	13	-	-	ADJ
ihlr-20834	116	14	obvious	obvious	ADJ
ihlr-20834	116	15	to	to	ADP
ihlr-20834	116	16	a	a	DET
ihlr-20834	116	17	person	person	NOUN
ihlr-20834	116	18	ordinarily	ordinarily	ADV
ihlr-20834	116	19	skilled	skilled	ADJ
ihlr-20834	116	20	in	in	ADP
ihlr-20834	116	21	the	the	DET
ihlr-20834	116	22	art.35	art.35	NOUN
ihlr-20834	116	23	the	the	DET
ihlr-20834	116	24	patent	patent	NOUN
ihlr-20834	116	25	subject	subject	NOUN
ihlr-20834	116	26	matter	matter	NOUN
ihlr-20834	116	27	must	must	AUX
ihlr-20834	116	28	also	also	ADV
ihlr-20834	116	29	be	be	AUX
ihlr-20834	116	30	patentable36	patentable36	NOUN
ihlr-20834	116	31	and	and	CCONJ
ihlr-20834	116	32	specified	specify	VERB
ihlr-20834	116	33	written	write	VERB
ihlr-20834	116	34	materials	material	NOUN
ihlr-20834	116	35	must	must	AUX
ihlr-20834	116	36	be	be	AUX
ihlr-20834	116	37	part	part	NOUN
ihlr-20834	116	38	of	of	ADP
ihlr-20834	116	39	every	every	DET
ihlr-20834	116	40	patent	patent	NOUN
ihlr-20834	116	41	application.37	application.37	NOUN
ihlr-20834	116	42	the	the	DET
ihlr-20834	116	43	original	original	ADJ
ihlr-20834	116	44	patent	patent	NOUN
ihlr-20834	116	45	holder	holder	NOUN
ihlr-20834	116	46	may	may	AUX
ihlr-20834	116	47	be	be	AUX
ihlr-20834	116	48	able	able	ADJ
ihlr-20834	116	49	to	to	PART
ihlr-20834	116	50	file	file	VERB
ihlr-20834	116	51	for	for	ADP
ihlr-20834	116	52	an	an	DET
ihlr-20834	116	53	extension	extension	NOUN
ihlr-20834	116	54	on	on	ADP
ihlr-20834	116	55	their	their	PRON
ihlr-20834	116	56	monopoly	monopoly	NOUN
ihlr-20834	116	57	powers	power	NOUN
ihlr-20834	116	58	.	.	PUNCT
ihlr-20834	117	1	these	these	DET
ihlr-20834	117	2	extensions	extension	NOUN
ihlr-20834	117	3	are	be	AUX
ihlr-20834	117	4	subject	subject	ADJ
ihlr-20834	117	5	to	to	ADP
ihlr-20834	117	6	their	their	PRON
ihlr-20834	117	7	own	own	ADJ
ihlr-20834	117	8	onerous	onerous	ADJ
ihlr-20834	117	9	requirements	requirement	NOUN
ihlr-20834	117	10	.	.	PUNCT
ihlr-20834	118	1	following	follow	VERB
ihlr-20834	118	2	the	the	DET
ihlr-20834	118	3	expiration	expiration	NOUN
ihlr-20834	118	4	of	of	ADP
ihlr-20834	118	5	the	the	DET
ihlr-20834	118	6	patent	patent	NOUN
ihlr-20834	118	7	term	term	NOUN
ihlr-20834	118	8	,	,	PUNCT
ihlr-20834	118	9	whether	whether	SCONJ
ihlr-20834	118	10	or	or	CCONJ
ihlr-20834	118	11	not	not	PART
ihlr-20834	118	12	an	an	DET
ihlr-20834	118	13	extension	extension	NOUN
ihlr-20834	118	14	has	have	AUX
ihlr-20834	118	15	been	be	AUX
ihlr-20834	118	16	granted	grant	VERB
ihlr-20834	118	17	,	,	PUNCT
ihlr-20834	118	18	generic	generic	ADJ
ihlr-20834	118	19	drug	drug	NOUN
ihlr-20834	118	20	manufacturers	manufacturer	NOUN
ihlr-20834	118	21	are	be	AUX
ihlr-20834	118	22	able	able	ADJ
ihlr-20834	118	23	to	to	PART
ihlr-20834	118	24	writings	writing	NOUN
ihlr-20834	118	25	and	and	CCONJ
ihlr-20834	118	26	discoveries	discovery	NOUN
ihlr-20834	118	27	.	.	PUNCT
ihlr-20834	118	28	”	"	PUNCT
ihlr-20834	118	29	)	)	PUNCT
ihlr-20834	118	30	.	.	PUNCT
ihlr-20834	119	1	34	34	NUM
ihlr-20834	119	2	35	35	NUM
ihlr-20834	119	3	u.s.c	u.s.c	NOUN
ihlr-20834	119	4	.	.	PUNCT
ihlr-20834	120	1	§	§	PROPN
ihlr-20834	120	2	154(a)(1	154(a)(1	NUM
ihlr-20834	120	3	)	)	PUNCT
ihlr-20834	120	4	(	(	PUNCT
ihlr-20834	120	5	2015	2015	NUM
ihlr-20834	120	6	)	)	PUNCT
ihlr-20834	120	7	.	.	PUNCT
ihlr-20834	121	1	35	35	NUM
ihlr-20834	121	2	appendix	appendix	NOUN
ihlr-20834	121	3	l	l	NOUN
ihlr-20834	121	4	consolidated	consolidated	ADJ
ihlr-20834	121	5	patent	patent	NOUN
ihlr-20834	121	6	laws	law	NOUN
ihlr-20834	121	7	,	,	PUNCT
ihlr-20834	121	8	uspto.gov	uspto.gov	PROPN
ihlr-20834	121	9	(	(	PUNCT
ihlr-20834	121	10	last	last	ADJ
ihlr-20834	121	11	visited	visit	VERB
ihlr-20834	121	12	mar	mar	PROPN
ihlr-20834	121	13	.	.	PROPN
ihlr-20834	121	14	16	16	NUM
ihlr-20834	121	15	,	,	PUNCT
ihlr-20834	121	16	2015	2015	NUM
ihlr-20834	121	17	)	)	PUNCT
ihlr-20834	121	18	,	,	PUNCT
ihlr-20834	121	19	http://www.uspto.gov/web/offices/pac/mpep/	http://www.uspto.gov/web/offices/pac/mpep/	NUM
ihlr-20834	121	20	consolidated_laws.pdf	consolidated_laws.pdf	NOUN
ihlr-20834	121	21	.	.	PUNCT
ihlr-20834	122	1	see	see	VERB
ihlr-20834	122	2	35	35	NUM
ihlr-20834	122	3	u.s.c	u.s.c	ADJ
ihlr-20834	122	4	.	.	PUNCT
ihlr-20834	123	1	§	§	PROPN
ihlr-20834	123	2	102	102	NUM
ihlr-20834	123	3	(	(	PUNCT
ihlr-20834	123	4	2015	2015	NUM
ihlr-20834	123	5	)	)	PUNCT
ihlr-20834	123	6	(	(	PUNCT
ihlr-20834	123	7	novelty	novelty	NOUN
ihlr-20834	123	8	)	)	PUNCT
ihlr-20834	123	9	;	;	PUNCT
ihlr-20834	123	10	see	see	VERB
ihlr-20834	123	11	also	also	ADV
ihlr-20834	123	12	cornell	cornell	PROPN
ihlr-20834	123	13	univ	univ	PROPN
ihlr-20834	123	14	.	.	PUNCT
ihlr-20834	124	1	l.	l.	PROPN
ihlr-20834	124	2	sch	sch	PROPN
ihlr-20834	124	3	.	.	PROPN
ihlr-20834	124	4	,	,	PUNCT
ihlr-20834	124	5	overview	overview	NOUN
ihlr-20834	124	6	,	,	PUNCT
ihlr-20834	124	7	legal	legal	ADJ
ihlr-20834	124	8	information	information	NOUN
ihlr-20834	124	9	institute	institute	NOUN
ihlr-20834	124	10	,	,	PUNCT
ihlr-20834	124	11	http://www.law.cornell.edu/wex/patent	http://www.law.cornell.edu/wex/patent	NOUN
ihlr-20834	124	12	(	(	PUNCT
ihlr-20834	124	13	last	last	ADJ
ihlr-20834	124	14	visited	visit	VERB
ihlr-20834	124	15	mar	mar	PROPN
ihlr-20834	124	16	.	.	PROPN
ihlr-20834	124	17	16	16	NUM
ihlr-20834	124	18	,	,	PUNCT
ihlr-20834	124	19	2015	2015	NUM
ihlr-20834	124	20	)	)	PUNCT
ihlr-20834	124	21	(	(	PUNCT
ihlr-20834	124	22	hereinafter	hereinafter	NOUN
ihlr-20834	124	23	overview	overview	NOUN
ihlr-20834	124	24	)	)	PUNCT
ihlr-20834	124	25	(	(	PUNCT
ihlr-20834	124	26	generally	generally	ADV
ihlr-20834	124	27	,	,	PUNCT
ihlr-20834	124	28	novelty	novelty	NOUN
ihlr-20834	124	29	requires	require	VERB
ihlr-20834	124	30	that	that	SCONJ
ihlr-20834	124	31	the	the	DET
ihlr-20834	124	32	invention	invention	NOUN
ihlr-20834	124	33	was	be	AUX
ihlr-20834	124	34	n’t	not	PART
ihlr-20834	124	35	known	know	VERB
ihlr-20834	124	36	or	or	CCONJ
ihlr-20834	124	37	used	use	VERB
ihlr-20834	124	38	by	by	ADP
ihlr-20834	124	39	others	other	NOUN
ihlr-20834	124	40	in	in	ADP
ihlr-20834	124	41	the	the	DET
ihlr-20834	124	42	united	united	PROPN
ihlr-20834	124	43	states	states	PROPN
ihlr-20834	124	44	,	,	PUNCT
ihlr-20834	124	45	or	or	CCONJ
ihlr-20834	124	46	patented	patent	VERB
ihlr-20834	124	47	/	/	SYM
ihlr-20834	124	48	described	describe	VERB
ihlr-20834	124	49	in	in	ADP
ihlr-20834	124	50	print	print	NOUN
ihlr-20834	124	51	or	or	CCONJ
ihlr-20834	124	52	publication	publication	NOUN
ihlr-20834	124	53	in	in	ADP
ihlr-20834	124	54	the	the	DET
ihlr-20834	124	55	united	united	PROPN
ihlr-20834	124	56	states	states	PROPN
ihlr-20834	124	57	or	or	CCONJ
ihlr-20834	124	58	other	other	ADJ
ihlr-20834	124	59	country	country	NOUN
ihlr-20834	124	60	.	.	PUNCT
ihlr-20834	125	1	to	to	PART
ihlr-20834	125	2	meet	meet	VERB
ihlr-20834	125	3	this	this	PRON
ihlr-20834	125	4	,	,	PUNCT
ihlr-20834	125	5	the	the	DET
ihlr-20834	125	6	invention	invention	NOUN
ihlr-20834	125	7	must	must	AUX
ihlr-20834	125	8	be	be	AUX
ihlr-20834	125	9	new	new	ADJ
ihlr-20834	125	10	compared	compare	VERB
ihlr-20834	125	11	to	to	ADP
ihlr-20834	125	12	prior	prior	ADJ
ihlr-20834	125	13	art	art	NOUN
ihlr-20834	125	14	)	)	PUNCT
ihlr-20834	125	15	.	.	PUNCT
ihlr-20834	126	1	see	see	VERB
ihlr-20834	126	2	35	35	NUM
ihlr-20834	126	3	u.s.c	u.s.c	ADJ
ihlr-20834	126	4	.	.	PUNCT
ihlr-20834	127	1	§	§	PROPN
ihlr-20834	127	2	101	101	NUM
ihlr-20834	127	3	(	(	PUNCT
ihlr-20834	127	4	2015	2015	NUM
ihlr-20834	127	5	)	)	PUNCT
ihlr-20834	127	6	(	(	PUNCT
ihlr-20834	127	7	utility	utility	NOUN
ihlr-20834	127	8	)	)	PUNCT
ihlr-20834	127	9	;	;	PUNCT
ihlr-20834	127	10	see	see	VERB
ihlr-20834	127	11	also	also	ADV
ihlr-20834	127	12	overview	overview	VERB
ihlr-20834	127	13	(	(	PUNCT
ihlr-20834	127	14	generally	generally	ADV
ihlr-20834	127	15	,	,	PUNCT
ihlr-20834	127	16	a	a	DET
ihlr-20834	127	17	patent	patent	NOUN
ihlr-20834	127	18	does	do	AUX
ihlr-20834	127	19	not	not	PART
ihlr-20834	127	20	have	have	VERB
ihlr-20834	127	21	to	to	PART
ihlr-20834	127	22	have	have	VERB
ihlr-20834	127	23	any	any	DET
ihlr-20834	127	24	economic	economic	ADJ
ihlr-20834	127	25	value	value	NOUN
ihlr-20834	127	26	whatsoever	whatsoever	ADV
ihlr-20834	127	27	,	,	PUNCT
ihlr-20834	127	28	but	but	CCONJ
ihlr-20834	127	29	it	it	PRON
ihlr-20834	127	30	is	be	AUX
ihlr-20834	127	31	required	require	VERB
ihlr-20834	127	32	that	that	SCONJ
ihlr-20834	127	33	the	the	DET
ihlr-20834	127	34	utility	utility	NOUN
ihlr-20834	127	35	asserted	assert	VERB
ihlr-20834	127	36	in	in	ADP
ihlr-20834	127	37	the	the	DET
ihlr-20834	127	38	application	application	NOUN
ihlr-20834	127	39	be	be	AUX
ihlr-20834	127	40	credible	credible	ADJ
ihlr-20834	127	41	,	,	PUNCT
ihlr-20834	127	42	specific	specific	ADJ
ihlr-20834	127	43	,	,	PUNCT
ihlr-20834	127	44	and	and	CCONJ
ihlr-20834	127	45	substantial	substantial	ADJ
ihlr-20834	127	46	)	)	PUNCT
ihlr-20834	127	47	.	.	PUNCT
ihlr-20834	128	1	see	see	VERB
ihlr-20834	128	2	35	35	NUM
ihlr-20834	128	3	u.s.c	u.s.c	ADJ
ihlr-20834	128	4	.	.	PUNCT
ihlr-20834	129	1	§	§	PROPN
ihlr-20834	129	2	103	103	NUM
ihlr-20834	129	3	(	(	PUNCT
ihlr-20834	129	4	2015	2015	NUM
ihlr-20834	129	5	)	)	PUNCT
ihlr-20834	129	6	(	(	PUNCT
ihlr-20834	129	7	non	non	ADJ
ihlr-20834	129	8	-	-	ADJ
ihlr-20834	129	9	obvious	obvious	ADJ
ihlr-20834	129	10	)	)	PUNCT
ihlr-20834	129	11	;	;	PUNCT
ihlr-20834	129	12	see	see	VERB
ihlr-20834	129	13	also	also	ADV
ihlr-20834	129	14	graham	graham	PROPN
ihlr-20834	129	15	v.	v.	PROPN
ihlr-20834	129	16	john	john	PROPN
ihlr-20834	129	17	deere	deere	PROPN
ihlr-20834	129	18	co.	co.	PROPN
ihlr-20834	129	19	of	of	ADP
ihlr-20834	129	20	kansas	kansas	PROPN
ihlr-20834	129	21	city	city	PROPN
ihlr-20834	129	22	,	,	PUNCT
ihlr-20834	129	23	383	383	NUM
ihlr-20834	129	24	u.s	u.s	PROPN
ihlr-20834	129	25	.	.	PROPN
ihlr-20834	129	26	1	1	NUM
ihlr-20834	129	27	(	(	PUNCT
ihlr-20834	129	28	1966	1966	NUM
ihlr-20834	129	29	)	)	PUNCT
ihlr-20834	129	30	(	(	PUNCT
ihlr-20834	129	31	establishing	establish	VERB
ihlr-20834	129	32	the	the	DET
ihlr-20834	129	33	test	test	NOUN
ihlr-20834	129	34	for	for	ADP
ihlr-20834	129	35	non	non	ADJ
ihlr-20834	129	36	-	-	ADJ
ihlr-20834	129	37	obvious	obvious	ADJ
ihlr-20834	129	38	as	as	ADP
ihlr-20834	129	39	whether	whether	SCONJ
ihlr-20834	129	40	the	the	DET
ihlr-20834	129	41	subject	subject	NOUN
ihlr-20834	129	42	matter	matter	NOUN
ihlr-20834	129	43	sought	seek	VERB
ihlr-20834	129	44	to	to	PART
ihlr-20834	129	45	be	be	AUX
ihlr-20834	129	46	patented	patent	VERB
ihlr-20834	129	47	and	and	CCONJ
ihlr-20834	129	48	prior	prior	ADJ
ihlr-20834	129	49	art	art	NOUN
ihlr-20834	129	50	as	as	ADP
ihlr-20834	129	51	such	such	ADJ
ihlr-20834	129	52	that	that	SCONJ
ihlr-20834	129	53	the	the	DET
ihlr-20834	129	54	subject	subject	NOUN
ihlr-20834	129	55	matter	matter	NOUN
ihlr-20834	129	56	as	as	ADP
ihlr-20834	129	57	a	a	DET
ihlr-20834	129	58	whole	whole	NOUN
ihlr-20834	129	59	would	would	AUX
ihlr-20834	129	60	’ve	’ve	VERB
ihlr-20834	129	61	been	be	AUX
ihlr-20834	129	62	obvious	obvious	ADJ
ihlr-20834	129	63	to	to	ADP
ihlr-20834	129	64	a	a	DET
ihlr-20834	129	65	person	person	NOUN
ihlr-20834	129	66	having	have	VERB
ihlr-20834	129	67	ordinary	ordinary	ADJ
ihlr-20834	129	68	skill	skill	NOUN
ihlr-20834	129	69	in	in	ADP
ihlr-20834	129	70	the	the	DET
ihlr-20834	129	71	art	art	NOUN
ihlr-20834	129	72	at	at	ADP
ihlr-20834	129	73	the	the	DET
ihlr-20834	129	74	time	time	NOUN
ihlr-20834	129	75	the	the	DET
ihlr-20834	129	76	invention	invention	NOUN
ihlr-20834	129	77	was	be	AUX
ihlr-20834	129	78	made	make	VERB
ihlr-20834	129	79	)	)	PUNCT
ihlr-20834	129	80	.	.	PUNCT
ihlr-20834	130	1	36	36	NUM
ihlr-20834	130	2	35	35	NUM
ihlr-20834	130	3	u.s.c	u.s.c	NOUN
ihlr-20834	130	4	.	.	PUNCT
ihlr-20834	131	1	§	§	PROPN
ihlr-20834	131	2	103	103	NUM
ihlr-20834	131	3	(	(	PUNCT
ihlr-20834	131	4	2015	2015	NUM
ihlr-20834	131	5	)	)	PUNCT
ihlr-20834	131	6	.	.	PUNCT
ihlr-20834	132	1	generally	generally	ADV
ihlr-20834	132	2	,	,	PUNCT
ihlr-20834	132	3	laws	law	NOUN
ihlr-20834	132	4	of	of	ADP
ihlr-20834	132	5	nature	nature	NOUN
ihlr-20834	132	6	,	,	PUNCT
ihlr-20834	132	7	physical	physical	ADJ
ihlr-20834	132	8	phenomena	phenomenon	NOUN
ihlr-20834	132	9	and	and	CCONJ
ihlr-20834	132	10	abstract	abstract	ADJ
ihlr-20834	132	11	ideas	idea	NOUN
ihlr-20834	132	12	are	be	AUX
ihlr-20834	132	13	not	not	PART
ihlr-20834	132	14	patentable	patentable	ADJ
ihlr-20834	132	15	.	.	PUNCT
ihlr-20834	133	1	the	the	DET
ihlr-20834	133	2	distinction	distinction	NOUN
ihlr-20834	133	3	between	between	ADP
ihlr-20834	133	4	patentable	patentable	ADJ
ihlr-20834	133	5	and	and	CCONJ
ihlr-20834	133	6	unpatentable	unpatentable	ADJ
ihlr-20834	133	7	subject	subject	ADJ
ihlr-20834	133	8	matter	matter	NOUN
ihlr-20834	133	9	is	be	AUX
ihlr-20834	133	10	between	between	ADP
ihlr-20834	133	11	products	product	NOUN
ihlr-20834	133	12	of	of	ADP
ihlr-20834	133	13	nature	nature	NOUN
ihlr-20834	133	14	,	,	PUNCT
ihlr-20834	133	15	living	living	NOUN
ihlr-20834	133	16	or	or	CCONJ
ihlr-20834	133	17	not	not	PART
ihlr-20834	133	18	,	,	PUNCT
ihlr-20834	133	19	and	and	CCONJ
ihlr-20834	133	20	human	human	NOUN
ihlr-20834	133	21	-	-	PUNCT
ihlr-20834	133	22	made	make	VERB
ihlr-20834	133	23	inventions	invention	NOUN
ihlr-20834	133	24	.	.	PUNCT
ihlr-20834	134	1	37	37	NUM
ihlr-20834	134	2	35	35	NUM
ihlr-20834	134	3	u.s.c	u.s.c	NOUN
ihlr-20834	134	4	.	.	PUNCT
ihlr-20834	135	1	§	§	PROPN
ihlr-20834	135	2	112	112	NUM
ihlr-20834	135	3	(	(	PUNCT
ihlr-20834	135	4	2015	2015	NUM
ihlr-20834	135	5	)	)	PUNCT
ihlr-20834	135	6	.	.	PUNCT
ihlr-20834	136	1	for	for	ADP
ihlr-20834	136	2	a	a	DET
ihlr-20834	136	3	more	more	ADV
ihlr-20834	136	4	detailed	detailed	ADJ
ihlr-20834	136	5	discussion	discussion	NOUN
ihlr-20834	136	6	of	of	ADP
ihlr-20834	136	7	specific	specific	ADJ
ihlr-20834	136	8	written	write	VERB
ihlr-20834	136	9	material	material	NOUN
ihlr-20834	136	10	requirements	requirement	NOUN
ihlr-20834	136	11	,	,	PUNCT
ihlr-20834	136	12	see	see	VERB
ihlr-20834	136	13	patent	patent	NOUN
ihlr-20834	136	14	,	,	PUNCT
ihlr-20834	136	15	legal	legal	ADJ
ihlr-20834	136	16	info	info	NOUN
ihlr-20834	136	17	.	.	PUNCT
ihlr-20834	137	1	inst	inst	PROPN
ihlr-20834	137	2	.	.	PROPN
ihlr-20834	137	3	,	,	PUNCT
ihlr-20834	137	4	https://www.law.cornell.edu/wex/patent	https://www.law.cornell.edu/wex/patent	NOUN
ihlr-20834	137	5	(	(	PUNCT
ihlr-20834	137	6	last	last	ADV
ihlr-20834	137	7	visited	visit	VERB
ihlr-20834	137	8	mar	mar	PROPN
ihlr-20834	137	9	.	.	PROPN
ihlr-20834	137	10	30	30	NUM
ihlr-20834	137	11	,	,	PUNCT
ihlr-20834	137	12	2015	2015	NUM
ihlr-20834	137	13	)	)	PUNCT
ihlr-20834	137	14	(	(	PUNCT
ihlr-20834	137	15	“	"	PUNCT
ihlr-20834	137	16	enablement	enablement	NOUN
ihlr-20834	137	17	is	be	AUX
ihlr-20834	137	18	understood	understand	VERB
ihlr-20834	137	19	as	as	ADP
ihlr-20834	137	20	encompassing	encompass	VERB
ihlr-20834	137	21	three	three	NUM
ihlr-20834	137	22	distinct	distinct	ADJ
ihlr-20834	137	23	requirements	requirement	NOUN
ihlr-20834	137	24	:	:	PUNCT
ihlr-20834	137	25	the	the	DET
ihlr-20834	137	26	enablement	enablement	NOUN
ihlr-20834	137	27	requirement	requirement	NOUN
ihlr-20834	137	28	,	,	PUNCT
ihlr-20834	137	29	the	the	DET
ihlr-20834	137	30	written	write	VERB
ihlr-20834	137	31	description	description	NOUN
ihlr-20834	137	32	requirement	requirement	NOUN
ihlr-20834	137	33	,	,	PUNCT
ihlr-20834	137	34	and	and	CCONJ
ihlr-20834	137	35	the	the	DET
ihlr-20834	137	36	best	good	ADJ
ihlr-20834	137	37	mode	mode	NOUN
ihlr-20834	137	38	requirement	requirement	NOUN
ihlr-20834	137	39	.	.	PUNCT
ihlr-20834	137	40	”	"	PUNCT
ihlr-20834	137	41	)	)	PUNCT
ihlr-20834	137	42	.	.	PUNCT
ihlr-20834	138	1	2015	2015	NUM
ihlr-20834	138	2	777	777	NUM
ihlr-20834	138	3	the	the	DET
ihlr-20834	138	4	supreme	supreme	PROPN
ihlr-20834	138	5	court	court	PROPN
ihlr-20834	138	6	’s	’s	PART
ihlr-20834	138	7	overreaching	overreach	VERB
ihlr-20834	138	8	preemption	preemption	NOUN
ihlr-20834	138	9	interpretation	interpretation	NOUN
ihlr-20834	138	10	and	and	CCONJ
ihlr-20834	138	11	it	it	PRON
ihlr-20834	138	12	’s	’	VERB
ihlr-20834	138	13	consequences	consequence	NOUN
ihlr-20834	138	14	enter	enter	VERB
ihlr-20834	138	15	into	into	ADP
ihlr-20834	138	16	the	the	DET
ihlr-20834	138	17	drug	drug	NOUN
ihlr-20834	138	18	market	market	NOUN
ihlr-20834	138	19	through	through	ADP
ihlr-20834	138	20	an	an	DET
ihlr-20834	138	21	abbreviated	abbreviate	VERB
ihlr-20834	138	22	approval	approval	NOUN
ihlr-20834	138	23	process.38	process.38	NOUN
ihlr-20834	138	24	2	2	X
ihlr-20834	138	25	.	.	PUNCT
ihlr-20834	139	1	the	the	DET
ihlr-20834	139	2	federal	federal	ADJ
ihlr-20834	139	3	food	food	NOUN
ihlr-20834	139	4	and	and	CCONJ
ihlr-20834	139	5	drugs	drug	NOUN
ihlr-20834	139	6	act	act	PROPN
ihlr-20834	139	7	,	,	PUNCT
ihlr-20834	139	8	the	the	DET
ihlr-20834	139	9	food	food	NOUN
ihlr-20834	139	10	drug	drug	NOUN
ihlr-20834	139	11	and	and	CCONJ
ihlr-20834	139	12	cosmetics	cosmetic	NOUN
ihlr-20834	139	13	act	act	NOUN
ihlr-20834	139	14	,	,	PUNCT
ihlr-20834	139	15	and	and	CCONJ
ihlr-20834	139	16	hatch	hatch	NOUN
ihlr-20834	139	17	-	-	PUNCT
ihlr-20834	139	18	waxman	waxman	PROPN
ihlr-20834	139	19	act	act	VERB
ihlr-20834	139	20	the	the	DET
ihlr-20834	139	21	origin	origin	NOUN
ihlr-20834	139	22	of	of	ADP
ihlr-20834	139	23	regulations	regulation	NOUN
ihlr-20834	139	24	for	for	ADP
ihlr-20834	139	25	health	health	NOUN
ihlr-20834	139	26	consumer	consumer	NOUN
ihlr-20834	139	27	goods	good	NOUN
ihlr-20834	139	28	was	be	AUX
ihlr-20834	139	29	created	create	VERB
ihlr-20834	139	30	in	in	ADP
ihlr-20834	139	31	1906	1906	NUM
ihlr-20834	139	32	.	.	PUNCT
ihlr-20834	140	1	the	the	DET
ihlr-20834	140	2	1906	1906	NUM
ihlr-20834	140	3	passage	passage	NOUN
ihlr-20834	140	4	of	of	ADP
ihlr-20834	140	5	the	the	DET
ihlr-20834	140	6	pure	pure	ADJ
ihlr-20834	140	7	food	food	NOUN
ihlr-20834	140	8	and	and	CCONJ
ihlr-20834	140	9	drugs	drug	NOUN
ihlr-20834	140	10	act	act	VERB
ihlr-20834	140	11	(	(	PUNCT
ihlr-20834	140	12	“	"	PUNCT
ihlr-20834	140	13	pfda	pfda	PROPN
ihlr-20834	140	14	”	"	PUNCT
ihlr-20834	140	15	)	)	PUNCT
ihlr-20834	140	16	began	begin	VERB
ihlr-20834	140	17	the	the	DET
ihlr-20834	140	18	fda	fda	PROPN
ihlr-20834	140	19	’s	’s	PART
ihlr-20834	140	20	origin	origin	NOUN
ihlr-20834	140	21	as	as	ADP
ihlr-20834	140	22	a	a	DET
ihlr-20834	140	23	federal	federal	ADJ
ihlr-20834	140	24	consumer	consumer	NOUN
ihlr-20834	140	25	protection	protection	NOUN
ihlr-20834	140	26	agency.39	agency.39	PROPN
ihlr-20834	140	27	the	the	DET
ihlr-20834	140	28	fda	fda	PROPN
ihlr-20834	140	29	’s	’s	PART
ihlr-20834	140	30	responsibilities	responsibility	NOUN
ihlr-20834	140	31	have	have	AUX
ihlr-20834	140	32	been	be	AUX
ihlr-20834	140	33	amended	amend	VERB
ihlr-20834	140	34	since	since	SCONJ
ihlr-20834	140	35	the	the	DET
ihlr-20834	140	36	initial	initial	ADJ
ihlr-20834	140	37	passage	passage	NOUN
ihlr-20834	140	38	of	of	ADP
ihlr-20834	140	39	the	the	DET
ihlr-20834	140	40	pfda	pfda	PROPN
ihlr-20834	140	41	and	and	CCONJ
ihlr-20834	140	42	the	the	DET
ihlr-20834	140	43	fda	fda	PROPN
ihlr-20834	140	44	’s	’s	PART
ihlr-20834	140	45	current	current	ADJ
ihlr-20834	140	46	responsibilities	responsibility	NOUN
ihlr-20834	140	47	in	in	ADP
ihlr-20834	140	48	the	the	DET
ihlr-20834	140	49	pharmaceutical	pharmaceutical	NOUN
ihlr-20834	140	50	industry	industry	NOUN
ihlr-20834	140	51	involve	involve	VERB
ihlr-20834	140	52	overseeing	oversee	VERB
ihlr-20834	140	53	drug	drug	NOUN
ihlr-20834	140	54	approval	approval	NOUN
ihlr-20834	140	55	and	and	CCONJ
ihlr-20834	140	56	post	post	VERB
ihlr-20834	140	57	approval	approval	NOUN
ihlr-20834	140	58	safety.40	safety.40	PROPN
ihlr-20834	140	59	the	the	DET
ihlr-20834	140	60	fda	fda	PROPN
ihlr-20834	140	61	acts	act	VERB
ihlr-20834	140	62	as	as	ADP
ihlr-20834	140	63	a	a	DET
ihlr-20834	140	64	gatekeeper	gatekeeper	NOUN
ihlr-20834	140	65	and	and	CCONJ
ihlr-20834	140	66	the	the	DET
ihlr-20834	140	67	agency	agency	NOUN
ihlr-20834	140	68	plays	play	VERB
ihlr-20834	140	69	an	an	DET
ihlr-20834	140	70	important	important	ADJ
ihlr-20834	140	71	role	role	NOUN
ihlr-20834	140	72	in	in	ADP
ihlr-20834	140	73	pharmaceutical	pharmaceutical	ADJ
ihlr-20834	140	74	regulation.41	regulation.41	NOUN
ihlr-20834	140	75	prior	prior	ADV
ihlr-20834	140	76	to	to	ADP
ihlr-20834	140	77	the	the	DET
ihlr-20834	140	78	pfda	pfda	PROPN
ihlr-20834	140	79	,	,	PUNCT
ihlr-20834	140	80	the	the	DET
ihlr-20834	140	81	“	"	PUNCT
ihlr-20834	140	82	[	[	X
ihlr-20834	140	83	u]se	u]se	PROPN
ihlr-20834	140	84	of	of	ADP
ihlr-20834	140	85	chemical	chemical	NOUN
ihlr-20834	140	86	preservatives	preservative	NOUN
ihlr-20834	140	87	.	.	PUNCT
ihlr-20834	140	88	.	.	PUNCT
ihlr-20834	141	1	.	.	PUNCT
ihlr-20834	142	1	was	be	AUX
ihlr-20834	142	2	virtually	virtually	ADV
ihlr-20834	142	3	uncontrolled	uncontrolled	ADJ
ihlr-20834	142	4	.	.	PUNCT
ihlr-20834	143	1	”42	”42	NOUN
ihlr-20834	143	2	manufacturers	manufacturer	NOUN
ihlr-20834	143	3	were	be	AUX
ihlr-20834	143	4	not	not	PART
ihlr-20834	143	5	subject	subject	ADJ
ihlr-20834	143	6	to	to	ADP
ihlr-20834	143	7	any	any	DET
ihlr-20834	143	8	approval	approval	NOUN
ihlr-20834	143	9	process	process	NOUN
ihlr-20834	143	10	and	and	CCONJ
ihlr-20834	143	11	could	could	AUX
ihlr-20834	143	12	freely	freely	ADV
ihlr-20834	143	13	enter	enter	VERB
ihlr-20834	143	14	the	the	DET
ihlr-20834	143	15	market	market	NOUN
ihlr-20834	143	16	and	and	CCONJ
ihlr-20834	143	17	sell	sell	VERB
ihlr-20834	143	18	drugs	drug	NOUN
ihlr-20834	143	19	.	.	PUNCT
ihlr-20834	144	1	the	the	DET
ihlr-20834	144	2	pfda	pfda	PROPN
ihlr-20834	144	3	passage43	passage43	NOUN
ihlr-20834	144	4	helped	helped	AUX
ihlr-20834	144	5	address	address	VERB
ihlr-20834	144	6	38	38	NUM
ihlr-20834	144	7	see	see	NOUN
ihlr-20834	144	8	infra	infra	NOUN
ihlr-20834	144	9	note	note	VERB
ihlr-20834	144	10	40	40	NUM
ihlr-20834	144	11	.	.	PUNCT
ihlr-20834	145	1	see	see	VERB
ihlr-20834	145	2	also	also	ADV
ihlr-20834	145	3	how	how	SCONJ
ihlr-20834	145	4	increased	increase	VERB
ihlr-20834	145	5	competition	competition	NOUN
ihlr-20834	145	6	from	from	ADP
ihlr-20834	145	7	generic	generic	ADJ
ihlr-20834	145	8	drugs	drug	NOUN
ihlr-20834	145	9	has	have	AUX
ihlr-20834	145	10	affected	affect	VERB
ihlr-20834	145	11	prices	price	NOUN
ihlr-20834	145	12	and	and	CCONJ
ihlr-20834	145	13	returns	return	NOUN
ihlr-20834	145	14	in	in	ADP
ihlr-20834	145	15	the	the	DET
ihlr-20834	145	16	pharmaceutical	pharmaceutical	ADJ
ihlr-20834	145	17	industry	industry	NOUN
ihlr-20834	145	18	,	,	PUNCT
ihlr-20834	145	19	cong	cong	NOUN
ihlr-20834	145	20	.	.	PUNCT
ihlr-20834	146	1	budget	budget	NOUN
ihlr-20834	146	2	off	off	ADP
ihlr-20834	146	3	.	.	PUNCT
ihlr-20834	147	1	,	,	PUNCT
ihlr-20834	147	2	http://www.cbo.gov/publication/	http://www.cbo.gov/publication/	PROPN
ihlr-20834	147	3	10938?index=655	10938?index=655	PROPN
ihlr-20834	147	4	(	(	PUNCT
ihlr-20834	147	5	last	last	ADV
ihlr-20834	147	6	visited	visit	VERB
ihlr-20834	147	7	mar	mar	PROPN
ihlr-20834	147	8	.	.	PROPN
ihlr-20834	147	9	16	16	NUM
ihlr-20834	147	10	,	,	PUNCT
ihlr-20834	147	11	2015	2015	NUM
ihlr-20834	147	12	)	)	PUNCT
ihlr-20834	147	13	(	(	PUNCT
ihlr-20834	147	14	hereinafter	hereinafter	VERB
ihlr-20834	147	15	how	how	SCONJ
ihlr-20834	147	16	increased	increase	VERB
ihlr-20834	147	17	competition	competition	NOUN
ihlr-20834	147	18	has	have	AUX
ihlr-20834	147	19	affected	affect	VERB
ihlr-20834	147	20	prices	price	NOUN
ihlr-20834	147	21	and	and	CCONJ
ihlr-20834	147	22	returns	return	NOUN
ihlr-20834	147	23	)	)	PUNCT
ihlr-20834	147	24	.	.	PUNCT
ihlr-20834	148	1	39	39	NUM
ihlr-20834	148	2	about	about	ADP
ihlr-20834	148	3	fda	fda	PROPN
ihlr-20834	148	4	:	:	PUNCT
ihlr-20834	148	5	when	when	SCONJ
ihlr-20834	148	6	and	and	CCONJ
ihlr-20834	148	7	why	why	SCONJ
ihlr-20834	148	8	was	be	AUX
ihlr-20834	148	9	fda	fda	PROPN
ihlr-20834	148	10	formed	form	VERB
ihlr-20834	148	11	?	?	PUNCT
ihlr-20834	148	12	,	,	PUNCT
ihlr-20834	148	13	u.s	u.s	PROPN
ihlr-20834	148	14	.	.	PROPN
ihlr-20834	148	15	food	food	PROPN
ihlr-20834	148	16	&	&	CCONJ
ihlr-20834	148	17	drug	drug	PROPN
ihlr-20834	148	18	admin	admin	PROPN
ihlr-20834	148	19	.	.	PROPN
ihlr-20834	148	20	,	,	PUNCT
ihlr-20834	148	21	http://www.fda.gov/aboutfda/transparency/	http://www.fda.gov/aboutfda/transparency/	PROPN
ihlr-20834	148	22	basics	basic	NOUN
ihlr-20834	148	23	/	/	SYM
ihlr-20834	148	24	ucm214403.htm	ucm214403.htm	NOUN
ihlr-20834	148	25	(	(	PUNCT
ihlr-20834	148	26	last	last	ADJ
ihlr-20834	148	27	visited	visit	VERB
ihlr-20834	148	28	mar	mar	PROPN
ihlr-20834	148	29	.	.	PROPN
ihlr-20834	148	30	16	16	NUM
ihlr-20834	148	31	,	,	PUNCT
ihlr-20834	148	32	2015	2015	NUM
ihlr-20834	148	33	)	)	PUNCT
ihlr-20834	148	34	.	.	PUNCT
ihlr-20834	149	1	40	40	NUM
ihlr-20834	149	2	about	about	ADP
ihlr-20834	149	3	fda	fda	PROPN
ihlr-20834	149	4	:	:	PUNCT
ihlr-20834	149	5	office	office	NOUN
ihlr-20834	149	6	of	of	ADP
ihlr-20834	149	7	medical	medical	ADJ
ihlr-20834	149	8	products	product	NOUN
ihlr-20834	149	9	and	and	CCONJ
ihlr-20834	149	10	tobacco	tobacco	NOUN
ihlr-20834	149	11	,	,	PUNCT
ihlr-20834	149	12	u.s	u.s	PROPN
ihlr-20834	149	13	.	.	PROPN
ihlr-20834	149	14	food	food	PROPN
ihlr-20834	149	15	&	&	CCONJ
ihlr-20834	149	16	drug	drug	PROPN
ihlr-20834	149	17	admin	admin	PROPN
ihlr-20834	149	18	.	.	PUNCT
ihlr-20834	149	19	,	,	PUNCT
ihlr-20834	149	20	http://www.fda.gov/aboutfda/centersoffices/	http://www.fda.gov/aboutfda/centersoffices/	PROPN
ihlr-20834	149	21	officeofmedicalproductsandtobacco	officeofmedicalproductsandtobacco	PROPN
ihlr-20834	149	22	/	/	SYM
ihlr-20834	149	23	ucm20025997.htm	ucm20025997.htm	PROPN
ihlr-20834	149	24	(	(	PUNCT
ihlr-20834	149	25	last	last	ADJ
ihlr-20834	149	26	visited	visit	VERB
ihlr-20834	149	27	mar	mar	PROPN
ihlr-20834	149	28	.	.	PROPN
ihlr-20834	149	29	16	16	NUM
ihlr-20834	149	30	,	,	PUNCT
ihlr-20834	149	31	2015	2015	NUM
ihlr-20834	149	32	)	)	PUNCT
ihlr-20834	149	33	.	.	PUNCT
ihlr-20834	150	1	41	41	NUM
ihlr-20834	150	2	steele	steele	PROPN
ihlr-20834	150	3	,	,	PUNCT
ihlr-20834	150	4	supra	supra	PROPN
ihlr-20834	150	5	note	note	VERB
ihlr-20834	150	6	7	7	NUM
ihlr-20834	150	7	at	at	ADP
ihlr-20834	150	8	469	469	NUM
ihlr-20834	150	9	(	(	PUNCT
ihlr-20834	150	10	the	the	DET
ihlr-20834	150	11	united	united	PROPN
ihlr-20834	150	12	state	state	PROPN
ihlr-20834	150	13	government	government	NOUN
ihlr-20834	150	14	and	and	CCONJ
ihlr-20834	150	15	accountability	accountability	NOUN
ihlr-20834	150	16	office	office	NOUN
ihlr-20834	150	17	(	(	PUNCT
ihlr-20834	150	18	“	"	PUNCT
ihlr-20834	150	19	gao	gao	PROPN
ihlr-20834	150	20	”	"	PUNCT
ihlr-20834	150	21	)	)	PUNCT
ihlr-20834	150	22	has	have	AUX
ihlr-20834	150	23	raised	raise	VERB
ihlr-20834	150	24	concerns	concern	NOUN
ihlr-20834	150	25	over	over	ADP
ihlr-20834	150	26	the	the	DET
ihlr-20834	150	27	fda	fda	PROPN
ihlr-20834	150	28	’s	’s	PART
ihlr-20834	150	29	“	"	PUNCT
ihlr-20834	150	30	management	management	NOUN
ihlr-20834	150	31	of	of	ADP
ihlr-20834	150	32	safety	safety	NOUN
ihlr-20834	150	33	issues	issue	NOUN
ihlr-20834	150	34	for	for	ADP
ihlr-20834	150	35	drugs	drug	NOUN
ihlr-20834	150	36	approved	approve	VERB
ihlr-20834	150	37	for	for	ADP
ihlr-20834	150	38	marketing	marketing	NOUN
ihlr-20834	150	39	.	.	PUNCT
ihlr-20834	150	40	”	"	PUNCT
ihlr-20834	151	1	the	the	DET
ihlr-20834	151	2	fda	fda	PROPN
ihlr-20834	151	3	staff	staff	NOUN
ihlr-20834	151	4	has	have	AUX
ihlr-20834	151	5	“	"	PUNCT
ihlr-20834	151	6	expressed	express	VERB
ihlr-20834	151	7	concern	concern	NOUN
ihlr-20834	151	8	about	about	ADP
ihlr-20834	151	9	their	their	PRON
ihlr-20834	151	10	ability	ability	NOUN
ihlr-20834	151	11	to	to	PART
ihlr-20834	151	12	meet	meet	VERB
ihlr-20834	151	13	a	a	DET
ihlr-20834	151	14	growing	grow	VERB
ihlr-20834	151	15	post	post	NOUN
ihlr-20834	151	16	market	market	NOUN
ihlr-20834	151	17	workload	workload	NOUN
ihlr-20834	151	18	,	,	PUNCT
ihlr-20834	151	19	with	with	ADP
ihlr-20834	151	20	some	some	PRON
ihlr-20834	151	21	maintaining	maintain	VERB
ihlr-20834	151	22	that	that	SCONJ
ihlr-20834	151	23	their	their	PRON
ihlr-20834	151	24	premarket	premarket	NOUN
ihlr-20834	151	25	responsibilities	responsibility	NOUN
ihlr-20834	151	26	are	be	AUX
ihlr-20834	151	27	considered	consider	VERB
ihlr-20834	151	28	a	a	DET
ihlr-20834	151	29	higher	high	ADJ
ihlr-20834	151	30	priority	priority	NOUN
ihlr-20834	151	31	.	.	PUNCT
ihlr-20834	151	32	”	"	PUNCT
ihlr-20834	152	1	(	(	PUNCT
ihlr-20834	152	2	citations	citation	NOUN
ihlr-20834	152	3	omitted	omit	VERB
ihlr-20834	152	4	)	)	PUNCT
ihlr-20834	152	5	)	)	PUNCT
ihlr-20834	152	6	.	.	PUNCT
ihlr-20834	153	1	42	42	NUM
ihlr-20834	153	2	wallace	wallace	PROPN
ihlr-20834	153	3	f.	f.	PROPN
ihlr-20834	153	4	janssen	janssen	PROPN
ihlr-20834	153	5	,	,	PUNCT
ihlr-20834	153	6	the	the	DET
ihlr-20834	153	7	story	story	NOUN
ihlr-20834	153	8	of	of	ADP
ihlr-20834	153	9	the	the	DET
ihlr-20834	153	10	laws	law	NOUN
ihlr-20834	153	11	behind	behind	ADP
ihlr-20834	153	12	the	the	DET
ihlr-20834	153	13	labels	label	NOUN
ihlr-20834	153	14	,	,	PUNCT
ihlr-20834	153	15	u.s	u.s	PROPN
ihlr-20834	153	16	.	.	PROPN
ihlr-20834	153	17	food	food	PROPN
ihlr-20834	153	18	&	&	CCONJ
ihlr-20834	153	19	drug	drug	PROPN
ihlr-20834	153	20	admin	admin	PROPN
ihlr-20834	153	21	.	.	PUNCT
ihlr-20834	153	22	(	(	PUNCT
ihlr-20834	153	23	june	june	PROPN
ihlr-20834	153	24	1981	1981	NUM
ihlr-20834	153	25	)	)	PUNCT
ihlr-20834	153	26	,	,	PUNCT
ihlr-20834	153	27	http://www.fda.gov/aboutfda	http://www.fda.gov/aboutfda	X
ihlr-20834	153	28	/whatwedo	/whatwedo	ADJ
ihlr-20834	153	29	/	/	SYM
ihlr-20834	153	30	history	history	NOUN
ihlr-20834	153	31	/	/	SYM
ihlr-20834	153	32	overviews	overview	NOUN
ihlr-20834	153	33	/	/	SYM
ihlr-20834	153	34	ucm056044.htm	ucm056044.htm	NOUN
ihlr-20834	153	35	.	.	PUNCT
ihlr-20834	154	1	43	43	NUM
ihlr-20834	154	2	34	34	NUM
ihlr-20834	154	3	stat	stat	NOUN
ihlr-20834	154	4	.	.	PUNCT
ihlr-20834	155	1	768	768	NUM
ihlr-20834	155	2	(	(	PUNCT
ihlr-20834	155	3	1906	1906	NUM
ihlr-20834	155	4	)	)	PUNCT
ihlr-20834	155	5	(	(	PUNCT
ihlr-20834	155	6	repealed	repeal	VERB
ihlr-20834	155	7	in	in	ADP
ihlr-20834	155	8	1938	1938	NUM
ihlr-20834	155	9	by	by	ADP
ihlr-20834	155	10	21	21	NUM
ihlr-20834	155	11	u.s.c	u.s.c	NOUN
ihlr-20834	155	12	.	.	PUNCT
ihlr-20834	156	1	§	§	PROPN
ihlr-20834	156	2	329(a	329(a	PROPN
ihlr-20834	156	3	)	)	PUNCT
ihlr-20834	156	4	)	)	PUNCT
ihlr-20834	156	5	.	.	PUNCT
ihlr-20834	157	1	778	778	NUM
ihlr-20834	157	2	indiana	indiana	PROPN
ihlr-20834	157	3	health	health	PROPN
ihlr-20834	157	4	law	law	PROPN
ihlr-20834	157	5	review	review	NOUN
ihlr-20834	157	6	vol	vol	NOUN
ihlr-20834	157	7	.	.	PUNCT
ihlr-20834	158	1	12:2	12:2	NUM
ihlr-20834	158	2	the	the	DET
ihlr-20834	158	3	uncontrolled	uncontrolled	ADJ
ihlr-20834	158	4	industry	industry	NOUN
ihlr-20834	158	5	by	by	ADP
ihlr-20834	158	6	prohibiting	prohibit	VERB
ihlr-20834	158	7	the	the	DET
ihlr-20834	158	8	manufacturing	manufacturing	NOUN
ihlr-20834	158	9	or	or	CCONJ
ihlr-20834	158	10	interstate	interstate	ADJ
ihlr-20834	158	11	shipment	shipment	NOUN
ihlr-20834	158	12	of	of	ADP
ihlr-20834	158	13	adulterated	adulterate	VERB
ihlr-20834	158	14	or	or	CCONJ
ihlr-20834	158	15	misbranded	misbranded	ADJ
ihlr-20834	158	16	drugs	drug	NOUN
ihlr-20834	158	17	.	.	PUNCT
ihlr-20834	159	1	the	the	DET
ihlr-20834	159	2	pfda	pfda	PROPN
ihlr-20834	159	3	also	also	ADV
ihlr-20834	159	4	helped	help	VERB
ihlr-20834	159	5	by	by	ADP
ihlr-20834	159	6	supplementing	supplement	VERB
ihlr-20834	159	7	consumer	consumer	NOUN
ihlr-20834	159	8	protections	protection	NOUN
ihlr-20834	159	9	already	already	ADV
ihlr-20834	159	10	provided	provide	VERB
ihlr-20834	159	11	by	by	ADP
ihlr-20834	159	12	state	state	NOUN
ihlr-20834	159	13	regulation	regulation	NOUN
ihlr-20834	159	14	and	and	CCONJ
ihlr-20834	159	15	common	common	ADJ
ihlr-20834	159	16	law	law	NOUN
ihlr-20834	159	17	liability	liability	NOUN
ihlr-20834	159	18	.	.	PUNCT
ihlr-20834	159	19	44	44	NUM
ihlr-20834	159	20	after	after	ADP
ihlr-20834	159	21	expressing	express	VERB
ihlr-20834	159	22	concern	concern	NOUN
ihlr-20834	159	23	about	about	ADP
ihlr-20834	159	24	unsafe	unsafe	ADJ
ihlr-20834	159	25	drugs	drug	NOUN
ihlr-20834	159	26	and	and	CCONJ
ihlr-20834	159	27	fraudulent	fraudulent	ADJ
ihlr-20834	159	28	marketing	marketing	NOUN
ihlr-20834	159	29	,	,	PUNCT
ihlr-20834	159	30	congress	congress	PROPN
ihlr-20834	159	31	enacted	enact	VERB
ihlr-20834	159	32	the	the	DET
ihlr-20834	159	33	federal	federal	ADJ
ihlr-20834	159	34	food	food	NOUN
ihlr-20834	159	35	,	,	PUNCT
ihlr-20834	159	36	drug	drug	NOUN
ihlr-20834	159	37	,	,	PUNCT
ihlr-20834	159	38	and	and	CCONJ
ihlr-20834	159	39	cosmetic	cosmetic	ADJ
ihlr-20834	159	40	act	act	NOUN
ihlr-20834	159	41	(	(	PUNCT
ihlr-20834	159	42	“	"	PUNCT
ihlr-20834	159	43	fdca”).45	fdca”).45	VERB
ihlr-20834	159	44	this	this	PRON
ihlr-20834	159	45	required	require	VERB
ihlr-20834	159	46	the	the	DET
ihlr-20834	159	47	premarket	premarket	NOUN
ihlr-20834	159	48	approval	approval	NOUN
ihlr-20834	159	49	of	of	ADP
ihlr-20834	159	50	new	new	ADJ
ihlr-20834	159	51	drugs	drug	NOUN
ihlr-20834	159	52	by	by	ADP
ihlr-20834	159	53	requiring	require	VERB
ihlr-20834	159	54	every	every	DET
ihlr-20834	159	55	drug	drug	NOUN
ihlr-20834	159	56	manufacturer	manufacturer	NOUN
ihlr-20834	159	57	to	to	PART
ihlr-20834	159	58	submit	submit	VERB
ihlr-20834	159	59	a	a	DET
ihlr-20834	159	60	new	new	ADJ
ihlr-20834	159	61	drug	drug	NOUN
ihlr-20834	159	62	application	application	NOUN
ihlr-20834	159	63	(	(	PUNCT
ihlr-20834	159	64	“	"	PUNCT
ihlr-20834	159	65	nda	nda	PROPN
ihlr-20834	159	66	”	"	PUNCT
ihlr-20834	159	67	)	)	PUNCT
ihlr-20834	159	68	,	,	PUNCT
ihlr-20834	159	69	including	include	VERB
ihlr-20834	159	70	all	all	DET
ihlr-20834	159	71	reports	report	NOUN
ihlr-20834	159	72	and	and	CCONJ
ihlr-20834	159	73	investigations	investigation	NOUN
ihlr-20834	159	74	,	,	PUNCT
ihlr-20834	159	75	to	to	ADP
ihlr-20834	159	76	the	the	DET
ihlr-20834	159	77	fda	fda	PROPN
ihlr-20834	159	78	for	for	ADP
ihlr-20834	159	79	review.46	review.46	PROPN
ihlr-20834	159	80	congress	congress	PROPN
ihlr-20834	159	81	amended	amend	VERB
ihlr-20834	159	82	the	the	DET
ihlr-20834	159	83	fdca	fdca	NOUN
ihlr-20834	159	84	in	in	ADP
ihlr-20834	159	85	1962	1962	NUM
ihlr-20834	159	86	.	.	PUNCT
ihlr-20834	160	1	47	47	NUM
ihlr-20834	160	2	this	this	DET
ihlr-20834	160	3	amendment	amendment	NOUN
ihlr-20834	160	4	shifted	shift	VERB
ihlr-20834	160	5	the	the	DET
ihlr-20834	160	6	burden	burden	NOUN
ihlr-20834	160	7	of	of	ADP
ihlr-20834	160	8	proof	proof	NOUN
ihlr-20834	160	9	from	from	ADP
ihlr-20834	160	10	the	the	DET
ihlr-20834	160	11	fda	fda	PROPN
ihlr-20834	160	12	to	to	ADP
ihlr-20834	160	13	the	the	DET
ihlr-20834	160	14	manufacturer	manufacturer	NOUN
ihlr-20834	160	15	to	to	PART
ihlr-20834	160	16	gain	gain	VERB
ihlr-20834	160	17	drug	drug	NOUN
ihlr-20834	160	18	approval	approval	NOUN
ihlr-20834	160	19	.	.	PUNCT
ihlr-20834	161	1	this	this	DET
ihlr-20834	161	2	amendment	amendment	NOUN
ihlr-20834	161	3	also	also	ADV
ihlr-20834	161	4	requires	require	VERB
ihlr-20834	161	5	manufacturers	manufacturer	NOUN
ihlr-20834	161	6	to	to	PART
ihlr-20834	161	7	prove	prove	VERB
ihlr-20834	161	8	a	a	DET
ihlr-20834	161	9	drug	drug	NOUN
ihlr-20834	161	10	’s	’s	PART
ihlr-20834	161	11	effectiveness	effectiveness	NOUN
ihlr-20834	161	12	by	by	ADP
ihlr-20834	161	13	introducing	introduce	VERB
ihlr-20834	161	14	“	"	PUNCT
ihlr-20834	161	15	substantial	substantial	ADJ
ihlr-20834	161	16	evidence	evidence	NOUN
ihlr-20834	161	17	.	.	PUNCT
ihlr-20834	161	18	.	.	PUNCT
ihlr-20834	161	19	.	.	PUNCT
ihlr-20834	162	1	that	that	SCONJ
ihlr-20834	162	2	the	the	DET
ihlr-20834	162	3	drug	drug	NOUN
ihlr-20834	162	4	will	will	AUX
ihlr-20834	162	5	have	have	VERB
ihlr-20834	162	6	the	the	DET
ihlr-20834	162	7	effect	effect	NOUN
ihlr-20834	162	8	it	it	PRON
ihlr-20834	162	9	purports	purport	VERB
ihlr-20834	162	10	or	or	CCONJ
ihlr-20834	162	11	is	be	AUX
ihlr-20834	162	12	represented	represent	VERB
ihlr-20834	162	13	to	to	PART
ihlr-20834	162	14	have	have	VERB
ihlr-20834	162	15	under	under	ADP
ihlr-20834	162	16	the	the	DET
ihlr-20834	162	17	conditions	condition	NOUN
ihlr-20834	162	18	of	of	ADP
ihlr-20834	162	19	use	use	NOUN
ihlr-20834	162	20	prescribed	prescribe	VERB
ihlr-20834	162	21	,	,	PUNCT
ihlr-20834	162	22	recommended	recommend	VERB
ihlr-20834	162	23	,	,	PUNCT
ihlr-20834	162	24	or	or	CCONJ
ihlr-20834	162	25	suggested	suggest	VERB
ihlr-20834	162	26	in	in	ADP
ihlr-20834	162	27	the	the	DET
ihlr-20834	162	28	proposed	propose	VERB
ihlr-20834	162	29	labeling	labeling	NOUN
ihlr-20834	162	30	.	.	PUNCT
ihlr-20834	163	1	”48	”48	PROPN
ihlr-20834	163	2	furthermore	furthermore	ADV
ihlr-20834	163	3	,	,	PUNCT
ihlr-20834	163	4	this	this	DET
ihlr-20834	163	5	amendment	amendment	NOUN
ihlr-20834	163	6	added	add	VERB
ihlr-20834	163	7	a	a	DET
ihlr-20834	163	8	clause	clause	NOUN
ihlr-20834	163	9	stating	state	VERB
ihlr-20834	163	10	that	that	SCONJ
ihlr-20834	163	11	state	state	NOUN
ihlr-20834	163	12	law	law	NOUN
ihlr-20834	163	13	would	would	AUX
ihlr-20834	163	14	be	be	AUX
ihlr-20834	163	15	invalidated	invalidate	VERB
ihlr-20834	163	16	only	only	ADV
ihlr-20834	163	17	upon	upon	SCONJ
ihlr-20834	163	18	a	a	DET
ihlr-20834	163	19	“	"	PUNCT
ihlr-20834	163	20	direct	direct	ADJ
ihlr-20834	163	21	and	and	CCONJ
ihlr-20834	163	22	positive	positive	ADJ
ihlr-20834	163	23	conflict	conflict	NOUN
ihlr-20834	163	24	”	"	PUNCT
ihlr-20834	163	25	with	with	ADP
ihlr-20834	163	26	the	the	DET
ihlr-20834	163	27	fdca.49	fdca.49	NOUN
ihlr-20834	163	28	this	this	DET
ihlr-20834	163	29	clause	clause	NOUN
ihlr-20834	163	30	remains	remain	VERB
ihlr-20834	163	31	important	important	ADJ
ihlr-20834	163	32	to	to	ADP
ihlr-20834	163	33	current	current	ADJ
ihlr-20834	163	34	preemption	preemption	NOUN
ihlr-20834	163	35	analysis	analysis	NOUN
ihlr-20834	163	36	and	and	CCONJ
ihlr-20834	163	37	it	it	PRON
ihlr-20834	163	38	will	will	AUX
ihlr-20834	163	39	be	be	AUX
ihlr-20834	163	40	analyzed	analyze	VERB
ihlr-20834	163	41	in	in	ADP
ihlr-20834	163	42	depth	depth	NOUN
ihlr-20834	163	43	below	below	ADV
ihlr-20834	163	44	.	.	PUNCT
ihlr-20834	164	1	congress	congress	PROPN
ihlr-20834	164	2	sought	seek	VERB
ihlr-20834	164	3	to	to	PART
ihlr-20834	164	4	facilitate	facilitate	VERB
ihlr-20834	164	5	the	the	DET
ihlr-20834	164	6	quicker	quick	ADJ
ihlr-20834	164	7	approval	approval	NOUN
ihlr-20834	164	8	of	of	ADP
ihlr-20834	164	9	generic	generic	ADJ
ihlr-20834	164	10	drugs	drug	NOUN
ihlr-20834	164	11	into	into	ADP
ihlr-20834	164	12	the	the	DET
ihlr-20834	164	13	marketplace	marketplace	NOUN
ihlr-20834	164	14	.	.	PUNCT
ihlr-20834	165	1	to	to	PART
ihlr-20834	165	2	streamline	streamline	VERB
ihlr-20834	165	3	the	the	DET
ihlr-20834	165	4	generic	generic	ADJ
ihlr-20834	165	5	drug	drug	NOUN
ihlr-20834	165	6	approval	approval	NOUN
ihlr-20834	165	7	process	process	NOUN
ihlr-20834	165	8	,	,	PUNCT
ihlr-20834	165	9	congress	congress	PROPN
ihlr-20834	165	10	enacted	enact	VERB
ihlr-20834	165	11	the	the	DET
ihlr-20834	165	12	drug	drug	NOUN
ihlr-20834	165	13	price	price	NOUN
ihlr-20834	165	14	competition	competition	NOUN
ihlr-20834	165	15	and	and	CCONJ
ihlr-20834	165	16	patent	patent	NOUN
ihlr-20834	165	17	term	term	NOUN
ihlr-20834	165	18	restoration	restoration	NOUN
ihlr-20834	165	19	act	act	NOUN
ihlr-20834	165	20	in	in	ADP
ihlr-20834	165	21	1984	1984	NUM
ihlr-20834	165	22	(	(	PUNCT
ihlr-20834	165	23	hereinafter	hereinafter	VERB
ihlr-20834	165	24	the	the	DET
ihlr-20834	165	25	“	"	PUNCT
ihlr-20834	165	26	hatch	hatch	NOUN
ihlr-20834	165	27	-	-	PUNCT
ihlr-20834	165	28	waxman	waxman	NOUN
ihlr-20834	165	29	act”).50	act”).50	PROPN
ihlr-20834	165	30	prior	prior	ADV
ihlr-20834	165	31	to	to	ADP
ihlr-20834	165	32	enacting	enact	VERB
ihlr-20834	165	33	the	the	DET
ihlr-20834	165	34	hatch	hatch	NOUN
ihlr-20834	165	35	-	-	PUNCT
ihlr-20834	165	36	waxman	waxman	PROPN
ihlr-20834	165	37	act	act	PROPN
ihlr-20834	165	38	,	,	PUNCT
ihlr-20834	165	39	generic	generic	ADJ
ihlr-20834	165	40	drug	drug	NOUN
ihlr-20834	165	41	manufacturers	manufacturer	NOUN
ihlr-20834	165	42	were	be	AUX
ihlr-20834	165	43	required	require	VERB
ihlr-20834	165	44	to	to	PART
ihlr-20834	165	45	undertake	undertake	VERB
ihlr-20834	165	46	the	the	DET
ihlr-20834	165	47	same	same	ADJ
ihlr-20834	165	48	approval	approval	NOUN
ihlr-20834	165	49	as	as	ADP
ihlr-20834	165	50	brand	brand	NOUN
ihlr-20834	165	51	name	name	NOUN
ihlr-20834	165	52	44	44	NUM
ihlr-20834	165	53	i	i	PRON
ihlr-20834	165	54	d.	d.	PROPN
ihlr-20834	165	55	45	45	NUM
ihlr-20834	165	56	pub	pub	NOUN
ihlr-20834	165	57	.	.	PUNCT
ihlr-20834	166	1	l.	l.	PROPN
ihlr-20834	166	2	no	no	INTJ
ihlr-20834	166	3	.	.	PROPN
ihlr-20834	167	1	75	75	NUM
ihlr-20834	167	2	-	-	SYM
ihlr-20834	167	3	717	717	NUM
ihlr-20834	167	4	,	,	PUNCT
ihlr-20834	167	5	52	52	NUM
ihlr-20834	167	6	stat	stat	NOUN
ihlr-20834	167	7	.	.	PUNCT
ihlr-20834	168	1	1040	1040	NUM
ihlr-20834	168	2	(	(	PUNCT
ihlr-20834	168	3	1938	1938	NUM
ihlr-20834	168	4	)	)	PUNCT
ihlr-20834	168	5	.	.	PUNCT
ihlr-20834	169	1	46	46	NUM
ihlr-20834	170	1	i	i	PRON
ihlr-20834	170	2	d.	d.	PROPN
ihlr-20834	170	3	47	47	NUM
ihlr-20834	171	1	pub.l	pub.l	PROPN
ihlr-20834	171	2	.	.	PUNCT
ihlr-20834	172	1	no	no	INTJ
ihlr-20834	172	2	.	.	PUNCT
ihlr-20834	173	1	87	87	NUM
ihlr-20834	173	2	-	-	SYM
ihlr-20834	173	3	781	781	NUM
ihlr-20834	173	4	,	,	PUNCT
ihlr-20834	173	5	76	76	NUM
ihlr-20834	173	6	stat	stat	NOUN
ihlr-20834	173	7	.	.	PUNCT
ihlr-20834	174	1	780	780	NUM
ihlr-20834	174	2	(	(	PUNCT
ihlr-20834	174	3	1962	1962	NUM
ihlr-20834	174	4	)	)	PUNCT
ihlr-20834	174	5	(	(	PUNCT
ihlr-20834	174	6	codified	codify	VERB
ihlr-20834	174	7	as	as	SCONJ
ihlr-20834	174	8	amended	amend	VERB
ihlr-20834	174	9	in	in	ADP
ihlr-20834	174	10	scattered	scatter	VERB
ihlr-20834	174	11	sections	section	NOUN
ihlr-20834	174	12	of	of	ADP
ihlr-20834	174	13	21	21	NUM
ihlr-20834	174	14	u.s.c	u.s.c	ADJ
ihlr-20834	174	15	.	.	PUNCT
ihlr-20834	174	16	)	)	PUNCT
ihlr-20834	174	17	.	.	PUNCT
ihlr-20834	175	1	48	48	NUM
ihlr-20834	176	1	i	i	PRON
ihlr-20834	176	2	d.	d.	PROPN
ihlr-20834	176	3	49	49	NUM
ihlr-20834	176	4	wyeth	wyeth	PROPN
ihlr-20834	176	5	v.	v.	PROPN
ihlr-20834	176	6	levine	levine	PROPN
ihlr-20834	176	7	,	,	PUNCT
ihlr-20834	176	8	555	555	NUM
ihlr-20834	176	9	u.s	u.s	PROPN
ihlr-20834	176	10	.	.	PROPN
ihlr-20834	176	11	555	555	NUM
ihlr-20834	176	12	,	,	PUNCT
ihlr-20834	176	13	567	567	NUM
ihlr-20834	176	14	(	(	PUNCT
ihlr-20834	176	15	2009	2009	NUM
ihlr-20834	176	16	)	)	PUNCT
ihlr-20834	176	17	(	(	PUNCT
ihlr-20834	176	18	citations	citation	NOUN
ihlr-20834	176	19	omitted)(emphasis	omitted)(emphasis	NOUN
ihlr-20834	176	20	added	add	VERB
ihlr-20834	176	21	)	)	PUNCT
ihlr-20834	176	22	.	.	PUNCT
ihlr-20834	177	1	50	50	NUM
ihlr-20834	177	2	drug	drug	NOUN
ihlr-20834	177	3	price	price	NOUN
ihlr-20834	177	4	competition	competition	NOUN
ihlr-20834	177	5	and	and	CCONJ
ihlr-20834	177	6	patent	patent	NOUN
ihlr-20834	177	7	term	term	NOUN
ihlr-20834	177	8	restoration	restoration	NOUN
ihlr-20834	177	9	act	act	NOUN
ihlr-20834	177	10	,	,	PUNCT
ihlr-20834	177	11	pub	pub	NOUN
ihlr-20834	177	12	.	.	PUNCT
ihlr-20834	178	1	l.	l.	PROPN
ihlr-20834	178	2	no	no	INTJ
ihlr-20834	178	3	.	.	PROPN
ihlr-20834	179	1	98	98	NUM
ihlr-20834	179	2	-	-	SYM
ihlr-20834	179	3	417	417	NUM
ihlr-20834	179	4	,	,	PUNCT
ihlr-20834	179	5	98	98	NUM
ihlr-20834	179	6	stat	stat	NOUN
ihlr-20834	179	7	.	.	PUNCT
ihlr-20834	180	1	1585	1585	NUM
ihlr-20834	180	2	(	(	PUNCT
ihlr-20834	180	3	codified	codify	VERB
ihlr-20834	180	4	as	as	SCONJ
ihlr-20834	180	5	amended	amend	VERB
ihlr-20834	180	6	in	in	ADP
ihlr-20834	180	7	scattered	scatter	VERB
ihlr-20834	180	8	sections	section	NOUN
ihlr-20834	180	9	of	of	ADP
ihlr-20834	180	10	21	21	NUM
ihlr-20834	180	11	u.s.c	u.s.c	ADJ
ihlr-20834	180	12	.	.	PUNCT
ihlr-20834	180	13	)	)	PUNCT
ihlr-20834	180	14	.	.	PUNCT
ihlr-20834	181	1	2015	2015	NUM
ihlr-20834	181	2	779	779	NUM
ihlr-20834	181	3	the	the	DET
ihlr-20834	181	4	supreme	supreme	PROPN
ihlr-20834	181	5	court	court	PROPN
ihlr-20834	181	6	’s	’s	PART
ihlr-20834	181	7	overreaching	overreach	VERB
ihlr-20834	181	8	preemption	preemption	NOUN
ihlr-20834	181	9	interpretation	interpretation	NOUN
ihlr-20834	181	10	and	and	CCONJ
ihlr-20834	181	11	it	it	PRON
ihlr-20834	181	12	’s	’	VERB
ihlr-20834	181	13	consequences	consequence	VERB
ihlr-20834	181	14	drug	drug	NOUN
ihlr-20834	181	15	manufacturers	manufacturer	NOUN
ihlr-20834	181	16	.	.	PUNCT
ihlr-20834	182	1	this	this	DET
ihlr-20834	182	2	demanding	demand	VERB
ihlr-20834	182	3	approval	approval	NOUN
ihlr-20834	182	4	process	process	NOUN
ihlr-20834	182	5	deterred	deter	VERB
ihlr-20834	182	6	the	the	DET
ihlr-20834	182	7	drug	drug	NOUN
ihlr-20834	182	8	approval	approval	NOUN
ihlr-20834	182	9	applications	application	NOUN
ihlr-20834	182	10	by	by	ADP
ihlr-20834	182	11	generic	generic	ADJ
ihlr-20834	182	12	drug	drug	NOUN
ihlr-20834	182	13	manufacturers	manufacturer	NOUN
ihlr-20834	182	14	because	because	SCONJ
ihlr-20834	182	15	the	the	DET
ihlr-20834	182	16	cost	cost	NOUN
ihlr-20834	182	17	of	of	ADP
ihlr-20834	182	18	such	such	ADJ
ihlr-20834	182	19	approvals	approval	NOUN
ihlr-20834	182	20	would	would	AUX
ihlr-20834	182	21	rarely	rarely	ADV
ihlr-20834	182	22	be	be	AUX
ihlr-20834	182	23	outweighed	outweigh	VERB
ihlr-20834	182	24	by	by	ADP
ihlr-20834	182	25	the	the	DET
ihlr-20834	182	26	profit	profit	NOUN
ihlr-20834	182	27	potential	potential	NOUN
ihlr-20834	182	28	.	.	PUNCT
ihlr-20834	183	1	this	this	DET
ihlr-20834	183	2	act	act	NOUN
ihlr-20834	183	3	(	(	PUNCT
ihlr-20834	183	4	and	and	CCONJ
ihlr-20834	183	5	subsequent	subsequent	ADJ
ihlr-20834	183	6	amendments	amendment	NOUN
ihlr-20834	183	7	)	)	PUNCT
ihlr-20834	183	8	created	create	VERB
ihlr-20834	183	9	the	the	DET
ihlr-20834	183	10	abbreviated	abbreviate	VERB
ihlr-20834	183	11	new	new	ADJ
ihlr-20834	183	12	drug	drug	NOUN
ihlr-20834	183	13	application	application	NOUN
ihlr-20834	183	14	(	(	PUNCT
ihlr-20834	183	15	“	"	PUNCT
ihlr-20834	183	16	anda	anda	PROPN
ihlr-20834	183	17	”	"	PUNCT
ihlr-20834	183	18	)	)	PUNCT
ihlr-20834	183	19	,	,	PUNCT
ihlr-20834	183	20	a	a	DET
ihlr-20834	183	21	rule	rule	NOUN
ihlr-20834	183	22	that	that	PRON
ihlr-20834	183	23	expedites	expedite	VERB
ihlr-20834	183	24	generic	generic	ADJ
ihlr-20834	183	25	drug	drug	NOUN
ihlr-20834	183	26	approval	approval	NOUN
ihlr-20834	183	27	by	by	ADP
ihlr-20834	183	28	permitting	permit	VERB
ihlr-20834	183	29	reliance	reliance	NOUN
ihlr-20834	183	30	on	on	ADP
ihlr-20834	183	31	brand	brand	NOUN
ihlr-20834	183	32	name	name	NOUN
ihlr-20834	183	33	drug	drug	NOUN
ihlr-20834	183	34	data.51	data.51	PROPN
ihlr-20834	183	35	it	it	PRON
ihlr-20834	183	36	is	be	AUX
ihlr-20834	183	37	important	important	ADJ
ihlr-20834	183	38	to	to	PART
ihlr-20834	183	39	note	note	VERB
ihlr-20834	183	40	that	that	SCONJ
ihlr-20834	183	41	the	the	DET
ihlr-20834	183	42	hatch	hatch	PROPN
ihlr-20834	183	43	-	-	PUNCT
ihlr-20834	183	44	waxman	waxman	PROPN
ihlr-20834	183	45	act	act	NOUN
ihlr-20834	183	46	focused	focus	VERB
ihlr-20834	183	47	largely	largely	ADV
ihlr-20834	183	48	on	on	ADP
ihlr-20834	183	49	small	small	ADJ
ihlr-20834	183	50	molecule	molecule	NOUN
ihlr-20834	183	51	drugs	drug	NOUN
ihlr-20834	183	52	(	(	PUNCT
ihlr-20834	183	53	“	"	PUNCT
ihlr-20834	183	54	smd	smd	PROPN
ihlr-20834	183	55	’s	’s	PART
ihlr-20834	183	56	”	"	PUNCT
ihlr-20834	183	57	)	)	PUNCT
ihlr-20834	183	58	versus	versus	ADP
ihlr-20834	183	59	biologics	biologic	NOUN
ihlr-20834	183	60	.	.	PUNCT
ihlr-20834	184	1	these	these	DET
ihlr-20834	184	2	smd	smd	NOUN
ihlr-20834	184	3	’s	’s	PART
ihlr-20834	184	4	are	be	AUX
ihlr-20834	184	5	different	different	ADJ
ihlr-20834	184	6	in	in	ADP
ihlr-20834	184	7	that	that	SCONJ
ihlr-20834	184	8	they	they	PRON
ihlr-20834	184	9	are	be	AUX
ihlr-20834	184	10	often	often	ADV
ihlr-20834	184	11	small	small	ADJ
ihlr-20834	184	12	(	(	PUNCT
ihlr-20834	184	13	sometimes	sometimes	ADV
ihlr-20834	184	14	a	a	DET
ihlr-20834	184	15	single	single	ADJ
ihlr-20834	184	16	molecule	molecule	NOUN
ihlr-20834	184	17	)	)	PUNCT
ihlr-20834	184	18	,	,	PUNCT
ihlr-20834	184	19	they	they	PRON
ihlr-20834	184	20	are	be	AUX
ihlr-20834	184	21	produced	produce	VERB
ihlr-20834	184	22	by	by	ADP
ihlr-20834	184	23	chemical	chemical	ADJ
ihlr-20834	184	24	synthesis	synthesis	NOUN
ihlr-20834	184	25	and	and	CCONJ
ihlr-20834	184	26	they	they	PRON
ihlr-20834	184	27	are	be	AUX
ihlr-20834	184	28	often	often	ADV
ihlr-20834	184	29	stable	stable	ADJ
ihlr-20834	184	30	,	,	PUNCT
ihlr-20834	184	31	whereas	whereas	SCONJ
ihlr-20834	184	32	biologics	biologic	NOUN
ihlr-20834	184	33	are	be	AUX
ihlr-20834	184	34	large	large	ADJ
ihlr-20834	184	35	(	(	PUNCT
ihlr-20834	184	36	molecule	molecule	NOUN
ihlr-20834	184	37	mixtures	mixture	NOUN
ihlr-20834	184	38	)	)	PUNCT
ihlr-20834	184	39	,	,	PUNCT
ihlr-20834	184	40	complex	complex	ADJ
ihlr-20834	184	41	,	,	PUNCT
ihlr-20834	184	42	produced	produce	VERB
ihlr-20834	184	43	by	by	ADP
ihlr-20834	184	44	living	live	VERB
ihlr-20834	184	45	cell	cell	NOUN
ihlr-20834	184	46	cultures	culture	NOUN
ihlr-20834	184	47	and	and	CCONJ
ihlr-20834	184	48	difficult	difficult	ADJ
ihlr-20834	184	49	to	to	PART
ihlr-20834	184	50	control.52	control.52	NOUN
ihlr-20834	184	51	while	while	SCONJ
ihlr-20834	184	52	generic	generic	ADJ
ihlr-20834	184	53	drug	drug	NOUN
ihlr-20834	184	54	approval	approval	NOUN
ihlr-20834	184	55	is	be	AUX
ihlr-20834	184	56	available	available	ADJ
ihlr-20834	184	57	,	,	PUNCT
ihlr-20834	184	58	such	such	ADJ
ihlr-20834	184	59	analysis	analysis	NOUN
ihlr-20834	184	60	is	be	AUX
ihlr-20834	184	61	not	not	PART
ihlr-20834	184	62	the	the	DET
ihlr-20834	184	63	subject	subject	NOUN
ihlr-20834	184	64	of	of	ADP
ihlr-20834	184	65	this	this	DET
ihlr-20834	184	66	note	note	NOUN
ihlr-20834	184	67	.	.	PUNCT
ihlr-20834	185	1	generic	generic	ADJ
ihlr-20834	185	2	drug	drug	NOUN
ihlr-20834	185	3	approval	approval	NOUN
ihlr-20834	185	4	is	be	AUX
ihlr-20834	185	5	available	available	ADJ
ihlr-20834	185	6	for	for	ADP
ihlr-20834	185	7	biologics.53	biologics.53	NOUN
ihlr-20834	185	8	to	to	PART
ihlr-20834	185	9	provide	provide	VERB
ihlr-20834	185	10	a	a	DET
ihlr-20834	185	11	brief	brief	ADJ
ihlr-20834	185	12	summary	summary	NOUN
ihlr-20834	185	13	,	,	PUNCT
ihlr-20834	185	14	the	the	DET
ihlr-20834	185	15	biologics	biologic	NOUN
ihlr-20834	185	16	price	price	NOUN
ihlr-20834	185	17	competition	competition	NOUN
ihlr-20834	185	18	and	and	CCONJ
ihlr-20834	185	19	innovation	innovation	NOUN
ihlr-20834	185	20	act	act	NOUN
ihlr-20834	185	21	(	(	PUNCT
ihlr-20834	185	22	which	which	PRON
ihlr-20834	185	23	is	be	AUX
ihlr-20834	185	24	included	include	VERB
ihlr-20834	185	25	in	in	ADP
ihlr-20834	185	26	the	the	DET
ihlr-20834	185	27	patient	patient	NOUN
ihlr-20834	185	28	protection	protection	NOUN
ihlr-20834	185	29	and	and	CCONJ
ihlr-20834	185	30	affordable	affordable	ADJ
ihlr-20834	185	31	care	care	NOUN
ihlr-20834	185	32	act	act	NOUN
ihlr-20834	185	33	of	of	ADP
ihlr-20834	185	34	2009	2009	NUM
ihlr-20834	185	35	)	)	PUNCT
ihlr-20834	185	36	helped	help	VERB
ihlr-20834	185	37	address	address	VERB
ihlr-20834	185	38	the	the	DET
ihlr-20834	185	39	availability	availability	NOUN
ihlr-20834	185	40	of	of	ADP
ihlr-20834	185	41	biologics	biologic	NOUN
ihlr-20834	185	42	by	by	ADP
ihlr-20834	185	43	“	"	PUNCT
ihlr-20834	185	44	allow[ing	allow[e	VERB
ihlr-20834	185	45	]	]	PUNCT
ihlr-20834	185	46	the	the	DET
ihlr-20834	185	47	submission	submission	NOUN
ihlr-20834	185	48	of	of	ADP
ihlr-20834	185	49	a	a	DET
ihlr-20834	185	50	biological	biological	ADJ
ihlr-20834	185	51	license	license	NOUN
ihlr-20834	185	52	application	application	NOUN
ihlr-20834	185	53	(	(	PUNCT
ihlr-20834	185	54	bla	bla	NOUN
ihlr-20834	185	55	)	)	PUNCT
ihlr-20834	185	56	for	for	ADP
ihlr-20834	185	57	a	a	DET
ihlr-20834	185	58	biosimilar	biosimilar	NOUN
ihlr-20834	185	59	or	or	CCONJ
ihlr-20834	185	60	interchangeable	interchangeable	ADJ
ihlr-20834	185	61	biological	biological	NOUN
ihlr-20834	185	62	.	.	PUNCT
ihlr-20834	186	1	”54	”54	AUX
ihlr-20834	186	2	this	this	DET
ihlr-20834	186	3	regulatory	regulatory	ADJ
ihlr-20834	186	4	scheme	scheme	NOUN
ihlr-20834	186	5	mirrors	mirror	NOUN
ihlr-20834	186	6	the	the	DET
ihlr-20834	186	7	anda	anda	PROPN
ihlr-20834	186	8	process	process	NOUN
ihlr-20834	186	9	by	by	ADP
ihlr-20834	186	10	51	51	NUM
ihlr-20834	186	11	see	see	VERB
ihlr-20834	186	12	generally	generally	ADV
ihlr-20834	186	13	21	21	NUM
ihlr-20834	186	14	c.f.r	c.f.r	NOUN
ihlr-20834	186	15	.	.	PUNCT
ihlr-20834	187	1	§	§	PROPN
ihlr-20834	187	2	314	314	NUM
ihlr-20834	187	3	et	et	PROPN
ihlr-20834	187	4	seq	seq	PROPN
ihlr-20834	187	5	.	.	PUNCT
ihlr-20834	188	1	(	(	PUNCT
ihlr-20834	188	2	2015	2015	NUM
ihlr-20834	188	3	)	)	PUNCT
ihlr-20834	188	4	.	.	PUNCT
ihlr-20834	189	1	52	52	NUM
ihlr-20834	189	2	small	small	ADJ
ihlr-20834	189	3	molecule	molecule	NOUN
ihlr-20834	189	4	drugs	drug	NOUN
ihlr-20834	189	5	versus	versus	ADP
ihlr-20834	189	6	biological	biological	ADJ
ihlr-20834	189	7	drugs	drug	NOUN
ihlr-20834	189	8	,	,	PUNCT
ihlr-20834	189	9	generics	generics	PROPN
ihlr-20834	189	10	&	&	CCONJ
ihlr-20834	189	11	biosimilars	biosimilars	PROPN
ihlr-20834	189	12	initiative	initiative	NOUN
ihlr-20834	189	13	(	(	PUNCT
ihlr-20834	189	14	june	june	PROPN
ihlr-20834	189	15	29	29	NUM
ihlr-20834	189	16	,	,	PUNCT
ihlr-20834	189	17	2012	2012	NUM
ihlr-20834	189	18	)	)	PUNCT
ihlr-20834	189	19	,	,	PUNCT
ihlr-20834	189	20	http://www.gabionline.net/biosimilars/research/small-molecule-versusbiological-drugs	http://www.gabionline.net/biosimilars/research/small-molecule-versusbiological-drug	NOUN
ihlr-20834	189	21	.	.	PUNCT
ihlr-20834	190	1	53	53	NUM
ihlr-20834	190	2	biologics	biologic	NOUN
ihlr-20834	190	3	is	be	AUX
ihlr-20834	190	4	a	a	DET
ihlr-20834	190	5	large	large	ADJ
ihlr-20834	190	6	and	and	CCONJ
ihlr-20834	190	7	complex	complex	ADJ
ihlr-20834	190	8	issue	issue	NOUN
ihlr-20834	190	9	that	that	PRON
ihlr-20834	190	10	has	have	AUX
ihlr-20834	190	11	been	be	AUX
ihlr-20834	190	12	the	the	DET
ihlr-20834	190	13	topic	topic	NOUN
ihlr-20834	190	14	of	of	ADP
ihlr-20834	190	15	several	several	ADJ
ihlr-20834	190	16	articles	article	NOUN
ihlr-20834	190	17	,	,	PUNCT
ihlr-20834	190	18	commentaries	commentary	NOUN
ihlr-20834	190	19	,	,	PUNCT
ihlr-20834	190	20	and	and	CCONJ
ihlr-20834	190	21	studies	study	NOUN
ihlr-20834	190	22	which	which	PRON
ihlr-20834	190	23	analyze	analyze	VERB
ihlr-20834	190	24	the	the	DET
ihlr-20834	190	25	biologics	biologic	NOUN
ihlr-20834	190	26	act	act	PROPN
ihlr-20834	190	27	,	,	PUNCT
ihlr-20834	190	28	the	the	DET
ihlr-20834	190	29	similarities	similarity	NOUN
ihlr-20834	190	30	this	this	DET
ihlr-20834	190	31	act	act	NOUN
ihlr-20834	190	32	has	have	VERB
ihlr-20834	190	33	to	to	ADP
ihlr-20834	190	34	the	the	DET
ihlr-20834	190	35	anda	anda	PROPN
ihlr-20834	190	36	process	process	NOUN
ihlr-20834	190	37	,	,	PUNCT
ihlr-20834	190	38	and	and	CCONJ
ihlr-20834	190	39	the	the	DET
ihlr-20834	190	40	complexities	complexity	NOUN
ihlr-20834	190	41	of	of	ADP
ihlr-20834	190	42	biologics	biologic	NOUN
ihlr-20834	190	43	.	.	PUNCT
ihlr-20834	191	1	see	see	VERB
ihlr-20834	191	2	brenda	brenda	PROPN
ihlr-20834	191	3	f.	f.	PROPN
ihlr-20834	191	4	gehani	gehani	PROPN
ihlr-20834	191	5	,	,	PUNCT
ihlr-20834	191	6	the	the	DET
ihlr-20834	191	7	biologics	biologic	NOUN
ihlr-20834	191	8	act	act	PROPN
ihlr-20834	191	9	:	:	PUNCT
ihlr-20834	191	10	hopes	hope	VERB
ihlr-20834	191	11	for	for	ADP
ihlr-20834	191	12	access	access	NOUN
ihlr-20834	191	13	to	to	ADP
ihlr-20834	191	14	generic	generic	ADJ
ihlr-20834	191	15	biologics	biologic	NOUN
ihlr-20834	191	16	may	may	AUX
ihlr-20834	191	17	instead	instead	ADV
ihlr-20834	191	18	be	be	AUX
ihlr-20834	191	19	a	a	DET
ihlr-20834	191	20	catalyst	catalyst	NOUN
ihlr-20834	191	21	for	for	ADP
ihlr-20834	191	22	new	new	ADJ
ihlr-20834	191	23	innovation	innovation	NOUN
ihlr-20834	191	24	,	,	PUNCT
ihlr-20834	191	25	20	20	NUM
ihlr-20834	191	26	annals	annal	VERB
ihlr-20834	191	27	health	health	PROPN
ihlr-20834	191	28	l.	l.	PROPN
ihlr-20834	191	29	170	170	NUM
ihlr-20834	191	30	(	(	PUNCT
ihlr-20834	191	31	2011	2011	NUM
ihlr-20834	191	32	)	)	PUNCT
ihlr-20834	191	33	.	.	PUNCT
ihlr-20834	192	1	see	see	VERB
ihlr-20834	192	2	also	also	ADV
ihlr-20834	192	3	parker	parker	PROPN
ihlr-20834	192	4	tresmer	tresmer	PROPN
ihlr-20834	192	5	,	,	PUNCT
ihlr-20834	192	6	interests	interest	NOUN
ihlr-20834	192	7	in	in	ADP
ihlr-20834	192	8	the	the	DET
ihlr-20834	192	9	balance	balance	NOUN
ihlr-20834	192	10	fda	fda	PROPN
ihlr-20834	192	11	regulations	regulation	NOUN
ihlr-20834	192	12	under	under	ADP
ihlr-20834	192	13	the	the	DET
ihlr-20834	192	14	biologics	biologic	NOUN
ihlr-20834	192	15	price	price	NOUN
ihlr-20834	192	16	competition	competition	NOUN
ihlr-20834	192	17	and	and	CCONJ
ihlr-20834	192	18	innovation	innovation	NOUN
ihlr-20834	192	19	act	act	PROPN
ihlr-20834	192	20	,	,	PUNCT
ihlr-20834	192	21	16	16	NUM
ihlr-20834	192	22	ulca	ulca	PROPN
ihlr-20834	192	23	j.	j.	PROPN
ihlr-20834	192	24	l.	l.	PROPN
ihlr-20834	192	25	&	&	CCONJ
ihlr-20834	192	26	tech	tech	PROPN
ihlr-20834	192	27	.	.	PUNCT
ihlr-20834	193	1	1	1	NUM
ihlr-20834	193	2	(	(	PUNCT
ihlr-20834	193	3	2012	2012	NUM
ihlr-20834	193	4	)	)	PUNCT
ihlr-20834	193	5	;	;	PUNCT
ihlr-20834	194	1	sara	sara	PROPN
ihlr-20834	194	2	margolis	margolis	PROPN
ihlr-20834	194	3	,	,	PUNCT
ihlr-20834	194	4	destined	destine	VERB
ihlr-20834	194	5	for	for	ADP
ihlr-20834	194	6	failure	failure	NOUN
ihlr-20834	194	7	?	?	PUNCT
ihlr-20834	195	1	an	an	DET
ihlr-20834	195	2	analysis	analysis	NOUN
ihlr-20834	195	3	of	of	ADP
ihlr-20834	195	4	the	the	DET
ihlr-20834	195	5	biologics	biologic	NOUN
ihlr-20834	195	6	price	price	NOUN
ihlr-20834	195	7	competition	competition	NOUN
ihlr-20834	195	8	and	and	CCONJ
ihlr-20834	195	9	innovation	innovation	NOUN
ihlr-20834	195	10	act	act	NOUN
ihlr-20834	195	11	of	of	ADP
ihlr-20834	195	12	2009	2009	NUM
ihlr-20834	195	13	,	,	PUNCT
ihlr-20834	195	14	2013	2013	NUM
ihlr-20834	195	15	colum	colum	NOUN
ihlr-20834	195	16	.	.	PUNCT
ihlr-20834	196	1	bus	bus	NOUN
ihlr-20834	196	2	.	.	PUNCT
ihlr-20834	197	1	l.	l.	PROPN
ihlr-20834	197	2	rev	rev	PROPN
ihlr-20834	197	3	.	.	PROPN
ihlr-20834	198	1	209	209	NUM
ihlr-20834	198	2	(	(	PUNCT
ihlr-20834	198	3	2013	2013	NUM
ihlr-20834	198	4	)	)	PUNCT
ihlr-20834	198	5	.	.	PUNCT
ihlr-20834	199	1	54	54	NUM
ihlr-20834	199	2	biologics	biologic	NOUN
ihlr-20834	199	3	price	price	NOUN
ihlr-20834	199	4	competition	competition	NOUN
ihlr-20834	199	5	and	and	CCONJ
ihlr-20834	199	6	innovation	innovation	NOUN
ihlr-20834	199	7	act	act	PROPN
ihlr-20834	199	8	,	,	PUNCT
ihlr-20834	199	9	democratic	democratic	ADJ
ihlr-20834	199	10	pol’y	pol’y	NOUN
ihlr-20834	199	11	&	&	CCONJ
ihlr-20834	199	12	comm	comm	NOUN
ihlr-20834	199	13	.	.	PUNCT
ihlr-20834	200	1	center	center	PROPN
ihlr-20834	200	2	,	,	PUNCT
ihlr-20834	200	3	http://www.dpc.senate.gov/healthreformbill/	http://www.dpc.senate.gov/healthreformbill/	PUNCT
ihlr-20834	200	4	healthbill70.pdf	healthbill70.pdf	PROPN
ihlr-20834	200	5	(	(	PUNCT
ihlr-20834	200	6	last	last	ADV
ihlr-20834	200	7	visited	visit	VERB
ihlr-20834	200	8	mar	mar	PROPN
ihlr-20834	200	9	.	.	PROPN
ihlr-20834	200	10	18	18	NUM
ihlr-20834	200	11	,	,	PUNCT
ihlr-20834	200	12	2015	2015	NUM
ihlr-20834	200	13	)	)	PUNCT
ihlr-20834	200	14	.	.	PUNCT
ihlr-20834	201	1	780	780	NUM
ihlr-20834	201	2	indiana	indiana	PROPN
ihlr-20834	201	3	health	health	NOUN
ihlr-20834	201	4	law	law	PROPN
ihlr-20834	201	5	review	review	NOUN
ihlr-20834	201	6	vol	vol	NOUN
ihlr-20834	201	7	.	.	PUNCT
ihlr-20834	202	1	12:2	12:2	NUM
ihlr-20834	202	2	“	"	PUNCT
ihlr-20834	202	3	[	[	X
ihlr-20834	202	4	p]ermit[ting	p]ermit[ting	NOUN
ihlr-20834	202	5	]	]	PUNCT
ihlr-20834	202	6	the	the	DET
ihlr-20834	202	7	fda	fda	PROPN
ihlr-20834	202	8	,	,	PUNCT
ihlr-20834	202	9	following	follow	VERB
ihlr-20834	202	10	a	a	DET
ihlr-20834	202	11	public	public	ADJ
ihlr-20834	202	12	process	process	NOUN
ihlr-20834	202	13	,	,	PUNCT
ihlr-20834	202	14	to	to	PART
ihlr-20834	202	15	issue	issue	VERB
ihlr-20834	202	16	guidance	guidance	NOUN
ihlr-20834	202	17	related	relate	VERB
ihlr-20834	202	18	to	to	ADP
ihlr-20834	202	19	the	the	DET
ihlr-20834	202	20	approval	approval	NOUN
ihlr-20834	202	21	of	of	ADP
ihlr-20834	202	22	biosimilar	biosimilar	NOUN
ihlr-20834	202	23	and	and	CCONJ
ihlr-20834	202	24	interchangeable	interchangeable	ADJ
ihlr-20834	202	25	biological	biological	ADJ
ihlr-20834	202	26	products	product	NOUN
ihlr-20834	202	27	.	.	PUNCT
ihlr-20834	203	1	”55	”55	PROPN
ihlr-20834	203	2	when	when	SCONJ
ihlr-20834	203	3	the	the	DET
ihlr-20834	203	4	hatch	hatch	NOUN
ihlr-20834	203	5	-	-	PUNCT
ihlr-20834	203	6	waxman	waxman	PROPN
ihlr-20834	203	7	act	act	NOUN
ihlr-20834	203	8	was	be	AUX
ihlr-20834	203	9	enacted	enact	VERB
ihlr-20834	203	10	in	in	ADP
ihlr-20834	203	11	1984	1984	NUM
ihlr-20834	203	12	,	,	PUNCT
ihlr-20834	203	13	generic	generic	ADJ
ihlr-20834	203	14	drugs	drug	NOUN
ihlr-20834	203	15	accounted	account	VERB
ihlr-20834	203	16	for	for	ADP
ihlr-20834	203	17	19	19	NUM
ihlr-20834	203	18	%	%	NOUN
ihlr-20834	203	19	of	of	ADP
ihlr-20834	203	20	all	all	DET
ihlr-20834	203	21	drug	drug	NOUN
ihlr-20834	203	22	sales	sale	NOUN
ihlr-20834	203	23	in	in	ADP
ihlr-20834	203	24	the	the	DET
ihlr-20834	203	25	united	united	PROPN
ihlr-20834	203	26	states.56	states.56	PROPN
ihlr-20834	203	27	the	the	DET
ihlr-20834	203	28	hatch	hatch	NOUN
ihlr-20834	203	29	-	-	PUNCT
ihlr-20834	203	30	waxman	waxman	PROPN
ihlr-20834	203	31	act	act	PROPN
ihlr-20834	203	32	’s	’s	PART
ihlr-20834	203	33	anda	anda	PROPN
ihlr-20834	203	34	process	process	NOUN
ihlr-20834	203	35	allowed	allow	VERB
ihlr-20834	203	36	generic	generic	ADJ
ihlr-20834	203	37	drug	drug	NOUN
ihlr-20834	203	38	manufacturers	manufacturer	NOUN
ihlr-20834	203	39	to	to	PART
ihlr-20834	203	40	enter	enter	VERB
ihlr-20834	203	41	the	the	DET
ihlr-20834	203	42	marketplace	marketplace	NOUN
ihlr-20834	203	43	without	without	ADP
ihlr-20834	203	44	the	the	DET
ihlr-20834	203	45	restraints	restraint	NOUN
ihlr-20834	203	46	new	new	ADJ
ihlr-20834	203	47	brand	brand	NOUN
ihlr-20834	203	48	name	name	NOUN
ihlr-20834	203	49	drug	drug	NOUN
ihlr-20834	203	50	manufacturers	manufacturer	NOUN
ihlr-20834	203	51	face	face	VERB
ihlr-20834	203	52	.	.	PUNCT
ihlr-20834	204	1	as	as	ADP
ihlr-20834	204	2	such	such	ADJ
ihlr-20834	204	3	,	,	PUNCT
ihlr-20834	204	4	it	it	PRON
ihlr-20834	204	5	was	be	AUX
ihlr-20834	204	6	not	not	PART
ihlr-20834	204	7	long	long	ADV
ihlr-20834	204	8	before	before	SCONJ
ihlr-20834	204	9	generic	generic	ADJ
ihlr-20834	204	10	drugs	drug	NOUN
ihlr-20834	204	11	comprised	comprise	VERB
ihlr-20834	204	12	the	the	DET
ihlr-20834	204	13	majority	majority	NOUN
ihlr-20834	204	14	of	of	ADP
ihlr-20834	204	15	the	the	DET
ihlr-20834	204	16	market	market	NOUN
ihlr-20834	204	17	.	.	PUNCT
ihlr-20834	205	1	generic	generic	ADJ
ihlr-20834	205	2	drug	drug	NOUN
ihlr-20834	205	3	approval	approval	NOUN
ihlr-20834	205	4	costs	cost	NOUN
ihlr-20834	205	5	dropped	drop	VERB
ihlr-20834	205	6	substantially	substantially	ADV
ihlr-20834	205	7	due	due	ADP
ihlr-20834	205	8	to	to	ADP
ihlr-20834	205	9	the	the	DET
ihlr-20834	205	10	anda	anda	PROPN
ihlr-20834	205	11	process	process	NOUN
ihlr-20834	205	12	.	.	PUNCT
ihlr-20834	206	1	57	57	NUM
ihlr-20834	206	2	as	as	ADP
ihlr-20834	206	3	a	a	DET
ihlr-20834	206	4	result	result	NOUN
ihlr-20834	206	5	,	,	PUNCT
ihlr-20834	206	6	the	the	DET
ihlr-20834	206	7	generic	generic	ADJ
ihlr-20834	206	8	drug	drug	NOUN
ihlr-20834	206	9	approval	approval	NOUN
ihlr-20834	206	10	applications	application	NOUN
ihlr-20834	206	11	and	and	CCONJ
ihlr-20834	206	12	sales	sale	NOUN
ihlr-20834	206	13	steadily	steadily	ADV
ihlr-20834	206	14	increased	increase	VERB
ihlr-20834	206	15	.	.	PUNCT
ihlr-20834	207	1	currently	currently	ADV
ihlr-20834	207	2	,	,	PUNCT
ihlr-20834	207	3	90	90	NUM
ihlr-20834	207	4	%	%	NOUN
ihlr-20834	207	5	of	of	ADP
ihlr-20834	207	6	drug	drug	NOUN
ihlr-20834	207	7	prescriptions	prescription	NOUN
ihlr-20834	207	8	are	be	AUX
ihlr-20834	207	9	filled	fill	VERB
ihlr-20834	207	10	with	with	ADP
ihlr-20834	207	11	generic	generic	PROPN
ihlr-20834	207	12	counterparts.58	counterparts.58	PROPN
ihlr-20834	207	13	the	the	DET
ihlr-20834	207	14	most	most	ADV
ihlr-20834	207	15	recent	recent	ADJ
ihlr-20834	207	16	fdca	fdca	ADJ
ihlr-20834	207	17	amendment	amendment	NOUN
ihlr-20834	207	18	relating	relate	VERB
ihlr-20834	207	19	to	to	ADP
ihlr-20834	207	20	pharmaceuticals	pharmaceutical	NOUN
ihlr-20834	207	21	was	be	AUX
ihlr-20834	207	22	passed	pass	VERB
ihlr-20834	207	23	in	in	ADP
ihlr-20834	207	24	2007	2007	NUM
ihlr-20834	207	25	when	when	SCONJ
ihlr-20834	207	26	congress	congress	PROPN
ihlr-20834	207	27	“	"	PUNCT
ihlr-20834	207	28	adopted	adopt	VERB
ihlr-20834	207	29	a	a	DET
ihlr-20834	207	30	rule	rule	NOUN
ihlr-20834	207	31	of	of	ADP
ihlr-20834	207	32	construction	construction	NOUN
ihlr-20834	207	33	to	to	PART
ihlr-20834	207	34	make	make	VERB
ihlr-20834	207	35	it	it	PRON
ihlr-20834	207	36	clear	clear	ADJ
ihlr-20834	207	37	that	that	SCONJ
ihlr-20834	207	38	manufacturers	manufacturer	NOUN
ihlr-20834	207	39	remain	remain	VERB
ihlr-20834	207	40	responsible	responsible	ADJ
ihlr-20834	207	41	for	for	ADP
ihlr-20834	207	42	updating	update	VERB
ihlr-20834	207	43	their	their	PRON
ihlr-20834	207	44	labels	label	NOUN
ihlr-20834	207	45	.	.	PUNCT
ihlr-20834	208	1	”59	”59	VERB
ihlr-20834	208	2	the	the	DET
ihlr-20834	208	3	food	food	NOUN
ihlr-20834	208	4	and	and	CCONJ
ihlr-20834	208	5	drug	drug	PROPN
ihlr-20834	208	6	administration	administration	PROPN
ihlr-20834	208	7	amendments	amendment	NOUN
ihlr-20834	208	8	act	act	VERB
ihlr-20834	208	9	(	(	PUNCT
ihlr-20834	208	10	“	"	PUNCT
ihlr-20834	208	11	fdaaa	fdaaa	NOUN
ihlr-20834	208	12	”	"	PUNCT
ihlr-20834	208	13	)	)	PUNCT
ihlr-20834	208	14	increased	increase	VERB
ihlr-20834	208	15	the	the	DET
ihlr-20834	208	16	burden	burden	NOUN
ihlr-20834	208	17	placed	place	VERB
ihlr-20834	208	18	on	on	ADP
ihlr-20834	208	19	drug	drug	NOUN
ihlr-20834	208	20	manufacturers.60	manufacturers.60	PROPN
ihlr-20834	208	21	importantly	importantly	ADV
ihlr-20834	208	22	,	,	PUNCT
ihlr-20834	208	23	the	the	DET
ihlr-20834	208	24	fda	fda	PROPN
ihlr-20834	208	25	granted	grant	VERB
ihlr-20834	208	26	statutory	statutory	ADJ
ihlr-20834	208	27	authority	authority	NOUN
ihlr-20834	208	28	under	under	ADP
ihlr-20834	208	29	the	the	DET
ihlr-20834	208	30	fdaaa	fdaaa	NOUN
ihlr-20834	208	31	(	(	PUNCT
ihlr-20834	208	32	and	and	CCONJ
ihlr-20834	208	33	other	other	ADJ
ihlr-20834	208	34	parts	part	NOUN
ihlr-20834	208	35	of	of	ADP
ihlr-20834	208	36	the	the	DET
ihlr-20834	208	37	fdca	fdca	NOUN
ihlr-20834	208	38	)	)	PUNCT
ihlr-20834	208	39	allowing	allow	VERB
ihlr-20834	208	40	it	it	PRON
ihlr-20834	208	41	to	to	PART
ihlr-20834	208	42	require	require	VERB
ihlr-20834	208	43	drug	drug	NOUN
ihlr-20834	208	44	manufacturers	manufacturer	NOUN
ihlr-20834	208	45	to	to	PART
ihlr-20834	208	46	change	change	VERB
ihlr-20834	208	47	drug	drug	NOUN
ihlr-20834	208	48	labels	label	NOUN
ihlr-20834	208	49	based	base	VERB
ihlr-20834	208	50	upon	upon	SCONJ
ihlr-20834	208	51	information	information	NOUN
ihlr-20834	208	52	discovered	discover	VERB
ihlr-20834	208	53	after	after	SCONJ
ihlr-20834	208	54	a	a	DET
ihlr-20834	208	55	drug	drug	NOUN
ihlr-20834	208	56	has	have	AUX
ihlr-20834	208	57	been	be	AUX
ihlr-20834	208	58	approved	approve	VERB
ihlr-20834	208	59	for	for	ADP
ihlr-20834	208	60	market.61	market.61	NOUN
ihlr-20834	208	61	that	that	PRON
ihlr-20834	208	62	is	be	AUX
ihlr-20834	208	63	because	because	SCONJ
ihlr-20834	208	64	manufacturers	manufacturer	NOUN
ihlr-20834	208	65	55	55	NUM
ihlr-20834	208	66	i	i	PROPN
ihlr-20834	208	67	d.	d.	PROPN
ihlr-20834	208	68	(	(	PUNCT
ihlr-20834	208	69	noting	note	VERB
ihlr-20834	208	70	that	that	SCONJ
ihlr-20834	208	71	this	this	DET
ihlr-20834	208	72	act	act	NOUN
ihlr-20834	208	73	“	"	PUNCT
ihlr-20834	208	74	[	[	X
ihlr-20834	208	75	a]wards	a]wards	PROPN
ihlr-20834	208	76	brand	brand	NOUN
ihlr-20834	208	77	manufacturers	manufacturer	NOUN
ihlr-20834	208	78	and	and	CCONJ
ihlr-20834	208	79	innovators	innovator	NOUN
ihlr-20834	208	80	12	12	NUM
ihlr-20834	208	81	years	year	NOUN
ihlr-20834	208	82	of	of	ADP
ihlr-20834	208	83	data	datum	NOUN
ihlr-20834	208	84	exclusivity	exclusivity	NOUN
ihlr-20834	208	85	from	from	ADP
ihlr-20834	208	86	the	the	DET
ihlr-20834	208	87	approval	approval	NOUN
ihlr-20834	208	88	date	date	NOUN
ihlr-20834	208	89	of	of	ADP
ihlr-20834	208	90	the	the	DET
ihlr-20834	208	91	product	product	NOUN
ihlr-20834	208	92	.	.	PUNCT
ihlr-20834	208	93	”	"	PUNCT
ihlr-20834	209	1	this	this	PRON
ihlr-20834	209	2	will	will	AUX
ihlr-20834	209	3	essentially	essentially	ADV
ihlr-20834	209	4	expand	expand	VERB
ihlr-20834	209	5	the	the	DET
ihlr-20834	209	6	viable	viable	ADJ
ihlr-20834	209	7	monopoly	monopoly	NOUN
ihlr-20834	209	8	sale	sale	NOUN
ihlr-20834	209	9	time	time	NOUN
ihlr-20834	209	10	of	of	ADP
ihlr-20834	209	11	the	the	DET
ihlr-20834	209	12	brand	brand	NOUN
ihlr-20834	209	13	-	-	PUNCT
ihlr-20834	209	14	name	name	NOUN
ihlr-20834	209	15	biologic	biologic	NOUN
ihlr-20834	209	16	by	by	ADP
ihlr-20834	209	17	preventing	prevent	VERB
ihlr-20834	209	18	generic	generic	ADJ
ihlr-20834	209	19	companies	company	NOUN
ihlr-20834	209	20	from	from	ADP
ihlr-20834	209	21	relying	rely	VERB
ihlr-20834	209	22	on	on	ADP
ihlr-20834	209	23	their	their	PRON
ihlr-20834	209	24	previous	previous	ADJ
ihlr-20834	209	25	research	research	NOUN
ihlr-20834	209	26	)	)	PUNCT
ihlr-20834	209	27	.	.	PUNCT
ihlr-20834	210	1	56	56	NUM
ihlr-20834	210	2	how	how	SCONJ
ihlr-20834	210	3	increased	increase	VERB
ihlr-20834	210	4	competition	competition	NOUN
ihlr-20834	210	5	has	have	AUX
ihlr-20834	210	6	affected	affect	VERB
ihlr-20834	210	7	prices	price	NOUN
ihlr-20834	210	8	and	and	CCONJ
ihlr-20834	210	9	returns	return	NOUN
ihlr-20834	210	10	,	,	PUNCT
ihlr-20834	210	11	supra	supra	PROPN
ihlr-20834	210	12	note	note	NOUN
ihlr-20834	210	13	35	35	NUM
ihlr-20834	210	14	.	.	PUNCT
ihlr-20834	211	1	57	57	NUM
ihlr-20834	211	2	steele	steele	PROPN
ihlr-20834	211	3	,	,	PUNCT
ihlr-20834	211	4	supra	supra	PROPN
ihlr-20834	211	5	note	note	VERB
ihlr-20834	211	6	7	7	NUM
ihlr-20834	211	7	at	at	ADP
ihlr-20834	211	8	451	451	NUM
ihlr-20834	211	9	(	(	PUNCT
ihlr-20834	211	10	noting	note	VERB
ihlr-20834	211	11	that	that	SCONJ
ihlr-20834	211	12	“	"	PUNCT
ihlr-20834	211	13	the	the	DET
ihlr-20834	211	14	average	average	ADJ
ihlr-20834	211	15	cost	cost	NOUN
ihlr-20834	211	16	of	of	ADP
ihlr-20834	211	17	bringing	bring	VERB
ihlr-20834	211	18	a	a	DET
ihlr-20834	211	19	generic	generic	NOUN
ihlr-20834	211	20	to	to	ADP
ihlr-20834	211	21	market	market	NOUN
ihlr-20834	211	22	is	be	AUX
ihlr-20834	211	23	under	under	ADP
ihlr-20834	211	24	$	$	SYM
ihlr-20834	211	25	2	2	NUM
ihlr-20834	211	26	million	million	NUM
ihlr-20834	211	27	,	,	PUNCT
ihlr-20834	211	28	less	less	ADJ
ihlr-20834	211	29	than	than	ADP
ihlr-20834	211	30	a	a	DET
ihlr-20834	211	31	quarter	quarter	NOUN
ihlr-20834	211	32	of	of	ADP
ihlr-20834	211	33	the	the	DET
ihlr-20834	211	34	average	average	ADJ
ihlr-20834	211	35	costs	cost	NOUN
ihlr-20834	211	36	associated	associate	VERB
ihlr-20834	211	37	with	with	ADP
ihlr-20834	211	38	novel	novel	ADJ
ihlr-20834	211	39	drugs	drug	NOUN
ihlr-20834	211	40	.	.	PUNCT
ihlr-20834	211	41	”	"	PUNCT
ihlr-20834	211	42	)	)	PUNCT
ihlr-20834	211	43	.	.	PUNCT
ihlr-20834	212	1	58	58	NUM
ihlr-20834	212	2	steele	steele	PROPN
ihlr-20834	212	3	,	,	PUNCT
ihlr-20834	212	4	supra	supra	PROPN
ihlr-20834	212	5	note	note	VERB
ihlr-20834	212	6	7	7	NUM
ihlr-20834	212	7	at	at	ADP
ihlr-20834	212	8	442	442	NUM
ihlr-20834	212	9	.	.	PUNCT
ihlr-20834	213	1	59	59	NUM
ihlr-20834	213	2	wyeth	wyeth	PROPN
ihlr-20834	213	3	,	,	PUNCT
ihlr-20834	213	4	555	555	NUM
ihlr-20834	213	5	u.s	u.s	PROPN
ihlr-20834	213	6	.	.	PROPN
ihlr-20834	213	7	555	555	NUM
ihlr-20834	213	8	,	,	PUNCT
ihlr-20834	213	9	568	568	NUM
ihlr-20834	213	10	(	(	PUNCT
ihlr-20834	213	11	2009	2009	NUM
ihlr-20834	213	12	)	)	PUNCT
ihlr-20834	213	13	(	(	PUNCT
ihlr-20834	213	14	citations	citation	NOUN
ihlr-20834	213	15	omitted	omit	VERB
ihlr-20834	213	16	)	)	PUNCT
ihlr-20834	213	17	(	(	PUNCT
ihlr-20834	213	18	emphasis	emphasis	NOUN
ihlr-20834	213	19	added	add	VERB
ihlr-20834	213	20	)	)	PUNCT
ihlr-20834	213	21	.	.	PUNCT
ihlr-20834	214	1	60	60	NUM
ihlr-20834	214	2	pub	pub	NOUN
ihlr-20834	214	3	.	.	PUNCT
ihlr-20834	215	1	l.	l.	PROPN
ihlr-20834	215	2	no	no	INTJ
ihlr-20834	215	3	.	.	PROPN
ihlr-20834	216	1	110	110	NUM
ihlr-20834	216	2	-	-	SYM
ihlr-20834	216	3	85	85	NUM
ihlr-20834	216	4	.	.	PUNCT
ihlr-20834	217	1	121	121	NUM
ihlr-20834	217	2	stat	stat	NOUN
ihlr-20834	217	3	.	.	PUNCT
ihlr-20834	218	1	83	83	NUM
ihlr-20834	218	2	(	(	PUNCT
ihlr-20834	218	3	2007	2007	NUM
ihlr-20834	218	4	)	)	PUNCT
ihlr-20834	218	5	.	.	PUNCT
ihlr-20834	219	1	61	61	NUM
ihlr-20834	219	2	food	food	NOUN
ihlr-20834	219	3	and	and	CCONJ
ihlr-20834	219	4	drug	drug	PROPN
ihlr-20834	219	5	administration	administration	PROPN
ihlr-20834	219	6	amendments	amendment	NOUN
ihlr-20834	219	7	act	act	VERB
ihlr-20834	219	8	of	of	ADP
ihlr-20834	219	9	2007	2007	NUM
ihlr-20834	219	10	,	,	PUNCT
ihlr-20834	219	11	pub	pub	NOUN
ihlr-20834	219	12	.	.	PUNCT
ihlr-20834	220	1	l.	l.	PROPN
ihlr-20834	220	2	no	no	INTJ
ihlr-20834	220	3	.	.	NOUN
ihlr-20834	221	1	110	110	NUM
ihlr-20834	221	2	-	-	SYM
ihlr-20834	221	3	85	85	NUM
ihlr-20834	221	4	,	,	PUNCT
ihlr-20834	221	5	121	121	NUM
ihlr-20834	221	6	stat	stat	NOUN
ihlr-20834	221	7	.	.	PUNCT
ihlr-20834	222	1	823	823	NUM
ihlr-20834	222	2	(	(	PUNCT
ihlr-20834	222	3	codified	codify	VERB
ihlr-20834	222	4	as	as	SCONJ
ihlr-20834	222	5	amended	amend	VERB
ihlr-20834	222	6	in	in	ADP
ihlr-20834	222	7	scattered	scatter	VERB
ihlr-20834	222	8	sections	section	NOUN
ihlr-20834	222	9	of	of	ADP
ihlr-20834	222	10	21	21	NUM
ihlr-20834	222	11	u.s.c	u.s.c	ADJ
ihlr-20834	222	12	.	.	PUNCT
ihlr-20834	222	13	)	)	PUNCT
ihlr-20834	222	14	.	.	PUNCT
ihlr-20834	223	1	2015	2015	NUM
ihlr-20834	223	2	781	781	NUM
ihlr-20834	223	3	the	the	DET
ihlr-20834	223	4	supreme	supreme	PROPN
ihlr-20834	223	5	court	court	PROPN
ihlr-20834	223	6	’s	’s	PART
ihlr-20834	223	7	overreaching	overreach	VERB
ihlr-20834	223	8	preemption	preemption	NOUN
ihlr-20834	223	9	interpretation	interpretation	NOUN
ihlr-20834	223	10	and	and	CCONJ
ihlr-20834	223	11	it	it	PRON
ihlr-20834	223	12	’s	’	VERB
ihlr-20834	223	13	consequences	consequence	NOUN
ihlr-20834	223	14	who	who	PRON
ihlr-20834	223	15	have	have	VERB
ihlr-20834	223	16	greater	great	ADJ
ihlr-20834	223	17	“	"	PUNCT
ihlr-20834	223	18	access	access	NOUN
ihlr-20834	223	19	to	to	ADP
ihlr-20834	223	20	information	information	NOUN
ihlr-20834	223	21	about	about	ADP
ihlr-20834	223	22	their	their	PRON
ihlr-20834	223	23	drugs	drug	NOUN
ihlr-20834	223	24	”	"	PUNCT
ihlr-20834	223	25	than	than	SCONJ
ihlr-20834	223	26	the	the	DET
ihlr-20834	223	27	fda	fda	PROPN
ihlr-20834	223	28	retain	retain	VERB
ihlr-20834	223	29	the	the	DET
ihlr-20834	223	30	ultimate	ultimate	ADJ
ihlr-20834	223	31	responsibility	responsibility	NOUN
ihlr-20834	223	32	for	for	ADP
ihlr-20834	223	33	the	the	DET
ihlr-20834	223	34	safety	safety	NOUN
ihlr-20834	223	35	of	of	ADP
ihlr-20834	223	36	their	their	PRON
ihlr-20834	223	37	products	product	NOUN
ihlr-20834	223	38	.	.	PUNCT
ihlr-20834	224	1	62	62	NUM
ihlr-20834	224	2	therefore	therefore	ADV
ihlr-20834	224	3	,	,	PUNCT
ihlr-20834	224	4	this	this	DET
ihlr-20834	224	5	requirement	requirement	NOUN
ihlr-20834	224	6	would	would	AUX
ihlr-20834	224	7	place	place	VERB
ihlr-20834	224	8	the	the	DET
ihlr-20834	224	9	burden	burden	NOUN
ihlr-20834	224	10	on	on	ADP
ihlr-20834	224	11	drug	drug	NOUN
ihlr-20834	224	12	manufacturers	manufacturer	NOUN
ihlr-20834	224	13	and	and	CCONJ
ihlr-20834	224	14	it	it	PRON
ihlr-20834	224	15	provides	provide	VERB
ihlr-20834	224	16	incentives	incentive	NOUN
ihlr-20834	224	17	for	for	SCONJ
ihlr-20834	224	18	manufacturers	manufacturer	NOUN
ihlr-20834	224	19	to	to	PART
ihlr-20834	224	20	provide	provide	VERB
ihlr-20834	224	21	wholly	wholly	ADV
ihlr-20834	224	22	accurate	accurate	ADJ
ihlr-20834	224	23	and	and	CCONJ
ihlr-20834	224	24	timely	timely	ADJ
ihlr-20834	224	25	updates	update	NOUN
ihlr-20834	224	26	because	because	SCONJ
ihlr-20834	224	27	it	it	PRON
ihlr-20834	224	28	is	be	AUX
ihlr-20834	224	29	their	their	PRON
ihlr-20834	224	30	potential	potential	ADJ
ihlr-20834	224	31	liability	liability	NOUN
ihlr-20834	224	32	for	for	ADP
ihlr-20834	224	33	failing	fail	VERB
ihlr-20834	224	34	to	to	PART
ihlr-20834	224	35	do	do	VERB
ihlr-20834	224	36	so	so	ADV
ihlr-20834	224	37	.	.	PUNCT
ihlr-20834	225	1	b.	b.	PROPN
ihlr-20834	225	2	current	current	ADJ
ihlr-20834	225	3	regulatory	regulatory	ADJ
ihlr-20834	225	4	laws	law	NOUN
ihlr-20834	225	5	affecting	affect	VERB
ihlr-20834	225	6	pharmaceutical	pharmaceutical	ADJ
ihlr-20834	225	7	drugs	drug	NOUN
ihlr-20834	225	8	under	under	ADP
ihlr-20834	225	9	current	current	ADJ
ihlr-20834	225	10	law	law	NOUN
ihlr-20834	225	11	,	,	PUNCT
ihlr-20834	225	12	if	if	SCONJ
ihlr-20834	225	13	a	a	DET
ihlr-20834	225	14	generic	generic	ADJ
ihlr-20834	225	15	drug	drug	NOUN
ihlr-20834	225	16	is	be	AUX
ihlr-20834	225	17	identical	identical	ADJ
ihlr-20834	225	18	to	to	ADP
ihlr-20834	225	19	an	an	DET
ihlr-20834	225	20	fda	fda	PROPN
ihlr-20834	225	21	approved	approve	VERB
ihlr-20834	225	22	brand	brand	NOUN
ihlr-20834	225	23	-	-	PUNCT
ihlr-20834	225	24	name	name	NOUN
ihlr-20834	225	25	drug	drug	NOUN
ihlr-20834	225	26	in	in	ADP
ihlr-20834	225	27	several	several	ADJ
ihlr-20834	225	28	aspects	aspect	NOUN
ihlr-20834	225	29	,	,	PUNCT
ihlr-20834	225	30	it	it	PRON
ihlr-20834	225	31	may	may	AUX
ihlr-20834	225	32	be	be	AUX
ihlr-20834	225	33	approved	approve	VERB
ihlr-20834	225	34	without	without	ADP
ihlr-20834	225	35	the	the	DET
ihlr-20834	225	36	same	same	ADJ
ihlr-20834	225	37	onerous	onerous	ADJ
ihlr-20834	225	38	requirements	requirement	NOUN
ihlr-20834	225	39	of	of	ADP
ihlr-20834	225	40	brand	brand	NOUN
ihlr-20834	225	41	-	-	PUNCT
ihlr-20834	225	42	name	name	NOUN
ihlr-20834	225	43	drugs.63	drugs.63	NOUN
ihlr-20834	225	44	first	first	ADV
ihlr-20834	225	45	,	,	PUNCT
ihlr-20834	225	46	the	the	DET
ihlr-20834	225	47	proposed	propose	VERB
ihlr-20834	225	48	generic	generic	ADJ
ihlr-20834	225	49	drug	drug	NOUN
ihlr-20834	225	50	must	must	AUX
ihlr-20834	225	51	be	be	AUX
ihlr-20834	225	52	chemically	chemically	ADV
ihlr-20834	225	53	equivalent	equivalent	ADJ
ihlr-20834	225	54	to	to	ADP
ihlr-20834	225	55	the	the	DET
ihlr-20834	225	56	approved	approve	VERB
ihlr-20834	225	57	brand	brand	NOUN
ihlr-20834	225	58	-	-	PUNCT
ihlr-20834	225	59	name	name	NOUN
ihlr-20834	225	60	drug	drug	NOUN
ihlr-20834	225	61	.	.	PUNCT
ihlr-20834	226	1	64	64	NUM
ihlr-20834	226	2	this	this	PRON
ihlr-20834	226	3	requires	require	VERB
ihlr-20834	226	4	the	the	DET
ihlr-20834	226	5	generic	generic	ADJ
ihlr-20834	226	6	drug	drug	NOUN
ihlr-20834	226	7	to	to	PART
ihlr-20834	226	8	have	have	VERB
ihlr-20834	226	9	the	the	DET
ihlr-20834	226	10	same	same	ADJ
ihlr-20834	226	11	“	"	PUNCT
ihlr-20834	226	12	active	active	ADJ
ihlr-20834	226	13	ingredient	ingredient	NOUN
ihlr-20834	226	14	”	"	PUNCT
ihlr-20834	226	15	or	or	CCONJ
ihlr-20834	226	16	“	"	PUNCT
ihlr-20834	226	17	active	active	ADJ
ihlr-20834	226	18	ingredients	ingredient	NOUN
ihlr-20834	226	19	,	,	PUNCT
ihlr-20834	226	20	”	"	PUNCT
ihlr-20834	226	21	“	"	PUNCT
ihlr-20834	226	22	route	route	NOUN
ihlr-20834	226	23	of	of	ADP
ihlr-20834	226	24	administration	administration	NOUN
ihlr-20834	226	25	,	,	PUNCT
ihlr-20834	226	26	”	"	PUNCT
ihlr-20834	226	27	“	"	PUNCT
ihlr-20834	226	28	dosage	dosage	NOUN
ihlr-20834	226	29	form	form	NOUN
ihlr-20834	226	30	,	,	PUNCT
ihlr-20834	226	31	”	"	PUNCT
ihlr-20834	226	32	and	and	CCONJ
ihlr-20834	226	33	“	"	PUNCT
ihlr-20834	226	34	strength	strength	NOUN
ihlr-20834	226	35	”	"	PUNCT
ihlr-20834	226	36	as	as	ADP
ihlr-20834	226	37	the	the	DET
ihlr-20834	226	38	approved	approve	VERB
ihlr-20834	226	39	brand	brand	NOUN
ihlr-20834	226	40	-	-	PUNCT
ihlr-20834	226	41	name	name	NOUN
ihlr-20834	226	42	drug	drug	NOUN
ihlr-20834	226	43	.	.	PUNCT
ihlr-20834	227	1	65	65	NUM
ihlr-20834	227	2	second	second	ADJ
ihlr-20834	227	3	,	,	PUNCT
ihlr-20834	227	4	the	the	DET
ihlr-20834	227	5	generic	generic	ADJ
ihlr-20834	227	6	drug	drug	NOUN
ihlr-20834	227	7	must	must	AUX
ihlr-20834	227	8	be	be	AUX
ihlr-20834	227	9	“	"	PUNCT
ihlr-20834	227	10	bioequivalent	bioequivalent	NOUN
ihlr-20834	227	11	”	"	PUNCT
ihlr-20834	227	12	to	to	ADP
ihlr-20834	227	13	the	the	DET
ihlr-20834	227	14	approved	approve	VERB
ihlr-20834	227	15	brand	brand	NOUN
ihlr-20834	227	16	-	-	PUNCT
ihlr-20834	227	17	name	name	NOUN
ihlr-20834	227	18	drug.66	drug.66	NOUN
ihlr-20834	227	19	to	to	PART
ihlr-20834	227	20	be	be	AUX
ihlr-20834	227	21	considered	consider	VERB
ihlr-20834	227	22	bioequivalent	bioequivalent	NOUN
ihlr-20834	227	23	,	,	PUNCT
ihlr-20834	227	24	a	a	DET
ihlr-20834	227	25	generic	generic	ADJ
ihlr-20834	227	26	drug	drug	NOUN
ihlr-20834	227	27	has	have	VERB
ihlr-20834	227	28	to	to	PART
ihlr-20834	227	29	have	have	VERB
ihlr-20834	227	30	the	the	DET
ihlr-20834	227	31	same	same	ADJ
ihlr-20834	227	32	“	"	PUNCT
ihlr-20834	227	33	rate	rate	NOUN
ihlr-20834	227	34	and	and	CCONJ
ihlr-20834	227	35	extent	extent	NOUN
ihlr-20834	227	36	of	of	ADP
ihlr-20834	227	37	absorption	absorption	NOUN
ihlr-20834	227	38	.	.	PUNCT
ihlr-20834	227	39	.	.	PUNCT
ihlr-20834	227	40	.	.	PUNCT
ihlr-20834	227	41	”	"	PUNCT
ihlr-20834	228	1	as	as	ADP
ihlr-20834	228	2	its	its	PRON
ihlr-20834	228	3	brandname	brandname	NOUN
ihlr-20834	228	4	counterpart	counterpart	NOUN
ihlr-20834	228	5	.	.	PUNCT
ihlr-20834	229	1	67	67	NUM
ihlr-20834	229	2	third	third	ADJ
ihlr-20834	229	3	,	,	PUNCT
ihlr-20834	229	4	generic	generic	ADJ
ihlr-20834	229	5	drug	drug	NOUN
ihlr-20834	229	6	manufacturers	manufacturer	NOUN
ihlr-20834	229	7	must	must	AUX
ihlr-20834	229	8	show	show	VERB
ihlr-20834	229	9	that	that	SCONJ
ihlr-20834	229	10	the	the	DET
ihlr-20834	229	11	“	"	PUNCT
ihlr-20834	229	12	labeling	labeling	NOUN
ihlr-20834	229	13	proposed	propose	VERB
ihlr-20834	229	14	for	for	ADP
ihlr-20834	229	15	the	the	DET
ihlr-20834	229	16	new	new	ADJ
ihlr-20834	229	17	drug	drug	NOUN
ihlr-20834	229	18	is	be	AUX
ihlr-20834	229	19	the	the	DET
ihlr-20834	229	20	same	same	ADJ
ihlr-20834	229	21	as	as	ADP
ihlr-20834	229	22	the	the	DET
ihlr-20834	229	23	labeling	labeling	NOUN
ihlr-20834	229	24	approved	approve	VERB
ihlr-20834	229	25	for	for	ADP
ihlr-20834	229	26	the	the	DET
ihlr-20834	229	27	listed	list	VERB
ihlr-20834	229	28	drug	drug	NOUN
ihlr-20834	229	29	.	.	PUNCT
ihlr-20834	229	30	.	.	PUNCT
ihlr-20834	229	31	.	.	PUNCT
ihlr-20834	230	1	.”68	.”68	PUNCT
ihlr-20834	231	1	this	this	DET
ihlr-20834	231	2	labeling	labeling	NOUN
ihlr-20834	231	3	requirement	requirement	NOUN
ihlr-20834	231	4	has	have	AUX
ihlr-20834	231	5	been	be	AUX
ihlr-20834	231	6	argued	argue	VERB
ihlr-20834	231	7	(	(	PUNCT
ihlr-20834	231	8	and	and	CCONJ
ihlr-20834	231	9	interpreted	interpret	VERB
ihlr-20834	231	10	)	)	PUNCT
ihlr-20834	231	11	as	as	ADP
ihlr-20834	231	12	meaning	mean	VERB
ihlr-20834	231	13	generic	generic	ADJ
ihlr-20834	231	14	drug	drug	NOUN
ihlr-20834	231	15	manufacturers	manufacturer	NOUN
ihlr-20834	231	16	are	be	AUX
ihlr-20834	231	17	not	not	PART
ihlr-20834	231	18	able	able	ADJ
ihlr-20834	231	19	to	to	PART
ihlr-20834	231	20	unilaterally	unilaterally	ADV
ihlr-20834	231	21	change	change	VERB
ihlr-20834	231	22	their	their	PRON
ihlr-20834	231	23	labels	label	NOUN
ihlr-20834	231	24	to	to	PART
ihlr-20834	231	25	strengthen	strengthen	VERB
ihlr-20834	231	26	warnings.69	warnings.69	NOUN
ihlr-20834	231	27	the	the	DET
ihlr-20834	231	28	fda	fda	PROPN
ihlr-20834	231	29	approves	approve	VERB
ihlr-20834	231	30	generic	generic	ADJ
ihlr-20834	231	31	drugs	drug	NOUN
ihlr-20834	231	32	only	only	ADV
ihlr-20834	231	33	if	if	SCONJ
ihlr-20834	231	34	they	they	PRON
ihlr-20834	231	35	are	be	AUX
ihlr-20834	231	36	determined	determined	ADJ
ihlr-20834	231	37	“	"	PUNCT
ihlr-20834	231	38	safe	safe	ADJ
ihlr-20834	231	39	for	for	ADP
ihlr-20834	231	40	use	use	NOUN
ihlr-20834	231	41	”	"	PUNCT
ihlr-20834	231	42	under	under	ADP
ihlr-20834	231	43	“	"	PUNCT
ihlr-20834	231	44	conditions	condition	NOUN
ihlr-20834	231	45	of	of	ADP
ihlr-20834	231	46	use	use	NOUN
ihlr-20834	231	47	62	62	NUM
ihlr-20834	231	48	wyeth	wyeth	NOUN
ihlr-20834	231	49	,	,	PUNCT
ihlr-20834	231	50	555	555	NUM
ihlr-20834	231	51	u.s	u.s	PROPN
ihlr-20834	231	52	.	.	PROPN
ihlr-20834	231	53	at	at	ADP
ihlr-20834	231	54	578	578	NUM
ihlr-20834	231	55	-	-	SYM
ihlr-20834	231	56	79	79	NUM
ihlr-20834	231	57	.	.	PUNCT
ihlr-20834	232	1	63	63	NUM
ihlr-20834	232	2	bartlett	bartlett	NOUN
ihlr-20834	232	3	,	,	PUNCT
ihlr-20834	232	4	133	133	NUM
ihlr-20834	232	5	s.ct	s.ct	NOUN
ihlr-20834	232	6	.	.	PUNCT
ihlr-20834	232	7	at	at	ADP
ihlr-20834	232	8	2471	2471	NUM
ihlr-20834	232	9	.	.	PUNCT
ihlr-20834	233	1	64	64	NUM
ihlr-20834	233	2	21	21	NUM
ihlr-20834	233	3	u.s.c	u.s.c	NOUN
ihlr-20834	233	4	.	.	PUNCT
ihlr-20834	234	1	§	§	PROPN
ihlr-20834	234	2	355(j)(2)(a)(ii	355(j)(2)(a)(ii	NUM
ihlr-20834	234	3	)	)	PUNCT
ihlr-20834	234	4	(	(	PUNCT
ihlr-20834	234	5	2015	2015	NUM
ihlr-20834	234	6	)	)	PUNCT
ihlr-20834	234	7	.	.	PUNCT
ihlr-20834	235	1	65	65	NUM
ihlr-20834	236	1	i	i	PRON
ihlr-20834	236	2	d.	d.	PROPN
ihlr-20834	236	3	§	§	PROPN
ihlr-20834	236	4	§	§	PROPN
ihlr-20834	236	5	355(j)(2)(a)(ii)-(iii	355(j)(2)(a)(ii)-(iii	NUM
ihlr-20834	236	6	)	)	PUNCT
ihlr-20834	236	7	(	(	PUNCT
ihlr-20834	236	8	2015	2015	NUM
ihlr-20834	236	9	)	)	PUNCT
ihlr-20834	236	10	.	.	PUNCT
ihlr-20834	237	1	66	66	NUM
ihlr-20834	238	1	i	i	PRON
ihlr-20834	238	2	d.	d.	PROPN
ihlr-20834	238	3	§	§	PROPN
ihlr-20834	238	4	355(j)(2)(a)(iv	355(j)(2)(a)(iv	PROPN
ihlr-20834	238	5	)	)	PUNCT
ihlr-20834	238	6	.	.	PUNCT
ihlr-20834	239	1	67	67	NUM
ihlr-20834	240	1	i	i	PRON
ihlr-20834	240	2	d.	d.	PROPN
ihlr-20834	240	3	§	§	PROPN
ihlr-20834	240	4	355(j)(8)(b)(i	355(j)(8)(b)(i	NUM
ihlr-20834	240	5	)	)	PUNCT
ihlr-20834	240	6	.	.	PUNCT
ihlr-20834	241	1	68	68	NUM
ihlr-20834	242	1	i	i	PRON
ihlr-20834	242	2	d.	d.	PROPN
ihlr-20834	242	3	§	§	PROPN
ihlr-20834	242	4	355(j)(2)(a)(v	355(j)(2)(a)(v	PROPN
ihlr-20834	242	5	)	)	PUNCT
ihlr-20834	242	6	.	.	PUNCT
ihlr-20834	243	1	69	69	NUM
ihlr-20834	243	2	pliva	pliva	PROPN
ihlr-20834	243	3	,	,	PUNCT
ihlr-20834	243	4	inc	inc	PROPN
ihlr-20834	243	5	.	.	PROPN
ihlr-20834	244	1	v.	v.	CCONJ
ihlr-20834	244	2	mensing	mense	VERB
ihlr-20834	244	3	,	,	PUNCT
ihlr-20834	244	4	131	131	NUM
ihlr-20834	244	5	s.ct	s.ct	NOUN
ihlr-20834	244	6	.	.	PROPN
ihlr-20834	244	7	2575	2575	NUM
ihlr-20834	244	8	(	(	PUNCT
ihlr-20834	244	9	2011	2011	NUM
ihlr-20834	244	10	)	)	PUNCT
ihlr-20834	244	11	.	.	PUNCT
ihlr-20834	245	1	782	782	NUM
ihlr-20834	245	2	indiana	indiana	PROPN
ihlr-20834	245	3	health	health	PROPN
ihlr-20834	245	4	law	law	PROPN
ihlr-20834	245	5	review	review	NOUN
ihlr-20834	245	6	vol	vol	NOUN
ihlr-20834	245	7	.	.	PROPN
ihlr-20834	245	8	12:2	12:2	NUM
ihlr-20834	245	9	prescribed	prescribe	VERB
ihlr-20834	245	10	,	,	PUNCT
ihlr-20834	245	11	recommended	recommend	VERB
ihlr-20834	245	12	,	,	PUNCT
ihlr-20834	245	13	or	or	CCONJ
ihlr-20834	245	14	suggested	suggest	VERB
ihlr-20834	245	15	in	in	ADP
ihlr-20834	245	16	the	the	DET
ihlr-20834	245	17	proposed	propose	VERB
ihlr-20834	245	18	label	label	NOUN
ihlr-20834	245	19	thereof	thereof	ADV
ihlr-20834	245	20	.	.	PUNCT
ihlr-20834	246	1	”70	”70	VERB
ihlr-20834	246	2	the	the	DET
ihlr-20834	246	3	risk	risk	NOUN
ihlr-20834	246	4	of	of	ADP
ihlr-20834	246	5	harm	harm	NOUN
ihlr-20834	246	6	must	must	AUX
ihlr-20834	246	7	be	be	AUX
ihlr-20834	246	8	outweighed	outweigh	VERB
ihlr-20834	246	9	by	by	ADP
ihlr-20834	246	10	the	the	DET
ihlr-20834	246	11	“	"	PUNCT
ihlr-20834	246	12	probable	probable	ADJ
ihlr-20834	246	13	therapeutic	therapeutic	ADJ
ihlr-20834	246	14	benefits	benefit	NOUN
ihlr-20834	246	15	.	.	PUNCT
ihlr-20834	246	16	.	.	PUNCT
ihlr-20834	246	17	.	.	PUNCT
ihlr-20834	247	1	.”71	.”71	PROPN
ihlr-20834	248	1	once	once	SCONJ
ihlr-20834	248	2	a	a	DET
ihlr-20834	248	3	generic	generic	ADJ
ihlr-20834	248	4	drug	drug	NOUN
ihlr-20834	248	5	is	be	AUX
ihlr-20834	248	6	approved	approve	VERB
ihlr-20834	248	7	,	,	PUNCT
ihlr-20834	248	8	a	a	DET
ihlr-20834	248	9	manufacturer	manufacturer	NOUN
ihlr-20834	248	10	is	be	AUX
ihlr-20834	248	11	prohibited	prohibit	VERB
ihlr-20834	248	12	from	from	ADP
ihlr-20834	248	13	making	make	VERB
ihlr-20834	248	14	any	any	DET
ihlr-20834	248	15	major	major	ADJ
ihlr-20834	248	16	changes	change	NOUN
ihlr-20834	248	17	to	to	ADP
ihlr-20834	248	18	the	the	DET
ihlr-20834	248	19	quantitative	quantitative	ADJ
ihlr-20834	248	20	or	or	CCONJ
ihlr-20834	248	21	qualitative	qualitative	ADJ
ihlr-20834	248	22	formulation	formulation	NOUN
ihlr-20834	248	23	of	of	ADP
ihlr-20834	248	24	the	the	DET
ihlr-20834	248	25	drug	drug	NOUN
ihlr-20834	248	26	,	,	PUNCT
ihlr-20834	248	27	including	include	VERB
ihlr-20834	248	28	but	but	CCONJ
ihlr-20834	248	29	not	not	PART
ihlr-20834	248	30	limited	limit	VERB
ihlr-20834	248	31	to	to	ADP
ihlr-20834	248	32	its	its	PRON
ihlr-20834	248	33	active	active	ADJ
ihlr-20834	248	34	ingredients	ingredient	NOUN
ihlr-20834	248	35	or	or	CCONJ
ihlr-20834	248	36	specifications	specification	NOUN
ihlr-20834	248	37	included	include	VERB
ihlr-20834	248	38	in	in	ADP
ihlr-20834	248	39	the	the	DET
ihlr-20834	248	40	approved	approve	VERB
ihlr-20834	248	41	application.72	application.72	NOUN
ihlr-20834	248	42	therefore	therefore	ADV
ihlr-20834	248	43	,	,	PUNCT
ihlr-20834	248	44	generic	generic	ADJ
ihlr-20834	248	45	drugs	drug	NOUN
ihlr-20834	248	46	are	be	AUX
ihlr-20834	248	47	required	require	VERB
ihlr-20834	248	48	to	to	PART
ihlr-20834	248	49	have	have	VERB
ihlr-20834	248	50	the	the	DET
ihlr-20834	248	51	same	same	ADJ
ihlr-20834	248	52	dosage	dosage	NOUN
ihlr-20834	248	53	form	form	NOUN
ihlr-20834	248	54	,	,	PUNCT
ihlr-20834	248	55	strength	strength	NOUN
ihlr-20834	248	56	,	,	PUNCT
ihlr-20834	248	57	active	active	ADJ
ihlr-20834	248	58	ingredients	ingredient	NOUN
ihlr-20834	248	59	,	,	PUNCT
ihlr-20834	248	60	and	and	CCONJ
ihlr-20834	248	61	route	route	NOUN
ihlr-20834	248	62	of	of	ADP
ihlr-20834	248	63	administration	administration	NOUN
ihlr-20834	248	64	as	as	ADP
ihlr-20834	248	65	their	their	PRON
ihlr-20834	248	66	brand	brand	NOUN
ihlr-20834	248	67	-	-	PUNCT
ihlr-20834	248	68	name	name	NOUN
ihlr-20834	248	69	counterpart.73	counterpart.73	NOUN
ihlr-20834	248	70	in	in	ADP
ihlr-20834	248	71	an	an	DET
ihlr-20834	248	72	attempt	attempt	NOUN
ihlr-20834	248	73	to	to	PART
ihlr-20834	248	74	continually	continually	ADV
ihlr-20834	248	75	promote	promote	VERB
ihlr-20834	248	76	drug	drug	NOUN
ihlr-20834	248	77	efficacy	efficacy	NOUN
ihlr-20834	248	78	and	and	CCONJ
ihlr-20834	248	79	safety	safety	NOUN
ihlr-20834	248	80	,	,	PUNCT
ihlr-20834	248	81	both	both	DET
ihlr-20834	248	82	anda	anda	PROPN
ihlr-20834	248	83	’s	’s	PROPN
ihlr-20834	248	84	and	and	CCONJ
ihlr-20834	248	85	nda	nda	PROPN
ihlr-20834	248	86	’s	’s	PART
ihlr-20834	248	87	are	be	AUX
ihlr-20834	248	88	required	require	VERB
ihlr-20834	248	89	by	by	ADP
ihlr-20834	248	90	federal	federal	ADJ
ihlr-20834	248	91	regulations	regulation	NOUN
ihlr-20834	248	92	to	to	PART
ihlr-20834	248	93	comply	comply	VERB
ihlr-20834	248	94	with	with	ADP
ihlr-20834	248	95	reporting	reporting	NOUN
ihlr-20834	248	96	and	and	CCONJ
ihlr-20834	248	97	monitoring	monitoring	NOUN
ihlr-20834	248	98	requirements	requirement	NOUN
ihlr-20834	248	99	regarding	regard	VERB
ihlr-20834	248	100	drug	drug	NOUN
ihlr-20834	248	101	safety	safety	NOUN
ihlr-20834	248	102	.	.	PUNCT
ihlr-20834	249	1	74	74	NUM
ihlr-20834	249	2	failure	failure	NOUN
ihlr-20834	249	3	to	to	PART
ihlr-20834	249	4	comply	comply	VERB
ihlr-20834	249	5	with	with	ADP
ihlr-20834	249	6	these	these	DET
ihlr-20834	249	7	regulations	regulation	NOUN
ihlr-20834	249	8	by	by	ADP
ihlr-20834	249	9	establishing	establish	VERB
ihlr-20834	249	10	and	and	CCONJ
ihlr-20834	249	11	maintaining	maintain	VERB
ihlr-20834	249	12	records	record	NOUN
ihlr-20834	249	13	may	may	AUX
ihlr-20834	249	14	result	result	VERB
ihlr-20834	249	15	in	in	ADP
ihlr-20834	249	16	the	the	DET
ihlr-20834	249	17	fda	fda	PROPN
ihlr-20834	249	18	“	"	PUNCT
ihlr-20834	249	19	withdraw[ing	withdraw[e	VERB
ihlr-20834	249	20	]	]	PUNCT
ihlr-20834	249	21	approval	approval	NOUN
ihlr-20834	249	22	of	of	ADP
ihlr-20834	249	23	the	the	DET
ihlr-20834	249	24	application	application	NOUN
ihlr-20834	249	25	and	and	CCONJ
ihlr-20834	249	26	,	,	PUNCT
ihlr-20834	249	27	thus	thus	ADV
ihlr-20834	249	28	,	,	PUNCT
ihlr-20834	249	29	prohibit[ing	prohibit[e	VERB
ihlr-20834	249	30	]	]	PUNCT
ihlr-20834	249	31	continued	continue	VERB
ihlr-20834	249	32	marketing	marketing	NOUN
ihlr-20834	249	33	of	of	ADP
ihlr-20834	249	34	the	the	DET
ihlr-20834	249	35	drug	drug	NOUN
ihlr-20834	249	36	product	product	NOUN
ihlr-20834	249	37	that	that	PRON
ihlr-20834	249	38	is	be	AUX
ihlr-20834	249	39	the	the	DET
ihlr-20834	249	40	subject	subject	NOUN
ihlr-20834	249	41	of	of	ADP
ihlr-20834	249	42	the	the	DET
ihlr-20834	249	43	application	application	NOUN
ihlr-20834	249	44	.	.	PUNCT
ihlr-20834	250	1	”75	”75	PROPN
ihlr-20834	250	2	furthermore	furthermore	ADV
ihlr-20834	250	3	,	,	PUNCT
ihlr-20834	250	4	to	to	PART
ihlr-20834	250	5	facilitate	facilitate	VERB
ihlr-20834	250	6	consumer	consumer	NOUN
ihlr-20834	250	7	safety	safety	NOUN
ihlr-20834	250	8	,	,	PUNCT
ihlr-20834	250	9	drug	drug	NOUN
ihlr-20834	250	10	manufacturers	manufacturer	NOUN
ihlr-20834	250	11	may	may	AUX
ihlr-20834	250	12	“	"	PUNCT
ihlr-20834	250	13	add	add	VERB
ihlr-20834	250	14	or	or	CCONJ
ihlr-20834	250	15	strengthen	strengthen	VERB
ihlr-20834	250	16	a	a	DET
ihlr-20834	250	17	contraindication	contraindication	NOUN
ihlr-20834	250	18	,	,	PUNCT
ihlr-20834	250	19	warning	warning	NOUN
ihlr-20834	250	20	,	,	PUNCT
ihlr-20834	250	21	precaution	precaution	NOUN
ihlr-20834	250	22	,	,	PUNCT
ihlr-20834	250	23	or	or	CCONJ
ihlr-20834	250	24	adverse	adverse	ADJ
ihlr-20834	250	25	reaction	reaction	NOUN
ihlr-20834	250	26	.	.	PUNCT
ihlr-20834	250	27	.	.	PUNCT
ihlr-20834	251	1	.	.	PUNCT
ihlr-20834	251	2	”	"	PUNCT
ihlr-20834	252	1	without	without	ADP
ihlr-20834	252	2	prior	prior	ADJ
ihlr-20834	252	3	approval	approval	NOUN
ihlr-20834	252	4	so	so	ADV
ihlr-20834	252	5	long	long	ADV
ihlr-20834	252	6	as	as	SCONJ
ihlr-20834	252	7	they	they	PRON
ihlr-20834	252	8	notify	notify	VERB
ihlr-20834	252	9	the	the	DET
ihlr-20834	252	10	fda	fda	PROPN
ihlr-20834	252	11	thirty	thirty	NUM
ihlr-20834	252	12	days	day	NOUN
ihlr-20834	252	13	prior	prior	ADV
ihlr-20834	252	14	to	to	ADP
ihlr-20834	252	15	drug	drug	NOUN
ihlr-20834	252	16	distribution	distribution	NOUN
ihlr-20834	252	17	.	.	PUNCT
ihlr-20834	253	1	76	76	NUM
ihlr-20834	253	2	it	it	PRON
ihlr-20834	253	3	would	would	AUX
ihlr-20834	253	4	appear	appear	VERB
ihlr-20834	253	5	that	that	SCONJ
ihlr-20834	253	6	the	the	DET
ihlr-20834	253	7	previous	previous	ADJ
ihlr-20834	253	8	responsibility	responsibility	NOUN
ihlr-20834	253	9	would	would	AUX
ihlr-20834	253	10	hold	hold	VERB
ihlr-20834	253	11	generic	generic	ADJ
ihlr-20834	253	12	drug	drug	NOUN
ihlr-20834	253	13	manufacturers	manufacturer	NOUN
ihlr-20834	253	14	liable	liable	ADJ
ihlr-20834	253	15	for	for	ADP
ihlr-20834	253	16	failing	fail	VERB
ihlr-20834	253	17	to	to	PART
ihlr-20834	253	18	update	update	VERB
ihlr-20834	253	19	their	their	PRON
ihlr-20834	253	20	labels	label	NOUN
ihlr-20834	253	21	.	.	PUNCT
ihlr-20834	254	1	however	however	ADV
ihlr-20834	254	2	,	,	PUNCT
ihlr-20834	254	3	as	as	SCONJ
ihlr-20834	254	4	discussed	discuss	VERB
ihlr-20834	254	5	below	below	ADV
ihlr-20834	254	6	,	,	PUNCT
ihlr-20834	254	7	the	the	DET
ihlr-20834	254	8	duty	duty	NOUN
ihlr-20834	254	9	of	of	ADP
ihlr-20834	254	10	sameness	sameness	NOUN
ihlr-20834	254	11	absolves	absolve	VERB
ihlr-20834	254	12	generic	generic	ADJ
ihlr-20834	254	13	drug	drug	NOUN
ihlr-20834	254	14	manufacturers	manufacturer	NOUN
ihlr-20834	254	15	of	of	ADP
ihlr-20834	254	16	liability	liability	NOUN
ihlr-20834	254	17	.	.	PUNCT
ihlr-20834	255	1	70	70	NUM
ihlr-20834	255	2	21	21	NUM
ihlr-20834	255	3	u.s.c	u.s.c	NOUN
ihlr-20834	255	4	.	.	PUNCT
ihlr-20834	256	1	§	§	PROPN
ihlr-20834	256	2	355(d	355(d	PROPN
ihlr-20834	256	3	)	)	PUNCT
ihlr-20834	256	4	(	(	PUNCT
ihlr-20834	256	5	2015	2015	NUM
ihlr-20834	256	6	)	)	PUNCT
ihlr-20834	256	7	.	.	PUNCT
ihlr-20834	257	1	71	71	NUM
ihlr-20834	257	2	fda	fda	PROPN
ihlr-20834	257	3	v.	v.	PROPN
ihlr-20834	257	4	brown	brown	PROPN
ihlr-20834	257	5	&	&	CCONJ
ihlr-20834	257	6	williamson	williamson	PROPN
ihlr-20834	257	7	tobacco	tobacco	PROPN
ihlr-20834	257	8	corp	corp	PROPN
ihlr-20834	257	9	.	.	PROPN
ihlr-20834	257	10	,	,	PUNCT
ihlr-20834	257	11	529	529	NUM
ihlr-20834	257	12	u.s	u.s	PROPN
ihlr-20834	257	13	.	.	PROPN
ihlr-20834	257	14	120	120	NUM
ihlr-20834	257	15	,	,	PUNCT
ihlr-20834	257	16	140	140	NUM
ihlr-20834	257	17	(	(	PUNCT
ihlr-20834	257	18	2000	2000	NUM
ihlr-20834	257	19	)	)	PUNCT
ihlr-20834	257	20	.	.	PUNCT
ihlr-20834	258	1	72	72	NUM
ihlr-20834	258	2	21	21	NUM
ihlr-20834	258	3	c.f.r	c.f.r	NOUN
ihlr-20834	258	4	.	.	PUNCT
ihlr-20834	259	1	§	§	PROPN
ihlr-20834	259	2	314.70(b)(2)(i	314.70(b)(2)(i	NUM
ihlr-20834	259	3	)	)	PUNCT
ihlr-20834	259	4	(	(	PUNCT
ihlr-20834	259	5	2015	2015	NUM
ihlr-20834	259	6	)	)	PUNCT
ihlr-20834	259	7	.	.	PUNCT
ihlr-20834	260	1	73	73	NUM
ihlr-20834	260	2	21	21	NUM
ihlr-20834	260	3	u.s.c	u.s.c	NOUN
ihlr-20834	260	4	.	.	PUNCT
ihlr-20834	261	1	§	§	PROPN
ihlr-20834	261	2	355(j	355(j	PROPN
ihlr-20834	261	3	)	)	PUNCT
ihlr-20834	261	4	(	(	PUNCT
ihlr-20834	261	5	2015	2015	NUM
ihlr-20834	261	6	)	)	PUNCT
ihlr-20834	261	7	.	.	PUNCT
ihlr-20834	262	1	74	74	NUM
ihlr-20834	262	2	21	21	NUM
ihlr-20834	262	3	c.f.r	c.f.r	NOUN
ihlr-20834	262	4	.	.	PUNCT
ihlr-20834	263	1	§	§	PROPN
ihlr-20834	263	2	314.98(a	314.98(a	NUM
ihlr-20834	263	3	)	)	PUNCT
ihlr-20834	263	4	(	(	PUNCT
ihlr-20834	263	5	“	"	PUNCT
ihlr-20834	263	6	[	[	X
ihlr-20834	263	7	e]ach	e]ach	X
ihlr-20834	263	8	applicant	applicant	NOUN
ihlr-20834	263	9	having	have	VERB
ihlr-20834	263	10	an	an	DET
ihlr-20834	263	11	approved	approve	VERB
ihlr-20834	263	12	abbreviated	abbreviate	VERB
ihlr-20834	263	13	new	new	ADJ
ihlr-20834	263	14	drug	drug	NOUN
ihlr-20834	263	15	application	application	NOUN
ihlr-20834	263	16	.	.	PUNCT
ihlr-20834	263	17	.	.	PUNCT
ihlr-20834	263	18	.	.	PUNCT
ihlr-20834	264	1	that	that	PRON
ihlr-20834	264	2	is	be	AUX
ihlr-20834	264	3	effective	effective	ADJ
ihlr-20834	264	4	shall	shall	AUX
ihlr-20834	264	5	comply	comply	VERB
ihlr-20834	264	6	with	with	ADP
ihlr-20834	264	7	the	the	DET
ihlr-20834	264	8	requirements	requirement	NOUN
ihlr-20834	264	9	of	of	ADP
ihlr-20834	264	10	§	§	NOUN
ihlr-20834	264	11	314.80	314.80	NUM
ihlr-20834	264	12	regarding	regard	VERB
ihlr-20834	264	13	the	the	DET
ihlr-20834	264	14	reporting	reporting	NOUN
ihlr-20834	264	15	and	and	CCONJ
ihlr-20834	264	16	recordkeeping	recordkeeping	NOUN
ihlr-20834	264	17	of	of	ADP
ihlr-20834	264	18	adverse	adverse	ADJ
ihlr-20834	264	19	drug	drug	NOUN
ihlr-20834	264	20	experiences	experience	NOUN
ihlr-20834	264	21	.	.	PUNCT
ihlr-20834	264	22	”	"	PUNCT
ihlr-20834	264	23	)	)	PUNCT
ihlr-20834	264	24	.	.	PUNCT
ihlr-20834	265	1	see	see	VERB
ihlr-20834	265	2	21	21	NUM
ihlr-20834	265	3	c.f.r	c.f.r	NOUN
ihlr-20834	265	4	.	.	PUNCT
ihlr-20834	266	1	§	§	PROPN
ihlr-20834	266	2	314.80	314.80	NUM
ihlr-20834	266	3	for	for	ADP
ihlr-20834	266	4	requirements	requirement	NOUN
ihlr-20834	266	5	.	.	PUNCT
ihlr-20834	267	1	75	75	NUM
ihlr-20834	267	2	21	21	NUM
ihlr-20834	267	3	c.f.r	c.f.r	NOUN
ihlr-20834	267	4	.	.	PUNCT
ihlr-20834	268	1	§	§	PROPN
ihlr-20834	268	2	314.80(j	314.80(j	NUM
ihlr-20834	268	3	)	)	PUNCT
ihlr-20834	268	4	(	(	PUNCT
ihlr-20834	268	5	“	"	PUNCT
ihlr-20834	268	6	withdrawal	withdrawal	NOUN
ihlr-20834	268	7	of	of	ADP
ihlr-20834	268	8	approval	approval	NOUN
ihlr-20834	268	9	.	.	PUNCT
ihlr-20834	269	1	if	if	SCONJ
ihlr-20834	269	2	an	an	DET
ihlr-20834	269	3	applicant	applicant	NOUN
ihlr-20834	269	4	fails	fail	VERB
ihlr-20834	269	5	to	to	PART
ihlr-20834	269	6	establish	establish	VERB
ihlr-20834	269	7	and	and	CCONJ
ihlr-20834	269	8	maintain	maintain	VERB
ihlr-20834	269	9	records	record	NOUN
ihlr-20834	269	10	and	and	CCONJ
ihlr-20834	269	11	make	make	VERB
ihlr-20834	269	12	reports	report	NOUN
ihlr-20834	269	13	required	require	VERB
ihlr-20834	269	14	under	under	ADP
ihlr-20834	269	15	this	this	DET
ihlr-20834	269	16	section	section	NOUN
ihlr-20834	269	17	,	,	PUNCT
ihlr-20834	269	18	fda	fda	PROPN
ihlr-20834	269	19	may	may	AUX
ihlr-20834	269	20	withdraw	withdraw	VERB
ihlr-20834	269	21	approval	approval	NOUN
ihlr-20834	269	22	of	of	ADP
ihlr-20834	269	23	the	the	DET
ihlr-20834	269	24	application	application	NOUN
ihlr-20834	269	25	and	and	CCONJ
ihlr-20834	269	26	,	,	PUNCT
ihlr-20834	269	27	thus	thus	ADV
ihlr-20834	269	28	,	,	PUNCT
ihlr-20834	269	29	prohibit	prohibit	VERB
ihlr-20834	269	30	continued	continue	VERB
ihlr-20834	269	31	marketing	marketing	NOUN
ihlr-20834	269	32	of	of	ADP
ihlr-20834	269	33	the	the	DET
ihlr-20834	269	34	drug	drug	NOUN
ihlr-20834	269	35	product	product	NOUN
ihlr-20834	269	36	that	that	PRON
ihlr-20834	269	37	is	be	AUX
ihlr-20834	269	38	the	the	DET
ihlr-20834	269	39	subject	subject	NOUN
ihlr-20834	269	40	of	of	ADP
ihlr-20834	269	41	the	the	DET
ihlr-20834	269	42	application	application	NOUN
ihlr-20834	269	43	.	.	PUNCT
ihlr-20834	269	44	”	"	PUNCT
ihlr-20834	269	45	)	)	PUNCT
ihlr-20834	269	46	.	.	PUNCT
ihlr-20834	270	1	76	76	NUM
ihlr-20834	270	2	21	21	NUM
ihlr-20834	270	3	c.f.r	c.f.r	NOUN
ihlr-20834	270	4	.	.	PUNCT
ihlr-20834	271	1	§	§	PROPN
ihlr-20834	271	2	314.70(c)(6)(iii	314.70(c)(6)(iii	NUM
ihlr-20834	271	3	)	)	PUNCT
ihlr-20834	271	4	(	(	PUNCT
ihlr-20834	271	5	2015	2015	NUM
ihlr-20834	271	6	)	)	PUNCT
ihlr-20834	271	7	.	.	PUNCT
ihlr-20834	272	1	2015	2015	NUM
ihlr-20834	272	2	783	783	NUM
ihlr-20834	272	3	the	the	DET
ihlr-20834	272	4	supreme	supreme	PROPN
ihlr-20834	272	5	court	court	PROPN
ihlr-20834	272	6	’s	’s	PART
ihlr-20834	272	7	overreaching	overreach	VERB
ihlr-20834	272	8	preemption	preemption	NOUN
ihlr-20834	272	9	interpretation	interpretation	NOUN
ihlr-20834	272	10	and	and	CCONJ
ihlr-20834	272	11	it	it	PRON
ihlr-20834	272	12	’s	’	VERB
ihlr-20834	272	13	consequences	consequence	NOUN
ihlr-20834	272	14	iii	iii	PROPN
ihlr-20834	272	15	.	.	PROPN
ihlr-20834	272	16	preemption	preemption	PROPN
ihlr-20834	272	17	doctrine	doctrine	NOUN
ihlr-20834	272	18	analysis	analysis	NOUN
ihlr-20834	272	19	the	the	DET
ihlr-20834	272	20	preemption	preemption	NOUN
ihlr-20834	272	21	doctrine	doctrine	NOUN
ihlr-20834	272	22	plays	play	VERB
ihlr-20834	272	23	an	an	DET
ihlr-20834	272	24	important	important	ADJ
ihlr-20834	272	25	role	role	NOUN
ihlr-20834	272	26	in	in	ADP
ihlr-20834	272	27	understanding	understand	VERB
ihlr-20834	272	28	the	the	DET
ihlr-20834	272	29	shortcomings	shortcoming	NOUN
ihlr-20834	272	30	of	of	ADP
ihlr-20834	272	31	these	these	DET
ihlr-20834	272	32	two	two	NUM
ihlr-20834	272	33	recently	recently	ADV
ihlr-20834	272	34	decided	decide	VERB
ihlr-20834	272	35	supreme	supreme	PROPN
ihlr-20834	272	36	court	court	PROPN
ihlr-20834	272	37	cases	case	NOUN
ihlr-20834	272	38	,	,	PUNCT
ihlr-20834	272	39	pliva	pliva	NOUN
ihlr-20834	272	40	and	and	CCONJ
ihlr-20834	272	41	bartlett	bartlett	PROPN
ihlr-20834	272	42	.	.	PUNCT
ihlr-20834	273	1	to	to	PART
ihlr-20834	273	2	facilitate	facilitate	VERB
ihlr-20834	273	3	the	the	DET
ihlr-20834	273	4	understanding	understanding	NOUN
ihlr-20834	273	5	of	of	ADP
ihlr-20834	273	6	this	this	DET
ihlr-20834	273	7	doctrine	doctrine	NOUN
ihlr-20834	273	8	,	,	PUNCT
ihlr-20834	273	9	this	this	DET
ihlr-20834	273	10	section	section	NOUN
ihlr-20834	273	11	will	will	AUX
ihlr-20834	273	12	explore	explore	VERB
ihlr-20834	273	13	the	the	DET
ihlr-20834	273	14	origin	origin	NOUN
ihlr-20834	273	15	of	of	ADP
ihlr-20834	273	16	the	the	DET
ihlr-20834	273	17	preemption	preemption	NOUN
ihlr-20834	273	18	doctrine	doctrine	NOUN
ihlr-20834	273	19	while	while	SCONJ
ihlr-20834	273	20	providing	provide	VERB
ihlr-20834	273	21	scenarios	scenario	NOUN
ihlr-20834	273	22	where	where	SCONJ
ihlr-20834	273	23	the	the	DET
ihlr-20834	273	24	doctrine	doctrine	NOUN
ihlr-20834	273	25	may	may	AUX
ihlr-20834	273	26	be	be	AUX
ihlr-20834	273	27	applicable	applicable	ADJ
ihlr-20834	273	28	.	.	PUNCT
ihlr-20834	274	1	a.	a.	NOUN
ihlr-20834	274	2	preemption	preemption	PROPN
ihlr-20834	274	3	doctrine	doctrine	NOUN
ihlr-20834	274	4	the	the	DET
ihlr-20834	274	5	preemption	preemption	NOUN
ihlr-20834	274	6	doctrine	doctrine	NOUN
ihlr-20834	274	7	originated	originate	VERB
ihlr-20834	274	8	through	through	ADP
ihlr-20834	274	9	judicial	judicial	ADJ
ihlr-20834	274	10	interpretation	interpretation	NOUN
ihlr-20834	274	11	from	from	ADP
ihlr-20834	274	12	the	the	DET
ihlr-20834	274	13	supremacy	supremacy	NOUN
ihlr-20834	274	14	clause	clause	NOUN
ihlr-20834	274	15	.	.	PUNCT
ihlr-20834	275	1	the	the	DET
ihlr-20834	275	2	supreme	supreme	PROPN
ihlr-20834	275	3	court	court	PROPN
ihlr-20834	275	4	first	first	ADV
ihlr-20834	275	5	relied	rely	VERB
ihlr-20834	275	6	on	on	ADP
ihlr-20834	275	7	the	the	DET
ihlr-20834	275	8	supremacy	supremacy	NOUN
ihlr-20834	275	9	clause	clause	NOUN
ihlr-20834	275	10	in	in	ADP
ihlr-20834	275	11	the	the	DET
ihlr-20834	275	12	1796	1796	NUM
ihlr-20834	275	13	case	case	NOUN
ihlr-20834	275	14	ware	ware	VERB
ihlr-20834	275	15	v.	v.	ADP
ihlr-20834	275	16	hylton.77	hylton.77	ADV
ihlr-20834	275	17	the	the	DET
ihlr-20834	275	18	supremacy	supremacy	NOUN
ihlr-20834	275	19	clause	clause	NOUN
ihlr-20834	275	20	states	state	NOUN
ihlr-20834	275	21	,	,	PUNCT
ihlr-20834	275	22	in	in	ADP
ihlr-20834	275	23	part	part	NOUN
ihlr-20834	275	24	,	,	PUNCT
ihlr-20834	276	1	that	that	SCONJ
ihlr-20834	276	2	the	the	DET
ihlr-20834	276	3	“	"	PUNCT
ihlr-20834	276	4	constitution	constitution	NOUN
ihlr-20834	276	5	,	,	PUNCT
ihlr-20834	276	6	and	and	CCONJ
ihlr-20834	276	7	the	the	DET
ihlr-20834	276	8	laws	law	NOUN
ihlr-20834	276	9	of	of	ADP
ihlr-20834	276	10	the	the	DET
ihlr-20834	276	11	united	united	PROPN
ihlr-20834	276	12	states	states	PROPN
ihlr-20834	276	13	.	.	PUNCT
ihlr-20834	276	14	.	.	PUNCT
ihlr-20834	276	15	.	.	PUNCT
ihlr-20834	276	16	shall	shall	AUX
ihlr-20834	276	17	be	be	AUX
ihlr-20834	276	18	the	the	DET
ihlr-20834	276	19	supreme	supreme	ADJ
ihlr-20834	276	20	law	law	NOUN
ihlr-20834	276	21	of	of	ADP
ihlr-20834	276	22	the	the	DET
ihlr-20834	276	23	land	land	NOUN
ihlr-20834	276	24	.	.	PUNCT
ihlr-20834	277	1	.	.	PUNCT
ihlr-20834	278	1	.	.	PUNCT
ihlr-20834	279	1	.”78	.”78	PUNCT
ihlr-20834	280	1	therefore	therefore	ADV
ihlr-20834	280	2	,	,	PUNCT
ihlr-20834	280	3	the	the	DET
ihlr-20834	280	4	supremacy	supremacy	NOUN
ihlr-20834	280	5	clause	clause	NOUN
ihlr-20834	280	6	has	have	VERB
ihlr-20834	280	7	federal	federal	ADJ
ihlr-20834	280	8	law	law	NOUN
ihlr-20834	280	9	preempt	preempt	VERB
ihlr-20834	280	10	(	(	PUNCT
ihlr-20834	280	11	or	or	CCONJ
ihlr-20834	280	12	reign	reign	NOUN
ihlr-20834	280	13	supreme	supreme	ADJ
ihlr-20834	280	14	)	)	PUNCT
ihlr-20834	280	15	over	over	ADP
ihlr-20834	280	16	state	state	NOUN
ihlr-20834	280	17	law	law	NOUN
ihlr-20834	280	18	when	when	SCONJ
ihlr-20834	280	19	two	two	NUM
ihlr-20834	280	20	laws	law	NOUN
ihlr-20834	280	21	conflict	conflict	NOUN
ihlr-20834	280	22	.	.	PUNCT
ihlr-20834	281	1	in	in	ADP
ihlr-20834	281	2	circumstances	circumstance	NOUN
ihlr-20834	281	3	where	where	SCONJ
ihlr-20834	281	4	the	the	DET
ihlr-20834	281	5	supremacy	supremacy	NOUN
ihlr-20834	281	6	clause	clause	NOUN
ihlr-20834	281	7	is	be	AUX
ihlr-20834	281	8	applicable	applicable	ADJ
ihlr-20834	281	9	,	,	PUNCT
ihlr-20834	281	10	the	the	DET
ihlr-20834	281	11	state	state	NOUN
ihlr-20834	281	12	law	law	NOUN
ihlr-20834	281	13	that	that	PRON
ihlr-20834	281	14	conflicts	conflict	VERB
ihlr-20834	281	15	with	with	ADP
ihlr-20834	281	16	the	the	DET
ihlr-20834	281	17	federal	federal	ADJ
ihlr-20834	281	18	law	law	NOUN
ihlr-20834	281	19	is	be	AUX
ihlr-20834	281	20	generally	generally	ADV
ihlr-20834	281	21	“	"	PUNCT
ihlr-20834	281	22	without	without	ADP
ihlr-20834	281	23	effect	effect	NOUN
ihlr-20834	281	24	.	.	PUNCT
ihlr-20834	282	1	”79	”79	PROPN
ihlr-20834	282	2	federal	federal	ADJ
ihlr-20834	282	3	preemption	preemption	NOUN
ihlr-20834	282	4	is	be	AUX
ihlr-20834	282	5	often	often	ADV
ihlr-20834	282	6	divided	divide	VERB
ihlr-20834	282	7	into	into	ADP
ihlr-20834	282	8	two	two	NUM
ihlr-20834	282	9	categories	category	NOUN
ihlr-20834	282	10	:	:	PUNCT
ihlr-20834	282	11	express	express	VERB
ihlr-20834	282	12	preemption	preemption	NOUN
ihlr-20834	282	13	and	and	CCONJ
ihlr-20834	282	14	implied	imply	VERB
ihlr-20834	282	15	preemption	preemption	NOUN
ihlr-20834	282	16	.	.	PUNCT
ihlr-20834	283	1	80	80	NUM
ihlr-20834	283	2	express	express	ADJ
ihlr-20834	283	3	preemption	preemption	NOUN
ihlr-20834	283	4	exists	exist	VERB
ihlr-20834	283	5	when	when	SCONJ
ihlr-20834	283	6	there	there	PRON
ihlr-20834	283	7	is	be	VERB
ihlr-20834	283	8	an	an	DET
ihlr-20834	283	9	explicit	explicit	ADJ
ihlr-20834	283	10	statutory	statutory	ADJ
ihlr-20834	283	11	provision	provision	NOUN
ihlr-20834	283	12	stating	state	VERB
ihlr-20834	283	13	that	that	SCONJ
ihlr-20834	283	14	federal	federal	ADJ
ihlr-20834	283	15	law	law	NOUN
ihlr-20834	283	16	will	will	AUX
ihlr-20834	283	17	supersede	supersede	VERB
ihlr-20834	283	18	law	law	NOUN
ihlr-20834	283	19	.	.	PUNCT
ihlr-20834	284	1	81	81	NUM
ihlr-20834	284	2	therefore	therefore	ADV
ihlr-20834	284	3	,	,	PUNCT
ihlr-20834	284	4	when	when	SCONJ
ihlr-20834	284	5	an	an	DET
ihlr-20834	284	6	explicit	explicit	ADJ
ihlr-20834	284	7	statutory	statutory	ADJ
ihlr-20834	284	8	provision	provision	NOUN
ihlr-20834	284	9	exists	exist	VERB
ihlr-20834	284	10	stating	state	VERB
ihlr-20834	284	11	federal	federal	ADJ
ihlr-20834	284	12	law	law	NOUN
ihlr-20834	284	13	supersedes	supersede	VERB
ihlr-20834	284	14	all	all	DET
ihlr-20834	284	15	other	other	ADJ
ihlr-20834	284	16	laws	law	NOUN
ihlr-20834	284	17	,	,	PUNCT
ihlr-20834	284	18	the	the	DET
ihlr-20834	284	19	general	general	ADJ
ihlr-20834	284	20	inquiry	inquiry	NOUN
ihlr-20834	284	21	is	be	AUX
ihlr-20834	284	22	whether	whether	SCONJ
ihlr-20834	284	23	the	the	DET
ihlr-20834	284	24	state	state	NOUN
ihlr-20834	284	25	law	law	NOUN
ihlr-20834	284	26	falls	fall	VERB
ihlr-20834	284	27	with	with	ADP
ihlr-20834	284	28	the	the	DET
ihlr-20834	284	29	scope	scope	NOUN
ihlr-20834	284	30	of	of	ADP
ihlr-20834	284	31	the	the	DET
ihlr-20834	284	32	federal	federal	ADJ
ihlr-20834	284	33	law	law	NOUN
ihlr-20834	284	34	.	.	PUNCT
ihlr-20834	285	1	82	82	NUM
ihlr-20834	285	2	to	to	PART
ihlr-20834	285	3	illustrate	illustrate	VERB
ihlr-20834	285	4	,	,	PUNCT
ihlr-20834	285	5	the	the	DET
ihlr-20834	285	6	employee	employee	NOUN
ihlr-20834	285	7	retirement	retirement	VERB
ihlr-20834	285	8	77	77	NUM
ihlr-20834	285	9	ware	ware	NOUN
ihlr-20834	285	10	v.	v.	ADP
ihlr-20834	285	11	hylton	hylton	PROPN
ihlr-20834	285	12	,	,	PUNCT
ihlr-20834	285	13	3	3	NUM
ihlr-20834	285	14	u.s	u.s	PROPN
ihlr-20834	285	15	.	.	PROPN
ihlr-20834	285	16	199	199	NUM
ihlr-20834	285	17	(	(	PUNCT
ihlr-20834	285	18	1796	1796	NUM
ihlr-20834	285	19	)	)	PUNCT
ihlr-20834	285	20	(	(	PUNCT
ihlr-20834	285	21	invalidating	invalidate	VERB
ihlr-20834	285	22	a	a	DET
ihlr-20834	285	23	virginia	virginia	PROPN
ihlr-20834	285	24	law	law	NOUN
ihlr-20834	285	25	providing	provide	VERB
ihlr-20834	285	26	for	for	ADP
ihlr-20834	285	27	confiscation	confiscation	NOUN
ihlr-20834	285	28	of	of	ADP
ihlr-20834	285	29	debts	debt	NOUN
ihlr-20834	285	30	owed	owe	VERB
ihlr-20834	285	31	to	to	ADP
ihlr-20834	285	32	a	a	DET
ihlr-20834	285	33	british	british	ADJ
ihlr-20834	285	34	subject	subject	NOUN
ihlr-20834	285	35	under	under	ADP
ihlr-20834	285	36	the	the	DET
ihlr-20834	285	37	supremacy	supremacy	NOUN
ihlr-20834	285	38	clause	clause	NOUN
ihlr-20834	285	39	)	)	PUNCT
ihlr-20834	285	40	.	.	PUNCT
ihlr-20834	286	1	78	78	NUM
ihlr-20834	287	1	u.s	u.s	PROPN
ihlr-20834	287	2	.	.	PROPN
ihlr-20834	287	3	const	const	PROPN
ihlr-20834	287	4	.	.	PUNCT
ihlr-20834	288	1	art	art	NOUN
ihlr-20834	288	2	.	.	PUNCT
ihlr-20834	289	1	vi	vi	NOUN
ihlr-20834	289	2	,	,	PUNCT
ihlr-20834	289	3	cl	cl	NOUN
ihlr-20834	289	4	.	.	NOUN
ihlr-20834	289	5	2	2	NUM
ihlr-20834	289	6	(	(	PUNCT
ihlr-20834	289	7	emphasis	emphasis	NOUN
ihlr-20834	289	8	added	add	VERB
ihlr-20834	289	9	)	)	PUNCT
ihlr-20834	289	10	.	.	PUNCT
ihlr-20834	290	1	79	79	NUM
ihlr-20834	290	2	maryland	maryland	PROPN
ihlr-20834	290	3	v.	v.	ADP
ihlr-20834	290	4	louisana	louisana	PROPN
ihlr-20834	290	5	,	,	PUNCT
ihlr-20834	290	6	451	451	NUM
ihlr-20834	290	7	u.s	u.s	PROPN
ihlr-20834	290	8	.	.	PROPN
ihlr-20834	290	9	725	725	NUM
ihlr-20834	290	10	,	,	PUNCT
ihlr-20834	290	11	746	746	NUM
ihlr-20834	290	12	(	(	PUNCT
ihlr-20834	290	13	1981	1981	NUM
ihlr-20834	290	14	)	)	PUNCT
ihlr-20834	290	15	.	.	PUNCT
ihlr-20834	291	1	80	80	NUM
ihlr-20834	291	2	jennifer	jennifer	PROPN
ihlr-20834	291	3	s.	s.	PROPN
ihlr-20834	291	4	hendricks	hendricks	PROPN
ihlr-20834	291	5	,	,	PUNCT
ihlr-20834	291	6	preemption	preemption	NOUN
ihlr-20834	291	7	of	of	ADP
ihlr-20834	291	8	common	common	ADJ
ihlr-20834	291	9	law	law	NOUN
ihlr-20834	291	10	claims	claim	NOUN
ihlr-20834	291	11	and	and	CCONJ
ihlr-20834	291	12	the	the	DET
ihlr-20834	291	13	prospects	prospect	NOUN
ihlr-20834	291	14	for	for	ADP
ihlr-20834	291	15	fifra	fifra	NOUN
ihlr-20834	291	16	:	:	PUNCT
ihlr-20834	291	17	justice	justice	PROPN
ihlr-20834	291	18	stevens	stevens	PROPN
ihlr-20834	291	19	puts	put	VERB
ihlr-20834	291	20	the	the	DET
ihlr-20834	291	21	genie	genie	NOUN
ihlr-20834	291	22	back	back	ADV
ihlr-20834	291	23	in	in	ADP
ihlr-20834	291	24	the	the	DET
ihlr-20834	291	25	bottle	bottle	NOUN
ihlr-20834	291	26	,	,	PUNCT
ihlr-20834	291	27	15	15	NUM
ihlr-20834	291	28	duke	duke	NOUN
ihlr-20834	291	29	envtl	envtl	PROPN
ihlr-20834	291	30	.	.	PUNCT
ihlr-20834	291	31	,	,	PUNCT
ihlr-20834	291	32	l.	l.	PROPN
ihlr-20834	291	33	&	&	CCONJ
ihlr-20834	291	34	pol’y	pol’y	PROPN
ihlr-20834	291	35	f.	f.	PROPN
ihlr-20834	291	36	65	65	NUM
ihlr-20834	291	37	,	,	PUNCT
ihlr-20834	291	38	69	69	NUM
ihlr-20834	291	39	(	(	PUNCT
ihlr-20834	291	40	2004	2004	NUM
ihlr-20834	291	41	)	)	PUNCT
ihlr-20834	291	42	.	.	PUNCT
ihlr-20834	292	1	81	81	NUM
ihlr-20834	293	1	i	i	PRON
ihlr-20834	293	2	d.	d.	PROPN
ihlr-20834	293	3	82	82	NUM
ihlr-20834	294	1	i	i	PRON
ihlr-20834	294	2	d.	d.	PROPN
ihlr-20834	294	3	at	at	ADP
ihlr-20834	294	4	70	70	NUM
ihlr-20834	294	5	.	.	PUNCT
ihlr-20834	295	1	784	784	NUM
ihlr-20834	295	2	indiana	indiana	PROPN
ihlr-20834	295	3	health	health	PROPN
ihlr-20834	295	4	law	law	PROPN
ihlr-20834	295	5	review	review	NOUN
ihlr-20834	295	6	vol	vol	NOUN
ihlr-20834	295	7	.	.	PUNCT
ihlr-20834	295	8	12:2	12:2	NUM
ihlr-20834	295	9	income	income	NOUN
ihlr-20834	295	10	security	security	NOUN
ihlr-20834	295	11	act	act	NOUN
ihlr-20834	295	12	(	(	PUNCT
ihlr-20834	295	13	often	often	ADV
ihlr-20834	295	14	referred	refer	VERB
ihlr-20834	295	15	to	to	ADP
ihlr-20834	295	16	as	as	ADP
ihlr-20834	295	17	“	"	PUNCT
ihlr-20834	295	18	erisa	erisa	NOUN
ihlr-20834	295	19	”	"	PUNCT
ihlr-20834	295	20	)	)	PUNCT
ihlr-20834	295	21	section	section	NOUN
ihlr-20834	295	22	514	514	NUM
ihlr-20834	295	23	expressly	expressly	ADV
ihlr-20834	295	24	preempts	preempt	VERB
ihlr-20834	295	25	all	all	DET
ihlr-20834	295	26	state	state	NOUN
ihlr-20834	295	27	laws	law	NOUN
ihlr-20834	295	28	“	"	PUNCT
ihlr-20834	295	29	relating	relate	VERB
ihlr-20834	295	30	to	to	ADP
ihlr-20834	295	31	”	"	PUNCT
ihlr-20834	295	32	employer	employer	NOUN
ihlr-20834	295	33	-	-	PUNCT
ihlr-20834	295	34	sponsored	sponsor	VERB
ihlr-20834	295	35	health	health	NOUN
ihlr-20834	295	36	plans.83	plans.83	NOUN
ihlr-20834	295	37	implied	imply	VERB
ihlr-20834	295	38	preemption	preemption	NOUN
ihlr-20834	295	39	exists	exist	VERB
ihlr-20834	295	40	in	in	ADP
ihlr-20834	295	41	three	three	NUM
ihlr-20834	295	42	scenarios	scenario	NOUN
ihlr-20834	295	43	.	.	PUNCT
ihlr-20834	296	1	first	first	ADV
ihlr-20834	296	2	,	,	PUNCT
ihlr-20834	296	3	implied	imply	VERB
ihlr-20834	296	4	preemption	preemption	NOUN
ihlr-20834	296	5	may	may	AUX
ihlr-20834	296	6	exist	exist	VERB
ihlr-20834	296	7	where	where	SCONJ
ihlr-20834	296	8	state	state	NOUN
ihlr-20834	296	9	law	law	NOUN
ihlr-20834	296	10	creates	create	VERB
ihlr-20834	296	11	an	an	DET
ihlr-20834	296	12	obstacle	obstacle	NOUN
ihlr-20834	296	13	for	for	ADP
ihlr-20834	296	14	compliance	compliance	NOUN
ihlr-20834	296	15	with	with	ADP
ihlr-20834	296	16	federal	federal	ADJ
ihlr-20834	296	17	law.84	law.84	NOUN
ihlr-20834	296	18	for	for	ADP
ihlr-20834	296	19	example	example	NOUN
ihlr-20834	296	20	,	,	PUNCT
ihlr-20834	296	21	in	in	ADP
ihlr-20834	296	22	hines	hine	NOUN
ihlr-20834	296	23	v.	v.	ADP
ihlr-20834	296	24	davidowitz	davidowitz	NOUN
ihlr-20834	296	25	the	the	DET
ihlr-20834	296	26	court	court	NOUN
ihlr-20834	296	27	held	hold	VERB
ihlr-20834	296	28	that	that	SCONJ
ihlr-20834	296	29	pennsylvania	pennsylvania	PROPN
ihlr-20834	296	30	’s	’s	PART
ihlr-20834	296	31	alien	alien	ADJ
ihlr-20834	296	32	registration	registration	NOUN
ihlr-20834	296	33	system	system	NOUN
ihlr-20834	296	34	stood	stand	VERB
ihlr-20834	296	35	“	"	PUNCT
ihlr-20834	296	36	as	as	ADP
ihlr-20834	296	37	an	an	DET
ihlr-20834	296	38	obstacle	obstacle	NOUN
ihlr-20834	296	39	to	to	ADP
ihlr-20834	296	40	the	the	DET
ihlr-20834	296	41	accomplishment	accomplishment	NOUN
ihlr-20834	296	42	and	and	CCONJ
ihlr-20834	296	43	execution	execution	NOUN
ihlr-20834	296	44	of	of	ADP
ihlr-20834	296	45	the	the	DET
ihlr-20834	296	46	full	full	ADJ
ihlr-20834	296	47	purposes	purpose	NOUN
ihlr-20834	296	48	and	and	CCONJ
ihlr-20834	296	49	objectives	objective	NOUN
ihlr-20834	296	50	of	of	ADP
ihlr-20834	296	51	congress	congress	PROPN
ihlr-20834	296	52	[	[	X
ihlr-20834	296	53	‘	‘	X
ihlr-20834	296	54	]	]	X
ihlr-20834	297	1	[	[	X
ihlr-20834	297	2	alien	alien	ADJ
ihlr-20834	297	3	registration	registration	NOUN
ihlr-20834	297	4	act	act	NOUN
ihlr-20834	297	5	.	.	PUNCT
ihlr-20834	298	1	]	]	X
ihlr-20834	298	2	”	"	PUNCT
ihlr-20834	298	3	.	.	PUNCT
ihlr-20834	298	4	85	85	NUM
ihlr-20834	298	5	pennsylvania	pennsylvania	PROPN
ihlr-20834	298	6	’s	’s	PART
ihlr-20834	298	7	alien	alien	ADJ
ihlr-20834	298	8	registration	registration	NOUN
ihlr-20834	298	9	was	be	AUX
ihlr-20834	298	10	preempted	preempt	VERB
ihlr-20834	298	11	by	by	ADP
ihlr-20834	298	12	congress	congress	PROPN
ihlr-20834	298	13	’	'	PUNCT
ihlr-20834	298	14	alien	alien	ADJ
ihlr-20834	298	15	registration	registration	NOUN
ihlr-20834	298	16	act	act	NOUN
ihlr-20834	298	17	and	and	CCONJ
ihlr-20834	298	18	was	be	AUX
ihlr-20834	298	19	held	hold	VERB
ihlr-20834	298	20	invalid	invalid	ADJ
ihlr-20834	298	21	.	.	PUNCT
ihlr-20834	299	1	second	second	ADJ
ihlr-20834	299	2	,	,	PUNCT
ihlr-20834	299	3	implied	imply	VERB
ihlr-20834	299	4	preemption	preemption	NOUN
ihlr-20834	299	5	may	may	AUX
ihlr-20834	299	6	exist	exist	VERB
ihlr-20834	299	7	where	where	SCONJ
ihlr-20834	299	8	congressional	congressional	ADJ
ihlr-20834	299	9	law	law	NOUN
ihlr-20834	299	10	occupies	occupy	VERB
ihlr-20834	299	11	an	an	DET
ihlr-20834	299	12	entire	entire	ADJ
ihlr-20834	299	13	field	field	NOUN
ihlr-20834	299	14	so	so	SCONJ
ihlr-20834	299	15	as	as	SCONJ
ihlr-20834	299	16	to	to	PART
ihlr-20834	299	17	create	create	VERB
ihlr-20834	299	18	an	an	DET
ihlr-20834	299	19	“	"	PUNCT
ihlr-20834	299	20	inference	inference	NOUN
ihlr-20834	299	21	of	of	ADP
ihlr-20834	299	22	federal	federal	ADJ
ihlr-20834	299	23	exclusivity	exclusivity	NOUN
ihlr-20834	299	24	.	.	PUNCT
ihlr-20834	299	25	”	"	PUNCT
ihlr-20834	300	1	86	86	NUM
ihlr-20834	300	2	for	for	ADP
ihlr-20834	300	3	example	example	NOUN
ihlr-20834	300	4	,	,	PUNCT
ihlr-20834	300	5	in	in	ADP
ihlr-20834	300	6	gade	gade	PROPN
ihlr-20834	300	7	v.	v.	ADP
ihlr-20834	300	8	national	national	ADJ
ihlr-20834	300	9	solid	solid	ADJ
ihlr-20834	300	10	wastes	waste	NOUN
ihlr-20834	300	11	management	management	NOUN
ihlr-20834	300	12	association	association	NOUN
ihlr-20834	300	13	the	the	DET
ihlr-20834	300	14	court	court	NOUN
ihlr-20834	300	15	determined	determine	VERB
ihlr-20834	300	16	that	that	SCONJ
ihlr-20834	300	17	an	an	DET
ihlr-20834	300	18	illinois	illinois	PROPN
ihlr-20834	300	19	provision	provision	NOUN
ihlr-20834	300	20	applicable	applicable	ADJ
ihlr-20834	300	21	to	to	ADP
ihlr-20834	300	22	licensing	license	VERB
ihlr-20834	300	23	workers	worker	NOUN
ihlr-20834	300	24	who	who	PRON
ihlr-20834	300	25	handled	handle	VERB
ihlr-20834	300	26	hazardous	hazardous	ADJ
ihlr-20834	300	27	waste	waste	NOUN
ihlr-20834	300	28	materials	material	NOUN
ihlr-20834	300	29	was	be	AUX
ihlr-20834	300	30	preempted	preempt	VERB
ihlr-20834	300	31	by	by	ADP
ihlr-20834	300	32	federal	federal	ADJ
ihlr-20834	300	33	occupational	occupational	ADJ
ihlr-20834	300	34	safety	safety	NOUN
ihlr-20834	300	35	and	and	CCONJ
ihlr-20834	300	36	health	health	NOUN
ihlr-20834	300	37	administration	administration	NOUN
ihlr-20834	300	38	regulations	regulation	NOUN
ihlr-20834	300	39	because	because	SCONJ
ihlr-20834	300	40	such	such	ADJ
ihlr-20834	300	41	regulations	regulation	NOUN
ihlr-20834	300	42	occupied	occupy	VERB
ihlr-20834	300	43	the	the	DET
ihlr-20834	300	44	whole	whole	ADJ
ihlr-20834	300	45	field	field	NOUN
ihlr-20834	300	46	of	of	ADP
ihlr-20834	300	47	handling	handle	VERB
ihlr-20834	300	48	hazardous	hazardous	ADJ
ihlr-20834	300	49	waste	waste	NOUN
ihlr-20834	300	50	material.87	material.87	PROPN
ihlr-20834	300	51	third	third	ADJ
ihlr-20834	300	52	,	,	PUNCT
ihlr-20834	300	53	implied	imply	VERB
ihlr-20834	300	54	preemption	preemption	NOUN
ihlr-20834	300	55	may	may	AUX
ihlr-20834	300	56	occur	occur	VERB
ihlr-20834	300	57	where	where	SCONJ
ihlr-20834	300	58	it	it	PRON
ihlr-20834	300	59	is	be	AUX
ihlr-20834	300	60	impossible	impossible	ADJ
ihlr-20834	300	61	for	for	SCONJ
ihlr-20834	300	62	one	one	NUM
ihlr-20834	300	63	to	to	PART
ihlr-20834	300	64	comply	comply	VERB
ihlr-20834	300	65	with	with	ADP
ihlr-20834	300	66	both	both	CCONJ
ihlr-20834	300	67	federal	federal	ADJ
ihlr-20834	300	68	and	and	CCONJ
ihlr-20834	300	69	state	state	NOUN
ihlr-20834	300	70	law	law	NOUN
ihlr-20834	300	71	due	due	ADP
ihlr-20834	300	72	to	to	ADP
ihlr-20834	300	73	direct	direct	ADJ
ihlr-20834	300	74	conflict	conflict	NOUN
ihlr-20834	300	75	between	between	ADP
ihlr-20834	300	76	federal	federal	ADJ
ihlr-20834	300	77	and	and	CCONJ
ihlr-20834	300	78	state	state	NOUN
ihlr-20834	300	79	law.88	law.88	PROPN
ihlr-20834	300	80	for	for	ADP
ihlr-20834	300	81	example	example	NOUN
ihlr-20834	300	82	,	,	PUNCT
ihlr-20834	300	83	if	if	SCONJ
ihlr-20834	300	84	a	a	DET
ihlr-20834	300	85	state	state	NOUN
ihlr-20834	300	86	law	law	NOUN
ihlr-20834	300	87	explicitly	explicitly	ADV
ihlr-20834	300	88	permits	permit	VERB
ihlr-20834	300	89	something	something	PRON
ihlr-20834	300	90	federal	federal	ADJ
ihlr-20834	300	91	law	law	NOUN
ihlr-20834	300	92	forbids	forbid	VERB
ihlr-20834	300	93	,	,	PUNCT
ihlr-20834	300	94	a	a	DET
ihlr-20834	300	95	direct	direct	ADJ
ihlr-20834	300	96	conflict	conflict	NOUN
ihlr-20834	300	97	would	would	AUX
ihlr-20834	300	98	likely	likely	ADV
ihlr-20834	300	99	exist	exist	VERB
ihlr-20834	300	100	and	and	CCONJ
ihlr-20834	300	101	state	state	NOUN
ihlr-20834	300	102	law	law	NOUN
ihlr-20834	300	103	would	would	AUX
ihlr-20834	300	104	probably	probably	ADV
ihlr-20834	300	105	be	be	AUX
ihlr-20834	300	106	preempted.89	preempted.89	NOUN
ihlr-20834	300	107	it	it	PRON
ihlr-20834	300	108	is	be	AUX
ihlr-20834	300	109	important	important	ADJ
ihlr-20834	300	110	to	to	PART
ihlr-20834	300	111	note	note	VERB
ihlr-20834	300	112	that	that	SCONJ
ihlr-20834	300	113	raising	raise	VERB
ihlr-20834	300	114	impossibility	impossibility	NOUN
ihlr-20834	300	115	preemption	preemption	NOUN
ihlr-20834	300	116	is	be	AUX
ihlr-20834	300	117	a	a	DET
ihlr-20834	300	118	demanding	demanding	ADJ
ihlr-20834	300	119	defense.90	defense.90	NOUN
ihlr-20834	300	120	the	the	DET
ihlr-20834	300	121	main	main	ADJ
ihlr-20834	300	122	inquiry	inquiry	NOUN
ihlr-20834	300	123	is	be	AUX
ihlr-20834	300	124	whether	whether	SCONJ
ihlr-20834	300	125	the	the	DET
ihlr-20834	300	126	private	private	ADJ
ihlr-20834	300	127	party	party	NOUN
ihlr-20834	300	128	could	could	AUX
ihlr-20834	300	129	83	83	NUM
ihlr-20834	300	130	29	29	NUM
ihlr-20834	300	131	u.s.c	u.s.c	NOUN
ihlr-20834	300	132	.	.	PUNCT
ihlr-20834	301	1	§	§	PROPN
ihlr-20834	301	2	1144(a	1144(a	PROPN
ihlr-20834	301	3	)	)	PUNCT
ihlr-20834	301	4	(	(	PUNCT
ihlr-20834	301	5	2015	2015	NUM
ihlr-20834	301	6	)	)	PUNCT
ihlr-20834	301	7	.	.	PUNCT
ihlr-20834	302	1	for	for	ADP
ihlr-20834	302	2	a	a	DET
ihlr-20834	302	3	more	more	ADV
ihlr-20834	302	4	detailed	detailed	ADJ
ihlr-20834	302	5	erisa	erisa	NOUN
ihlr-20834	302	6	analysis	analysis	NOUN
ihlr-20834	302	7	,	,	PUNCT
ihlr-20834	302	8	see	see	VERB
ihlr-20834	302	9	erisa	erisa	NOUN
ihlr-20834	302	10	preemption	preemption	NOUN
ihlr-20834	302	11	primer	primer	NOUN
ihlr-20834	302	12	,	,	PUNCT
ihlr-20834	302	13	nat’l	nat’l	NOUN
ihlr-20834	302	14	acad	acad	NOUN
ihlr-20834	302	15	.	.	PUNCT
ihlr-20834	303	1	for	for	ADP
ihlr-20834	303	2	state	state	NOUN
ihlr-20834	303	3	health	health	NOUN
ihlr-20834	303	4	pol’y	pol’y	NOUN
ihlr-20834	303	5	,	,	PUNCT
ihlr-20834	303	6	http://nashp.org/sites/default/files/erisa_primer.pdf	http://nashp.org/sites/default/files/erisa_primer.pdf	NOUN
ihlr-20834	303	7	?	?	PUNCT
ihlr-20834	303	8	q	q	X
ihlr-20834	303	9	=	=	NOUN
ihlr-20834	303	10	files	file	NOUN
ihlr-20834	303	11	/	/	SYM
ihlr-20834	303	12	erisa_primer.pdf	erisa_primer.pdf	PROPN
ihlr-20834	303	13	(	(	PUNCT
ihlr-20834	303	14	last	last	ADV
ihlr-20834	303	15	visited	visit	VERB
ihlr-20834	303	16	mar	mar	PROPN
ihlr-20834	303	17	.	.	PROPN
ihlr-20834	303	18	20	20	NUM
ihlr-20834	303	19	,	,	PUNCT
ihlr-20834	303	20	2015	2015	NUM
ihlr-20834	303	21	)	)	PUNCT
ihlr-20834	303	22	.	.	PUNCT
ihlr-20834	304	1	84	84	NUM
ihlr-20834	304	2	hendricks	hendrick	NOUN
ihlr-20834	304	3	,	,	PUNCT
ihlr-20834	304	4	supra	supra	PROPN
ihlr-20834	304	5	note	note	NOUN
ihlr-20834	304	6	80	80	NUM
ihlr-20834	304	7	at	at	ADP
ihlr-20834	304	8	70	70	NUM
ihlr-20834	304	9	.	.	PUNCT
ihlr-20834	304	10	85	85	NUM
ihlr-20834	304	11	hines	hine	NOUN
ihlr-20834	304	12	v.	v.	ADP
ihlr-20834	304	13	davidowitz	davidowitz	PROPN
ihlr-20834	304	14	,	,	PUNCT
ihlr-20834	304	15	312	312	NUM
ihlr-20834	304	16	u.s	u.s	PROPN
ihlr-20834	304	17	.	.	PROPN
ihlr-20834	304	18	52	52	NUM
ihlr-20834	304	19	,	,	PUNCT
ihlr-20834	304	20	68	68	NUM
ihlr-20834	304	21	(	(	PUNCT
ihlr-20834	304	22	1941	1941	NUM
ihlr-20834	304	23	)	)	PUNCT
ihlr-20834	304	24	.	.	PUNCT
ihlr-20834	305	1	86	86	NUM
ihlr-20834	305	2	hendricks	hendrick	NOUN
ihlr-20834	305	3	,	,	PUNCT
ihlr-20834	305	4	supra	supra	PROPN
ihlr-20834	305	5	note	note	NOUN
ihlr-20834	305	6	80	80	NUM
ihlr-20834	305	7	at	at	ADP
ihlr-20834	305	8	70	70	NUM
ihlr-20834	305	9	.	.	PUNCT
ihlr-20834	306	1	87	87	NUM
ihlr-20834	306	2	gade	gade	PROPN
ihlr-20834	306	3	v.	v.	ADP
ihlr-20834	306	4	nat’l	nat’l	PROPN
ihlr-20834	306	5	solid	solid	ADJ
ihlr-20834	306	6	wastes	waste	NOUN
ihlr-20834	306	7	mgmt	mgmt	NOUN
ihlr-20834	306	8	.	.	PUNCT
ihlr-20834	307	1	ass’n	ass’n	PROPN
ihlr-20834	307	2	.	.	PUNCT
ihlr-20834	308	1	,	,	PUNCT
ihlr-20834	308	2	505	505	NUM
ihlr-20834	308	3	u.s	u.s	PROPN
ihlr-20834	308	4	.	.	PROPN
ihlr-20834	308	5	88	88	NUM
ihlr-20834	308	6	(	(	PUNCT
ihlr-20834	308	7	1992	1992	NUM
ihlr-20834	308	8	)	)	PUNCT
ihlr-20834	308	9	.	.	PUNCT
ihlr-20834	309	1	88	88	NUM
ihlr-20834	309	2	hendricks	hendrick	NOUN
ihlr-20834	309	3	,	,	PUNCT
ihlr-20834	309	4	supra	supra	PROPN
ihlr-20834	309	5	note	note	NOUN
ihlr-20834	309	6	80	80	NUM
ihlr-20834	309	7	at	at	ADP
ihlr-20834	309	8	70	70	NUM
ihlr-20834	309	9	.	.	PUNCT
ihlr-20834	309	10	89	89	NUM
ihlr-20834	310	1	i	i	PRON
ihlr-20834	310	2	d.	d.	PROPN
ihlr-20834	310	3	90	90	NUM
ihlr-20834	310	4	wyeth	wyeth	PROPN
ihlr-20834	310	5	v.	v.	PROPN
ihlr-20834	310	6	levine	levine	PROPN
ihlr-20834	310	7	,	,	PUNCT
ihlr-20834	310	8	555	555	NUM
ihlr-20834	310	9	u.s	u.s	PROPN
ihlr-20834	310	10	.	.	PROPN
ihlr-20834	310	11	555	555	NUM
ihlr-20834	310	12	,	,	PUNCT
ihlr-20834	310	13	573	573	NUM
ihlr-20834	310	14	(	(	PUNCT
ihlr-20834	310	15	2009	2009	NUM
ihlr-20834	310	16	)	)	PUNCT
ihlr-20834	310	17	.	.	PUNCT
ihlr-20834	311	1	2015	2015	NUM
ihlr-20834	311	2	785	785	NUM
ihlr-20834	311	3	the	the	DET
ihlr-20834	311	4	supreme	supreme	PROPN
ihlr-20834	311	5	court	court	PROPN
ihlr-20834	311	6	’s	’s	PART
ihlr-20834	311	7	overreaching	overreach	VERB
ihlr-20834	311	8	preemption	preemption	NOUN
ihlr-20834	311	9	interpretation	interpretation	NOUN
ihlr-20834	311	10	and	and	CCONJ
ihlr-20834	311	11	it	it	PRON
ihlr-20834	311	12	’s	’	VERB
ihlr-20834	311	13	consequences	consequence	NOUN
ihlr-20834	311	14	independently	independently	ADV
ihlr-20834	311	15	do	do	VERB
ihlr-20834	311	16	under	under	ADP
ihlr-20834	311	17	federal	federal	ADJ
ihlr-20834	311	18	law	law	NOUN
ihlr-20834	311	19	what	what	PRON
ihlr-20834	311	20	state	state	NOUN
ihlr-20834	311	21	law	law	NOUN
ihlr-20834	311	22	requires	require	VERB
ihlr-20834	311	23	of	of	ADP
ihlr-20834	311	24	it.91	it.91	NOUN
ihlr-20834	311	25	when	when	SCONJ
ihlr-20834	311	26	state	state	NOUN
ihlr-20834	311	27	and	and	CCONJ
ihlr-20834	311	28	federal	federal	ADJ
ihlr-20834	311	29	law	law	NOUN
ihlr-20834	311	30	impose	impose	VERB
ihlr-20834	311	31	irreconcilable	irreconcilable	ADJ
ihlr-20834	311	32	conflicting	conflicting	ADJ
ihlr-20834	311	33	affirmative	affirmative	ADJ
ihlr-20834	311	34	requirements	requirement	NOUN
ihlr-20834	311	35	,	,	PUNCT
ihlr-20834	311	36	an	an	DET
ihlr-20834	311	37	inquiry	inquiry	NOUN
ihlr-20834	311	38	into	into	ADP
ihlr-20834	311	39	congressional	congressional	ADJ
ihlr-20834	311	40	design	design	NOUN
ihlr-20834	311	41	is	be	AUX
ihlr-20834	311	42	unnecessary	unnecessary	ADJ
ihlr-20834	311	43	because	because	SCONJ
ihlr-20834	311	44	congress	congress	PROPN
ihlr-20834	311	45	’	'	PUNCT
ihlr-20834	311	46	intent	intent	NOUN
ihlr-20834	311	47	to	to	PART
ihlr-20834	311	48	have	have	AUX
ihlr-20834	311	49	federal	federal	ADJ
ihlr-20834	311	50	law	law	NOUN
ihlr-20834	311	51	displace	displace	VERB
ihlr-20834	311	52	the	the	DET
ihlr-20834	311	53	conflicting	conflict	VERB
ihlr-20834	311	54	state	state	NOUN
ihlr-20834	311	55	law	law	NOUN
ihlr-20834	311	56	“	"	PUNCT
ihlr-20834	311	57	is	be	AUX
ihlr-20834	311	58	inescapable	inescapable	ADJ
ihlr-20834	311	59	.	.	PUNCT
ihlr-20834	312	1	”92	”92	ADJ
ihlr-20834	312	2	because	because	SCONJ
ihlr-20834	312	3	there	there	PRON
ihlr-20834	312	4	is	be	VERB
ihlr-20834	312	5	a	a	DET
ihlr-20834	312	6	presumption	presumption	NOUN
ihlr-20834	312	7	against	against	ADP
ihlr-20834	312	8	finding	find	VERB
ihlr-20834	312	9	preemption	preemption	NOUN
ihlr-20834	312	10	,	,	PUNCT
ihlr-20834	312	11	it	it	PRON
ihlr-20834	312	12	is	be	AUX
ihlr-20834	312	13	much	much	ADV
ihlr-20834	312	14	less	less	ADV
ihlr-20834	312	15	common	common	ADJ
ihlr-20834	312	16	for	for	SCONJ
ihlr-20834	312	17	courts	court	NOUN
ihlr-20834	312	18	to	to	PART
ihlr-20834	312	19	find	find	VERB
ihlr-20834	312	20	preemption	preemption	NOUN
ihlr-20834	312	21	than	than	SCONJ
ihlr-20834	312	22	to	to	ADP
ihlr-20834	312	23	not.93	not.93	PROPN
ihlr-20834	312	24	congress	congress	PROPN
ihlr-20834	312	25	plays	play	VERB
ihlr-20834	312	26	an	an	DET
ihlr-20834	312	27	important	important	ADJ
ihlr-20834	312	28	role	role	NOUN
ihlr-20834	312	29	of	of	ADP
ihlr-20834	312	30	being	be	AUX
ihlr-20834	312	31	the	the	DET
ihlr-20834	312	32	“	"	PUNCT
ihlr-20834	312	33	‘	'	PUNCT
ihlr-20834	312	34	ultimate	ultimate	ADJ
ihlr-20834	312	35	touchstone	touchstone	NOUN
ihlr-20834	312	36	’	'	PUNCT
ihlr-20834	312	37	in	in	ADP
ihlr-20834	312	38	every	every	DET
ihlr-20834	312	39	pre	pre	ADJ
ihlr-20834	312	40	-	-	ADJ
ihlr-20834	312	41	emption	emption	ADJ
ihlr-20834	312	42	case	case	NOUN
ihlr-20834	312	43	.	.	PUNCT
ihlr-20834	313	1	”94	”94	PROPN
ihlr-20834	313	2	therefore	therefore	ADV
ihlr-20834	313	3	,	,	PUNCT
ihlr-20834	313	4	courts	court	NOUN
ihlr-20834	313	5	should	should	AUX
ihlr-20834	313	6	defer	defer	VERB
ihlr-20834	313	7	to	to	ADP
ihlr-20834	313	8	congress	congress	PROPN
ihlr-20834	313	9	’	'	PUNCT
ihlr-20834	313	10	intent	intent	NOUN
ihlr-20834	313	11	in	in	ADP
ihlr-20834	313	12	deciding	decide	VERB
ihlr-20834	313	13	whether	whether	SCONJ
ihlr-20834	313	14	preemption	preemption	NOUN
ihlr-20834	313	15	should	should	AUX
ihlr-20834	313	16	apply	apply	VERB
ihlr-20834	313	17	.	.	PUNCT
ihlr-20834	314	1	unless	unless	SCONJ
ihlr-20834	314	2	it	it	PRON
ihlr-20834	314	3	was	be	AUX
ihlr-20834	314	4	the	the	DET
ihlr-20834	314	5	clear	clear	ADJ
ihlr-20834	314	6	intent	intent	NOUN
ihlr-20834	314	7	and	and	CCONJ
ihlr-20834	314	8	purpose	purpose	NOUN
ihlr-20834	314	9	of	of	ADP
ihlr-20834	314	10	congress	congress	PROPN
ihlr-20834	314	11	to	to	PART
ihlr-20834	314	12	have	have	VERB
ihlr-20834	314	13	a	a	DET
ihlr-20834	314	14	federal	federal	ADJ
ihlr-20834	314	15	act	act	NOUN
ihlr-20834	314	16	supersede	supersede	VERB
ihlr-20834	314	17	state	state	NOUN
ihlr-20834	314	18	law	law	NOUN
ihlr-20834	314	19	,	,	PUNCT
ihlr-20834	314	20	police	police	NOUN
ihlr-20834	314	21	powers	power	NOUN
ihlr-20834	314	22	of	of	ADP
ihlr-20834	314	23	the	the	DET
ihlr-20834	314	24	state	state	NOUN
ihlr-20834	314	25	should	should	AUX
ihlr-20834	314	26	not	not	PART
ihlr-20834	314	27	be	be	AUX
ihlr-20834	314	28	held	hold	VERB
ihlr-20834	314	29	preempted.95	preempted.95	NOUN
ihlr-20834	314	30	furthermore	furthermore	ADV
ihlr-20834	314	31	,	,	PUNCT
ihlr-20834	314	32	when	when	SCONJ
ihlr-20834	314	33	congress	congress	PROPN
ihlr-20834	314	34	has	have	AUX
ihlr-20834	314	35	legislated	legislate	VERB
ihlr-20834	314	36	in	in	ADP
ihlr-20834	314	37	a	a	DET
ihlr-20834	314	38	field	field	NOUN
ihlr-20834	314	39	traditionally	traditionally	ADV
ihlr-20834	314	40	occupied	occupy	VERB
ihlr-20834	314	41	by	by	ADP
ihlr-20834	314	42	the	the	DET
ihlr-20834	314	43	states“[t]hat	states“[t]hat	PROPN
ihlr-20834	314	44	assumption	assumption	NOUN
ihlr-20834	314	45	.	.	PUNCT
ihlr-20834	314	46	.	.	PUNCT
ihlr-20834	315	1	.	.	PUNCT
ihlr-20834	316	1	applies	apply	VERB
ihlr-20834	316	2	with	with	ADP
ihlr-20834	316	3	particular	particular	ADJ
ihlr-20834	316	4	force	force	NOUN
ihlr-20834	316	5	.	.	PUNCT
ihlr-20834	316	6	.	.	PUNCT
ihlr-20834	316	7	.	.	PUNCT
ihlr-20834	316	8	.	.	PUNCT
ihlr-20834	316	9	”	"	PUNCT
ihlr-20834	317	1	96	96	NUM
ihlr-20834	317	2	therefore	therefore	ADV
ihlr-20834	317	3	,	,	PUNCT
ihlr-20834	317	4	absent	absent	ADJ
ihlr-20834	317	5	direct	direct	ADJ
ihlr-20834	317	6	conflict	conflict	NOUN
ihlr-20834	317	7	,	,	PUNCT
ihlr-20834	317	8	courts	court	NOUN
ihlr-20834	317	9	can	can	AUX
ihlr-20834	317	10	not	not	PART
ihlr-20834	317	11	assume	assume	VERB
ihlr-20834	317	12	congress	congress	PROPN
ihlr-20834	317	13	intended	intend	VERB
ihlr-20834	317	14	for	for	SCONJ
ihlr-20834	317	15	preemption	preemption	NOUN
ihlr-20834	317	16	to	to	PART
ihlr-20834	317	17	exist	exist	VERB
ihlr-20834	317	18	.	.	PUNCT
ihlr-20834	318	1	97	97	NUM
ihlr-20834	318	2	a	a	DET
ihlr-20834	318	3	detailed	detailed	ADJ
ihlr-20834	318	4	inquiry	inquiry	NOUN
ihlr-20834	318	5	into	into	ADP
ihlr-20834	318	6	congressional	congressional	ADJ
ihlr-20834	318	7	intent	intent	NOUN
ihlr-20834	318	8	should	should	AUX
ihlr-20834	318	9	be	be	AUX
ihlr-20834	318	10	made	make	VERB
ihlr-20834	318	11	,	,	PUNCT
ihlr-20834	318	12	and	and	CCONJ
ihlr-20834	318	13	where	where	SCONJ
ihlr-20834	318	14	a	a	DET
ihlr-20834	318	15	statute	statute	NOUN
ihlr-20834	318	16	contains	contain	VERB
ihlr-20834	318	17	no	no	DET
ihlr-20834	318	18	explicit	explicit	ADJ
ihlr-20834	318	19	preemption	preemption	NOUN
ihlr-20834	318	20	command	command	NOUN
ihlr-20834	318	21	,	,	PUNCT
ihlr-20834	318	22	courts	court	NOUN
ihlr-20834	318	23	may	may	AUX
ihlr-20834	318	24	infer	infer	VERB
ihlr-20834	318	25	that	that	SCONJ
ihlr-20834	318	26	the	the	DET
ihlr-20834	318	27	administrative	administrative	ADJ
ihlr-20834	318	28	agency	agency	PROPN
ihlr-20834	318	29	has	have	VERB
ihlr-20834	318	30	a	a	DET
ihlr-20834	318	31	degree	degree	NOUN
ihlr-20834	318	32	of	of	ADP
ihlr-20834	318	33	leeway	leeway	NOUN
ihlr-20834	318	34	to	to	PART
ihlr-20834	318	35	determine	determine	VERB
ihlr-20834	318	36	the	the	DET
ihlr-20834	318	37	extent	extent	NOUN
ihlr-20834	318	38	to	to	PART
ihlr-20834	318	39	which	which	PRON
ihlr-20834	318	40	“	"	PUNCT
ihlr-20834	318	41	statutes	statute	NOUN
ihlr-20834	318	42	,	,	PUNCT
ihlr-20834	318	43	rules	rule	NOUN
ihlr-20834	318	44	,	,	PUNCT
ihlr-20834	318	45	regulations	regulation	NOUN
ihlr-20834	318	46	or	or	CCONJ
ihlr-20834	318	47	other	other	ADJ
ihlr-20834	318	48	administrative	administrative	ADJ
ihlr-20834	318	49	actions	action	NOUN
ihlr-20834	318	50	have	have	VERB
ihlr-20834	318	51	preemptive	preemptive	ADJ
ihlr-20834	318	52	effect	effect	NOUN
ihlr-20834	318	53	.	.	PUNCT
ihlr-20834	318	54	”	"	PUNCT
ihlr-20834	319	1	98	98	NUM
ihlr-20834	319	2	these	these	DET
ihlr-20834	319	3	fundamental	fundamental	ADJ
ihlr-20834	319	4	principles	principle	NOUN
ihlr-20834	319	5	were	be	AUX
ihlr-20834	319	6	91	91	NUM
ihlr-20834	319	7	i	i	NOUN
ihlr-20834	319	8	d.	d.	PROPN
ihlr-20834	319	9	92	92	NUM
ihlr-20834	319	10	see	see	VERB
ihlr-20834	319	11	mut	mut	PROPN
ihlr-20834	319	12	.	.	PUNCT
ihlr-20834	320	1	pharm	pharm	PROPN
ihlr-20834	320	2	.	.	PUNCT
ihlr-20834	321	1	co.	co.	PROPN
ihlr-20834	321	2	,133	,133	PUNCT
ihlr-20834	321	3	s.ct	s.ct	PROPN
ihlr-20834	321	4	.	.	PROPN
ihlr-20834	322	1	at	at	ADP
ihlr-20834	322	2	2473	2473	NUM
ihlr-20834	322	3	(	(	PUNCT
ihlr-20834	322	4	citing	cite	VERB
ihlr-20834	322	5	florida	florida	PROPN
ihlr-20834	322	6	lime	lime	PROPN
ihlr-20834	322	7	&	&	CCONJ
ihlr-20834	322	8	avocado	avocado	ADJ
ihlr-20834	322	9	growers	grower	NOUN
ihlr-20834	322	10	,	,	PUNCT
ihlr-20834	322	11	inc	inc	PROPN
ihlr-20834	322	12	.	.	PROPN
ihlr-20834	323	1	v.	v.	PROPN
ihlr-20834	323	2	paul	paul	PROPN
ihlr-20834	323	3	,	,	PUNCT
ihlr-20834	323	4	373	373	NUM
ihlr-20834	323	5	u.s	u.s	PROPN
ihlr-20834	323	6	.	.	PROPN
ihlr-20834	323	7	132	132	NUM
ihlr-20834	323	8	,	,	PUNCT
ihlr-20834	323	9	142	142	NUM
ihlr-20834	323	10	-	-	SYM
ihlr-20834	323	11	43	43	NUM
ihlr-20834	323	12	(	(	PUNCT
ihlr-20834	323	13	“	"	PUNCT
ihlr-20834	323	14	a	a	DET
ihlr-20834	323	15	holding	holding	NOUN
ihlr-20834	323	16	of	of	ADP
ihlr-20834	323	17	federal	federal	ADJ
ihlr-20834	323	18	exclusion	exclusion	NOUN
ihlr-20834	323	19	of	of	ADP
ihlr-20834	323	20	state	state	NOUN
ihlr-20834	323	21	law	law	NOUN
ihlr-20834	323	22	is	be	AUX
ihlr-20834	323	23	inescapable	inescapable	ADJ
ihlr-20834	323	24	and	and	CCONJ
ihlr-20834	323	25	requires	require	VERB
ihlr-20834	323	26	no	no	DET
ihlr-20834	323	27	inquiry	inquiry	NOUN
ihlr-20834	323	28	into	into	ADP
ihlr-20834	323	29	congressional	congressional	ADJ
ihlr-20834	323	30	design	design	NOUN
ihlr-20834	323	31	where	where	SCONJ
ihlr-20834	323	32	compliance	compliance	NOUN
ihlr-20834	323	33	with	with	ADP
ihlr-20834	323	34	both	both	CCONJ
ihlr-20834	323	35	federal	federal	ADJ
ihlr-20834	323	36	and	and	CCONJ
ihlr-20834	323	37	state	state	NOUN
ihlr-20834	323	38	regulations	regulation	NOUN
ihlr-20834	323	39	is	be	AUX
ihlr-20834	323	40	a	a	DET
ihlr-20834	323	41	physical	physical	ADJ
ihlr-20834	323	42	impossibility	impossibility	NOUN
ihlr-20834	323	43	for	for	ADP
ihlr-20834	323	44	one	one	NUM
ihlr-20834	323	45	engaged	engage	VERB
ihlr-20834	323	46	in	in	ADP
ihlr-20834	323	47	interstate	interstate	ADJ
ihlr-20834	323	48	commerce	commerce	NOUN
ihlr-20834	323	49	.	.	PUNCT
ihlr-20834	323	50	”	"	PUNCT
ihlr-20834	323	51	)	)	PUNCT
ihlr-20834	323	52	)	)	PUNCT
ihlr-20834	323	53	.	.	PUNCT
ihlr-20834	324	1	93	93	NUM
ihlr-20834	324	2	kerry	kerry	PROPN
ihlr-20834	324	3	abrams	abrams	PROPN
ihlr-20834	324	4	,	,	PUNCT
ihlr-20834	324	5	plenary	plenary	ADJ
ihlr-20834	324	6	power	power	NOUN
ihlr-20834	324	7	preemption	preemption	NOUN
ihlr-20834	324	8	,	,	PUNCT
ihlr-20834	324	9	99	99	NUM
ihlr-20834	324	10	va	va	NOUN
ihlr-20834	324	11	.	.	PUNCT
ihlr-20834	325	1	l.	l.	PROPN
ihlr-20834	325	2	rev	rev	PROPN
ihlr-20834	325	3	.	.	PROPN
ihlr-20834	325	4	601	601	NUM
ihlr-20834	325	5	,	,	PUNCT
ihlr-20834	325	6	608	608	NUM
ihlr-20834	325	7	(	(	PUNCT
ihlr-20834	325	8	2013	2013	NUM
ihlr-20834	325	9	)	)	PUNCT
ihlr-20834	325	10	.	.	PUNCT
ihlr-20834	326	1	94	94	NUM
ihlr-20834	326	2	medtronic	medtronic	PROPN
ihlr-20834	326	3	,	,	PUNCT
ihlr-20834	326	4	inc	inc	PROPN
ihlr-20834	326	5	.	.	PROPN
ihlr-20834	326	6	v.	v.	PROPN
ihlr-20834	326	7	lohr	lohr	PROPN
ihlr-20834	326	8	,	,	PUNCT
ihlr-20834	326	9	518	518	NUM
ihlr-20834	326	10	u.s	u.s	PROPN
ihlr-20834	326	11	.	.	PROPN
ihlr-20834	326	12	470	470	NUM
ihlr-20834	326	13	,	,	PUNCT
ihlr-20834	326	14	485	485	NUM
ihlr-20834	326	15	(	(	PUNCT
ihlr-20834	326	16	1996	1996	NUM
ihlr-20834	326	17	)	)	PUNCT
ihlr-20834	326	18	.	.	PUNCT
ihlr-20834	327	1	95	95	NUM
ihlr-20834	328	1	i	i	PRON
ihlr-20834	328	2	d.	d.	PROPN
ihlr-20834	328	3	(	(	PUNCT
ihlr-20834	328	4	citing	cite	VERB
ihlr-20834	328	5	altria	altria	PROPN
ihlr-20834	328	6	group	group	PROPN
ihlr-20834	328	7	,	,	PUNCT
ihlr-20834	328	8	inc	inc	PROPN
ihlr-20834	328	9	.	.	PROPN
ihlr-20834	329	1	v.	v.	ADP
ihlr-20834	329	2	good	good	ADJ
ihlr-20834	329	3	,	,	PUNCT
ihlr-20834	329	4	555	555	NUM
ihlr-20834	329	5	u.s	u.s	PROPN
ihlr-20834	329	6	.	.	PROPN
ihlr-20834	329	7	70	70	NUM
ihlr-20834	329	8	,	,	PUNCT
ihlr-20834	329	9	77	77	NUM
ihlr-20834	329	10	(	(	PUNCT
ihlr-20834	329	11	2008	2008	NUM
ihlr-20834	329	12	)	)	PUNCT
ihlr-20834	329	13	)	)	PUNCT
ihlr-20834	329	14	.	.	PUNCT
ihlr-20834	330	1	96	96	NUM
ihlr-20834	331	1	i	i	PRON
ihlr-20834	331	2	d.	d.	PROPN
ihlr-20834	331	3	(	(	PUNCT
ihlr-20834	331	4	citing	cite	VERB
ihlr-20834	331	5	altria	altria	PROPN
ihlr-20834	331	6	group	group	PROPN
ihlr-20834	331	7	,	,	PUNCT
ihlr-20834	331	8	inc	inc	PROPN
ihlr-20834	331	9	.	.	PROPN
ihlr-20834	332	1	v.	v.	ADP
ihlr-20834	332	2	good	good	ADJ
ihlr-20834	332	3	,	,	PUNCT
ihlr-20834	332	4	555	555	NUM
ihlr-20834	332	5	u.s	u.s	PROPN
ihlr-20834	332	6	.	.	PROPN
ihlr-20834	332	7	70	70	NUM
ihlr-20834	332	8	,	,	PUNCT
ihlr-20834	332	9	77	77	NUM
ihlr-20834	332	10	(	(	PUNCT
ihlr-20834	332	11	2008	2008	NUM
ihlr-20834	332	12	)	)	PUNCT
ihlr-20834	332	13	)	)	PUNCT
ihlr-20834	332	14	.	.	PUNCT
ihlr-20834	333	1	97	97	NUM
ihlr-20834	334	1	i	i	PRON
ihlr-20834	334	2	d.	d.	PROPN
ihlr-20834	334	3	at	at	ADP
ihlr-20834	334	4	2486	2486	NUM
ihlr-20834	334	5	.	.	PUNCT
ihlr-20834	335	1	98	98	NUM
ihlr-20834	336	1	i	i	PRON
ihlr-20834	336	2	d.	d.	PROPN
ihlr-20834	336	3	at	at	ADP
ihlr-20834	336	4	2481	2481	NUM
ihlr-20834	336	5	(	(	PUNCT
ihlr-20834	336	6	breyer	breyer	NOUN
ihlr-20834	336	7	,	,	PUNCT
ihlr-20834	336	8	j.	j.	PROPN
ihlr-20834	336	9	,	,	PUNCT
ihlr-20834	336	10	dissenting	dissent	VERB
ihlr-20834	336	11	)	)	PUNCT
ihlr-20834	336	12	(	(	PUNCT
ihlr-20834	336	13	citing	cite	VERB
ihlr-20834	336	14	smiley	smiley	NOUN
ihlr-20834	336	15	v.	v.	ADP
ihlr-20834	336	16	citibank	citibank	PROPN
ihlr-20834	336	17	(	(	PUNCT
ihlr-20834	336	18	south	south	PROPN
ihlr-20834	336	19	dakota	dakota	PROPN
ihlr-20834	336	20	)	)	PUNCT
ihlr-20834	336	21	,	,	PUNCT
ihlr-20834	336	22	517	517	NUM
ihlr-20834	336	23	u.s	u.s	PROPN
ihlr-20834	336	24	.	.	PROPN
ihlr-20834	336	25	735	735	NUM
ihlr-20834	336	26	,	,	PUNCT
ihlr-20834	336	27	739	739	NUM
ihlr-20834	336	28	-	-	SYM
ihlr-20834	336	29	41	41	NUM
ihlr-20834	336	30	(	(	PUNCT
ihlr-20834	336	31	1996	1996	NUM
ihlr-20834	336	32	)	)	PUNCT
ihlr-20834	336	33	)	)	PUNCT
ihlr-20834	336	34	.	.	PUNCT
ihlr-20834	337	1	http://dx.doi.org/10.2139/ssrn.2278341	http://dx.doi.org/10.2139/ssrn.2278341	X
ihlr-20834	337	2	786	786	NUM
ihlr-20834	337	3	indiana	indiana	PROPN
ihlr-20834	337	4	health	health	PROPN
ihlr-20834	337	5	law	law	PROPN
ihlr-20834	337	6	review	review	NOUN
ihlr-20834	337	7	vol	vol	NOUN
ihlr-20834	337	8	.	.	PUNCT
ihlr-20834	338	1	12:2	12:2	NUM
ihlr-20834	338	2	applied	apply	VERB
ihlr-20834	338	3	to	to	ADP
ihlr-20834	338	4	the	the	DET
ihlr-20834	338	5	fdca	fdca	NOUN
ihlr-20834	338	6	in	in	ADP
ihlr-20834	338	7	the	the	DET
ihlr-20834	338	8	first	first	ADJ
ihlr-20834	338	9	of	of	ADP
ihlr-20834	338	10	three	three	NUM
ihlr-20834	338	11	fundamental	fundamental	ADJ
ihlr-20834	338	12	cases	case	NOUN
ihlr-20834	338	13	,	,	PUNCT
ihlr-20834	338	14	wyeth	wyeth	PROPN
ihlr-20834	338	15	v.	v.	PROPN
ihlr-20834	338	16	levine.99	levine.99	PROPN
ihlr-20834	338	17	iv	iv	PROPN
ihlr-20834	338	18	.	.	PUNCT
ihlr-20834	338	19	case	case	NOUN
ihlr-20834	338	20	law	law	NOUN
ihlr-20834	338	21	,	,	PUNCT
ihlr-20834	338	22	indiana	indiana	PROPN
ihlr-20834	338	23	statutory	statutory	ADJ
ihlr-20834	338	24	dissemination	dissemination	NOUN
ihlr-20834	338	25	,	,	PUNCT
ihlr-20834	338	26	and	and	CCONJ
ihlr-20834	338	27	recourse	recourse	VERB
ihlr-20834	338	28	available	available	ADJ
ihlr-20834	338	29	for	for	ADP
ihlr-20834	338	30	generic	generic	ADJ
ihlr-20834	338	31	drug	drug	NOUN
ihlr-20834	338	32	consumers	consumer	NOUN
ihlr-20834	338	33	this	this	DET
ihlr-20834	338	34	section	section	NOUN
ihlr-20834	338	35	will	will	AUX
ihlr-20834	338	36	explore	explore	VERB
ihlr-20834	338	37	the	the	DET
ihlr-20834	338	38	three	three	NUM
ihlr-20834	338	39	recently	recently	ADV
ihlr-20834	338	40	decide	decide	VERB
ihlr-20834	338	41	supreme	supreme	ADJ
ihlr-20834	338	42	cases	case	NOUN
ihlr-20834	338	43	relevant	relevant	ADJ
ihlr-20834	338	44	to	to	ADP
ihlr-20834	338	45	the	the	DET
ihlr-20834	338	46	preemption	preemption	NOUN
ihlr-20834	338	47	inquiry	inquiry	NOUN
ihlr-20834	338	48	.	.	PUNCT
ihlr-20834	339	1	this	this	DET
ihlr-20834	339	2	section	section	NOUN
ihlr-20834	339	3	will	will	AUX
ihlr-20834	339	4	then	then	ADV
ihlr-20834	339	5	continue	continue	VERB
ihlr-20834	339	6	by	by	ADP
ihlr-20834	339	7	exploring	explore	VERB
ihlr-20834	339	8	indiana	indiana	PROPN
ihlr-20834	339	9	law	law	PROPN
ihlr-20834	339	10	as	as	SCONJ
ihlr-20834	339	11	it	it	PRON
ihlr-20834	339	12	relates	relate	VERB
ihlr-20834	339	13	to	to	ADP
ihlr-20834	339	14	this	this	DET
ihlr-20834	339	15	precedent	precedent	NOUN
ihlr-20834	339	16	and	and	CCONJ
ihlr-20834	339	17	it	it	PRON
ihlr-20834	339	18	will	will	AUX
ihlr-20834	339	19	demonstrate	demonstrate	VERB
ihlr-20834	339	20	how	how	SCONJ
ihlr-20834	339	21	previously	previously	ADV
ihlr-20834	339	22	decided	decide	VERB
ihlr-20834	339	23	cases	case	NOUN
ihlr-20834	339	24	would	would	AUX
ihlr-20834	339	25	likely	likely	ADV
ihlr-20834	339	26	result	result	VERB
ihlr-20834	339	27	in	in	ADP
ihlr-20834	339	28	unjust	unjust	ADJ
ihlr-20834	339	29	and	and	CCONJ
ihlr-20834	339	30	inequitable	inequitable	ADJ
ihlr-20834	339	31	decisions	decision	NOUN
ihlr-20834	339	32	following	follow	VERB
ihlr-20834	339	33	the	the	DET
ihlr-20834	339	34	court	court	NOUN
ihlr-20834	339	35	’s	’s	PART
ihlr-20834	339	36	precedent	precedent	NOUN
ihlr-20834	339	37	.	.	PUNCT
ihlr-20834	340	1	finally	finally	ADV
ihlr-20834	340	2	,	,	PUNCT
ihlr-20834	340	3	this	this	DET
ihlr-20834	340	4	section	section	NOUN
ihlr-20834	340	5	will	will	AUX
ihlr-20834	340	6	explore	explore	VERB
ihlr-20834	340	7	alternative	alternative	ADJ
ihlr-20834	340	8	options	option	NOUN
ihlr-20834	340	9	available	available	ADJ
ihlr-20834	340	10	for	for	SCONJ
ihlr-20834	340	11	generic	generic	ADJ
ihlr-20834	340	12	drug	drug	NOUN
ihlr-20834	340	13	consumers	consumer	NOUN
ihlr-20834	340	14	to	to	PART
ihlr-20834	340	15	protect	protect	VERB
ihlr-20834	340	16	themselves	themselves	PRON
ihlr-20834	340	17	.	.	PUNCT
ihlr-20834	341	1	a.	a.	PROPN
ihlr-20834	341	2	wyeth	wyeth	PROPN
ihlr-20834	341	3	,	,	PUNCT
ihlr-20834	341	4	pliva	pliva	NOUN
ihlr-20834	341	5	and	and	CCONJ
ihlr-20834	341	6	bartlett	bartlett	PROPN
ihlr-20834	341	7	1	1	NUM
ihlr-20834	341	8	.	.	PUNCT
ihlr-20834	341	9	wyeth	wyeth	PROPN
ihlr-20834	341	10	–	–	PUNCT
ihlr-20834	341	11	no	no	DET
ihlr-20834	341	12	state	state	NOUN
ihlr-20834	341	13	tort	tort	NOUN
ihlr-20834	341	14	law	law	NOUN
ihlr-20834	341	15	preemption	preemption	NOUN
ihlr-20834	341	16	from	from	ADP
ihlr-20834	341	17	fda	fda	PROPN
ihlr-20834	341	18	’s	’s	PART
ihlr-20834	341	19	brand	brand	NOUN
ihlr-20834	341	20	-	-	PUNCT
ihlr-20834	341	21	name	name	NOUN
ihlr-20834	341	22	drug	drug	NOUN
ihlr-20834	341	23	regulations	regulation	NOUN
ihlr-20834	341	24	the	the	DET
ihlr-20834	341	25	first	first	ADJ
ihlr-20834	341	26	of	of	ADP
ihlr-20834	341	27	the	the	DET
ihlr-20834	341	28	three	three	NUM
ihlr-20834	341	29	supreme	supreme	ADJ
ihlr-20834	341	30	court	court	NOUN
ihlr-20834	341	31	cases	case	NOUN
ihlr-20834	341	32	involved	involve	VERB
ihlr-20834	341	33	a	a	DET
ihlr-20834	341	34	plaintiff	plaintiff	NOUN
ihlr-20834	341	35	that	that	PRON
ihlr-20834	341	36	brought	bring	VERB
ihlr-20834	341	37	suit	suit	NOUN
ihlr-20834	341	38	against	against	ADP
ihlr-20834	341	39	a	a	DET
ihlr-20834	341	40	brand	brand	NOUN
ihlr-20834	341	41	-	-	PUNCT
ihlr-20834	341	42	name	name	NOUN
ihlr-20834	341	43	drug	drug	NOUN
ihlr-20834	341	44	manufacturer	manufacturer	NOUN
ihlr-20834	341	45	on	on	ADP
ihlr-20834	341	46	a	a	DET
ihlr-20834	341	47	failure	failure	NOUN
ihlr-20834	341	48	-	-	PUNCT
ihlr-20834	341	49	to	to	PART
ihlr-20834	341	50	-	-	PUNCT
ihlr-20834	341	51	warn	warn	VERB
ihlr-20834	341	52	claim	claim	NOUN
ihlr-20834	341	53	.	.	PUNCT
ihlr-20834	342	1	100	100	NUM
ihlr-20834	342	2	in	in	ADP
ihlr-20834	342	3	wyeth	wyeth	PROPN
ihlr-20834	342	4	v.	v.	PROPN
ihlr-20834	342	5	levine	levine	PROPN
ihlr-20834	342	6	,	,	PUNCT
ihlr-20834	342	7	respondent	respondent	PROPN
ihlr-20834	342	8	diana	diana	PROPN
ihlr-20834	342	9	levine	levine	PROPN
ihlr-20834	342	10	suffered	suffer	VERB
ihlr-20834	342	11	injuries	injury	NOUN
ihlr-20834	342	12	from	from	ADP
ihlr-20834	342	13	an	an	DET
ihlr-20834	342	14	iv	iv	NUM
ihlr-20834	342	15	-	-	PUNCT
ihlr-20834	342	16	push	push	NOUN
ihlr-20834	342	17	injection	injection	NOUN
ihlr-20834	342	18	of	of	ADP
ihlr-20834	342	19	phenergan.101	phenergan.101	PROPN
ihlr-20834	342	20	as	as	ADP
ihlr-20834	342	21	a	a	DET
ihlr-20834	342	22	result	result	NOUN
ihlr-20834	342	23	from	from	ADP
ihlr-20834	342	24	such	such	ADJ
ihlr-20834	342	25	injuries	injury	NOUN
ihlr-20834	342	26	,	,	PUNCT
ihlr-20834	342	27	ms	ms	PROPN
ihlr-20834	342	28	.	.	PROPN
ihlr-20834	342	29	levine	levine	PROPN
ihlr-20834	342	30	was	be	AUX
ihlr-20834	342	31	required	require	VERB
ihlr-20834	342	32	to	to	PART
ihlr-20834	342	33	have	have	VERB
ihlr-20834	342	34	her	her	PRON
ihlr-20834	342	35	right	right	ADJ
ihlr-20834	342	36	hand	hand	NOUN
ihlr-20834	342	37	and	and	CCONJ
ihlr-20834	342	38	forearm	forearm	NOUN
ihlr-20834	342	39	amputated.102	amputated.102	PRON
ihlr-20834	342	40	ms	ms	PROPN
ihlr-20834	342	41	.	.	PROPN
ihlr-20834	342	42	levine	levine	PROPN
ihlr-20834	342	43	suffered	suffer	VERB
ihlr-20834	342	44	substantial	substantial	ADJ
ihlr-20834	342	45	medical	medical	ADJ
ihlr-20834	342	46	expenses	expense	NOUN
ihlr-20834	342	47	and	and	CCONJ
ihlr-20834	342	48	the	the	DET
ihlr-20834	342	49	loss	loss	NOUN
ihlr-20834	342	50	of	of	ADP
ihlr-20834	342	51	her	her	PRON
ihlr-20834	342	52	livelihood	livelihood	NOUN
ihlr-20834	342	53	as	as	ADP
ihlr-20834	342	54	professional	professional	ADJ
ihlr-20834	342	55	musician.103	musician.103	ADJ
ihlr-20834	342	56	in	in	ADP
ihlr-20834	342	57	their	their	PRON
ihlr-20834	342	58	decision	decision	NOUN
ihlr-20834	342	59	,	,	PUNCT
ihlr-20834	342	60	the	the	DET
ihlr-20834	342	61	jury	jury	NOUN
ihlr-20834	342	62	found	find	VERB
ihlr-20834	342	63	wyeth	wyeth	PROPN
ihlr-20834	342	64	negligent	negligent	ADJ
ihlr-20834	342	65	and	and	CCONJ
ihlr-20834	342	66	concluded	conclude	VERB
ihlr-20834	342	67	that	that	SCONJ
ihlr-20834	342	68	phenergan	phenergan	PROPN
ihlr-20834	342	69	was	be	AUX
ihlr-20834	342	70	a	a	DET
ihlr-20834	342	71	defective	defective	ADJ
ihlr-20834	342	72	product	product	NOUN
ihlr-20834	342	73	that	that	PRON
ihlr-20834	342	74	had	have	VERB
ihlr-20834	342	75	inadequate	inadequate	ADJ
ihlr-20834	342	76	warnings	warning	NOUN
ihlr-20834	342	77	and	and	CCONJ
ihlr-20834	342	78	instructions.104	instructions.104	NOUN
ihlr-20834	342	79	specifically	specifically	ADV
ihlr-20834	342	80	,	,	PUNCT
ihlr-20834	342	81	the	the	DET
ihlr-20834	342	82	instructions	instruction	NOUN
ihlr-20834	342	83	had	have	AUX
ihlr-20834	342	84	failed	fail	VERB
ihlr-20834	342	85	to	to	PART
ihlr-20834	342	86	“	"	PUNCT
ihlr-20834	342	87	instruct	instruct	VERB
ihlr-20834	342	88	clinicians	clinician	NOUN
ihlr-20834	342	89	to	to	PART
ihlr-20834	342	90	use	use	VERB
ihlr-20834	342	91	the	the	DET
ihlr-20834	342	92	iv	iv	NOUN
ihlr-20834	342	93	-	-	PUNCT
ihlr-20834	342	94	drip	drip	NOUN
ihlr-20834	342	95	method	method	NOUN
ihlr-20834	342	96	of	of	ADP
ihlr-20834	342	97	intravenous	intravenous	ADJ
ihlr-20834	342	98	99	99	NUM
ihlr-20834	342	99	wyeth	wyeth	PROPN
ihlr-20834	342	100	v.	v.	PROPN
ihlr-20834	342	101	levine	levine	PROPN
ihlr-20834	342	102	,	,	PUNCT
ihlr-20834	342	103	555	555	NUM
ihlr-20834	342	104	u.s	u.s	PROPN
ihlr-20834	342	105	.	.	PROPN
ihlr-20834	342	106	555	555	NUM
ihlr-20834	342	107	,	,	PUNCT
ihlr-20834	342	108	581	581	NUM
ihlr-20834	342	109	(	(	PUNCT
ihlr-20834	342	110	2009	2009	NUM
ihlr-20834	342	111	)	)	PUNCT
ihlr-20834	342	112	.	.	PUNCT
ihlr-20834	343	1	100	100	NUM
ihlr-20834	344	1	i	i	PRON
ihlr-20834	344	2	d.	d.	PROPN
ihlr-20834	344	3	at	at	ADP
ihlr-20834	344	4	560	560	NUM
ihlr-20834	344	5	.	.	PUNCT
ihlr-20834	345	1	101	101	NUM
ihlr-20834	346	1	i	i	PRON
ihlr-20834	346	2	d.	d.	PROPN
ihlr-20834	346	3	102	102	NUM
ihlr-20834	347	1	i	i	PRON
ihlr-20834	347	2	d.	d.	PROPN
ihlr-20834	347	3	at	at	ADP
ihlr-20834	347	4	559	559	NUM
ihlr-20834	347	5	.	.	PUNCT
ihlr-20834	347	6	103	103	NUM
ihlr-20834	348	1	i	i	PRON
ihlr-20834	348	2	d.	d.	PROPN
ihlr-20834	348	3	104	104	NUM
ihlr-20834	349	1	i	i	PRON
ihlr-20834	349	2	d.	d.	PROPN
ihlr-20834	349	3	at	at	ADP
ihlr-20834	349	4	562	562	NUM
ihlr-20834	349	5	.	.	PUNCT
ihlr-20834	350	1	2015	2015	NUM
ihlr-20834	350	2	787	787	NUM
ihlr-20834	350	3	the	the	DET
ihlr-20834	350	4	supreme	supreme	PROPN
ihlr-20834	350	5	court	court	PROPN
ihlr-20834	350	6	’s	’s	PART
ihlr-20834	350	7	overreaching	overreach	VERB
ihlr-20834	350	8	preemption	preemption	NOUN
ihlr-20834	350	9	interpretation	interpretation	NOUN
ihlr-20834	350	10	and	and	CCONJ
ihlr-20834	350	11	it	it	PRON
ihlr-20834	350	12	’s	’	VERB
ihlr-20834	350	13	consequences	consequence	VERB
ihlr-20834	350	14	administration	administration	NOUN
ihlr-20834	350	15	instead	instead	ADV
ihlr-20834	350	16	of	of	ADP
ihlr-20834	350	17	the	the	DET
ihlr-20834	350	18	higher	high	ADJ
ihlr-20834	350	19	risk	risk	NOUN
ihlr-20834	350	20	iv	iv	NOUN
ihlr-20834	350	21	-	-	PUNCT
ihlr-20834	350	22	push	push	NOUN
ihlr-20834	350	23	method	method	NOUN
ihlr-20834	350	24	”	"	PUNCT
ihlr-20834	350	25	that	that	PRON
ihlr-20834	350	26	was	be	AUX
ihlr-20834	350	27	used	use	VERB
ihlr-20834	350	28	on	on	ADP
ihlr-20834	350	29	ms	ms	PROPN
ihlr-20834	350	30	.	.	PROPN
ihlr-20834	350	31	levine.105	levine.105	PROPN
ihlr-20834	350	32	the	the	DET
ihlr-20834	350	33	drug	drug	NOUN
ihlr-20834	350	34	manufacturer	manufacturer	NOUN
ihlr-20834	350	35	claimed	claim	VERB
ihlr-20834	350	36	impossibility	impossibility	NOUN
ihlr-20834	350	37	preemption	preemption	NOUN
ihlr-20834	350	38	in	in	ADP
ihlr-20834	350	39	the	the	DET
ihlr-20834	350	40	appeal.106	appeal.106	NOUN
ihlr-20834	350	41	the	the	DET
ihlr-20834	350	42	manufacturer	manufacturer	NOUN
ihlr-20834	350	43	argued	argue	VERB
ihlr-20834	350	44	it	it	PRON
ihlr-20834	350	45	was	be	AUX
ihlr-20834	350	46	impossible	impossible	ADJ
ihlr-20834	350	47	to	to	PART
ihlr-20834	350	48	comply	comply	VERB
ihlr-20834	350	49	with	with	ADP
ihlr-20834	350	50	the	the	DET
ihlr-20834	350	51	state	state	NOUN
ihlr-20834	350	52	-	-	PUNCT
ihlr-20834	350	53	law	law	NOUN
ihlr-20834	350	54	duty	duty	NOUN
ihlr-20834	350	55	to	to	PART
ihlr-20834	350	56	modify	modify	VERB
ihlr-20834	350	57	phenergan	phenergan	PROPN
ihlr-20834	350	58	’s	’s	PART
ihlr-20834	350	59	label	label	NOUN
ihlr-20834	350	60	because	because	SCONJ
ihlr-20834	350	61	federal	federal	ADJ
ihlr-20834	350	62	law	law	NOUN
ihlr-20834	350	63	prohibited	prohibit	VERB
ihlr-20834	350	64	the	the	DET
ihlr-20834	350	65	unilateral	unilateral	ADJ
ihlr-20834	350	66	change	change	NOUN
ihlr-20834	350	67	of	of	ADP
ihlr-20834	350	68	a	a	DET
ihlr-20834	350	69	drugs	drug	NOUN
ihlr-20834	350	70	label.107	label.107	VERB
ihlr-20834	350	71	in	in	ADP
ihlr-20834	350	72	dispensing	dispense	VERB
ihlr-20834	350	73	with	with	ADP
ihlr-20834	350	74	this	this	DET
ihlr-20834	350	75	argument	argument	NOUN
ihlr-20834	350	76	,	,	PUNCT
ihlr-20834	350	77	the	the	DET
ihlr-20834	350	78	court	court	NOUN
ihlr-20834	350	79	reasoned	reason	VERB
ihlr-20834	350	80	the	the	DET
ihlr-20834	350	81	manufacturer	manufacturer	NOUN
ihlr-20834	350	82	failed	fail	VERB
ihlr-20834	350	83	to	to	PART
ihlr-20834	350	84	demonstrate	demonstrate	VERB
ihlr-20834	350	85	it	it	PRON
ihlr-20834	350	86	was	be	AUX
ihlr-20834	350	87	impossible	impossible	ADJ
ihlr-20834	350	88	to	to	PART
ihlr-20834	350	89	comply	comply	VERB
ihlr-20834	350	90	with	with	ADP
ihlr-20834	350	91	both	both	CCONJ
ihlr-20834	350	92	federal	federal	ADJ
ihlr-20834	350	93	and	and	CCONJ
ihlr-20834	350	94	state	state	NOUN
ihlr-20834	350	95	law.108	law.108	NOUN
ihlr-20834	350	96	under	under	ADP
ihlr-20834	350	97	the	the	DET
ihlr-20834	350	98	court	court	NOUN
ihlr-20834	350	99	’s	’s	PART
ihlr-20834	350	100	analysis	analysis	NOUN
ihlr-20834	350	101	,	,	PUNCT
ihlr-20834	350	102	the	the	DET
ihlr-20834	350	103	changes	change	NOUN
ihlr-20834	350	104	being	be	AUX
ihlr-20834	350	105	effected	effect	VERB
ihlr-20834	350	106	(	(	PUNCT
ihlr-20834	350	107	“	"	PUNCT
ihlr-20834	350	108	cbe	cbe	PROPN
ihlr-20834	350	109	”	"	PUNCT
ihlr-20834	350	110	)	)	PUNCT
ihlr-20834	350	111	regulation	regulation	NOUN
ihlr-20834	350	112	allowed	allow	VERB
ihlr-20834	350	113	manufacturers	manufacturer	NOUN
ihlr-20834	350	114	to	to	PART
ihlr-20834	350	115	supplement	supplement	VERB
ihlr-20834	350	116	and	and	CCONJ
ihlr-20834	350	117	change	change	VERB
ihlr-20834	350	118	their	their	PRON
ihlr-20834	350	119	label	label	NOUN
ihlr-20834	350	120	.	.	PUNCT
ihlr-20834	351	1	109	109	NUM
ihlr-20834	351	2	this	this	DET
ihlr-20834	351	3	“	"	PUNCT
ihlr-20834	351	4	permitted	permit	VERB
ihlr-20834	351	5	wyeth	wyeth	PROPN
ihlr-20834	351	6	to	to	PART
ihlr-20834	351	7	unilaterally	unilaterally	ADV
ihlr-20834	351	8	strengthen	strengthen	VERB
ihlr-20834	351	9	its	its	PRON
ihlr-20834	351	10	warning	warning	NOUN
ihlr-20834	351	11	,	,	PUNCT
ihlr-20834	351	12	and	and	CCONJ
ihlr-20834	351	13	the	the	DET
ihlr-20834	351	14	mere	mere	ADJ
ihlr-20834	351	15	fact	fact	NOUN
ihlr-20834	351	16	that	that	SCONJ
ihlr-20834	351	17	the	the	DET
ihlr-20834	351	18	fda	fda	PROPN
ihlr-20834	351	19	approved	approve	VERB
ihlr-20834	351	20	phenergan	phenergan	PROPN
ihlr-20834	351	21	’s	’s	PART
ihlr-20834	351	22	label	label	NOUN
ihlr-20834	351	23	[	[	AUX
ihlr-20834	351	24	did	do	AUX
ihlr-20834	351	25	]	]	PUNCT
ihlr-20834	351	26	not	not	PART
ihlr-20834	351	27	establish	establish	VERB
ihlr-20834	351	28	that	that	SCONJ
ihlr-20834	351	29	it	it	PRON
ihlr-20834	351	30	would	would	AUX
ihlr-20834	351	31	have	have	AUX
ihlr-20834	351	32	prohibited	prohibit	VERB
ihlr-20834	351	33	such	such	DET
ihlr-20834	351	34	a	a	DET
ihlr-20834	351	35	change	change	NOUN
ihlr-20834	351	36	.	.	PUNCT
ihlr-20834	351	37	”110	”110	PUNCT
ihlr-20834	352	1	in	in	ADP
ihlr-20834	352	2	the	the	DET
ihlr-20834	352	3	concurrence	concurrence	NOUN
ihlr-20834	352	4	,	,	PUNCT
ihlr-20834	352	5	justice	justice	NOUN
ihlr-20834	352	6	breyer	breyer	NOUN
ihlr-20834	352	7	stated	state	VERB
ihlr-20834	352	8	the	the	DET
ihlr-20834	352	9	court	court	NOUN
ihlr-20834	352	10	had	have	VERB
ihlr-20834	352	11	“	"	PUNCT
ihlr-20834	352	12	no	no	DET
ihlr-20834	352	13	occasion	occasion	NOUN
ihlr-20834	352	14	in	in	ADP
ihlr-20834	352	15	this	this	DET
ihlr-20834	352	16	case	case	NOUN
ihlr-20834	352	17	to	to	PART
ihlr-20834	352	18	consider	consider	VERB
ihlr-20834	352	19	the	the	DET
ihlr-20834	352	20	pre	pre	ADJ
ihlr-20834	352	21	-	-	ADJ
ihlr-20834	352	22	emptive	emptive	ADJ
ihlr-20834	352	23	effect	effect	NOUN
ihlr-20834	352	24	of	of	ADP
ihlr-20834	352	25	a	a	DET
ihlr-20834	352	26	specific	specific	ADJ
ihlr-20834	352	27	agency	agency	NOUN
ihlr-20834	352	28	regulation	regulation	NOUN
ihlr-20834	352	29	being	be	AUX
ihlr-20834	352	30	the	the	DET
ihlr-20834	352	31	force	force	NOUN
ihlr-20834	352	32	of	of	ADP
ihlr-20834	352	33	law	law	NOUN
ihlr-20834	352	34	.	.	PUNCT
ihlr-20834	352	35	”111	”111	PROPN
ihlr-20834	353	1	he	he	PRON
ihlr-20834	353	2	continued	continue	VERB
ihlr-20834	353	3	by	by	ADP
ihlr-20834	353	4	reasoning	reason	VERB
ihlr-20834	353	5	that	that	SCONJ
ihlr-20834	353	6	federal	federal	ADJ
ihlr-20834	353	7	statutes	statute	NOUN
ihlr-20834	353	8	and	and	CCONJ
ihlr-20834	353	9	regulations	regulation	NOUN
ihlr-20834	353	10	neither	neither	CCONJ
ihlr-20834	353	11	protected	protect	VERB
ihlr-20834	353	12	the	the	DET
ihlr-20834	353	13	manufacturer	manufacturer	NOUN
ihlr-20834	353	14	from	from	ADP
ihlr-20834	353	15	the	the	DET
ihlr-20834	353	16	risk	risk	NOUN
ihlr-20834	353	17	of	of	ADP
ihlr-20834	353	18	state	state	NOUN
ihlr-20834	353	19	-	-	PUNCT
ihlr-20834	353	20	law	law	NOUN
ihlr-20834	353	21	liability	liability	NOUN
ihlr-20834	353	22	nor	nor	CCONJ
ihlr-20834	353	23	prohibited	prohibit	VERB
ihlr-20834	353	24	the	the	DET
ihlr-20834	353	25	stronger	strong	ADJ
ihlr-20834	353	26	warning	warning	NOUN
ihlr-20834	353	27	label	label	NOUN
ihlr-20834	353	28	required	require	VERB
ihlr-20834	353	29	by	by	ADP
ihlr-20834	353	30	the	the	DET
ihlr-20834	353	31	state	state	NOUN
ihlr-20834	353	32	court	court	NOUN
ihlr-20834	353	33	’s	’s	PART
ihlr-20834	353	34	judgment	judgment	NOUN
ihlr-20834	353	35	.	.	PUNCT
ihlr-20834	354	1	112	112	NUM
ihlr-20834	354	2	comparatively	comparatively	ADV
ihlr-20834	354	3	,	,	PUNCT
ihlr-20834	354	4	in	in	ADP
ihlr-20834	354	5	another	another	DET
ihlr-20834	354	6	concurrence	concurrence	NOUN
ihlr-20834	354	7	,	,	PUNCT
ihlr-20834	354	8	justice	justice	PROPN
ihlr-20834	354	9	thomas	thomas	PROPN
ihlr-20834	354	10	concluded	conclude	VERB
ihlr-20834	354	11	that	that	SCONJ
ihlr-20834	354	12	with	with	ADP
ihlr-20834	354	13	no	no	DET
ihlr-20834	354	14	“	"	PUNCT
ihlr-20834	354	15	direct	direct	ADJ
ihlr-20834	354	16	conflict	conflict	NOUN
ihlr-20834	354	17	”	"	PUNCT
ihlr-20834	354	18	between	between	ADP
ihlr-20834	354	19	the	the	DET
ihlr-20834	354	20	federal	federal	ADJ
ihlr-20834	354	21	and	and	CCONJ
ihlr-20834	354	22	state	state	NOUN
ihlr-20834	354	23	law	law	NOUN
ihlr-20834	354	24	,	,	PUNCT
ihlr-20834	354	25	the	the	DET
ihlr-20834	354	26	state	state	NOUN
ihlr-20834	354	27	-	-	PUNCT
ihlr-20834	354	28	law	law	NOUN
ihlr-20834	354	29	judgment	judgment	NOUN
ihlr-20834	354	30	was	be	AUX
ihlr-20834	354	31	not	not	PART
ihlr-20834	354	32	preempted.113	preempted.113	ADJ
ihlr-20834	354	33	the	the	DET
ihlr-20834	354	34	majority	majority	NOUN
ihlr-20834	354	35	decision	decision	NOUN
ihlr-20834	354	36	was	be	AUX
ihlr-20834	354	37	consistent	consistent	ADJ
ihlr-20834	354	38	with	with	ADP
ihlr-20834	354	39	the	the	DET
ihlr-20834	354	40	long	long	ADV
ihlr-20834	354	41	-	-	PUNCT
ihlr-20834	354	42	established	establish	VERB
ihlr-20834	354	43	presumption	presumption	NOUN
ihlr-20834	354	44	against	against	ADP
ihlr-20834	354	45	finding	find	VERB
ihlr-20834	354	46	105	105	NUM
ihlr-20834	354	47	i	i	PRON
ihlr-20834	354	48	d.	d.	PROPN
ihlr-20834	354	49	at	at	ADP
ihlr-20834	354	50	560	560	NUM
ihlr-20834	354	51	.	.	NOUN
ihlr-20834	354	52	106	106	NUM
ihlr-20834	355	1	i	i	PRON
ihlr-20834	355	2	d.	d.	PROPN
ihlr-20834	355	3	107	107	NUM
ihlr-20834	356	1	i	i	PRON
ihlr-20834	356	2	d.	d.	PROPN
ihlr-20834	356	3	at	at	ADP
ihlr-20834	356	4	563	563	NUM
ihlr-20834	356	5	-	-	SYM
ihlr-20834	356	6	64	64	NUM
ihlr-20834	356	7	.	.	NUM
ihlr-20834	356	8	108	108	NUM
ihlr-20834	357	1	i	i	PRON
ihlr-20834	357	2	d.	d.	NOUN
ihlr-20834	357	3	at	at	ADP
ihlr-20834	357	4	573	573	NUM
ihlr-20834	357	5	.	.	PUNCT
ihlr-20834	358	1	109	109	NUM
ihlr-20834	359	1	i	i	PROPN
ihlr-20834	359	2	d.	d.	NOUN
ihlr-20834	359	3	110	110	NUM
ihlr-20834	360	1	i	i	PROPN
ihlr-20834	360	2	d.	d.	PROPN
ihlr-20834	360	3	111	111	NUM
ihlr-20834	361	1	i	i	PRON
ihlr-20834	361	2	d.	d.	NOUN
ihlr-20834	361	3	at	at	ADP
ihlr-20834	361	4	581	581	NUM
ihlr-20834	361	5	(	(	PUNCT
ihlr-20834	361	6	breyer	breyer	NOUN
ihlr-20834	361	7	,	,	PUNCT
ihlr-20834	361	8	j.	j.	PROPN
ihlr-20834	361	9	,	,	PUNCT
ihlr-20834	361	10	concurring	concur	VERB
ihlr-20834	361	11	)	)	PUNCT
ihlr-20834	361	12	.	.	PUNCT
ihlr-20834	362	1	112	112	NUM
ihlr-20834	363	1	i	i	PRON
ihlr-20834	363	2	d.	d.	PROPN
ihlr-20834	363	3	at	at	ADP
ihlr-20834	363	4	583	583	NUM
ihlr-20834	363	5	.	.	PUNCT
ihlr-20834	364	1	113	113	NUM
ihlr-20834	365	1	i	i	PRON
ihlr-20834	365	2	d.	d.	NOUN
ihlr-20834	365	3	at	at	ADP
ihlr-20834	365	4	593	593	NUM
ihlr-20834	365	5	(	(	PUNCT
ihlr-20834	365	6	thomas	thomas	PROPN
ihlr-20834	365	7	,	,	PUNCT
ihlr-20834	365	8	j.	j.	PROPN
ihlr-20834	365	9	,	,	PUNCT
ihlr-20834	365	10	concurring	concur	VERB
ihlr-20834	365	11	)	)	PUNCT
ihlr-20834	365	12	(	(	PUNCT
ihlr-20834	365	13	citing	cite	VERB
ihlr-20834	365	14	am	be	AUX
ihlr-20834	365	15	.	.	PUNCT
ihlr-20834	366	1	tel	tel	PROPN
ihlr-20834	366	2	.	.	PROPN
ihlr-20834	366	3	&	&	CCONJ
ihlr-20834	366	4	tel	tel	PROPN
ihlr-20834	366	5	.	.	PROPN
ihlr-20834	366	6	co.	co.	PROPN
ihlr-20834	367	1	v.	v.	ADP
ihlr-20834	367	2	cent	cent	NOUN
ihlr-20834	367	3	.	.	PUNCT
ihlr-20834	368	1	off	off	ADP
ihlr-20834	368	2	.	.	PUNCT
ihlr-20834	369	1	tel	tel	AUX
ihlr-20834	369	2	.	.	PROPN
ihlr-20834	369	3	,	,	PUNCT
ihlr-20834	369	4	inc	inc	PROPN
ihlr-20834	369	5	.	.	PROPN
ihlr-20834	369	6	,	,	PUNCT
ihlr-20834	369	7	524	524	NUM
ihlr-20834	369	8	u.s	u.s	PROPN
ihlr-20834	369	9	.	.	PROPN
ihlr-20834	369	10	214	214	NUM
ihlr-20834	369	11	,	,	PUNCT
ihlr-20834	369	12	221	221	NUM
ihlr-20834	369	13	-	-	SYM
ihlr-20834	369	14	26	26	NUM
ihlr-20834	369	15	(	(	PUNCT
ihlr-20834	369	16	1998	1998	NUM
ihlr-20834	369	17	)	)	PUNCT
ihlr-20834	369	18	(	(	PUNCT
ihlr-20834	369	19	finding	find	VERB
ihlr-20834	369	20	preemption	preemption	NOUN
ihlr-20834	369	21	where	where	SCONJ
ihlr-20834	369	22	federal	federal	ADJ
ihlr-20834	369	23	law	law	NOUN
ihlr-20834	369	24	forbade	forbid	VERB
ihlr-20834	369	25	common	common	ADJ
ihlr-20834	369	26	carriers	carrier	NOUN
ihlr-20834	369	27	from	from	ADP
ihlr-20834	369	28	extending	extend	VERB
ihlr-20834	369	29	communications	communication	NOUN
ihlr-20834	369	30	privileges	privilege	NOUN
ihlr-20834	369	31	requested	request	VERB
ihlr-20834	369	32	by	by	ADP
ihlr-20834	369	33	state	state	NOUN
ihlr-20834	369	34	-	-	PUNCT
ihlr-20834	369	35	law	law	NOUN
ihlr-20834	369	36	claims	claim	NOUN
ihlr-20834	369	37	)	)	PUNCT
ihlr-20834	369	38	)	)	PUNCT
ihlr-20834	369	39	.	.	PUNCT
ihlr-20834	370	1	788	788	NUM
ihlr-20834	370	2	indiana	indiana	PROPN
ihlr-20834	370	3	health	health	PROPN
ihlr-20834	370	4	law	law	PROPN
ihlr-20834	370	5	review	review	NOUN
ihlr-20834	370	6	vol	vol	NOUN
ihlr-20834	370	7	.	.	PUNCT
ihlr-20834	370	8	12:2	12:2	NUM
ihlr-20834	370	9	preemption	preemption	NOUN
ihlr-20834	370	10	.	.	PUNCT
ihlr-20834	371	1	this	this	DET
ihlr-20834	371	2	presumption	presumption	NOUN
ihlr-20834	371	3	would	would	AUX
ihlr-20834	371	4	be	be	AUX
ihlr-20834	371	5	discarded	discard	VERB
ihlr-20834	371	6	less	less	ADJ
ihlr-20834	371	7	than	than	ADP
ihlr-20834	371	8	two	two	NUM
ihlr-20834	371	9	years	year	NOUN
ihlr-20834	371	10	later	later	ADV
ihlr-20834	371	11	in	in	ADP
ihlr-20834	371	12	a	a	DET
ihlr-20834	371	13	subsequent	subsequent	ADJ
ihlr-20834	371	14	supreme	supreme	PROPN
ihlr-20834	371	15	court	court	NOUN
ihlr-20834	371	16	decision	decision	NOUN
ihlr-20834	371	17	.	.	PUNCT
ihlr-20834	372	1	2	2	X
ihlr-20834	372	2	.	.	X
ihlr-20834	372	3	pliva	pliva	NOUN
ihlr-20834	372	4	–	–	PUNCT
ihlr-20834	372	5	state	state	NOUN
ihlr-20834	372	6	tort	tort	NOUN
ihlr-20834	372	7	law	law	NOUN
ihlr-20834	372	8	preemption	preemption	NOUN
ihlr-20834	372	9	for	for	ADP
ihlr-20834	372	10	failure	failure	NOUN
ihlr-20834	372	11	-	-	PUNCT
ihlr-20834	372	12	towarn	towarn	NOUN
ihlr-20834	372	13	claims	claim	NOUN
ihlr-20834	372	14	against	against	ADP
ihlr-20834	372	15	generic	generic	ADJ
ihlr-20834	372	16	manufacturers	manufacturer	NOUN
ihlr-20834	372	17	the	the	DET
ihlr-20834	372	18	court	court	NOUN
ihlr-20834	372	19	in	in	ADP
ihlr-20834	372	20	pliva	pliva	PROPN
ihlr-20834	372	21	v.	v.	ADP
ihlr-20834	372	22	mensing	mense	VERB
ihlr-20834	372	23	went	go	VERB
ihlr-20834	372	24	directly	directly	ADV
ihlr-20834	372	25	against	against	ADP
ihlr-20834	372	26	the	the	DET
ihlr-20834	372	27	reasoning	reasoning	NOUN
ihlr-20834	372	28	and	and	CCONJ
ihlr-20834	372	29	holding	hold	VERB
ihlr-20834	372	30	in	in	ADP
ihlr-20834	372	31	wyeth	wyeth	PROPN
ihlr-20834	372	32	.	.	PUNCT
ihlr-20834	373	1	in	in	ADP
ihlr-20834	373	2	pliva	pliva	PROPN
ihlr-20834	373	3	v.	v.	CCONJ
ihlr-20834	373	4	mensing	mensing	PROPN
ihlr-20834	373	5	,	,	PUNCT
ihlr-20834	373	6	the	the	DET
ihlr-20834	373	7	court	court	NOUN
ihlr-20834	373	8	expanded	expand	VERB
ihlr-20834	373	9	the	the	DET
ihlr-20834	373	10	scope	scope	NOUN
ihlr-20834	373	11	of	of	ADP
ihlr-20834	373	12	the	the	DET
ihlr-20834	373	13	impossibility	impossibility	NOUN
ihlr-20834	373	14	preemption	preemption	NOUN
ihlr-20834	373	15	,	,	PUNCT
ihlr-20834	373	16	which	which	PRON
ihlr-20834	373	17	resulted	result	VERB
ihlr-20834	373	18	in	in	ADP
ihlr-20834	373	19	granting	grant	VERB
ihlr-20834	373	20	immunity	immunity	NOUN
ihlr-20834	373	21	to	to	ADP
ihlr-20834	373	22	generic	generic	ADJ
ihlr-20834	373	23	drug	drug	NOUN
ihlr-20834	373	24	manufacturers	manufacturer	NOUN
ihlr-20834	373	25	in	in	ADP
ihlr-20834	373	26	state	state	NOUN
ihlr-20834	373	27	-	-	PUNCT
ihlr-20834	373	28	law	law	NOUN
ihlr-20834	373	29	failure	failure	NOUN
ihlr-20834	373	30	-	-	PUNCT
ihlr-20834	373	31	to	to	PART
ihlr-20834	373	32	-	-	PUNCT
ihlr-20834	373	33	warn	warn	VERB
ihlr-20834	373	34	claims.114	claims.114	NOUN
ihlr-20834	373	35	two	two	NUM
ihlr-20834	373	36	separate	separate	ADJ
ihlr-20834	373	37	suits	suit	NOUN
ihlr-20834	373	38	were	be	AUX
ihlr-20834	373	39	consolidated	consolidate	VERB
ihlr-20834	373	40	into	into	ADP
ihlr-20834	373	41	one	one	NUM
ihlr-20834	373	42	lawsuit	lawsuit	NOUN
ihlr-20834	373	43	and	and	CCONJ
ihlr-20834	373	44	the	the	DET
ihlr-20834	373	45	drug	drug	NOUN
ihlr-20834	373	46	at	at	ADP
ihlr-20834	373	47	issue	issue	NOUN
ihlr-20834	373	48	was	be	AUX
ihlr-20834	373	49	a	a	DET
ihlr-20834	373	50	generic	generic	ADJ
ihlr-20834	373	51	equivalent	equivalent	NOUN
ihlr-20834	373	52	,	,	PUNCT
ihlr-20834	373	53	not	not	PART
ihlr-20834	373	54	the	the	DET
ihlr-20834	373	55	brand	brand	NOUN
ihlr-20834	373	56	-	-	PUNCT
ihlr-20834	373	57	name	name	NOUN
ihlr-20834	373	58	drug	drug	NOUN
ihlr-20834	373	59	.	.	PUNCT
ihlr-20834	374	1	115	115	NUM
ihlr-20834	375	1	both	both	DET
ihlr-20834	375	2	plaintiffs	plaintiff	NOUN
ihlr-20834	375	3	had	have	AUX
ihlr-20834	375	4	been	be	AUX
ihlr-20834	375	5	prescribed	prescribe	VERB
ihlr-20834	375	6	metoclopramide	metoclopramide	NOUN
ihlr-20834	375	7	a	a	DET
ihlr-20834	375	8	generic	generic	ADJ
ihlr-20834	375	9	version	version	NOUN
ihlr-20834	375	10	of	of	ADP
ihlr-20834	375	11	the	the	DET
ihlr-20834	375	12	drug	drug	NOUN
ihlr-20834	375	13	reglan	reglan	PROPN
ihlr-20834	375	14	to	to	PART
ihlr-20834	375	15	treat	treat	VERB
ihlr-20834	375	16	their	their	PRON
ihlr-20834	375	17	digestive	digestive	ADJ
ihlr-20834	375	18	tract	tract	NOUN
ihlr-20834	375	19	problems	problem	NOUN
ihlr-20834	375	20	.	.	PUNCT
ihlr-20834	376	1	116	116	NUM
ihlr-20834	376	2	after	after	ADP
ihlr-20834	376	3	taking	take	VERB
ihlr-20834	376	4	the	the	DET
ihlr-20834	376	5	generic	generic	ADJ
ihlr-20834	376	6	drug	drug	NOUN
ihlr-20834	376	7	for	for	ADP
ihlr-20834	376	8	several	several	ADJ
ihlr-20834	376	9	years	year	NOUN
ihlr-20834	376	10	,	,	PUNCT
ihlr-20834	376	11	both	both	DET
ihlr-20834	376	12	plaintiffs	plaintiff	NOUN
ihlr-20834	376	13	developed	develop	VERB
ihlr-20834	376	14	tardive	tardive	ADJ
ihlr-20834	376	15	dyskinesia	dyskinesia	NOUN
ihlr-20834	376	16	,	,	PUNCT
ihlr-20834	376	17	a	a	DET
ihlr-20834	376	18	disorder	disorder	NOUN
ihlr-20834	376	19	of	of	ADP
ihlr-20834	376	20	involuntary	involuntary	ADJ
ihlr-20834	376	21	bodily	bodily	ADJ
ihlr-20834	376	22	movements	movement	NOUN
ihlr-20834	376	23	.	.	PUNCT
ihlr-20834	377	1	117	117	NUM
ihlr-20834	377	2	the	the	DET
ihlr-20834	377	3	plaintiffs	plaintiff	NOUN
ihlr-20834	377	4	argued	argue	VERB
ihlr-20834	377	5	the	the	DET
ihlr-20834	377	6	generic	generic	ADJ
ihlr-20834	377	7	drug	drug	NOUN
ihlr-20834	377	8	manufacturer	manufacturer	NOUN
ihlr-20834	377	9	was	be	AUX
ihlr-20834	377	10	liable	liable	ADJ
ihlr-20834	377	11	for	for	ADP
ihlr-20834	377	12	failing	fail	VERB
ihlr-20834	377	13	to	to	PART
ihlr-20834	377	14	provide	provide	VERB
ihlr-20834	377	15	adequate	adequate	ADJ
ihlr-20834	377	16	warning	warning	NOUN
ihlr-20834	377	17	labels	label	NOUN
ihlr-20834	377	18	,	,	PUNCT
ihlr-20834	377	19	as	as	SCONJ
ihlr-20834	377	20	required	require	VERB
ihlr-20834	377	21	by	by	ADP
ihlr-20834	377	22	state	state	NOUN
ihlr-20834	377	23	law.118	law.118	VERB
ihlr-20834	377	24	the	the	DET
ihlr-20834	377	25	plaintiffs	plaintiff	NOUN
ihlr-20834	377	26	also	also	ADV
ihlr-20834	377	27	argued	argue	VERB
ihlr-20834	377	28	that	that	SCONJ
ihlr-20834	377	29	the	the	DET
ihlr-20834	377	30	cbe	cbe	PROPN
ihlr-20834	377	31	process	process	NOUN
ihlr-20834	377	32	explicitly	explicitly	ADV
ihlr-20834	377	33	permitted	permit	VERB
ihlr-20834	377	34	manufacturers	manufacturer	NOUN
ihlr-20834	377	35	to	to	PART
ihlr-20834	377	36	change	change	VERB
ihlr-20834	377	37	their	their	PRON
ihlr-20834	377	38	labels	label	NOUN
ihlr-20834	377	39	when	when	SCONJ
ihlr-20834	377	40	additional	additional	ADJ
ihlr-20834	377	41	information	information	NOUN
ihlr-20834	377	42	is	be	AUX
ihlr-20834	377	43	available.119	available.119	ADV
ihlr-20834	377	44	the	the	DET
ihlr-20834	377	45	cbe	cbe	PROPN
ihlr-20834	377	46	process	process	NOUN
ihlr-20834	377	47	permits	permit	VERB
ihlr-20834	377	48	drug	drug	NOUN
ihlr-20834	377	49	manufacturers	manufacturer	NOUN
ihlr-20834	377	50	to	to	PART
ihlr-20834	377	51	“	"	PUNCT
ihlr-20834	377	52	add	add	VERB
ihlr-20834	377	53	or	or	CCONJ
ihlr-20834	377	54	strengthen	strengthen	VERB
ihlr-20834	377	55	”	"	PUNCT
ihlr-20834	377	56	its	its	PRON
ihlr-20834	377	57	labels.120	labels.120	NOUN
ihlr-20834	377	58	the	the	DET
ihlr-20834	377	59	fda	fda	PROPN
ihlr-20834	377	60	told	tell	VERB
ihlr-20834	377	61	the	the	DET
ihlr-20834	377	62	court	court	NOUN
ihlr-20834	377	63	that	that	PRON
ihlr-20834	377	64	label	label	VERB
ihlr-20834	377	65	strengthening	strengthen	VERB
ihlr-20834	377	66	by	by	ADP
ihlr-20834	377	67	a	a	DET
ihlr-20834	377	68	generic	generic	ADJ
ihlr-20834	377	69	drug	drug	NOUN
ihlr-20834	377	70	manufacturer	manufacturer	NOUN
ihlr-20834	377	71	is	be	AUX
ihlr-20834	377	72	permissible	permissible	ADJ
ihlr-20834	377	73	only	only	ADV
ihlr-20834	377	74	if	if	SCONJ
ihlr-20834	377	75	the	the	DET
ihlr-20834	377	76	generic	generic	ADJ
ihlr-20834	377	77	drug	drug	NOUN
ihlr-20834	377	78	manufacturer	manufacturer	NOUN
ihlr-20834	377	79	sought	seek	VERB
ihlr-20834	377	80	to	to	PART
ihlr-20834	377	81	change	change	VERB
ihlr-20834	377	82	the	the	DET
ihlr-20834	377	83	label	label	NOUN
ihlr-20834	377	84	to	to	PART
ihlr-20834	377	85	match	match	VERB
ihlr-20834	377	86	that	that	PRON
ihlr-20834	377	87	of	of	ADP
ihlr-20834	377	88	an	an	DET
ihlr-20834	377	89	updated	update	VERB
ihlr-20834	377	90	brand	brand	NOUN
ihlr-20834	377	91	-	-	PUNCT
ihlr-20834	377	92	name	name	NOUN
ihlr-20834	377	93	drug	drug	NOUN
ihlr-20834	377	94	.	.	PUNCT
ihlr-20834	378	1	121	121	NUM
ihlr-20834	378	2	the	the	DET
ihlr-20834	378	3	fda	fda	PROPN
ihlr-20834	378	4	continued	continue	VERB
ihlr-20834	378	5	by	by	ADP
ihlr-20834	378	6	arguing	argue	VERB
ihlr-20834	378	7	its	its	PRON
ihlr-20834	378	8	interpretation	interpretation	NOUN
ihlr-20834	378	9	was	be	AUX
ihlr-20834	378	10	not	not	PART
ihlr-20834	378	11	determined	determined	ADJ
ihlr-20834	378	12	to	to	PART
ihlr-20834	378	13	be	be	AUX
ihlr-20834	378	14	“	"	PUNCT
ihlr-20834	378	15	plainly	plainly	ADV
ihlr-20834	378	16	erroneous	erroneous	ADJ
ihlr-20834	378	17	or	or	CCONJ
ihlr-20834	378	18	inconsistent	inconsistent	ADJ
ihlr-20834	378	19	with	with	ADP
ihlr-20834	378	20	the	the	DET
ihlr-20834	378	21	regulation	regulation	NOUN
ihlr-20834	378	22	.	.	PUNCT
ihlr-20834	378	23	”122	”122	PUNCT
ihlr-20834	379	1	furthermore	furthermore	ADV
ihlr-20834	379	2	,	,	PUNCT
ihlr-20834	379	3	the	the	DET
ihlr-20834	379	4	fda	fda	PROPN
ihlr-20834	379	5	opined	opine	VERB
ihlr-20834	379	6	for	for	ADP
ihlr-20834	379	7	114	114	NUM
ihlr-20834	379	8	pliva	pliva	NOUN
ihlr-20834	379	9	,	,	PUNCT
ihlr-20834	379	10	inc	inc	PROPN
ihlr-20834	379	11	.	.	PROPN
ihlr-20834	379	12	v.	v.	CCONJ
ihlr-20834	380	1	mensing	mense	VERB
ihlr-20834	380	2	,	,	PUNCT
ihlr-20834	380	3	131	131	NUM
ihlr-20834	380	4	s.ct	s.ct	NOUN
ihlr-20834	380	5	.	.	PROPN
ihlr-20834	380	6	2572	2572	NUM
ihlr-20834	380	7	(	(	PUNCT
ihlr-20834	380	8	2011	2011	NUM
ihlr-20834	380	9	)	)	PUNCT
ihlr-20834	380	10	.	.	PUNCT
ihlr-20834	381	1	115	115	NUM
ihlr-20834	382	1	i	i	PRON
ihlr-20834	382	2	d.	d.	PROPN
ihlr-20834	382	3	116	116	NUM
ihlr-20834	383	1	i	i	PRON
ihlr-20834	383	2	d.	d.	PROPN
ihlr-20834	383	3	at	at	ADP
ihlr-20834	383	4	2572	2572	NUM
ihlr-20834	383	5	-	-	SYM
ihlr-20834	383	6	73	73	NUM
ihlr-20834	383	7	.	.	PUNCT
ihlr-20834	384	1	117	117	NUM
ihlr-20834	384	2	i	i	PROPN
ihlr-20834	384	3	d.	d.	PROPN
ihlr-20834	384	4	at	at	ADP
ihlr-20834	384	5	2573	2573	NUM
ihlr-20834	384	6	.	.	PUNCT
ihlr-20834	385	1	118	118	NUM
ihlr-20834	385	2	i	i	NOUN
ihlr-20834	385	3	d.	d.	PROPN
ihlr-20834	385	4	119	119	NUM
ihlr-20834	386	1	i	i	PRON
ihlr-20834	386	2	d.	d.	PROPN
ihlr-20834	386	3	at	at	ADP
ihlr-20834	386	4	2575	2575	NUM
ihlr-20834	386	5	.	.	PUNCT
ihlr-20834	387	1	120	120	NUM
ihlr-20834	387	2	21	21	NUM
ihlr-20834	387	3	c.f.r	c.f.r	NOUN
ihlr-20834	387	4	.	.	PUNCT
ihlr-20834	388	1	§	§	PROPN
ihlr-20834	388	2	314.70(c)(6)(iii)(a	314.70(c)(6)(iii)(a	NUM
ihlr-20834	388	3	)	)	PUNCT
ihlr-20834	388	4	(	(	PUNCT
ihlr-20834	388	5	2015	2015	NUM
ihlr-20834	388	6	)	)	PUNCT
ihlr-20834	388	7	.	.	PUNCT
ihlr-20834	389	1	121	121	NUM
ihlr-20834	389	2	pliva	pliva	NOUN
ihlr-20834	389	3	,	,	PUNCT
ihlr-20834	389	4	inc	inc	PROPN
ihlr-20834	389	5	.	.	PROPN
ihlr-20834	389	6	,	,	PUNCT
ihlr-20834	389	7	131	131	NUM
ihlr-20834	389	8	s.ct	s.ct	NOUN
ihlr-20834	389	9	.	.	PUNCT
ihlr-20834	390	1	at	at	ADP
ihlr-20834	390	2	2575	2575	NUM
ihlr-20834	390	3	.	.	PUNCT
ihlr-20834	391	1	122	122	NUM
ihlr-20834	392	1	i	i	PRON
ihlr-20834	392	2	d.	d.	PROPN
ihlr-20834	392	3	2015	2015	NUM
ihlr-20834	392	4	789	789	NUM
ihlr-20834	392	5	the	the	DET
ihlr-20834	392	6	supreme	supreme	PROPN
ihlr-20834	392	7	court	court	PROPN
ihlr-20834	392	8	’s	’s	PART
ihlr-20834	392	9	overreaching	overreach	VERB
ihlr-20834	392	10	preemption	preemption	NOUN
ihlr-20834	392	11	interpretation	interpretation	NOUN
ihlr-20834	392	12	and	and	CCONJ
ihlr-20834	392	13	it	it	PRON
ihlr-20834	392	14	’s	’	VERB
ihlr-20834	392	15	consequences	consequence	VERB
ihlr-20834	392	16	the	the	DET
ihlr-20834	392	17	court	court	NOUN
ihlr-20834	392	18	to	to	PART
ihlr-20834	392	19	hold	hold	VERB
ihlr-20834	392	20	the	the	DET
ihlr-20834	392	21	manufacturer	manufacturer	NOUN
ihlr-20834	392	22	to	to	ADP
ihlr-20834	392	23	the	the	DET
ihlr-20834	392	24	“	"	PUNCT
ihlr-20834	392	25	duty	duty	NOUN
ihlr-20834	392	26	of	of	ADP
ihlr-20834	392	27	sameness	sameness	NOUN
ihlr-20834	392	28	”	"	PUNCT
ihlr-20834	392	29	standard	standard	NOUN
ihlr-20834	392	30	and	and	CCONJ
ihlr-20834	392	31	to	to	PART
ihlr-20834	392	32	not	not	PART
ihlr-20834	392	33	permit	permit	VERB
ihlr-20834	392	34	the	the	DET
ihlr-20834	392	35	unilateral	unilateral	ADJ
ihlr-20834	392	36	label	label	NOUN
ihlr-20834	392	37	change	change	NOUN
ihlr-20834	392	38	under	under	ADP
ihlr-20834	392	39	the	the	DET
ihlr-20834	392	40	cbe	cbe	PROPN
ihlr-20834	392	41	process.123	process.123	VERB
ihlr-20834	392	42	the	the	DET
ihlr-20834	392	43	generic	generic	ADJ
ihlr-20834	392	44	drug	drug	NOUN
ihlr-20834	392	45	manufacturer	manufacturer	NOUN
ihlr-20834	392	46	argued	argue	VERB
ihlr-20834	392	47	that	that	SCONJ
ihlr-20834	392	48	fda	fda	PROPN
ihlr-20834	392	49	regulations	regulation	NOUN
ihlr-20834	392	50	and	and	CCONJ
ihlr-20834	392	51	federal	federal	ADJ
ihlr-20834	392	52	statute	statute	NOUN
ihlr-20834	392	53	preempted	preempt	VERB
ihlr-20834	392	54	state	state	NOUN
ihlr-20834	392	55	law	law	NOUN
ihlr-20834	392	56	tort	tort	NOUN
ihlr-20834	392	57	claims	claim	VERB
ihlr-20834	392	58	because	because	SCONJ
ihlr-20834	392	59	the	the	DET
ihlr-20834	392	60	federal	federal	ADJ
ihlr-20834	392	61	“	"	PUNCT
ihlr-20834	392	62	duty	duty	NOUN
ihlr-20834	392	63	of	of	ADP
ihlr-20834	392	64	sameness	sameness	NOUN
ihlr-20834	392	65	”	"	PUNCT
ihlr-20834	392	66	required	require	VERB
ihlr-20834	392	67	the	the	DET
ihlr-20834	392	68	same	same	ADJ
ihlr-20834	392	69	labeling	labeling	NOUN
ihlr-20834	392	70	for	for	ADP
ihlr-20834	392	71	their	their	PRON
ihlr-20834	392	72	generic	generic	ADJ
ihlr-20834	392	73	drug	drug	NOUN
ihlr-20834	392	74	metoclopramide124	metoclopramide124	PROPN
ihlr-20834	392	75	as	as	SCONJ
ihlr-20834	392	76	the	the	DET
ihlr-20834	392	77	non	non	ADJ
ihlr-20834	392	78	-	-	ADJ
ihlr-20834	392	79	generic	generic	ADJ
ihlr-20834	392	80	drug	drug	NOUN
ihlr-20834	392	81	reglan	reglan	PROPN
ihlr-20834	392	82	had.125	had.125	NOUN
ihlr-20834	392	83	the	the	DET
ihlr-20834	392	84	court	court	NOUN
ihlr-20834	392	85	agreed	agree	VERB
ihlr-20834	392	86	and	and	CCONJ
ihlr-20834	392	87	found	find	VERB
ihlr-20834	392	88	that	that	SCONJ
ihlr-20834	392	89	impossibility	impossibility	NOUN
ihlr-20834	392	90	preemption	preemption	NOUN
ihlr-20834	392	91	was	be	AUX
ihlr-20834	392	92	present	present	ADJ
ihlr-20834	392	93	because	because	SCONJ
ihlr-20834	392	94	the	the	DET
ihlr-20834	392	95	state	state	NOUN
ihlr-20834	392	96	law	law	NOUN
ihlr-20834	392	97	required	require	VERB
ihlr-20834	392	98	the	the	DET
ihlr-20834	392	99	generic	generic	ADJ
ihlr-20834	392	100	manufacturer	manufacturer	NOUN
ihlr-20834	392	101	to	to	PART
ihlr-20834	392	102	change	change	VERB
ihlr-20834	392	103	the	the	DET
ihlr-20834	392	104	drug	drug	NOUN
ihlr-20834	392	105	label	label	NOUN
ihlr-20834	392	106	in	in	ADP
ihlr-20834	392	107	a	a	DET
ihlr-20834	392	108	way	way	NOUN
ihlr-20834	392	109	to	to	PART
ihlr-20834	392	110	make	make	VERB
ihlr-20834	392	111	it	it	PRON
ihlr-20834	392	112	reasonably	reasonably	ADV
ihlr-20834	392	113	safe	safe	ADJ
ihlr-20834	392	114	while	while	SCONJ
ihlr-20834	392	115	the	the	DET
ihlr-20834	392	116	fda	fda	PROPN
ihlr-20834	392	117	regulation	regulation	NOUN
ihlr-20834	392	118	explicitly	explicitly	ADV
ihlr-20834	392	119	prevented	prevent	VERB
ihlr-20834	392	120	generic	generic	ADJ
ihlr-20834	392	121	drug	drug	NOUN
ihlr-20834	392	122	manufacturers	manufacturer	NOUN
ihlr-20834	392	123	from	from	ADP
ihlr-20834	392	124	independently	independently	ADV
ihlr-20834	392	125	changing	change	VERB
ihlr-20834	392	126	their	their	PRON
ihlr-20834	392	127	generic	generic	ADJ
ihlr-20834	392	128	drug	drug	NOUN
ihlr-20834	392	129	safety	safety	NOUN
ihlr-20834	392	130	labels.126	labels.126	NOUN
ihlr-20834	392	131	therefore	therefore	ADV
ihlr-20834	392	132	,	,	PUNCT
ihlr-20834	392	133	as	as	SCONJ
ihlr-20834	392	134	pointed	point	VERB
ihlr-20834	392	135	out	out	ADP
ihlr-20834	392	136	in	in	ADP
ihlr-20834	392	137	justice	justice	PROPN
ihlr-20834	392	138	sotomayor	sotomayor	PROPN
ihlr-20834	392	139	’s	’s	PART
ihlr-20834	392	140	dissent	dissent	NOUN
ihlr-20834	392	141	,	,	PUNCT
ihlr-20834	392	142	the	the	DET
ihlr-20834	392	143	majority	majority	NOUN
ihlr-20834	392	144	assumed	assume	VERB
ihlr-20834	392	145	that	that	SCONJ
ihlr-20834	392	146	generic	generic	ADJ
ihlr-20834	392	147	drug	drug	NOUN
ihlr-20834	392	148	manufacturers	manufacturer	NOUN
ihlr-20834	392	149	“	"	PUNCT
ihlr-20834	392	150	read	read	VERB
ihlr-20834	392	151	the	the	DET
ihlr-20834	392	152	fda	fda	PROPN
ihlr-20834	392	153	regulation	regulation	NOUN
ihlr-20834	392	154	to	to	PART
ihlr-20834	392	155	require	require	VERB
ihlr-20834	392	156	them	they	PRON
ihlr-20834	392	157	only	only	ADV
ihlr-20834	392	158	to	to	PART
ihlr-20834	392	159	ensure	ensure	VERB
ihlr-20834	392	160	that	that	SCONJ
ihlr-20834	392	161	their	their	PRON
ihlr-20834	392	162	labels	label	NOUN
ihlr-20834	392	163	match	match	VERB
ihlr-20834	392	164	the	the	DET
ihlr-20834	392	165	brand	brand	NOUN
ihlr-20834	392	166	-	-	PUNCT
ihlr-20834	392	167	name	name	NOUN
ihlr-20834	392	168	labels	label	NOUN
ihlr-20834	392	169	.	.	PUNCT
ihlr-20834	392	170	”127	”127	PUNCT
ihlr-20834	392	171	under	under	ADP
ihlr-20834	392	172	current	current	ADJ
ihlr-20834	392	173	law	law	NOUN
ihlr-20834	392	174	,	,	PUNCT
ihlr-20834	392	175	a	a	DET
ihlr-20834	392	176	drug	drug	NOUN
ihlr-20834	392	177	’s	’s	PART
ihlr-20834	392	178	“	"	PUNCT
ihlr-20834	392	179	labeling	labeling	NOUN
ihlr-20834	392	180	must	must	AUX
ihlr-20834	392	181	be	be	AUX
ihlr-20834	392	182	revised	revise	VERB
ihlr-20834	392	183	to	to	PART
ihlr-20834	392	184	include	include	VERB
ihlr-20834	392	185	a	a	DET
ihlr-20834	392	186	warning	warning	NOUN
ihlr-20834	392	187	about	about	ADP
ihlr-20834	392	188	a	a	DET
ihlr-20834	392	189	clinically	clinically	ADV
ihlr-20834	392	190	significant	significant	ADJ
ihlr-20834	392	191	hazard	hazard	NOUN
ihlr-20834	392	192	as	as	ADV
ihlr-20834	392	193	soon	soon	ADV
ihlr-20834	392	194	as	as	SCONJ
ihlr-20834	392	195	there	there	PRON
ihlr-20834	392	196	is	be	VERB
ihlr-20834	392	197	reasonable	reasonable	ADJ
ihlr-20834	392	198	evidence	evidence	NOUN
ihlr-20834	392	199	of	of	ADP
ihlr-20834	392	200	a	a	DET
ihlr-20834	392	201	causal	causal	ADJ
ihlr-20834	392	202	association	association	NOUN
ihlr-20834	392	203	with	with	ADP
ihlr-20834	392	204	a	a	DET
ihlr-20834	392	205	drug	drug	NOUN
ihlr-20834	392	206	;	;	PUNCT
ihlr-20834	392	207	a	a	DET
ihlr-20834	392	208	causal	causal	ADJ
ihlr-20834	392	209	relationship	relationship	NOUN
ihlr-20834	392	210	need	need	AUX
ihlr-20834	392	211	not	not	PART
ihlr-20834	392	212	have	have	AUX
ihlr-20834	392	213	been	be	AUX
ihlr-20834	392	214	definitely	definitely	ADV
ihlr-20834	392	215	established	establish	VERB
ihlr-20834	392	216	.	.	PUNCT
ihlr-20834	392	217	”	"	PUNCT
ihlr-20834	393	1	128	128	NUM
ihlr-20834	393	2	however	however	ADV
ihlr-20834	393	3	,	,	PUNCT
ihlr-20834	393	4	the	the	DET
ihlr-20834	393	5	court	court	NOUN
ihlr-20834	393	6	did	do	AUX
ihlr-20834	393	7	not	not	PART
ihlr-20834	393	8	address	address	VERB
ihlr-20834	393	9	the	the	DET
ihlr-20834	393	10	issue	issue	NOUN
ihlr-20834	393	11	of	of	ADP
ihlr-20834	393	12	whether	whether	SCONJ
ihlr-20834	393	13	the	the	DET
ihlr-20834	393	14	generic	generic	ADJ
ihlr-20834	393	15	drug	drug	NOUN
ihlr-20834	393	16	manufacturer	manufacturer	NOUN
ihlr-20834	393	17	had	have	AUX
ihlr-20834	393	18	a	a	DET
ihlr-20834	393	19	duty	duty	NOUN
ihlr-20834	393	20	to	to	PART
ihlr-20834	393	21	request	request	VERB
ihlr-20834	393	22	a	a	DET
ihlr-20834	393	23	strengthened	strengthen	VERB
ihlr-20834	393	24	label	label	NOUN
ihlr-20834	393	25	from	from	ADP
ihlr-20834	393	26	the	the	DET
ihlr-20834	393	27	fda	fda	PROPN
ihlr-20834	393	28	;	;	PUNCT
ihlr-20834	393	29	“	"	PUNCT
ihlr-20834	393	30	[	[	X
ihlr-20834	393	31	b]ecause	b]ecause	ADP
ihlr-20834	393	32	[	[	X
ihlr-20834	393	33	the	the	DET
ihlr-20834	393	34	court	court	NOUN
ihlr-20834	393	35	]	]	PUNCT
ihlr-20834	393	36	ultimately	ultimately	ADV
ihlr-20834	393	37	[	[	X
ihlr-20834	393	38	found	find	VERB
ihlr-20834	393	39	]	]	X
ihlr-20834	393	40	preemption	preemption	NOUN
ihlr-20834	393	41	even	even	ADV
ihlr-20834	393	42	assuming	assume	VERB
ihlr-20834	393	43	such	such	DET
ihlr-20834	393	44	a	a	DET
ihlr-20834	393	45	duty	duty	NOUN
ihlr-20834	393	46	[	[	AUX
ihlr-20834	393	47	to	to	PART
ihlr-20834	393	48	request	request	VERB
ihlr-20834	393	49	a	a	DET
ihlr-20834	393	50	strengthened	strengthen	VERB
ihlr-20834	393	51	label	label	NOUN
ihlr-20834	393	52	]	]	PUNCT
ihlr-20834	393	53	existed	exist	VERB
ihlr-20834	393	54	,	,	PUNCT
ihlr-20834	393	55	[	[	X
ihlr-20834	393	56	the	the	DET
ihlr-20834	393	57	court	court	NOUN
ihlr-20834	393	58	did	do	AUX
ihlr-20834	393	59	]	]	PUNCT
ihlr-20834	393	60	not	not	PART
ihlr-20834	393	61	resolve	resolve	VERB
ihlr-20834	393	62	the	the	DET
ihlr-20834	393	63	matter	matter	NOUN
ihlr-20834	393	64	”	"	PUNCT
ihlr-20834	393	65	of	of	ADP
ihlr-20834	393	66	whether	whether	SCONJ
ihlr-20834	393	67	there	there	PRON
ihlr-20834	393	68	was	be	VERB
ihlr-20834	393	69	a	a	DET
ihlr-20834	393	70	duty	duty	NOUN
ihlr-20834	393	71	on	on	ADP
ihlr-20834	393	72	the	the	DET
ihlr-20834	393	73	generic	generic	ADJ
ihlr-20834	393	74	drug	drug	NOUN
ihlr-20834	393	75	manufacturer	manufacturer	NOUN
ihlr-20834	393	76	to	to	PART
ihlr-20834	393	77	request	request	VERB
ihlr-20834	393	78	a	a	DET
ihlr-20834	393	79	strengthened	strengthen	VERB
ihlr-20834	393	80	label.129	label.129	ADJ
ihlr-20834	393	81	thus	thus	ADV
ihlr-20834	393	82	,	,	PUNCT
ihlr-20834	393	83	under	under	ADP
ihlr-20834	393	84	the	the	DET
ihlr-20834	393	85	majorities	majority	NOUN
ihlr-20834	393	86	’	'	PUNCT
ihlr-20834	393	87	flawed	flaw	VERB
ihlr-20834	393	88	reasoning	reasoning	NOUN
ihlr-20834	393	89	,	,	PUNCT
ihlr-20834	393	90	“	"	PUNCT
ihlr-20834	393	91	[	[	X
ihlr-20834	393	92	h]ad	h]ad	NOUN
ihlr-20834	394	1	[	[	X
ihlr-20834	394	2	petitioners	petitioner	NOUN
ihlr-20834	394	3	]	]	PUNCT
ihlr-20834	394	4	taken	take	VERB
ihlr-20834	394	5	reglan	reglan	PROPN
ihlr-20834	394	6	,	,	PUNCT
ihlr-20834	394	7	the	the	DET
ihlr-20834	394	8	brand	brand	NOUN
ihlr-20834	394	9	-	-	PUNCT
ihlr-20834	394	10	name	name	NOUN
ihlr-20834	394	11	drug	drug	NOUN
ihlr-20834	394	12	prescribed	prescribe	VERB
ihlr-20834	394	13	by	by	ADP
ihlr-20834	394	14	their	their	PRON
ihlr-20834	394	15	doctors	doctor	NOUN
ihlr-20834	394	16	,	,	PUNCT
ihlr-20834	394	17	wyeth	wyeth	PROPN
ihlr-20834	394	18	would	would	AUX
ihlr-20834	394	19	control	control	VERB
ihlr-20834	394	20	and	and	CCONJ
ihlr-20834	394	21	their	their	PRON
ihlr-20834	394	22	lawsuits	lawsuit	NOUN
ihlr-20834	394	23	would	would	AUX
ihlr-20834	394	24	not	not	PART
ihlr-20834	394	25	be	be	AUX
ihlr-20834	394	26	pre	pre	VERB
ihlr-20834	394	27	-	-	VERB
ihlr-20834	394	28	empted	empte	VERB
ihlr-20834	394	29	.	.	PUNCT
ihlr-20834	395	1	but	but	CCONJ
ihlr-20834	395	2	123	123	NUM
ihlr-20834	396	1	i	i	PRON
ihlr-20834	396	2	d.	d.	PROPN
ihlr-20834	396	3	124	124	NUM
ihlr-20834	397	1	i	i	PRON
ihlr-20834	397	2	d.	d.	PROPN
ihlr-20834	397	3	at	at	ADP
ihlr-20834	397	4	2573	2573	NUM
ihlr-20834	397	5	.	.	PUNCT
ihlr-20834	398	1	125	125	NUM
ihlr-20834	398	2	i	i	PRON
ihlr-20834	398	3	d.	d.	PROPN
ihlr-20834	398	4	at	at	ADP
ihlr-20834	398	5	2572	2572	NUM
ihlr-20834	398	6	.	.	PUNCT
ihlr-20834	399	1	126	126	NUM
ihlr-20834	399	2	i	i	PRON
ihlr-20834	399	3	d.	d.	NOUN
ihlr-20834	399	4	at	at	ADP
ihlr-20834	399	5	2577	2577	NUM
ihlr-20834	399	6	-	-	SYM
ihlr-20834	399	7	78	78	NUM
ihlr-20834	399	8	.	.	PUNCT
ihlr-20834	400	1	127	127	NUM
ihlr-20834	400	2	i	i	PRON
ihlr-20834	400	3	d.	d.	PROPN
ihlr-20834	400	4	at	at	ADP
ihlr-20834	400	5	2586	2586	NUM
ihlr-20834	400	6	(	(	PUNCT
ihlr-20834	400	7	sotomayor	sotomayor	PROPN
ihlr-20834	400	8	,	,	PUNCT
ihlr-20834	400	9	j.	j.	PROPN
ihlr-20834	400	10	,	,	PUNCT
ihlr-20834	400	11	dissenting	dissent	VERB
ihlr-20834	400	12	)	)	PUNCT
ihlr-20834	400	13	.	.	PUNCT
ihlr-20834	401	1	128	128	NUM
ihlr-20834	401	2	21	21	NUM
ihlr-20834	401	3	c.f.r	c.f.r	NOUN
ihlr-20834	401	4	.	.	PUNCT
ihlr-20834	402	1	§	§	PROPN
ihlr-20834	402	2	201.57(c)(6)(i	201.57(c)(6)(i	NUM
ihlr-20834	402	3	)	)	PUNCT
ihlr-20834	402	4	(	(	PUNCT
ihlr-20834	402	5	2015	2015	NUM
ihlr-20834	402	6	)	)	PUNCT
ihlr-20834	402	7	.	.	PUNCT
ihlr-20834	403	1	129	129	NUM
ihlr-20834	403	2	pliva	pliva	PROPN
ihlr-20834	403	3	,	,	PUNCT
ihlr-20834	403	4	inc	inc	PROPN
ihlr-20834	403	5	.	.	PROPN
ihlr-20834	403	6	,	,	PUNCT
ihlr-20834	403	7	131	131	NUM
ihlr-20834	403	8	s.ct	s.ct	NOUN
ihlr-20834	403	9	.	.	PUNCT
ihlr-20834	404	1	at	at	ADP
ihlr-20834	404	2	2576	2576	NUM
ihlr-20834	404	3	,	,	PUNCT
ihlr-20834	404	4	2577	2577	NUM
ihlr-20834	404	5	.	.	PUNCT
ihlr-20834	405	1	790	790	NUM
ihlr-20834	405	2	indiana	indiana	PROPN
ihlr-20834	405	3	health	health	PROPN
ihlr-20834	405	4	law	law	PROPN
ihlr-20834	405	5	review	review	NOUN
ihlr-20834	405	6	vol	vol	NOUN
ihlr-20834	405	7	.	.	PUNCT
ihlr-20834	405	8	12:2	12:2	NUM
ihlr-20834	405	9	because	because	SCONJ
ihlr-20834	405	10	[	[	X
ihlr-20834	405	11	they	they	PRON
ihlr-20834	405	12	were	be	AUX
ihlr-20834	405	13	prescribed	prescribe	VERB
ihlr-20834	405	14	with	with	ADP
ihlr-20834	405	15	]	]	PUNCT
ihlr-20834	405	16	metoclopramide	metoclopramide	NOUN
ihlr-20834	405	17	instead	instead	ADV
ihlr-20834	405	18	,	,	PUNCT
ihlr-20834	405	19	federal	federal	ADJ
ihlr-20834	405	20	law	law	NOUN
ihlr-20834	405	21	preempts	preempt	VERB
ihlr-20834	405	22	these	these	DET
ihlr-20834	405	23	lawsuits	lawsuit	NOUN
ihlr-20834	405	24	.	.	PUNCT
ihlr-20834	406	1	”130	”130	PROPN
ihlr-20834	406	2	generic	generic	ADJ
ihlr-20834	406	3	drug	drug	NOUN
ihlr-20834	406	4	manufacturers	manufacturer	NOUN
ihlr-20834	406	5	should	should	AUX
ihlr-20834	406	6	not	not	PART
ihlr-20834	406	7	be	be	AUX
ihlr-20834	406	8	permitted	permit	VERB
ihlr-20834	406	9	to	to	PART
ihlr-20834	406	10	“	"	PUNCT
ihlr-20834	406	11	sustain	sustain	VERB
ihlr-20834	406	12	their	their	PRON
ihlr-20834	406	13	burden	burden	NOUN
ihlr-20834	406	14	of	of	ADP
ihlr-20834	406	15	showing	show	VERB
ihlr-20834	406	16	impossibility	impossibility	NOUN
ihlr-20834	406	17	if	if	SCONJ
ihlr-20834	406	18	they	they	PRON
ihlr-20834	406	19	have	have	AUX
ihlr-20834	406	20	not	not	PART
ihlr-20834	406	21	even	even	ADV
ihlr-20834	406	22	attempted	attempt	VERB
ihlr-20834	406	23	to	to	PART
ihlr-20834	406	24	employ	employ	VERB
ihlr-20834	406	25	that	that	DET
ihlr-20834	406	26	mechanism	mechanism	NOUN
ihlr-20834	406	27	.	.	PUNCT
ihlr-20834	406	28	”	"	PUNCT
ihlr-20834	407	1	131	131	NUM
ihlr-20834	407	2	a	a	DET
ihlr-20834	407	3	generic	generic	ADJ
ihlr-20834	407	4	drug	drug	NOUN
ihlr-20834	407	5	manufacturer	manufacturer	NOUN
ihlr-20834	407	6	should	should	AUX
ihlr-20834	407	7	have	have	VERB
ihlr-20834	407	8	the	the	DET
ihlr-20834	407	9	burden	burden	NOUN
ihlr-20834	407	10	to	to	PART
ihlr-20834	407	11	propose	propose	VERB
ihlr-20834	407	12	label	label	NOUN
ihlr-20834	407	13	changes	change	NOUN
ihlr-20834	407	14	to	to	ADP
ihlr-20834	407	15	the	the	DET
ihlr-20834	407	16	fda	fda	PROPN
ihlr-20834	407	17	,	,	PUNCT
ihlr-20834	407	18	and	and	CCONJ
ihlr-20834	407	19	in	in	ADP
ihlr-20834	407	20	the	the	DET
ihlr-20834	407	21	event	event	NOUN
ihlr-20834	407	22	such	such	ADJ
ihlr-20834	407	23	proposal	proposal	NOUN
ihlr-20834	407	24	is	be	AUX
ihlr-20834	407	25	denied	deny	VERB
ihlr-20834	407	26	,	,	PUNCT
ihlr-20834	407	27	then	then	ADV
ihlr-20834	407	28	it	it	PRON
ihlr-20834	407	29	would	would	AUX
ihlr-20834	407	30	be	be	AUX
ihlr-20834	407	31	possible	possible	ADJ
ihlr-20834	407	32	for	for	SCONJ
ihlr-20834	407	33	impossibility	impossibility	NOUN
ihlr-20834	407	34	preemption	preemption	NOUN
ihlr-20834	407	35	to	to	PART
ihlr-20834	407	36	exist.132	exist.132	VERB
ihlr-20834	407	37	as	as	ADP
ihlr-20834	407	38	such	such	ADJ
ihlr-20834	407	39	,	,	PUNCT
ihlr-20834	407	40	generic	generic	ADJ
ihlr-20834	407	41	drug	drug	NOUN
ihlr-20834	407	42	manufacturers	manufacturer	NOUN
ihlr-20834	407	43	should	should	AUX
ihlr-20834	407	44	not	not	PART
ihlr-20834	407	45	be	be	AUX
ihlr-20834	407	46	granted	grant	VERB
ihlr-20834	407	47	preemption	preemption	NOUN
ihlr-20834	407	48	protection	protection	NOUN
ihlr-20834	407	49	without	without	ADP
ihlr-20834	407	50	even	even	ADV
ihlr-20834	407	51	attempting	attempt	VERB
ihlr-20834	407	52	to	to	PART
ihlr-20834	407	53	propose	propose	VERB
ihlr-20834	407	54	change	change	NOUN
ihlr-20834	407	55	.	.	PUNCT
ihlr-20834	408	1	as	as	ADP
ihlr-20834	408	2	a	a	DET
ihlr-20834	408	3	result	result	NOUN
ihlr-20834	408	4	of	of	ADP
ihlr-20834	408	5	the	the	DET
ihlr-20834	408	6	court	court	NOUN
ihlr-20834	408	7	’s	’s	PART
ihlr-20834	408	8	decision	decision	NOUN
ihlr-20834	408	9	in	in	ADP
ihlr-20834	408	10	pliva	pliva	NOUN
ihlr-20834	408	11	,	,	PUNCT
ihlr-20834	408	12	generic	generic	ADJ
ihlr-20834	408	13	drug	drug	NOUN
ihlr-20834	408	14	consumers	consumer	NOUN
ihlr-20834	408	15	have	have	VERB
ihlr-20834	408	16	no	no	DET
ihlr-20834	408	17	legal	legal	ADJ
ihlr-20834	408	18	recourse	recourse	NOUN
ihlr-20834	408	19	against	against	ADP
ihlr-20834	408	20	generic	generic	ADJ
ihlr-20834	408	21	drug	drug	NOUN
ihlr-20834	408	22	manufacturers	manufacturer	NOUN
ihlr-20834	408	23	who	who	PRON
ihlr-20834	408	24	fail	fail	VERB
ihlr-20834	408	25	to	to	PART
ihlr-20834	408	26	update	update	VERB
ihlr-20834	408	27	their	their	PRON
ihlr-20834	408	28	labels	label	NOUN
ihlr-20834	408	29	.	.	PUNCT
ihlr-20834	409	1	consequently	consequently	ADV
ihlr-20834	409	2	,	,	PUNCT
ihlr-20834	409	3	generic	generic	ADJ
ihlr-20834	409	4	drug	drug	NOUN
ihlr-20834	409	5	manufacturers	manufacturer	NOUN
ihlr-20834	409	6	no	no	ADV
ihlr-20834	409	7	longer	long	ADV
ihlr-20834	409	8	will	will	AUX
ihlr-20834	409	9	“	"	PUNCT
ihlr-20834	409	10	monitor	monitor	VERB
ihlr-20834	409	11	and	and	CCONJ
ihlr-20834	409	12	disclose	disclose	VERB
ihlr-20834	409	13	safety	safety	NOUN
ihlr-20834	409	14	risks	risk	NOUN
ihlr-20834	409	15	”	"	PUNCT
ihlr-20834	409	16	they	they	PRON
ihlr-20834	409	17	find	find	VERB
ihlr-20834	409	18	as	as	SCONJ
ihlr-20834	409	19	they	they	PRON
ihlr-20834	409	20	will	will	AUX
ihlr-20834	409	21	be	be	AUX
ihlr-20834	409	22	able	able	ADJ
ihlr-20834	409	23	to	to	PART
ihlr-20834	409	24	rely	rely	VERB
ihlr-20834	409	25	solely	solely	ADV
ihlr-20834	409	26	on	on	ADP
ihlr-20834	409	27	brandname	brandname	ADJ
ihlr-20834	409	28	manufacturer	manufacturer	NOUN
ihlr-20834	409	29	label	label	NOUN
ihlr-20834	409	30	changes	change	NOUN
ihlr-20834	409	31	or	or	CCONJ
ihlr-20834	409	32	being	be	AUX
ihlr-20834	409	33	immune	immune	ADJ
ihlr-20834	409	34	through	through	ADP
ihlr-20834	409	35	the	the	DET
ihlr-20834	409	36	preemption	preemption	NOUN
ihlr-20834	409	37	doctrine	doctrine	NOUN
ihlr-20834	409	38	.	.	PUNCT
ihlr-20834	410	1	133	133	NUM
ihlr-20834	410	2	currently	currently	ADV
ihlr-20834	410	3	90	90	NUM
ihlr-20834	410	4	%	%	NOUN
ihlr-20834	410	5	of	of	ADP
ihlr-20834	410	6	consumers	consumer	NOUN
ihlr-20834	410	7	opt	opt	VERB
ihlr-20834	410	8	for	for	ADP
ihlr-20834	410	9	generic	generic	ADJ
ihlr-20834	410	10	drug	drug	NOUN
ihlr-20834	410	11	alternatives	alternative	NOUN
ihlr-20834	410	12	,	,	PUNCT
ihlr-20834	410	13	and	and	CCONJ
ihlr-20834	410	14	under	under	ADP
ihlr-20834	410	15	this	this	DET
ihlr-20834	410	16	dangerous	dangerous	ADJ
ihlr-20834	410	17	precedent	precedent	NOUN
ihlr-20834	410	18	,	,	PUNCT
ihlr-20834	410	19	many	many	ADJ
ihlr-20834	410	20	consumers	consumer	NOUN
ihlr-20834	410	21	may	may	AUX
ihlr-20834	410	22	not	not	PART
ihlr-20834	410	23	have	have	VERB
ihlr-20834	410	24	modes	mode	NOUN
ihlr-20834	410	25	of	of	ADP
ihlr-20834	410	26	relief	relief	NOUN
ihlr-20834	410	27	for	for	ADP
ihlr-20834	410	28	injuries	injury	NOUN
ihlr-20834	410	29	against	against	ADP
ihlr-20834	410	30	generic	generic	ADJ
ihlr-20834	410	31	drug	drug	NOUN
ihlr-20834	411	1	manufacturers.134	manufacturers.134	PROPN
ihlr-20834	412	1	it	it	PRON
ihlr-20834	412	2	was	be	AUX
ihlr-20834	412	3	not	not	PART
ihlr-20834	412	4	impossible	impossible	ADJ
ihlr-20834	412	5	for	for	SCONJ
ihlr-20834	412	6	the	the	DET
ihlr-20834	412	7	generic	generic	ADJ
ihlr-20834	412	8	drug	drug	NOUN
ihlr-20834	412	9	manufacturer	manufacturer	NOUN
ihlr-20834	412	10	to	to	PART
ihlr-20834	412	11	comply	comply	VERB
ihlr-20834	412	12	with	with	ADP
ihlr-20834	412	13	federal	federal	ADJ
ihlr-20834	412	14	and	and	CCONJ
ihlr-20834	412	15	state	state	NOUN
ihlr-20834	412	16	law	law	NOUN
ihlr-20834	412	17	in	in	ADP
ihlr-20834	412	18	pliva	pliva	NOUN
ihlr-20834	412	19	.	.	PUNCT
ihlr-20834	413	1	the	the	DET
ihlr-20834	413	2	manufacturer	manufacturer	NOUN
ihlr-20834	413	3	could	could	AUX
ihlr-20834	413	4	have	have	AUX
ihlr-20834	413	5	approached	approach	VERB
ihlr-20834	413	6	the	the	DET
ihlr-20834	413	7	fda	fda	PROPN
ihlr-20834	413	8	and	and	CCONJ
ihlr-20834	413	9	the	the	DET
ihlr-20834	413	10	agency	agency	NOUN
ihlr-20834	413	11	may	may	AUX
ihlr-20834	413	12	well	well	ADV
ihlr-20834	413	13	have	have	AUX
ihlr-20834	413	14	agreed	agree	VERB
ihlr-20834	413	15	that	that	SCONJ
ihlr-20834	413	16	a	a	DET
ihlr-20834	413	17	change	change	NOUN
ihlr-20834	413	18	to	to	ADP
ihlr-20834	413	19	the	the	DET
ihlr-20834	413	20	label	label	NOUN
ihlr-20834	413	21	was	be	AUX
ihlr-20834	413	22	necessary.135	necessary.135	NOUN
ihlr-20834	413	23	however	however	ADV
ihlr-20834	413	24	,	,	PUNCT
ihlr-20834	413	25	the	the	DET
ihlr-20834	413	26	court	court	NOUN
ihlr-20834	413	27	created	create	VERB
ihlr-20834	413	28	a	a	DET
ihlr-20834	413	29	new	new	ADJ
ihlr-20834	413	30	law	law	NOUN
ihlr-20834	413	31	:	:	PUNCT
ihlr-20834	413	32	“	"	PUNCT
ihlr-20834	413	33	[	[	X
ihlr-20834	413	34	t]he	t]he	ADV
ihlr-20834	413	35	question	question	NOUN
ihlr-20834	413	36	for	for	ADP
ihlr-20834	413	37	‘	'	PUNCT
ihlr-20834	413	38	impossibility	impossibility	NOUN
ihlr-20834	413	39	’	'	PUNCT
ihlr-20834	413	40	is	be	AUX
ihlr-20834	413	41	whether	whether	SCONJ
ihlr-20834	413	42	the	the	DET
ihlr-20834	413	43	private	private	ADJ
ihlr-20834	413	44	party	party	NOUN
ihlr-20834	413	45	could	could	AUX
ihlr-20834	413	46	independently	independently	ADV
ihlr-20834	413	47	do	do	VERB
ihlr-20834	413	48	under	under	ADP
ihlr-20834	413	49	federal	federal	ADJ
ihlr-20834	413	50	law	law	NOUN
ihlr-20834	413	51	what	what	DET
ihlr-20834	413	52	state	state	NOUN
ihlr-20834	413	53	law	law	NOUN
ihlr-20834	413	54	130	130	NUM
ihlr-20834	413	55	i	i	PRON
ihlr-20834	413	56	d.	d.	NOUN
ihlr-20834	413	57	at	at	ADP
ihlr-20834	413	58	2581	2581	NUM
ihlr-20834	413	59	.	.	PUNCT
ihlr-20834	414	1	131	131	NUM
ihlr-20834	414	2	i	i	PRON
ihlr-20834	414	3	d.	d.	PROPN
ihlr-20834	414	4	at	at	ADP
ihlr-20834	414	5	2589	2589	NUM
ihlr-20834	414	6	(	(	PUNCT
ihlr-20834	414	7	sotomayor	sotomayor	PROPN
ihlr-20834	414	8	,	,	PUNCT
ihlr-20834	414	9	j.	j.	PROPN
ihlr-20834	414	10	,	,	PUNCT
ihlr-20834	414	11	dissenting	dissent	VERB
ihlr-20834	414	12	)	)	PUNCT
ihlr-20834	414	13	.	.	PUNCT
ihlr-20834	415	1	132	132	NUM
ihlr-20834	415	2	i	i	PRON
ihlr-20834	415	3	d.	d.	PROPN
ihlr-20834	415	4	at	at	ADP
ihlr-20834	415	5	2588	2588	NUM
ihlr-20834	415	6	.	.	PUNCT
ihlr-20834	416	1	133	133	NUM
ihlr-20834	416	2	unequal	unequal	ADJ
ihlr-20834	416	3	justice	justice	NOUN
ihlr-20834	416	4	:	:	PUNCT
ihlr-20834	416	5	pliva	pliva	PROPN
ihlr-20834	416	6	v.	v.	CCONJ
ihlr-20834	416	7	mensing	mensing	PROPN
ihlr-20834	416	8	,	,	PUNCT
ihlr-20834	416	9	alliance	alliance	NOUN
ihlr-20834	416	10	for	for	ADP
ihlr-20834	416	11	just	just	ADV
ihlr-20834	416	12	.	.	PUNCT
ihlr-20834	416	13	,	,	PUNCT
ihlr-20834	416	14	http://www.afj.org/multimedia/first-monday-films/unequal-justice-plivav-mensing	http://www.afj.org/multimedia/first-monday-films/unequal-justice-plivav-mense	VERB
ihlr-20834	416	15	(	(	PUNCT
ihlr-20834	416	16	last	last	ADV
ihlr-20834	416	17	visited	visit	VERB
ihlr-20834	416	18	mar	mar	PROPN
ihlr-20834	416	19	.	.	PROPN
ihlr-20834	416	20	20	20	NUM
ihlr-20834	416	21	,	,	PUNCT
ihlr-20834	416	22	2015	2015	NUM
ihlr-20834	416	23	)	)	PUNCT
ihlr-20834	416	24	.	.	PUNCT
ihlr-20834	417	1	134	134	NUM
ihlr-20834	417	2	brian	brian	PROPN
ihlr-20834	417	3	wolfman	wolfman	PROPN
ihlr-20834	417	4	&	&	CCONJ
ihlr-20834	417	5	anne	anne	PROPN
ihlr-20834	417	6	king	king	PROPN
ihlr-20834	417	7	,	,	PUNCT
ihlr-20834	417	8	mutual	mutual	ADJ
ihlr-20834	417	9	pharmaceutical	pharmaceutical	PROPN
ihlr-20834	417	10	co.	co.	PROPN
ihlr-20834	417	11	v.	v.	ADP
ihlr-20834	417	12	bartlett	bartlett	PROPN
ihlr-20834	417	13	and	and	CCONJ
ihlr-20834	417	14	its	its	PRON
ihlr-20834	417	15	implications	implication	NOUN
ihlr-20834	417	16	,	,	PUNCT
ihlr-20834	417	17	bureau	bureau	NOUN
ihlr-20834	417	18	of	of	ADP
ihlr-20834	417	19	nat’l	nat’l	PROPN
ihlr-20834	417	20	aff	aff	PROPN
ihlr-20834	417	21	.	.	PROPN
ihlr-20834	417	22	,	,	PUNCT
ihlr-20834	417	23	http://about.bloomberglaw.com/practitioner-contributions/mutualpharmaceutical-co-v-bartlett-and-its-implications/	http://about.bloomberglaw.com/practitioner-contributions/mutualpharmaceutical-co-v-bartlett-and-its-implications/	PROPN
ihlr-20834	417	24	(	(	PUNCT
ihlr-20834	417	25	last	last	ADV
ihlr-20834	417	26	visited	visit	VERB
ihlr-20834	417	27	mar	mar	PROPN
ihlr-20834	417	28	.	.	PROPN
ihlr-20834	417	29	20	20	NUM
ihlr-20834	417	30	,	,	PUNCT
ihlr-20834	417	31	2015	2015	NUM
ihlr-20834	417	32	)	)	PUNCT
ihlr-20834	417	33	.	.	PUNCT
ihlr-20834	418	1	135	135	NUM
ihlr-20834	418	2	pliva	pliva	PROPN
ihlr-20834	418	3	,	,	PUNCT
ihlr-20834	418	4	inc	inc	PROPN
ihlr-20834	418	5	.	.	PROPN
ihlr-20834	418	6	,	,	PUNCT
ihlr-20834	418	7	131	131	NUM
ihlr-20834	418	8	s.ct	s.ct	NOUN
ihlr-20834	418	9	.	.	PUNCT
ihlr-20834	419	1	at	at	ADP
ihlr-20834	419	2	2587	2587	NUM
ihlr-20834	419	3	(	(	PUNCT
ihlr-20834	419	4	sotomayor	sotomayor	PROPN
ihlr-20834	419	5	,	,	PUNCT
ihlr-20834	419	6	j.	j.	PROPN
ihlr-20834	419	7	,	,	PUNCT
ihlr-20834	419	8	dissenting	dissent	VERB
ihlr-20834	419	9	)	)	PUNCT
ihlr-20834	419	10	.	.	PUNCT
ihlr-20834	420	1	2015	2015	NUM
ihlr-20834	420	2	791	791	NUM
ihlr-20834	420	3	the	the	DET
ihlr-20834	420	4	supreme	supreme	PROPN
ihlr-20834	420	5	court	court	PROPN
ihlr-20834	420	6	’s	’s	PART
ihlr-20834	420	7	overreaching	overreach	VERB
ihlr-20834	420	8	preemption	preemption	NOUN
ihlr-20834	420	9	interpretation	interpretation	NOUN
ihlr-20834	420	10	and	and	CCONJ
ihlr-20834	420	11	it	it	PRON
ihlr-20834	420	12	’s	’	VERB
ihlr-20834	420	13	consequences	consequence	NOUN
ihlr-20834	420	14	requires	require	VERB
ihlr-20834	420	15	of	of	ADP
ihlr-20834	420	16	it	it	PRON
ihlr-20834	420	17	.	.	PUNCT
ihlr-20834	420	18	”	"	PUNCT
ihlr-20834	421	1	136	136	NUM
ihlr-20834	421	2	this	this	DET
ihlr-20834	421	3	interpretation	interpretation	NOUN
ihlr-20834	421	4	flew	fly	VERB
ihlr-20834	421	5	against	against	ADP
ihlr-20834	421	6	the	the	DET
ihlr-20834	421	7	longstanding	longstanding	ADJ
ihlr-20834	421	8	presumption	presumption	NOUN
ihlr-20834	421	9	against	against	ADP
ihlr-20834	421	10	preemption	preemption	NOUN
ihlr-20834	421	11	such	such	ADJ
ihlr-20834	421	12	that	that	SCONJ
ihlr-20834	421	13	courts	court	NOUN
ihlr-20834	421	14	required	require	VERB
ihlr-20834	421	15	a	a	DET
ihlr-20834	421	16	“	"	PUNCT
ihlr-20834	421	17	strong	strong	ADJ
ihlr-20834	421	18	”	"	PUNCT
ihlr-20834	421	19	showing	showing	NOUN
ihlr-20834	421	20	of	of	ADP
ihlr-20834	421	21	conflict	conflict	NOUN
ihlr-20834	421	22	“	"	PUNCT
ihlr-20834	421	23	to	to	PART
ihlr-20834	421	24	overcome	overcome	VERB
ihlr-20834	421	25	the	the	DET
ihlr-20834	421	26	presumption	presumption	NOUN
ihlr-20834	421	27	that	that	SCONJ
ihlr-20834	421	28	state	state	NOUN
ihlr-20834	421	29	and	and	CCONJ
ihlr-20834	421	30	local	local	ADJ
ihlr-20834	421	31	regulation	regulation	NOUN
ihlr-20834	421	32	can	can	AUX
ihlr-20834	421	33	constitutionally	constitutionally	ADV
ihlr-20834	421	34	coexist	coexist	VERB
ihlr-20834	421	35	with	with	ADP
ihlr-20834	421	36	federal	federal	ADJ
ihlr-20834	421	37	regulation	regulation	NOUN
ihlr-20834	421	38	.	.	PUNCT
ihlr-20834	421	39	”137	”137	PUNCT
ihlr-20834	422	1	the	the	DET
ihlr-20834	422	2	pliva	pliva	NOUN
ihlr-20834	422	3	decision	decision	NOUN
ihlr-20834	422	4	indirectly	indirectly	ADV
ihlr-20834	422	5	gives	give	VERB
ihlr-20834	422	6	physicians	physician	NOUN
ihlr-20834	422	7	the	the	DET
ihlr-20834	422	8	authority	authority	NOUN
ihlr-20834	422	9	to	to	PART
ihlr-20834	422	10	tell	tell	VERB
ihlr-20834	422	11	patients	patient	NOUN
ihlr-20834	422	12	that	that	SCONJ
ihlr-20834	422	13	while	while	SCONJ
ihlr-20834	422	14	it	it	PRON
ihlr-20834	422	15	may	may	AUX
ihlr-20834	422	16	be	be	AUX
ihlr-20834	422	17	cheaper	cheap	ADJ
ihlr-20834	422	18	to	to	PART
ihlr-20834	422	19	use	use	VERB
ihlr-20834	422	20	generic	generic	ADJ
ihlr-20834	422	21	drugs	drug	NOUN
ihlr-20834	422	22	,	,	PUNCT
ihlr-20834	422	23	they	they	PRON
ihlr-20834	422	24	may	may	AUX
ihlr-20834	422	25	have	have	VERB
ihlr-20834	422	26	no	no	DET
ihlr-20834	422	27	legal	legal	ADJ
ihlr-20834	422	28	protections	protection	NOUN
ihlr-20834	422	29	if	if	SCONJ
ihlr-20834	422	30	the	the	DET
ihlr-20834	422	31	generic	generic	ADJ
ihlr-20834	422	32	drug	drug	NOUN
ihlr-20834	422	33	injures	injure	VERB
ihlr-20834	422	34	them	they	PRON
ihlr-20834	422	35	.	.	PUNCT
ihlr-20834	423	1	notably	notably	ADV
ihlr-20834	423	2	,	,	PUNCT
ihlr-20834	423	3	“	"	PUNCT
ihlr-20834	423	4	the	the	DET
ihlr-20834	423	5	dispensing	dispensing	NOUN
ihlr-20834	423	6	of	of	ADP
ihlr-20834	423	7	generic	generic	ADJ
ihlr-20834	423	8	drugs	drug	NOUN
ihlr-20834	423	9	on	on	ADP
ihlr-20834	423	10	‘	'	PUNCT
ihlr-20834	423	11	brand	brand	NOUN
ihlr-20834	423	12	-	-	PUNCT
ihlr-20834	423	13	written	write	VERB
ihlr-20834	423	14	’	'	PUNCT
ihlr-20834	423	15	prescriptions	prescription	NOUN
ihlr-20834	423	16	rather	rather	ADV
ihlr-20834	423	17	than	than	ADP
ihlr-20834	423	18	generically	generically	ADV
ihlr-20834	423	19	written	write	VERB
ihlr-20834	423	20	prescriptions	prescription	NOUN
ihlr-20834	423	21	[	[	X
ihlr-20834	423	22	have	have	AUX
ihlr-20834	423	23	]	]	PUNCT
ihlr-20834	423	24	become	become	VERB
ihlr-20834	423	25	the	the	DET
ihlr-20834	423	26	chief	chief	ADJ
ihlr-20834	423	27	source	source	NOUN
ihlr-20834	423	28	of	of	ADP
ihlr-20834	423	29	generic	generic	ADJ
ihlr-20834	423	30	drug	drug	NOUN
ihlr-20834	423	31	sales	sale	NOUN
ihlr-20834	423	32	through	through	ADP
ihlr-20834	423	33	pharmacies	pharmacy	NOUN
ihlr-20834	423	34	.	.	PUNCT
ihlr-20834	423	35	”	"	PUNCT
ihlr-20834	424	1	138	138	NUM
ihlr-20834	424	2	furthermore	furthermore	ADV
ihlr-20834	424	3	,	,	PUNCT
ihlr-20834	424	4	every	every	DET
ihlr-20834	424	5	state	state	NOUN
ihlr-20834	424	6	has	have	VERB
ihlr-20834	424	7	a	a	DET
ihlr-20834	424	8	law	law	NOUN
ihlr-20834	424	9	governing	govern	VERB
ihlr-20834	424	10	generic	generic	ADJ
ihlr-20834	424	11	drug	drug	NOUN
ihlr-20834	424	12	substitution	substitution	NOUN
ihlr-20834	424	13	and	and	CCONJ
ihlr-20834	424	14	fourteen	fourteen	NUM
ihlr-20834	424	15	states	state	NOUN
ihlr-20834	424	16	mandate	mandate	VERB
ihlr-20834	424	17	generic	generic	ADJ
ihlr-20834	424	18	substitution	substitution	NOUN
ihlr-20834	424	19	if	if	SCONJ
ihlr-20834	424	20	“	"	PUNCT
ihlr-20834	424	21	brand	brand	NOUN
ihlr-20834	424	22	only	only	ADV
ihlr-20834	424	23	”	"	PUNCT
ihlr-20834	424	24	is	be	AUX
ihlr-20834	424	25	n’t	not	PART
ihlr-20834	424	26	indicated	indicate	VERB
ihlr-20834	424	27	by	by	ADP
ihlr-20834	424	28	the	the	DET
ihlr-20834	424	29	prescribing	prescribe	VERB
ihlr-20834	424	30	physician.139	physician.139	NOUN
ihlr-20834	424	31	the	the	DET
ihlr-20834	424	32	danger	danger	NOUN
ihlr-20834	424	33	of	of	ADP
ihlr-20834	424	34	these	these	DET
ihlr-20834	424	35	substitution	substitution	NOUN
ihlr-20834	424	36	laws	law	NOUN
ihlr-20834	424	37	is	be	AUX
ihlr-20834	424	38	that	that	SCONJ
ihlr-20834	424	39	a	a	DET
ihlr-20834	424	40	patient	patient	NOUN
ihlr-20834	424	41	may	may	AUX
ihlr-20834	424	42	unknowingly	unknowingly	ADV
ihlr-20834	424	43	be	be	AUX
ihlr-20834	424	44	given	give	VERB
ihlr-20834	424	45	a	a	DET
ihlr-20834	424	46	generic	generic	ADJ
ihlr-20834	424	47	drug	drug	NOUN
ihlr-20834	424	48	,	,	PUNCT
ihlr-20834	424	49	which	which	PRON
ihlr-20834	424	50	further	far	ADV
ihlr-20834	424	51	exacerbates	exacerbate	VERB
ihlr-20834	424	52	the	the	DET
ihlr-20834	424	53	likelihood	likelihood	NOUN
ihlr-20834	424	54	of	of	ADP
ihlr-20834	424	55	a	a	DET
ihlr-20834	424	56	consumer	consumer	NOUN
ihlr-20834	424	57	taking	take	VERB
ihlr-20834	424	58	a	a	DET
ihlr-20834	424	59	drug	drug	NOUN
ihlr-20834	424	60	in	in	ADP
ihlr-20834	424	61	which	which	PRON
ihlr-20834	424	62	they	they	PRON
ihlr-20834	424	63	have	have	VERB
ihlr-20834	424	64	no	no	DET
ihlr-20834	424	65	legal	legal	ADJ
ihlr-20834	424	66	recourse	recourse	NOUN
ihlr-20834	424	67	against	against	ADP
ihlr-20834	424	68	the	the	DET
ihlr-20834	424	69	manufacturer	manufacturer	NOUN
ihlr-20834	424	70	.	.	PUNCT
ihlr-20834	425	1	140	140	NUM
ihlr-20834	425	2	pharmacists	pharmacist	NOUN
ihlr-20834	425	3	also	also	ADV
ihlr-20834	425	4	have	have	VERB
ihlr-20834	425	5	financial	financial	ADJ
ihlr-20834	425	6	incentives	incentive	NOUN
ihlr-20834	425	7	to	to	PART
ihlr-20834	425	8	dispense	dispense	VERB
ihlr-20834	425	9	generics	generic	NOUN
ihlr-20834	425	10	because	because	SCONJ
ihlr-20834	425	11	it	it	PRON
ihlr-20834	425	12	increases	increase	VERB
ihlr-20834	425	13	profit	profit	NOUN
ihlr-20834	425	14	margins.141	margins.141	NOUN
ihlr-20834	425	15	balancing	balancing	NOUN
ihlr-20834	425	16	affordability	affordability	NOUN
ihlr-20834	425	17	with	with	ADP
ihlr-20834	425	18	safety	safety	NOUN
ihlr-20834	425	19	is	be	AUX
ihlr-20834	425	20	an	an	DET
ihlr-20834	425	21	inequitable	inequitable	ADJ
ihlr-20834	425	22	decision	decision	NOUN
ihlr-20834	425	23	innocent	innocent	ADJ
ihlr-20834	425	24	consumers	consumer	NOUN
ihlr-20834	425	25	should	should	AUX
ihlr-20834	425	26	not	not	PART
ihlr-20834	425	27	be	be	AUX
ihlr-20834	425	28	faced	face	VERB
ihlr-20834	425	29	with	with	ADP
ihlr-20834	425	30	.	.	PUNCT
ihlr-20834	426	1	in	in	ADP
ihlr-20834	426	2	pliva	pliva	PROPN
ihlr-20834	426	3	,	,	PUNCT
ihlr-20834	426	4	the	the	DET
ihlr-20834	426	5	majority	majority	NOUN
ihlr-20834	426	6	did	do	AUX
ihlr-20834	426	7	not	not	PART
ihlr-20834	426	8	show	show	VERB
ihlr-20834	426	9	a	a	DET
ihlr-20834	426	10	“	"	PUNCT
ihlr-20834	426	11	clear	clear	ADJ
ihlr-20834	426	12	and	and	CCONJ
ihlr-20834	426	13	manifest	manifest	ADJ
ihlr-20834	426	14	purpose	purpose	NOUN
ihlr-20834	426	15	of	of	ADP
ihlr-20834	426	16	congress	congress	PROPN
ihlr-20834	426	17	”	"	PUNCT
ihlr-20834	426	18	because	because	SCONJ
ihlr-20834	426	19	congress	congress	PROPN
ihlr-20834	426	20	did	do	AUX
ihlr-20834	426	21	not	not	PART
ihlr-20834	426	22	expressly	expressly	ADV
ihlr-20834	426	23	preempt	preempt	VERB
ihlr-20834	426	24	label	label	NOUN
ihlr-20834	426	25	changing.142	changing.142	PRON
ihlr-20834	426	26	congress	congress	PROPN
ihlr-20834	426	27	explicitly	explicitly	ADV
ihlr-20834	426	28	enacted	enact	VERB
ihlr-20834	426	29	an	an	DET
ihlr-20834	426	30	express	express	ADJ
ihlr-20834	426	31	preemption	preemption	NOUN
ihlr-20834	426	32	provision	provision	NOUN
ihlr-20834	426	33	for	for	ADP
ihlr-20834	426	34	medical	medical	ADJ
ihlr-20834	426	35	devices	device	NOUN
ihlr-20834	426	36	in	in	ADP
ihlr-20834	426	37	1976	1976	NUM
ihlr-20834	426	38	and	and	CCONJ
ihlr-20834	426	39	it	it	PRON
ihlr-20834	426	40	declined	decline	VERB
ihlr-20834	426	41	to	to	PART
ihlr-20834	426	42	do	do	VERB
ihlr-20834	426	43	so	so	ADV
ihlr-20834	426	44	for	for	ADP
ihlr-20834	426	45	pharmaceuticals.143	pharmaceuticals.143	NOUN
ihlr-20834	426	46	it	it	PRON
ihlr-20834	426	47	would	would	AUX
ihlr-20834	426	48	136	136	NUM
ihlr-20834	427	1	i	i	PRON
ihlr-20834	427	2	d.	d.	NOUN
ihlr-20834	427	3	at	at	ADP
ihlr-20834	427	4	2579	2579	NUM
ihlr-20834	427	5	.	.	PUNCT
ihlr-20834	428	1	137	137	NUM
ihlr-20834	428	2	i	i	PRON
ihlr-20834	428	3	d.	d.	NOUN
ihlr-20834	428	4	at	at	ADP
ihlr-20834	428	5	2591	2591	NUM
ihlr-20834	428	6	(	(	PUNCT
ihlr-20834	428	7	sotomayor	sotomayor	PROPN
ihlr-20834	428	8	,	,	PUNCT
ihlr-20834	428	9	j.	j.	PROPN
ihlr-20834	428	10	,	,	PUNCT
ihlr-20834	428	11	dissenting	dissent	VERB
ihlr-20834	428	12	)	)	PUNCT
ihlr-20834	428	13	(	(	PUNCT
ihlr-20834	428	14	citing	cite	VERB
ihlr-20834	428	15	hillsborough	hillsborough	PROPN
ihlr-20834	428	16	cnty	cnty	NOUN
ihlr-20834	428	17	.	.	PUNCT
ihlr-20834	429	1	v.	v.	ADP
ihlr-20834	429	2	automated	automate	VERB
ihlr-20834	429	3	medical	medical	ADJ
ihlr-20834	429	4	laboratories	laboratory	NOUN
ihlr-20834	429	5	,	,	PUNCT
ihlr-20834	429	6	inc	inc	PROPN
ihlr-20834	429	7	.	.	PROPN
ihlr-20834	429	8	,	,	PUNCT
ihlr-20834	429	9	471	471	NUM
ihlr-20834	429	10	u.s	u.s	PROPN
ihlr-20834	429	11	.	.	PROPN
ihlr-20834	429	12	707	707	NUM
ihlr-20834	429	13	(	(	PUNCT
ihlr-20834	429	14	1985	1985	NUM
ihlr-20834	429	15	)	)	PUNCT
ihlr-20834	429	16	)	)	PUNCT
ihlr-20834	429	17	.	.	PUNCT
ihlr-20834	430	1	138	138	NUM
ihlr-20834	430	2	steele	steele	PROPN
ihlr-20834	430	3	,	,	PUNCT
ihlr-20834	430	4	supra	supra	PROPN
ihlr-20834	430	5	note	note	VERB
ihlr-20834	430	6	7	7	NUM
ihlr-20834	430	7	at	at	ADP
ihlr-20834	430	8	461	461	NUM
ihlr-20834	430	9	.	.	PUNCT
ihlr-20834	430	10	139	139	NUM
ihlr-20834	430	11	expanding	expand	VERB
ihlr-20834	430	12	the	the	DET
ihlr-20834	430	13	use	use	NOUN
ihlr-20834	430	14	of	of	ADP
ihlr-20834	430	15	generic	generic	ADJ
ihlr-20834	430	16	drugs	drug	NOUN
ihlr-20834	430	17	,	,	PUNCT
ihlr-20834	430	18	u.s	u.s	PROPN
ihlr-20834	430	19	.	.	PROPN
ihlr-20834	430	20	dep’t	dep’t	PROPN
ihlr-20834	430	21	of	of	ADP
ihlr-20834	430	22	health	health	PROPN
ihlr-20834	430	23	&	&	CCONJ
ihlr-20834	430	24	human	human	PROPN
ihlr-20834	430	25	servs	servs	PROPN
ihlr-20834	430	26	.	.	PUNCT
ihlr-20834	430	27	,	,	PUNCT
ihlr-20834	430	28	(	(	PUNCT
ihlr-20834	430	29	dec	dec	PROPN
ihlr-20834	430	30	.	.	PROPN
ihlr-20834	430	31	1	1	NUM
ihlr-20834	430	32	,	,	PUNCT
ihlr-20834	430	33	2010	2010	NUM
ihlr-20834	430	34	)	)	PUNCT
ihlr-20834	430	35	,	,	PUNCT
ihlr-20834	430	36	http://aspe.hhs.gov/sp/reports/2010/genericdrugs/ib.pdf	http://aspe.hhs.gov/sp/reports/2010/genericdrugs/ib.pdf	PROPN
ihlr-20834	430	37	.	.	PROPN
ihlr-20834	431	1	140	140	NUM
ihlr-20834	432	1	i	i	NOUN
ihlr-20834	432	2	d.	d.	PROPN
ihlr-20834	432	3	141	141	NUM
ihlr-20834	432	4	steele	steele	PROPN
ihlr-20834	432	5	,	,	PUNCT
ihlr-20834	432	6	supra	supra	PROPN
ihlr-20834	432	7	note	note	VERB
ihlr-20834	432	8	7	7	NUM
ihlr-20834	432	9	at	at	ADP
ihlr-20834	432	10	462	462	NUM
ihlr-20834	432	11	.	.	PUNCT
ihlr-20834	433	1	142	142	NUM
ihlr-20834	433	2	wyeth	wyeth	PROPN
ihlr-20834	433	3	v.	v.	PROPN
ihlr-20834	433	4	levine	levine	PROPN
ihlr-20834	433	5	,	,	PUNCT
ihlr-20834	433	6	555	555	NUM
ihlr-20834	433	7	u.s	u.s	PROPN
ihlr-20834	433	8	.	.	PROPN
ihlr-20834	433	9	555	555	NUM
ihlr-20834	433	10	,	,	PUNCT
ihlr-20834	433	11	565	565	NUM
ihlr-20834	433	12	(	(	PUNCT
ihlr-20834	433	13	2009	2009	NUM
ihlr-20834	433	14	)	)	PUNCT
ihlr-20834	433	15	.	.	PUNCT
ihlr-20834	434	1	143	143	NUM
ihlr-20834	434	2	21	21	NUM
ihlr-20834	434	3	u.s.c	u.s.c	NOUN
ihlr-20834	434	4	.	.	PUNCT
ihlr-20834	435	1	§	§	PROPN
ihlr-20834	435	2	360k(a	360k(a	NUM
ihlr-20834	435	3	)	)	PUNCT
ihlr-20834	435	4	(	(	PUNCT
ihlr-20834	435	5	2015	2015	NUM
ihlr-20834	435	6	)	)	PUNCT
ihlr-20834	435	7	.	.	PUNCT
ihlr-20834	436	1	792	792	NUM
ihlr-20834	436	2	indiana	indiana	PROPN
ihlr-20834	436	3	health	health	PROPN
ihlr-20834	436	4	law	law	PROPN
ihlr-20834	436	5	review	review	NOUN
ihlr-20834	436	6	vol	vol	NOUN
ihlr-20834	436	7	.	.	PUNCT
ihlr-20834	436	8	12:2	12:2	NUM
ihlr-20834	436	9	seem	seem	VERB
ihlr-20834	436	10	more	more	ADV
ihlr-20834	436	11	likely	likely	ADJ
ihlr-20834	436	12	than	than	SCONJ
ihlr-20834	436	13	not	not	PART
ihlr-20834	436	14	that	that	SCONJ
ihlr-20834	436	15	congress	congress	PROPN
ihlr-20834	436	16	did	do	AUX
ihlr-20834	436	17	not	not	PART
ihlr-20834	436	18	intend	intend	VERB
ihlr-20834	436	19	for	for	ADP
ihlr-20834	436	20	prescription	prescription	NOUN
ihlr-20834	436	21	drugs	drug	NOUN
ihlr-20834	436	22	to	to	PART
ihlr-20834	436	23	be	be	AUX
ihlr-20834	436	24	governed	govern	VERB
ihlr-20834	436	25	by	by	ADP
ihlr-20834	436	26	preemption	preemption	NOUN
ihlr-20834	436	27	provisions	provision	NOUN
ihlr-20834	436	28	.	.	PUNCT
ihlr-20834	437	1	the	the	DET
ihlr-20834	437	2	holding	holding	NOUN
ihlr-20834	437	3	goes	go	VERB
ihlr-20834	437	4	against	against	ADP
ihlr-20834	437	5	the	the	DET
ihlr-20834	437	6	holding	holding	NOUN
ihlr-20834	437	7	in	in	ADP
ihlr-20834	437	8	wyeth	wyeth	PROPN
ihlr-20834	437	9	and	and	CCONJ
ihlr-20834	437	10	the	the	DET
ihlr-20834	437	11	commonly	commonly	ADV
ihlr-20834	437	12	held	hold	VERB
ihlr-20834	437	13	notion	notion	NOUN
ihlr-20834	437	14	to	to	PART
ihlr-20834	437	15	fdca	fdca	VERB
ihlr-20834	437	16	and	and	CCONJ
ihlr-20834	437	17	fda	fda	PROPN
ihlr-20834	437	18	regulations	regulation	NOUN
ihlr-20834	437	19	that	that	SCONJ
ihlr-20834	437	20	the	the	DET
ihlr-20834	437	21	manufacturer	manufacturer	NOUN
ihlr-20834	437	22	bears	bear	VERB
ihlr-20834	437	23	responsibility	responsibility	NOUN
ihlr-20834	437	24	for	for	ADP
ihlr-20834	437	25	the	the	DET
ihlr-20834	437	26	content	content	NOUN
ihlr-20834	437	27	of	of	ADP
ihlr-20834	437	28	its	its	PRON
ihlr-20834	437	29	label	label	NOUN
ihlr-20834	437	30	“	"	PUNCT
ihlr-20834	437	31	at	at	ADP
ihlr-20834	437	32	all	all	DET
ihlr-20834	437	33	times	time	NOUN
ihlr-20834	437	34	.	.	PUNCT
ihlr-20834	437	35	”144	”144	PUNCT
ihlr-20834	438	1	after	after	ADV
ihlr-20834	438	2	all	all	ADV
ihlr-20834	438	3	,	,	PUNCT
ihlr-20834	438	4	the	the	DET
ihlr-20834	438	5	court	court	NOUN
ihlr-20834	438	6	itself	itself	PRON
ihlr-20834	438	7	agreed	agree	VERB
ihlr-20834	438	8	that	that	SCONJ
ihlr-20834	438	9	holding	hold	VERB
ihlr-20834	438	10	a	a	DET
ihlr-20834	438	11	brand	brand	NOUN
ihlr-20834	438	12	-	-	PUNCT
ihlr-20834	438	13	name	name	NOUN
ihlr-20834	438	14	manufacturer	manufacturer	NOUN
ihlr-20834	438	15	and	and	CCONJ
ihlr-20834	438	16	not	not	PART
ihlr-20834	438	17	a	a	DET
ihlr-20834	438	18	generic	generic	ADJ
ihlr-20834	438	19	drug	drug	NOUN
ihlr-20834	438	20	manufacturer	manufacturer	NOUN
ihlr-20834	438	21	liable	liable	ADJ
ihlr-20834	438	22	“	"	PUNCT
ihlr-20834	438	23	makes	make	VERB
ihlr-20834	438	24	little	little	ADJ
ihlr-20834	438	25	sense	sense	NOUN
ihlr-20834	438	26	.	.	PUNCT
ihlr-20834	438	27	”145	”145	PROPN
ihlr-20834	439	1	3	3	NUM
ihlr-20834	439	2	.	.	PUNCT
ihlr-20834	439	3	bartlett	bartlett	PROPN
ihlr-20834	439	4	state	state	PROPN
ihlr-20834	439	5	tort	tort	PROPN
ihlr-20834	439	6	law	law	NOUN
ihlr-20834	439	7	preemption	preemption	NOUN
ihlr-20834	439	8	for	for	ADP
ihlr-20834	439	9	design	design	NOUN
ihlr-20834	439	10	defect	defect	NOUN
ihlr-20834	439	11	claims	claim	NOUN
ihlr-20834	439	12	against	against	ADP
ihlr-20834	439	13	generic	generic	ADJ
ihlr-20834	439	14	manufacturers	manufacturer	NOUN
ihlr-20834	439	15	two	two	NUM
ihlr-20834	439	16	years	year	NOUN
ihlr-20834	439	17	following	follow	VERB
ihlr-20834	439	18	the	the	DET
ihlr-20834	439	19	pliva	pliva	NOUN
ihlr-20834	439	20	decision	decision	NOUN
ihlr-20834	439	21	the	the	DET
ihlr-20834	439	22	court	court	NOUN
ihlr-20834	439	23	unnecessarily	unnecessarily	ADV
ihlr-20834	439	24	expanded	expand	VERB
ihlr-20834	439	25	the	the	DET
ihlr-20834	439	26	already	already	ADV
ihlr-20834	439	27	overreaching	overreach	VERB
ihlr-20834	439	28	application	application	NOUN
ihlr-20834	439	29	of	of	ADP
ihlr-20834	439	30	the	the	DET
ihlr-20834	439	31	preemption	preemption	NOUN
ihlr-20834	439	32	doctrine	doctrine	NOUN
ihlr-20834	439	33	.	.	PUNCT
ihlr-20834	440	1	146	146	NUM
ihlr-20834	440	2	in	in	ADP
ihlr-20834	440	3	mutual	mutual	ADJ
ihlr-20834	440	4	pharmaceutical	pharmaceutical	PROPN
ihlr-20834	440	5	co.	co.	PROPN
ihlr-20834	440	6	v.	v.	ADP
ihlr-20834	440	7	bartlett	bartlett	PROPN
ihlr-20834	440	8	karen	karen	PROPN
ihlr-20834	440	9	bartlett	bartlett	PROPN
ihlr-20834	440	10	,	,	PUNCT
ihlr-20834	440	11	the	the	DET
ihlr-20834	440	12	plaintiff	plaintiff	NOUN
ihlr-20834	440	13	,	,	PUNCT
ihlr-20834	440	14	was	be	AUX
ihlr-20834	440	15	prescribed	prescribe	VERB
ihlr-20834	440	16	sulindac	sulindac	NOUN
ihlr-20834	440	17	a	a	DET
ihlr-20834	440	18	generic	generic	ADJ
ihlr-20834	440	19	version	version	NOUN
ihlr-20834	440	20	of	of	ADP
ihlr-20834	440	21	the	the	DET
ihlr-20834	440	22	drug	drug	NOUN
ihlr-20834	440	23	clinoril	clinoril	NOUN
ihlr-20834	440	24	for	for	ADP
ihlr-20834	440	25	her	her	PRON
ihlr-20834	440	26	shoulder	shoulder	NOUN
ihlr-20834	440	27	pain.147	pain.147	NOUN
ihlr-20834	440	28	as	as	ADP
ihlr-20834	440	29	a	a	DET
ihlr-20834	440	30	result	result	NOUN
ihlr-20834	440	31	of	of	ADP
ihlr-20834	440	32	taking	take	VERB
ihlr-20834	440	33	sulindac	sulindac	NOUN
ihlr-20834	440	34	,	,	PUNCT
ihlr-20834	440	35	ms	ms	PROPN
ihlr-20834	440	36	.	.	PROPN
ihlr-20834	440	37	bartlett	bartlett	PROPN
ihlr-20834	440	38	developed	develop	VERB
ihlr-20834	440	39	toxic	toxic	ADJ
ihlr-20834	440	40	epidermal	epidermal	ADJ
ihlr-20834	440	41	necrolysis	necrolysis	NOUN
ihlr-20834	440	42	a	a	DET
ihlr-20834	440	43	skin	skin	NOUN
ihlr-20834	440	44	condition	condition	NOUN
ihlr-20834	440	45	that	that	PRON
ihlr-20834	440	46	causes	cause	VERB
ihlr-20834	440	47	ones	one	NOUN
ihlr-20834	440	48	skin	skin	VERB
ihlr-20834	440	49	to	to	PART
ihlr-20834	440	50	peel	peel	VERB
ihlr-20834	440	51	in	in	ADP
ihlr-20834	440	52	sheets	sheet	NOUN
ihlr-20834	440	53	leaving	leave	VERB
ihlr-20834	440	54	large	large	ADJ
ihlr-20834	440	55	areas	area	NOUN
ihlr-20834	440	56	of	of	ADP
ihlr-20834	440	57	her	her	PRON
ihlr-20834	440	58	skin	skin	NOUN
ihlr-20834	440	59	exposed	expose	VERB
ihlr-20834	440	60	.	.	PUNCT
ihlr-20834	441	1	148	148	NUM
ihlr-20834	441	2	when	when	SCONJ
ihlr-20834	441	3	ms	ms	PROPN
ihlr-20834	441	4	.	.	PROPN
ihlr-20834	441	5	bartlett	bartlett	PROPN
ihlr-20834	441	6	was	be	AUX
ihlr-20834	441	7	prescribed	prescribe	VERB
ihlr-20834	441	8	sulindac	sulindac	NOUN
ihlr-20834	441	9	the	the	DET
ihlr-20834	441	10	drug	drug	NOUN
ihlr-20834	441	11	did	do	AUX
ihlr-20834	441	12	not	not	PART
ihlr-20834	441	13	warn	warn	VERB
ihlr-20834	441	14	of	of	ADP
ihlr-20834	441	15	the	the	DET
ihlr-20834	441	16	risk	risk	NOUN
ihlr-20834	441	17	of	of	ADP
ihlr-20834	441	18	developing	develop	VERB
ihlr-20834	441	19	toxic	toxic	ADJ
ihlr-20834	441	20	epidermal	epidermal	ADJ
ihlr-20834	441	21	necrolysis.149	necrolysis.149	NOUN
ihlr-20834	441	22	soon	soon	ADV
ihlr-20834	441	23	144	144	NUM
ihlr-20834	441	24	wyeth	wyeth	PROPN
ihlr-20834	441	25	,	,	PUNCT
ihlr-20834	441	26	555	555	NUM
ihlr-20834	441	27	u.s	u.s	PROPN
ihlr-20834	441	28	.	.	PROPN
ihlr-20834	441	29	at	at	ADP
ihlr-20834	441	30	571	571	NUM
ihlr-20834	441	31	.	.	PUNCT
ihlr-20834	442	1	145	145	NUM
ihlr-20834	442	2	pliva	pliva	PROPN
ihlr-20834	442	3	,	,	PUNCT
ihlr-20834	442	4	inc	inc	PROPN
ihlr-20834	442	5	.	.	PROPN
ihlr-20834	443	1	v.	v.	CCONJ
ihlr-20834	443	2	mensing	mense	VERB
ihlr-20834	443	3	,	,	PUNCT
ihlr-20834	443	4	131	131	NUM
ihlr-20834	443	5	s.ct	s.ct	NOUN
ihlr-20834	443	6	.	.	PROPN
ihlr-20834	444	1	2581	2581	NUM
ihlr-20834	444	2	(	(	PUNCT
ihlr-20834	444	3	2011	2011	NUM
ihlr-20834	444	4	)	)	PUNCT
ihlr-20834	444	5	.	.	PUNCT
ihlr-20834	445	1	146	146	NUM
ihlr-20834	445	2	mut	mut	NOUN
ihlr-20834	445	3	.	.	PUNCT
ihlr-20834	446	1	pharm	pharm	PROPN
ihlr-20834	446	2	.	.	PUNCT
ihlr-20834	447	1	co.	co.	PROPN
ihlr-20834	447	2	,	,	PUNCT
ihlr-20834	447	3	inc	inc	PROPN
ihlr-20834	447	4	.	.	PROPN
ihlr-20834	448	1	v.	v.	ADP
ihlr-20834	448	2	bartlett	bartlett	PROPN
ihlr-20834	448	3	,	,	PUNCT
ihlr-20834	448	4	133	133	NUM
ihlr-20834	448	5	s.ct	s.ct	PROPN
ihlr-20834	448	6	2466	2466	NUM
ihlr-20834	448	7	(	(	PUNCT
ihlr-20834	448	8	2013	2013	NUM
ihlr-20834	448	9	)	)	PUNCT
ihlr-20834	448	10	.	.	PUNCT
ihlr-20834	449	1	147	147	NUM
ihlr-20834	450	1	i	i	PRON
ihlr-20834	450	2	d.	d.	PROPN
ihlr-20834	450	3	at	at	ADP
ihlr-20834	450	4	2472	2472	NUM
ihlr-20834	450	5	.	.	PUNCT
ihlr-20834	451	1	sulindac	sulindac	PROPN
ihlr-20834	451	2	is	be	AUX
ihlr-20834	451	3	a	a	DET
ihlr-20834	451	4	“	"	PUNCT
ihlr-20834	451	5	non	non	ADJ
ihlr-20834	451	6	-	-	ADJ
ihlr-20834	451	7	steroidal	steroidal	ADJ
ihlr-20834	451	8	,	,	PUNCT
ihlr-20834	451	9	anti	anti	ADJ
ihlr-20834	451	10	-	-	ADJ
ihlr-20834	451	11	inflammatory	inflammatory	ADJ
ihlr-20834	451	12	indene	indene	NOUN
ihlr-20834	451	13	derivative	derivative	NOUN
ihlr-20834	451	14	designated	designate	VERB
ihlr-20834	451	15	chemically	chemically	ADV
ihlr-20834	451	16	.	.	PUNCT
ihlr-20834	451	17	.	.	PUNCT
ihlr-20834	451	18	.	.	PUNCT
ihlr-20834	451	19	.	.	PUNCT
ihlr-20834	451	20	”	"	PUNCT
ihlr-20834	452	1	clinoril	clinoril	PROPN
ihlr-20834	452	2	gained	gain	VERB
ihlr-20834	452	3	fda	fda	PROPN
ihlr-20834	452	4	approval	approval	NOUN
ihlr-20834	452	5	in	in	ADP
ihlr-20834	452	6	1978	1978	NUM
ihlr-20834	452	7	and	and	CCONJ
ihlr-20834	452	8	clinical	clinical	ADJ
ihlr-20834	452	9	trials	trial	NOUN
ihlr-20834	452	10	at	at	ADP
ihlr-20834	452	11	that	that	DET
ihlr-20834	452	12	time	time	NOUN
ihlr-20834	452	13	revealed	reveal	VERB
ihlr-20834	452	14	negative	negative	ADJ
ihlr-20834	452	15	side	side	NOUN
ihlr-20834	452	16	effects	effect	NOUN
ihlr-20834	452	17	as	as	ADP
ihlr-20834	452	18	“	"	PUNCT
ihlr-20834	452	19	relatively	relatively	ADV
ihlr-20834	452	20	mild	mild	ADJ
ihlr-20834	452	21	.	.	PUNCT
ihlr-20834	452	22	”	"	PUNCT
ihlr-20834	453	1	see	see	VERB
ihlr-20834	453	2	clinoril	clinoril	NOUN
ihlr-20834	453	3	,	,	PUNCT
ihlr-20834	453	4	rxlist	rxlist	NOUN
ihlr-20834	453	5	,	,	PUNCT
ihlr-20834	453	6	http://www.rxlist.com/clinoril-drug.htm	http://www.rxlist.com/clinoril-drug.htm	PROPN
ihlr-20834	453	7	(	(	PUNCT
ihlr-20834	453	8	last	last	ADJ
ihlr-20834	453	9	visited	visit	VERB
ihlr-20834	453	10	mar	mar	PROPN
ihlr-20834	453	11	.	.	PROPN
ihlr-20834	453	12	21	21	NUM
ihlr-20834	453	13	,	,	PUNCT
ihlr-20834	453	14	2015	2015	NUM
ihlr-20834	453	15	)	)	PUNCT
ihlr-20834	453	16	.	.	PUNCT
ihlr-20834	454	1	see	see	VERB
ihlr-20834	454	2	also	also	ADV
ihlr-20834	454	3	brief	brief	ADJ
ihlr-20834	454	4	for	for	ADP
ihlr-20834	454	5	respondent	respondent	NOUN
ihlr-20834	454	6	,	,	PUNCT
ihlr-20834	454	7	mut	mut	PROPN
ihlr-20834	454	8	.	.	PUNCT
ihlr-20834	455	1	pharm	pharm	PROPN
ihlr-20834	455	2	.	.	PUNCT
ihlr-20834	456	1	co.	co.	PROPN
ihlr-20834	456	2	,	,	PUNCT
ihlr-20834	456	3	inc	inc	PROPN
ihlr-20834	456	4	.	.	PROPN
ihlr-20834	457	1	v.	v.	ADP
ihlr-20834	457	2	bartlett	bartlett	PROPN
ihlr-20834	457	3	,	,	PUNCT
ihlr-20834	457	4	133	133	NUM
ihlr-20834	457	5	s.ct	s.ct	PROPN
ihlr-20834	457	6	2466	2466	NUM
ihlr-20834	457	7	(	(	PUNCT
ihlr-20834	457	8	2013	2013	NUM
ihlr-20834	457	9	)	)	PUNCT
ihlr-20834	457	10	(	(	PUNCT
ihlr-20834	457	11	no	no	INTJ
ihlr-20834	457	12	.	.	NOUN
ihlr-20834	457	13	12	12	NUM
ihlr-20834	457	14	-	-	SYM
ihlr-20834	457	15	142	142	NUM
ihlr-20834	457	16	)	)	PUNCT
ihlr-20834	457	17	,	,	PUNCT
ihlr-20834	457	18	2013	2013	NUM
ihlr-20834	457	19	wl	wl	NOUN
ihlr-20834	457	20	602909	602909	NUM
ihlr-20834	457	21	,	,	PUNCT
ihlr-20834	457	22	at	at	ADP
ihlr-20834	457	23	*	*	NOUN
ihlr-20834	457	24	5	5	NUM
ihlr-20834	457	25	(	(	PUNCT
ihlr-20834	458	1	noting	note	VERB
ihlr-20834	458	2	that	that	SCONJ
ihlr-20834	458	3	mutual	mutual	ADJ
ihlr-20834	458	4	pharmaceutical	pharmaceutical	NOUN
ihlr-20834	458	5	’s	’s	PART
ihlr-20834	458	6	anda	anda	PROPN
ihlr-20834	458	7	was	be	AUX
ihlr-20834	458	8	approved	approve	VERB
ihlr-20834	458	9	in	in	ADP
ihlr-20834	458	10	1991	1991	NUM
ihlr-20834	458	11	)	)	PUNCT
ihlr-20834	458	12	.	.	PUNCT
ihlr-20834	459	1	148	148	NUM
ihlr-20834	459	2	mut	mut	NOUN
ihlr-20834	459	3	.	.	PUNCT
ihlr-20834	460	1	pharm	pharm	PROPN
ihlr-20834	460	2	.	.	PUNCT
ihlr-20834	461	1	co.	co.	PROPN
ihlr-20834	461	2	,	,	PUNCT
ihlr-20834	461	3	133	133	NUM
ihlr-20834	461	4	s.ct	s.ct	NOUN
ihlr-20834	461	5	.	.	PUNCT
ihlr-20834	461	6	at	at	ADP
ihlr-20834	461	7	2472	2472	NUM
ihlr-20834	461	8	.	.	PUNCT
ihlr-20834	462	1	see	see	VERB
ihlr-20834	462	2	also	also	ADV
ihlr-20834	462	3	toxic	toxic	ADJ
ihlr-20834	462	4	epidermal	epidermal	ADJ
ihlr-20834	462	5	necrolysis	necrolysis	NOUN
ihlr-20834	462	6	,	,	PUNCT
ihlr-20834	462	7	johns	johns	PROPN
ihlr-20834	462	8	hopkins	hopkins	PROPN
ihlr-20834	462	9	med	med	PROPN
ihlr-20834	462	10	.	.	PROPN
ihlr-20834	462	11	,	,	PUNCT
ihlr-20834	462	12	http://www.hopkinsmedicine.org/	http://www.hopkinsmedicine.org/	PROPN
ihlr-20834	462	13	healthlibrary	healthlibrary	ADJ
ihlr-20834	462	14	/	/	SYM
ihlr-20834	462	15	conditions	condition	NOUN
ihlr-20834	462	16	/	/	SYM
ihlr-20834	462	17	dermatology	dermatology	NOUN
ihlr-20834	462	18	/	/	SYM
ihlr-20834	462	19	toxic_epidermal_necrolysis_85,p0	toxic_epidermal_necrolysis_85,p0	NOUN
ihlr-20834	462	20	0321/	0321/	NUM
ihlr-20834	463	1	(	(	PUNCT
ihlr-20834	463	2	last	last	ADJ
ihlr-20834	463	3	visited	visit	VERB
ihlr-20834	463	4	mar	mar	PROPN
ihlr-20834	463	5	.	.	PROPN
ihlr-20834	463	6	21	21	NUM
ihlr-20834	463	7	,	,	PUNCT
ihlr-20834	463	8	2015	2015	NUM
ihlr-20834	463	9	)	)	PUNCT
ihlr-20834	463	10	(	(	PUNCT
ihlr-20834	463	11	noting	note	VERB
ihlr-20834	463	12	that	that	SCONJ
ihlr-20834	463	13	the	the	DET
ihlr-20834	463	14	disease	disease	NOUN
ihlr-20834	463	15	progresses	progress	VERB
ihlr-20834	463	16	fast	fast	ADJ
ihlr-20834	463	17	and	and	CCONJ
ihlr-20834	463	18	treatment	treatment	NOUN
ihlr-20834	463	19	involves	involve	VERB
ihlr-20834	463	20	hospitalization	hospitalization	NOUN
ihlr-20834	463	21	in	in	ADP
ihlr-20834	463	22	a	a	DET
ihlr-20834	463	23	burn	burn	NOUN
ihlr-20834	463	24	unit	unit	NOUN
ihlr-20834	463	25	and	and	CCONJ
ihlr-20834	463	26	includes	include	VERB
ihlr-20834	463	27	antibiotics	antibiotic	NOUN
ihlr-20834	463	28	,	,	PUNCT
ihlr-20834	463	29	protective	protective	ADJ
ihlr-20834	463	30	bandages	bandage	NOUN
ihlr-20834	463	31	,	,	PUNCT
ihlr-20834	463	32	and	and	CCONJ
ihlr-20834	463	33	intravenous	intravenous	ADJ
ihlr-20834	463	34	immunoglobulin	immunoglobulin	NOUN
ihlr-20834	463	35	g	g	PROPN
ihlr-20834	463	36	(	(	PUNCT
ihlr-20834	463	37	used	use	VERB
ihlr-20834	463	38	to	to	PART
ihlr-20834	463	39	prevent	prevent	VERB
ihlr-20834	463	40	further	further	ADJ
ihlr-20834	463	41	immune	immune	ADJ
ihlr-20834	463	42	system	system	NOUN
ihlr-20834	463	43	damage	damage	NOUN
ihlr-20834	463	44	)	)	PUNCT
ihlr-20834	463	45	)	)	PUNCT
ihlr-20834	463	46	.	.	PUNCT
ihlr-20834	464	1	149	149	NUM
ihlr-20834	464	2	mut	mut	NOUN
ihlr-20834	464	3	.	.	PUNCT
ihlr-20834	465	1	pharm	pharm	PROPN
ihlr-20834	465	2	.	.	PUNCT
ihlr-20834	466	1	co.	co.	PROPN
ihlr-20834	466	2	,	,	PUNCT
ihlr-20834	466	3	133	133	NUM
ihlr-20834	466	4	s.ct	s.ct	NOUN
ihlr-20834	466	5	.	.	PUNCT
ihlr-20834	466	6	at	at	ADP
ihlr-20834	466	7	2472	2472	NUM
ihlr-20834	466	8	.	.	PUNCT
ihlr-20834	467	1	2015	2015	NUM
ihlr-20834	467	2	793	793	NUM
ihlr-20834	467	3	the	the	DET
ihlr-20834	467	4	supreme	supreme	PROPN
ihlr-20834	467	5	court	court	PROPN
ihlr-20834	467	6	’s	’s	PART
ihlr-20834	467	7	overreaching	overreach	VERB
ihlr-20834	467	8	preemption	preemption	NOUN
ihlr-20834	467	9	interpretation	interpretation	NOUN
ihlr-20834	467	10	and	and	CCONJ
ihlr-20834	467	11	it	it	PRON
ihlr-20834	467	12	’s	’	VERB
ihlr-20834	467	13	consequences	consequence	NOUN
ihlr-20834	467	14	after	after	SCONJ
ihlr-20834	467	15	ms	ms	PROPN
ihlr-20834	467	16	.	.	PROPN
ihlr-20834	467	17	bartlett	bartlett	PROPN
ihlr-20834	467	18	filed	file	VERB
ihlr-20834	467	19	suit	suit	NOUN
ihlr-20834	467	20	in	in	ADP
ihlr-20834	467	21	new	new	PROPN
ihlr-20834	467	22	hampshire	hampshire	PROPN
ihlr-20834	467	23	state	state	PROPN
ihlr-20834	467	24	court	court	PROPN
ihlr-20834	467	25	,	,	PUNCT
ihlr-20834	467	26	the	the	DET
ihlr-20834	467	27	case	case	NOUN
ihlr-20834	467	28	was	be	AUX
ihlr-20834	467	29	removed	remove	VERB
ihlr-20834	467	30	to	to	ADP
ihlr-20834	467	31	federal	federal	ADJ
ihlr-20834	467	32	court	court	NOUN
ihlr-20834	467	33	and	and	CCONJ
ihlr-20834	467	34	a	a	DET
ihlr-20834	467	35	jury	jury	NOUN
ihlr-20834	467	36	found	find	VERB
ihlr-20834	467	37	mutual	mutual	ADJ
ihlr-20834	467	38	pharmaceutical	pharmaceutical	NOUN
ihlr-20834	467	39	liable	liable	ADJ
ihlr-20834	467	40	under	under	ADP
ihlr-20834	467	41	a	a	DET
ihlr-20834	467	42	design	design	NOUN
ihlr-20834	467	43	-	-	PUNCT
ihlr-20834	467	44	defect	defect	NOUN
ihlr-20834	467	45	claim.150	claim.150	NOUN
ihlr-20834	467	46	the	the	DET
ihlr-20834	467	47	first	first	ADJ
ihlr-20834	467	48	circuit	circuit	NOUN
ihlr-20834	467	49	affirmed	affirm	VERB
ihlr-20834	467	50	the	the	DET
ihlr-20834	467	51	decision	decision	NOUN
ihlr-20834	467	52	of	of	ADP
ihlr-20834	467	53	the	the	DET
ihlr-20834	467	54	jury	jury	NOUN
ihlr-20834	467	55	,	,	PUNCT
ihlr-20834	467	56	finding	find	VERB
ihlr-20834	467	57	no	no	DET
ihlr-20834	467	58	preemption.151	preemption.151	NOUN
ihlr-20834	467	59	however	however	ADV
ihlr-20834	467	60	,	,	PUNCT
ihlr-20834	467	61	mutual	mutual	ADJ
ihlr-20834	467	62	pharmaceutical	pharmaceutical	NOUN
ihlr-20834	467	63	appealed	appeal	VERB
ihlr-20834	467	64	the	the	DET
ihlr-20834	467	65	decision	decision	NOUN
ihlr-20834	467	66	and	and	CCONJ
ihlr-20834	467	67	the	the	DET
ihlr-20834	467	68	supreme	supreme	PROPN
ihlr-20834	467	69	court	court	PROPN
ihlr-20834	467	70	held	hold	VERB
ihlr-20834	467	71	designdefect	designdefect	ADJ
ihlr-20834	467	72	claims	claim	NOUN
ihlr-20834	467	73	turning	turn	VERB
ihlr-20834	467	74	on	on	ADP
ihlr-20834	467	75	the	the	DET
ihlr-20834	467	76	adequacy	adequacy	NOUN
ihlr-20834	467	77	of	of	ADP
ihlr-20834	467	78	a	a	DET
ihlr-20834	467	79	drugs	drug	NOUN
ihlr-20834	467	80	warning	warn	VERB
ihlr-20834	467	81	are	be	AUX
ihlr-20834	467	82	preempted.152	preempted.152	PROPN
ihlr-20834	467	83	new	new	PROPN
ihlr-20834	467	84	hampshire	hampshire	PROPN
ihlr-20834	467	85	courts	court	NOUN
ihlr-20834	467	86	employ	employ	VERB
ihlr-20834	467	87	a	a	DET
ihlr-20834	467	88	“	"	PUNCT
ihlr-20834	467	89	risk	risk	NOUN
ihlr-20834	467	90	-	-	PUNCT
ihlr-20834	467	91	utility	utility	NOUN
ihlr-20834	467	92	approach	approach	NOUN
ihlr-20834	467	93	”	"	PUNCT
ihlr-20834	467	94	in	in	ADP
ihlr-20834	467	95	the	the	DET
ihlr-20834	467	96	design	design	NOUN
ihlr-20834	467	97	-	-	PUNCT
ihlr-20834	467	98	defect	defect	NOUN
ihlr-20834	467	99	analysis.153	analysis.153	NUM
ihlr-20834	467	100	new	new	PROPN
ihlr-20834	467	101	hampshire	hampshire	PROPN
ihlr-20834	467	102	courts	court	NOUN
ihlr-20834	467	103	ask	ask	VERB
ihlr-20834	467	104	whether	whether	SCONJ
ihlr-20834	467	105	“	"	PUNCT
ihlr-20834	467	106	magnitude	magnitude	NOUN
ihlr-20834	467	107	of	of	ADP
ihlr-20834	467	108	the	the	DET
ihlr-20834	467	109	danger	danger	NOUN
ihlr-20834	467	110	outweighs	outweigh	VERB
ihlr-20834	467	111	the	the	DET
ihlr-20834	467	112	utility	utility	NOUN
ihlr-20834	467	113	of	of	ADP
ihlr-20834	467	114	the	the	DET
ihlr-20834	467	115	product	product	NOUN
ihlr-20834	467	116	.	.	PUNCT
ihlr-20834	467	117	”154	”154	PROPN
ihlr-20834	468	1	generally	generally	ADV
ihlr-20834	468	2	,	,	PUNCT
ihlr-20834	468	3	new	new	PROPN
ihlr-20834	468	4	hampshire	hampshire	PROPN
ihlr-20834	468	5	courts	court	NOUN
ihlr-20834	468	6	consider	consider	VERB
ihlr-20834	468	7	three	three	NUM
ihlr-20834	468	8	main	main	ADJ
ihlr-20834	468	9	factors	factor	NOUN
ihlr-20834	468	10	,	,	PUNCT
ihlr-20834	468	11	although	although	SCONJ
ihlr-20834	468	12	such	such	ADJ
ihlr-20834	468	13	are	be	AUX
ihlr-20834	468	14	non	non	ADJ
ihlr-20834	468	15	-	-	ADJ
ihlr-20834	468	16	exhaustive	exhaustive	ADJ
ihlr-20834	468	17	,	,	PUNCT
ihlr-20834	468	18	which	which	PRON
ihlr-20834	468	19	include	include	VERB
ihlr-20834	468	20	:	:	PUNCT
ihlr-20834	468	21	“	"	PUNCT
ihlr-20834	468	22	[	[	X
ihlr-20834	468	23	1	1	X
ihlr-20834	468	24	]	]	PUNCT
ihlr-20834	468	25	the	the	DET
ihlr-20834	468	26	usefulness	usefulness	NOUN
ihlr-20834	468	27	and	and	CCONJ
ihlr-20834	468	28	desirability	desirability	NOUN
ihlr-20834	468	29	of	of	ADP
ihlr-20834	468	30	the	the	DET
ihlr-20834	468	31	product	product	NOUN
ihlr-20834	468	32	to	to	ADP
ihlr-20834	468	33	the	the	DET
ihlr-20834	468	34	public	public	NOUN
ihlr-20834	468	35	as	as	ADP
ihlr-20834	468	36	a	a	DET
ihlr-20834	468	37	whole	whole	NOUN
ihlr-20834	468	38	,	,	PUNCT
ihlr-20834	469	1	[	[	X
ihlr-20834	469	2	2	2	X
ihlr-20834	469	3	]	]	PUNCT
ihlr-20834	469	4	whether	whether	SCONJ
ihlr-20834	469	5	the	the	DET
ihlr-20834	469	6	risk	risk	NOUN
ihlr-20834	469	7	of	of	ADP
ihlr-20834	469	8	danger	danger	NOUN
ihlr-20834	469	9	could	could	AUX
ihlr-20834	469	10	have	have	AUX
ihlr-20834	469	11	been	be	AUX
ihlr-20834	469	12	reduced	reduce	VERB
ihlr-20834	469	13	without	without	ADP
ihlr-20834	469	14	significantly	significantly	ADV
ihlr-20834	469	15	affecting	affect	VERB
ihlr-20834	469	16	either	either	CCONJ
ihlr-20834	469	17	the	the	DET
ihlr-20834	469	18	product	product	NOUN
ihlr-20834	469	19	’s	’s	PART
ihlr-20834	469	20	effectiveness	effectiveness	NOUN
ihlr-20834	469	21	or	or	CCONJ
ihlr-20834	469	22	manufacturing	manufacturing	NOUN
ihlr-20834	469	23	cost	cost	NOUN
ihlr-20834	469	24	,	,	PUNCT
ihlr-20834	469	25	and	and	CCONJ
ihlr-20834	469	26	[	[	X
ihlr-20834	469	27	3	3	X
ihlr-20834	469	28	]	]	X
ihlr-20834	469	29	the	the	DET
ihlr-20834	469	30	presence	presence	NOUN
ihlr-20834	469	31	and	and	CCONJ
ihlr-20834	469	32	efficacy	efficacy	NOUN
ihlr-20834	469	33	of	of	ADP
ihlr-20834	469	34	a	a	DET
ihlr-20834	469	35	warning	warning	NOUN
ihlr-20834	469	36	to	to	PART
ihlr-20834	469	37	avoid	avoid	VERB
ihlr-20834	469	38	an	an	DET
ihlr-20834	469	39	unreasonable	unreasonable	ADJ
ihlr-20834	469	40	risk	risk	NOUN
ihlr-20834	469	41	of	of	ADP
ihlr-20834	469	42	harm	harm	NOUN
ihlr-20834	469	43	from	from	ADP
ihlr-20834	469	44	hidden	hidden	ADJ
ihlr-20834	469	45	dangers	danger	NOUN
ihlr-20834	469	46	or	or	CCONJ
ihlr-20834	469	47	from	from	ADP
ihlr-20834	469	48	foreseeable	foreseeable	ADJ
ihlr-20834	469	49	uses	use	NOUN
ihlr-20834	469	50	.	.	PUNCT
ihlr-20834	469	51	”	"	PUNCT
ihlr-20834	470	1	155	155	NUM
ihlr-20834	470	2	the	the	DET
ihlr-20834	470	3	supreme	supreme	PROPN
ihlr-20834	470	4	court	court	PROPN
ihlr-20834	470	5	reasoned	reason	VERB
ihlr-20834	470	6	in	in	ADP
ihlr-20834	470	7	their	their	PRON
ihlr-20834	470	8	decision	decision	NOUN
ihlr-20834	470	9	that	that	SCONJ
ihlr-20834	470	10	increasing	increase	VERB
ihlr-20834	470	11	sulindac	sulindac	NOUN
ihlr-20834	470	12	’s	’s	PART
ihlr-20834	470	13	“	"	PUNCT
ihlr-20834	470	14	usefulness	usefulness	NOUN
ihlr-20834	470	15	”	"	PUNCT
ihlr-20834	470	16	or	or	CCONJ
ihlr-20834	470	17	reducing	reduce	VERB
ihlr-20834	470	18	its	its	PRON
ihlr-20834	470	19	“	"	PUNCT
ihlr-20834	470	20	risk	risk	NOUN
ihlr-20834	470	21	of	of	ADP
ihlr-20834	470	22	danger	danger	NOUN
ihlr-20834	470	23	”	"	PUNCT
ihlr-20834	470	24	was	be	AUX
ihlr-20834	470	25	not	not	PART
ihlr-20834	470	26	possible	possible	ADJ
ihlr-20834	470	27	because	because	SCONJ
ihlr-20834	470	28	the	the	DET
ihlr-20834	470	29	fdca	fdca	NOUN
ihlr-20834	470	30	explicitly	explicitly	ADV
ihlr-20834	470	31	requires	require	VERB
ihlr-20834	470	32	generic	generic	ADJ
ihlr-20834	470	33	drugs	drug	NOUN
ihlr-20834	470	34	to	to	PART
ihlr-20834	470	35	have	have	VERB
ihlr-20834	470	36	the	the	DET
ihlr-20834	470	37	same	same	ADJ
ihlr-20834	470	38	active	active	ADJ
ihlr-20834	470	39	ingredients	ingredient	NOUN
ihlr-20834	470	40	156	156	NUM
ihlr-20834	470	41	and	and	CCONJ
ihlr-20834	470	42	because	because	SCONJ
ihlr-20834	470	43	the	the	DET
ihlr-20834	470	44	simple	simple	ADJ
ihlr-20834	470	45	composition	composition	NOUN
ihlr-20834	470	46	of	of	ADP
ihlr-20834	470	47	sulindac	sulindac	NOUN
ihlr-20834	470	48	prevented	prevent	VERB
ihlr-20834	470	49	it	it	PRON
ihlr-20834	470	50	from	from	ADP
ihlr-20834	470	51	being	be	AUX
ihlr-20834	470	52	redesigned.157	redesigned.157	NOUN
ihlr-20834	470	53	the	the	DET
ihlr-20834	470	54	court	court	NOUN
ihlr-20834	470	55	further	far	ADV
ihlr-20834	470	56	reasoned	reason	VERB
ihlr-20834	470	57	that	that	SCONJ
ihlr-20834	470	58	strengthening	strengthen	VERB
ihlr-20834	470	59	sulindac	sulindac	NOUN
ihlr-20834	470	60	’s	’s	PART
ihlr-20834	470	61	warning	warning	NOUN
ihlr-20834	470	62	label	label	NOUN
ihlr-20834	470	63	was	be	AUX
ihlr-20834	470	64	mutual	mutual	ADJ
ihlr-20834	470	65	pharmaceutical	pharmaceutical	NOUN
ihlr-20834	470	66	’s	’s	PART
ihlr-20834	470	67	only	only	ADJ
ihlr-20834	470	68	way	way	NOUN
ihlr-20834	470	69	to	to	PART
ihlr-20834	470	70	minimize	minimize	VERB
ihlr-20834	470	71	its	its	PRON
ihlr-20834	470	72	“	"	PUNCT
ihlr-20834	470	73	risk	risk	NOUN
ihlr-20834	470	74	-	-	PUNCT
ihlr-20834	470	75	utility	utility	NOUN
ihlr-20834	470	76	”	"	PUNCT
ihlr-20834	470	77	profile	profile	NOUN
ihlr-20834	470	78	.	.	PUNCT
ihlr-20834	471	1	158	158	NUM
ihlr-20834	471	2	therefore	therefore	ADV
ihlr-20834	471	3	,	,	PUNCT
ihlr-20834	471	4	because	because	SCONJ
ihlr-20834	471	5	mutual	mutual	ADJ
ihlr-20834	471	6	pharmaceutical	pharmaceutical	NOUN
ihlr-20834	471	7	was	be	AUX
ihlr-20834	471	8	not	not	PART
ihlr-20834	471	9	permitted	permit	VERB
ihlr-20834	471	10	to	to	PART
ihlr-20834	471	11	strengthen	strengthen	VERB
ihlr-20834	471	12	their	their	PRON
ihlr-20834	471	13	label	label	NOUN
ihlr-20834	471	14	,	,	PUNCT
ihlr-20834	471	15	150	150	NUM
ihlr-20834	471	16	i	i	NOUN
ihlr-20834	471	17	d.	d.	PROPN
ihlr-20834	471	18	151	151	NUM
ihlr-20834	472	1	i	i	PRON
ihlr-20834	472	2	d.	d.	PROPN
ihlr-20834	472	3	152	152	NUM
ihlr-20834	473	1	i	i	PRON
ihlr-20834	473	2	d.	d.	PROPN
ihlr-20834	473	3	at	at	ADP
ihlr-20834	473	4	2473	2473	NUM
ihlr-20834	473	5	.	.	PUNCT
ihlr-20834	474	1	153	153	NUM
ihlr-20834	474	2	i	i	PROPN
ihlr-20834	474	3	d.	d.	PROPN
ihlr-20834	474	4	at	at	ADP
ihlr-20834	474	5	2474	2474	NUM
ihlr-20834	474	6	.	.	PUNCT
ihlr-20834	475	1	154	154	NUM
ihlr-20834	475	2	i	i	PRON
ihlr-20834	475	3	d.	d.	PROPN
ihlr-20834	475	4	155	155	NUM
ihlr-20834	476	1	i	i	PROPN
ihlr-20834	476	2	d.	d.	PROPN
ihlr-20834	476	3	at	at	ADP
ihlr-20834	476	4	2475	2475	NUM
ihlr-20834	476	5	.	.	PUNCT
ihlr-20834	477	1	156	156	NUM
ihlr-20834	477	2	21	21	NUM
ihlr-20834	477	3	u.s.c	u.s.c	NOUN
ihlr-20834	477	4	.	.	PUNCT
ihlr-20834	478	1	§	§	PROPN
ihlr-20834	478	2	§	§	PROPN
ihlr-20834	478	3	355(j)(2)(a)(ii)-(iii	355(j)(2)(a)(ii)-(iii	NUM
ihlr-20834	478	4	)	)	PUNCT
ihlr-20834	478	5	(	(	PUNCT
ihlr-20834	478	6	2015	2015	NUM
ihlr-20834	478	7	)	)	PUNCT
ihlr-20834	478	8	.	.	PUNCT
ihlr-20834	479	1	157	157	NUM
ihlr-20834	479	2	mut	mut	NOUN
ihlr-20834	479	3	.	.	PUNCT
ihlr-20834	480	1	pharm	pharm	PROPN
ihlr-20834	480	2	.	.	PUNCT
ihlr-20834	481	1	co.	co.	PROPN
ihlr-20834	481	2	,	,	PUNCT
ihlr-20834	481	3	133	133	NUM
ihlr-20834	481	4	s.ct	s.ct	NOUN
ihlr-20834	481	5	.	.	PUNCT
ihlr-20834	481	6	at	at	ADP
ihlr-20834	481	7	2475	2475	NUM
ihlr-20834	481	8	.	.	PUNCT
ihlr-20834	482	1	158	158	NUM
ihlr-20834	483	1	i	i	PRON
ihlr-20834	483	2	d.	d.	PROPN
ihlr-20834	483	3	794	794	NUM
ihlr-20834	483	4	indiana	indiana	PROPN
ihlr-20834	483	5	health	health	PROPN
ihlr-20834	483	6	law	law	PROPN
ihlr-20834	483	7	review	review	NOUN
ihlr-20834	483	8	vol	vol	NOUN
ihlr-20834	483	9	.	.	PUNCT
ihlr-20834	484	1	12:2	12:2	NUM
ihlr-20834	484	2	the	the	DET
ihlr-20834	484	3	court	court	NOUN
ihlr-20834	484	4	concluded	conclude	VERB
ihlr-20834	484	5	that	that	SCONJ
ihlr-20834	484	6	federal	federal	ADJ
ihlr-20834	484	7	law	law	NOUN
ihlr-20834	484	8	as	as	SCONJ
ihlr-20834	484	9	discussed	discuss	VERB
ihlr-20834	484	10	under	under	ADP
ihlr-20834	484	11	pliva	pliva	NOUN
ihlr-20834	484	12	prevented	prevent	VERB
ihlr-20834	484	13	a	a	DET
ihlr-20834	484	14	unilateral	unilateral	ADJ
ihlr-20834	484	15	change	change	NOUN
ihlr-20834	484	16	to	to	ADP
ihlr-20834	484	17	sulindac	sulindac	PROPN
ihlr-20834	484	18	’s	’s	ADV
ihlr-20834	484	19	label.159	label.159	NUM
ihlr-20834	484	20	the	the	DET
ihlr-20834	484	21	court	court	NOUN
ihlr-20834	484	22	’s	’s	PART
ihlr-20834	484	23	holding	hold	VERB
ihlr-20834	484	24	presupposes	presuppose	NOUN
ihlr-20834	484	25	that	that	SCONJ
ihlr-20834	484	26	drug	drug	NOUN
ihlr-20834	484	27	manufacturers	manufacturer	NOUN
ihlr-20834	484	28	have	have	VERB
ihlr-20834	484	29	a	a	DET
ihlr-20834	484	30	right	right	NOUN
ihlr-20834	484	31	to	to	PART
ihlr-20834	484	32	continue	continue	VERB
ihlr-20834	484	33	to	to	PART
ihlr-20834	484	34	sell	sell	VERB
ihlr-20834	484	35	drugs	drug	NOUN
ihlr-20834	484	36	free	free	ADJ
ihlr-20834	484	37	of	of	ADP
ihlr-20834	484	38	liability	liability	NOUN
ihlr-20834	484	39	once	once	ADV
ihlr-20834	484	40	approval	approval	NOUN
ihlr-20834	484	41	has	have	AUX
ihlr-20834	484	42	been	be	AUX
ihlr-20834	484	43	given	give	VERB
ihlr-20834	484	44	.	.	PUNCT
ihlr-20834	485	1	160	160	NUM
ihlr-20834	485	2	however	however	ADV
ihlr-20834	485	3	,	,	PUNCT
ihlr-20834	485	4	rejecting	reject	VERB
ihlr-20834	485	5	impossibility	impossibility	NOUN
ihlr-20834	485	6	preemption	preemption	NOUN
ihlr-20834	485	7	here	here	ADV
ihlr-20834	485	8	would	would	AUX
ihlr-20834	485	9	not	not	PART
ihlr-20834	485	10	render	render	VERB
ihlr-20834	485	11	preemption	preemption	NOUN
ihlr-20834	485	12	a	a	DET
ihlr-20834	485	13	“	"	PUNCT
ihlr-20834	485	14	dead	dead	ADJ
ihlr-20834	485	15	letter	letter	NOUN
ihlr-20834	485	16	”	"	PUNCT
ihlr-20834	485	17	161	161	NUM
ihlr-20834	485	18	because	because	SCONJ
ihlr-20834	485	19	mutual	mutual	ADJ
ihlr-20834	485	20	pharmaceutical	pharmaceutical	NOUN
ihlr-20834	485	21	was	be	AUX
ihlr-20834	485	22	not	not	PART
ihlr-20834	485	23	legally	legally	ADV
ihlr-20834	485	24	obligated	obligate	VERB
ihlr-20834	485	25	by	by	ADP
ihlr-20834	485	26	new	new	PROPN
ihlr-20834	485	27	hampshire	hampshire	PROPN
ihlr-20834	485	28	’s	’s	PART
ihlr-20834	485	29	design	design	NOUN
ihlr-20834	485	30	-	-	PUNCT
ihlr-20834	485	31	defect	defect	NOUN
ihlr-20834	485	32	law	law	NOUN
ihlr-20834	485	33	to	to	PART
ihlr-20834	485	34	modify	modify	VERB
ihlr-20834	485	35	its	its	PRON
ihlr-20834	485	36	label	label	NOUN
ihlr-20834	485	37	in	in	ADP
ihlr-20834	485	38	a	a	DET
ihlr-20834	485	39	way	way	NOUN
ihlr-20834	485	40	that	that	PRON
ihlr-20834	485	41	federal	federal	ADJ
ihlr-20834	485	42	law	law	NOUN
ihlr-20834	485	43	prohibits	prohibit	VERB
ihlr-20834	485	44	.	.	PUNCT
ihlr-20834	486	1	162	162	NUM
ihlr-20834	486	2	under	under	ADP
ihlr-20834	486	3	applicable	applicable	ADJ
ihlr-20834	486	4	new	new	PROPN
ihlr-20834	486	5	hampshire	hampshire	PROPN
ihlr-20834	486	6	law	law	PROPN
ihlr-20834	486	7	,	,	PUNCT
ihlr-20834	486	8	an	an	DET
ihlr-20834	486	9	unreasonably	unreasonably	ADV
ihlr-20834	486	10	dangerous	dangerous	ADJ
ihlr-20834	486	11	drug	drug	NOUN
ihlr-20834	486	12	manufacturer	manufacturer	NOUN
ihlr-20834	486	13	has	have	VERB
ihlr-20834	486	14	several	several	ADJ
ihlr-20834	486	15	options	option	NOUN
ihlr-20834	486	16	:	:	PUNCT
ihlr-20834	486	17	“	"	PUNCT
ihlr-20834	486	18	it	it	PRON
ihlr-20834	486	19	can	can	AUX
ihlr-20834	486	20	change	change	VERB
ihlr-20834	486	21	the	the	DET
ihlr-20834	486	22	drug	drug	NOUN
ihlr-20834	486	23	’s	’s	PART
ihlr-20834	486	24	design	design	NOUN
ihlr-20834	486	25	or	or	CCONJ
ihlr-20834	486	26	label	label	NOUN
ihlr-20834	486	27	.	.	PUNCT
ihlr-20834	486	28	.	.	PUNCT
ihlr-20834	486	29	.	.	PUNCT
ihlr-20834	487	1	to	to	PART
ihlr-20834	487	2	alter	alter	VERB
ihlr-20834	487	3	its	its	PRON
ihlr-20834	487	4	risk	risk	NOUN
ihlr-20834	487	5	-	-	PUNCT
ihlr-20834	487	6	benefit	benefit	NOUN
ihlr-20834	487	7	profile	profile	NOUN
ihlr-20834	487	8	,	,	PUNCT
ihlr-20834	487	9	remove	remove	VERB
ihlr-20834	487	10	the	the	DET
ihlr-20834	487	11	drug	drug	NOUN
ihlr-20834	487	12	from	from	ADP
ihlr-20834	487	13	the	the	DET
ihlr-20834	487	14	market	market	NOUN
ihlr-20834	487	15	,	,	PUNCT
ihlr-20834	487	16	or	or	CCONJ
ihlr-20834	487	17	pay	pay	VERB
ihlr-20834	487	18	compensation	compensation	NOUN
ihlr-20834	487	19	as	as	ADP
ihlr-20834	487	20	a	a	DET
ihlr-20834	487	21	cost	cost	NOUN
ihlr-20834	487	22	of	of	ADP
ihlr-20834	487	23	doing	do	VERB
ihlr-20834	487	24	business	business	NOUN
ihlr-20834	487	25	.	.	PUNCT
ihlr-20834	488	1	”163	”163	PUNCT
ihlr-20834	488	2	therefore	therefore	ADV
ihlr-20834	488	3	,	,	PUNCT
ihlr-20834	488	4	new	new	PROPN
ihlr-20834	488	5	hampshire	hampshire	PROPN
ihlr-20834	488	6	law	law	PROPN
ihlr-20834	488	7	allowed	allow	VERB
ihlr-20834	488	8	this	this	DET
ihlr-20834	488	9	manufacturer	manufacturer	NOUN
ihlr-20834	488	10	to	to	ADP
ihlr-20834	488	11	either	either	CCONJ
ihlr-20834	488	12	remove	remove	VERB
ihlr-20834	488	13	sulindac	sulindac	NOUN
ihlr-20834	488	14	from	from	ADP
ihlr-20834	488	15	the	the	DET
ihlr-20834	488	16	market	market	NOUN
ihlr-20834	488	17	or	or	CCONJ
ihlr-20834	488	18	pay	pay	VERB
ihlr-20834	488	19	compensation	compensation	NOUN
ihlr-20834	488	20	to	to	ADP
ihlr-20834	488	21	the	the	DET
ihlr-20834	488	22	injured	injure	VERB
ihlr-20834	488	23	party	party	NOUN
ihlr-20834	488	24	as	as	ADP
ihlr-20834	488	25	a	a	DET
ihlr-20834	488	26	result	result	NOUN
ihlr-20834	488	27	of	of	ADP
ihlr-20834	488	28	the	the	DET
ihlr-20834	488	29	injury.164	injury.164	ADJ
ihlr-20834	488	30	new	new	PROPN
ihlr-20834	488	31	hampshire	hampshire	PROPN
ihlr-20834	488	32	’s	’s	PART
ihlr-20834	488	33	design	design	NOUN
ihlr-20834	488	34	-	-	PUNCT
ihlr-20834	488	35	defect	defect	NOUN
ihlr-20834	488	36	law	law	NOUN
ihlr-20834	488	37	did	do	AUX
ihlr-20834	488	38	not	not	PART
ihlr-20834	488	39	explicitly	explicitly	ADV
ihlr-20834	488	40	require	require	VERB
ihlr-20834	488	41	mutual	mutual	ADJ
ihlr-20834	488	42	to	to	PART
ihlr-20834	488	43	change	change	VERB
ihlr-20834	488	44	the	the	DET
ihlr-20834	488	45	label	label	NOUN
ihlr-20834	488	46	for	for	ADP
ihlr-20834	488	47	sulindac	sulindac	NOUN
ihlr-20834	488	48	and	and	CCONJ
ihlr-20834	488	49	it	it	PRON
ihlr-20834	488	50	did	do	AUX
ihlr-20834	488	51	not	not	PART
ihlr-20834	488	52	mandate	mandate	VERB
ihlr-20834	488	53	a	a	DET
ihlr-20834	488	54	change	change	NOUN
ihlr-20834	488	55	to	to	ADP
ihlr-20834	488	56	sulindac	sulindac	PROPN
ihlr-20834	488	57	’s	’s	PART
ihlr-20834	488	58	design	design	NOUN
ihlr-20834	488	59	.	.	PUNCT
ihlr-20834	489	1	165	165	NUM
ihlr-20834	489	2	rather	rather	ADV
ihlr-20834	489	3	,	,	PUNCT
ihlr-20834	489	4	under	under	ADP
ihlr-20834	489	5	new	new	PROPN
ihlr-20834	489	6	hampshire	hampshire	PROPN
ihlr-20834	489	7	law	law	PROPN
ihlr-20834	489	8	,	,	PUNCT
ihlr-20834	489	9	the	the	DET
ihlr-20834	489	10	warning	warning	NOUN
ihlr-20834	489	11	label	label	NOUN
ihlr-20834	489	12	is	be	AUX
ihlr-20834	489	13	one	one	NUM
ihlr-20834	489	14	factor	factor	NOUN
ihlr-20834	489	15	in	in	ADP
ihlr-20834	489	16	a	a	DET
ihlr-20834	489	17	non	non	ADJ
ihlr-20834	489	18	-	-	ADJ
ihlr-20834	489	19	exhaustive	exhaustive	ADJ
ihlr-20834	489	20	list.166	list.166	NOUN
ihlr-20834	489	21	the	the	DET
ihlr-20834	489	22	applicable	applicable	ADJ
ihlr-20834	489	23	new	new	PROPN
ihlr-20834	489	24	hampshire	hampshire	PROPN
ihlr-20834	489	25	law	law	PROPN
ihlr-20834	489	26	required	require	VERB
ihlr-20834	489	27	nothing	nothing	PRON
ihlr-20834	489	28	more	more	ADJ
ihlr-20834	489	29	than	than	ADP
ihlr-20834	489	30	compensating	compensate	VERB
ihlr-20834	489	31	an	an	DET
ihlr-20834	489	32	individual	individual	NOUN
ihlr-20834	489	33	who	who	PRON
ihlr-20834	489	34	was	be	AUX
ihlr-20834	489	35	determined	determine	VERB
ihlr-20834	489	36	by	by	ADP
ihlr-20834	489	37	a	a	DET
ihlr-20834	489	38	jury	jury	NOUN
ihlr-20834	489	39	to	to	PART
ihlr-20834	489	40	have	have	AUX
ihlr-20834	489	41	been	be	AUX
ihlr-20834	489	42	injured	injure	VERB
ihlr-20834	489	43	by	by	ADP
ihlr-20834	489	44	an	an	DET
ihlr-20834	489	45	“	"	PUNCT
ihlr-20834	489	46	unreasonably	unreasonably	ADV
ihlr-20834	489	47	dangerous	dangerous	ADJ
ihlr-20834	489	48	drug	drug	NOUN
ihlr-20834	489	49	.	.	PUNCT
ihlr-20834	489	50	”	"	PUNCT
ihlr-20834	490	1	167	167	NUM
ihlr-20834	490	2	as	as	SCONJ
ihlr-20834	490	3	the	the	DET
ihlr-20834	490	4	district	district	NOUN
ihlr-20834	490	5	court	court	NOUN
ihlr-20834	490	6	made	make	VERB
ihlr-20834	490	7	clear	clear	ADJ
ihlr-20834	490	8	,	,	PUNCT
ihlr-20834	490	9	mutual	mutual	ADJ
ihlr-20834	490	10	was	be	AUX
ihlr-20834	490	11	held	hold	VERB
ihlr-20834	490	12	liable	liable	ADJ
ihlr-20834	490	13	for	for	ADP
ihlr-20834	490	14	failing	fail	VERB
ihlr-20834	490	15	to	to	PART
ihlr-20834	490	16	adequately	adequately	ADV
ihlr-20834	490	17	label	label	VERB
ihlr-20834	490	18	sulindac	sulindac	NOUN
ihlr-20834	490	19	so	so	SCONJ
ihlr-20834	490	20	that	that	SCONJ
ihlr-20834	490	21	it	it	PRON
ihlr-20834	490	22	was	be	AUX
ihlr-20834	490	23	not	not	PART
ihlr-20834	490	24	“	"	PUNCT
ihlr-20834	490	25	unreasonably	unreasonably	ADV
ihlr-20834	490	26	dangerous	dangerous	ADJ
ihlr-20834	490	27	,	,	PUNCT
ihlr-20834	490	28	”	"	PUNCT
ihlr-20834	490	29	not	not	PART
ihlr-20834	490	30	for	for	ADP
ihlr-20834	490	31	“	"	PUNCT
ihlr-20834	490	32	failing	fail	VERB
ihlr-20834	490	33	to	to	PART
ihlr-20834	490	34	change	change	VERB
ihlr-20834	490	35	”	"	PUNCT
ihlr-20834	490	36	its	its	PRON
ihlr-20834	490	37	warning.168	warning.168	PROPN
ihlr-20834	490	38	new	new	PROPN
ihlr-20834	490	39	hampshire	hampshire	PROPN
ihlr-20834	490	40	sought	seek	VERB
ihlr-20834	490	41	to	to	PART
ihlr-20834	490	42	facilitate	facilitate	VERB
ihlr-20834	490	43	federal	federal	ADJ
ihlr-20834	490	44	statutes	statute	NOUN
ihlr-20834	490	45	by	by	ADP
ihlr-20834	490	46	providing	provide	VERB
ihlr-20834	490	47	legal	legal	ADJ
ihlr-20834	490	48	protection	protection	NOUN
ihlr-20834	490	49	to	to	ADP
ihlr-20834	490	50	its	its	PRON
ihlr-20834	490	51	residents	resident	NOUN
ihlr-20834	490	52	.	.	PUNCT
ihlr-20834	491	1	providing	provide	VERB
ihlr-20834	491	2	such	such	ADJ
ihlr-20834	491	3	legal	legal	ADJ
ihlr-20834	491	4	protection	protection	NOUN
ihlr-20834	491	5	159	159	NUM
ihlr-20834	491	6	i	i	PRON
ihlr-20834	491	7	d.	d.	PROPN
ihlr-20834	491	8	at	at	ADP
ihlr-20834	491	9	2476	2476	NUM
ihlr-20834	491	10	-	-	SYM
ihlr-20834	491	11	77	77	NUM
ihlr-20834	491	12	.	.	PUNCT
ihlr-20834	492	1	160	160	NUM
ihlr-20834	493	1	i	i	PRON
ihlr-20834	493	2	d.	d.	NOUN
ihlr-20834	493	3	at	at	ADP
ihlr-20834	493	4	2491	2491	NUM
ihlr-20834	493	5	-	-	SYM
ihlr-20834	493	6	92	92	NUM
ihlr-20834	493	7	(	(	PUNCT
ihlr-20834	493	8	sotomayor	sotomayor	PROPN
ihlr-20834	493	9	,	,	PUNCT
ihlr-20834	493	10	j.	j.	PROPN
ihlr-20834	493	11	,	,	PUNCT
ihlr-20834	493	12	dissenting	dissent	VERB
ihlr-20834	493	13	)	)	PUNCT
ihlr-20834	493	14	.	.	PUNCT
ihlr-20834	494	1	161	161	NUM
ihlr-20834	495	1	i	i	PRON
ihlr-20834	495	2	d.	d.	PROPN
ihlr-20834	495	3	at	at	ADP
ihlr-20834	495	4	2492	2492	NUM
ihlr-20834	495	5	.	.	PUNCT
ihlr-20834	496	1	162	162	NUM
ihlr-20834	497	1	i	i	PRON
ihlr-20834	497	2	d.	d.	PROPN
ihlr-20834	497	3	163	163	NUM
ihlr-20834	498	1	i	i	PRON
ihlr-20834	498	2	d.	d.	PROPN
ihlr-20834	498	3	at	at	ADP
ihlr-20834	498	4	2491	2491	NUM
ihlr-20834	498	5	.	.	PUNCT
ihlr-20834	499	1	164	164	NUM
ihlr-20834	499	2	i	i	PROPN
ihlr-20834	499	3	d.	d.	PROPN
ihlr-20834	499	4	165	165	NUM
ihlr-20834	500	1	i	i	PRON
ihlr-20834	500	2	d.	d.	PROPN
ihlr-20834	500	3	at	at	ADP
ihlr-20834	500	4	2487	2487	NUM
ihlr-20834	500	5	(	(	PUNCT
ihlr-20834	500	6	sotomayor	sotomayor	PROPN
ihlr-20834	500	7	,	,	PUNCT
ihlr-20834	500	8	j.	j.	PROPN
ihlr-20834	500	9	,	,	PUNCT
ihlr-20834	500	10	dissenting	dissent	VERB
ihlr-20834	500	11	)	)	PUNCT
ihlr-20834	500	12	.	.	PUNCT
ihlr-20834	501	1	166	166	NUM
ihlr-20834	501	2	see	see	VERB
ihlr-20834	501	3	i	i	PRON
ihlr-20834	501	4	d.	d.	PROPN
ihlr-20834	501	5	at	at	ADP
ihlr-20834	501	6	2475	2475	NUM
ihlr-20834	501	7	.	.	PUNCT
ihlr-20834	502	1	167	167	NUM
ihlr-20834	503	1	i	i	PRON
ihlr-20834	503	2	d.	d.	NOUN
ihlr-20834	503	3	at	at	ADP
ihlr-20834	503	4	2489	2489	NUM
ihlr-20834	503	5	(	(	PUNCT
ihlr-20834	503	6	sotomayor	sotomayor	PROPN
ihlr-20834	503	7	,	,	PUNCT
ihlr-20834	503	8	j.	j.	PROPN
ihlr-20834	503	9	,	,	PUNCT
ihlr-20834	503	10	dissenting	dissent	VERB
ihlr-20834	503	11	)	)	PUNCT
ihlr-20834	503	12	.	.	PUNCT
ihlr-20834	504	1	168	168	NUM
ihlr-20834	505	1	i	i	PRON
ihlr-20834	505	2	d.	d.	PROPN
ihlr-20834	505	3	at	at	ADP
ihlr-20834	505	4	2490	2490	NUM
ihlr-20834	505	5	.	.	PUNCT
ihlr-20834	506	1	2015	2015	NUM
ihlr-20834	506	2	795	795	NUM
ihlr-20834	506	3	the	the	DET
ihlr-20834	506	4	supreme	supreme	PROPN
ihlr-20834	506	5	court	court	PROPN
ihlr-20834	506	6	’s	’s	PART
ihlr-20834	506	7	overreaching	overreach	VERB
ihlr-20834	506	8	preemption	preemption	NOUN
ihlr-20834	506	9	interpretation	interpretation	NOUN
ihlr-20834	506	10	and	and	CCONJ
ihlr-20834	506	11	it	it	PRON
ihlr-20834	506	12	’s	’	VERB
ihlr-20834	506	13	consequences	consequence	NOUN
ihlr-20834	506	14	is	be	AUX
ihlr-20834	506	15	“	"	PUNCT
ihlr-20834	506	16	a	a	DET
ihlr-20834	506	17	choice	choice	NOUN
ihlr-20834	506	18	that	that	PRON
ihlr-20834	506	19	a	a	DET
ihlr-20834	506	20	sovereign	sovereign	ADJ
ihlr-20834	506	21	state	state	NOUN
ihlr-20834	506	22	may	may	AUX
ihlr-20834	506	23	[	[	X
ihlr-20834	506	24	and	and	CCONJ
ihlr-20834	506	25	often	often	ADV
ihlr-20834	506	26	does	do	AUX
ihlr-20834	506	27	]	]	X
ihlr-20834	506	28	impose	impose	VERB
ihlr-20834	506	29	to	to	PART
ihlr-20834	506	30	protect	protect	VERB
ihlr-20834	506	31	its	its	PRON
ihlr-20834	506	32	citizens	citizen	NOUN
ihlr-20834	506	33	from	from	ADP
ihlr-20834	506	34	dangerous	dangerous	ADJ
ihlr-20834	506	35	drugs	drug	NOUN
ihlr-20834	506	36	or	or	CCONJ
ihlr-20834	506	37	.	.	PUNCT
ihlr-20834	506	38	.	.	PUNCT
ihlr-20834	506	39	.	.	PUNCT
ihlr-20834	507	1	ensure	ensure	VERB
ihlr-20834	507	2	that	that	SCONJ
ihlr-20834	507	3	seriously	seriously	ADV
ihlr-20834	507	4	injured	injure	VERB
ihlr-20834	507	5	consumers	consumer	NOUN
ihlr-20834	507	6	receive	receive	VERB
ihlr-20834	507	7	compensation	compensation	NOUN
ihlr-20834	507	8	.	.	PUNCT
ihlr-20834	507	9	”169	”169	PUNCT
ihlr-20834	508	1	manufacturers	manufacturer	NOUN
ihlr-20834	508	2	should	should	AUX
ihlr-20834	508	3	have	have	VERB
ihlr-20834	508	4	a	a	DET
ihlr-20834	508	5	duty	duty	NOUN
ihlr-20834	508	6	to	to	PART
ihlr-20834	508	7	monitor	monitor	VERB
ihlr-20834	508	8	the	the	DET
ihlr-20834	508	9	safety	safety	NOUN
ihlr-20834	508	10	and	and	CCONJ
ihlr-20834	508	11	efficacy	efficacy	NOUN
ihlr-20834	508	12	of	of	ADP
ihlr-20834	508	13	their	their	PRON
ihlr-20834	508	14	products	product	NOUN
ihlr-20834	508	15	by	by	ADP
ihlr-20834	508	16	being	be	AUX
ihlr-20834	508	17	required	require	VERB
ihlr-20834	508	18	to	to	PART
ihlr-20834	508	19	approach	approach	VERB
ihlr-20834	508	20	the	the	DET
ihlr-20834	508	21	fda	fda	PROPN
ihlr-20834	508	22	to	to	PART
ihlr-20834	508	23	propose	propose	VERB
ihlr-20834	508	24	label	label	NOUN
ihlr-20834	508	25	changes	change	NOUN
ihlr-20834	508	26	when	when	SCONJ
ihlr-20834	508	27	necessary	necessary	ADJ
ihlr-20834	508	28	.	.	PUNCT
ihlr-20834	509	1	it	it	PRON
ihlr-20834	509	2	has	have	AUX
ihlr-20834	509	3	remained	remain	VERB
ihlr-20834	509	4	central	central	ADJ
ihlr-20834	509	5	to	to	PART
ihlr-20834	509	6	fdca	fdca	VERB
ihlr-20834	509	7	and	and	CCONJ
ihlr-20834	509	8	fda	fda	PROPN
ihlr-20834	509	9	regulations	regulation	NOUN
ihlr-20834	509	10	that	that	SCONJ
ihlr-20834	509	11	a	a	DET
ihlr-20834	509	12	drug	drug	NOUN
ihlr-20834	509	13	manufacturer	manufacturer	NOUN
ihlr-20834	509	14	bears	bear	VERB
ihlr-20834	509	15	the	the	DET
ihlr-20834	509	16	responsibility	responsibility	NOUN
ihlr-20834	509	17	for	for	ADP
ihlr-20834	509	18	the	the	DET
ihlr-20834	509	19	content	content	NOUN
ihlr-20834	509	20	of	of	ADP
ihlr-20834	509	21	its	its	PRON
ihlr-20834	509	22	label	label	NOUN
ihlr-20834	509	23	“	"	PUNCT
ihlr-20834	509	24	at	at	ADP
ihlr-20834	509	25	all	all	DET
ihlr-20834	509	26	times	time	NOUN
ihlr-20834	509	27	.	.	PUNCT
ihlr-20834	509	28	”	"	PUNCT
ihlr-20834	510	1	170	170	NUM
ihlr-20834	510	2	additionally	additionally	ADV
ihlr-20834	510	3	,	,	PUNCT
ihlr-20834	510	4	if	if	SCONJ
ihlr-20834	510	5	congress	congress	PROPN
ihlr-20834	510	6	thought	think	VERB
ihlr-20834	510	7	that	that	SCONJ
ihlr-20834	510	8	state	state	NOUN
ihlr-20834	510	9	-	-	PUNCT
ihlr-20834	510	10	law	law	NOUN
ihlr-20834	510	11	causes	cause	NOUN
ihlr-20834	510	12	of	of	ADP
ihlr-20834	510	13	action	action	NOUN
ihlr-20834	510	14	(	(	PUNCT
ihlr-20834	510	15	such	such	ADJ
ihlr-20834	510	16	as	as	ADP
ihlr-20834	510	17	new	new	PROPN
ihlr-20834	510	18	hampshire	hampshire	PROPN
ihlr-20834	510	19	’s	’s	PART
ihlr-20834	510	20	discussed	discuss	VERB
ihlr-20834	510	21	in	in	ADP
ihlr-20834	510	22	bartlett	bartlett	NOUN
ihlr-20834	510	23	)	)	PUNCT
ihlr-20834	510	24	posed	pose	VERB
ihlr-20834	510	25	an	an	DET
ihlr-20834	510	26	obstacle	obstacle	NOUN
ihlr-20834	510	27	to	to	ADP
ihlr-20834	510	28	statutory	statutory	ADJ
ihlr-20834	510	29	objectives	objective	NOUN
ihlr-20834	510	30	,	,	PUNCT
ihlr-20834	510	31	it	it	PRON
ihlr-20834	510	32	surely	surely	ADV
ihlr-20834	510	33	would	would	AUX
ihlr-20834	510	34	have	have	AUX
ihlr-20834	510	35	enacted	enact	VERB
ihlr-20834	510	36	express	express	ADJ
ihlr-20834	510	37	preemption	preemption	NOUN
ihlr-20834	510	38	provisions	provision	NOUN
ihlr-20834	510	39	at	at	ADP
ihlr-20834	510	40	some	some	DET
ihlr-20834	510	41	point	point	NOUN
ihlr-20834	510	42	during	during	ADP
ihlr-20834	510	43	the	the	DET
ihlr-20834	510	44	fdca	fdca	NOUN
ihlr-20834	510	45	’s	’s	PART
ihlr-20834	510	46	seventy	seventy	NUM
ihlr-20834	510	47	-	-	PUNCT
ihlr-20834	510	48	year	year	NOUN
ihlr-20834	510	49	history	history	NOUN
ihlr-20834	510	50	.	.	PUNCT
ihlr-20834	511	1	congress	congress	PROPN
ihlr-20834	511	2	had	have	VERB
ihlr-20834	511	3	the	the	DET
ihlr-20834	511	4	opportunity	opportunity	NOUN
ihlr-20834	511	5	to	to	PART
ihlr-20834	511	6	explicitly	explicitly	ADV
ihlr-20834	511	7	apply	apply	VERB
ihlr-20834	511	8	the	the	DET
ihlr-20834	511	9	preemption	preemption	NOUN
ihlr-20834	511	10	doctrine	doctrine	NOUN
ihlr-20834	511	11	to	to	ADP
ihlr-20834	511	12	pharmaceuticals	pharmaceutical	NOUN
ihlr-20834	511	13	,	,	PUNCT
ihlr-20834	511	14	yet	yet	CCONJ
ihlr-20834	511	15	it	it	PRON
ihlr-20834	511	16	declined	decline	VERB
ihlr-20834	511	17	to	to	PART
ihlr-20834	511	18	do	do	VERB
ihlr-20834	511	19	so	so	ADV
ihlr-20834	511	20	and	and	CCONJ
ihlr-20834	511	21	only	only	ADV
ihlr-20834	511	22	applied	apply	VERB
ihlr-20834	511	23	it	it	PRON
ihlr-20834	511	24	to	to	ADP
ihlr-20834	511	25	medical	medical	ADJ
ihlr-20834	511	26	devices.171	devices.171	NOUN
ihlr-20834	511	27	congress	congress	PROPN
ihlr-20834	511	28	has	have	AUX
ihlr-20834	511	29	never	never	ADV
ihlr-20834	511	30	explicitly	explicitly	ADV
ihlr-20834	511	31	preempted	preempt	VERB
ihlr-20834	511	32	state	state	NOUN
ihlr-20834	511	33	law	law	NOUN
ihlr-20834	511	34	tort	tort	NOUN
ihlr-20834	511	35	claims	claim	NOUN
ihlr-20834	511	36	against	against	ADP
ihlr-20834	511	37	drug	drug	NOUN
ihlr-20834	511	38	manufacturers	manufacturer	NOUN
ihlr-20834	511	39	.	.	PUNCT
ihlr-20834	512	1	172	172	NUM
ihlr-20834	512	2	while	while	SCONJ
ihlr-20834	512	3	it	it	PRON
ihlr-20834	512	4	is	be	AUX
ihlr-20834	512	5	possible	possible	ADJ
ihlr-20834	512	6	the	the	DET
ihlr-20834	512	7	court	court	NOUN
ihlr-20834	512	8	’s	’s	PART
ihlr-20834	512	9	“	"	PUNCT
ihlr-20834	512	10	statement	statement	NOUN
ihlr-20834	512	11	that	that	PRON
ihlr-20834	512	12	tort	tort	NOUN
ihlr-20834	512	13	remedies	remedy	NOUN
ihlr-20834	512	14	and	and	CCONJ
ihlr-20834	512	15	direct	direct	ADJ
ihlr-20834	512	16	regulation	regulation	NOUN
ihlr-20834	512	17	do	do	VERB
ihlr-20834	512	18	‘	'	PUNCT
ihlr-20834	512	19	the	the	DET
ihlr-20834	512	20	same	same	ADJ
ihlr-20834	512	21	thing	thing	NOUN
ihlr-20834	512	22	’	'	PUNCT
ihlr-20834	512	23	may	may	AUX
ihlr-20834	512	24	fade	fade	VERB
ihlr-20834	512	25	away	away	ADV
ihlr-20834	512	26	when	when	SCONJ
ihlr-20834	512	27	the	the	DET
ihlr-20834	512	28	court	court	NOUN
ihlr-20834	512	29	again	again	ADV
ihlr-20834	512	30	is	be	AUX
ihlr-20834	512	31	presented	present	VERB
ihlr-20834	512	32	with	with	ADP
ihlr-20834	512	33	the	the	DET
ihlr-20834	512	34	issue	issue	NOUN
ihlr-20834	512	35	and	and	CCONJ
ihlr-20834	512	36	has	have	VERB
ihlr-20834	512	37	the	the	DET
ihlr-20834	512	38	opportunity	opportunity	NOUN
ihlr-20834	512	39	to	to	PART
ihlr-20834	512	40	treat	treat	VERB
ihlr-20834	512	41	it	it	PRON
ihlr-20834	512	42	with	with	ADP
ihlr-20834	512	43	more	more	ADJ
ihlr-20834	512	44	care	care	NOUN
ihlr-20834	513	1	[	[	X
ihlr-20834	513	2	,	,	PUNCT
ihlr-20834	513	3	]	]	X
ihlr-20834	513	4	”	"	PUNCT
ihlr-20834	513	5	173	173	NUM
ihlr-20834	513	6	irreparable	irreparable	ADJ
ihlr-20834	513	7	harm	harm	NOUN
ihlr-20834	513	8	will	will	AUX
ihlr-20834	513	9	likely	likely	ADV
ihlr-20834	513	10	occur	occur	VERB
ihlr-20834	513	11	if	if	SCONJ
ihlr-20834	513	12	this	this	DET
ihlr-20834	513	13	issue	issue	NOUN
ihlr-20834	513	14	is	be	AUX
ihlr-20834	513	15	not	not	PART
ihlr-20834	513	16	addressed	address	VERB
ihlr-20834	513	17	sooner	soon	ADV
ihlr-20834	513	18	.	.	PUNCT
ihlr-20834	514	1	b.	b.	PROPN
ihlr-20834	514	2	indiana	indiana	PROPN
ihlr-20834	514	3	’s	’s	PART
ihlr-20834	514	4	statutory	statutory	ADJ
ihlr-20834	514	5	analysis	analysis	NOUN
ihlr-20834	514	6	and	and	CCONJ
ihlr-20834	514	7	the	the	DET
ihlr-20834	514	8	importance	importance	NOUN
ihlr-20834	514	9	of	of	ADP
ihlr-20834	514	10	state	state	NOUN
ihlr-20834	514	11	law	law	NOUN
ihlr-20834	514	12	state	state	NOUN
ihlr-20834	514	13	tort	tort	NOUN
ihlr-20834	514	14	law	law	NOUN
ihlr-20834	514	15	causes	cause	VERB
ihlr-20834	514	16	-	-	PUNCT
ihlr-20834	514	17	of	of	ADP
ihlr-20834	514	18	-	-	PUNCT
ihlr-20834	514	19	action	action	NOUN
ihlr-20834	514	20	provide	provide	VERB
ihlr-20834	514	21	remedies	remedy	NOUN
ihlr-20834	514	22	to	to	ADP
ihlr-20834	514	23	individuals	individual	NOUN
ihlr-20834	514	24	harmed	harm	VERB
ihlr-20834	514	25	by	by	ADP
ihlr-20834	514	26	the	the	DET
ihlr-20834	514	27	negligent	negligent	ADJ
ihlr-20834	514	28	acts	act	NOUN
ihlr-20834	514	29	of	of	ADP
ihlr-20834	514	30	others	other	NOUN
ihlr-20834	514	31	.	.	PUNCT
ihlr-20834	515	1	tort	tort	NOUN
ihlr-20834	515	2	laws	law	NOUN
ihlr-20834	515	3	play	play	VERB
ihlr-20834	515	4	an	an	DET
ihlr-20834	515	5	important	important	ADJ
ihlr-20834	515	6	role	role	NOUN
ihlr-20834	515	7	in	in	ADP
ihlr-20834	515	8	filling	fill	VERB
ihlr-20834	515	9	gaps	gap	NOUN
ihlr-20834	515	10	in	in	ADP
ihlr-20834	515	11	federal	federal	ADJ
ihlr-20834	515	12	law	law	NOUN
ihlr-20834	515	13	and	and	CCONJ
ihlr-20834	515	14	in	in	ADP
ihlr-20834	515	15	discovering	discover	VERB
ihlr-20834	515	16	risks	risk	NOUN
ihlr-20834	515	17	and	and	CCONJ
ihlr-20834	515	18	“	"	PUNCT
ihlr-20834	515	19	in	in	ADP
ihlr-20834	515	20	providing	provide	VERB
ihlr-20834	515	21	incentives	incentive	NOUN
ihlr-20834	515	22	for	for	SCONJ
ihlr-20834	515	23	manufacturers	manufacturer	NOUN
ihlr-20834	515	24	to	to	PART
ihlr-20834	515	25	remove	remove	VERB
ihlr-20834	515	26	dangerous	dangerous	ADJ
ihlr-20834	515	27	products	product	NOUN
ihlr-20834	515	28	from	from	ADP
ihlr-20834	515	29	the	the	DET
ihlr-20834	515	30	market	market	NOUN
ihlr-20834	515	31	promptly	promptly	ADV
ihlr-20834	515	32	.	.	PUNCT
ihlr-20834	515	33	”	"	PUNCT
ihlr-20834	516	1	174	174	NUM
ihlr-20834	516	2	in	in	ADP
ihlr-20834	516	3	holding	hold	VERB
ihlr-20834	516	4	a	a	DET
ihlr-20834	516	5	particular	particular	ADJ
ihlr-20834	516	6	state	state	NOUN
ihlr-20834	516	7	law	law	NOUN
ihlr-20834	516	8	169	169	NUM
ihlr-20834	517	1	i	i	PRON
ihlr-20834	517	2	d.	d.	PROPN
ihlr-20834	517	3	at	at	ADP
ihlr-20834	517	4	2491	2491	NUM
ihlr-20834	517	5	.	.	PUNCT
ihlr-20834	518	1	170	170	NUM
ihlr-20834	518	2	wyeth	wyeth	PROPN
ihlr-20834	518	3	v.	v.	PROPN
ihlr-20834	518	4	levine	levine	PROPN
ihlr-20834	518	5	,	,	PUNCT
ihlr-20834	518	6	555	555	NUM
ihlr-20834	518	7	u.s	u.s	PROPN
ihlr-20834	518	8	.	.	PROPN
ihlr-20834	518	9	555	555	NUM
ihlr-20834	518	10	,	,	PUNCT
ihlr-20834	518	11	570	570	NUM
ihlr-20834	518	12	-	-	SYM
ihlr-20834	518	13	71	71	NUM
ihlr-20834	518	14	(	(	PUNCT
ihlr-20834	518	15	2009	2009	NUM
ihlr-20834	518	16	)	)	PUNCT
ihlr-20834	518	17	.	.	PUNCT
ihlr-20834	519	1	171	171	NUM
ihlr-20834	519	2	see	see	VERB
ihlr-20834	519	3	riegel	riegel	PROPN
ihlr-20834	519	4	v.	v.	PROPN
ihlr-20834	519	5	medtronic	medtronic	PROPN
ihlr-20834	519	6	,	,	PUNCT
ihlr-20834	519	7	inc	inc	PROPN
ihlr-20834	519	8	.	.	PROPN
ihlr-20834	519	9	,	,	PUNCT
ihlr-20834	519	10	552	552	NUM
ihlr-20834	519	11	u.s	u.s	PROPN
ihlr-20834	519	12	.	.	PROPN
ihlr-20834	519	13	312	312	NUM
ihlr-20834	519	14	,	,	PUNCT
ihlr-20834	519	15	340	340	NUM
ihlr-20834	519	16	(	(	PUNCT
ihlr-20834	519	17	2008	2008	NUM
ihlr-20834	519	18	)	)	PUNCT
ihlr-20834	519	19	.	.	PUNCT
ihlr-20834	520	1	172	172	NUM
ihlr-20834	520	2	pliva	pliva	PROPN
ihlr-20834	520	3	,	,	PUNCT
ihlr-20834	520	4	inc	inc	PROPN
ihlr-20834	520	5	.	.	PROPN
ihlr-20834	521	1	v.	v.	CCONJ
ihlr-20834	521	2	mensing	mense	VERB
ihlr-20834	521	3	,	,	PUNCT
ihlr-20834	521	4	131	131	NUM
ihlr-20834	521	5	s.ct	s.ct	NOUN
ihlr-20834	521	6	.	.	PROPN
ihlr-20834	521	7	2577	2577	NUM
ihlr-20834	521	8	(	(	PUNCT
ihlr-20834	521	9	2011	2011	NUM
ihlr-20834	521	10	)	)	PUNCT
ihlr-20834	521	11	.	.	PUNCT
ihlr-20834	522	1	173	173	NUM
ihlr-20834	522	2	wolfman	wolfman	PROPN
ihlr-20834	522	3	&	&	CCONJ
ihlr-20834	522	4	king	king	PROPN
ihlr-20834	522	5	,	,	PUNCT
ihlr-20834	522	6	supra	supra	PROPN
ihlr-20834	522	7	note	note	PROPN
ihlr-20834	522	8	134	134	NUM
ihlr-20834	522	9	.	.	PUNCT
ihlr-20834	522	10	174	174	NUM
ihlr-20834	522	11	jocelyn	jocelyn	PROPN
ihlr-20834	522	12	bogdan	bogdan	PROPN
ihlr-20834	522	13	,	,	PUNCT
ihlr-20834	522	14	america	america	PROPN
ihlr-20834	522	15	’s	’s	PART
ihlr-20834	522	16	unaccountable	unaccountable	ADJ
ihlr-20834	522	17	generic	generic	ADJ
ihlr-20834	522	18	drug	drug	NOUN
ihlr-20834	522	19	796	796	NUM
ihlr-20834	522	20	indiana	indiana	PROPN
ihlr-20834	522	21	health	health	PROPN
ihlr-20834	522	22	law	law	PROPN
ihlr-20834	522	23	review	review	NOUN
ihlr-20834	522	24	vol	vol	NOUN
ihlr-20834	522	25	.	.	PUNCT
ihlr-20834	522	26	12:2	12:2	NUM
ihlr-20834	522	27	preempted	preempt	VERB
ihlr-20834	522	28	by	by	ADP
ihlr-20834	522	29	federal	federal	ADJ
ihlr-20834	522	30	law	law	NOUN
ihlr-20834	522	31	,	,	PUNCT
ihlr-20834	522	32	injured	injure	VERB
ihlr-20834	522	33	consumers	consumer	NOUN
ihlr-20834	522	34	often	often	ADV
ihlr-20834	522	35	have	have	VERB
ihlr-20834	522	36	to	to	PART
ihlr-20834	522	37	rely	rely	VERB
ihlr-20834	522	38	on	on	ADP
ihlr-20834	522	39	imperfect	imperfect	ADJ
ihlr-20834	522	40	federal	federal	ADJ
ihlr-20834	522	41	agencies	agency	NOUN
ihlr-20834	522	42	with	with	ADP
ihlr-20834	522	43	limited	limited	ADJ
ihlr-20834	522	44	resources	resource	NOUN
ihlr-20834	522	45	for	for	ADP
ihlr-20834	522	46	relief	relief	NOUN
ihlr-20834	522	47	.	.	PUNCT
ihlr-20834	523	1	175	175	NUM
ihlr-20834	523	2	because	because	SCONJ
ihlr-20834	523	3	detrimental	detrimental	ADJ
ihlr-20834	523	4	effects	effect	NOUN
ihlr-20834	523	5	may	may	AUX
ihlr-20834	523	6	occur	occur	VERB
ihlr-20834	523	7	when	when	SCONJ
ihlr-20834	523	8	federal	federal	ADJ
ihlr-20834	523	9	law	law	NOUN
ihlr-20834	523	10	preempts	preempt	VERB
ihlr-20834	523	11	state	state	NOUN
ihlr-20834	523	12	law	law	NOUN
ihlr-20834	523	13	,	,	PUNCT
ihlr-20834	523	14	congress	congress	PROPN
ihlr-20834	523	15	takes	take	VERB
ihlr-20834	523	16	affirmative	affirmative	ADJ
ihlr-20834	523	17	steps	step	NOUN
ihlr-20834	523	18	when	when	SCONJ
ihlr-20834	523	19	it	it	PRON
ihlr-20834	523	20	believes	believe	VERB
ihlr-20834	523	21	tort	tort	NOUN
ihlr-20834	523	22	law	law	NOUN
ihlr-20834	523	23	may	may	AUX
ihlr-20834	523	24	compromise	compromise	VERB
ihlr-20834	523	25	significant	significant	ADJ
ihlr-20834	523	26	federal	federal	ADJ
ihlr-20834	523	27	objectives	objective	NOUN
ihlr-20834	523	28	under	under	ADP
ihlr-20834	523	29	a	a	DET
ihlr-20834	523	30	scheme	scheme	NOUN
ihlr-20834	523	31	of	of	ADP
ihlr-20834	523	32	premarket	premarket	ADJ
ihlr-20834	523	33	regulatory	regulatory	ADJ
ihlr-20834	523	34	review	review	NOUN
ihlr-20834	523	35	for	for	ADP
ihlr-20834	523	36	products	product	NOUN
ihlr-20834	523	37	it	it	PRON
ihlr-20834	523	38	wants	want	VERB
ihlr-20834	523	39	to	to	PART
ihlr-20834	523	40	make	make	VERB
ihlr-20834	523	41	available.176	available.176	NOUN
ihlr-20834	523	42	federal	federal	ADJ
ihlr-20834	523	43	agencies	agency	NOUN
ihlr-20834	523	44	themselves	themselves	PRON
ihlr-20834	523	45	consider	consider	VERB
ihlr-20834	523	46	tort	tort	NOUN
ihlr-20834	523	47	litigation	litigation	NOUN
ihlr-20834	523	48	supplementary	supplementary	ADJ
ihlr-20834	523	49	to	to	ADP
ihlr-20834	523	50	its	its	PRON
ihlr-20834	523	51	agencies	agency	NOUN
ihlr-20834	523	52	regulations	regulation	NOUN
ihlr-20834	523	53	and	and	CCONJ
ihlr-20834	523	54	enforcement	enforcement	NOUN
ihlr-20834	523	55	activities.177	activities.177	PROPN
ihlr-20834	523	56	indiana	indiana	PROPN
ihlr-20834	523	57	law	law	PROPN
ihlr-20834	523	58	is	be	AUX
ihlr-20834	523	59	similar	similar	ADJ
ihlr-20834	523	60	to	to	ADP
ihlr-20834	523	61	new	new	PROPN
ihlr-20834	523	62	hampshire	hampshire	PROPN
ihlr-20834	523	63	law	law	PROPN
ihlr-20834	523	64	in	in	SCONJ
ihlr-20834	523	65	that	that	SCONJ
ihlr-20834	523	66	it	it	PRON
ihlr-20834	523	67	provides	provide	VERB
ihlr-20834	523	68	residents	resident	NOUN
ihlr-20834	523	69	with	with	ADP
ihlr-20834	523	70	state	state	NOUN
ihlr-20834	523	71	law	law	NOUN
ihlr-20834	523	72	causes	cause	VERB
ihlr-20834	523	73	-	-	PUNCT
ihlr-20834	523	74	of	of	ADP
ihlr-20834	523	75	-	-	PUNCT
ihlr-20834	523	76	action.178	action.178	NOUN
ihlr-20834	523	77	under	under	ADP
ihlr-20834	523	78	design	design	NOUN
ihlr-20834	523	79	-	-	PUNCT
ihlr-20834	523	80	defect	defect	NOUN
ihlr-20834	523	81	law	law	NOUN
ihlr-20834	523	82	in	in	ADP
ihlr-20834	523	83	indiana	indiana	PROPN
ihlr-20834	523	84	,	,	PUNCT
ihlr-20834	523	85	a	a	DET
ihlr-20834	523	86	product	product	NOUN
ihlr-20834	523	87	may	may	AUX
ihlr-20834	523	88	be	be	AUX
ihlr-20834	523	89	defective	defective	ADJ
ihlr-20834	523	90	through	through	ADP
ihlr-20834	523	91	manufacturing	manufacturing	NOUN
ihlr-20834	523	92	flaws	flaw	NOUN
ihlr-20834	523	93	,	,	PUNCT
ihlr-20834	523	94	defective	defective	ADJ
ihlr-20834	523	95	design	design	NOUN
ihlr-20834	523	96	,	,	PUNCT
ihlr-20834	523	97	or	or	CCONJ
ihlr-20834	523	98	by	by	ADP
ihlr-20834	523	99	a	a	DET
ihlr-20834	523	100	failure	failure	NOUN
ihlr-20834	523	101	to	to	PART
ihlr-20834	523	102	supply	supply	VERB
ihlr-20834	523	103	complete	complete	ADJ
ihlr-20834	523	104	information	information	NOUN
ihlr-20834	523	105	about	about	ADP
ihlr-20834	523	106	the	the	DET
ihlr-20834	523	107	product	product	NOUN
ihlr-20834	523	108	’s	’s	PART
ihlr-20834	523	109	dangers.179	dangers.179	ADJ
ihlr-20834	523	110	to	to	PART
ihlr-20834	523	111	establish	establish	VERB
ihlr-20834	523	112	a	a	DET
ihlr-20834	523	113	prima	prima	NOUN
ihlr-20834	523	114	facie	facie	NOUN
ihlr-20834	523	115	case	case	NOUN
ihlr-20834	523	116	of	of	ADP
ihlr-20834	523	117	strict	strict	ADJ
ihlr-20834	523	118	liability	liability	NOUN
ihlr-20834	523	119	in	in	ADP
ihlr-20834	523	120	indiana	indiana	PROPN
ihlr-20834	523	121	,	,	PUNCT
ihlr-20834	523	122	the	the	DET
ihlr-20834	523	123	plaintiff	plaintiff	NOUN
ihlr-20834	523	124	has	have	VERB
ihlr-20834	523	125	the	the	DET
ihlr-20834	523	126	burden	burden	NOUN
ihlr-20834	523	127	of	of	ADP
ihlr-20834	523	128	proving	prove	VERB
ihlr-20834	523	129	each	each	PRON
ihlr-20834	523	130	of	of	ADP
ihlr-20834	523	131	the	the	DET
ihlr-20834	523	132	following	following	NOUN
ihlr-20834	523	133	:	:	PUNCT
ihlr-20834	523	134	“	"	PUNCT
ihlr-20834	523	135	(	(	PUNCT
ihlr-20834	523	136	1	1	X
ihlr-20834	523	137	)	)	PUNCT
ihlr-20834	523	138	the	the	DET
ihlr-20834	523	139	product	product	NOUN
ihlr-20834	523	140	is	be	AUX
ihlr-20834	523	141	defective	defective	ADJ
ihlr-20834	523	142	and	and	CCONJ
ihlr-20834	523	143	unreasonably	unreasonably	ADV
ihlr-20834	523	144	dangerous	dangerous	ADJ
ihlr-20834	523	145	,	,	PUNCT
ihlr-20834	523	146	(	(	PUNCT
ihlr-20834	523	147	2	2	X
ihlr-20834	523	148	)	)	PUNCT
ihlr-20834	523	149	the	the	DET
ihlr-20834	523	150	defective	defective	ADJ
ihlr-20834	523	151	condition	condition	NOUN
ihlr-20834	523	152	existed	exist	VERB
ihlr-20834	523	153	at	at	ADP
ihlr-20834	523	154	the	the	DET
ihlr-20834	523	155	time	time	NOUN
ihlr-20834	523	156	the	the	DET
ihlr-20834	523	157	product	product	NOUN
ihlr-20834	523	158	left	leave	VERB
ihlr-20834	523	159	defendant	defendant	NOUN
ihlr-20834	523	160	’s	’s	PART
ihlr-20834	523	161	control	control	NOUN
ihlr-20834	523	162	,	,	PUNCT
ihlr-20834	523	163	and	and	CCONJ
ihlr-20834	523	164	(	(	PUNCT
ihlr-20834	523	165	3	3	X
ihlr-20834	523	166	)	)	PUNCT
ihlr-20834	523	167	the	the	DET
ihlr-20834	523	168	defective	defective	ADJ
ihlr-20834	523	169	condition	condition	NOUN
ihlr-20834	523	170	was	be	AUX
ihlr-20834	523	171	the	the	DET
ihlr-20834	523	172	proximate	proximate	NOUN
ihlr-20834	523	173	cause	cause	NOUN
ihlr-20834	523	174	of	of	ADP
ihlr-20834	523	175	the	the	DET
ihlr-20834	523	176	plaintiff	plaintiff	NOUN
ihlr-20834	523	177	’s	’s	PART
ihlr-20834	523	178	injuries	injury	NOUN
ihlr-20834	523	179	.	.	PUNCT
ihlr-20834	523	180	”180	”180	PROPN
ihlr-20834	524	1	a	a	DET
ihlr-20834	524	2	product	product	NOUN
ihlr-20834	524	3	liability	liability	NOUN
ihlr-20834	524	4	action	action	NOUN
ihlr-20834	524	5	based	base	VERB
ihlr-20834	524	6	on	on	ADP
ihlr-20834	524	7	the	the	DET
ihlr-20834	524	8	doctrine	doctrine	NOUN
ihlr-20834	524	9	of	of	ADP
ihlr-20834	524	10	strict	strict	ADJ
ihlr-20834	524	11	liability	liability	NOUN
ihlr-20834	524	12	may	may	AUX
ihlr-20834	524	13	not	not	PART
ihlr-20834	524	14	be	be	AUX
ihlr-20834	524	15	maintained	maintain	VERB
ihlr-20834	524	16	against	against	ADP
ihlr-20834	524	17	a	a	DET
ihlr-20834	524	18	seller	seller	NOUN
ihlr-20834	524	19	industry	industry	NOUN
ihlr-20834	524	20	:	:	PUNCT
ihlr-20834	524	21	how	how	SCONJ
ihlr-20834	524	22	legal	legal	ADJ
ihlr-20834	524	23	immunity	immunity	NOUN
ihlr-20834	524	24	could	could	AUX
ihlr-20834	524	25	be	be	AUX
ihlr-20834	524	26	making	make	VERB
ihlr-20834	524	27	you	you	PRON
ihlr-20834	524	28	sick	sick	ADJ
ihlr-20834	524	29	,	,	PUNCT
ihlr-20834	524	30	center	center	NOUN
ihlr-20834	524	31	for	for	ADP
ihlr-20834	524	32	justice	justice	NOUN
ihlr-20834	524	33	democracy	democracy	NOUN
ihlr-20834	524	34	(	(	PUNCT
ihlr-20834	524	35	dec	dec	PROPN
ihlr-20834	524	36	.	.	PROPN
ihlr-20834	524	37	2013	2013	NUM
ihlr-20834	524	38	)	)	PUNCT
ihlr-20834	524	39	,	,	PUNCT
ihlr-20834	524	40	http://centerjd.org/content/americasunaccountable-generic-drug-industry	http://centerjd.org/content/americasunaccountable-generic-drug-industry	PROPN
ihlr-20834	524	41	.	.	PUNCT
ihlr-20834	525	1	175	175	NUM
ihlr-20834	525	2	leslie	leslie	PROPN
ihlr-20834	525	3	pray	pray	PROPN
ihlr-20834	525	4	&	&	CCONJ
ihlr-20834	525	5	sally	sally	PROPN
ihlr-20834	525	6	robinson	robinson	PROPN
ihlr-20834	525	7	,	,	PUNCT
ihlr-20834	525	8	challenges	challenge	NOUN
ihlr-20834	525	9	for	for	ADP
ihlr-20834	525	10	the	the	DET
ihlr-20834	525	11	fda	fda	PROPN
ihlr-20834	525	12	:	:	PUNCT
ihlr-20834	525	13	the	the	DET
ihlr-20834	525	14	future	future	NOUN
ihlr-20834	525	15	of	of	ADP
ihlr-20834	525	16	drug	drug	NOUN
ihlr-20834	525	17	safety	safety	NOUN
ihlr-20834	525	18	(	(	PUNCT
ihlr-20834	525	19	2007	2007	NUM
ihlr-20834	525	20	)	)	PUNCT
ihlr-20834	525	21	,	,	PUNCT
ihlr-20834	525	22	available	available	ADJ
ihlr-20834	525	23	at	at	ADP
ihlr-20834	525	24	http://www.ncbi.nlm.nih.gov/books/nbk52926/	http://www.ncbi.nlm.nih.gov/books/nbk52926/	PROPN
ihlr-20834	525	25	(	(	PUNCT
ihlr-20834	525	26	according	accord	VERB
ihlr-20834	525	27	to	to	ADP
ihlr-20834	525	28	mr	mr	PROPN
ihlr-20834	525	29	.	.	PROPN
ihlr-20834	525	30	thompson	thompson	PROPN
ihlr-20834	525	31	,	,	PUNCT
ihlr-20834	525	32	the	the	DET
ihlr-20834	525	33	fda	fda	PROPN
ihlr-20834	525	34	has	have	AUX
ihlr-20834	525	35	been	be	AUX
ihlr-20834	525	36	chronically	chronically	ADV
ihlr-20834	525	37	under	under	ADV
ihlr-20834	525	38	-	-	PUNCT
ihlr-20834	525	39	funded	fund	VERB
ihlr-20834	525	40	in	in	ADP
ihlr-20834	525	41	carrying	carry	VERB
ihlr-20834	525	42	out	out	ADP
ihlr-20834	525	43	its	its	PRON
ihlr-20834	525	44	responsibilities	responsibility	NOUN
ihlr-20834	525	45	for	for	ADP
ihlr-20834	525	46	ensuring	ensure	VERB
ihlr-20834	525	47	the	the	DET
ihlr-20834	525	48	safety	safety	NOUN
ihlr-20834	525	49	of	of	ADP
ihlr-20834	525	50	drugs	drug	NOUN
ihlr-20834	525	51	,	,	PUNCT
ihlr-20834	525	52	medical	medical	ADJ
ihlr-20834	525	53	devices	device	NOUN
ihlr-20834	525	54	,	,	PUNCT
ihlr-20834	525	55	and	and	CCONJ
ihlr-20834	525	56	the	the	DET
ihlr-20834	525	57	nation	nation	NOUN
ihlr-20834	525	58	’s	’s	PART
ihlr-20834	525	59	food	food	NOUN
ihlr-20834	525	60	supply	supply	NOUN
ihlr-20834	525	61	.	.	PUNCT
ihlr-20834	526	1	while	while	SCONJ
ihlr-20834	526	2	the	the	DET
ihlr-20834	526	3	fda	fda	PROPN
ihlr-20834	526	4	is	be	AUX
ihlr-20834	526	5	commonly	commonly	ADV
ihlr-20834	526	6	viewed	view	VERB
ihlr-20834	526	7	as	as	ADP
ihlr-20834	526	8	the	the	DET
ihlr-20834	526	9	global	global	ADJ
ihlr-20834	526	10	gold	gold	PROPN
ihlr-20834	526	11	standard	standard	NOUN
ihlr-20834	526	12	for	for	ADP
ihlr-20834	526	13	consumer	consumer	NOUN
ihlr-20834	526	14	protection	protection	NOUN
ihlr-20834	526	15	,	,	PUNCT
ihlr-20834	526	16	it	it	PRON
ihlr-20834	526	17	faces	face	VERB
ihlr-20834	526	18	stiff	stiff	ADJ
ihlr-20834	526	19	competition	competition	NOUN
ihlr-20834	526	20	for	for	ADP
ihlr-20834	526	21	scarce	scarce	ADJ
ihlr-20834	526	22	resources	resource	NOUN
ihlr-20834	526	23	and	and	CCONJ
ihlr-20834	526	24	over	over	ADP
ihlr-20834	526	25	the	the	DET
ihlr-20834	526	26	past	past	ADJ
ihlr-20834	526	27	20	20	NUM
ihlr-20834	526	28	years	year	NOUN
ihlr-20834	526	29	has	have	AUX
ihlr-20834	526	30	been	be	AUX
ihlr-20834	526	31	tasked	task	VERB
ihlr-20834	526	32	to	to	PART
ihlr-20834	526	33	do	do	VERB
ihlr-20834	526	34	far	far	ADV
ihlr-20834	526	35	more	more	ADV
ihlr-20834	526	36	with	with	ADP
ihlr-20834	526	37	its	its	PRON
ihlr-20834	526	38	limited	limited	ADJ
ihlr-20834	526	39	resources	resource	NOUN
ihlr-20834	526	40	)	)	PUNCT
ihlr-20834	526	41	.	.	PUNCT
ihlr-20834	527	1	176	176	NUM
ihlr-20834	527	2	mut	mut	NOUN
ihlr-20834	527	3	.	.	PUNCT
ihlr-20834	528	1	pharm	pharm	PROPN
ihlr-20834	528	2	.	.	PUNCT
ihlr-20834	529	1	co.	co.	PROPN
ihlr-20834	529	2	,	,	PUNCT
ihlr-20834	529	3	inc	inc	PROPN
ihlr-20834	529	4	.	.	PROPN
ihlr-20834	530	1	v.	v.	ADP
ihlr-20834	530	2	bartlett	bartlett	PROPN
ihlr-20834	530	3	,	,	PUNCT
ihlr-20834	530	4	133	133	NUM
ihlr-20834	530	5	s.ct	s.ct	NOUN
ihlr-20834	530	6	.	.	PROPN
ihlr-20834	530	7	2466	2466	NUM
ihlr-20834	530	8	,	,	PUNCT
ihlr-20834	530	9	2496	2496	NUM
ihlr-20834	530	10	(	(	PUNCT
ihlr-20834	530	11	2013	2013	NUM
ihlr-20834	530	12	)	)	PUNCT
ihlr-20834	530	13	(	(	PUNCT
ihlr-20834	530	14	sotomayor	sotomayor	PROPN
ihlr-20834	530	15	,	,	PUNCT
ihlr-20834	530	16	j.	j.	PROPN
ihlr-20834	530	17	,	,	PUNCT
ihlr-20834	530	18	dissenting	dissent	VERB
ihlr-20834	530	19	)	)	PUNCT
ihlr-20834	530	20	.	.	PUNCT
ihlr-20834	531	1	177	177	NUM
ihlr-20834	531	2	i	i	PRON
ihlr-20834	531	3	d.	d.	PROPN
ihlr-20834	531	4	at	at	ADP
ihlr-20834	531	5	2485	2485	NUM
ihlr-20834	531	6	.	.	PUNCT
ihlr-20834	532	1	see	see	VERB
ihlr-20834	532	2	also	also	ADV
ihlr-20834	532	3	bates	bate	NOUN
ihlr-20834	532	4	v.	v.	ADP
ihlr-20834	532	5	dow	dow	PROPN
ihlr-20834	532	6	agrosciences	agrosciences	PROPN
ihlr-20834	532	7	llc	llc	PROPN
ihlr-20834	532	8	,	,	PUNCT
ihlr-20834	532	9	544	544	NUM
ihlr-20834	532	10	u.s	u.s	PROPN
ihlr-20834	532	11	.	.	PROPN
ihlr-20834	532	12	431	431	NUM
ihlr-20834	532	13	,	,	PUNCT
ihlr-20834	532	14	451	451	NUM
ihlr-20834	532	15	(	(	PUNCT
ihlr-20834	532	16	2005	2005	NUM
ihlr-20834	532	17	)	)	PUNCT
ihlr-20834	532	18	.	.	PUNCT
ihlr-20834	533	1	178	178	NUM
ihlr-20834	533	2	see	see	VERB
ihlr-20834	533	3	natural	natural	ADJ
ihlr-20834	533	4	gas	gas	NOUN
ihlr-20834	533	5	odorizing	odorizing	NOUN
ihlr-20834	533	6	,	,	PUNCT
ihlr-20834	533	7	inc	inc	PROPN
ihlr-20834	533	8	.	.	PROPN
ihlr-20834	534	1	v.	v.	ADP
ihlr-20834	534	2	downs	down	NOUN
ihlr-20834	534	3	,	,	PUNCT
ihlr-20834	534	4	685	685	NUM
ihlr-20834	534	5	n.e.2d	n.e.2d	NOUN
ihlr-20834	534	6	155	155	NUM
ihlr-20834	534	7	(	(	PUNCT
ihlr-20834	534	8	ind	ind	NOUN
ihlr-20834	534	9	.	.	PUNCT
ihlr-20834	535	1	ct	ct	PROPN
ihlr-20834	535	2	.	.	PUNCT
ihlr-20834	536	1	app	app	PROPN
ihlr-20834	536	2	.	.	PROPN
ihlr-20834	536	3	1997	1997	NUM
ihlr-20834	536	4	)	)	PUNCT
ihlr-20834	536	5	.	.	PUNCT
ihlr-20834	537	1	179	179	NUM
ihlr-20834	537	2	see	see	VERB
ihlr-20834	537	3	ind	ind	PROPN
ihlr-20834	537	4	.	.	PUNCT
ihlr-20834	538	1	code	code	PROPN
ihlr-20834	538	2	§	§	PROPN
ihlr-20834	538	3	34	34	NUM
ihlr-20834	538	4	-	-	SYM
ihlr-20834	538	5	20	20	NUM
ihlr-20834	538	6	et	et	NOUN
ihlr-20834	538	7	seq	seq	PROPN
ihlr-20834	538	8	.	.	PUNCT
ihlr-20834	539	1	(	(	PUNCT
ihlr-20834	539	2	2015	2015	NUM
ihlr-20834	539	3	)	)	PUNCT
ihlr-20834	539	4	.	.	PUNCT
ihlr-20834	540	1	180	180	NUM
ihlr-20834	540	2	natural	natural	ADJ
ihlr-20834	540	3	gas	gas	NOUN
ihlr-20834	540	4	odorizing	odorizing	NOUN
ihlr-20834	540	5	,	,	PUNCT
ihlr-20834	540	6	inc	inc	PROPN
ihlr-20834	540	7	.	.	PROPN
ihlr-20834	540	8	,	,	PUNCT
ihlr-20834	540	9	685	685	NUM
ihlr-20834	540	10	n.e.2d	n.e.2d	NOUN
ihlr-20834	540	11	at	at	ADP
ihlr-20834	540	12	160	160	NUM
ihlr-20834	540	13	.	.	NOUN
ihlr-20834	540	14	2015	2015	NUM
ihlr-20834	540	15	797	797	NUM
ihlr-20834	540	16	the	the	DET
ihlr-20834	540	17	supreme	supreme	PROPN
ihlr-20834	540	18	court	court	PROPN
ihlr-20834	540	19	’s	’s	PART
ihlr-20834	540	20	overreaching	overreach	VERB
ihlr-20834	540	21	preemption	preemption	NOUN
ihlr-20834	540	22	interpretation	interpretation	NOUN
ihlr-20834	540	23	and	and	CCONJ
ihlr-20834	540	24	it	it	PRON
ihlr-20834	540	25	’s	’	VERB
ihlr-20834	540	26	consequences	consequence	NOUN
ihlr-20834	540	27	unless	unless	SCONJ
ihlr-20834	540	28	the	the	DET
ihlr-20834	540	29	seller	seller	NOUN
ihlr-20834	540	30	is	be	AUX
ihlr-20834	540	31	a	a	DET
ihlr-20834	540	32	“	"	PUNCT
ihlr-20834	540	33	manufacturer	manufacturer	NOUN
ihlr-20834	540	34	of	of	ADP
ihlr-20834	540	35	the	the	DET
ihlr-20834	540	36	product	product	NOUN
ihlr-20834	540	37	or	or	CCONJ
ihlr-20834	540	38	of	of	ADP
ihlr-20834	540	39	the	the	DET
ihlr-20834	540	40	part	part	NOUN
ihlr-20834	540	41	of	of	ADP
ihlr-20834	540	42	the	the	DET
ihlr-20834	540	43	product	product	NOUN
ihlr-20834	540	44	alleged	allege	VERB
ihlr-20834	540	45	to	to	PART
ihlr-20834	540	46	be	be	AUX
ihlr-20834	540	47	defective	defective	ADJ
ihlr-20834	540	48	.	.	PUNCT
ihlr-20834	541	1	”181	”181	VERB
ihlr-20834	541	2	whether	whether	SCONJ
ihlr-20834	541	3	a	a	DET
ihlr-20834	541	4	product	product	NOUN
ihlr-20834	541	5	is	be	AUX
ihlr-20834	541	6	in	in	ADP
ihlr-20834	541	7	an	an	DET
ihlr-20834	541	8	unreasonably	unreasonably	ADV
ihlr-20834	541	9	dangerous	dangerous	ADJ
ihlr-20834	541	10	and	and	CCONJ
ihlr-20834	541	11	defective	defective	ADJ
ihlr-20834	541	12	condition	condition	NOUN
ihlr-20834	541	13	is	be	AUX
ihlr-20834	541	14	a	a	DET
ihlr-20834	541	15	question	question	NOUN
ihlr-20834	541	16	of	of	ADP
ihlr-20834	541	17	fact.182	fact.182	PROPN
ihlr-20834	541	18	indiana	indiana	PROPN
ihlr-20834	541	19	requires	require	VERB
ihlr-20834	541	20	that	that	SCONJ
ihlr-20834	541	21	the	the	DET
ihlr-20834	541	22	plaintiff	plaintiff	NOUN
ihlr-20834	541	23	show	show	VERB
ihlr-20834	541	24	that	that	SCONJ
ihlr-20834	541	25	a	a	DET
ihlr-20834	541	26	product	product	NOUN
ihlr-20834	541	27	is	be	AUX
ihlr-20834	541	28	in	in	ADP
ihlr-20834	541	29	a	a	DET
ihlr-20834	541	30	“	"	PUNCT
ihlr-20834	541	31	defective	defective	ADJ
ihlr-20834	541	32	condition	condition	NOUN
ihlr-20834	541	33	”	"	PUNCT
ihlr-20834	541	34	and	and	CCONJ
ihlr-20834	541	35	also	also	ADV
ihlr-20834	541	36	that	that	SCONJ
ihlr-20834	541	37	it	it	PRON
ihlr-20834	541	38	is	be	AUX
ihlr-20834	541	39	“	"	PUNCT
ihlr-20834	541	40	unreasonably	unreasonably	ADV
ihlr-20834	541	41	dangerous	dangerous	ADJ
ihlr-20834	541	42	.	.	PUNCT
ihlr-20834	541	43	”183	”183	PUNCT
ihlr-20834	542	1	an	an	DET
ihlr-20834	542	2	objective	objective	ADJ
ihlr-20834	542	3	inquiry	inquiry	NOUN
ihlr-20834	542	4	is	be	AUX
ihlr-20834	542	5	required	require	VERB
ihlr-20834	542	6	to	to	PART
ihlr-20834	542	7	determine	determine	VERB
ihlr-20834	542	8	whether	whether	SCONJ
ihlr-20834	542	9	a	a	DET
ihlr-20834	542	10	product	product	NOUN
ihlr-20834	542	11	is	be	AUX
ihlr-20834	542	12	defective	defective	ADJ
ihlr-20834	542	13	or	or	CCONJ
ihlr-20834	542	14	unreasonably	unreasonably	ADV
ihlr-20834	542	15	dangerous	dangerous	ADJ
ihlr-20834	542	16	.	.	PUNCT
ihlr-20834	543	1	this	this	DET
ihlr-20834	543	2	inquiry	inquiry	NOUN
ihlr-20834	543	3	focuses	focus	VERB
ihlr-20834	543	4	on	on	ADP
ihlr-20834	543	5	the	the	DET
ihlr-20834	543	6	product	product	NOUN
ihlr-20834	543	7	and	and	CCONJ
ihlr-20834	543	8	its	its	PRON
ihlr-20834	543	9	manufacturer	manufacturer	NOUN
ihlr-20834	543	10	or	or	CCONJ
ihlr-20834	543	11	seller	seller	NOUN
ihlr-20834	543	12	assessed	assess	VERB
ihlr-20834	543	13	by	by	ADP
ihlr-20834	543	14	an	an	DET
ihlr-20834	543	15	objective	objective	ADJ
ihlr-20834	543	16	standard	standard	NOUN
ihlr-20834	543	17	regarding	regard	VERB
ihlr-20834	543	18	expected	expect	VERB
ihlr-20834	543	19	use.184	use.184	VERB
ihlr-20834	543	20	the	the	DET
ihlr-20834	543	21	“	"	PUNCT
ihlr-20834	543	22	unreasonably	unreasonably	ADV
ihlr-20834	543	23	dangerous	dangerous	ADJ
ihlr-20834	543	24	”	"	PUNCT
ihlr-20834	543	25	requirement	requirement	NOUN
ihlr-20834	543	26	“	"	PUNCT
ihlr-20834	543	27	refers	refer	VERB
ihlr-20834	543	28	to	to	ADP
ihlr-20834	543	29	any	any	DET
ihlr-20834	543	30	situation	situation	NOUN
ihlr-20834	543	31	in	in	ADP
ihlr-20834	543	32	which	which	PRON
ihlr-20834	543	33	the	the	DET
ihlr-20834	543	34	use	use	NOUN
ihlr-20834	543	35	of	of	ADP
ihlr-20834	543	36	a	a	DET
ihlr-20834	543	37	product	product	NOUN
ihlr-20834	543	38	exposes	expose	VERB
ihlr-20834	543	39	the	the	DET
ihlr-20834	543	40	user	user	NOUN
ihlr-20834	543	41	or	or	CCONJ
ihlr-20834	543	42	consumer	consumer	NOUN
ihlr-20834	543	43	to	to	ADP
ihlr-20834	543	44	a	a	DET
ihlr-20834	543	45	risk	risk	NOUN
ihlr-20834	543	46	of	of	ADP
ihlr-20834	543	47	physical	physical	ADJ
ihlr-20834	543	48	harm	harm	NOUN
ihlr-20834	543	49	to	to	ADP
ihlr-20834	543	50	an	an	DET
ihlr-20834	543	51	extent	extent	NOUN
ihlr-20834	543	52	beyond	beyond	ADP
ihlr-20834	543	53	that	that	PRON
ihlr-20834	543	54	contemplated	contemplate	VERB
ihlr-20834	543	55	by	by	ADP
ihlr-20834	543	56	the	the	DET
ihlr-20834	543	57	ordinary	ordinary	ADJ
ihlr-20834	543	58	consumer	consumer	NOUN
ihlr-20834	543	59	who	who	PRON
ihlr-20834	543	60	purchases	purchase	VERB
ihlr-20834	543	61	the	the	DET
ihlr-20834	543	62	product	product	NOUN
ihlr-20834	543	63	with	with	ADP
ihlr-20834	543	64	the	the	DET
ihlr-20834	543	65	ordinary	ordinary	ADJ
ihlr-20834	543	66	knowledge	knowledge	NOUN
ihlr-20834	543	67	about	about	ADP
ihlr-20834	543	68	the	the	DET
ihlr-20834	543	69	product	product	NOUN
ihlr-20834	543	70	’s	’s	PART
ihlr-20834	543	71	characteristics	characteristic	NOUN
ihlr-20834	543	72	common	common	ADJ
ihlr-20834	543	73	to	to	ADP
ihlr-20834	543	74	the	the	DET
ihlr-20834	543	75	community	community	NOUN
ihlr-20834	543	76	of	of	ADP
ihlr-20834	543	77	consumers	consumer	NOUN
ihlr-20834	543	78	.	.	PUNCT
ihlr-20834	543	79	”185	”185	PUNCT
ihlr-20834	544	1	even	even	ADV
ihlr-20834	544	2	if	if	SCONJ
ihlr-20834	544	3	the	the	DET
ihlr-20834	544	4	seller	seller	NOUN
ihlr-20834	544	5	(	(	PUNCT
ihlr-20834	544	6	manufacturer	manufacturer	NOUN
ihlr-20834	544	7	)	)	PUNCT
ihlr-20834	544	8	has	have	AUX
ihlr-20834	544	9	exercised	exercise	VERB
ihlr-20834	544	10	all	all	DET
ihlr-20834	544	11	reasonable	reasonable	ADJ
ihlr-20834	544	12	care	care	NOUN
ihlr-20834	544	13	in	in	ADP
ihlr-20834	544	14	the	the	DET
ihlr-20834	544	15	preparation	preparation	NOUN
ihlr-20834	544	16	and	and	CCONJ
ihlr-20834	544	17	manufacturing	manufacturing	NOUN
ihlr-20834	544	18	of	of	ADP
ihlr-20834	544	19	a	a	DET
ihlr-20834	544	20	product	product	NOUN
ihlr-20834	544	21	,	,	PUNCT
ihlr-20834	544	22	a	a	DET
ihlr-20834	544	23	person	person	NOUN
ihlr-20834	544	24	selling	selling	NOUN
ihlr-20834	544	25	,	,	PUNCT
ihlr-20834	544	26	leasing	leasing	NOUN
ihlr-20834	544	27	,	,	PUNCT
ihlr-20834	544	28	or	or	CCONJ
ihlr-20834	544	29	otherwise	otherwise	ADV
ihlr-20834	544	30	putting	put	VERB
ihlr-20834	544	31	a	a	DET
ihlr-20834	544	32	defective	defective	ADJ
ihlr-20834	544	33	or	or	CCONJ
ihlr-20834	544	34	unreasonably	unreasonably	ADV
ihlr-20834	544	35	dangerous	dangerous	ADJ
ihlr-20834	544	36	product	product	NOUN
ihlr-20834	544	37	in	in	ADP
ihlr-20834	544	38	the	the	DET
ihlr-20834	544	39	stream	stream	NOUN
ihlr-20834	544	40	of	of	ADP
ihlr-20834	544	41	commerce	commerce	NOUN
ihlr-20834	544	42	is	be	AUX
ihlr-20834	544	43	subject	subject	ADJ
ihlr-20834	544	44	to	to	ADP
ihlr-20834	544	45	liability	liability	NOUN
ihlr-20834	544	46	.	.	PUNCT
ihlr-20834	545	1	186	186	NUM
ihlr-20834	545	2	however	however	ADV
ihlr-20834	545	3	actions	action	NOUN
ihlr-20834	545	4	claiming	claim	VERB
ihlr-20834	545	5	design	design	NOUN
ihlr-20834	545	6	-	-	PUNCT
ihlr-20834	545	7	defect	defect	NOUN
ihlr-20834	545	8	require	require	NOUN
ihlr-20834	545	9	that	that	SCONJ
ihlr-20834	545	10	the	the	DET
ihlr-20834	545	11	“	"	PUNCT
ihlr-20834	545	12	party	party	NOUN
ihlr-20834	545	13	making	make	VERB
ihlr-20834	545	14	the	the	DET
ihlr-20834	545	15	claim	claim	NOUN
ihlr-20834	545	16	must	must	AUX
ihlr-20834	545	17	establish	establish	VERB
ihlr-20834	545	18	that	that	SCONJ
ihlr-20834	545	19	the	the	DET
ihlr-20834	545	20	manufacturer	manufacturer	NOUN
ihlr-20834	545	21	or	or	CCONJ
ihlr-20834	545	22	seller	seller	NOUN
ihlr-20834	545	23	failed	fail	VERB
ihlr-20834	545	24	to	to	PART
ihlr-20834	545	25	exercise	exercise	VERB
ihlr-20834	545	26	reasonable	reasonable	ADJ
ihlr-20834	545	27	care	care	NOUN
ihlr-20834	545	28	under	under	ADP
ihlr-20834	545	29	the	the	DET
ihlr-20834	545	30	circumstances	circumstance	NOUN
ihlr-20834	545	31	in	in	ADP
ihlr-20834	545	32	designing	design	VERB
ihlr-20834	545	33	the	the	DET
ihlr-20834	545	34	product	product	NOUN
ihlr-20834	545	35	or	or	CCONJ
ihlr-20834	545	36	in	in	ADP
ihlr-20834	545	37	providing	provide	VERB
ihlr-20834	545	38	the	the	DET
ihlr-20834	545	39	warnings	warning	NOUN
ihlr-20834	545	40	or	or	CCONJ
ihlr-20834	545	41	instructions	instruction	NOUN
ihlr-20834	545	42	.	.	PUNCT
ihlr-20834	545	43	”	"	PUNCT
ihlr-20834	546	1	187	187	NUM
ihlr-20834	546	2	for	for	ADP
ihlr-20834	546	3	example	example	NOUN
ihlr-20834	546	4	,	,	PUNCT
ihlr-20834	546	5	in	in	ADP
ihlr-20834	546	6	indiana	indiana	PROPN
ihlr-20834	546	7	ms	ms	PROPN
ihlr-20834	546	8	.	.	PROPN
ihlr-20834	546	9	bartlett	bartlett	PROPN
ihlr-20834	546	10	would	would	AUX
ihlr-20834	546	11	have	have	AUX
ihlr-20834	546	12	had	have	VERB
ihlr-20834	546	13	to	to	PART
ihlr-20834	546	14	establish	establish	VERB
ihlr-20834	546	15	that	that	SCONJ
ihlr-20834	546	16	mutual	mutual	ADJ
ihlr-20834	546	17	pharmaceutical	pharmaceutical	NOUN
ihlr-20834	546	18	failed	fail	VERB
ihlr-20834	546	19	to	to	PART
ihlr-20834	546	20	exercise	exercise	VERB
ihlr-20834	546	21	reasonable	reasonable	ADJ
ihlr-20834	546	22	care	care	NOUN
ihlr-20834	546	23	in	in	ADP
ihlr-20834	546	24	providing	provide	VERB
ihlr-20834	546	25	warnings	warning	NOUN
ihlr-20834	546	26	for	for	ADP
ihlr-20834	546	27	their	their	PRON
ihlr-20834	546	28	drug	drug	NOUN
ihlr-20834	546	29	sulindac	sulindac	NOUN
ihlr-20834	546	30	.	.	PUNCT
ihlr-20834	547	1	181	181	NUM
ihlr-20834	547	2	ind	ind	NOUN
ihlr-20834	547	3	.	.	PUNCT
ihlr-20834	548	1	code	code	PROPN
ihlr-20834	548	2	§	§	PROPN
ihlr-20834	548	3	34	34	NUM
ihlr-20834	548	4	-	-	SYM
ihlr-20834	548	5	20	20	NUM
ihlr-20834	548	6	-	-	PUNCT
ihlr-20834	548	7	2	2	NUM
ihlr-20834	548	8	-	-	SYM
ihlr-20834	548	9	3	3	NUM
ihlr-20834	548	10	(	(	PUNCT
ihlr-20834	548	11	2015	2015	NUM
ihlr-20834	548	12	)	)	PUNCT
ihlr-20834	548	13	.	.	PUNCT
ihlr-20834	549	1	182	182	NUM
ihlr-20834	549	2	corbin	corbin	PROPN
ihlr-20834	549	3	v.	v.	PROPN
ihlr-20834	549	4	coleco	coleco	PROPN
ihlr-20834	549	5	indus	indus	PROPN
ihlr-20834	549	6	.	.	PROPN
ihlr-20834	549	7	,	,	PUNCT
ihlr-20834	549	8	inc	inc	PROPN
ihlr-20834	549	9	.	.	PROPN
ihlr-20834	549	10	,	,	PUNCT
ihlr-20834	549	11	748	748	NUM
ihlr-20834	549	12	f.2d	f.2d	NUM
ihlr-20834	549	13	411	411	NUM
ihlr-20834	549	14	,	,	PUNCT
ihlr-20834	549	15	419	419	NUM
ihlr-20834	549	16	(	(	PUNCT
ihlr-20834	549	17	7th	7th	ADJ
ihlr-20834	549	18	cir	cir	NOUN
ihlr-20834	549	19	.	.	PUNCT
ihlr-20834	549	20	1984	1984	NUM
ihlr-20834	549	21	)	)	PUNCT
ihlr-20834	549	22	.	.	PUNCT
ihlr-20834	550	1	183	183	NUM
ihlr-20834	550	2	bourne	bourne	NOUN
ihlr-20834	550	3	v.	v.	ADP
ihlr-20834	550	4	marty	marty	PROPN
ihlr-20834	550	5	gilman	gilman	PROPN
ihlr-20834	550	6	,	,	PUNCT
ihlr-20834	550	7	inc	inc	PROPN
ihlr-20834	550	8	.	.	PROPN
ihlr-20834	550	9	,	,	PUNCT
ihlr-20834	550	10	452	452	NUM
ihlr-20834	550	11	f.3d	f.3d	NUM
ihlr-20834	550	12	632	632	NUM
ihlr-20834	550	13	,	,	PUNCT
ihlr-20834	550	14	635	635	NUM
ihlr-20834	550	15	-	-	SYM
ihlr-20834	550	16	36	36	NUM
ihlr-20834	550	17	(	(	PUNCT
ihlr-20834	550	18	7th	7th	ADJ
ihlr-20834	550	19	cir	cir	NOUN
ihlr-20834	550	20	.	.	PUNCT
ihlr-20834	550	21	2006	2006	NUM
ihlr-20834	550	22	)	)	PUNCT
ihlr-20834	550	23	(	(	PUNCT
ihlr-20834	550	24	citing	cite	VERB
ihlr-20834	550	25	mcmahon	mcmahon	PROPN
ihlr-20834	550	26	v.	v.	PROPN
ihlr-20834	550	27	bunn	bunn	PROPN
ihlr-20834	550	28	-	-	PUNCT
ihlr-20834	550	29	o	o	PROPN
ihlr-20834	550	30	-	-	PROPN
ihlr-20834	550	31	matic	matic	PROPN
ihlr-20834	550	32	corp	corp	PROPN
ihlr-20834	550	33	.	.	PROPN
ihlr-20834	550	34	,	,	PUNCT
ihlr-20834	550	35	150	150	NUM
ihlr-20834	550	36	f.3d	f.3d	NUM
ihlr-20834	550	37	651	651	NUM
ihlr-20834	550	38	,	,	PUNCT
ihlr-20834	550	39	657	657	NUM
ihlr-20834	550	40	(	(	PUNCT
ihlr-20834	550	41	7th	7th	ADJ
ihlr-20834	550	42	cir	cir	NOUN
ihlr-20834	550	43	.	.	PUNCT
ihlr-20834	550	44	1998	1998	NUM
ihlr-20834	550	45	)	)	PUNCT
ihlr-20834	550	46	)	)	PUNCT
ihlr-20834	550	47	.	.	PUNCT
ihlr-20834	551	1	see	see	VERB
ihlr-20834	551	2	also	also	ADV
ihlr-20834	551	3	baker	baker	PROPN
ihlr-20834	551	4	v.	v.	PROPN
ihlr-20834	551	5	heye	heye	PROPN
ihlr-20834	551	6	america	america	PROPN
ihlr-20834	551	7	,	,	PUNCT
ihlr-20834	551	8	799	799	NUM
ihlr-20834	551	9	n.e.2d	n.e.2d	NOUN
ihlr-20834	551	10	1135	1135	NUM
ihlr-20834	551	11	,	,	PUNCT
ihlr-20834	551	12	1140	1140	NUM
ihlr-20834	551	13	(	(	PUNCT
ihlr-20834	551	14	ind	ind	NOUN
ihlr-20834	551	15	.	.	PUNCT
ihlr-20834	552	1	ct	ct	PROPN
ihlr-20834	552	2	.	.	PUNCT
ihlr-20834	553	1	app	app	PROPN
ihlr-20834	553	2	.	.	PROPN
ihlr-20834	553	3	2003	2003	NUM
ihlr-20834	553	4	)	)	PUNCT
ihlr-20834	553	5	)	)	PUNCT
ihlr-20834	553	6	.	.	PUNCT
ihlr-20834	554	1	184	184	NUM
ihlr-20834	554	2	moss	moss	NOUN
ihlr-20834	554	3	v.	v.	ADP
ihlr-20834	554	4	crosman	crosman	PROPN
ihlr-20834	554	5	corp	corp	PROPN
ihlr-20834	554	6	.	.	PROPN
ihlr-20834	554	7	,	,	PUNCT
ihlr-20834	554	8	945	945	NUM
ihlr-20834	554	9	f.supp	f.supp	ADJ
ihlr-20834	554	10	.	.	PROPN
ihlr-20834	554	11	1167	1167	NUM
ihlr-20834	554	12	,	,	PUNCT
ihlr-20834	554	13	1181	1181	NUM
ihlr-20834	554	14	(	(	PUNCT
ihlr-20834	554	15	n.d	n.d	PROPN
ihlr-20834	554	16	.	.	PROPN
ihlr-20834	554	17	ind	ind	PROPN
ihlr-20834	554	18	.	.	PUNCT
ihlr-20834	554	19	1996	1996	NUM
ihlr-20834	554	20	)	)	PUNCT
ihlr-20834	554	21	.	.	PUNCT
ihlr-20834	555	1	185	185	NUM
ihlr-20834	555	2	ind	ind	NOUN
ihlr-20834	555	3	.	.	PUNCT
ihlr-20834	555	4	code	code	PROPN
ihlr-20834	555	5	§	§	PROPN
ihlr-20834	555	6	34	34	NUM
ihlr-20834	555	7	-	-	SYM
ihlr-20834	555	8	6	6	NUM
ihlr-20834	555	9	-	-	PUNCT
ihlr-20834	555	10	2	2	NUM
ihlr-20834	555	11	-	-	SYM
ihlr-20834	555	12	146	146	NUM
ihlr-20834	555	13	(	(	PUNCT
ihlr-20834	555	14	2015	2015	NUM
ihlr-20834	555	15	)	)	PUNCT
ihlr-20834	555	16	.	.	PUNCT
ihlr-20834	556	1	186	186	NUM
ihlr-20834	556	2	ind	ind	NOUN
ihlr-20834	556	3	.	.	PUNCT
ihlr-20834	557	1	code	code	PROPN
ihlr-20834	557	2	§	§	PROPN
ihlr-20834	557	3	34	34	NUM
ihlr-20834	557	4	-	-	SYM
ihlr-20834	557	5	20	20	NUM
ihlr-20834	557	6	-	-	PUNCT
ihlr-20834	557	7	2	2	NUM
ihlr-20834	557	8	-	-	SYM
ihlr-20834	557	9	2	2	NUM
ihlr-20834	557	10	(	(	PUNCT
ihlr-20834	557	11	2015	2015	NUM
ihlr-20834	557	12	)	)	PUNCT
ihlr-20834	557	13	.	.	PUNCT
ihlr-20834	558	1	187	187	NUM
ihlr-20834	559	1	i	i	PRON
ihlr-20834	559	2	d.	d.	PROPN
ihlr-20834	559	3	798	798	NUM
ihlr-20834	559	4	indiana	indiana	PROPN
ihlr-20834	559	5	health	health	PROPN
ihlr-20834	559	6	law	law	PROPN
ihlr-20834	559	7	review	review	NOUN
ihlr-20834	559	8	vol	vol	NOUN
ihlr-20834	559	9	.	.	PUNCT
ihlr-20834	559	10	12:2	12:2	NUM
ihlr-20834	559	11	under	under	ADP
ihlr-20834	559	12	indiana	indiana	PROPN
ihlr-20834	559	13	law	law	PROPN
ihlr-20834	559	14	a	a	DET
ihlr-20834	559	15	product	product	NOUN
ihlr-20834	559	16	is	be	AUX
ihlr-20834	559	17	not	not	PART
ihlr-20834	559	18	presumed	presume	VERB
ihlr-20834	559	19	unreasonably	unreasonably	ADV
ihlr-20834	559	20	dangerous	dangerous	ADJ
ihlr-20834	559	21	if	if	SCONJ
ihlr-20834	559	22	it	it	PRON
ihlr-20834	559	23	injures	injure	VERB
ihlr-20834	559	24	a	a	DET
ihlr-20834	559	25	person	person	NOUN
ihlr-20834	559	26	in	in	ADP
ihlr-20834	559	27	a	a	DET
ihlr-20834	559	28	way	way	NOUN
ihlr-20834	559	29	known	know	VERB
ihlr-20834	559	30	to	to	ADP
ihlr-20834	559	31	the	the	DET
ihlr-20834	559	32	community	community	NOUN
ihlr-20834	559	33	of	of	ADP
ihlr-20834	559	34	persons	person	NOUN
ihlr-20834	559	35	consuming	consume	VERB
ihlr-20834	559	36	the	the	DET
ihlr-20834	559	37	product.188	product.188	NOUN
ihlr-20834	559	38	this	this	PRON
ihlr-20834	559	39	is	be	AUX
ihlr-20834	559	40	likely	likely	ADJ
ihlr-20834	559	41	not	not	PART
ihlr-20834	559	42	applicable	applicable	ADJ
ihlr-20834	559	43	in	in	ADP
ihlr-20834	559	44	pharmaceutical	pharmaceutical	ADJ
ihlr-20834	559	45	cases	case	NOUN
ihlr-20834	559	46	because	because	SCONJ
ihlr-20834	559	47	one	one	NUM
ihlr-20834	559	48	is	be	AUX
ihlr-20834	559	49	unlikely	unlikely	ADJ
ihlr-20834	559	50	to	to	PART
ihlr-20834	559	51	take	take	VERB
ihlr-20834	559	52	a	a	DET
ihlr-20834	559	53	drug	drug	NOUN
ihlr-20834	559	54	if	if	SCONJ
ihlr-20834	559	55	the	the	DET
ihlr-20834	559	56	community	community	NOUN
ihlr-20834	559	57	of	of	ADP
ihlr-20834	559	58	consumers	consumer	NOUN
ihlr-20834	559	59	knows	know	VERB
ihlr-20834	559	60	of	of	ADP
ihlr-20834	559	61	its	its	PRON
ihlr-20834	559	62	dangers	danger	NOUN
ihlr-20834	559	63	.	.	PUNCT
ihlr-20834	560	1	the	the	DET
ihlr-20834	560	2	relative	relative	ADJ
ihlr-20834	560	3	obviousness	obviousness	NOUN
ihlr-20834	560	4	of	of	ADP
ihlr-20834	560	5	a	a	DET
ihlr-20834	560	6	defect	defect	NOUN
ihlr-20834	560	7	is	be	AUX
ihlr-20834	560	8	relevant	relevant	ADJ
ihlr-20834	560	9	in	in	ADP
ihlr-20834	560	10	considering	consider	VERB
ihlr-20834	560	11	whether	whether	SCONJ
ihlr-20834	560	12	or	or	CCONJ
ihlr-20834	560	13	not	not	PART
ihlr-20834	560	14	a	a	DET
ihlr-20834	560	15	product	product	NOUN
ihlr-20834	560	16	is	be	AUX
ihlr-20834	560	17	defective	defective	ADJ
ihlr-20834	560	18	and	and	CCONJ
ihlr-20834	560	19	unreasonably	unreasonably	ADV
ihlr-20834	560	20	dangerous.189	dangerous.189	ADJ
ihlr-20834	560	21	the	the	DET
ihlr-20834	560	22	relative	relative	ADJ
ihlr-20834	560	23	obviousness	obviousness	NOUN
ihlr-20834	560	24	of	of	ADP
ihlr-20834	560	25	a	a	DET
ihlr-20834	560	26	defect	defect	NOUN
ihlr-20834	560	27	is	be	AUX
ihlr-20834	560	28	unlikely	unlikely	ADJ
ihlr-20834	560	29	to	to	PART
ihlr-20834	560	30	effect	effect	VERB
ihlr-20834	560	31	suit	suit	NOUN
ihlr-20834	560	32	against	against	ADP
ihlr-20834	560	33	a	a	DET
ihlr-20834	560	34	pharmaceutical	pharmaceutical	ADJ
ihlr-20834	560	35	manufacturer	manufacturer	NOUN
ihlr-20834	560	36	because	because	SCONJ
ihlr-20834	560	37	consumers	consumer	NOUN
ihlr-20834	560	38	will	will	AUX
ihlr-20834	560	39	not	not	PART
ihlr-20834	560	40	take	take	VERB
ihlr-20834	560	41	drugs	drug	NOUN
ihlr-20834	560	42	that	that	PRON
ihlr-20834	560	43	have	have	VERB
ihlr-20834	560	44	an	an	DET
ihlr-20834	560	45	obvious	obvious	ADJ
ihlr-20834	560	46	defect	defect	NOUN
ihlr-20834	560	47	.	.	PUNCT
ihlr-20834	561	1	furthermore	furthermore	ADV
ihlr-20834	561	2	,	,	PUNCT
ihlr-20834	561	3	obvious	obvious	ADJ
ihlr-20834	561	4	defective	defective	ADJ
ihlr-20834	561	5	drugs	drug	NOUN
ihlr-20834	561	6	would	would	AUX
ihlr-20834	561	7	not	not	PART
ihlr-20834	561	8	be	be	AUX
ihlr-20834	561	9	permitted	permit	VERB
ihlr-20834	561	10	for	for	ADP
ihlr-20834	561	11	sale	sale	NOUN
ihlr-20834	561	12	in	in	ADP
ihlr-20834	561	13	the	the	DET
ihlr-20834	561	14	market	market	NOUN
ihlr-20834	561	15	.	.	PUNCT
ihlr-20834	562	1	finally	finally	ADV
ihlr-20834	562	2	,	,	PUNCT
ihlr-20834	562	3	manufacturers	manufacturer	NOUN
ihlr-20834	562	4	are	be	AUX
ihlr-20834	562	5	legally	legally	ADV
ihlr-20834	562	6	bound	bind	VERB
ihlr-20834	562	7	to	to	PART
ihlr-20834	562	8	design	design	VERB
ihlr-20834	562	9	and	and	CCONJ
ihlr-20834	562	10	build	build	VERB
ihlr-20834	562	11	products	product	NOUN
ihlr-20834	562	12	that	that	PRON
ihlr-20834	562	13	are	be	AUX
ihlr-20834	562	14	reasonably	reasonably	ADV
ihlr-20834	562	15	fit	fit	ADJ
ihlr-20834	562	16	and	and	CCONJ
ihlr-20834	562	17	safe	safe	ADJ
ihlr-20834	562	18	for	for	SCONJ
ihlr-20834	562	19	their	their	PRON
ihlr-20834	562	20	intended	intend	VERB
ihlr-20834	562	21	purpose.190	purpose.190	NOUN
ihlr-20834	562	22	had	have	AUX
ihlr-20834	562	23	bartlett	bartlett	PROPN
ihlr-20834	562	24	been	be	AUX
ihlr-20834	562	25	decided	decide	VERB
ihlr-20834	562	26	years	year	NOUN
ihlr-20834	562	27	ago	ago	ADV
ihlr-20834	562	28	,	,	PUNCT
ihlr-20834	562	29	many	many	ADJ
ihlr-20834	562	30	past	past	ADJ
ihlr-20834	562	31	decisions	decision	NOUN
ihlr-20834	562	32	would	would	AUX
ihlr-20834	562	33	likely	likely	ADV
ihlr-20834	562	34	have	have	AUX
ihlr-20834	562	35	had	have	VERB
ihlr-20834	562	36	different	different	ADJ
ihlr-20834	562	37	outcomes	outcome	NOUN
ihlr-20834	562	38	.	.	PUNCT
ihlr-20834	563	1	examining	examine	VERB
ihlr-20834	563	2	the	the	DET
ihlr-20834	563	3	effects	effect	NOUN
ihlr-20834	563	4	of	of	ADP
ihlr-20834	563	5	this	this	DET
ihlr-20834	563	6	precedent	precedent	NOUN
ihlr-20834	563	7	on	on	ADP
ihlr-20834	563	8	previous	previous	ADJ
ihlr-20834	563	9	decisions	decision	NOUN
ihlr-20834	563	10	helps	helps	AUX
ihlr-20834	563	11	reveal	reveal	VERB
ihlr-20834	563	12	the	the	DET
ihlr-20834	563	13	danger	danger	NOUN
ihlr-20834	563	14	of	of	ADP
ihlr-20834	563	15	this	this	DET
ihlr-20834	563	16	precedent	precedent	NOUN
ihlr-20834	563	17	to	to	ADP
ihlr-20834	563	18	future	future	ADJ
ihlr-20834	563	19	cases	case	NOUN
ihlr-20834	563	20	.	.	PUNCT
ihlr-20834	564	1	in	in	ADP
ihlr-20834	564	2	bell	bell	PROPN
ihlr-20834	564	3	v.	v.	CCONJ
ihlr-20834	564	4	lollar	lollar	PROPN
ihlr-20834	564	5	,	,	PUNCT
ihlr-20834	564	6	the	the	DET
ihlr-20834	564	7	indiana	indiana	PROPN
ihlr-20834	564	8	court	court	PROPN
ihlr-20834	564	9	of	of	ADP
ihlr-20834	564	10	appeals	appeals	PROPN
ihlr-20834	564	11	reasoned	reason	VERB
ihlr-20834	564	12	that	that	SCONJ
ihlr-20834	564	13	a	a	DET
ihlr-20834	564	14	state	state	NOUN
ihlr-20834	564	15	-	-	PUNCT
ihlr-20834	564	16	law	law	NOUN
ihlr-20834	564	17	claim	claim	NOUN
ihlr-20834	564	18	against	against	ADP
ihlr-20834	564	19	a	a	DET
ihlr-20834	564	20	generic	generic	ADJ
ihlr-20834	564	21	drug	drug	NOUN
ihlr-20834	564	22	manufacturer	manufacturer	NOUN
ihlr-20834	564	23	in	in	ADP
ihlr-20834	564	24	a	a	DET
ihlr-20834	564	25	failure	failure	NOUN
ihlr-20834	564	26	-	-	PUNCT
ihlr-20834	564	27	to	to	PART
ihlr-20834	564	28	-	-	PUNCT
ihlr-20834	564	29	warn	warn	VERB
ihlr-20834	564	30	claim	claim	NOUN
ihlr-20834	564	31	was	be	AUX
ihlr-20834	564	32	not	not	PART
ihlr-20834	564	33	preempted	preempt	VERB
ihlr-20834	564	34	because	because	SCONJ
ihlr-20834	564	35	the	the	DET
ihlr-20834	564	36	manufacturer	manufacturer	NOUN
ihlr-20834	564	37	was	be	AUX
ihlr-20834	564	38	free	free	ADJ
ihlr-20834	564	39	to	to	PART
ihlr-20834	564	40	strengthen	strengthen	VERB
ihlr-20834	564	41	its	its	PRON
ihlr-20834	564	42	label.191	label.191	NOUN
ihlr-20834	564	43	the	the	DET
ihlr-20834	564	44	plaintiff	plaintiff	NOUN
ihlr-20834	564	45	,	,	PUNCT
ihlr-20834	564	46	lollar	lollar	PROPN
ihlr-20834	564	47	,	,	PUNCT
ihlr-20834	564	48	alleged	allege	VERB
ihlr-20834	564	49	the	the	DET
ihlr-20834	564	50	label	label	NOUN
ihlr-20834	564	51	was	be	AUX
ihlr-20834	564	52	in	in	ADP
ihlr-20834	564	53	a	a	DET
ihlr-20834	564	54	“	"	PUNCT
ihlr-20834	564	55	defective	defective	ADJ
ihlr-20834	564	56	and	and	CCONJ
ihlr-20834	564	57	unreasonably	unreasonably	ADV
ihlr-20834	564	58	dangerous	dangerous	ADJ
ihlr-20834	564	59	condition	condition	NOUN
ihlr-20834	564	60	”	"	PUNCT
ihlr-20834	564	61	because	because	SCONJ
ihlr-20834	564	62	the	the	DET
ihlr-20834	564	63	label	label	NOUN
ihlr-20834	564	64	failed	fail	VERB
ihlr-20834	564	65	to	to	PART
ihlr-20834	564	66	warn	warn	VERB
ihlr-20834	564	67	him	he	PRON
ihlr-20834	564	68	of	of	ADP
ihlr-20834	564	69	the	the	DET
ihlr-20834	564	70	“	"	PUNCT
ihlr-20834	564	71	risk	risk	NOUN
ihlr-20834	564	72	associated	associate	VERB
ihlr-20834	564	73	with	with	ADP
ihlr-20834	564	74	combining	combine	VERB
ihlr-20834	564	75	acetaminophen	acetaminophen	NOUN
ihlr-20834	564	76	and	and	CCONJ
ihlr-20834	564	77	alcohol	alcohol	NOUN
ihlr-20834	564	78	.	.	PUNCT
ihlr-20834	564	79	”	"	PUNCT
ihlr-20834	565	1	192	192	NUM
ihlr-20834	565	2	the	the	DET
ihlr-20834	565	3	court	court	NOUN
ihlr-20834	565	4	agreed	agree	VERB
ihlr-20834	565	5	,	,	PUNCT
ihlr-20834	565	6	holding	hold	VERB
ihlr-20834	565	7	that	that	SCONJ
ihlr-20834	565	8	the	the	DET
ihlr-20834	565	9	manufacturer	manufacturer	NOUN
ihlr-20834	565	10	“	"	PUNCT
ihlr-20834	565	11	was	be	AUX
ihlr-20834	565	12	free	free	ADJ
ihlr-20834	565	13	to	to	PART
ihlr-20834	565	14	strengthen	strengthen	VERB
ihlr-20834	565	15	its	its	PRON
ihlr-20834	565	16	label	label	NOUN
ihlr-20834	565	17	by	by	ADP
ihlr-20834	565	18	adding	add	VERB
ihlr-20834	565	19	an	an	DET
ihlr-20834	565	20	alcohol	alcohol	NOUN
ihlr-20834	565	21	warning	warning	NOUN
ihlr-20834	565	22	”	"	PUNCT
ihlr-20834	565	23	and	and	CCONJ
ihlr-20834	565	24	the	the	DET
ihlr-20834	565	25	188	188	NUM
ihlr-20834	565	26	moss	moss	NOUN
ihlr-20834	565	27	,	,	PUNCT
ihlr-20834	565	28	945	945	NUM
ihlr-20834	565	29	f.supp	f.supp	NOUN
ihlr-20834	565	30	.	.	PUNCT
ihlr-20834	566	1	at	at	ADP
ihlr-20834	566	2	1176	1176	NUM
ihlr-20834	566	3	.	.	PUNCT
ihlr-20834	567	1	189	189	NUM
ihlr-20834	567	2	johnson	johnson	PROPN
ihlr-20834	567	3	v.	v.	PROPN
ihlr-20834	567	4	kempler	kempler	PROPN
ihlr-20834	567	5	indus	indus	PROPN
ihlr-20834	567	6	.	.	PROPN
ihlr-20834	567	7	,	,	PUNCT
ihlr-20834	567	8	inc	inc	PROPN
ihlr-20834	567	9	.	.	PROPN
ihlr-20834	567	10	,	,	PUNCT
ihlr-20834	567	11	677	677	NUM
ihlr-20834	567	12	n.e.2d	n.e.2d	NOUN
ihlr-20834	567	13	531	531	NUM
ihlr-20834	567	14	,	,	PUNCT
ihlr-20834	567	15	538	538	NUM
ihlr-20834	567	16	(	(	PUNCT
ihlr-20834	567	17	ind	ind	NOUN
ihlr-20834	567	18	.	.	PUNCT
ihlr-20834	568	1	ct	ct	PROPN
ihlr-20834	568	2	.	.	PUNCT
ihlr-20834	569	1	app	app	PROPN
ihlr-20834	569	2	.	.	PROPN
ihlr-20834	569	3	1997	1997	NUM
ihlr-20834	569	4	)	)	PUNCT
ihlr-20834	569	5	.	.	PUNCT
ihlr-20834	570	1	190	190	NUM
ihlr-20834	570	2	liberty	liberty	PROPN
ihlr-20834	570	3	mut	mut	PROPN
ihlr-20834	570	4	.	.	PUNCT
ihlr-20834	570	5	ins	ins	PROPN
ihlr-20834	570	6	.	.	PUNCT
ihlr-20834	570	7	co.	co.	PROPN
ihlr-20834	570	8	v.	v.	ADP
ihlr-20834	570	9	rich	rich	ADJ
ihlr-20834	570	10	ladder	ladder	PROPN
ihlr-20834	570	11	co.	co.	PROPN
ihlr-20834	570	12	,	,	PUNCT
ihlr-20834	570	13	inc	inc	PROPN
ihlr-20834	570	14	.	.	PROPN
ihlr-20834	570	15	,	,	PUNCT
ihlr-20834	570	16	441	441	NUM
ihlr-20834	570	17	n.e.2d	n.e.2d	NOUN
ihlr-20834	570	18	996	996	NUM
ihlr-20834	570	19	,	,	PUNCT
ihlr-20834	570	20	999	999	NUM
ihlr-20834	570	21	(	(	PUNCT
ihlr-20834	570	22	ind	ind	NOUN
ihlr-20834	570	23	.	.	PUNCT
ihlr-20834	571	1	ct	ct	PROPN
ihlr-20834	571	2	.	.	PUNCT
ihlr-20834	572	1	app	app	PROPN
ihlr-20834	572	2	.	.	PROPN
ihlr-20834	572	3	1982	1982	NUM
ihlr-20834	572	4	)	)	PUNCT
ihlr-20834	572	5	.	.	PUNCT
ihlr-20834	573	1	191	191	NUM
ihlr-20834	573	2	bell	bell	NOUN
ihlr-20834	573	3	v.	v.	ADP
ihlr-20834	573	4	lollar	lollar	ADJ
ihlr-20834	573	5	,	,	PUNCT
ihlr-20834	573	6	791	791	NUM
ihlr-20834	573	7	n.e.2d	n.e.2d	NOUN
ihlr-20834	573	8	849	849	NUM
ihlr-20834	573	9	,	,	PUNCT
ihlr-20834	573	10	850	850	NUM
ihlr-20834	573	11	(	(	PUNCT
ihlr-20834	573	12	ind	ind	NOUN
ihlr-20834	573	13	.	.	PUNCT
ihlr-20834	574	1	ct	ct	PROPN
ihlr-20834	574	2	.	.	PUNCT
ihlr-20834	575	1	app	app	PROPN
ihlr-20834	575	2	.	.	PROPN
ihlr-20834	575	3	2003	2003	NUM
ihlr-20834	575	4	)	)	PUNCT
ihlr-20834	575	5	.	.	PUNCT
ihlr-20834	576	1	192	192	NUM
ihlr-20834	577	1	i	i	PRON
ihlr-20834	577	2	d.	d.	PROPN
ihlr-20834	577	3	at	at	ADP
ihlr-20834	577	4	851	851	NUM
ihlr-20834	577	5	.	.	PUNCT
ihlr-20834	578	1	see	see	AUX
ihlr-20834	578	2	also	also	ADV
ihlr-20834	578	3	acetaminophen	acetaminophen	NOUN
ihlr-20834	578	4	,	,	PUNCT
ihlr-20834	578	5	drugs.com	drugs.com	X
ihlr-20834	578	6	,	,	PUNCT
ihlr-20834	578	7	www.drugs.com/acetaminophen.html	www.drugs.com/acetaminophen.html	X
ihlr-20834	579	1	(	(	PUNCT
ihlr-20834	579	2	last	last	ADJ
ihlr-20834	579	3	visited	visit	VERB
ihlr-20834	579	4	mar	mar	PROPN
ihlr-20834	579	5	.	.	PROPN
ihlr-20834	579	6	21	21	NUM
ihlr-20834	579	7	,	,	PUNCT
ihlr-20834	579	8	2015	2015	NUM
ihlr-20834	579	9	)	)	PUNCT
ihlr-20834	579	10	(	(	PUNCT
ihlr-20834	579	11	acetaminophen	acetaminophen	NOUN
ihlr-20834	579	12	is	be	AUX
ihlr-20834	579	13	a	a	DET
ihlr-20834	579	14	drug	drug	NOUN
ihlr-20834	579	15	used	use	VERB
ihlr-20834	579	16	to	to	PART
ihlr-20834	579	17	reduce	reduce	VERB
ihlr-20834	579	18	fever	fever	NOUN
ihlr-20834	579	19	and	and	CCONJ
ihlr-20834	579	20	relieve	relieve	VERB
ihlr-20834	579	21	pain	pain	NOUN
ihlr-20834	579	22	that	that	PRON
ihlr-20834	579	23	is	be	AUX
ihlr-20834	579	24	used	use	VERB
ihlr-20834	579	25	to	to	PART
ihlr-20834	579	26	treat	treat	VERB
ihlr-20834	579	27	many	many	ADJ
ihlr-20834	579	28	conditions	condition	NOUN
ihlr-20834	579	29	,	,	PUNCT
ihlr-20834	579	30	including	include	VERB
ihlr-20834	579	31	“	"	PUNCT
ihlr-20834	579	32	headache	headache	NOUN
ihlr-20834	579	33	,	,	PUNCT
ihlr-20834	579	34	muscle	muscle	NOUN
ihlr-20834	579	35	aches	ache	VERB
ihlr-20834	579	36	,	,	PUNCT
ihlr-20834	579	37	arthritis	arthritis	NOUN
ihlr-20834	579	38	,	,	PUNCT
ihlr-20834	579	39	backache	backache	NOUN
ihlr-20834	579	40	,	,	PUNCT
ihlr-20834	579	41	toothaches	toothache	NOUN
ihlr-20834	579	42	,	,	PUNCT
ihlr-20834	579	43	colds	cold	NOUN
ihlr-20834	579	44	,	,	PUNCT
ihlr-20834	579	45	and	and	CCONJ
ihlr-20834	579	46	fevers	fever	NOUN
ihlr-20834	579	47	.	.	PUNCT
ihlr-20834	579	48	”	"	PUNCT
ihlr-20834	580	1	it	it	PRON
ihlr-20834	580	2	is	be	AUX
ihlr-20834	580	3	a	a	DET
ihlr-20834	580	4	common	common	ADJ
ihlr-20834	580	5	drug	drug	NOUN
ihlr-20834	580	6	and	and	CCONJ
ihlr-20834	580	7	there	there	PRON
ihlr-20834	580	8	are	be	VERB
ihlr-20834	580	9	many	many	ADJ
ihlr-20834	580	10	brands	brand	NOUN
ihlr-20834	580	11	and	and	CCONJ
ihlr-20834	580	12	forms	form	NOUN
ihlr-20834	580	13	available	available	ADJ
ihlr-20834	580	14	in	in	ADP
ihlr-20834	580	15	the	the	DET
ihlr-20834	580	16	marketplace	marketplace	NOUN
ihlr-20834	580	17	)	)	PUNCT
ihlr-20834	580	18	.	.	PUNCT
ihlr-20834	581	1	2015	2015	NUM
ihlr-20834	581	2	799	799	NUM
ihlr-20834	581	3	the	the	DET
ihlr-20834	581	4	supreme	supreme	PROPN
ihlr-20834	581	5	court	court	PROPN
ihlr-20834	581	6	’s	’s	PART
ihlr-20834	581	7	overreaching	overreach	VERB
ihlr-20834	581	8	preemption	preemption	NOUN
ihlr-20834	581	9	interpretation	interpretation	NOUN
ihlr-20834	581	10	and	and	CCONJ
ihlr-20834	581	11	it	it	PRON
ihlr-20834	581	12	’s	’	VERB
ihlr-20834	581	13	consequences	consequence	NOUN
ihlr-20834	581	14	plaintiff	plaintiff	NOUN
ihlr-20834	581	15	’s	’s	PART
ihlr-20834	581	16	“	"	PUNCT
ihlr-20834	581	17	state	state	NOUN
ihlr-20834	581	18	law	law	NOUN
ihlr-20834	581	19	claim	claim	NOUN
ihlr-20834	581	20	for	for	ADP
ihlr-20834	581	21	failure	failure	NOUN
ihlr-20834	581	22	to	to	PART
ihlr-20834	581	23	warn	warn	VERB
ihlr-20834	581	24	[	[	X
ihlr-20834	581	25	was	be	AUX
ihlr-20834	581	26	]	]	PUNCT
ihlr-20834	581	27	not	not	PART
ihlr-20834	581	28	implicitly	implicitly	ADV
ihlr-20834	581	29	preempted	preempt	VERB
ihlr-20834	581	30	by	by	ADP
ihlr-20834	581	31	the	the	DET
ihlr-20834	581	32	fdca	fdca	NOUN
ihlr-20834	581	33	.	.	PUNCT
ihlr-20834	581	34	”193	”193	PUNCT
ihlr-20834	582	1	if	if	SCONJ
ihlr-20834	582	2	the	the	DET
ihlr-20834	582	3	court	court	NOUN
ihlr-20834	582	4	in	in	ADP
ihlr-20834	582	5	lollar	lollar	PROPN
ihlr-20834	582	6	had	have	AUX
ihlr-20834	582	7	used	use	VERB
ihlr-20834	582	8	bartlett	bartlett	NOUN
ihlr-20834	582	9	as	as	ADP
ihlr-20834	582	10	precedent	precedent	NOUN
ihlr-20834	582	11	,	,	PUNCT
ihlr-20834	582	12	it	it	PRON
ihlr-20834	582	13	is	be	AUX
ihlr-20834	582	14	likely	likely	ADJ
ihlr-20834	582	15	mr	mr	PROPN
ihlr-20834	582	16	.	.	PROPN
ihlr-20834	582	17	lollar	lollar	PROPN
ihlr-20834	582	18	would	would	AUX
ihlr-20834	582	19	not	not	PART
ihlr-20834	582	20	have	have	AUX
ihlr-20834	582	21	had	have	VERB
ihlr-20834	582	22	a	a	DET
ihlr-20834	582	23	cause	cause	NOUN
ihlr-20834	582	24	of	of	ADP
ihlr-20834	582	25	action	action	NOUN
ihlr-20834	582	26	to	to	PART
ihlr-20834	582	27	supplant	supplant	VERB
ihlr-20834	582	28	his	his	PRON
ihlr-20834	582	29	“	"	PUNCT
ihlr-20834	582	30	alcoholic	alcoholic	ADJ
ihlr-20834	582	31	hepatitis	hepatitis	NOUN
ihlr-20834	582	32	,	,	PUNCT
ihlr-20834	582	33	alcoholic	alcoholic	ADJ
ihlr-20834	582	34	dependency	dependency	NOUN
ihlr-20834	582	35	continuous	continuous	ADJ
ihlr-20834	582	36	,	,	PUNCT
ihlr-20834	582	37	alcoholic	alcoholic	ADJ
ihlr-20834	582	38	gastritis	gastritis	NOUN
ihlr-20834	582	39	with	with	ADP
ihlr-20834	582	40	hemorrhage	hemorrhage	NOUN
ihlr-20834	582	41	,	,	PUNCT
ihlr-20834	582	42	and	and	CCONJ
ihlr-20834	582	43	acute	acute	ADJ
ihlr-20834	582	44	renal	renal	ADJ
ihlr-20834	582	45	failure	failure	NOUN
ihlr-20834	582	46	”	"	PUNCT
ihlr-20834	582	47	194	194	NUM
ihlr-20834	582	48	the	the	DET
ihlr-20834	582	49	decision	decision	NOUN
ihlr-20834	582	50	would	would	AUX
ihlr-20834	582	51	be	be	AUX
ihlr-20834	582	52	different	different	ADJ
ihlr-20834	582	53	under	under	ADP
ihlr-20834	582	54	bartlett	bartlett	NOUN
ihlr-20834	582	55	because	because	SCONJ
ihlr-20834	582	56	a	a	DET
ihlr-20834	582	57	generic	generic	ADJ
ihlr-20834	582	58	drug	drug	NOUN
ihlr-20834	582	59	manufacturer	manufacturer	NOUN
ihlr-20834	582	60	is	be	AUX
ihlr-20834	582	61	not	not	PART
ihlr-20834	582	62	able	able	ADJ
ihlr-20834	582	63	to	to	PART
ihlr-20834	582	64	unilaterally	unilaterally	ADV
ihlr-20834	582	65	change	change	VERB
ihlr-20834	582	66	the	the	DET
ihlr-20834	582	67	drugs	drug	NOUN
ihlr-20834	582	68	label	label	NOUN
ihlr-20834	582	69	,	,	PUNCT
ihlr-20834	582	70	other	other	ADJ
ihlr-20834	582	71	than	than	SCONJ
ihlr-20834	582	72	to	to	PART
ihlr-20834	582	73	match	match	VERB
ihlr-20834	582	74	the	the	DET
ihlr-20834	582	75	label	label	NOUN
ihlr-20834	582	76	of	of	ADP
ihlr-20834	582	77	a	a	DET
ihlr-20834	582	78	brand	brand	NOUN
ihlr-20834	582	79	-	-	PUNCT
ihlr-20834	582	80	name	name	NOUN
ihlr-20834	582	81	drug	drug	NOUN
ihlr-20834	582	82	as	as	SCONJ
ihlr-20834	582	83	required	require	VERB
ihlr-20834	582	84	under	under	ADP
ihlr-20834	582	85	the	the	DET
ihlr-20834	582	86	duty	duty	NOUN
ihlr-20834	582	87	-	-	PUNCT
ihlr-20834	582	88	ofsameness	ofsameness	NOUN
ihlr-20834	582	89	.	.	PUNCT
ihlr-20834	583	1	like	like	ADP
ihlr-20834	583	2	new	new	PROPN
ihlr-20834	583	3	hampshire	hampshire	PROPN
ihlr-20834	583	4	,	,	PUNCT
ihlr-20834	583	5	indiana	indiana	PROPN
ihlr-20834	583	6	as	as	ADP
ihlr-20834	583	7	a	a	DET
ihlr-20834	583	8	sovereign	sovereign	ADJ
ihlr-20834	583	9	state	state	NOUN
ihlr-20834	583	10	chose	choose	VERB
ihlr-20834	583	11	to	to	PART
ihlr-20834	583	12	create	create	VERB
ihlr-20834	583	13	certain	certain	ADJ
ihlr-20834	583	14	causes	cause	NOUN
ihlr-20834	583	15	-	-	PUNCT
ihlr-20834	583	16	of	of	ADP
ihlr-20834	583	17	-	-	PUNCT
ihlr-20834	583	18	action	action	NOUN
ihlr-20834	583	19	to	to	PART
ihlr-20834	583	20	protect	protect	VERB
ihlr-20834	583	21	its	its	PRON
ihlr-20834	583	22	citizens	citizen	NOUN
ihlr-20834	583	23	rights	right	NOUN
ihlr-20834	583	24	.	.	PUNCT
ihlr-20834	584	1	the	the	DET
ihlr-20834	584	2	underlying	underlying	ADJ
ihlr-20834	584	3	purpose	purpose	NOUN
ihlr-20834	584	4	of	of	ADP
ihlr-20834	584	5	indiana	indiana	PROPN
ihlr-20834	584	6	’s	’s	PART
ihlr-20834	584	7	(	(	PUNCT
ihlr-20834	584	8	and	and	CCONJ
ihlr-20834	584	9	new	new	PROPN
ihlr-20834	584	10	hampshire	hampshire	PROPN
ihlr-20834	584	11	’s	’s	PART
ihlr-20834	584	12	)	)	PUNCT
ihlr-20834	584	13	causes	cause	NOUN
ihlr-20834	584	14	-	-	PUNCT
ihlr-20834	584	15	of	of	ADP
ihlr-20834	584	16	-	-	PUNCT
ihlr-20834	584	17	action	action	NOUN
ihlr-20834	584	18	is	be	AUX
ihlr-20834	584	19	not	not	PART
ihlr-20834	584	20	to	to	PART
ihlr-20834	584	21	force	force	VERB
ihlr-20834	584	22	companies	company	NOUN
ihlr-20834	584	23	to	to	PART
ihlr-20834	584	24	change	change	VERB
ihlr-20834	584	25	their	their	PRON
ihlr-20834	584	26	labels	label	NOUN
ihlr-20834	584	27	,	,	PUNCT
ihlr-20834	584	28	but	but	CCONJ
ihlr-20834	584	29	to	to	PART
ihlr-20834	584	30	compensate	compensate	VERB
ihlr-20834	584	31	the	the	DET
ihlr-20834	584	32	injured	injure	VERB
ihlr-20834	584	33	and	and	CCONJ
ihlr-20834	584	34	to	to	PART
ihlr-20834	584	35	punish	punish	VERB
ihlr-20834	584	36	the	the	DET
ihlr-20834	584	37	negligent	negligent	ADJ
ihlr-20834	584	38	.	.	PUNCT
ihlr-20834	585	1	this	this	DET
ihlr-20834	585	2	rationale	rationale	NOUN
ihlr-20834	585	3	was	be	AUX
ihlr-20834	585	4	pointed	point	VERB
ihlr-20834	585	5	out	out	ADP
ihlr-20834	585	6	by	by	ADP
ihlr-20834	585	7	the	the	DET
ihlr-20834	585	8	dissent	dissent	NOUN
ihlr-20834	585	9	in	in	ADP
ihlr-20834	585	10	mutual	mutual	ADJ
ihlr-20834	585	11	which	which	PRON
ihlr-20834	585	12	stated	state	VERB
ihlr-20834	585	13	that	that	SCONJ
ihlr-20834	585	14	the	the	DET
ihlr-20834	585	15	manufacturer	manufacturer	NOUN
ihlr-20834	585	16	was	be	AUX
ihlr-20834	585	17	held	hold	VERB
ihlr-20834	585	18	liable	liable	ADJ
ihlr-20834	585	19	for	for	ADP
ihlr-20834	585	20	breaching	breach	VERB
ihlr-20834	585	21	the	the	DET
ihlr-20834	585	22	duty	duty	NOUN
ihlr-20834	585	23	to	to	PART
ihlr-20834	585	24	adequately	adequately	ADV
ihlr-20834	585	25	label	label	VERB
ihlr-20834	585	26	sulindac	sulindac	NOUN
ihlr-20834	585	27	so	so	SCONJ
ihlr-20834	585	28	that	that	SCONJ
ihlr-20834	585	29	it	it	PRON
ihlr-20834	585	30	was	be	AUX
ihlr-20834	585	31	not	not	PART
ihlr-20834	585	32	“	"	PUNCT
ihlr-20834	585	33	unreasonably	unreasonably	ADV
ihlr-20834	585	34	dangerous	dangerous	ADJ
ihlr-20834	585	35	,	,	PUNCT
ihlr-20834	585	36	”	"	PUNCT
ihlr-20834	585	37	not	not	PART
ihlr-20834	585	38	for	for	ADP
ihlr-20834	585	39	“	"	PUNCT
ihlr-20834	585	40	failing	fail	VERB
ihlr-20834	585	41	to	to	PART
ihlr-20834	585	42	change	change	VERB
ihlr-20834	585	43	”	"	PUNCT
ihlr-20834	585	44	its	its	PRON
ihlr-20834	585	45	warning.195	warning.195	NOUN
ihlr-20834	585	46	in	in	ADP
ihlr-20834	585	47	the	the	DET
ihlr-20834	585	48	similarly	similarly	ADV
ihlr-20834	585	49	decided	decide	VERB
ihlr-20834	585	50	indiana	indiana	PROPN
ihlr-20834	585	51	case	case	NOUN
ihlr-20834	585	52	,	,	PUNCT
ihlr-20834	585	53	tucker	tucker	PROPN
ihlr-20834	585	54	v.	v.	PROPN
ihlr-20834	585	55	smithkline	smithkline	PROPN
ihlr-20834	585	56	beecham	beecham	PROPN
ihlr-20834	585	57	corp	corp	PROPN
ihlr-20834	585	58	.	.	PROPN
ihlr-20834	585	59	,	,	PUNCT
ihlr-20834	585	60	the	the	DET
ihlr-20834	585	61	plaintiff	plaintiff	NOUN
ihlr-20834	585	62	brought	bring	VERB
ihlr-20834	585	63	a	a	DET
ihlr-20834	585	64	wrongful	wrongful	ADJ
ihlr-20834	585	65	death	death	NOUN
ihlr-20834	585	66	claim	claim	NOUN
ihlr-20834	585	67	under	under	ADP
ihlr-20834	585	68	indiana	indiana	PROPN
ihlr-20834	585	69	law	law	NOUN
ihlr-20834	585	70	against	against	ADP
ihlr-20834	585	71	the	the	DET
ihlr-20834	585	72	defendant	defendant	NOUN
ihlr-20834	585	73	drug	drug	NOUN
ihlr-20834	585	74	manufacturer	manufacturer	NOUN
ihlr-20834	585	75	,	,	PUNCT
ihlr-20834	585	76	claiming	claim	VERB
ihlr-20834	585	77	that	that	SCONJ
ihlr-20834	585	78	her	her	PRON
ihlr-20834	585	79	brother	brother	NOUN
ihlr-20834	585	80	committed	commit	VERB
ihlr-20834	585	81	suicide	suicide	NOUN
ihlr-20834	585	82	as	as	ADP
ihlr-20834	585	83	a	a	DET
ihlr-20834	585	84	result	result	NOUN
ihlr-20834	585	85	of	of	ADP
ihlr-20834	585	86	taking	take	VERB
ihlr-20834	585	87	the	the	DET
ihlr-20834	585	88	manufacturer	manufacturer	NOUN
ihlr-20834	585	89	’s	’s	PART
ihlr-20834	585	90	antidepressant	antidepressant	NOUN
ihlr-20834	585	91	and	and	CCONJ
ihlr-20834	585	92	that	that	SCONJ
ihlr-20834	585	93	the	the	DET
ihlr-20834	585	94	drug	drug	NOUN
ihlr-20834	585	95	manufacturer	manufacturer	NOUN
ihlr-20834	585	96	breached	breach	VERB
ihlr-20834	585	97	its	its	PRON
ihlr-20834	585	98	duty	duty	NOUN
ihlr-20834	585	99	to	to	PART
ihlr-20834	585	100	warn.196	warn.196	VERB
ihlr-20834	585	101	the	the	DET
ihlr-20834	585	102	court	court	NOUN
ihlr-20834	585	103	held	hold	VERB
ihlr-20834	585	104	that	that	SCONJ
ihlr-20834	585	105	there	there	PRON
ihlr-20834	585	106	was	be	VERB
ihlr-20834	585	107	no	no	DET
ihlr-20834	585	108	preemption	preemption	NOUN
ihlr-20834	585	109	by	by	ADP
ihlr-20834	585	110	reasoning	reason	VERB
ihlr-20834	585	111	that	that	SCONJ
ihlr-20834	585	112	the	the	DET
ihlr-20834	585	113	manufacturer	manufacturer	NOUN
ihlr-20834	585	114	had	have	VERB
ihlr-20834	585	115	a	a	DET
ihlr-20834	585	116	duty	duty	NOUN
ihlr-20834	585	117	to	to	PART
ihlr-20834	585	118	strengthen	strengthen	VERB
ihlr-20834	585	119	its	its	PRON
ihlr-20834	585	120	label	label	NOUN
ihlr-20834	585	121	and	and	CCONJ
ihlr-20834	585	122	that	that	SCONJ
ihlr-20834	585	123	“	"	PUNCT
ihlr-20834	585	124	if	if	SCONJ
ihlr-20834	585	125	the	the	DET
ihlr-20834	585	126	fda	fda	PROPN
ihlr-20834	585	127	exercise[d	exercise[d	PROPN
ihlr-20834	585	128	]	]	PUNCT
ihlr-20834	585	129	its	its	PRON
ihlr-20834	585	130	power	power	NOUN
ihlr-20834	585	131	to	to	PART
ihlr-20834	585	132	disapprove	disapprove	VERB
ihlr-20834	585	133	the	the	DET
ihlr-20834	585	134	revised	revise	VERB
ihlr-20834	585	135	label	label	NOUN
ihlr-20834	585	136	,	,	PUNCT
ihlr-20834	585	137	the	the	DET
ihlr-20834	585	138	fda	fda	PROPN
ihlr-20834	585	139	’s	’s	PART
ihlr-20834	585	140	disapproval	disapproval	NOUN
ihlr-20834	585	141	is	be	AUX
ihlr-20834	585	142	not	not	PART
ihlr-20834	585	143	retroactively	retroactively	ADV
ihlr-20834	585	144	illegal	illegal	ADJ
ihlr-20834	585	145	;	;	PUNCT
ihlr-20834	585	146	the	the	DET
ihlr-20834	585	147	manufacturer	manufacturer	NOUN
ihlr-20834	585	148	[	[	X
ihlr-20834	585	149	can	can	AUX
ihlr-20834	585	150	]	]	PART
ihlr-20834	585	151	simply	simply	ADV
ihlr-20834	585	152	stop	stop	VERB
ihlr-20834	585	153	[	[	X
ihlr-20834	585	154	]	]	X
ihlr-20834	585	155	distributing	distribute	VERB
ihlr-20834	585	156	the	the	DET
ihlr-20834	585	157	new	new	ADJ
ihlr-20834	585	158	label	label	NOUN
ihlr-20834	585	159	.	.	PUNCT
ihlr-20834	585	160	”197	”197	PUNCT
ihlr-20834	585	161	thus	thus	ADV
ihlr-20834	585	162	,	,	PUNCT
ihlr-20834	585	163	under	under	ADP
ihlr-20834	585	164	the	the	DET
ihlr-20834	585	165	court	court	NOUN
ihlr-20834	585	166	’s	’s	PART
ihlr-20834	585	167	holding	holding	NOUN
ihlr-20834	585	168	,	,	PUNCT
ihlr-20834	585	169	the	the	DET
ihlr-20834	585	170	deceased	deceased	ADJ
ihlr-20834	585	171	193	193	NUM
ihlr-20834	585	172	bell	bell	NOUN
ihlr-20834	585	173	,	,	PUNCT
ihlr-20834	585	174	791	791	NUM
ihlr-20834	585	175	n.e.2d	n.e.2d	NOUN
ihlr-20834	585	176	at	at	ADP
ihlr-20834	585	177	855	855	NUM
ihlr-20834	585	178	.	.	PUNCT
ihlr-20834	586	1	194	194	NUM
ihlr-20834	587	1	i	i	PRON
ihlr-20834	587	2	d.	d.	PROPN
ihlr-20834	587	3	at	at	ADP
ihlr-20834	587	4	850	850	NUM
ihlr-20834	587	5	.	.	PUNCT
ihlr-20834	587	6	195	195	NUM
ihlr-20834	587	7	mut	mut	NOUN
ihlr-20834	587	8	.	.	PUNCT
ihlr-20834	588	1	pharm	pharm	PROPN
ihlr-20834	588	2	.	.	PUNCT
ihlr-20834	589	1	co.	co.	PROPN
ihlr-20834	589	2	,	,	PUNCT
ihlr-20834	589	3	inc	inc	PROPN
ihlr-20834	589	4	.	.	PROPN
ihlr-20834	590	1	v.	v.	ADP
ihlr-20834	590	2	bartlett	bartlett	PROPN
ihlr-20834	590	3	,	,	PUNCT
ihlr-20834	590	4	133	133	NUM
ihlr-20834	590	5	s.ct	s.ct	PROPN
ihlr-20834	590	6	2466	2466	NUM
ihlr-20834	590	7	,	,	PUNCT
ihlr-20834	590	8	2490	2490	NUM
ihlr-20834	590	9	(	(	PUNCT
ihlr-20834	590	10	2013	2013	NUM
ihlr-20834	590	11	)	)	PUNCT
ihlr-20834	590	12	(	(	PUNCT
ihlr-20834	590	13	sotomayor	sotomayor	PROPN
ihlr-20834	590	14	,	,	PUNCT
ihlr-20834	590	15	j.	j.	PROPN
ihlr-20834	590	16	,	,	PUNCT
ihlr-20834	590	17	dissenting	dissent	VERB
ihlr-20834	590	18	)	)	PUNCT
ihlr-20834	590	19	.	.	PUNCT
ihlr-20834	591	1	196	196	NUM
ihlr-20834	591	2	tucker	tucker	PROPN
ihlr-20834	591	3	v.	v.	PROPN
ihlr-20834	591	4	smithkline	smithkline	PROPN
ihlr-20834	591	5	beecham	beecham	PROPN
ihlr-20834	591	6	corp	corp	PROPN
ihlr-20834	591	7	.	.	PROPN
ihlr-20834	591	8	,	,	PUNCT
ihlr-20834	591	9	596	596	NUM
ihlr-20834	591	10	f.supp.2d	f.supp.2d	NUM
ihlr-20834	591	11	1225	1225	NUM
ihlr-20834	591	12	,	,	PUNCT
ihlr-20834	591	13	1227	1227	NUM
ihlr-20834	591	14	(	(	PUNCT
ihlr-20834	591	15	s.d	s.d	PROPN
ihlr-20834	591	16	.	.	PROPN
ihlr-20834	591	17	ind	ind	PROPN
ihlr-20834	591	18	.	.	PUNCT
ihlr-20834	591	19	2008	2008	NUM
ihlr-20834	591	20	)	)	PUNCT
ihlr-20834	591	21	.	.	PUNCT
ihlr-20834	592	1	197	197	NUM
ihlr-20834	593	1	i	i	PRON
ihlr-20834	593	2	d.	d.	PROPN
ihlr-20834	593	3	at	at	ADP
ihlr-20834	593	4	1229	1229	NUM
ihlr-20834	593	5	(	(	PUNCT
ihlr-20834	593	6	citing	cite	VERB
ihlr-20834	593	7	21	21	NUM
ihlr-20834	593	8	c.f.r	c.f.r	NOUN
ihlr-20834	593	9	.	.	PUNCT
ihlr-20834	594	1	§	§	PROPN
ihlr-20834	594	2	314.70(c	314.70(c	NUM
ihlr-20834	594	3	)	)	PUNCT
ihlr-20834	594	4	;	;	PUNCT
ihlr-20834	595	1	witczak	witczak	X
ihlr-20834	595	2	v.	v.	CCONJ
ihlr-20834	595	3	pfizer	pfizer	PROPN
ihlr-20834	595	4	,	,	PUNCT
ihlr-20834	595	5	inc	inc	PROPN
ihlr-20834	595	6	.	.	PROPN
ihlr-20834	595	7	,	,	PUNCT
ihlr-20834	595	8	377	377	NUM
ihlr-20834	595	9	f.supp.2d	f.supp.2d	NOUN
ihlr-20834	595	10	726	726	NUM
ihlr-20834	595	11	,	,	PUNCT
ihlr-20834	595	12	729	729	NUM
ihlr-20834	595	13	(	(	PUNCT
ihlr-20834	595	14	d.	d.	PROPN
ihlr-20834	595	15	minn	minn	PROPN
ihlr-20834	595	16	.	.	PROPN
ihlr-20834	595	17	2005	2005	NUM
ihlr-20834	595	18	)	)	PUNCT
ihlr-20834	595	19	)	)	PUNCT
ihlr-20834	595	20	.	.	PUNCT
ihlr-20834	596	1	800	800	NUM
ihlr-20834	596	2	indiana	indiana	PROPN
ihlr-20834	596	3	health	health	PROPN
ihlr-20834	596	4	law	law	PROPN
ihlr-20834	596	5	review	review	NOUN
ihlr-20834	596	6	vol	vol	NOUN
ihlr-20834	596	7	.	.	PROPN
ihlr-20834	596	8	12:2	12:2	NUM
ihlr-20834	596	9	beneficiary	beneficiary	NOUN
ihlr-20834	596	10	/	/	SYM
ihlr-20834	596	11	next	next	ADJ
ihlr-20834	596	12	-	-	PUNCT
ihlr-20834	596	13	of	of	ADP
ihlr-20834	596	14	-	-	PUNCT
ihlr-20834	596	15	kin	kin	NOUN
ihlr-20834	596	16	would	would	AUX
ihlr-20834	596	17	have	have	VERB
ihlr-20834	596	18	a	a	DET
ihlr-20834	596	19	cause	cause	VERB
ihlr-20834	596	20	-	-	PUNCT
ihlr-20834	596	21	of	of	ADP
ihlr-20834	596	22	-	-	PUNCT
ihlr-20834	596	23	action	action	NOUN
ihlr-20834	596	24	because	because	SCONJ
ihlr-20834	596	25	the	the	DET
ihlr-20834	596	26	manufacturer	manufacturer	NOUN
ihlr-20834	596	27	failed	fail	VERB
ihlr-20834	596	28	in	in	ADP
ihlr-20834	596	29	its	its	PRON
ihlr-20834	596	30	duty	duty	NOUN
ihlr-20834	596	31	to	to	PART
ihlr-20834	596	32	provide	provide	VERB
ihlr-20834	596	33	a	a	DET
ihlr-20834	596	34	label	label	NOUN
ihlr-20834	596	35	that	that	PRON
ihlr-20834	596	36	is	be	AUX
ihlr-20834	596	37	not	not	PART
ihlr-20834	596	38	“	"	PUNCT
ihlr-20834	596	39	unreasonably	unreasonably	ADV
ihlr-20834	596	40	dangerous	dangerous	ADJ
ihlr-20834	596	41	.	.	PUNCT
ihlr-20834	596	42	”	"	PUNCT
ihlr-20834	597	1	the	the	DET
ihlr-20834	597	2	tucker	tucker	PROPN
ihlr-20834	597	3	decision	decision	NOUN
ihlr-20834	597	4	likely	likely	ADV
ihlr-20834	597	5	would	would	AUX
ihlr-20834	597	6	have	have	AUX
ihlr-20834	597	7	been	be	AUX
ihlr-20834	597	8	decided	decide	VERB
ihlr-20834	597	9	differently	differently	ADV
ihlr-20834	597	10	if	if	SCONJ
ihlr-20834	597	11	the	the	DET
ihlr-20834	597	12	court	court	NOUN
ihlr-20834	597	13	had	have	AUX
ihlr-20834	597	14	relied	rely	VERB
ihlr-20834	597	15	upon	upon	SCONJ
ihlr-20834	597	16	bartlett	bartlett	NOUN
ihlr-20834	597	17	as	as	ADP
ihlr-20834	597	18	precedent	precedent	NOUN
ihlr-20834	597	19	.	.	PUNCT
ihlr-20834	598	1	if	if	SCONJ
ihlr-20834	598	2	the	the	DET
ihlr-20834	598	3	tucker	tucker	PROPN
ihlr-20834	598	4	court	court	PROPN
ihlr-20834	598	5	relied	rely	VERB
ihlr-20834	598	6	on	on	ADP
ihlr-20834	598	7	bartlett	bartlett	PROPN
ihlr-20834	598	8	,	,	PUNCT
ihlr-20834	598	9	the	the	DET
ihlr-20834	598	10	court	court	NOUN
ihlr-20834	598	11	likely	likely	ADV
ihlr-20834	598	12	would	would	AUX
ihlr-20834	598	13	have	have	AUX
ihlr-20834	598	14	concluded	conclude	VERB
ihlr-20834	598	15	that	that	SCONJ
ihlr-20834	598	16	the	the	DET
ihlr-20834	598	17	preemption	preemption	NOUN
ihlr-20834	598	18	doctrine	doctrine	NOUN
ihlr-20834	598	19	would	would	AUX
ihlr-20834	598	20	apply	apply	VERB
ihlr-20834	598	21	because	because	SCONJ
ihlr-20834	598	22	it	it	PRON
ihlr-20834	598	23	would	would	AUX
ihlr-20834	598	24	be	be	AUX
ihlr-20834	598	25	impossible	impossible	ADJ
ihlr-20834	598	26	for	for	SCONJ
ihlr-20834	598	27	the	the	DET
ihlr-20834	598	28	drug	drug	NOUN
ihlr-20834	598	29	manufacturer	manufacturer	NOUN
ihlr-20834	598	30	to	to	PART
ihlr-20834	598	31	comply	comply	VERB
ihlr-20834	598	32	with	with	ADP
ihlr-20834	598	33	the	the	DET
ihlr-20834	598	34	state	state	NOUN
ihlr-20834	598	35	law	law	NOUN
ihlr-20834	598	36	of	of	ADP
ihlr-20834	598	37	strengthening	strengthen	VERB
ihlr-20834	598	38	the	the	DET
ihlr-20834	598	39	drug	drug	NOUN
ihlr-20834	598	40	’s	’s	PART
ihlr-20834	598	41	label	label	NOUN
ihlr-20834	598	42	so	so	SCONJ
ihlr-20834	598	43	as	as	SCONJ
ihlr-20834	598	44	to	to	PART
ihlr-20834	598	45	not	not	PART
ihlr-20834	598	46	make	make	VERB
ihlr-20834	598	47	it	it	PRON
ihlr-20834	598	48	unreasonably	unreasonably	ADV
ihlr-20834	598	49	dangerous	dangerous	ADJ
ihlr-20834	598	50	and	and	CCONJ
ihlr-20834	598	51	with	with	ADP
ihlr-20834	598	52	the	the	DET
ihlr-20834	598	53	federal	federal	ADJ
ihlr-20834	598	54	law	law	NOUN
ihlr-20834	598	55	requiring	require	VERB
ihlr-20834	598	56	the	the	DET
ihlr-20834	598	57	same	same	ADJ
ihlr-20834	598	58	label	label	NOUN
ihlr-20834	598	59	as	as	ADP
ihlr-20834	598	60	the	the	DET
ihlr-20834	598	61	brand	brand	NOUN
ihlr-20834	598	62	-	-	PUNCT
ihlr-20834	598	63	name	name	NOUN
ihlr-20834	598	64	counterpart	counterpart	NOUN
ihlr-20834	598	65	.	.	PUNCT
ihlr-20834	599	1	an	an	DET
ihlr-20834	599	2	inequitable	inequitable	ADJ
ihlr-20834	599	3	decision	decision	NOUN
ihlr-20834	599	4	would	would	AUX
ihlr-20834	599	5	have	have	AUX
ihlr-20834	599	6	resulted	result	VERB
ihlr-20834	599	7	,	,	PUNCT
ihlr-20834	599	8	as	as	SCONJ
ihlr-20834	599	9	a	a	DET
ihlr-20834	599	10	negligent	negligent	ADJ
ihlr-20834	599	11	drug	drug	NOUN
ihlr-20834	599	12	manufacturer	manufacturer	NOUN
ihlr-20834	599	13	would	would	AUX
ihlr-20834	599	14	have	have	AUX
ihlr-20834	599	15	left	leave	VERB
ihlr-20834	599	16	the	the	DET
ihlr-20834	599	17	injured	injured	ADJ
ihlr-20834	599	18	party	party	NOUN
ihlr-20834	599	19	’s	’s	PART
ihlr-20834	599	20	beneficiary	beneficiary	NOUN
ihlr-20834	599	21	/	/	SYM
ihlr-20834	599	22	next	next	ADJ
ihlr-20834	599	23	-	-	PUNCT
ihlr-20834	599	24	of	of	ADP
ihlr-20834	599	25	-	-	PUNCT
ihlr-20834	599	26	kin	kin	NOUN
ihlr-20834	599	27	without	without	ADP
ihlr-20834	599	28	legal	legal	ADJ
ihlr-20834	599	29	recourse	recourse	NOUN
ihlr-20834	599	30	to	to	PART
ihlr-20834	599	31	address	address	VERB
ihlr-20834	599	32	the	the	DET
ihlr-20834	599	33	manufacturer	manufacturer	NOUN
ihlr-20834	599	34	’s	’s	PART
ihlr-20834	599	35	negligence	negligence	NOUN
ihlr-20834	599	36	.	.	PUNCT
ihlr-20834	600	1	following	follow	VERB
ihlr-20834	600	2	the	the	DET
ihlr-20834	600	3	decisions	decision	NOUN
ihlr-20834	600	4	in	in	ADP
ihlr-20834	600	5	pliva	pliva	NOUN
ihlr-20834	600	6	and	and	CCONJ
ihlr-20834	600	7	bartlett	bartlett	PROPN
ihlr-20834	600	8	,	,	PUNCT
ihlr-20834	600	9	as	as	ADV
ihlr-20834	600	10	many	many	ADJ
ihlr-20834	600	11	as	as	ADP
ihlr-20834	600	12	6,596,855	6,596,855	NUM
ihlr-20834	600	13	indiana	indiana	PROPN
ihlr-20834	600	14	residents	resident	NOUN
ihlr-20834	600	15	may	may	AUX
ihlr-20834	600	16	be	be	AUX
ihlr-20834	600	17	left	leave	VERB
ihlr-20834	600	18	without	without	ADP
ihlr-20834	600	19	legal	legal	ADJ
ihlr-20834	600	20	recourse	recourse	NOUN
ihlr-20834	600	21	to	to	PART
ihlr-20834	600	22	address	address	VERB
ihlr-20834	600	23	generic	generic	ADJ
ihlr-20834	600	24	drug	drug	NOUN
ihlr-20834	600	25	manufacturer	manufacturer	NOUN
ihlr-20834	600	26	breaches.198	breaches.198	NOUN
ihlr-20834	600	27	these	these	DET
ihlr-20834	600	28	two	two	NUM
ihlr-20834	600	29	decisions	decision	NOUN
ihlr-20834	600	30	are	be	AUX
ihlr-20834	600	31	in	in	ADP
ihlr-20834	600	32	essence	essence	NOUN
ihlr-20834	600	33	providing	provide	VERB
ihlr-20834	600	34	legal	legal	ADJ
ihlr-20834	600	35	immunity	immunity	NOUN
ihlr-20834	600	36	to	to	ADP
ihlr-20834	600	37	generic	generic	ADJ
ihlr-20834	600	38	drug	drug	NOUN
ihlr-20834	600	39	manufacturers	manufacturer	NOUN
ihlr-20834	600	40	.	.	PUNCT
ihlr-20834	601	1	approximately	approximately	ADV
ihlr-20834	601	2	80	80	NUM
ihlr-20834	601	3	%	%	NOUN
ihlr-20834	601	4	of	of	ADP
ihlr-20834	601	5	all	all	DET
ihlr-20834	601	6	drugs	drug	NOUN
ihlr-20834	601	7	purchased	purchase	VERB
ihlr-20834	601	8	are	be	AUX
ihlr-20834	601	9	generic	generic	ADJ
ihlr-20834	601	10	.	.	PUNCT
ihlr-20834	602	1	therefore	therefore	ADV
ihlr-20834	602	2	,	,	PUNCT
ihlr-20834	602	3	as	as	ADV
ihlr-20834	602	4	many	many	ADJ
ihlr-20834	602	5	as	as	ADP
ihlr-20834	602	6	3,694,239	3,694,239	NUM
ihlr-20834	602	7	indiana	indiana	PROPN
ihlr-20834	602	8	residents	resident	NOUN
ihlr-20834	602	9	may	may	AUX
ihlr-20834	602	10	be	be	AUX
ihlr-20834	602	11	left	leave	VERB
ihlr-20834	602	12	without	without	ADP
ihlr-20834	602	13	the	the	DET
ihlr-20834	602	14	right	right	NOUN
ihlr-20834	602	15	to	to	PART
ihlr-20834	602	16	sue	sue	VERB
ihlr-20834	602	17	generic	generic	ADJ
ihlr-20834	602	18	drug	drug	NOUN
ihlr-20834	602	19	manufacturers.199	manufacturers.199	NOUN
ihlr-20834	602	20	it	it	PRON
ihlr-20834	602	21	remains	remain	VERB
ihlr-20834	602	22	important	important	ADJ
ihlr-20834	602	23	to	to	PART
ihlr-20834	602	24	address	address	VERB
ihlr-20834	602	25	this	this	DET
ihlr-20834	602	26	large	large	ADJ
ihlr-20834	602	27	legal	legal	ADJ
ihlr-20834	602	28	gap	gap	NOUN
ihlr-20834	602	29	.	.	PUNCT
ihlr-20834	603	1	c.	c.	NOUN
ihlr-20834	603	2	recourse	recourse	NOUN
ihlr-20834	603	3	available	available	ADJ
ihlr-20834	603	4	to	to	ADP
ihlr-20834	603	5	generic	generic	ADJ
ihlr-20834	603	6	drug	drug	NOUN
ihlr-20834	603	7	consumers	consumer	NOUN
ihlr-20834	603	8	today	today	NOUN
ihlr-20834	603	9	,	,	PUNCT
ihlr-20834	603	10	seven	seven	NUM
ihlr-20834	603	11	in	in	ADP
ihlr-20834	603	12	ten	ten	NUM
ihlr-20834	603	13	americans	americans	PROPN
ihlr-20834	603	14	take	take	VERB
ihlr-20834	603	15	prescription	prescription	NOUN
ihlr-20834	603	16	drugs	drug	NOUN
ihlr-20834	603	17	to	to	PART
ihlr-20834	603	18	treat	treat	VERB
ihlr-20834	603	19	various	various	ADJ
ihlr-20834	603	20	health	health	NOUN
ihlr-20834	603	21	issues.200	issues.200	VERB
ihlr-20834	603	22	a	a	DET
ihlr-20834	603	23	significant	significant	ADJ
ihlr-20834	603	24	portion	portion	NOUN
ihlr-20834	603	25	of	of	ADP
ihlr-20834	603	26	these	these	DET
ihlr-20834	603	27	198	198	NUM
ihlr-20834	603	28	indiana	indiana	PROPN
ihlr-20834	603	29	,	,	PUNCT
ihlr-20834	603	30	u.s	u.s	PROPN
ihlr-20834	603	31	.	.	PROPN
ihlr-20834	603	32	census	census	PROPN
ihlr-20834	603	33	bureau	bureau	PROPN
ihlr-20834	603	34	,	,	PUNCT
ihlr-20834	603	35	available	available	ADJ
ihlr-20834	603	36	at	at	ADP
ihlr-20834	603	37	http://quickfacts.census.gov/qfd/states/18000.html	http://quickfacts.census.gov/qfd/states/18000.html	PROPN
ihlr-20834	603	38	(	(	PUNCT
ihlr-20834	603	39	last	last	ADV
ihlr-20834	603	40	visited	visit	VERB
ihlr-20834	603	41	mar	mar	PROPN
ihlr-20834	603	42	.	.	PROPN
ihlr-20834	603	43	30	30	NUM
ihlr-20834	603	44	,	,	PUNCT
ihlr-20834	603	45	2015	2015	NUM
ihlr-20834	603	46	)	)	PUNCT
ihlr-20834	603	47	.	.	PUNCT
ihlr-20834	604	1	199	199	NUM
ihlr-20834	605	1	i	i	PRON
ihlr-20834	605	2	d.	d.	PROPN
ihlr-20834	605	3	see	see	AUX
ihlr-20834	605	4	also	also	ADV
ihlr-20834	605	5	footnote	footnote	VERB
ihlr-20834	605	6	1	1	NUM
ihlr-20834	605	7	.	.	PUNCT
ihlr-20834	606	1	because	because	SCONJ
ihlr-20834	606	2	approximately	approximately	ADV
ihlr-20834	606	3	7	7	NUM
ihlr-20834	606	4	in	in	ADP
ihlr-20834	606	5	10	10	NUM
ihlr-20834	606	6	americans	americans	PROPN
ihlr-20834	606	7	have	have	AUX
ihlr-20834	606	8	taken	take	VERB
ihlr-20834	606	9	prescription	prescription	NOUN
ihlr-20834	606	10	drugs	drug	NOUN
ihlr-20834	606	11	,	,	PUNCT
ihlr-20834	606	12	an	an	DET
ihlr-20834	606	13	estimated	estimate	VERB
ihlr-20834	606	14	4,617,798	4,617,798	NUM
ihlr-20834	606	15	indiana	indiana	PROPN
ihlr-20834	606	16	residents	resident	NOUN
ihlr-20834	606	17	have	have	AUX
ihlr-20834	606	18	taken	take	VERB
ihlr-20834	606	19	prescription	prescription	NOUN
ihlr-20834	606	20	drugs	drug	NOUN
ihlr-20834	606	21	.	.	PUNCT
ihlr-20834	607	1	because	because	SCONJ
ihlr-20834	607	2	80	80	NUM
ihlr-20834	607	3	%	%	NOUN
ihlr-20834	607	4	of	of	ADP
ihlr-20834	607	5	drugs	drug	NOUN
ihlr-20834	607	6	taken	take	VERB
ihlr-20834	607	7	are	be	AUX
ihlr-20834	607	8	generic	generic	ADJ
ihlr-20834	607	9	,	,	PUNCT
ihlr-20834	607	10	an	an	DET
ihlr-20834	607	11	estimated	estimate	VERB
ihlr-20834	607	12	3,694,239	3,694,239	NUM
ihlr-20834	607	13	indiana	indiana	NOUN
ihlr-20834	607	14	residents	resident	NOUN
ihlr-20834	607	15	have	have	AUX
ihlr-20834	607	16	taken	take	VERB
ihlr-20834	607	17	generic	generic	ADJ
ihlr-20834	607	18	prescription	prescription	NOUN
ihlr-20834	607	19	drugs	drug	NOUN
ihlr-20834	607	20	(	(	PUNCT
ihlr-20834	607	21	6,596,855	6,596,855	NUM
ihlr-20834	607	22	residents	resident	NOUN
ihlr-20834	607	23	divided	divide	VERB
ihlr-20834	607	24	by	by	ADP
ihlr-20834	607	25	70	70	NUM
ihlr-20834	607	26	%	%	NOUN
ihlr-20834	607	27	(	(	PUNCT
ihlr-20834	607	28	the	the	DET
ihlr-20834	607	29	percentage	percentage	NOUN
ihlr-20834	607	30	of	of	ADP
ihlr-20834	607	31	individuals	individual	NOUN
ihlr-20834	607	32	taking	take	VERB
ihlr-20834	607	33	prescription	prescription	NOUN
ihlr-20834	607	34	drugs	drug	NOUN
ihlr-20834	607	35	)	)	PUNCT
ihlr-20834	607	36	divided	divide	VERB
ihlr-20834	607	37	by	by	ADP
ihlr-20834	607	38	80	80	NUM
ihlr-20834	607	39	%	%	NOUN
ihlr-20834	607	40	(	(	PUNCT
ihlr-20834	607	41	the	the	DET
ihlr-20834	607	42	estimated	estimate	VERB
ihlr-20834	607	43	number	number	NOUN
ihlr-20834	607	44	of	of	ADP
ihlr-20834	607	45	individuals	individual	NOUN
ihlr-20834	607	46	that	that	PRON
ihlr-20834	607	47	take	take	VERB
ihlr-20834	607	48	generic	generic	ADJ
ihlr-20834	607	49	drugs	drug	NOUN
ihlr-20834	607	50	)	)	PUNCT
ihlr-20834	607	51	)	)	PUNCT
ihlr-20834	607	52	.	.	PUNCT
ihlr-20834	608	1	200	200	NUM
ihlr-20834	608	2	nearly	nearly	ADV
ihlr-20834	608	3	7	7	NUM
ihlr-20834	608	4	in	in	ADP
ihlr-20834	608	5	10	10	NUM
ihlr-20834	608	6	americans	americans	PROPN
ihlr-20834	608	7	,	,	PUNCT
ihlr-20834	608	8	supra	supra	PROPN
ihlr-20834	608	9	note	note	NOUN
ihlr-20834	608	10	4	4	NUM
ihlr-20834	608	11	.	.	NOUN
ihlr-20834	608	12	2015	2015	NUM
ihlr-20834	608	13	801	801	NUM
ihlr-20834	608	14	the	the	DET
ihlr-20834	608	15	supreme	supreme	PROPN
ihlr-20834	608	16	court	court	PROPN
ihlr-20834	608	17	’s	’s	PART
ihlr-20834	608	18	overreaching	overreach	VERB
ihlr-20834	608	19	preemption	preemption	NOUN
ihlr-20834	608	20	interpretation	interpretation	NOUN
ihlr-20834	608	21	and	and	CCONJ
ihlr-20834	608	22	it	it	PRON
ihlr-20834	608	23	’s	’	VERB
ihlr-20834	608	24	consequences	consequence	VERB
ihlr-20834	608	25	individuals	individual	NOUN
ihlr-20834	608	26	who	who	PRON
ihlr-20834	608	27	opt	opt	VERB
ihlr-20834	608	28	to	to	PART
ihlr-20834	608	29	take	take	VERB
ihlr-20834	608	30	generics	generic	NOUN
ihlr-20834	608	31	will	will	AUX
ihlr-20834	608	32	have	have	VERB
ihlr-20834	608	33	no	no	DET
ihlr-20834	608	34	access	access	NOUN
ihlr-20834	608	35	to	to	ADP
ihlr-20834	608	36	compensation	compensation	NOUN
ihlr-20834	608	37	if	if	SCONJ
ihlr-20834	608	38	injured	injure	VERB
ihlr-20834	608	39	as	as	ADP
ihlr-20834	608	40	a	a	DET
ihlr-20834	608	41	result	result	NOUN
ihlr-20834	608	42	of	of	ADP
ihlr-20834	608	43	a	a	DET
ihlr-20834	608	44	drug	drug	NOUN
ihlr-20834	608	45	manufacturer	manufacturer	NOUN
ihlr-20834	608	46	’s	’s	PART
ihlr-20834	608	47	design	design	NOUN
ihlr-20834	608	48	-	-	PUNCT
ihlr-20834	608	49	defect	defect	NOUN
ihlr-20834	608	50	or	or	CCONJ
ihlr-20834	608	51	failure	failure	NOUN
ihlr-20834	608	52	-	-	PUNCT
ihlr-20834	608	53	to	to	PART
ihlr-20834	608	54	-	-	PUNCT
ihlr-20834	608	55	warn	warn	VERB
ihlr-20834	608	56	.	.	PUNCT
ihlr-20834	609	1	many	many	ADJ
ihlr-20834	609	2	consumers	consumer	NOUN
ihlr-20834	609	3	are	be	AUX
ihlr-20834	609	4	not	not	PART
ihlr-20834	609	5	aware	aware	ADJ
ihlr-20834	609	6	of	of	ADP
ihlr-20834	609	7	this	this	DET
ihlr-20834	609	8	legal	legal	ADJ
ihlr-20834	609	9	loophole	loophole	NOUN
ihlr-20834	609	10	and	and	CCONJ
ihlr-20834	609	11	those	those	PRON
ihlr-20834	609	12	that	that	PRON
ihlr-20834	609	13	are	be	AUX
ihlr-20834	609	14	face	face	NOUN
ihlr-20834	609	15	a	a	DET
ihlr-20834	609	16	very	very	ADV
ihlr-20834	609	17	difficult	difficult	ADJ
ihlr-20834	609	18	situation	situation	NOUN
ihlr-20834	609	19	:	:	PUNCT
ihlr-20834	609	20	should	should	AUX
ihlr-20834	609	21	they	they	PRON
ihlr-20834	609	22	purchase	purchase	VERB
ihlr-20834	609	23	the	the	DET
ihlr-20834	609	24	more	more	ADV
ihlr-20834	609	25	expensive	expensive	ADJ
ihlr-20834	609	26	brand	brand	NOUN
ihlr-20834	609	27	-	-	PUNCT
ihlr-20834	609	28	name	name	NOUN
ihlr-20834	609	29	drugs	drug	NOUN
ihlr-20834	609	30	that	that	PRON
ihlr-20834	609	31	provide	provide	VERB
ihlr-20834	609	32	legal	legal	ADJ
ihlr-20834	609	33	protection	protection	NOUN
ihlr-20834	609	34	or	or	CCONJ
ihlr-20834	609	35	should	should	AUX
ihlr-20834	609	36	they	they	PRON
ihlr-20834	609	37	purchase	purchase	VERB
ihlr-20834	609	38	the	the	DET
ihlr-20834	609	39	more	more	ADV
ihlr-20834	609	40	affordable	affordable	ADJ
ihlr-20834	609	41	generic	generic	ADJ
ihlr-20834	609	42	equivalent	equivalent	NOUN
ihlr-20834	609	43	without	without	ADP
ihlr-20834	609	44	such	such	ADJ
ihlr-20834	609	45	protection	protection	NOUN
ihlr-20834	609	46	?	?	PUNCT
ihlr-20834	610	1	this	this	PRON
ihlr-20834	610	2	assumes	assume	VERB
ihlr-20834	610	3	consumers	consumer	NOUN
ihlr-20834	610	4	have	have	VERB
ihlr-20834	610	5	the	the	DET
ihlr-20834	610	6	ability	ability	NOUN
ihlr-20834	610	7	to	to	PART
ihlr-20834	610	8	purchase	purchase	VERB
ihlr-20834	610	9	more	more	ADV
ihlr-20834	610	10	expensive	expensive	ADJ
ihlr-20834	610	11	brand	brand	NOUN
ihlr-20834	610	12	-	-	PUNCT
ihlr-20834	610	13	name	name	NOUN
ihlr-20834	610	14	drugs	drug	NOUN
ihlr-20834	610	15	,	,	PUNCT
ihlr-20834	610	16	when	when	SCONJ
ihlr-20834	610	17	in	in	ADP
ihlr-20834	610	18	fact	fact	NOUN
ihlr-20834	610	19	many	many	ADJ
ihlr-20834	610	20	are	be	AUX
ihlr-20834	610	21	unable	unable	ADJ
ihlr-20834	610	22	to	to	PART
ihlr-20834	610	23	do	do	VERB
ihlr-20834	610	24	so	so	ADV
ihlr-20834	610	25	.	.	PUNCT
ihlr-20834	611	1	furthermore	furthermore	ADV
ihlr-20834	611	2	,	,	PUNCT
ihlr-20834	611	3	many	many	ADJ
ihlr-20834	611	4	prescriptions	prescription	NOUN
ihlr-20834	611	5	are	be	AUX
ihlr-20834	611	6	unknowingly	unknowingly	ADV
ihlr-20834	611	7	filled	fill	VERB
ihlr-20834	611	8	by	by	ADP
ihlr-20834	611	9	generic	generic	ADJ
ihlr-20834	611	10	equivalents	equivalent	NOUN
ihlr-20834	611	11	at	at	ADP
ihlr-20834	611	12	pharmacies	pharmacy	NOUN
ihlr-20834	611	13	.	.	PUNCT
ihlr-20834	612	1	legal	legal	ADJ
ihlr-20834	612	2	scholars	scholar	NOUN
ihlr-20834	612	3	have	have	AUX
ihlr-20834	612	4	discussed	discuss	VERB
ihlr-20834	612	5	creative	creative	ADJ
ihlr-20834	612	6	arguments	argument	NOUN
ihlr-20834	612	7	to	to	PART
ihlr-20834	612	8	avoid	avoid	VERB
ihlr-20834	612	9	this	this	DET
ihlr-20834	612	10	preemption	preemption	NOUN
ihlr-20834	612	11	barrier	barrier	NOUN
ihlr-20834	612	12	.	.	PUNCT
ihlr-20834	613	1	one	one	NUM
ihlr-20834	613	2	strategy	strategy	NOUN
ihlr-20834	613	3	to	to	PART
ihlr-20834	613	4	avoid	avoid	VERB
ihlr-20834	613	5	being	be	AUX
ihlr-20834	613	6	preempted	preempt	VERB
ihlr-20834	613	7	is	be	AUX
ihlr-20834	613	8	to	to	PART
ihlr-20834	613	9	file	file	VERB
ihlr-20834	613	10	a	a	DET
ihlr-20834	613	11	“	"	PUNCT
ihlr-20834	613	12	failure	failure	NOUN
ihlr-20834	613	13	to	to	PART
ihlr-20834	613	14	update	update	VERB
ihlr-20834	613	15	”	"	PUNCT
ihlr-20834	613	16	claim	claim	NOUN
ihlr-20834	613	17	accusing	accuse	VERB
ihlr-20834	613	18	generic	generic	ADJ
ihlr-20834	613	19	manufacturers	manufacturer	NOUN
ihlr-20834	613	20	of	of	ADP
ihlr-20834	613	21	not	not	PART
ihlr-20834	613	22	changing	change	VERB
ihlr-20834	613	23	labels	label	NOUN
ihlr-20834	613	24	quickly	quickly	ADV
ihlr-20834	613	25	enough	enough	ADV
ihlr-20834	613	26	after	after	SCONJ
ihlr-20834	613	27	the	the	DET
ihlr-20834	613	28	brand	brand	NOUN
ihlr-20834	613	29	-	-	PUNCT
ihlr-20834	613	30	name	name	NOUN
ihlr-20834	613	31	equivalent	equivalent	NOUN
ihlr-20834	613	32	updated	update	VERB
ihlr-20834	613	33	their	their	PRON
ihlr-20834	613	34	label.201	label.201	NOUN
ihlr-20834	613	35	this	this	DET
ihlr-20834	613	36	claim	claim	NOUN
ihlr-20834	613	37	would	would	AUX
ihlr-20834	613	38	only	only	ADV
ihlr-20834	613	39	be	be	AUX
ihlr-20834	613	40	plausible	plausible	ADJ
ihlr-20834	613	41	if	if	SCONJ
ihlr-20834	613	42	the	the	DET
ihlr-20834	613	43	brandname	brandname	NOUN
ihlr-20834	613	44	manufacturer	manufacturer	NOUN
ihlr-20834	613	45	had	have	AUX
ihlr-20834	613	46	already	already	ADV
ihlr-20834	613	47	discovered	discover	VERB
ihlr-20834	613	48	this	this	DET
ihlr-20834	613	49	issue	issue	NOUN
ihlr-20834	613	50	and	and	CCONJ
ihlr-20834	613	51	had	have	AUX
ihlr-20834	613	52	changed	change	VERB
ihlr-20834	613	53	the	the	DET
ihlr-20834	613	54	drugs	drug	NOUN
ihlr-20834	613	55	label	label	NOUN
ihlr-20834	613	56	.	.	PUNCT
ihlr-20834	614	1	assuming	assume	VERB
ihlr-20834	614	2	the	the	DET
ihlr-20834	614	3	brand	brand	NOUN
ihlr-20834	614	4	-	-	PUNCT
ihlr-20834	614	5	name	name	NOUN
ihlr-20834	614	6	drug	drug	NOUN
ihlr-20834	614	7	manufacturer	manufacturer	NOUN
ihlr-20834	614	8	has	have	AUX
ihlr-20834	614	9	not	not	PART
ihlr-20834	614	10	discovered	discover	VERB
ihlr-20834	614	11	the	the	DET
ihlr-20834	614	12	issue	issue	NOUN
ihlr-20834	614	13	,	,	PUNCT
ihlr-20834	614	14	four	four	NUM
ihlr-20834	614	15	potential	potential	ADJ
ihlr-20834	614	16	course	course	NOUN
ihlr-20834	614	17	of	of	ADP
ihlr-20834	614	18	action	action	NOUN
ihlr-20834	614	19	remain	remain	VERB
ihlr-20834	614	20	.	.	PUNCT
ihlr-20834	615	1	first	first	ADV
ihlr-20834	615	2	,	,	PUNCT
ihlr-20834	615	3	one	one	PRON
ihlr-20834	615	4	could	could	AUX
ihlr-20834	615	5	sue	sue	VERB
ihlr-20834	615	6	the	the	DET
ihlr-20834	615	7	brand	brand	NOUN
ihlr-20834	615	8	-	-	PUNCT
ihlr-20834	615	9	name	name	NOUN
ihlr-20834	615	10	manufacturer	manufacturer	NOUN
ihlr-20834	615	11	alleging	allege	VERB
ihlr-20834	615	12	they	they	PRON
ihlr-20834	615	13	bear	bear	VERB
ihlr-20834	615	14	responsibility	responsibility	NOUN
ihlr-20834	615	15	for	for	ADP
ihlr-20834	615	16	the	the	DET
ihlr-20834	615	17	generic	generic	ADJ
ihlr-20834	615	18	drug	drug	NOUN
ihlr-20834	615	19	’s	’s	PART
ihlr-20834	615	20	shortcomings	shortcoming	NOUN
ihlr-20834	615	21	.	.	PUNCT
ihlr-20834	616	1	second	second	ADJ
ihlr-20834	616	2	,	,	PUNCT
ihlr-20834	616	3	one	one	PRON
ihlr-20834	616	4	could	could	AUX
ihlr-20834	616	5	sue	sue	VERB
ihlr-20834	616	6	the	the	DET
ihlr-20834	616	7	generic	generic	ADJ
ihlr-20834	616	8	drug	drug	NOUN
ihlr-20834	616	9	manufacturer	manufacturer	NOUN
ihlr-20834	616	10	under	under	ADP
ihlr-20834	616	11	the	the	DET
ihlr-20834	616	12	fdca	fdca	NOUN
ihlr-20834	616	13	’s	’s	PART
ihlr-20834	616	14	misbranding	misbranding	NOUN
ihlr-20834	616	15	statute	statute	NOUN
ihlr-20834	616	16	.	.	PUNCT
ihlr-20834	617	1	third	third	ADV
ihlr-20834	617	2	,	,	PUNCT
ihlr-20834	617	3	one	one	PRON
ihlr-20834	617	4	could	could	AUX
ihlr-20834	617	5	opt	opt	VERB
ihlr-20834	617	6	to	to	PART
ihlr-20834	617	7	purchase	purchase	VERB
ihlr-20834	617	8	brand	brand	NOUN
ihlr-20834	617	9	-	-	PUNCT
ihlr-20834	617	10	name	name	NOUN
ihlr-20834	617	11	drugs	drug	NOUN
ihlr-20834	617	12	and	and	CCONJ
ihlr-20834	617	13	not	not	PART
ihlr-20834	617	14	their	their	PRON
ihlr-20834	617	15	generic	generic	ADJ
ihlr-20834	617	16	counterparts	counterpart	NOUN
ihlr-20834	617	17	.	.	PUNCT
ihlr-20834	618	1	the	the	DET
ihlr-20834	618	2	final	final	ADJ
ihlr-20834	618	3	and	and	CCONJ
ihlr-20834	618	4	most	most	ADV
ihlr-20834	618	5	complete	complete	ADJ
ihlr-20834	618	6	solution	solution	NOUN
ihlr-20834	618	7	would	would	AUX
ihlr-20834	618	8	be	be	AUX
ihlr-20834	618	9	to	to	PART
ihlr-20834	618	10	petition	petition	VERB
ihlr-20834	618	11	congress	congress	PROPN
ihlr-20834	618	12	and	and	CCONJ
ihlr-20834	618	13	the	the	DET
ihlr-20834	618	14	fda	fda	PROPN
ihlr-20834	618	15	to	to	PART
ihlr-20834	618	16	take	take	VERB
ihlr-20834	618	17	action	action	NOUN
ihlr-20834	618	18	to	to	PART
ihlr-20834	618	19	correct	correct	VERB
ihlr-20834	618	20	this	this	DET
ihlr-20834	618	21	dangerous	dangerous	ADJ
ihlr-20834	618	22	precedent	precedent	NOUN
ihlr-20834	618	23	.	.	PUNCT
ihlr-20834	619	1	1	1	X
ihlr-20834	619	2	.	.	X
ihlr-20834	619	3	option	option	NOUN
ihlr-20834	619	4	one	one	NUM
ihlr-20834	619	5	suing	sue	VERB
ihlr-20834	619	6	the	the	DET
ihlr-20834	619	7	name	name	NOUN
ihlr-20834	619	8	brand	brand	NOUN
ihlr-20834	619	9	manufacturer	manufacturer	NOUN
ihlr-20834	619	10	the	the	DET
ihlr-20834	619	11	first	first	ADJ
ihlr-20834	619	12	option	option	NOUN
ihlr-20834	619	13	available	available	ADJ
ihlr-20834	619	14	to	to	ADP
ihlr-20834	619	15	consumers	consumer	NOUN
ihlr-20834	619	16	injured	injure	VERB
ihlr-20834	619	17	by	by	ADP
ihlr-20834	619	18	generic	generic	ADJ
ihlr-20834	619	19	drugs	drug	NOUN
ihlr-20834	619	20	would	would	AUX
ihlr-20834	619	21	be	be	AUX
ihlr-20834	619	22	to	to	PART
ihlr-20834	619	23	sue	sue	VERB
ihlr-20834	619	24	the	the	DET
ihlr-20834	619	25	brand	brand	NOUN
ihlr-20834	619	26	-	-	PUNCT
ihlr-20834	619	27	name	name	NOUN
ihlr-20834	619	28	equivalent	equivalent	ADJ
ihlr-20834	619	29	manufacturer	manufacturer	NOUN
ihlr-20834	619	30	.	.	PUNCT
ihlr-20834	620	1	under	under	ADP
ihlr-20834	620	2	this	this	DET
ihlr-20834	620	3	cause	cause	NOUN
ihlr-20834	620	4	of	of	ADP
ihlr-20834	620	5	action	action	NOUN
ihlr-20834	620	6	that	that	PRON
ihlr-20834	620	7	is	be	AUX
ihlr-20834	620	8	often	often	ADV
ihlr-20834	620	9	201	201	NUM
ihlr-20834	620	10	lorelei	lorelei	PROPN
ihlr-20834	620	11	laird	laird	PROPN
ihlr-20834	620	12	,	,	PUNCT
ihlr-20834	620	13	generic	generic	ADJ
ihlr-20834	620	14	drugs	drug	NOUN
ihlr-20834	620	15	leave	leave	VERB
ihlr-20834	620	16	a	a	DET
ihlr-20834	620	17	bad	bad	ADJ
ihlr-20834	620	18	taste	taste	NOUN
ihlr-20834	620	19	for	for	ADP
ihlr-20834	620	20	patients	patient	NOUN
ihlr-20834	620	21	filing	file	VERB
ihlr-20834	620	22	tort	tort	NOUN
ihlr-20834	620	23	suits	suit	NOUN
ihlr-20834	620	24	,	,	PUNCT
ihlr-20834	620	25	aba	aba	PROPN
ihlr-20834	620	26	j.	j.	PROPN
ihlr-20834	620	27	(	(	PUNCT
ihlr-20834	620	28	feb	feb	PROPN
ihlr-20834	620	29	.	.	PROPN
ihlr-20834	620	30	1	1	NUM
ihlr-20834	620	31	,	,	PUNCT
ihlr-20834	620	32	2014	2014	NUM
ihlr-20834	620	33	,	,	PUNCT
ihlr-20834	620	34	9:20	9:20	NUM
ihlr-20834	620	35	am	am	NOUN
ihlr-20834	620	36	)	)	PUNCT
ihlr-20834	620	37	,	,	PUNCT
ihlr-20834	620	38	http://www.abajournal.com/mobile/mag_article/generic_drugs_leave_a_b	http://www.abajournal.com/mobile/mag_article/generic_drugs_leave_a_b	PROPN
ihlr-20834	620	39	ad_taste_for_patients_filing_tort_suits	ad_taste_for_patients_filing_tort_suits	PROPN
ihlr-20834	620	40	.	.	PUNCT
ihlr-20834	621	1	802	802	NUM
ihlr-20834	621	2	indiana	indiana	PROPN
ihlr-20834	621	3	health	health	PROPN
ihlr-20834	621	4	law	law	PROPN
ihlr-20834	621	5	review	review	NOUN
ihlr-20834	621	6	vol	vol	NOUN
ihlr-20834	621	7	.	.	PROPN
ihlr-20834	621	8	12:2	12:2	NUM
ihlr-20834	621	9	referred	refer	VERB
ihlr-20834	621	10	to	to	ADP
ihlr-20834	621	11	as	as	ADP
ihlr-20834	621	12	“	"	PUNCT
ihlr-20834	621	13	innovator	innovator	NOUN
ihlr-20834	621	14	liability	liability	NOUN
ihlr-20834	621	15	,	,	PUNCT
ihlr-20834	621	16	”	"	PUNCT
ihlr-20834	621	17	injured	injure	VERB
ihlr-20834	621	18	drug	drug	NOUN
ihlr-20834	621	19	consumers	consumer	NOUN
ihlr-20834	621	20	could	could	AUX
ihlr-20834	621	21	file	file	VERB
ihlr-20834	621	22	suit	suit	NOUN
ihlr-20834	621	23	against	against	ADP
ihlr-20834	621	24	brand	brand	NOUN
ihlr-20834	621	25	-	-	PUNCT
ihlr-20834	621	26	name	name	NOUN
ihlr-20834	621	27	manufacturers	manufacturer	NOUN
ihlr-20834	621	28	claiming	claim	VERB
ihlr-20834	621	29	that	that	SCONJ
ihlr-20834	621	30	they	they	PRON
ihlr-20834	621	31	bear	bear	VERB
ihlr-20834	621	32	sole	sole	ADJ
ihlr-20834	621	33	responsibility	responsibility	NOUN
ihlr-20834	621	34	for	for	ADP
ihlr-20834	621	35	a	a	DET
ihlr-20834	621	36	generic	generic	ADJ
ihlr-20834	621	37	manufacturer	manufacturer	NOUN
ihlr-20834	621	38	’s	’s	X
ihlr-20834	622	1	label.202	label.202	NOUN
ihlr-20834	622	2	as	as	SCONJ
ihlr-20834	622	3	it	it	PRON
ihlr-20834	622	4	currently	currently	ADV
ihlr-20834	622	5	stands	stand	VERB
ihlr-20834	622	6	,	,	PUNCT
ihlr-20834	622	7	“	"	PUNCT
ihlr-20834	622	8	pliva	pliva	NOUN
ihlr-20834	622	9	and	and	CCONJ
ihlr-20834	622	10	mutual	mutual	ADJ
ihlr-20834	622	11	may	may	AUX
ihlr-20834	622	12	provide	provide	VERB
ihlr-20834	622	13	complete	complete	ADJ
ihlr-20834	622	14	(	(	PUNCT
ihlr-20834	622	15	or	or	CCONJ
ihlr-20834	622	16	at	at	ADP
ihlr-20834	622	17	least	least	ADJ
ihlr-20834	622	18	substantial	substantial	ADJ
ihlr-20834	622	19	)	)	PUNCT
ihlr-20834	622	20	immunity	immunity	NOUN
ihlr-20834	622	21	to	to	ADP
ihlr-20834	622	22	generic	generic	ADJ
ihlr-20834	622	23	manufacturers	manufacturer	NOUN
ihlr-20834	622	24	,	,	PUNCT
ihlr-20834	622	25	but	but	CCONJ
ihlr-20834	622	26	their	their	PRON
ihlr-20834	622	27	reasoning	reasoning	NOUN
ihlr-20834	622	28	that	that	SCONJ
ihlr-20834	622	29	generic	generic	ADJ
ihlr-20834	622	30	drug	drug	NOUN
ihlr-20834	622	31	labels	label	NOUN
ihlr-20834	622	32	are	be	AUX
ihlr-20834	622	33	the	the	DET
ihlr-20834	622	34	province	province	NOUN
ihlr-20834	622	35	of	of	ADP
ihlr-20834	622	36	brand	brand	NOUN
ihlr-20834	622	37	-	-	PUNCT
ihlr-20834	622	38	name	name	NOUN
ihlr-20834	622	39	manufacturers	manufacturer	NOUN
ihlr-20834	622	40	is	be	AUX
ihlr-20834	622	41	consistent	consistent	ADJ
ihlr-20834	622	42	with	with	ADP
ihlr-20834	622	43	a	a	DET
ihlr-20834	622	44	state	state	NOUN
ihlr-20834	622	45	-	-	PUNCT
ihlr-20834	622	46	law	law	NOUN
ihlr-20834	622	47	duty	duty	NOUN
ihlr-20834	622	48	that	that	PRON
ihlr-20834	622	49	makes	make	VERB
ihlr-20834	622	50	brand	brand	NOUN
ihlr-20834	622	51	-	-	PUNCT
ihlr-20834	622	52	name	name	NOUN
ihlr-20834	622	53	manufacturers	manufacturer	NOUN
ihlr-20834	622	54	responsible	responsible	ADJ
ihlr-20834	622	55	.	.	PUNCT
ihlr-20834	622	56	”	"	PUNCT
ihlr-20834	623	1	203	203	NUM
ihlr-20834	623	2	thus	thus	ADV
ihlr-20834	623	3	,	,	PUNCT
ihlr-20834	623	4	these	these	DET
ihlr-20834	623	5	brand	brand	NOUN
ihlr-20834	623	6	-	-	PUNCT
ihlr-20834	623	7	name	name	NOUN
ihlr-20834	623	8	suits	suit	NOUN
ihlr-20834	623	9	would	would	AUX
ihlr-20834	623	10	be	be	AUX
ihlr-20834	623	11	based	base	VERB
ihlr-20834	623	12	on	on	ADP
ihlr-20834	623	13	claims	claim	NOUN
ihlr-20834	623	14	of	of	ADP
ihlr-20834	623	15	“	"	PUNCT
ihlr-20834	623	16	negligent	negligent	ADJ
ihlr-20834	623	17	and/or	and/or	CCONJ
ihlr-20834	623	18	intentional	intentional	ADJ
ihlr-20834	623	19	misrepresentation	misrepresentation	NOUN
ihlr-20834	623	20	,	,	PUNCT
ihlr-20834	623	21	which	which	PRON
ihlr-20834	623	22	plaintiffs	plaintiff	NOUN
ihlr-20834	623	23	[	[	X
ihlr-20834	623	24	could	could	AUX
ihlr-20834	623	25	argue	argue	VERB
ihlr-20834	623	26	]	]	PUNCT
ihlr-20834	623	27	.	.	PUNCT
ihlr-20834	623	28	.	.	PUNCT
ihlr-20834	624	1	.	.	PUNCT
ihlr-20834	625	1	authorizes	authorize	VERB
ihlr-20834	625	2	liability	liability	NOUN
ihlr-20834	625	3	against	against	ADP
ihlr-20834	625	4	a	a	DET
ihlr-20834	625	5	non	non	ADJ
ihlr-20834	625	6	-	-	NOUN
ihlr-20834	625	7	seller	seller	NOUN
ihlr-20834	625	8	who	who	PRON
ihlr-20834	625	9	has	have	VERB
ihlr-20834	625	10	reason	reason	NOUN
ihlr-20834	625	11	to	to	PART
ihlr-20834	625	12	know	know	VERB
ihlr-20834	625	13	that	that	SCONJ
ihlr-20834	625	14	a	a	DET
ihlr-20834	625	15	third	third	ADJ
ihlr-20834	625	16	party	party	NOUN
ihlr-20834	625	17	could	could	AUX
ihlr-20834	625	18	suffer	suffer	VERB
ihlr-20834	625	19	harm	harm	NOUN
ihlr-20834	625	20	.	.	PUNCT
ihlr-20834	625	21	”	"	PUNCT
ihlr-20834	626	1	204	204	NUM
ihlr-20834	626	2	many	many	ADJ
ihlr-20834	626	3	states	state	NOUN
ihlr-20834	626	4	,	,	PUNCT
ihlr-20834	626	5	including	include	VERB
ihlr-20834	626	6	indiana	indiana	PROPN
ihlr-20834	626	7	,	,	PUNCT
ihlr-20834	626	8	do	do	AUX
ihlr-20834	626	9	recognize	recognize	VERB
ihlr-20834	626	10	liability	liability	NOUN
ihlr-20834	626	11	for	for	ADP
ihlr-20834	626	12	negligent	negligent	ADJ
ihlr-20834	626	13	misrepresentation	misrepresentation	NOUN
ihlr-20834	626	14	.	.	PUNCT
ihlr-20834	627	1	205	205	NUM
ihlr-20834	627	2	however	however	ADV
ihlr-20834	627	3	,	,	PUNCT
ihlr-20834	627	4	no	no	DET
ihlr-20834	627	5	indiana	indiana	NOUN
ihlr-20834	627	6	precedent	precedent	NOUN
ihlr-20834	627	7	has	have	AUX
ihlr-20834	627	8	been	be	AUX
ihlr-20834	627	9	established	establish	VERB
ihlr-20834	627	10	on	on	ADP
ihlr-20834	627	11	this	this	DET
ihlr-20834	627	12	issue	issue	NOUN
ihlr-20834	627	13	and	and	CCONJ
ihlr-20834	627	14	many	many	ADJ
ihlr-20834	627	15	states	state	NOUN
ihlr-20834	627	16	have	have	AUX
ihlr-20834	627	17	held	hold	VERB
ihlr-20834	627	18	that	that	SCONJ
ihlr-20834	627	19	brand	brand	NOUN
ihlr-20834	627	20	-	-	PUNCT
ihlr-20834	627	21	name	name	NOUN
ihlr-20834	627	22	suits	suit	NOUN
ihlr-20834	627	23	are	be	AUX
ihlr-20834	627	24	202	202	NUM
ihlr-20834	627	25	see	see	VERB
ihlr-20834	627	26	fullington	fullington	NOUN
ihlr-20834	627	27	v.	v.	ADP
ihlr-20834	627	28	pfizer	pfizer	PROPN
ihlr-20834	627	29	,	,	PUNCT
ihlr-20834	627	30	inc	inc	PROPN
ihlr-20834	627	31	.	.	PROPN
ihlr-20834	627	32	,	,	PUNCT
ihlr-20834	627	33	720	720	NUM
ihlr-20834	627	34	f.3d	f.3d	NUM
ihlr-20834	627	35	739	739	NUM
ihlr-20834	627	36	,	,	PUNCT
ihlr-20834	627	37	747	747	NUM
ihlr-20834	627	38	-	-	SYM
ihlr-20834	627	39	48	48	NUM
ihlr-20834	627	40	(	(	PUNCT
ihlr-20834	627	41	8th	8th	ADJ
ihlr-20834	627	42	cir	cir	NOUN
ihlr-20834	627	43	.	.	PROPN
ihlr-20834	627	44	2013	2013	NUM
ihlr-20834	627	45	)	)	PUNCT
ihlr-20834	627	46	(	(	PUNCT
ihlr-20834	627	47	murphy	murphy	PROPN
ihlr-20834	627	48	,	,	PUNCT
ihlr-20834	627	49	j.	j.	PROPN
ihlr-20834	627	50	,	,	PUNCT
ihlr-20834	627	51	concurring	concur	VERB
ihlr-20834	627	52	)	)	PUNCT
ihlr-20834	627	53	(	(	PUNCT
ihlr-20834	627	54	explaining	explain	VERB
ihlr-20834	627	55	in	in	ADP
ihlr-20834	627	56	dicta	dicta	ADV
ihlr-20834	627	57	that	that	DET
ihlr-20834	627	58	pliva	pliva	NOUN
ihlr-20834	627	59	and	and	CCONJ
ihlr-20834	627	60	bartlett	bartlett	PROPN
ihlr-20834	627	61	“	"	PUNCT
ihlr-20834	627	62	severely	severely	ADV
ihlr-20834	627	63	eroded	erode	VERB
ihlr-20834	627	64	the	the	DET
ihlr-20834	627	65	foundation	foundation	NOUN
ihlr-20834	627	66	of	of	ADP
ihlr-20834	627	67	th[e	th[e	PROPN
ihlr-20834	627	68	]	]	PUNCT
ihlr-20834	627	69	analysis	analysis	NOUN
ihlr-20834	627	70	”	"	PUNCT
ihlr-20834	627	71	of	of	ADP
ihlr-20834	627	72	the	the	DET
ihlr-20834	627	73	courts	court	NOUN
ihlr-20834	627	74	that	that	PRON
ihlr-20834	627	75	have	have	AUX
ihlr-20834	627	76	rejected	reject	VERB
ihlr-20834	627	77	brand	brand	NOUN
ihlr-20834	627	78	-	-	PUNCT
ihlr-20834	627	79	name	name	NOUN
ihlr-20834	627	80	suits	suit	NOUN
ihlr-20834	627	81	because	because	SCONJ
ihlr-20834	627	82	that	that	SCONJ
ihlr-20834	627	83	analysis	analysis	NOUN
ihlr-20834	627	84	has	have	AUX
ihlr-20834	627	85	“	"	PUNCT
ihlr-20834	627	86	generally	generally	ADV
ihlr-20834	627	87	been	be	AUX
ihlr-20834	627	88	predicated	predicate	VERB
ihlr-20834	627	89	on	on	ADP
ihlr-20834	627	90	the	the	DET
ihlr-20834	627	91	assumption	assumption	NOUN
ihlr-20834	627	92	that	that	SCONJ
ihlr-20834	627	93	the	the	DET
ihlr-20834	627	94	generic	generic	ADJ
ihlr-20834	627	95	manufacturers	manufacturer	NOUN
ihlr-20834	627	96	could	could	AUX
ihlr-20834	627	97	independently	independently	ADV
ihlr-20834	627	98	safeguard	safeguard	VERB
ihlr-20834	627	99	and	and	CCONJ
ihlr-20834	627	100	strengthen	strengthen	VERB
ihlr-20834	627	101	their	their	PRON
ihlr-20834	627	102	own	own	ADJ
ihlr-20834	627	103	labels	label	NOUN
ihlr-20834	627	104	”	"	PUNCT
ihlr-20834	627	105	)	)	PUNCT
ihlr-20834	627	106	.	.	PUNCT
ihlr-20834	628	1	203	203	NUM
ihlr-20834	628	2	wolfman	wolfman	PROPN
ihlr-20834	628	3	&	&	CCONJ
ihlr-20834	628	4	king	king	PROPN
ihlr-20834	628	5	,	,	PUNCT
ihlr-20834	628	6	supra	supra	PROPN
ihlr-20834	628	7	note	note	NOUN
ihlr-20834	628	8	134	134	NUM
ihlr-20834	628	9	.	.	NUM
ihlr-20834	628	10	204	204	NUM
ihlr-20834	628	11	i	i	PRON
ihlr-20834	628	12	d.	d.	PROPN
ihlr-20834	628	13	(	(	PUNCT
ihlr-20834	628	14	citing	cite	VERB
ihlr-20834	628	15	conte	conte	PROPN
ihlr-20834	628	16	v.	v.	ADP
ihlr-20834	628	17	wyeth	wyeth	PROPN
ihlr-20834	628	18	,	,	PUNCT
ihlr-20834	628	19	inc	inc	PROPN
ihlr-20834	628	20	.	.	PROPN
ihlr-20834	628	21	,	,	PUNCT
ihlr-20834	628	22	85	85	NUM
ihlr-20834	628	23	cal	cal	NOUN
ihlr-20834	628	24	.	.	PUNCT
ihlr-20834	629	1	rptr	rptr	PROPN
ihlr-20834	629	2	.	.	PUNCT
ihlr-20834	630	1	3d	3d	PROPN
ihlr-20834	630	2	299	299	NUM
ihlr-20834	630	3	,	,	PUNCT
ihlr-20834	630	4	309	309	NUM
ihlr-20834	630	5	-	-	SYM
ihlr-20834	630	6	10	10	NUM
ihlr-20834	630	7	(	(	PUNCT
ihlr-20834	630	8	cal	cal	PROPN
ihlr-20834	630	9	.	.	PUNCT
ihlr-20834	631	1	ct	ct	PROPN
ihlr-20834	631	2	.	.	PUNCT
ihlr-20834	632	1	app	app	PROPN
ihlr-20834	632	2	.	.	PROPN
ihlr-20834	632	3	2008	2008	NUM
ihlr-20834	632	4	)	)	PUNCT
ihlr-20834	633	1	(	(	PUNCT
ihlr-20834	633	2	explaining	explain	VERB
ihlr-20834	633	3	differences	difference	NOUN
ihlr-20834	633	4	in	in	ADP
ihlr-20834	633	5	strict	strict	ADJ
ihlr-20834	633	6	products	product	NOUN
ihlr-20834	633	7	liability	liability	NOUN
ihlr-20834	633	8	and	and	CCONJ
ihlr-20834	633	9	misrepresentation	misrepresentation	NOUN
ihlr-20834	633	10	theories	theory	NOUN
ihlr-20834	633	11	in	in	ADP
ihlr-20834	633	12	case	case	NOUN
ihlr-20834	633	13	brought	bring	VERB
ihlr-20834	633	14	by	by	ADP
ihlr-20834	633	15	generic	generic	ADJ
ihlr-20834	633	16	drug	drug	NOUN
ihlr-20834	633	17	user	user	NOUN
ihlr-20834	633	18	who	who	PRON
ihlr-20834	633	19	sued	sue	VERB
ihlr-20834	633	20	brand	brand	NOUN
ihlr-20834	633	21	-	-	PUNCT
ihlr-20834	633	22	name	name	NOUN
ihlr-20834	633	23	manufacturer	manufacturer	NOUN
ihlr-20834	633	24	on	on	ADP
ihlr-20834	633	25	misrepresentation	misrepresentation	NOUN
ihlr-20834	633	26	theory	theory	NOUN
ihlr-20834	633	27	)	)	PUNCT
ihlr-20834	633	28	)	)	PUNCT
ihlr-20834	633	29	.	.	PUNCT
ihlr-20834	634	1	see	see	AUX
ihlr-20834	634	2	also	also	ADV
ihlr-20834	634	3	restatement	restatement	VERB
ihlr-20834	634	4	(	(	PUNCT
ihlr-20834	634	5	second	second	ADJ
ihlr-20834	634	6	)	)	PUNCT
ihlr-20834	634	7	of	of	ADP
ihlr-20834	634	8	torts	torts	PROPN
ihlr-20834	634	9	§	§	PROPN
ihlr-20834	634	10	311	311	NUM
ihlr-20834	634	11	(	(	PUNCT
ihlr-20834	634	12	1965	1965	NUM
ihlr-20834	634	13	)	)	PUNCT
ihlr-20834	634	14	(	(	PUNCT
ihlr-20834	634	15	“	"	PUNCT
ihlr-20834	634	16	one	one	NUM
ihlr-20834	634	17	who	who	PRON
ihlr-20834	634	18	negligently	negligently	ADV
ihlr-20834	634	19	gives	give	VERB
ihlr-20834	634	20	false	false	ADJ
ihlr-20834	634	21	information	information	NOUN
ihlr-20834	634	22	to	to	ADP
ihlr-20834	634	23	another	another	PRON
ihlr-20834	634	24	is	be	AUX
ihlr-20834	634	25	subject	subject	ADJ
ihlr-20834	634	26	to	to	ADP
ihlr-20834	634	27	liability	liability	NOUN
ihlr-20834	634	28	for	for	ADP
ihlr-20834	634	29	physical	physical	ADJ
ihlr-20834	634	30	harm	harm	NOUN
ihlr-20834	634	31	caused	cause	VERB
ihlr-20834	634	32	by	by	ADP
ihlr-20834	634	33	action	action	NOUN
ihlr-20834	634	34	taken	take	VERB
ihlr-20834	634	35	by	by	ADP
ihlr-20834	634	36	the	the	DET
ihlr-20834	634	37	other	other	ADJ
ihlr-20834	634	38	in	in	ADP
ihlr-20834	634	39	reasonable	reasonable	ADJ
ihlr-20834	634	40	reliance	reliance	NOUN
ihlr-20834	634	41	upon	upon	SCONJ
ihlr-20834	634	42	such	such	ADJ
ihlr-20834	634	43	information	information	NOUN
ihlr-20834	634	44	,	,	PUNCT
ihlr-20834	634	45	where	where	SCONJ
ihlr-20834	634	46	such	such	ADJ
ihlr-20834	634	47	harm	harm	NOUN
ihlr-20834	634	48	results	result	VERB
ihlr-20834	634	49	.	.	PUNCT
ihlr-20834	634	50	.	.	PUNCT
ihlr-20834	634	51	.	.	PUNCT
ihlr-20834	635	1	to	to	ADP
ihlr-20834	635	2	such	such	ADJ
ihlr-20834	635	3	third	third	ADJ
ihlr-20834	635	4	persons	person	NOUN
ihlr-20834	635	5	as	as	SCONJ
ihlr-20834	635	6	the	the	DET
ihlr-20834	635	7	actor	actor	NOUN
ihlr-20834	635	8	should	should	AUX
ihlr-20834	635	9	expect	expect	VERB
ihlr-20834	635	10	to	to	PART
ihlr-20834	635	11	be	be	AUX
ihlr-20834	635	12	put	put	VERB
ihlr-20834	635	13	in	in	ADP
ihlr-20834	635	14	peril	peril	NOUN
ihlr-20834	635	15	by	by	ADP
ihlr-20834	635	16	the	the	DET
ihlr-20834	635	17	action	action	NOUN
ihlr-20834	635	18	taken	take	VERB
ihlr-20834	635	19	.	.	PUNCT
ihlr-20834	635	20	”	"	PUNCT
ihlr-20834	635	21	)	)	PUNCT
ihlr-20834	635	22	.	.	PUNCT
ihlr-20834	636	1	205	205	NUM
ihlr-20834	636	2	see	see	VERB
ihlr-20834	636	3	passmore	passmore	NOUN
ihlr-20834	636	4	v.	v.	ADP
ihlr-20834	636	5	multi	multi	ADJ
ihlr-20834	636	6	-	-	ADJ
ihlr-20834	636	7	mgmt	mgmt	ADJ
ihlr-20834	636	8	.	.	PUNCT
ihlr-20834	637	1	servs	servs	PROPN
ihlr-20834	637	2	.	.	PROPN
ihlr-20834	637	3	,	,	PUNCT
ihlr-20834	637	4	inc	inc	PROPN
ihlr-20834	637	5	.	.	PROPN
ihlr-20834	637	6	,	,	PUNCT
ihlr-20834	637	7	810	810	NUM
ihlr-20834	637	8	n.e.2d	n.e.2d	NOUN
ihlr-20834	637	9	1022	1022	NUM
ihlr-20834	637	10	,	,	PUNCT
ihlr-20834	637	11	1025	1025	NUM
ihlr-20834	637	12	(	(	PUNCT
ihlr-20834	637	13	ind	ind	NOUN
ihlr-20834	637	14	.	.	PUNCT
ihlr-20834	637	15	2004	2004	NUM
ihlr-20834	637	16	)	)	PUNCT
ihlr-20834	637	17	.	.	PUNCT
ihlr-20834	638	1	see	see	VERB
ihlr-20834	638	2	also	also	ADV
ihlr-20834	638	3	kimball	kimball	PROPN
ihlr-20834	638	4	parker	parker	PROPN
ihlr-20834	638	5	,	,	PUNCT
ihlr-20834	638	6	a	a	DET
ihlr-20834	638	7	historical	historical	ADJ
ihlr-20834	638	8	approach	approach	NOUN
ihlr-20834	638	9	to	to	ADP
ihlr-20834	638	10	negligent	negligent	ADJ
ihlr-20834	638	11	misrepresentation	misrepresentation	NOUN
ihlr-20834	638	12	and	and	CCONJ
ihlr-20834	638	13	federal	federal	ADJ
ihlr-20834	638	14	rule	rule	NOUN
ihlr-20834	638	15	of	of	ADP
ihlr-20834	638	16	civil	civil	ADJ
ihlr-20834	638	17	procedure	procedure	NOUN
ihlr-20834	638	18	9(b	9(b	NUM
ihlr-20834	638	19	)	)	PUNCT
ihlr-20834	638	20	,	,	PUNCT
ihlr-20834	638	21	80	80	NUM
ihlr-20834	638	22	u.	u.	NOUN
ihlr-20834	638	23	chi	chi	PROPN
ihlr-20834	638	24	.	.	PUNCT
ihlr-20834	639	1	l.	l.	PROPN
ihlr-20834	639	2	rev	rev	PROPN
ihlr-20834	639	3	.	.	PROPN
ihlr-20834	639	4	1461	1461	NUM
ihlr-20834	639	5	(	(	PUNCT
ihlr-20834	639	6	2013	2013	NUM
ihlr-20834	639	7	)	)	PUNCT
ihlr-20834	639	8	(	(	PUNCT
ihlr-20834	639	9	discussing	discuss	VERB
ihlr-20834	639	10	different	different	ADJ
ihlr-20834	639	11	circuits	circuit	NOUN
ihlr-20834	639	12	interpretations	interpretation	NOUN
ihlr-20834	639	13	and	and	CCONJ
ihlr-20834	639	14	treatments	treatment	NOUN
ihlr-20834	639	15	of	of	ADP
ihlr-20834	639	16	negligent	negligent	ADJ
ihlr-20834	639	17	misrepresentation	misrepresentation	NOUN
ihlr-20834	639	18	claims	claim	NOUN
ihlr-20834	639	19	)	)	PUNCT
ihlr-20834	639	20	.	.	PUNCT
ihlr-20834	640	1	2015	2015	NUM
ihlr-20834	640	2	803	803	NUM
ihlr-20834	640	3	the	the	DET
ihlr-20834	640	4	supreme	supreme	PROPN
ihlr-20834	640	5	court	court	PROPN
ihlr-20834	640	6	’s	’s	PART
ihlr-20834	640	7	overreaching	overreach	VERB
ihlr-20834	640	8	preemption	preemption	NOUN
ihlr-20834	640	9	interpretation	interpretation	NOUN
ihlr-20834	640	10	and	and	CCONJ
ihlr-20834	640	11	it	it	PRON
ihlr-20834	640	12	’s	’	VERB
ihlr-20834	640	13	consequences	consequence	NOUN
ihlr-20834	640	14	not	not	PART
ihlr-20834	640	15	viable	viable	ADJ
ihlr-20834	640	16	under	under	ADP
ihlr-20834	640	17	state	state	NOUN
ihlr-20834	640	18	law	law	NOUN
ihlr-20834	640	19	due	due	ADP
ihlr-20834	640	20	to	to	ADP
ihlr-20834	640	21	their	their	PRON
ihlr-20834	640	22	stretched	stretch	VERB
ihlr-20834	640	23	foreseeability	foreseeability	NOUN
ihlr-20834	640	24	concept.206	concept.206	VERB
ihlr-20834	640	25	the	the	DET
ihlr-20834	640	26	alabama	alabama	PROPN
ihlr-20834	640	27	supreme	supreme	PROPN
ihlr-20834	640	28	court	court	PROPN
ihlr-20834	640	29	established	establish	VERB
ihlr-20834	640	30	precedent	precedent	NOUN
ihlr-20834	640	31	on	on	ADP
ihlr-20834	640	32	the	the	DET
ihlr-20834	640	33	above	above	ADJ
ihlr-20834	640	34	theory	theory	NOUN
ihlr-20834	640	35	in	in	ADP
ihlr-20834	640	36	wyeth	wyeth	PROPN
ihlr-20834	640	37	,	,	PUNCT
ihlr-20834	640	38	inc	inc	PROPN
ihlr-20834	640	39	.	.	PROPN
ihlr-20834	641	1	v.	v.	ADP
ihlr-20834	641	2	weeks	week	NOUN
ihlr-20834	641	3	by	by	ADP
ihlr-20834	641	4	holding	hold	VERB
ihlr-20834	641	5	that	that	SCONJ
ihlr-20834	641	6	their	their	PRON
ihlr-20834	641	7	law	law	NOUN
ihlr-20834	641	8	permits	permit	VERB
ihlr-20834	641	9	brand	brand	NOUN
ihlr-20834	641	10	-	-	PUNCT
ihlr-20834	641	11	name	name	NOUN
ihlr-20834	641	12	drug	drug	NOUN
ihlr-20834	641	13	manufacturers	manufacturer	NOUN
ihlr-20834	641	14	to	to	PART
ihlr-20834	641	15	be	be	AUX
ihlr-20834	641	16	held	hold	VERB
ihlr-20834	641	17	liable	liable	ADJ
ihlr-20834	641	18	for	for	ADP
ihlr-20834	641	19	misrepresentations	misrepresentation	NOUN
ihlr-20834	641	20	,	,	PUNCT
ihlr-20834	641	21	even	even	ADV
ihlr-20834	641	22	if	if	SCONJ
ihlr-20834	641	23	a	a	DET
ihlr-20834	641	24	generic	generic	ADJ
ihlr-20834	641	25	equivalent	equivalent	ADJ
ihlr-20834	641	26	drug	drug	NOUN
ihlr-20834	641	27	was	be	AUX
ihlr-20834	641	28	taken	take	VERB
ihlr-20834	641	29	.	.	PUNCT
ihlr-20834	642	1	207	207	NUM
ihlr-20834	642	2	the	the	DET
ihlr-20834	642	3	court	court	NOUN
ihlr-20834	642	4	addressed	address	VERB
ihlr-20834	642	5	the	the	DET
ihlr-20834	642	6	unfairness	unfairness	ADJ
ihlr-20834	642	7	argument	argument	NOUN
ihlr-20834	642	8	by	by	ADP
ihlr-20834	642	9	stating	state	VERB
ihlr-20834	642	10	that	that	SCONJ
ihlr-20834	642	11	“	"	PUNCT
ihlr-20834	642	12	alleged	allege	VERB
ihlr-20834	642	13	misrepresentations	misrepresentation	NOUN
ihlr-20834	642	14	were	be	AUX
ihlr-20834	642	15	drafted	draft	VERB
ihlr-20834	642	16	by	by	ADP
ihlr-20834	642	17	the	the	DET
ihlr-20834	642	18	brand	brand	NOUN
ihlr-20834	642	19	-	-	PUNCT
ihlr-20834	642	20	name	name	NOUN
ihlr-20834	642	21	manufacturer	manufacturer	NOUN
ihlr-20834	642	22	and	and	CCONJ
ihlr-20834	642	23	merely	merely	ADV
ihlr-20834	642	24	repeated	repeat	VERB
ihlr-20834	642	25	.	.	PUNCT
ihlr-20834	642	26	.	.	PUNCT
ihlr-20834	642	27	.	.	PUNCT
ihlr-20834	643	1	by	by	ADP
ihlr-20834	643	2	the	the	DET
ihlr-20834	643	3	generic	generic	ADJ
ihlr-20834	643	4	manufacturer	manufacturer	NOUN
ihlr-20834	643	5	.	.	PUNCT
ihlr-20834	643	6	”	"	PUNCT
ihlr-20834	643	7	208	208	NUM
ihlr-20834	643	8	the	the	DET
ihlr-20834	643	9	court	court	NOUN
ihlr-20834	643	10	reasoned	reason	VERB
ihlr-20834	643	11	that	that	SCONJ
ihlr-20834	643	12	the	the	DET
ihlr-20834	643	13	special	special	ADJ
ihlr-20834	643	14	sameness	sameness	NOUN
ihlr-20834	643	15	requirement	requirement	NOUN
ihlr-20834	643	16	gave	give	VERB
ihlr-20834	643	17	them	they	PRON
ihlr-20834	643	18	the	the	DET
ihlr-20834	643	19	ability	ability	NOUN
ihlr-20834	643	20	to	to	PART
ihlr-20834	643	21	consider	consider	VERB
ihlr-20834	643	22	the	the	DET
ihlr-20834	643	23	innovator	innovator	NOUN
ihlr-20834	643	24	liability	liability	NOUN
ihlr-20834	643	25	argument	argument	NOUN
ihlr-20834	643	26	.	.	PUNCT
ihlr-20834	644	1	209	209	NUM
ihlr-20834	644	2	the	the	DET
ihlr-20834	644	3	court	court	NOUN
ihlr-20834	644	4	cited	cite	VERB
ihlr-20834	644	5	to	to	ADP
ihlr-20834	644	6	the	the	DET
ihlr-20834	644	7	unique	unique	ADJ
ihlr-20834	644	8	relationship	relationship	NOUN
ihlr-20834	644	9	between	between	ADP
ihlr-20834	644	10	the	the	DET
ihlr-20834	644	11	brand	brand	NOUN
ihlr-20834	644	12	-	-	PUNCT
ihlr-20834	644	13	name	name	NOUN
ihlr-20834	644	14	and	and	CCONJ
ihlr-20834	644	15	generic	generic	ADJ
ihlr-20834	644	16	drugs.210	drugs.210	NOUN
ihlr-20834	644	17	the	the	DET
ihlr-20834	644	18	alabama	alabama	PROPN
ihlr-20834	644	19	supreme	supreme	PROPN
ihlr-20834	644	20	court	court	PROPN
ihlr-20834	644	21	reheard	reheard	PROPN
ihlr-20834	645	1	the	the	DET
ihlr-20834	645	2	case	case	NOUN
ihlr-20834	645	3	in	in	ADP
ihlr-20834	645	4	september	september	PROPN
ihlr-20834	645	5	2013.211	2013.211	NUM
ihlr-20834	645	6	after	after	ADP
ihlr-20834	645	7	rehearing	rehear	VERB
ihlr-20834	645	8	,	,	PUNCT
ihlr-20834	645	9	the	the	DET
ihlr-20834	645	10	alabama	alabama	PROPN
ihlr-20834	645	11	supreme	supreme	PROPN
ihlr-20834	645	12	court	court	PROPN
ihlr-20834	645	13	affirmed	affirm	VERB
ihlr-20834	645	14	their	their	PRON
ihlr-20834	645	15	previous	previous	ADJ
ihlr-20834	645	16	ruling	ruling	NOUN
ihlr-20834	645	17	in	in	ADP
ihlr-20834	645	18	a	a	DET
ihlr-20834	645	19	6	6	NUM
ihlr-20834	645	20	-	-	SYM
ihlr-20834	645	21	3	3	NUM
ihlr-20834	645	22	decision	decision	NOUN
ihlr-20834	645	23	.	.	PUNCT
ihlr-20834	646	1	many	many	ADJ
ihlr-20834	646	2	argued	argue	VERB
ihlr-20834	646	3	against	against	ADP
ihlr-20834	646	4	this	this	DET
ihlr-20834	646	5	decision	decision	NOUN
ihlr-20834	646	6	claiming	claim	VERB
ihlr-20834	646	7	it	it	PRON
ihlr-20834	646	8	is	be	AUX
ihlr-20834	646	9	“	"	PUNCT
ihlr-20834	646	10	a	a	DET
ihlr-20834	646	11	basic	basic	NOUN
ihlr-20834	646	12	of	of	ADP
ihlr-20834	646	13	products	product	NOUN
ihlr-20834	646	14	liability	liability	NOUN
ihlr-20834	646	15	,	,	PUNCT
ihlr-20834	646	16	it	it	PRON
ihlr-20834	646	17	’s	’	VERB
ihlr-20834	646	18	in	in	ADP
ihlr-20834	646	19	the	the	DET
ihlr-20834	646	20	restatement	restatement	NOUN
ihlr-20834	646	21	of	of	ADP
ihlr-20834	646	22	torts	tort	NOUN
ihlr-20834	646	23	…	…	PUNCT
ihlr-20834	646	24	that	that	SCONJ
ihlr-20834	646	25	a	a	DET
ihlr-20834	646	26	manufacturer	manufacturer	NOUN
ihlr-20834	646	27	is	be	AUX
ihlr-20834	646	28	responsible	responsible	ADJ
ihlr-20834	647	1	[	[	PUNCT
ihlr-20834	647	2	only	only	ADV
ihlr-20834	647	3	]	]	PUNCT
ihlr-20834	647	4	for	for	ADP
ihlr-20834	647	5	the	the	DET
ihlr-20834	647	6	products	product	NOUN
ihlr-20834	647	7	it	it	PRON
ihlr-20834	647	8	makes	make	VERB
ihlr-20834	647	9	.	.	PUNCT
ihlr-20834	647	10	.	.	PUNCT
ihlr-20834	647	11	.	.	PUNCT
ihlr-20834	647	12	.”212	.”212	PUNCT
ihlr-20834	648	1	unfortunately	unfortunately	ADV
ihlr-20834	648	2	,	,	PUNCT
ihlr-20834	648	3	there	there	PRON
ihlr-20834	648	4	are	be	VERB
ihlr-20834	648	5	several	several	ADJ
ihlr-20834	648	6	cases	case	NOUN
ihlr-20834	648	7	in	in	ADP
ihlr-20834	648	8	their	their	PRON
ihlr-20834	648	9	favor	favor	NOUN
ihlr-20834	648	10	;	;	PUNCT
ihlr-20834	648	11	as	as	ADP
ihlr-20834	648	12	of	of	ADP
ihlr-20834	648	13	january	january	PROPN
ihlr-20834	648	14	2014	2014	NUM
ihlr-20834	648	15	,	,	PUNCT
ihlr-20834	648	16	“	"	PUNCT
ihlr-20834	648	17	77	77	NUM
ihlr-20834	648	18	cases	case	NOUN
ihlr-20834	648	19	[	[	X
ihlr-20834	648	20	said	say	VERB
ihlr-20834	648	21	]	]	PUNCT
ihlr-20834	648	22	name	name	NOUN
ihlr-20834	648	23	-	-	PUNCT
ihlr-20834	648	24	brand	brand	NOUN
ihlr-20834	648	25	manufacturers	manufacturer	NOUN
ihlr-20834	648	26	do	do	AUX
ihlr-20834	648	27	n’t	not	PART
ihlr-20834	648	28	owe	owe	VERB
ihlr-20834	648	29	any	any	DET
ihlr-20834	648	30	duty	duty	NOUN
ihlr-20834	648	31	to	to	ADP
ihlr-20834	648	32	people	people	NOUN
ihlr-20834	648	33	who	who	PRON
ihlr-20834	648	34	never	never	ADV
ihlr-20834	648	35	took	take	VERB
ihlr-20834	648	36	their	their	PRON
ihlr-20834	648	37	products	product	NOUN
ihlr-20834	648	38	[	[	X
ihlr-20834	648	39	and	and	CCONJ
ihlr-20834	648	40	]	]	X
ihlr-20834	649	1	[	[	X
ihlr-20834	649	2	s]ix	s]ix	ADJ
ihlr-20834	649	3	federal	federal	ADJ
ihlr-20834	649	4	appeals	appeal	NOUN
ihlr-20834	649	5	courts	court	NOUN
ihlr-20834	649	6	have	have	AUX
ihlr-20834	649	7	ruled	rule	VERB
ihlr-20834	649	8	that	that	DET
ihlr-20834	649	9	way	way	NOUN
ihlr-20834	649	10	.	.	PUNCT
ihlr-20834	650	1	”213	”213	VERB
ihlr-20834	650	2	the	the	DET
ihlr-20834	650	3	supreme	supreme	PROPN
ihlr-20834	650	4	court	court	PROPN
ihlr-20834	650	5	of	of	ADP
ihlr-20834	650	6	iowa	iowa	PROPN
ihlr-20834	650	7	recently	recently	ADV
ihlr-20834	650	8	rejected	reject	VERB
ihlr-20834	650	9	this	this	DET
ihlr-20834	650	10	innovator	innovator	NOUN
ihlr-20834	650	11	liability	liability	NOUN
ihlr-20834	650	12	theory	theory	NOUN
ihlr-20834	650	13	in	in	ADP
ihlr-20834	650	14	the	the	DET
ihlr-20834	650	15	decision	decision	NOUN
ihlr-20834	650	16	huck	huck	PROPN
ihlr-20834	650	17	v.	v.	CCONJ
ihlr-20834	650	18	wyeth.214	wyeth.214	PROPN
ihlr-20834	650	19	206	206	NUM
ihlr-20834	650	20	see	see	VERB
ihlr-20834	650	21	foster	foster	ADV
ihlr-20834	650	22	v.	v.	ADP
ihlr-20834	650	23	am	be	AUX
ihlr-20834	650	24	.	.	PUNCT
ihlr-20834	651	1	home	home	NOUN
ihlr-20834	651	2	prods	prod	NOUN
ihlr-20834	651	3	.	.	PUNCT
ihlr-20834	652	1	corp	corp	PROPN
ihlr-20834	652	2	.	.	PROPN
ihlr-20834	652	3	,	,	PUNCT
ihlr-20834	652	4	29	29	NUM
ihlr-20834	652	5	f.3d	f.3d	NUM
ihlr-20834	652	6	165	165	NUM
ihlr-20834	652	7	(	(	PUNCT
ihlr-20834	652	8	4th	4th	ADJ
ihlr-20834	652	9	cir	cir	NOUN
ihlr-20834	652	10	.	.	PROPN
ihlr-20834	652	11	1994	1994	NUM
ihlr-20834	652	12	)	)	PUNCT
ihlr-20834	652	13	;	;	PUNCT
ihlr-20834	653	1	baymiller	baymiller	PROPN
ihlr-20834	653	2	v.	v.	PROPN
ihlr-20834	653	3	ranbaxy	ranbaxy	PROPN
ihlr-20834	653	4	pharm	pharm	PROPN
ihlr-20834	653	5	.	.	PROPN
ihlr-20834	653	6	,	,	PUNCT
ihlr-20834	653	7	inc	inc	PROPN
ihlr-20834	653	8	.	.	PROPN
ihlr-20834	653	9	,	,	PUNCT
ihlr-20834	653	10	894	894	NUM
ihlr-20834	653	11	f.supp.2d	f.supp.2d	X
ihlr-20834	653	12	1302	1302	NUM
ihlr-20834	653	13	(	(	PUNCT
ihlr-20834	653	14	d.	d.	PROPN
ihlr-20834	653	15	nev	nev	PROPN
ihlr-20834	653	16	.	.	PROPN
ihlr-20834	653	17	2012	2012	NUM
ihlr-20834	653	18	)	)	PUNCT
ihlr-20834	654	1	(	(	PUNCT
ihlr-20834	654	2	holding	hold	VERB
ihlr-20834	654	3	that	that	DET
ihlr-20834	654	4	consumer	consumer	NOUN
ihlr-20834	654	5	’s	’s	PART
ihlr-20834	654	6	use	use	NOUN
ihlr-20834	654	7	of	of	ADP
ihlr-20834	654	8	generic	generic	ADJ
ihlr-20834	654	9	pharmaceutical	pharmaceutical	NOUN
ihlr-20834	654	10	precluded	preclude	VERB
ihlr-20834	654	11	claims	claim	NOUN
ihlr-20834	654	12	of	of	ADP
ihlr-20834	654	13	strict	strict	ADJ
ihlr-20834	654	14	products	product	NOUN
ihlr-20834	654	15	liability	liability	NOUN
ihlr-20834	654	16	against	against	ADP
ihlr-20834	654	17	brand	brand	NOUN
ihlr-20834	654	18	-	-	PUNCT
ihlr-20834	654	19	name	name	NOUN
ihlr-20834	654	20	manufacturer	manufacturer	NOUN
ihlr-20834	654	21	)	)	PUNCT
ihlr-20834	654	22	.	.	PUNCT
ihlr-20834	655	1	207	207	NUM
ihlr-20834	655	2	wyeth	wyeth	PROPN
ihlr-20834	655	3	,	,	PUNCT
ihlr-20834	655	4	inc	inc	PROPN
ihlr-20834	655	5	.	.	PROPN
ihlr-20834	655	6	v.	v.	ADP
ihlr-20834	655	7	weeks	week	NOUN
ihlr-20834	655	8	,	,	PUNCT
ihlr-20834	655	9	1101397	1101397	NUM
ihlr-20834	655	10	,	,	PUNCT
ihlr-20834	655	11	2014	2014	NUM
ihlr-20834	655	12	wl	wl	SYM
ihlr-20834	655	13	4055813	4055813	NUM
ihlr-20834	655	14	(	(	PUNCT
ihlr-20834	655	15	ala	ala	PROPN
ihlr-20834	655	16	.	.	PUNCT
ihlr-20834	655	17	aug	aug	PROPN
ihlr-20834	655	18	.	.	PROPN
ihlr-20834	655	19	15	15	NUM
ihlr-20834	655	20	,	,	PUNCT
ihlr-20834	655	21	2014	2014	NUM
ihlr-20834	655	22	)	)	PUNCT
ihlr-20834	655	23	.	.	PUNCT
ihlr-20834	656	1	208	208	NUM
ihlr-20834	657	1	i	i	PRON
ihlr-20834	657	2	d.	d.	NOUN
ihlr-20834	657	3	at	at	ADP
ihlr-20834	657	4	*	*	PROPN
ihlr-20834	657	5	23	23	NUM
ihlr-20834	657	6	.	.	PUNCT
ihlr-20834	658	1	209	209	NUM
ihlr-20834	659	1	i	i	PRON
ihlr-20834	659	2	d.	d.	PROPN
ihlr-20834	659	3	210	210	NUM
ihlr-20834	660	1	i	i	PRON
ihlr-20834	660	2	d.	d.	PROPN
ihlr-20834	660	3	211	211	NUM
ihlr-20834	661	1	i	i	PRON
ihlr-20834	661	2	d.	d.	PROPN
ihlr-20834	661	3	212	212	NUM
ihlr-20834	661	4	laird	laird	PROPN
ihlr-20834	661	5	,	,	PUNCT
ihlr-20834	661	6	supra	supra	PROPN
ihlr-20834	661	7	note	note	PROPN
ihlr-20834	661	8	201	201	NUM
ihlr-20834	661	9	.	.	NOUN
ihlr-20834	661	10	213	213	NUM
ihlr-20834	662	1	i	i	PRON
ihlr-20834	662	2	d.	d.	PROPN
ihlr-20834	662	3	214	214	PROPN
ihlr-20834	662	4	huck	huck	PROPN
ihlr-20834	662	5	v.	v.	PROPN
ihlr-20834	662	6	wyeth	wyeth	PROPN
ihlr-20834	662	7	,	,	PUNCT
ihlr-20834	662	8	inc	inc	PROPN
ihlr-20834	662	9	.	.	PROPN
ihlr-20834	662	10	,	,	PUNCT
ihlr-20834	662	11	850	850	NUM
ihlr-20834	662	12	n.w.2d	n.w.2d	ADP
ihlr-20834	662	13	353	353	NUM
ihlr-20834	662	14	(	(	PUNCT
ihlr-20834	662	15	iowa	iowa	PROPN
ihlr-20834	662	16	2014	2014	NUM
ihlr-20834	662	17	)	)	PUNCT
ihlr-20834	662	18	.	.	PUNCT
ihlr-20834	663	1	804	804	NUM
ihlr-20834	663	2	indiana	indiana	PROPN
ihlr-20834	663	3	health	health	PROPN
ihlr-20834	663	4	law	law	PROPN
ihlr-20834	663	5	review	review	NOUN
ihlr-20834	663	6	vol	vol	NOUN
ihlr-20834	663	7	.	.	PUNCT
ihlr-20834	663	8	12:2	12:2	NUM
ihlr-20834	663	9	an	an	DET
ihlr-20834	663	10	innovator	innovator	NOUN
ihlr-20834	663	11	liability	liability	NOUN
ihlr-20834	663	12	cause	cause	NOUN
ihlr-20834	663	13	of	of	ADP
ihlr-20834	663	14	action	action	NOUN
ihlr-20834	663	15	would	would	AUX
ihlr-20834	663	16	be	be	AUX
ihlr-20834	663	17	based	base	VERB
ihlr-20834	663	18	on	on	ADP
ihlr-20834	663	19	negligent	negligent	ADJ
ihlr-20834	663	20	and/or	and/or	CCONJ
ihlr-20834	663	21	intentional	intentional	ADJ
ihlr-20834	663	22	misrepresentation	misrepresentation	NOUN
ihlr-20834	663	23	and	and	CCONJ
ihlr-20834	663	24	not	not	PART
ihlr-20834	663	25	on	on	ADP
ihlr-20834	663	26	strict	strict	ADJ
ihlr-20834	663	27	product	product	NOUN
ihlr-20834	663	28	liability	liability	NOUN
ihlr-20834	663	29	.	.	PUNCT
ihlr-20834	664	1	the	the	DET
ihlr-20834	664	2	negligent	negligent	ADJ
ihlr-20834	664	3	and/or	and/or	CCONJ
ihlr-20834	664	4	intentional	intentional	ADJ
ihlr-20834	664	5	misrepresentation	misrepresentation	NOUN
ihlr-20834	664	6	suit	suit	NOUN
ihlr-20834	664	7	would	would	AUX
ihlr-20834	664	8	“	"	PUNCT
ihlr-20834	664	9	authorize	authorize	VERB
ihlr-20834	664	10	[	[	X
ihlr-20834	664	11	]	]	X
ihlr-20834	664	12	liability	liability	NOUN
ihlr-20834	664	13	against	against	ADP
ihlr-20834	664	14	a	a	DET
ihlr-20834	664	15	non	non	ADJ
ihlr-20834	664	16	-	-	NOUN
ihlr-20834	664	17	seller	seller	NOUN
ihlr-20834	664	18	who	who	PRON
ihlr-20834	664	19	has	have	VERB
ihlr-20834	664	20	reason	reason	NOUN
ihlr-20834	664	21	to	to	PART
ihlr-20834	664	22	know	know	VERB
ihlr-20834	664	23	that	that	SCONJ
ihlr-20834	664	24	a	a	DET
ihlr-20834	664	25	third	third	ADJ
ihlr-20834	664	26	party	party	NOUN
ihlr-20834	664	27	could	could	AUX
ihlr-20834	664	28	suffer	suffer	VERB
ihlr-20834	664	29	harm	harm	NOUN
ihlr-20834	664	30	.	.	PUNCT
ihlr-20834	665	1	”215	”215	PROPN
ihlr-20834	665	2	thus	thus	ADV
ihlr-20834	665	3	,	,	PUNCT
ihlr-20834	665	4	the	the	DET
ihlr-20834	665	5	injured	injure	VERB
ihlr-20834	665	6	party	party	NOUN
ihlr-20834	665	7	could	could	AUX
ihlr-20834	665	8	allege	allege	VERB
ihlr-20834	665	9	that	that	SCONJ
ihlr-20834	665	10	even	even	ADV
ihlr-20834	665	11	if	if	SCONJ
ihlr-20834	665	12	a	a	DET
ihlr-20834	665	13	generic	generic	ADJ
ihlr-20834	665	14	equivalent	equivalent	ADJ
ihlr-20834	665	15	drug	drug	NOUN
ihlr-20834	665	16	was	be	AUX
ihlr-20834	665	17	taken	take	VERB
ihlr-20834	665	18	,	,	PUNCT
ihlr-20834	665	19	the	the	DET
ihlr-20834	665	20	brandname	brandname	NOUN
ihlr-20834	665	21	manufacturer	manufacturer	NOUN
ihlr-20834	665	22	’s	’s	PART
ihlr-20834	665	23	label	label	NOUN
ihlr-20834	665	24	error	error	NOUN
ihlr-20834	665	25	was	be	AUX
ihlr-20834	665	26	a	a	DET
ihlr-20834	665	27	foreseeable	foreseeable	ADJ
ihlr-20834	665	28	cause	cause	NOUN
ihlr-20834	665	29	of	of	ADP
ihlr-20834	665	30	his	his	PRON
ihlr-20834	665	31	/	/	SYM
ihlr-20834	665	32	her	her	PRON
ihlr-20834	665	33	injuries	injury	NOUN
ihlr-20834	665	34	because	because	SCONJ
ihlr-20834	665	35	the	the	DET
ihlr-20834	665	36	generic	generic	ADJ
ihlr-20834	665	37	drug	drug	NOUN
ihlr-20834	665	38	manufacturer	manufacturer	NOUN
ihlr-20834	665	39	should	should	AUX
ihlr-20834	665	40	reasonably	reasonably	ADV
ihlr-20834	665	41	know	know	VERB
ihlr-20834	665	42	that	that	SCONJ
ihlr-20834	665	43	“	"	PUNCT
ihlr-20834	665	44	whenever	whenever	SCONJ
ihlr-20834	665	45	one	one	NUM
ihlr-20834	665	46	of	of	ADP
ihlr-20834	665	47	its	its	PRON
ihlr-20834	665	48	products	product	NOUN
ihlr-20834	665	49	is	be	AUX
ihlr-20834	665	50	mislabeled	mislabele	VERB
ihlr-20834	665	51	,	,	PUNCT
ihlr-20834	665	52	the	the	DET
ihlr-20834	665	53	generic	generic	ADJ
ihlr-20834	665	54	product	product	NOUN
ihlr-20834	665	55	will	will	AUX
ihlr-20834	665	56	be	be	AUX
ihlr-20834	665	57	as	as	ADV
ihlr-20834	665	58	well	well	ADV
ihlr-20834	665	59	.	.	PUNCT
ihlr-20834	666	1	”216	”216	NOUN
ihlr-20834	667	1	most	most	ADJ
ihlr-20834	667	2	courts	court	NOUN
ihlr-20834	667	3	have	have	AUX
ihlr-20834	667	4	dismissed	dismiss	VERB
ihlr-20834	667	5	these	these	DET
ihlr-20834	667	6	types	type	NOUN
ihlr-20834	667	7	of	of	ADP
ihlr-20834	667	8	“	"	PUNCT
ihlr-20834	667	9	innovator	innovator	NOUN
ihlr-20834	667	10	liability	liability	NOUN
ihlr-20834	667	11	claims	claim	NOUN
ihlr-20834	667	12	”	"	PUNCT
ihlr-20834	667	13	by	by	ADP
ihlr-20834	667	14	reasoning	reason	VERB
ihlr-20834	667	15	that	that	SCONJ
ihlr-20834	667	16	plaintiffs	plaintiff	NOUN
ihlr-20834	667	17	should	should	AUX
ihlr-20834	667	18	not	not	PART
ihlr-20834	667	19	be	be	AUX
ihlr-20834	667	20	able	able	ADJ
ihlr-20834	667	21	to	to	PART
ihlr-20834	667	22	sue	sue	VERB
ihlr-20834	667	23	drug	drug	NOUN
ihlr-20834	667	24	manufacturers	manufacturer	NOUN
ihlr-20834	667	25	that	that	PRON
ihlr-20834	667	26	did	do	AUX
ihlr-20834	667	27	not	not	PART
ihlr-20834	667	28	make	make	VERB
ihlr-20834	667	29	the	the	DET
ihlr-20834	667	30	drug	drug	NOUN
ihlr-20834	667	31	they	they	PRON
ihlr-20834	667	32	consumed.217	consumed.217	VERB
ihlr-20834	667	33	2	2	NUM
ihlr-20834	667	34	.	.	PUNCT
ihlr-20834	667	35	option	option	NOUN
ihlr-20834	667	36	two	two	NUM
ihlr-20834	667	37	–	–	PUNCT
ihlr-20834	667	38	suing	sue	VERB
ihlr-20834	667	39	the	the	DET
ihlr-20834	667	40	generic	generic	ADJ
ihlr-20834	667	41	drug	drug	NOUN
ihlr-20834	667	42	manufacturer	manufacturer	NOUN
ihlr-20834	667	43	for	for	ADP
ihlr-20834	667	44	misbranding	misbrande	VERB
ihlr-20834	667	45	an	an	DET
ihlr-20834	667	46	individual	individual	NOUN
ihlr-20834	667	47	injured	injure	VERB
ihlr-20834	667	48	from	from	ADP
ihlr-20834	667	49	a	a	DET
ihlr-20834	667	50	generic	generic	ADJ
ihlr-20834	667	51	drug	drug	NOUN
ihlr-20834	667	52	could	could	AUX
ihlr-20834	667	53	bring	bring	VERB
ihlr-20834	667	54	suit	suit	NOUN
ihlr-20834	667	55	against	against	ADP
ihlr-20834	667	56	the	the	DET
ihlr-20834	667	57	generic	generic	ADJ
ihlr-20834	667	58	drug	drug	NOUN
ihlr-20834	667	59	manufacturer	manufacturer	NOUN
ihlr-20834	667	60	under	under	ADP
ihlr-20834	667	61	the	the	DET
ihlr-20834	667	62	fdca	fdca	NOUN
ihlr-20834	667	63	’s	’s	PART
ihlr-20834	667	64	misbranding	misbrande	VERB
ihlr-20834	667	65	statute.218	statute.218	NOUN
ihlr-20834	667	66	this	this	DET
ihlr-20834	667	67	misbranding	misbranding	NOUN
ihlr-20834	667	68	statute	statute	NOUN
ihlr-20834	667	69	provides	provide	VERB
ihlr-20834	667	70	that	that	SCONJ
ihlr-20834	667	71	a	a	DET
ihlr-20834	667	72	drug	drug	NOUN
ihlr-20834	667	73	is	be	AUX
ihlr-20834	667	74	misbranded	misbrande	VERB
ihlr-20834	667	75	if	if	SCONJ
ihlr-20834	667	76	,	,	PUNCT
ihlr-20834	667	77	amongst	amongst	ADP
ihlr-20834	667	78	other	other	ADJ
ihlr-20834	667	79	things	thing	NOUN
ihlr-20834	667	80	,	,	PUNCT
ihlr-20834	667	81	“	"	PUNCT
ihlr-20834	667	82	[	[	X
ihlr-20834	667	83	i]t	i]t	NOUN
ihlr-20834	667	84	is	be	AUX
ihlr-20834	667	85	dangerous	dangerous	ADJ
ihlr-20834	667	86	to	to	ADP
ihlr-20834	667	87	health	health	NOUN
ihlr-20834	667	88	when	when	SCONJ
ihlr-20834	667	89	used	use	VERB
ihlr-20834	667	90	in	in	ADP
ihlr-20834	667	91	the	the	DET
ihlr-20834	667	92	dosage	dosage	NOUN
ihlr-20834	667	93	or	or	CCONJ
ihlr-20834	667	94	manner	manner	NOUN
ihlr-20834	667	95	,	,	PUNCT
ihlr-20834	667	96	or	or	CCONJ
ihlr-20834	667	97	with	with	ADP
ihlr-20834	667	98	the	the	DET
ihlr-20834	667	99	frequency	frequency	NOUN
ihlr-20834	667	100	or	or	CCONJ
ihlr-20834	667	101	duration	duration	NOUN
ihlr-20834	667	102	prescribed	prescribe	VERB
ihlr-20834	667	103	,	,	PUNCT
ihlr-20834	667	104	recommended	recommend	VERB
ihlr-20834	667	105	,	,	PUNCT
ihlr-20834	667	106	or	or	CCONJ
ihlr-20834	667	107	suggested	suggest	VERB
ihlr-20834	667	108	in	in	ADP
ihlr-20834	667	109	the	the	DET
ihlr-20834	667	110	labeling	labeling	NOUN
ihlr-20834	667	111	.	.	PUNCT
ihlr-20834	667	112	.	.	PUNCT
ihlr-20834	667	113	.	.	PUNCT
ihlr-20834	668	1	.	.	PUNCT
ihlr-20834	668	2	”	"	PUNCT
ihlr-20834	669	1	219	219	NUM
ihlr-20834	669	2	mutual	mutual	ADJ
ihlr-20834	669	3	’s	’s	NOUN
ihlr-20834	669	4	majority	majority	NOUN
ihlr-20834	669	5	reasoned	reason	VERB
ihlr-20834	669	6	that	that	SCONJ
ihlr-20834	669	7	“	"	PUNCT
ihlr-20834	669	8	[	[	X
ihlr-20834	669	9	f]ederal	f]ederal	ADJ
ihlr-20834	669	10	law	law	NOUN
ihlr-20834	669	11	itself	itself	PRON
ihlr-20834	669	12	bars	bar	VERB
ihlr-20834	669	13	the	the	DET
ihlr-20834	669	14	sale	sale	NOUN
ihlr-20834	669	15	of	of	ADP
ihlr-20834	669	16	previously	previously	ADV
ihlr-20834	669	17	approved	approve	VERB
ihlr-20834	669	18	drugs	drug	NOUN
ihlr-20834	669	19	if	if	SCONJ
ihlr-20834	669	20	new	new	ADJ
ihlr-20834	669	21	information	information	NOUN
ihlr-20834	669	22	comes	come	VERB
ihlr-20834	669	23	to	to	ADP
ihlr-20834	669	24	light	light	ADJ
ihlr-20834	669	25	demonstrating	demonstrating	NOUN
ihlr-20834	669	26	that	that	SCONJ
ihlr-20834	669	27	the	the	DET
ihlr-20834	669	28	drug	drug	NOUN
ihlr-20834	669	29	is	be	AUX
ihlr-20834	669	30	‘	'	PUNCT
ihlr-20834	669	31	dangerous	dangerous	ADJ
ihlr-20834	669	32	to	to	ADP
ihlr-20834	669	33	health	health	NOUN
ihlr-20834	669	34	’	'	PUNCT
ihlr-20834	669	35	and	and	CCONJ
ihlr-20834	669	36	thus	thus	ADV
ihlr-20834	669	37	‘	'	PUNCT
ihlr-20834	669	38	misbranded	misbrande	VERB
ihlr-20834	669	39	.	.	PUNCT
ihlr-20834	669	40	’”220	’”220	ADJ
ihlr-20834	669	41	however	however	ADV
ihlr-20834	669	42	,	,	PUNCT
ihlr-20834	669	43	following	follow	VERB
ihlr-20834	669	44	the	the	DET
ihlr-20834	669	45	pliva	pliva	NOUN
ihlr-20834	669	46	decision	decision	NOUN
ihlr-20834	669	47	,	,	PUNCT
ihlr-20834	669	48	a	a	DET
ihlr-20834	669	49	misbrand	misbrand	NOUN
ihlr-20834	669	50	-	-	PUNCT
ihlr-20834	669	51	based	base	VERB
ihlr-20834	669	52	claim	claim	NOUN
ihlr-20834	669	53	would	would	AUX
ihlr-20834	669	54	probably	probably	ADV
ihlr-20834	669	55	215	215	NUM
ihlr-20834	669	56	wolfman	wolfman	NOUN
ihlr-20834	669	57	&	&	CCONJ
ihlr-20834	669	58	king	king	PROPN
ihlr-20834	669	59	,	,	PUNCT
ihlr-20834	669	60	supra	supra	PROPN
ihlr-20834	669	61	note	note	NOUN
ihlr-20834	669	62	134	134	NUM
ihlr-20834	669	63	.	.	NUM
ihlr-20834	669	64	216	216	NUM
ihlr-20834	670	1	i	i	PROPN
ihlr-20834	670	2	d.	d.	PROPN
ihlr-20834	670	3	217	217	NUM
ihlr-20834	670	4	lorelei	lorelei	PROPN
ihlr-20834	670	5	,	,	PUNCT
ihlr-20834	670	6	supra	supra	PROPN
ihlr-20834	670	7	note	note	PROPN
ihlr-20834	670	8	201	201	NUM
ihlr-20834	670	9	.	.	PUNCT
ihlr-20834	670	10	218	218	NUM
ihlr-20834	670	11	see	see	VERB
ihlr-20834	670	12	21	21	NUM
ihlr-20834	670	13	u.s.c	u.s.c	ADJ
ihlr-20834	670	14	.	.	PUNCT
ihlr-20834	671	1	§	§	PROPN
ihlr-20834	671	2	352	352	NUM
ihlr-20834	671	3	(	(	PUNCT
ihlr-20834	671	4	2015	2015	NUM
ihlr-20834	671	5	)	)	PUNCT
ihlr-20834	671	6	.	.	PUNCT
ihlr-20834	672	1	219	219	NUM
ihlr-20834	672	2	labeling	labeling	NOUN
ihlr-20834	672	3	requirements	requirement	NOUN
ihlr-20834	672	4	–	–	PUNCT
ihlr-20834	672	5	misbranding	misbranding	NOUN
ihlr-20834	672	6	,	,	PUNCT
ihlr-20834	672	7	u.s	u.s	PROPN
ihlr-20834	672	8	.	.	PROPN
ihlr-20834	672	9	food	food	PROPN
ihlr-20834	672	10	&	&	CCONJ
ihlr-20834	672	11	drug	drug	PROPN
ihlr-20834	672	12	admin	admin	PROPN
ihlr-20834	672	13	.	.	PROPN
ihlr-20834	672	14	,	,	PUNCT
ihlr-20834	672	15	http://www.fda.gov/medicaldevices/	http://www.fda.gov/medicaldevices/	PROPN
ihlr-20834	672	16	deviceregulationandguidance	deviceregulationandguidance	PROPN
ihlr-20834	672	17	/	/	SYM
ihlr-20834	672	18	overview	overview	NOUN
ihlr-20834	672	19	/	/	SYM
ihlr-20834	672	20	devicelabeling	devicelabeling	NOUN
ihlr-20834	672	21	/	/	SYM
ihlr-20834	672	22	generaldevice	generaldevice	NOUN
ihlr-20834	672	23	labelingrequirements	labelingrequirement	NOUN
ihlr-20834	672	24	/	/	SYM
ihlr-20834	672	25	ucm052190.htm	ucm052190.htm	NOUN
ihlr-20834	672	26	(	(	PUNCT
ihlr-20834	672	27	last	last	ADJ
ihlr-20834	672	28	updated	update	VERB
ihlr-20834	672	29	mar	mar	PROPN
ihlr-20834	672	30	.	.	PROPN
ihlr-20834	672	31	11	11	NUM
ihlr-20834	672	32	,	,	PUNCT
ihlr-20834	672	33	2015	2015	NUM
ihlr-20834	672	34	)	)	PUNCT
ihlr-20834	672	35	.	.	PUNCT
ihlr-20834	673	1	220	220	NUM
ihlr-20834	673	2	mut	mut	NOUN
ihlr-20834	673	3	.	.	PUNCT
ihlr-20834	674	1	pharm	pharm	PROPN
ihlr-20834	674	2	.	.	PUNCT
ihlr-20834	675	1	co.	co.	PROPN
ihlr-20834	675	2	,	,	PUNCT
ihlr-20834	675	3	inc	inc	PROPN
ihlr-20834	675	4	.	.	PROPN
ihlr-20834	676	1	v.	v.	ADP
ihlr-20834	676	2	bartlett	bartlett	PROPN
ihlr-20834	676	3	133	133	NUM
ihlr-20834	676	4	s.ct	s.ct	NOUN
ihlr-20834	676	5	.	.	PROPN
ihlr-20834	676	6	2466	2466	NUM
ihlr-20834	676	7	,	,	PUNCT
ihlr-20834	676	8	2492	2492	NUM
ihlr-20834	676	9	(	(	PUNCT
ihlr-20834	676	10	2013	2013	NUM
ihlr-20834	676	11	)	)	PUNCT
ihlr-20834	676	12	(	(	PUNCT
ihlr-20834	676	13	citing	cite	VERB
ihlr-20834	676	14	21	21	NUM
ihlr-20834	676	15	u.s.c	u.s.c	ADJ
ihlr-20834	676	16	.	.	PUNCT
ihlr-20834	677	1	§	§	PROPN
ihlr-20834	677	2	§	§	PROPN
ihlr-20834	677	3	331(a	331(a	PROPN
ihlr-20834	677	4	)	)	PUNCT
ihlr-20834	677	5	,	,	PUNCT
ihlr-20834	677	6	352(j	352(j	PROPN
ihlr-20834	677	7	)	)	PUNCT
ihlr-20834	677	8	(	(	PUNCT
ihlr-20834	677	9	2015	2015	NUM
ihlr-20834	677	10	)	)	PUNCT
ihlr-20834	677	11	)	)	PUNCT
ihlr-20834	677	12	.	.	PUNCT
ihlr-20834	678	1	2015	2015	NUM
ihlr-20834	678	2	805	805	NUM
ihlr-20834	678	3	the	the	DET
ihlr-20834	678	4	supreme	supreme	PROPN
ihlr-20834	678	5	court	court	PROPN
ihlr-20834	678	6	’s	’s	PART
ihlr-20834	678	7	overreaching	overreach	VERB
ihlr-20834	678	8	preemption	preemption	NOUN
ihlr-20834	678	9	interpretation	interpretation	NOUN
ihlr-20834	678	10	and	and	CCONJ
ihlr-20834	678	11	it	it	PRON
ihlr-20834	678	12	’s	’	VERB
ihlr-20834	678	13	consequences	consequence	NOUN
ihlr-20834	678	14	need	need	VERB
ihlr-20834	678	15	to	to	PART
ihlr-20834	678	16	be	be	AUX
ihlr-20834	678	17	brought	bring	VERB
ihlr-20834	678	18	as	as	ADP
ihlr-20834	678	19	a	a	DET
ihlr-20834	678	20	design	design	NOUN
ihlr-20834	678	21	-	-	PUNCT
ihlr-20834	678	22	defect	defect	NOUN
ihlr-20834	678	23	claim	claim	NOUN
ihlr-20834	678	24	.	.	PUNCT
ihlr-20834	679	1	although	although	SCONJ
ihlr-20834	679	2	unlikely	unlikely	ADJ
ihlr-20834	679	3	to	to	PART
ihlr-20834	679	4	succeed	succeed	VERB
ihlr-20834	679	5	,	,	PUNCT
ihlr-20834	679	6	this	this	DET
ihlr-20834	679	7	type	type	NOUN
ihlr-20834	679	8	of	of	ADP
ihlr-20834	679	9	lawsuit	lawsuit	NOUN
ihlr-20834	679	10	does	do	AUX
ihlr-20834	679	11	remain	remain	VERB
ihlr-20834	679	12	available	available	ADJ
ihlr-20834	679	13	.	.	PUNCT
ihlr-20834	680	1	3	3	X
ihlr-20834	680	2	.	.	X
ihlr-20834	680	3	option	option	NOUN
ihlr-20834	680	4	three	three	NUM
ihlr-20834	680	5	–	–	PUNCT
ihlr-20834	680	6	paying	pay	VERB
ihlr-20834	680	7	for	for	ADP
ihlr-20834	680	8	protection	protection	NOUN
ihlr-20834	680	9	through	through	ADP
ihlr-20834	680	10	brand	brand	NOUN
ihlr-20834	680	11	name	name	NOUN
ihlr-20834	680	12	drugs	drug	NOUN
ihlr-20834	680	13	individuals	individual	NOUN
ihlr-20834	680	14	seeking	seek	VERB
ihlr-20834	680	15	to	to	PART
ihlr-20834	680	16	avoid	avoid	VERB
ihlr-20834	680	17	injury	injury	NOUN
ihlr-20834	680	18	without	without	ADP
ihlr-20834	680	19	recourse	recourse	NOUN
ihlr-20834	680	20	may	may	AUX
ihlr-20834	680	21	purchase	purchase	VERB
ihlr-20834	680	22	brand	brand	NOUN
ihlr-20834	680	23	-	-	PUNCT
ihlr-20834	680	24	name	name	NOUN
ihlr-20834	680	25	drugs	drug	NOUN
ihlr-20834	680	26	as	as	SCONJ
ihlr-20834	680	27	opposed	oppose	VERB
ihlr-20834	680	28	to	to	ADP
ihlr-20834	680	29	their	their	PRON
ihlr-20834	680	30	generic	generic	ADJ
ihlr-20834	680	31	equivalents	equivalent	NOUN
ihlr-20834	680	32	.	.	PUNCT
ihlr-20834	681	1	the	the	DET
ihlr-20834	681	2	cost	cost	NOUN
ihlr-20834	681	3	difference	difference	NOUN
ihlr-20834	681	4	is	be	AUX
ihlr-20834	681	5	often	often	ADV
ihlr-20834	681	6	substantial	substantial	ADJ
ihlr-20834	681	7	and	and	CCONJ
ihlr-20834	681	8	consumers	consumer	NOUN
ihlr-20834	681	9	will	will	AUX
ihlr-20834	681	10	have	have	VERB
ihlr-20834	681	11	to	to	PART
ihlr-20834	681	12	decide	decide	VERB
ihlr-20834	681	13	if	if	SCONJ
ihlr-20834	681	14	the	the	DET
ihlr-20834	681	15	average	average	ADJ
ihlr-20834	681	16	$	$	SYM
ihlr-20834	681	17	100	100	NUM
ihlr-20834	681	18	price	price	NOUN
ihlr-20834	681	19	difference	difference	NOUN
ihlr-20834	681	20	is	be	AUX
ihlr-20834	681	21	worth	worth	ADJ
ihlr-20834	681	22	the	the	DET
ihlr-20834	681	23	risk	risk	NOUN
ihlr-20834	681	24	.	.	PUNCT
ihlr-20834	682	1	221	221	NUM
ihlr-20834	682	2	having	have	VERB
ihlr-20834	682	3	this	this	DET
ihlr-20834	682	4	option	option	NOUN
ihlr-20834	682	5	as	as	ADP
ihlr-20834	682	6	a	a	DET
ihlr-20834	682	7	solution	solution	NOUN
ihlr-20834	682	8	is	be	AUX
ihlr-20834	682	9	not	not	PART
ihlr-20834	682	10	sufficient	sufficient	ADJ
ihlr-20834	682	11	to	to	PART
ihlr-20834	682	12	protect	protect	VERB
ihlr-20834	682	13	the	the	DET
ihlr-20834	682	14	estimate	estimate	NOUN
ihlr-20834	682	15	1,015,916	1,015,916	NUM
ihlr-20834	682	16	indiana	indiana	NOUN
ihlr-20834	682	17	residents	resident	NOUN
ihlr-20834	682	18	living	live	VERB
ihlr-20834	682	19	under	under	ADP
ihlr-20834	682	20	the	the	DET
ihlr-20834	682	21	poverty	poverty	NOUN
ihlr-20834	682	22	rate	rate	NOUN
ihlr-20834	682	23	.	.	PUNCT
ihlr-20834	683	1	222	222	NUM
ihlr-20834	683	2	furthermore	furthermore	ADV
ihlr-20834	683	3	,	,	PUNCT
ihlr-20834	683	4	some	some	DET
ihlr-20834	683	5	health	health	NOUN
ihlr-20834	683	6	insurance	insurance	NOUN
ihlr-20834	683	7	providers	provider	NOUN
ihlr-20834	683	8	will	will	AUX
ihlr-20834	683	9	not	not	PART
ihlr-20834	683	10	pay	pay	VERB
ihlr-20834	683	11	for	for	ADP
ihlr-20834	683	12	brand	brand	NOUN
ihlr-20834	683	13	-	-	PUNCT
ihlr-20834	683	14	name	name	NOUN
ihlr-20834	683	15	drugs	drug	NOUN
ihlr-20834	683	16	if	if	SCONJ
ihlr-20834	683	17	a	a	DET
ihlr-20834	683	18	generic	generic	ADJ
ihlr-20834	683	19	equivalent	equivalent	NOUN
ihlr-20834	683	20	is	be	AUX
ihlr-20834	683	21	available.223	available.223	NOUN
ihlr-20834	683	22	therefore	therefore	ADV
ihlr-20834	683	23	,	,	PUNCT
ihlr-20834	683	24	this	this	DET
ihlr-20834	683	25	option	option	NOUN
ihlr-20834	683	26	would	would	AUX
ihlr-20834	683	27	only	only	ADV
ihlr-20834	683	28	help	help	VERB
ihlr-20834	683	29	certain	certain	ADJ
ihlr-20834	683	30	individuals	individual	NOUN
ihlr-20834	683	31	that	that	PRON
ihlr-20834	683	32	know	know	VERB
ihlr-20834	683	33	of	of	ADP
ihlr-20834	683	34	this	this	DET
ihlr-20834	683	35	legal	legal	ADJ
ihlr-20834	683	36	issue	issue	NOUN
ihlr-20834	683	37	and	and	CCONJ
ihlr-20834	683	38	are	be	AUX
ihlr-20834	683	39	able	able	ADJ
ihlr-20834	683	40	and	and	CCONJ
ihlr-20834	683	41	willing	willing	ADJ
ihlr-20834	683	42	to	to	PART
ihlr-20834	683	43	purchase	purchase	VERB
ihlr-20834	683	44	brand	brand	NOUN
ihlr-20834	683	45	-	-	PUNCT
ihlr-20834	683	46	name	name	NOUN
ihlr-20834	683	47	drugs	drug	NOUN
ihlr-20834	683	48	.	.	PUNCT
ihlr-20834	684	1	221	221	NUM
ihlr-20834	684	2	see	see	VERB
ihlr-20834	684	3	generic	generic	ADJ
ihlr-20834	684	4	versus	versus	ADP
ihlr-20834	684	5	brand	brand	NOUN
ihlr-20834	684	6	medications	medication	NOUN
ihlr-20834	684	7	,	,	PUNCT
ihlr-20834	684	8	healthsmart	healthsmart	NOUN
ihlr-20834	684	9	,	,	PUNCT
ihlr-20834	684	10	http://www.healthsmart.com/smarterhealth/genericvsbranddrugs.asp	http://www.healthsmart.com/smarterhealth/genericvsbranddrugs.asp	PROPN
ihlr-20834	684	11	x	x	INTJ
ihlr-20834	684	12	(	(	PUNCT
ihlr-20834	684	13	last	last	ADJ
ihlr-20834	684	14	visited	visit	VERB
ihlr-20834	684	15	mar	mar	PROPN
ihlr-20834	684	16	.	.	PROPN
ihlr-20834	684	17	21	21	NUM
ihlr-20834	684	18	,	,	PUNCT
ihlr-20834	684	19	2015	2015	NUM
ihlr-20834	684	20	)	)	PUNCT
ihlr-20834	684	21	(	(	PUNCT
ihlr-20834	684	22	noting	note	VERB
ihlr-20834	684	23	that	that	SCONJ
ihlr-20834	684	24	in	in	ADP
ihlr-20834	684	25	2008	2008	NUM
ihlr-20834	684	26	the	the	DET
ihlr-20834	684	27	average	average	ADJ
ihlr-20834	684	28	price	price	NOUN
ihlr-20834	684	29	of	of	ADP
ihlr-20834	684	30	a	a	DET
ihlr-20834	684	31	brand	brand	NOUN
ihlr-20834	684	32	-	-	PUNCT
ihlr-20834	684	33	name	name	NOUN
ihlr-20834	684	34	drug	drug	NOUN
ihlr-20834	684	35	was	be	AUX
ihlr-20834	684	36	$	$	SYM
ihlr-20834	684	37	137.90	137.90	NUM
ihlr-20834	684	38	,	,	PUNCT
ihlr-20834	684	39	while	while	SCONJ
ihlr-20834	684	40	their	their	PRON
ihlr-20834	684	41	generic	generic	ADJ
ihlr-20834	684	42	counterparts	counterpart	NOUN
ihlr-20834	684	43	were	be	AUX
ihlr-20834	684	44	only	only	ADV
ihlr-20834	684	45	$	$	SYM
ihlr-20834	684	46	35.22	35.22	NUM
ihlr-20834	684	47	)	)	PUNCT
ihlr-20834	684	48	.	.	PUNCT
ihlr-20834	685	1	222	222	NUM
ihlr-20834	685	2	indiana	indiana	PROPN
ihlr-20834	685	3	,	,	PUNCT
ihlr-20834	685	4	u.s	u.s	PROPN
ihlr-20834	685	5	.	.	PROPN
ihlr-20834	685	6	census	census	PROPN
ihlr-20834	685	7	bureau	bureau	PROPN
ihlr-20834	685	8	,	,	PUNCT
ihlr-20834	685	9	available	available	ADJ
ihlr-20834	685	10	at	at	ADP
ihlr-20834	685	11	http://quickfacts.census.gov/qfd/states/18000.html	http://quickfacts.census.gov/qfd/states/18000.html	PROPN
ihlr-20834	685	12	(	(	PUNCT
ihlr-20834	685	13	last	last	ADV
ihlr-20834	685	14	visited	visit	VERB
ihlr-20834	685	15	mar	mar	PROPN
ihlr-20834	685	16	.	.	PROPN
ihlr-20834	685	17	30	30	NUM
ihlr-20834	685	18	,	,	PUNCT
ihlr-20834	685	19	2015	2015	NUM
ihlr-20834	685	20	)	)	PUNCT
ihlr-20834	685	21	(	(	PUNCT
ihlr-20834	685	22	6,596,855	6,596,855	NUM
ihlr-20834	685	23	x	x	SYM
ihlr-20834	685	24	.154	.154	NUM
ihlr-20834	685	25	persons	person	NOUN
ihlr-20834	685	26	below	below	ADP
ihlr-20834	685	27	the	the	DET
ihlr-20834	685	28	poverty	poverty	NOUN
ihlr-20834	685	29	level	level	NOUN
ihlr-20834	685	30	from	from	ADP
ihlr-20834	685	31	2009	2009	NUM
ihlr-20834	685	32	-	-	SYM
ihlr-20834	685	33	2013	2013	NUM
ihlr-20834	685	34	averaged	average	VERB
ihlr-20834	685	35	15.4	15.4	NUM
ihlr-20834	685	36	%	%	NOUN
ihlr-20834	685	37	.	.	PUNCT
ihlr-20834	686	1	for	for	ADP
ihlr-20834	686	2	purposes	purpose	NOUN
ihlr-20834	686	3	of	of	ADP
ihlr-20834	686	4	this	this	DET
ihlr-20834	686	5	example	example	NOUN
ihlr-20834	686	6	i	i	PRON
ihlr-20834	686	7	have	have	AUX
ihlr-20834	686	8	assumed	assume	VERB
ihlr-20834	686	9	the	the	DET
ihlr-20834	686	10	poverty	poverty	NOUN
ihlr-20834	686	11	level	level	NOUN
ihlr-20834	686	12	would	would	AUX
ihlr-20834	686	13	remain	remain	VERB
ihlr-20834	686	14	15.4	15.4	NUM
ihlr-20834	686	15	%	%	NOUN
ihlr-20834	686	16	in	in	ADP
ihlr-20834	686	17	2014	2014	NUM
ihlr-20834	686	18	)	)	PUNCT
ihlr-20834	686	19	)	)	PUNCT
ihlr-20834	686	20	.	.	PUNCT
ihlr-20834	687	1	223	223	NUM
ihlr-20834	687	2	see	see	VERB
ihlr-20834	687	3	michael	michael	PROPN
ihlr-20834	687	4	bihari	bihari	PROPN
ihlr-20834	687	5	,	,	PUNCT
ihlr-20834	687	6	understanding	understand	VERB
ihlr-20834	687	7	your	your	PRON
ihlr-20834	687	8	health	health	NOUN
ihlr-20834	687	9	plan	plan	NOUN
ihlr-20834	687	10	,	,	PUNCT
ihlr-20834	687	11	about.com	about.com	X
ihlr-20834	687	12	http://healthinsurance.about.com/od/prescriptiondrugs/a/understanding	http://healthinsurance.about.com/od/prescriptiondrugs/a/understande	VERB
ihlr-20834	687	13	_	_	ADJ
ihlr-20834	687	14	formulary.htm	formulary.htm	X
ihlr-20834	687	15	(	(	PUNCT
ihlr-20834	687	16	last	last	ADJ
ihlr-20834	687	17	visited	visit	VERB
ihlr-20834	687	18	mar	mar	PROPN
ihlr-20834	687	19	.	.	PROPN
ihlr-20834	687	20	21	21	NUM
ihlr-20834	687	21	,	,	PUNCT
ihlr-20834	687	22	2015	2015	NUM
ihlr-20834	687	23	)	)	PUNCT
ihlr-20834	687	24	(	(	PUNCT
ihlr-20834	687	25	drugs	drug	NOUN
ihlr-20834	687	26	are	be	AUX
ihlr-20834	687	27	often	often	ADV
ihlr-20834	687	28	grouped	group	VERB
ihlr-20834	687	29	into	into	ADP
ihlr-20834	687	30	tiers	tier	NOUN
ihlr-20834	687	31	and	and	CCONJ
ihlr-20834	687	32	“	"	PUNCT
ihlr-20834	687	33	[	[	X
ihlr-20834	687	34	t]ier	t]ier	NOUN
ihlr-20834	687	35	1	1	NUM
ihlr-20834	687	36	has	have	VERB
ihlr-20834	687	37	the	the	DET
ihlr-20834	687	38	lowest	low	ADJ
ihlr-20834	687	39	co	co	NOUN
ihlr-20834	687	40	-	-	NOUN
ihlr-20834	687	41	payment	payment	NOUN
ihlr-20834	687	42	and	and	CCONJ
ihlr-20834	687	43	usually	usually	ADV
ihlr-20834	687	44	includes	include	VERB
ihlr-20834	687	45	generic	generic	ADJ
ihlr-20834	687	46	medications	medication	NOUN
ihlr-20834	687	47	.	.	PUNCT
ihlr-20834	687	48	”	"	PUNCT
ihlr-20834	688	1	“	"	PUNCT
ihlr-20834	688	2	tier	tier	NOUN
ihlr-20834	688	3	2	2	NUM
ihlr-20834	688	4	has	have	VERB
ihlr-20834	688	5	a	a	DET
ihlr-20834	688	6	higher	high	ADJ
ihlr-20834	688	7	co	co	NOUN
ihlr-20834	688	8	-	-	NOUN
ihlr-20834	688	9	payment	payment	NOUN
ihlr-20834	688	10	than	than	ADP
ihlr-20834	688	11	tier	tier	NOUN
ihlr-20834	688	12	1	1	NUM
ihlr-20834	688	13	and	and	CCONJ
ihlr-20834	688	14	usually	usually	ADV
ihlr-20834	688	15	includes	include	VERB
ihlr-20834	688	16	preferred	preferred	ADJ
ihlr-20834	688	17	brand	brand	NOUN
ihlr-20834	688	18	-	-	PUNCT
ihlr-20834	688	19	name	name	NOUN
ihlr-20834	688	20	medications	medication	NOUN
ihlr-20834	688	21	.	.	PUNCT
ihlr-20834	688	22	”	"	PUNCT
ihlr-20834	689	1	finally	finally	ADV
ihlr-20834	689	2	,	,	PUNCT
ihlr-20834	689	3	“	"	PUNCT
ihlr-20834	689	4	[	[	X
ihlr-20834	689	5	t]ier	t]ier	NOUN
ihlr-20834	689	6	3	3	NUM
ihlr-20834	689	7	has	have	VERB
ihlr-20834	689	8	the	the	DET
ihlr-20834	689	9	highest	high	ADJ
ihlr-20834	689	10	co	co	NOUN
ihlr-20834	689	11	-	-	NOUN
ihlr-20834	689	12	payment	payment	NOUN
ihlr-20834	689	13	and	and	CCONJ
ihlr-20834	689	14	usually	usually	ADV
ihlr-20834	689	15	includes	include	VERB
ihlr-20834	689	16	non	non	ADJ
ihlr-20834	689	17	-	-	ADJ
ihlr-20834	689	18	preferred	preferred	ADJ
ihlr-20834	689	19	brandname	brandname	NOUN
ihlr-20834	689	20	medications	medication	NOUN
ihlr-20834	689	21	.	.	PUNCT
ihlr-20834	689	22	”	"	PUNCT
ihlr-20834	689	23	)	)	PUNCT
ihlr-20834	689	24	.	.	PUNCT
ihlr-20834	690	1	806	806	NUM
ihlr-20834	690	2	indiana	indiana	PROPN
ihlr-20834	690	3	health	health	PROPN
ihlr-20834	690	4	law	law	PROPN
ihlr-20834	690	5	review	review	NOUN
ihlr-20834	690	6	vol	vol	NOUN
ihlr-20834	690	7	.	.	PUNCT
ihlr-20834	691	1	12:2	12:2	NUM
ihlr-20834	691	2	4	4	NUM
ihlr-20834	691	3	.	.	PUNCT
ihlr-20834	692	1	option	option	NOUN
ihlr-20834	692	2	four	four	NUM
ihlr-20834	692	3	legislative	legislative	ADJ
ihlr-20834	692	4	amendment	amendment	NOUN
ihlr-20834	692	5	attorneys	attorney	NOUN
ihlr-20834	692	6	are	be	AUX
ihlr-20834	692	7	capable	capable	ADJ
ihlr-20834	692	8	of	of	ADP
ihlr-20834	692	9	crafting	craft	VERB
ihlr-20834	692	10	creative	creative	ADJ
ihlr-20834	692	11	arguments	argument	NOUN
ihlr-20834	692	12	and	and	CCONJ
ihlr-20834	692	13	some	some	DET
ihlr-20834	692	14	consumers	consumer	NOUN
ihlr-20834	692	15	are	be	AUX
ihlr-20834	692	16	capable	capable	ADJ
ihlr-20834	692	17	of	of	ADP
ihlr-20834	692	18	purchasing	purchase	VERB
ihlr-20834	692	19	brand	brand	NOUN
ihlr-20834	692	20	-	-	PUNCT
ihlr-20834	692	21	name	name	NOUN
ihlr-20834	692	22	drugs	drug	NOUN
ihlr-20834	692	23	as	as	SCONJ
ihlr-20834	692	24	opposed	oppose	VERB
ihlr-20834	692	25	to	to	ADP
ihlr-20834	692	26	their	their	PRON
ihlr-20834	692	27	generic	generic	ADJ
ihlr-20834	692	28	equivalents	equivalent	NOUN
ihlr-20834	692	29	.	.	PUNCT
ihlr-20834	693	1	however	however	ADV
ihlr-20834	693	2	,	,	PUNCT
ihlr-20834	693	3	both	both	PRON
ihlr-20834	693	4	of	of	ADP
ihlr-20834	693	5	these	these	DET
ihlr-20834	693	6	options	option	NOUN
ihlr-20834	693	7	fail	fail	VERB
ihlr-20834	693	8	to	to	PART
ihlr-20834	693	9	address	address	VERB
ihlr-20834	693	10	the	the	DET
ihlr-20834	693	11	issue	issue	NOUN
ihlr-20834	693	12	at	at	ADP
ihlr-20834	693	13	hand	hand	NOUN
ihlr-20834	693	14	which	which	PRON
ihlr-20834	693	15	is	be	AUX
ihlr-20834	693	16	the	the	DET
ihlr-20834	693	17	dangerous	dangerous	ADJ
ihlr-20834	693	18	legal	legal	ADJ
ihlr-20834	693	19	precedent	precedent	NOUN
ihlr-20834	693	20	established	establish	VERB
ihlr-20834	693	21	by	by	ADP
ihlr-20834	693	22	the	the	DET
ihlr-20834	693	23	court	court	NOUN
ihlr-20834	693	24	.	.	PUNCT
ihlr-20834	694	1	the	the	DET
ihlr-20834	694	2	only	only	ADJ
ihlr-20834	694	3	complete	complete	ADJ
ihlr-20834	694	4	solution	solution	NOUN
ihlr-20834	694	5	to	to	ADP
ihlr-20834	694	6	this	this	DET
ihlr-20834	694	7	legal	legal	ADJ
ihlr-20834	694	8	dilemma	dilemma	NOUN
ihlr-20834	694	9	is	be	AUX
ihlr-20834	694	10	to	to	PART
ihlr-20834	694	11	amend	amend	VERB
ihlr-20834	694	12	the	the	DET
ihlr-20834	694	13	labeling	labeling	NOUN
ihlr-20834	694	14	requirements	requirement	NOUN
ihlr-20834	694	15	and	and	CCONJ
ihlr-20834	694	16	duties	duty	NOUN
ihlr-20834	694	17	of	of	ADP
ihlr-20834	694	18	all	all	DET
ihlr-20834	694	19	drug	drug	NOUN
ihlr-20834	694	20	manufacturers	manufacturer	NOUN
ihlr-20834	694	21	.	.	PUNCT
ihlr-20834	695	1	furthermore	furthermore	ADV
ihlr-20834	695	2	,	,	PUNCT
ihlr-20834	695	3	congress	congress	PROPN
ihlr-20834	695	4	could	could	AUX
ihlr-20834	695	5	solve	solve	VERB
ihlr-20834	695	6	the	the	DET
ihlr-20834	695	7	issue	issue	NOUN
ihlr-20834	695	8	of	of	ADP
ihlr-20834	695	9	preemption	preemption	NOUN
ihlr-20834	695	10	by	by	ADP
ihlr-20834	695	11	explicitly	explicitly	ADV
ihlr-20834	695	12	saying	say	VERB
ihlr-20834	695	13	preemption	preemption	NOUN
ihlr-20834	695	14	is	be	AUX
ihlr-20834	695	15	not	not	PART
ihlr-20834	695	16	present	present	ADJ
ihlr-20834	695	17	and	and	CCONJ
ihlr-20834	695	18	that	that	SCONJ
ihlr-20834	695	19	a	a	DET
ihlr-20834	695	20	state	state	NOUN
ihlr-20834	695	21	law	law	NOUN
ihlr-20834	695	22	provides	provide	VERB
ihlr-20834	695	23	recourse	recourse	NOUN
ihlr-20834	695	24	to	to	ADP
ihlr-20834	695	25	individuals	individual	NOUN
ihlr-20834	695	26	injured	injure	VERB
ihlr-20834	695	27	by	by	ADP
ihlr-20834	695	28	generic	generic	ADJ
ihlr-20834	695	29	drugs	drug	NOUN
ihlr-20834	695	30	.	.	PUNCT
ihlr-20834	696	1	one	one	PRON
ihlr-20834	696	2	could	could	AUX
ihlr-20834	696	3	argue	argue	VERB
ihlr-20834	696	4	that	that	SCONJ
ihlr-20834	696	5	the	the	DET
ihlr-20834	696	6	fda	fda	PROPN
ihlr-20834	696	7	may	may	AUX
ihlr-20834	696	8	have	have	VERB
ihlr-20834	696	9	authority	authority	NOUN
ihlr-20834	696	10	to	to	PART
ihlr-20834	696	11	solve	solve	VERB
ihlr-20834	696	12	such	such	DET
ihlr-20834	696	13	an	an	DET
ihlr-20834	696	14	issue	issue	NOUN
ihlr-20834	696	15	,	,	PUNCT
ihlr-20834	696	16	but	but	CCONJ
ihlr-20834	696	17	to	to	PART
ihlr-20834	696	18	avoid	avoid	VERB
ihlr-20834	696	19	future	future	ADJ
ihlr-20834	696	20	lapse	lapse	NOUN
ihlr-20834	696	21	of	of	ADP
ihlr-20834	696	22	legal	legal	ADJ
ihlr-20834	696	23	recourse	recourse	NOUN
ihlr-20834	696	24	224	224	NUM
ihlr-20834	696	25	it	it	PRON
ihlr-20834	696	26	would	would	AUX
ihlr-20834	696	27	best	good	ADJ
ihlr-20834	696	28	to	to	PART
ihlr-20834	696	29	statutorily	statutorily	ADV
ihlr-20834	696	30	amend	amend	VERB
ihlr-20834	696	31	the	the	DET
ihlr-20834	696	32	law	law	NOUN
ihlr-20834	696	33	.	.	PUNCT
ihlr-20834	697	1	by	by	ADP
ihlr-20834	697	2	amending	amend	VERB
ihlr-20834	697	3	the	the	DET
ihlr-20834	697	4	hatch	hatch	NOUN
ihlr-20834	697	5	-	-	PUNCT
ihlr-20834	697	6	waxman	waxman	PROPN
ihlr-20834	697	7	act	act	PROPN
ihlr-20834	697	8	,	,	PUNCT
ihlr-20834	697	9	congress	congress	PROPN
ihlr-20834	697	10	could	could	AUX
ihlr-20834	697	11	hold	hold	VERB
ihlr-20834	697	12	generic	generic	ADJ
ihlr-20834	697	13	manufacturers	manufacturer	NOUN
ihlr-20834	697	14	liable	liable	ADJ
ihlr-20834	697	15	for	for	ADP
ihlr-20834	697	16	failing	fail	VERB
ihlr-20834	697	17	-	-	PUNCT
ihlr-20834	697	18	to	to	PART
ihlr-20834	697	19	-	-	PUNCT
ihlr-20834	697	20	warn	warn	VERB
ihlr-20834	697	21	or	or	CCONJ
ihlr-20834	697	22	failing	fail	VERB
ihlr-20834	697	23	-	-	PUNCT
ihlr-20834	697	24	to	to	ADP
ihlr-20834	697	25	-	-	PUNCT
ihlr-20834	697	26	update	update	VERB
ihlr-20834	697	27	their	their	PRON
ihlr-20834	697	28	labels	label	NOUN
ihlr-20834	697	29	,	,	PUNCT
ihlr-20834	697	30	which	which	PRON
ihlr-20834	697	31	would	would	AUX
ihlr-20834	697	32	invariably	invariably	ADV
ihlr-20834	697	33	allow	allow	VERB
ihlr-20834	697	34	injured	injure	VERB
ihlr-20834	697	35	consumers	consumer	NOUN
ihlr-20834	697	36	legal	legal	ADJ
ihlr-20834	697	37	recourse	recourse	NOUN
ihlr-20834	697	38	.	.	PUNCT
ihlr-20834	698	1	currently	currently	ADV
ihlr-20834	698	2	,	,	PUNCT
ihlr-20834	698	3	unilateral	unilateral	ADJ
ihlr-20834	698	4	changes	change	NOUN
ihlr-20834	698	5	by	by	ADP
ihlr-20834	698	6	generic	generic	ADJ
ihlr-20834	698	7	drug	drug	NOUN
ihlr-20834	698	8	manufacturers	manufacturer	NOUN
ihlr-20834	698	9	are	be	AUX
ihlr-20834	698	10	not	not	PART
ihlr-20834	698	11	permitted	permit	VERB
ihlr-20834	698	12	because	because	SCONJ
ihlr-20834	698	13	generic	generic	ADJ
ihlr-20834	698	14	drug	drug	NOUN
ihlr-20834	698	15	manufacturers	manufacturer	NOUN
ihlr-20834	698	16	must	must	AUX
ihlr-20834	698	17	abide	abide	VERB
ihlr-20834	698	18	to	to	ADP
ihlr-20834	698	19	a	a	DET
ihlr-20834	698	20	duty	duty	NOUN
ihlr-20834	698	21	of	of	ADP
ihlr-20834	698	22	sameness.225	sameness.225	PRON
ihlr-20834	698	23	modifying	modify	VERB
ihlr-20834	698	24	the	the	DET
ihlr-20834	698	25	appropriate	appropriate	ADJ
ihlr-20834	698	26	provision	provision	NOUN
ihlr-20834	698	27	to	to	PART
ihlr-20834	698	28	allow	allow	VERB
ihlr-20834	698	29	and	and	CCONJ
ihlr-20834	698	30	even	even	ADV
ihlr-20834	698	31	require	require	VERB
ihlr-20834	698	32	generic	generic	ADJ
ihlr-20834	698	33	drug	drug	NOUN
ihlr-20834	698	34	manufacturers	manufacturer	NOUN
ihlr-20834	698	35	to	to	PART
ihlr-20834	698	36	update	update	VERB
ihlr-20834	698	37	their	their	PRON
ihlr-20834	698	38	labels	label	NOUN
ihlr-20834	698	39	would	would	AUX
ihlr-20834	698	40	properly	properly	ADV
ihlr-20834	698	41	shift	shift	VERB
ihlr-20834	698	42	the	the	DET
ihlr-20834	698	43	burden	burden	NOUN
ihlr-20834	698	44	onto	onto	ADP
ihlr-20834	698	45	the	the	DET
ihlr-20834	698	46	manufacturer	manufacturer	NOUN
ihlr-20834	698	47	and	and	CCONJ
ihlr-20834	698	48	it	it	PRON
ihlr-20834	698	49	would	would	AUX
ihlr-20834	698	50	permit	permit	VERB
ihlr-20834	698	51	consumers	consumer	NOUN
ihlr-20834	698	52	legal	legal	ADJ
ihlr-20834	698	53	recourse	recourse	NOUN
ihlr-20834	698	54	if	if	SCONJ
ihlr-20834	698	55	these	these	DET
ihlr-20834	698	56	manufacturers	manufacturer	NOUN
ihlr-20834	698	57	failed	fail	VERB
ihlr-20834	698	58	in	in	ADP
ihlr-20834	698	59	this	this	DET
ihlr-20834	698	60	duty	duty	NOUN
ihlr-20834	698	61	.	.	PUNCT
ihlr-20834	699	1	another	another	DET
ihlr-20834	699	2	possible	possible	ADJ
ihlr-20834	699	3	solution	solution	NOUN
ihlr-20834	699	4	available	available	ADJ
ihlr-20834	699	5	to	to	ADP
ihlr-20834	699	6	congress	congress	PROPN
ihlr-20834	699	7	would	would	AUX
ihlr-20834	699	8	be	be	AUX
ihlr-20834	699	9	to	to	PART
ihlr-20834	699	10	“	"	PUNCT
ihlr-20834	699	11	provide	provide	VERB
ihlr-20834	699	12	that	that	DET
ihlr-20834	699	13	generic	generic	ADJ
ihlr-20834	699	14	drug	drug	NOUN
ihlr-20834	699	15	manufacturers	manufacturer	NOUN
ihlr-20834	699	16	.	.	PUNCT
ihlr-20834	699	17	.	.	PUNCT
ihlr-20834	700	1	.	.	PUNCT
ihlr-20834	701	1	are	be	AUX
ihlr-20834	701	2	authorized	authorize	VERB
ihlr-20834	701	3	to	to	PART
ihlr-20834	701	4	use	use	VERB
ihlr-20834	701	5	the	the	DET
ihlr-20834	701	6	cbe	cbe	PROPN
ihlr-20834	701	7	process	process	NOUN
ihlr-20834	701	8	.	.	PUNCT
ihlr-20834	701	9	”	"	PUNCT
ihlr-20834	702	1	226	226	NUM
ihlr-20834	702	2	currently	currently	ADV
ihlr-20834	702	3	,	,	PUNCT
ihlr-20834	702	4	cbe	cbe	PROPN
ihlr-20834	702	5	224	224	NUM
ihlr-20834	702	6	see	see	VERB
ihlr-20834	702	7	wyeth	wyeth	PROPN
ihlr-20834	702	8	v.	v.	PROPN
ihlr-20834	702	9	levine	levine	PROPN
ihlr-20834	702	10	,	,	PUNCT
ihlr-20834	702	11	555	555	NUM
ihlr-20834	702	12	u.s	u.s	PROPN
ihlr-20834	702	13	.	.	PROPN
ihlr-20834	702	14	555	555	NUM
ihlr-20834	702	15	,	,	PUNCT
ihlr-20834	702	16	567	567	NUM
ihlr-20834	702	17	(	(	PUNCT
ihlr-20834	702	18	2009	2009	NUM
ihlr-20834	702	19	)	)	PUNCT
ihlr-20834	702	20	(	(	PUNCT
ihlr-20834	702	21	the	the	DET
ihlr-20834	702	22	fda	fda	PROPN
ihlr-20834	702	23	may	may	AUX
ihlr-20834	702	24	not	not	PART
ihlr-20834	702	25	have	have	VERB
ihlr-20834	702	26	the	the	DET
ihlr-20834	702	27	authority	authority	NOUN
ihlr-20834	702	28	to	to	PART
ihlr-20834	702	29	modify	modify	VERB
ihlr-20834	702	30	the	the	DET
ihlr-20834	702	31	“	"	PUNCT
ihlr-20834	702	32	sameness	sameness	NOUN
ihlr-20834	702	33	”	"	PUNCT
ihlr-20834	702	34	requirement	requirement	NOUN
ihlr-20834	702	35	to	to	PART
ihlr-20834	702	36	allow	allow	VERB
ihlr-20834	702	37	generic	generic	ADJ
ihlr-20834	702	38	drug	drug	NOUN
ihlr-20834	702	39	manufacturers	manufacturer	NOUN
ihlr-20834	702	40	to	to	PART
ihlr-20834	702	41	be	be	AUX
ihlr-20834	702	42	liable	liable	ADJ
ihlr-20834	702	43	for	for	ADP
ihlr-20834	702	44	design	design	NOUN
ihlr-20834	702	45	-	-	PUNCT
ihlr-20834	702	46	defect	defect	NOUN
ihlr-20834	702	47	claims	claim	NOUN
ihlr-20834	702	48	.	.	PUNCT
ihlr-20834	703	1	indeed	indeed	ADV
ihlr-20834	703	2	,	,	PUNCT
ihlr-20834	703	3	prior	prior	ADV
ihlr-20834	703	4	to	to	ADP
ihlr-20834	703	5	2007	2007	NUM
ihlr-20834	703	6	,	,	PUNCT
ihlr-20834	703	7	the	the	DET
ihlr-20834	703	8	fda	fda	PROPN
ihlr-20834	703	9	lacked	lack	VERB
ihlr-20834	703	10	the	the	DET
ihlr-20834	703	11	authority	authority	NOUN
ihlr-20834	703	12	to	to	PART
ihlr-20834	703	13	order	order	VERB
ihlr-20834	703	14	manufacturers	manufacturer	NOUN
ihlr-20834	703	15	to	to	PART
ihlr-20834	703	16	revise	revise	VERB
ihlr-20834	703	17	their	their	PRON
ihlr-20834	703	18	label	label	NOUN
ihlr-20834	703	19	and	and	CCONJ
ihlr-20834	703	20	only	only	ADV
ihlr-20834	703	21	when	when	SCONJ
ihlr-20834	703	22	congress	congress	PROPN
ihlr-20834	703	23	granted	grant	VERB
ihlr-20834	703	24	the	the	DET
ihlr-20834	703	25	fda	fda	PROPN
ihlr-20834	703	26	this	this	DET
ihlr-20834	703	27	authority	authority	NOUN
ihlr-20834	703	28	did	do	AUX
ihlr-20834	703	29	the	the	DET
ihlr-20834	703	30	agency	agency	NOUN
ihlr-20834	703	31	have	have	VERB
ihlr-20834	703	32	the	the	DET
ihlr-20834	703	33	ability	ability	NOUN
ihlr-20834	703	34	to	to	PART
ihlr-20834	703	35	modify	modify	VERB
ihlr-20834	703	36	the	the	DET
ihlr-20834	703	37	rule	rule	NOUN
ihlr-20834	703	38	)	)	PUNCT
ihlr-20834	703	39	;	;	PUNCT
ihlr-20834	703	40	louisiana	louisiana	PROPN
ihlr-20834	703	41	pub	pub	PROPN
ihlr-20834	703	42	.	.	PUNCT
ihlr-20834	704	1	serv	serv	AUX
ihlr-20834	704	2	.	.	PUNCT
ihlr-20834	704	3	com’n	com’n	X
ihlr-20834	704	4	v.	v.	ADP
ihlr-20834	704	5	f.c.c	f.c.c	PROPN
ihlr-20834	704	6	.	.	PUNCT
ihlr-20834	704	7	,	,	PUNCT
ihlr-20834	705	1	476	476	NUM
ihlr-20834	705	2	u.s	u.s	PROPN
ihlr-20834	705	3	.	.	PROPN
ihlr-20834	705	4	355	355	NUM
ihlr-20834	705	5	,	,	PUNCT
ihlr-20834	705	6	374	374	NUM
ihlr-20834	705	7	(	(	PUNCT
ihlr-20834	705	8	1986	1986	NUM
ihlr-20834	705	9	)	)	PUNCT
ihlr-20834	705	10	(	(	PUNCT
ihlr-20834	705	11	“	"	PUNCT
ihlr-20834	705	12	[	[	X
ihlr-20834	705	13	a	a	X
ihlr-20834	705	14	]	]	X
ihlr-20834	705	15	federal	federal	ADJ
ihlr-20834	705	16	agency	agency	NOUN
ihlr-20834	705	17	may	may	AUX
ihlr-20834	705	18	pre	pre	VERB
ihlr-20834	705	19	-	-	VERB
ihlr-20834	705	20	empt	empt	VERB
ihlr-20834	705	21	state	state	NOUN
ihlr-20834	705	22	law	law	NOUN
ihlr-20834	705	23	only	only	ADV
ihlr-20834	705	24	when	when	SCONJ
ihlr-20834	705	25	and	and	CCONJ
ihlr-20834	705	26	if	if	SCONJ
ihlr-20834	705	27	it	it	PRON
ihlr-20834	705	28	is	be	AUX
ihlr-20834	705	29	acting	act	VERB
ihlr-20834	705	30	within	within	ADP
ihlr-20834	705	31	the	the	DET
ihlr-20834	705	32	scope	scope	NOUN
ihlr-20834	705	33	of	of	ADP
ihlr-20834	705	34	its	its	PRON
ihlr-20834	705	35	congressionally	congressionally	ADV
ihlr-20834	705	36	delegated	delegate	VERB
ihlr-20834	705	37	authority	authority	NOUN
ihlr-20834	705	38	.	.	PUNCT
ihlr-20834	705	39	”	"	PUNCT
ihlr-20834	705	40	)	)	PUNCT
ihlr-20834	705	41	.	.	PUNCT
ihlr-20834	706	1	225	225	NUM
ihlr-20834	706	2	see	see	VERB
ihlr-20834	706	3	generally	generally	ADV
ihlr-20834	706	4	21	21	NUM
ihlr-20834	706	5	c.f.r	c.f.r	NOUN
ihlr-20834	706	6	.	.	PUNCT
ihlr-20834	707	1	§	§	PROPN
ihlr-20834	707	2	314.150	314.150	NUM
ihlr-20834	707	3	(	(	PUNCT
ihlr-20834	707	4	2015	2015	NUM
ihlr-20834	707	5	)	)	PUNCT
ihlr-20834	707	6	.	.	PUNCT
ihlr-20834	708	1	226	226	NUM
ihlr-20834	708	2	wolfman	wolfman	PROPN
ihlr-20834	708	3	&	&	CCONJ
ihlr-20834	708	4	king	king	PROPN
ihlr-20834	708	5	,	,	PUNCT
ihlr-20834	708	6	supra	supra	PROPN
ihlr-20834	708	7	note	note	NOUN
ihlr-20834	708	8	134	134	NUM
ihlr-20834	708	9	.	.	NOUN
ihlr-20834	708	10	2015	2015	NUM
ihlr-20834	708	11	807	807	NUM
ihlr-20834	708	12	the	the	DET
ihlr-20834	708	13	supreme	supreme	PROPN
ihlr-20834	708	14	court	court	PROPN
ihlr-20834	708	15	’s	’s	PART
ihlr-20834	708	16	overreaching	overreach	VERB
ihlr-20834	708	17	preemption	preemption	NOUN
ihlr-20834	708	18	interpretation	interpretation	NOUN
ihlr-20834	708	19	and	and	CCONJ
ihlr-20834	708	20	it	it	PRON
ihlr-20834	708	21	’s	’	VERB
ihlr-20834	708	22	consequences	consequence	NOUN
ihlr-20834	708	23	rules	rule	NOUN
ihlr-20834	708	24	allowing	allow	VERB
ihlr-20834	708	25	non	non	ADJ
ihlr-20834	708	26	-	-	ADJ
ihlr-20834	708	27	generic	generic	ADJ
ihlr-20834	708	28	drug	drug	NOUN
ihlr-20834	708	29	manufacturers	manufacturer	NOUN
ihlr-20834	708	30	to	to	PART
ihlr-20834	708	31	unilaterally	unilaterally	ADV
ihlr-20834	708	32	change	change	VERB
ihlr-20834	708	33	and	and	CCONJ
ihlr-20834	708	34	strengthen	strengthen	VERB
ihlr-20834	708	35	their	their	PRON
ihlr-20834	708	36	labels	label	NOUN
ihlr-20834	708	37	are	be	AUX
ihlr-20834	708	38	unavailable	unavailable	ADJ
ihlr-20834	708	39	to	to	ADP
ihlr-20834	708	40	anda	anda	PROPN
ihlr-20834	708	41	holders	holders	PROPN
ihlr-20834	708	42	.	.	PUNCT
ihlr-20834	709	1	because	because	SCONJ
ihlr-20834	709	2	generic	generic	ADJ
ihlr-20834	709	3	drugs	drug	NOUN
ihlr-20834	709	4	have	have	AUX
ihlr-20834	709	5	taken	take	VERB
ihlr-20834	709	6	the	the	DET
ihlr-20834	709	7	majority	majority	NOUN
ihlr-20834	709	8	of	of	ADP
ihlr-20834	709	9	the	the	DET
ihlr-20834	709	10	pharmaceutical	pharmaceutical	ADJ
ihlr-20834	709	11	market	market	NOUN
ihlr-20834	709	12	share	share	NOUN
ihlr-20834	709	13	,	,	PUNCT
ihlr-20834	709	14	these	these	DET
ihlr-20834	709	15	manufacturers	manufacturer	NOUN
ihlr-20834	709	16	are	be	AUX
ihlr-20834	709	17	in	in	ADP
ihlr-20834	709	18	a	a	DET
ihlr-20834	709	19	better	well	ADJ
ihlr-20834	709	20	position	position	NOUN
ihlr-20834	709	21	to	to	PART
ihlr-20834	709	22	collect	collect	VERB
ihlr-20834	709	23	and	and	CCONJ
ihlr-20834	709	24	report	report	VERB
ihlr-20834	709	25	data	datum	NOUN
ihlr-20834	709	26	.	.	PUNCT
ihlr-20834	710	1	this	this	DET
ihlr-20834	710	2	amendment	amendment	NOUN
ihlr-20834	710	3	would	would	AUX
ihlr-20834	710	4	be	be	AUX
ihlr-20834	710	5	especially	especially	ADV
ihlr-20834	710	6	important	important	ADJ
ihlr-20834	710	7	for	for	ADP
ihlr-20834	710	8	the	the	DET
ihlr-20834	710	9	one	one	NUM
ihlr-20834	710	10	-	-	PUNCT
ihlr-20834	710	11	third	third	NOUN
ihlr-20834	710	12	market	market	NOUN
ihlr-20834	710	13	-	-	PUNCT
ihlr-20834	710	14	share	share	NOUN
ihlr-20834	710	15	that	that	PRON
ihlr-20834	710	16	has	have	VERB
ihlr-20834	710	17	no	no	DET
ihlr-20834	710	18	brand	brand	NOUN
ihlr-20834	710	19	-	-	PUNCT
ihlr-20834	710	20	name	name	NOUN
ihlr-20834	710	21	counterpart	counterpart	NOUN
ihlr-20834	710	22	on	on	ADP
ihlr-20834	710	23	the	the	DET
ihlr-20834	710	24	market	market	NOUN
ihlr-20834	710	25	at	at	ADV
ihlr-20834	710	26	all	all	ADV
ihlr-20834	710	27	.	.	PUNCT
ihlr-20834	711	1	227	227	NUM
ihlr-20834	711	2	by	by	ADP
ihlr-20834	711	3	modifying	modify	VERB
ihlr-20834	711	4	the	the	DET
ihlr-20834	711	5	cbe	cbe	PROPN
ihlr-20834	711	6	statute	statute	PROPN
ihlr-20834	711	7	,	,	PUNCT
ihlr-20834	711	8	generic	generic	ADJ
ihlr-20834	711	9	drug	drug	NOUN
ihlr-20834	711	10	manufacturers	manufacturer	NOUN
ihlr-20834	711	11	would	would	AUX
ihlr-20834	711	12	be	be	AUX
ihlr-20834	711	13	required	require	VERB
ihlr-20834	711	14	to	to	PART
ihlr-20834	711	15	unilaterally	unilaterally	ADV
ihlr-20834	711	16	strengthen	strengthen	VERB
ihlr-20834	711	17	their	their	PRON
ihlr-20834	711	18	warnings	warning	NOUN
ihlr-20834	711	19	without	without	ADP
ihlr-20834	711	20	having	have	VERB
ihlr-20834	711	21	to	to	PART
ihlr-20834	711	22	comply	comply	VERB
ihlr-20834	711	23	with	with	ADP
ihlr-20834	711	24	the	the	DET
ihlr-20834	711	25	sameness	sameness	NOUN
ihlr-20834	711	26	requirements	requirement	NOUN
ihlr-20834	711	27	.	.	PUNCT
ihlr-20834	712	1	legislation	legislation	NOUN
ihlr-20834	712	2	was	be	AUX
ihlr-20834	712	3	previously	previously	ADV
ihlr-20834	712	4	introduced	introduce	VERB
ihlr-20834	712	5	into	into	ADP
ihlr-20834	712	6	the	the	DET
ihlr-20834	712	7	senate	senate	PROPN
ihlr-20834	712	8	and	and	CCONJ
ihlr-20834	712	9	house	house	PROPN
ihlr-20834	712	10	of	of	ADP
ihlr-20834	712	11	representatives	representative	NOUN
ihlr-20834	712	12	in	in	ADP
ihlr-20834	712	13	2012	2012	NUM
ihlr-20834	712	14	to	to	PART
ihlr-20834	712	15	give	give	VERB
ihlr-20834	712	16	anda	anda	PROPN
ihlr-20834	712	17	holders	holder	NOUN
ihlr-20834	712	18	the	the	DET
ihlr-20834	712	19	ability	ability	NOUN
ihlr-20834	712	20	to	to	PART
ihlr-20834	712	21	change	change	VERB
ihlr-20834	712	22	labeling	labeling	NOUN
ihlr-20834	712	23	but	but	CCONJ
ihlr-20834	712	24	the	the	DET
ihlr-20834	712	25	bill	bill	NOUN
ihlr-20834	712	26	never	never	ADV
ihlr-20834	712	27	reached	reach	VERB
ihlr-20834	712	28	the	the	DET
ihlr-20834	712	29	floor.228	floor.228	NOUN
ihlr-20834	712	30	following	follow	VERB
ihlr-20834	712	31	the	the	DET
ihlr-20834	712	32	bartlett	bartlett	PROPN
ihlr-20834	712	33	decision	decision	NOUN
ihlr-20834	712	34	and	and	CCONJ
ihlr-20834	712	35	public	public	ADJ
ihlr-20834	712	36	outcry	outcry	NOUN
ihlr-20834	712	37	,	,	PUNCT
ihlr-20834	712	38	the	the	DET
ihlr-20834	712	39	fda	fda	PROPN
ihlr-20834	712	40	acknowledged	acknowledge	VERB
ihlr-20834	712	41	it	it	PRON
ihlr-20834	712	42	“	"	PUNCT
ihlr-20834	712	43	is	be	AUX
ihlr-20834	712	44	considering	consider	VERB
ihlr-20834	712	45	a	a	DET
ihlr-20834	712	46	regulatory	regulatory	ADJ
ihlr-20834	712	47	change	change	NOUN
ihlr-20834	712	48	that	that	PRON
ihlr-20834	712	49	would	would	AUX
ihlr-20834	712	50	allow	allow	VERB
ihlr-20834	712	51	generic	generic	ADJ
ihlr-20834	712	52	manufacturers	manufacturer	NOUN
ihlr-20834	712	53	,	,	PUNCT
ihlr-20834	712	54	like	like	ADP
ihlr-20834	712	55	brand	brand	NOUN
ihlr-20834	712	56	-	-	PUNCT
ihlr-20834	712	57	name	name	NOUN
ihlr-20834	712	58	manufacturers	manufacturer	NOUN
ihlr-20834	712	59	,	,	PUNCT
ihlr-20834	712	60	to	to	PART
ihlr-20834	712	61	change	change	VERB
ihlr-20834	712	62	their	their	PRON
ihlr-20834	712	63	labeling	labeling	NOUN
ihlr-20834	712	64	in	in	ADP
ihlr-20834	712	65	appropriate	appropriate	ADJ
ihlr-20834	712	66	circumstances	circumstance	NOUN
ihlr-20834	712	67	,	,	PUNCT
ihlr-20834	712	68	”	"	PUNCT
ihlr-20834	712	69	adding	add	VERB
ihlr-20834	712	70	that	that	SCONJ
ihlr-20834	712	71	“	"	PUNCT
ihlr-20834	712	72	if	if	SCONJ
ihlr-20834	712	73	such	such	DET
ihlr-20834	712	74	a	a	DET
ihlr-20834	712	75	regulatory	regulatory	ADJ
ihlr-20834	712	76	change	change	NOUN
ihlr-20834	712	77	is	be	AUX
ihlr-20834	712	78	adopted	adopt	VERB
ihlr-20834	712	79	,	,	PUNCT
ihlr-20834	712	80	it	it	PRON
ihlr-20834	712	81	could	could	AUX
ihlr-20834	712	82	eliminate	eliminate	VERB
ihlr-20834	712	83	failure	failure	NOUN
ihlr-20834	712	84	-	-	PUNCT
ihlr-20834	712	85	to	to	PART
ihlr-20834	712	86	-	-	PUNCT
ihlr-20834	712	87	warn	warn	VERB
ihlr-20834	712	88	preemption	preemption	NOUN
ihlr-20834	712	89	claims	claim	NOUN
ihlr-20834	712	90	against	against	ADP
ihlr-20834	712	91	generic	generic	ADJ
ihlr-20834	712	92	-	-	PUNCT
ihlr-20834	712	93	drug	drug	NOUN
ihlr-20834	712	94	manufacturers	manufacturer	NOUN
ihlr-20834	712	95	.	.	PUNCT
ihlr-20834	712	96	”229	”229	PUNCT
ihlr-20834	713	1	the	the	DET
ihlr-20834	713	2	fda	fda	PROPN
ihlr-20834	713	3	has	have	AUX
ihlr-20834	713	4	announced	announce	VERB
ihlr-20834	713	5	that	that	SCONJ
ihlr-20834	713	6	they	they	PRON
ihlr-20834	713	7	are	be	AUX
ihlr-20834	713	8	working	work	VERB
ihlr-20834	713	9	on	on	ADP
ihlr-20834	713	10	label	label	NOUN
ihlr-20834	713	11	requirement	requirement	NOUN
ihlr-20834	713	12	modification	modification	NOUN
ihlr-20834	713	13	requirements	requirement	NOUN
ihlr-20834	713	14	;	;	PUNCT
ihlr-20834	713	15	the	the	DET
ihlr-20834	713	16	fda	fda	PROPN
ihlr-20834	713	17	’s	’s	PART
ihlr-20834	713	18	notice	notice	NOUN
ihlr-20834	713	19	of	of	ADP
ihlr-20834	713	20	proposed	propose	VERB
ihlr-20834	713	21	rulemaking	rulemaking	NOUN
ihlr-20834	713	22	entitled	entitle	VERB
ihlr-20834	713	23	“	"	PUNCT
ihlr-20834	713	24	’	'	PUNCT
ihlr-20834	713	25	supplemental	supplemental	ADJ
ihlr-20834	713	26	applications	application	NOUN
ihlr-20834	713	27	proposing	propose	VERB
ihlr-20834	713	28	labeling	labeling	NOUN
ihlr-20834	713	29	changes	change	NOUN
ihlr-20834	713	30	for	for	ADP
ihlr-20834	713	31	approved	approve	VERB
ihlr-20834	713	32	drugs	drug	NOUN
ihlr-20834	713	33	and	and	CCONJ
ihlr-20834	713	34	biological	biological	ADJ
ihlr-20834	713	35	products	product	NOUN
ihlr-20834	713	36	”	"	PUNCT
ihlr-20834	713	37	has	have	AUX
ihlr-20834	713	38	been	be	AUX
ihlr-20834	713	39	identified	identify	VERB
ihlr-20834	713	40	as	as	ADP
ihlr-20834	713	41	seeking	seek	VERB
ihlr-20834	713	42	to	to	PART
ihlr-20834	713	43	“	"	PUNCT
ihlr-20834	713	44	revise	revise	VERB
ihlr-20834	713	45	and	and	CCONJ
ihlr-20834	713	46	clarify	clarify	VERB
ihlr-20834	713	47	procedures	procedure	NOUN
ihlr-20834	713	48	for	for	ADP
ihlr-20834	713	49	application	application	NOUN
ihlr-20834	713	50	holders	holder	NOUN
ihlr-20834	713	51	of	of	ADP
ihlr-20834	713	52	an	an	DET
ihlr-20834	713	53	approved	approve	VERB
ihlr-20834	713	54	drug	drug	NOUN
ihlr-20834	713	55	or	or	CCONJ
ihlr-20834	713	56	biological	biological	ADJ
ihlr-20834	713	57	product	product	NOUN
ihlr-20834	713	58	to	to	PART
ihlr-20834	713	59	change	change	VERB
ihlr-20834	713	60	the	the	DET
ihlr-20834	713	61	product	product	NOUN
ihlr-20834	713	62	labeling	labeling	NOUN
ihlr-20834	713	63	to	to	PART
ihlr-20834	713	64	reflect	reflect	VERB
ihlr-20834	713	65	certain	certain	ADJ
ihlr-20834	713	66	types	type	NOUN
ihlr-20834	713	67	of	of	ADP
ihlr-20834	713	68	newly	newly	ADV
ihlr-20834	713	69	acquired	acquire	VERB
ihlr-20834	713	70	information	information	NOUN
ihlr-20834	713	71	in	in	ADP
ihlr-20834	713	72	227	227	NUM
ihlr-20834	713	73	transcript	transcript	NOUN
ihlr-20834	713	74	of	of	ADP
ihlr-20834	713	75	oral	oral	ADJ
ihlr-20834	713	76	argument	argument	NOUN
ihlr-20834	713	77	at	at	ADP
ihlr-20834	713	78	41	41	NUM
ihlr-20834	713	79	,	,	PUNCT
ihlr-20834	713	80	pliva	pliva	PROPN
ihlr-20834	713	81	,	,	PUNCT
ihlr-20834	713	82	inc	inc	PROPN
ihlr-20834	713	83	.	.	PROPN
ihlr-20834	714	1	v.	v.	CCONJ
ihlr-20834	714	2	mensing	mense	VERB
ihlr-20834	714	3	,	,	PUNCT
ihlr-20834	714	4	131	131	NUM
ihlr-20834	714	5	s.ct	s.ct	NOUN
ihlr-20834	714	6	.	.	PROPN
ihlr-20834	714	7	2567	2567	NUM
ihlr-20834	714	8	(	(	PUNCT
ihlr-20834	714	9	2011	2011	NUM
ihlr-20834	714	10	)	)	PUNCT
ihlr-20834	714	11	(	(	PUNCT
ihlr-20834	714	12	no	no	INTJ
ihlr-20834	714	13	.	.	NOUN
ihlr-20834	714	14	09	09	NUM
ihlr-20834	714	15	-	-	SYM
ihlr-20834	714	16	993	993	NUM
ihlr-20834	714	17	)	)	PUNCT
ihlr-20834	714	18	,	,	PUNCT
ihlr-20834	715	1	available	available	ADJ
ihlr-20834	715	2	at	at	ADP
ihlr-20834	715	3	http://www.supremecourt.gov/oral_arguments/argument_transcripts/09993.pdf	http://www.supremecourt.gov/oral_arguments/argument_transcripts/09993.pdf	PROPN
ihlr-20834	715	4	.	.	PUNCT
ihlr-20834	716	1	228	228	NUM
ihlr-20834	716	2	see	see	VERB
ihlr-20834	716	3	patient	patient	ADJ
ihlr-20834	716	4	safety	safety	NOUN
ihlr-20834	716	5	and	and	CCONJ
ihlr-20834	716	6	generic	generic	ADJ
ihlr-20834	716	7	labeling	labeling	NOUN
ihlr-20834	716	8	improvement	improvement	NOUN
ihlr-20834	716	9	act	act	PROPN
ihlr-20834	716	10	,	,	PUNCT
ihlr-20834	716	11	s.	s.	PROPN
ihlr-20834	716	12	2295	2295	NUM
ihlr-20834	716	13	,	,	PUNCT
ihlr-20834	716	14	112th	112th	PROPN
ihlr-20834	716	15	cong	cong	NOUN
ihlr-20834	716	16	.	.	PUNCT
ihlr-20834	717	1	(	(	PUNCT
ihlr-20834	717	2	2012	2012	NUM
ihlr-20834	717	3	)	)	PUNCT
ihlr-20834	717	4	;	;	PUNCT
ihlr-20834	717	5	patient	patient	ADJ
ihlr-20834	717	6	safety	safety	NOUN
ihlr-20834	717	7	and	and	CCONJ
ihlr-20834	717	8	drug	drug	NOUN
ihlr-20834	717	9	labeling	labeling	NOUN
ihlr-20834	717	10	improvement	improvement	NOUN
ihlr-20834	717	11	act	act	PROPN
ihlr-20834	717	12	,	,	PUNCT
ihlr-20834	717	13	h.r	h.r	PROPN
ihlr-20834	717	14	.	.	PROPN
ihlr-20834	717	15	4384	4384	NUM
ihlr-20834	717	16	,	,	PUNCT
ihlr-20834	717	17	112th	112th	PROPN
ihlr-20834	717	18	cong	cong	NOUN
ihlr-20834	717	19	.	.	PUNCT
ihlr-20834	718	1	(	(	PUNCT
ihlr-20834	718	2	2012	2012	NUM
ihlr-20834	718	3	)	)	PUNCT
ihlr-20834	718	4	.	.	PUNCT
ihlr-20834	719	1	229	229	NUM
ihlr-20834	719	2	wolfman	wolfman	PROPN
ihlr-20834	719	3	&	&	CCONJ
ihlr-20834	719	4	king	king	PROPN
ihlr-20834	719	5	,	,	PUNCT
ihlr-20834	719	6	supra	supra	PROPN
ihlr-20834	719	7	note	note	NOUN
ihlr-20834	719	8	134	134	NUM
ihlr-20834	719	9	.	.	PUNCT
ihlr-20834	719	10	808	808	NUM
ihlr-20834	719	11	indiana	indiana	PROPN
ihlr-20834	719	12	health	health	PROPN
ihlr-20834	719	13	law	law	PROPN
ihlr-20834	719	14	review	review	NOUN
ihlr-20834	719	15	vol	vol	NOUN
ihlr-20834	719	16	.	.	PUNCT
ihlr-20834	719	17	12:2	12:2	NUM
ihlr-20834	719	18	advance	advance	NOUN
ihlr-20834	719	19	of	of	ADP
ihlr-20834	719	20	fda	fda	PROPN
ihlr-20834	719	21	’s	’s	PART
ihlr-20834	719	22	review	review	NOUN
ihlr-20834	719	23	of	of	ADP
ihlr-20834	719	24	the	the	DET
ihlr-20834	719	25	change	change	NOUN
ihlr-20834	719	26	.	.	PUNCT
ihlr-20834	720	1	”230	”230	PUNCT
ihlr-20834	720	2	according	accord	VERB
ihlr-20834	720	3	to	to	ADP
ihlr-20834	720	4	the	the	DET
ihlr-20834	720	5	fda	fda	PROPN
ihlr-20834	720	6	,	,	PUNCT
ihlr-20834	720	7	this	this	DET
ihlr-20834	720	8	proposed	propose	VERB
ihlr-20834	720	9	provision	provision	NOUN
ihlr-20834	720	10	would	would	AUX
ihlr-20834	720	11	create	create	VERB
ihlr-20834	720	12	“	"	PUNCT
ihlr-20834	720	13	parity	parity	NOUN
ihlr-20834	720	14	”	"	PUNCT
ihlr-20834	720	15	between	between	ADP
ihlr-20834	720	16	nda	nda	PROPN
ihlr-20834	720	17	and	and	CCONJ
ihlr-20834	720	18	anda	anda	PROPN
ihlr-20834	720	19	holders	holder	NOUN
ihlr-20834	720	20	with	with	ADP
ihlr-20834	720	21	respect	respect	NOUN
ihlr-20834	720	22	to	to	ADP
ihlr-20834	720	23	cbe’s.231	cbe’s.231	PROPN
ihlr-20834	720	24	again	again	ADV
ihlr-20834	720	25	,	,	PUNCT
ihlr-20834	720	26	while	while	SCONJ
ihlr-20834	720	27	it	it	PRON
ihlr-20834	720	28	would	would	AUX
ihlr-20834	720	29	likely	likely	ADV
ihlr-20834	720	30	face	face	VERB
ihlr-20834	720	31	opposition232	opposition232	ADP
ihlr-20834	720	32	the	the	DET
ihlr-20834	720	33	ultimate	ultimate	ADJ
ihlr-20834	720	34	goal	goal	NOUN
ihlr-20834	720	35	of	of	ADP
ihlr-20834	720	36	the	the	DET
ihlr-20834	720	37	fda	fda	PROPN
ihlr-20834	720	38	should	should	AUX
ihlr-20834	720	39	be	be	AUX
ihlr-20834	720	40	to	to	PART
ihlr-20834	720	41	foster	foster	VERB
ihlr-20834	720	42	public	public	ADJ
ihlr-20834	720	43	safety	safety	NOUN
ihlr-20834	720	44	.	.	PUNCT
ihlr-20834	721	1	such	such	DET
ihlr-20834	721	2	an	an	DET
ihlr-20834	721	3	amendment	amendment	NOUN
ihlr-20834	721	4	would	would	AUX
ihlr-20834	721	5	help	help	VERB
ihlr-20834	721	6	achieve	achieve	VERB
ihlr-20834	721	7	this	this	DET
ihlr-20834	721	8	goal	goal	NOUN
ihlr-20834	721	9	.	.	PUNCT
ihlr-20834	722	1	the	the	DET
ihlr-20834	722	2	fda	fda	PROPN
ihlr-20834	722	3	has	have	AUX
ihlr-20834	722	4	acknowledged	acknowledge	VERB
ihlr-20834	722	5	difficulty	difficulty	NOUN
ihlr-20834	722	6	in	in	ADP
ihlr-20834	722	7	handling	handle	VERB
ihlr-20834	722	8	the	the	DET
ihlr-20834	722	9	growing	grow	VERB
ihlr-20834	722	10	pharmaceutical	pharmaceutical	ADJ
ihlr-20834	722	11	industry	industry	NOUN
ihlr-20834	722	12	.	.	PUNCT
ihlr-20834	723	1	it	it	PRON
ihlr-20834	723	2	is	be	AUX
ihlr-20834	723	3	likely	likely	ADJ
ihlr-20834	723	4	this	this	DET
ihlr-20834	723	5	issue	issue	NOUN
ihlr-20834	723	6	will	will	AUX
ihlr-20834	723	7	continue	continue	VERB
ihlr-20834	723	8	to	to	PART
ihlr-20834	723	9	worsen	worsen	VERB
ihlr-20834	723	10	as	as	SCONJ
ihlr-20834	723	11	the	the	DET
ihlr-20834	723	12	medical	medical	ADJ
ihlr-20834	723	13	industry	industry	NOUN
ihlr-20834	723	14	becomes	become	VERB
ihlr-20834	723	15	more	more	ADV
ihlr-20834	723	16	complex	complex	ADJ
ihlr-20834	723	17	and	and	CCONJ
ihlr-20834	723	18	as	as	SCONJ
ihlr-20834	723	19	drug	drug	NOUN
ihlr-20834	723	20	sales	sale	NOUN
ihlr-20834	723	21	continue	continue	VERB
ihlr-20834	723	22	to	to	PART
ihlr-20834	723	23	grow	grow	VERB
ihlr-20834	723	24	.	.	PUNCT
ihlr-20834	724	1	tort	tort	NOUN
ihlr-20834	724	2	laws	law	NOUN
ihlr-20834	724	3	play	play	VERB
ihlr-20834	724	4	an	an	DET
ihlr-20834	724	5	important	important	ADJ
ihlr-20834	724	6	role	role	NOUN
ihlr-20834	724	7	in	in	ADP
ihlr-20834	724	8	supplementing	supplement	VERB
ihlr-20834	724	9	the	the	DET
ihlr-20834	724	10	fda	fda	PROPN
ihlr-20834	724	11	because	because	SCONJ
ihlr-20834	724	12	the	the	DET
ihlr-20834	724	13	fda	fda	PROPN
ihlr-20834	724	14	neither	neither	CCONJ
ihlr-20834	724	15	provide	provide	VERB
ihlr-20834	724	16	remedies	remedy	NOUN
ihlr-20834	724	17	nor	nor	CCONJ
ihlr-20834	724	18	compensates	compensate	VERB
ihlr-20834	724	19	victims	victim	NOUN
ihlr-20834	724	20	for	for	ADP
ihlr-20834	724	21	their	their	PRON
ihlr-20834	724	22	injuries	injury	NOUN
ihlr-20834	724	23	.	.	PUNCT
ihlr-20834	725	1	furthermore	furthermore	ADV
ihlr-20834	725	2	,	,	PUNCT
ihlr-20834	725	3	tort	tort	NOUN
ihlr-20834	725	4	laws	law	NOUN
ihlr-20834	725	5	play	play	VERB
ihlr-20834	725	6	a	a	DET
ihlr-20834	725	7	crucial	crucial	ADJ
ihlr-20834	725	8	role	role	NOUN
ihlr-20834	725	9	in	in	ADP
ihlr-20834	725	10	ensuring	ensure	VERB
ihlr-20834	725	11	safety	safety	NOUN
ihlr-20834	725	12	compliance	compliance	NOUN
ihlr-20834	725	13	within	within	ADP
ihlr-20834	725	14	the	the	DET
ihlr-20834	725	15	pharmaceutical	pharmaceutical	ADJ
ihlr-20834	725	16	industry	industry	NOUN
ihlr-20834	725	17	.	.	PUNCT
ihlr-20834	726	1	while	while	SCONJ
ihlr-20834	726	2	reducing	reduce	VERB
ihlr-20834	726	3	tort	tort	NOUN
ihlr-20834	726	4	liability	liability	NOUN
ihlr-20834	726	5	for	for	ADP
ihlr-20834	726	6	generic	generic	ADJ
ihlr-20834	726	7	manufacturers	manufacturer	NOUN
ihlr-20834	726	8	may	may	AUX
ihlr-20834	726	9	eventually	eventually	ADV
ihlr-20834	726	10	result	result	VERB
ihlr-20834	726	11	in	in	ADP
ihlr-20834	726	12	more	more	ADJ
ihlr-20834	726	13	affordable	affordable	ADJ
ihlr-20834	726	14	230	230	NUM
ihlr-20834	726	15	leslie	leslie	PROPN
ihlr-20834	726	16	kux	kux	NOUN
ihlr-20834	726	17	,	,	PUNCT
ihlr-20834	726	18	supplemental	supplemental	ADJ
ihlr-20834	726	19	applications	application	NOUN
ihlr-20834	726	20	proposing	propose	VERB
ihlr-20834	726	21	labeling	labeling	NOUN
ihlr-20834	726	22	changes	change	NOUN
ihlr-20834	726	23	for	for	ADP
ihlr-20834	726	24	approved	approve	VERB
ihlr-20834	726	25	drugs	drug	NOUN
ihlr-20834	726	26	and	and	CCONJ
ihlr-20834	726	27	biological	biological	ADJ
ihlr-20834	726	28	products	product	NOUN
ihlr-20834	726	29	,	,	PUNCT
ihlr-20834	726	30	fed	fed	PROPN
ihlr-20834	726	31	.	.	PUNCT
ihlr-20834	727	1	reg	reg	PROPN
ihlr-20834	727	2	.	.	PUNCT
ihlr-20834	728	1	(	(	PUNCT
ihlr-20834	728	2	nov	nov	PROPN
ihlr-20834	728	3	.	.	PROPN
ihlr-20834	728	4	5	5	NUM
ihlr-20834	728	5	,	,	PUNCT
ihlr-20834	728	6	2013	2013	NUM
ihlr-20834	728	7	)	)	PUNCT
ihlr-20834	728	8	,	,	PUNCT
ihlr-20834	728	9	https://www.federalregister.gov/articles/2013/11/13/201326799/supplemental-applications-proposing-labeling-changes-forapproved-drugs-and-biological-products	https://www.federalregister.gov/articles/2013/11/13/201326799/supplemental-applications-proposing-labeling-changes-forapproved-drugs-and-biological-product	NOUN
ihlr-20834	728	10	.	.	PUNCT
ihlr-20834	729	1	231	231	NUM
ihlr-20834	729	2	i	i	PRON
ihlr-20834	729	3	d.	d.	PROPN
ihlr-20834	729	4	232	232	NUM
ihlr-20834	729	5	see	see	VERB
ihlr-20834	729	6	rich	rich	ADJ
ihlr-20834	729	7	samp	samp	NOUN
ihlr-20834	729	8	,	,	PUNCT
ihlr-20834	729	9	can	can	AUX
ihlr-20834	729	10	fda	fda	PROPN
ihlr-20834	729	11	lawfully	lawfully	ADV
ihlr-20834	729	12	overrule	overrule	VERB
ihlr-20834	729	13	scotus	scotus	PROPN
ihlr-20834	729	14	generic	generic	PROPN
ihlr-20834	729	15	drug	drug	PROPN
ihlr-20834	729	16	preemption	preemption	NOUN
ihlr-20834	729	17	decision	decision	NOUN
ihlr-20834	729	18	through	through	ADP
ihlr-20834	729	19	regulation	regulation	NOUN
ihlr-20834	729	20	?	?	PUNCT
ihlr-20834	729	21	,	,	PUNCT
ihlr-20834	729	22	forbes	forbes	PROPN
ihlr-20834	729	23	(	(	PUNCT
ihlr-20834	729	24	aug	aug	PROPN
ihlr-20834	729	25	.	.	PROPN
ihlr-20834	729	26	2	2	NUM
ihlr-20834	729	27	,	,	PUNCT
ihlr-20834	729	28	2013	2013	NUM
ihlr-20834	729	29	,	,	PUNCT
ihlr-20834	729	30	10:17	10:17	NUM
ihlr-20834	729	31	am	am	NOUN
ihlr-20834	729	32	)	)	PUNCT
ihlr-20834	729	33	,	,	PUNCT
ihlr-20834	729	34	http://www.forbes.com/sites/wlf/2013/08/02/can-fda-lawfullyoverrule-scotus-generic-drug-preemption-decision-through-regulation/2/	http://www.forbes.com/sites/wlf/2013/08/02/can-fda-lawfullyoverrule-scotus-generic-drug-preemption-decision-through-regulation/2/	NOUN
ihlr-20834	729	35	(	(	PUNCT
ihlr-20834	729	36	opponents	opponent	NOUN
ihlr-20834	729	37	could	could	AUX
ihlr-20834	729	38	argue	argue	VERB
ihlr-20834	729	39	that	that	SCONJ
ihlr-20834	729	40	it	it	PRON
ihlr-20834	729	41	makes	make	VERB
ihlr-20834	729	42	little	little	ADJ
ihlr-20834	729	43	sense	sense	NOUN
ihlr-20834	729	44	to	to	PART
ihlr-20834	729	45	hold	hold	VERB
ihlr-20834	729	46	generic	generic	ADJ
ihlr-20834	729	47	drug	drug	NOUN
ihlr-20834	729	48	manufacturers	manufacturer	NOUN
ihlr-20834	729	49	,	,	PUNCT
ihlr-20834	729	50	who	who	PRON
ihlr-20834	729	51	are	be	AUX
ihlr-20834	729	52	by	by	ADP
ihlr-20834	729	53	definition	definition	NOUN
ihlr-20834	729	54	relying	rely	VERB
ihlr-20834	729	55	on	on	ADP
ihlr-20834	729	56	others	other	NOUN
ihlr-20834	729	57	’	’	PART
ihlr-20834	729	58	safety	safety	NOUN
ihlr-20834	729	59	data	datum	NOUN
ihlr-20834	729	60	in	in	ADP
ihlr-20834	729	61	marking	mark	VERB
ihlr-20834	729	62	their	their	PRON
ihlr-20834	729	63	products	product	NOUN
ihlr-20834	729	64	,	,	PUNCT
ihlr-20834	729	65	to	to	PART
ihlr-20834	729	66	make	make	VERB
ihlr-20834	729	67	unilateral	unilateral	ADJ
ihlr-20834	729	68	determinations	determination	NOUN
ihlr-20834	729	69	that	that	PRON
ihlr-20834	729	70	the	the	DET
ihlr-20834	729	71	fda	fda	PROPN
ihlr-20834	729	72	’s	’s	PART
ihlr-20834	729	73	judgments	judgment	NOUN
ihlr-20834	729	74	regarding	regard	VERB
ihlr-20834	729	75	proper	proper	ADJ
ihlr-20834	729	76	labeling	labeling	NOUN
ihlr-20834	729	77	should	should	AUX
ihlr-20834	729	78	be	be	AUX
ihlr-20834	729	79	overridden	overridden	ADJ
ihlr-20834	729	80	.	.	PUNCT
ihlr-20834	730	1	it	it	PRON
ihlr-20834	730	2	is	be	AUX
ihlr-20834	730	3	also	also	ADV
ihlr-20834	730	4	likely	likely	ADJ
ihlr-20834	730	5	that	that	SCONJ
ihlr-20834	730	6	generic	generic	ADJ
ihlr-20834	730	7	drug	drug	NOUN
ihlr-20834	730	8	manufacturers	manufacturer	NOUN
ihlr-20834	730	9	will	will	AUX
ihlr-20834	730	10	seek	seek	VERB
ihlr-20834	730	11	to	to	PART
ihlr-20834	730	12	influence	influence	VERB
ihlr-20834	730	13	such	such	DET
ihlr-20834	730	14	a	a	DET
ihlr-20834	730	15	law	law	NOUN
ihlr-20834	730	16	,	,	PUNCT
ihlr-20834	730	17	as	as	SCONJ
ihlr-20834	730	18	its	its	PRON
ihlr-20834	730	19	passing	passing	NOUN
ihlr-20834	730	20	would	would	AUX
ihlr-20834	730	21	likely	likely	ADV
ihlr-20834	730	22	hold	hold	VERB
ihlr-20834	730	23	them	they	PRON
ihlr-20834	730	24	more	more	ADV
ihlr-20834	730	25	accountable	accountable	ADJ
ihlr-20834	730	26	and	and	CCONJ
ihlr-20834	730	27	likely	likely	ADJ
ihlr-20834	730	28	to	to	PART
ihlr-20834	730	29	be	be	AUX
ihlr-20834	730	30	sued	sue	VERB
ihlr-20834	730	31	.	.	PUNCT
ihlr-20834	730	32	)	)	PUNCT
ihlr-20834	730	33	.	.	PUNCT
ihlr-20834	731	1	see	see	VERB
ihlr-20834	731	2	also	also	ADV
ihlr-20834	731	3	wyeth	wyeth	PROPN
ihlr-20834	731	4	v.	v.	PROPN
ihlr-20834	731	5	levine	levine	PROPN
ihlr-20834	731	6	,	,	PUNCT
ihlr-20834	731	7	555	555	NUM
ihlr-20834	731	8	u.s	u.s	PROPN
ihlr-20834	731	9	.	.	PROPN
ihlr-20834	731	10	555	555	NUM
ihlr-20834	731	11	,	,	PUNCT
ihlr-20834	731	12	582	582	NUM
ihlr-20834	731	13	(	(	PUNCT
ihlr-20834	731	14	2009	2009	NUM
ihlr-20834	731	15	)	)	PUNCT
ihlr-20834	731	16	(	(	PUNCT
ihlr-20834	731	17	breyer	breyer	NOUN
ihlr-20834	731	18	,	,	PUNCT
ihlr-20834	731	19	j.	j.	PROPN
ihlr-20834	731	20	,	,	PUNCT
ihlr-20834	731	21	concurring	concur	VERB
ihlr-20834	731	22	)	)	PUNCT
ihlr-20834	731	23	(	(	PUNCT
ihlr-20834	731	24	“	"	PUNCT
ihlr-20834	731	25	i	i	PRON
ihlr-20834	731	26	also	also	ADV
ihlr-20834	731	27	note	note	VERB
ihlr-20834	731	28	that	that	SCONJ
ihlr-20834	731	29	some	some	PRON
ihlr-20834	731	30	have	have	AUX
ihlr-20834	731	31	argued	argue	VERB
ihlr-20834	731	32	that	that	SCONJ
ihlr-20834	731	33	state	state	NOUN
ihlr-20834	731	34	tort	tort	NOUN
ihlr-20834	731	35	law	law	NOUN
ihlr-20834	731	36	can	can	AUX
ihlr-20834	731	37	sometimes	sometimes	ADV
ihlr-20834	731	38	raise	raise	VERB
ihlr-20834	731	39	prices	price	NOUN
ihlr-20834	731	40	to	to	ADP
ihlr-20834	731	41	the	the	DET
ihlr-20834	731	42	point	point	NOUN
ihlr-20834	731	43	where	where	SCONJ
ihlr-20834	731	44	those	those	PRON
ihlr-20834	731	45	who	who	PRON
ihlr-20834	731	46	are	be	AUX
ihlr-20834	731	47	sick	sick	ADJ
ihlr-20834	731	48	are	be	AUX
ihlr-20834	731	49	unable	unable	ADJ
ihlr-20834	731	50	to	to	PART
ihlr-20834	731	51	obtain	obtain	VERB
ihlr-20834	731	52	the	the	DET
ihlr-20834	731	53	drugs	drug	NOUN
ihlr-20834	731	54	they	they	PRON
ihlr-20834	731	55	need	need	VERB
ihlr-20834	731	56	.	.	PUNCT
ihlr-20834	731	57	”	"	PUNCT
ihlr-20834	731	58	)	)	PUNCT
ihlr-20834	731	59	)	)	PUNCT
ihlr-20834	731	60	;	;	PUNCT
ihlr-20834	731	61	travis	travis	PROPN
ihlr-20834	731	62	sales	sales	PROPN
ihlr-20834	731	63	et	et	PROPN
ihlr-20834	731	64	al	al	PROPN
ihlr-20834	731	65	.	.	PROPN
ihlr-20834	731	66	,	,	PUNCT
ihlr-20834	731	67	fda	fda	PROPN
ihlr-20834	731	68	and	and	CCONJ
ihlr-20834	731	69	potential	potential	ADJ
ihlr-20834	731	70	new	new	ADJ
ihlr-20834	731	71	rules	rule	NOUN
ihlr-20834	731	72	for	for	ADP
ihlr-20834	731	73	labeling	labeling	NOUN
ihlr-20834	731	74	of	of	ADP
ihlr-20834	731	75	generic	generic	ADJ
ihlr-20834	731	76	drugs	drug	NOUN
ihlr-20834	731	77	,	,	PUNCT
ihlr-20834	731	78	pharmaceutical	pharmaceutical	ADJ
ihlr-20834	731	79	compliance	compliance	NOUN
ihlr-20834	731	80	monitor	monitor	NOUN
ihlr-20834	731	81	(	(	PUNCT
ihlr-20834	731	82	october	october	PROPN
ihlr-20834	731	83	7	7	NUM
ihlr-20834	731	84	,	,	PUNCT
ihlr-20834	731	85	2013	2013	NUM
ihlr-20834	731	86	)	)	PUNCT
ihlr-20834	731	87	,	,	PUNCT
ihlr-20834	731	88	http://www.pharmacompliancemonitor.com/fda-and-potential-new-rulesfor-labeling-of-generic-drugs/5664/#_edn2	http://www.pharmacompliancemonitor.com/fda-and-potential-new-rulesfor-labeling-of-generic-drugs/5664/#_edn2	PROPN
ihlr-20834	731	89	(	(	PUNCT
ihlr-20834	731	90	opponents	opponent	NOUN
ihlr-20834	731	91	may	may	AUX
ihlr-20834	731	92	argue	argue	VERB
ihlr-20834	731	93	that	that	SCONJ
ihlr-20834	731	94	the	the	DET
ihlr-20834	731	95	sameness	sameness	NOUN
ihlr-20834	731	96	requirement	requirement	NOUN
ihlr-20834	731	97	is	be	AUX
ihlr-20834	731	98	important	important	ADJ
ihlr-20834	731	99	to	to	PART
ihlr-20834	731	100	“	"	PUNCT
ihlr-20834	731	101	minimize	minimize	VERB
ihlr-20834	731	102	any	any	DET
ihlr-20834	731	103	confusion	confusion	NOUN
ihlr-20834	731	104	among	among	ADP
ihlr-20834	731	105	healthcare	healthcare	NOUN
ihlr-20834	731	106	professionals	professional	NOUN
ihlr-20834	731	107	and	and	CCONJ
ihlr-20834	731	108	consumers	consumer	NOUN
ihlr-20834	731	109	as	as	ADV
ihlr-20834	731	110	well	well	ADV
ihlr-20834	731	111	as	as	ADP
ihlr-20834	731	112	to	to	PART
ihlr-20834	731	113	preclude	preclude	VERB
ihlr-20834	731	114	a	a	DET
ihlr-20834	731	115	basis	basis	NOUN
ihlr-20834	731	116	for	for	ADP
ihlr-20834	731	117	lack	lack	NOUN
ihlr-20834	731	118	of	of	ADP
ihlr-20834	731	119	confidence	confidence	NOUN
ihlr-20834	731	120	in	in	ADP
ihlr-20834	731	121	the	the	DET
ihlr-20834	731	122	equivalency	equivalency	NOUN
ihlr-20834	731	123	of	of	ADP
ihlr-20834	731	124	generic	generic	ADJ
ihlr-20834	731	125	versus	versus	ADP
ihlr-20834	731	126	brandname	brandname	NOUN
ihlr-20834	731	127	products	product	NOUN
ihlr-20834	731	128	”	"	PUNCT
ihlr-20834	731	129	)	)	PUNCT
ihlr-20834	731	130	.	.	PUNCT
ihlr-20834	732	1	2015	2015	NUM
ihlr-20834	732	2	809	809	NUM
ihlr-20834	732	3	the	the	DET
ihlr-20834	732	4	supreme	supreme	PROPN
ihlr-20834	732	5	court	court	PROPN
ihlr-20834	732	6	’s	’s	PART
ihlr-20834	732	7	overreaching	overreach	VERB
ihlr-20834	732	8	preemption	preemption	NOUN
ihlr-20834	732	9	interpretation	interpretation	NOUN
ihlr-20834	732	10	and	and	CCONJ
ihlr-20834	732	11	it	it	PRON
ihlr-20834	732	12	’s	’	VERB
ihlr-20834	732	13	consequences	consequence	NOUN
ihlr-20834	732	14	drugs	drug	NOUN
ihlr-20834	732	15	,	,	PUNCT
ihlr-20834	732	16	the	the	DET
ihlr-20834	732	17	consequences	consequence	NOUN
ihlr-20834	732	18	of	of	ADP
ihlr-20834	732	19	legal	legal	ADJ
ihlr-20834	732	20	immunity	immunity	NOUN
ihlr-20834	732	21	and	and	CCONJ
ihlr-20834	732	22	public	public	ADJ
ihlr-20834	732	23	safety	safety	NOUN
ihlr-20834	732	24	outweigh	outweigh	VERB
ihlr-20834	732	25	this	this	DET
ihlr-20834	732	26	position	position	NOUN
ihlr-20834	732	27	.	.	PUNCT
ihlr-20834	733	1	as	as	SCONJ
ihlr-20834	733	2	summarized	summarize	VERB
ihlr-20834	733	3	by	by	ADP
ihlr-20834	733	4	the	the	DET
ihlr-20834	733	5	court	court	NOUN
ihlr-20834	733	6	in	in	ADP
ihlr-20834	733	7	wyeth	wyeth	PROPN
ihlr-20834	733	8	,	,	PUNCT
ihlr-20834	733	9	“	"	PUNCT
ihlr-20834	733	10	[	[	X
ihlr-20834	733	11	s]tate	s]tate	NOUN
ihlr-20834	733	12	tort	tort	NOUN
ihlr-20834	733	13	suits	suit	NOUN
ihlr-20834	733	14	uncover	uncover	VERB
ihlr-20834	733	15	unknown	unknown	ADJ
ihlr-20834	733	16	drug	drug	NOUN
ihlr-20834	733	17	hazards	hazard	NOUN
ihlr-20834	733	18	and	and	CCONJ
ihlr-20834	733	19	provide	provide	VERB
ihlr-20834	733	20	incentives	incentive	NOUN
ihlr-20834	733	21	for	for	SCONJ
ihlr-20834	733	22	drug	drug	NOUN
ihlr-20834	733	23	manufacturers	manufacturer	NOUN
ihlr-20834	733	24	to	to	PART
ihlr-20834	733	25	disclose	disclose	VERB
ihlr-20834	733	26	safety	safety	NOUN
ihlr-20834	733	27	risks	risk	NOUN
ihlr-20834	733	28	promptly	promptly	ADV
ihlr-20834	733	29	.	.	PUNCT
ihlr-20834	734	1	”233	”233	PROPN
ihlr-20834	735	1	v.	v.	ADP
ihlr-20834	735	2	conclusion	conclusion	NOUN
ihlr-20834	735	3	congress	congress	PROPN
ihlr-20834	735	4	should	should	AUX
ihlr-20834	735	5	,	,	PUNCT
ihlr-20834	735	6	and	and	CCONJ
ihlr-20834	735	7	indeed	indeed	ADV
ihlr-20834	735	8	must	must	AUX
ihlr-20834	735	9	act	act	VERB
ihlr-20834	735	10	to	to	PART
ihlr-20834	735	11	protect	protect	VERB
ihlr-20834	735	12	its	its	PRON
ihlr-20834	735	13	constituents	constituent	NOUN
ihlr-20834	735	14	from	from	ADP
ihlr-20834	735	15	the	the	DET
ihlr-20834	735	16	legal	legal	ADJ
ihlr-20834	735	17	loophole	loophole	NOUN
ihlr-20834	735	18	resulting	result	VERB
ihlr-20834	735	19	from	from	ADP
ihlr-20834	735	20	the	the	DET
ihlr-20834	735	21	court	court	NOUN
ihlr-20834	735	22	’s	’s	PART
ihlr-20834	735	23	two	two	NUM
ihlr-20834	735	24	recent	recent	ADJ
ihlr-20834	735	25	decisions	decision	NOUN
ihlr-20834	735	26	in	in	ADP
ihlr-20834	735	27	pliva	pliva	NOUN
ihlr-20834	735	28	and	and	CCONJ
ihlr-20834	735	29	bartlett	bartlett	PROPN
ihlr-20834	735	30	.	.	PUNCT
ihlr-20834	736	1	consumers	consumer	NOUN
ihlr-20834	736	2	should	should	AUX
ihlr-20834	736	3	not	not	PART
ihlr-20834	736	4	face	face	VERB
ihlr-20834	736	5	the	the	DET
ihlr-20834	736	6	decision	decision	NOUN
ihlr-20834	736	7	of	of	ADP
ihlr-20834	736	8	choosing	choose	VERB
ihlr-20834	736	9	between	between	ADP
ihlr-20834	736	10	legal	legal	ADJ
ihlr-20834	736	11	protection	protection	NOUN
ihlr-20834	736	12	and	and	CCONJ
ihlr-20834	736	13	essential	essential	ADJ
ihlr-20834	736	14	living	living	NOUN
ihlr-20834	736	15	supplies	supply	NOUN
ihlr-20834	736	16	.	.	PUNCT
ihlr-20834	737	1	attorneys	attorney	NOUN
ihlr-20834	737	2	are	be	AUX
ihlr-20834	737	3	able	able	ADJ
ihlr-20834	737	4	to	to	PART
ihlr-20834	737	5	craft	craft	VERB
ihlr-20834	737	6	creative	creative	ADJ
ihlr-20834	737	7	legal	legal	ADJ
ihlr-20834	737	8	arguments	argument	NOUN
ihlr-20834	737	9	,	,	PUNCT
ihlr-20834	737	10	but	but	CCONJ
ihlr-20834	737	11	at	at	ADP
ihlr-20834	737	12	the	the	DET
ihlr-20834	737	13	expense	expense	NOUN
ihlr-20834	737	14	of	of	ADP
ihlr-20834	737	15	clients	client	NOUN
ihlr-20834	737	16	and	and	CCONJ
ihlr-20834	737	17	their	their	PRON
ihlr-20834	737	18	own	own	ADJ
ihlr-20834	737	19	peril	peril	NOUN
ihlr-20834	737	20	.	.	PUNCT
ihlr-20834	738	1	the	the	DET
ihlr-20834	738	2	only	only	ADJ
ihlr-20834	738	3	true	true	ADJ
ihlr-20834	738	4	solution	solution	NOUN
ihlr-20834	738	5	to	to	ADP
ihlr-20834	738	6	the	the	DET
ihlr-20834	738	7	loophole	loophole	NOUN
ihlr-20834	738	8	is	be	AUX
ihlr-20834	738	9	legislative	legislative	ADJ
ihlr-20834	738	10	reform	reform	NOUN
ihlr-20834	738	11	.	.	PUNCT
ihlr-20834	739	1	without	without	ADP
ihlr-20834	739	2	such	such	ADJ
ihlr-20834	739	3	action	action	NOUN
ihlr-20834	739	4	,	,	PUNCT
ihlr-20834	739	5	generic	generic	ADJ
ihlr-20834	739	6	drug	drug	NOUN
ihlr-20834	739	7	manufacturers	manufacturer	NOUN
ihlr-20834	739	8	will	will	AUX
ihlr-20834	739	9	remain	remain	VERB
ihlr-20834	739	10	free	free	ADJ
ihlr-20834	739	11	from	from	ADP
ihlr-20834	739	12	liability	liability	NOUN
ihlr-20834	739	13	and	and	CCONJ
ihlr-20834	739	14	many	many	ADJ
ihlr-20834	739	15	injured	injure	VERB
ihlr-20834	739	16	generic	generic	ADJ
ihlr-20834	739	17	-	-	PUNCT
ihlr-20834	739	18	drug	drug	NOUN
ihlr-20834	739	19	consumers	consumer	NOUN
ihlr-20834	739	20	will	will	AUX
ihlr-20834	739	21	remain	remain	VERB
ihlr-20834	739	22	without	without	ADP
ihlr-20834	739	23	any	any	DET
ihlr-20834	739	24	legal	legal	ADJ
ihlr-20834	739	25	remedies	remedy	NOUN
ihlr-20834	739	26	.	.	PUNCT
ihlr-20834	740	1	233	233	NUM
ihlr-20834	740	2	wyeth	wyeth	PROPN
ihlr-20834	740	3	v.	v.	PROPN
ihlr-20834	740	4	levine	levine	PROPN
ihlr-20834	740	5	,	,	PUNCT
ihlr-20834	740	6	555	555	NUM
ihlr-20834	740	7	u.s	u.s	PROPN
ihlr-20834	740	8	.	.	PROPN
ihlr-20834	740	9	555	555	NUM
ihlr-20834	740	10	,	,	PUNCT
ihlr-20834	740	11	579	579	NUM
ihlr-20834	740	12	(	(	PUNCT
ihlr-20834	740	13	2009	2009	NUM
ihlr-20834	740	14	)	)	PUNCT
ihlr-20834	740	15	.	.	PUNCT
ihlr-20834	741	1	i.	i.	PROPN
ihlr-20834	741	2	introduction	introduction	PROPN
ihlr-20834	741	3	a.	a.	PROPN
ihlr-20834	741	4	issue	issue	PROPN
ihlr-20834	741	5	b.	b.	PROPN
ihlr-20834	741	6	roadmap	roadmap	PROPN
ihlr-20834	741	7	ii	ii	PROPN
ihlr-20834	741	8	.	.	PUNCT
ihlr-20834	742	1	the	the	DET
ihlr-20834	742	2	law	law	NOUN
ihlr-20834	742	3	and	and	CCONJ
ihlr-20834	742	4	regulatory	regulatory	ADJ
ihlr-20834	742	5	rules	rule	NOUN
ihlr-20834	742	6	of	of	ADP
ihlr-20834	742	7	the	the	DET
ihlr-20834	742	8	pharmaceutical	pharmaceutical	ADJ
ihlr-20834	742	9	industry	industry	NOUN
ihlr-20834	742	10	a.	a.	NOUN
ihlr-20834	742	11	historical	historical	ADJ
ihlr-20834	742	12	background	background	NOUN
ihlr-20834	742	13	1	1	NUM
ihlr-20834	742	14	.	.	PUNCT
ihlr-20834	742	15	patent	patent	NOUN
ihlr-20834	742	16	law	law	NOUN
ihlr-20834	742	17	2	2	NUM
ihlr-20834	742	18	.	.	PUNCT
ihlr-20834	743	1	the	the	DET
ihlr-20834	743	2	federal	federal	ADJ
ihlr-20834	743	3	food	food	NOUN
ihlr-20834	743	4	and	and	CCONJ
ihlr-20834	743	5	drugs	drug	NOUN
ihlr-20834	743	6	act	act	PROPN
ihlr-20834	743	7	,	,	PUNCT
ihlr-20834	743	8	the	the	DET
ihlr-20834	743	9	food	food	NOUN
ihlr-20834	743	10	drug	drug	NOUN
ihlr-20834	743	11	and	and	CCONJ
ihlr-20834	743	12	cosmetics	cosmetic	NOUN
ihlr-20834	743	13	act	act	NOUN
ihlr-20834	743	14	,	,	PUNCT
ihlr-20834	743	15	and	and	CCONJ
ihlr-20834	743	16	hatch	hatch	NOUN
ihlr-20834	743	17	-	-	PUNCT
ihlr-20834	743	18	waxman	waxman	PROPN
ihlr-20834	743	19	act	act	PROPN
ihlr-20834	743	20	b.	b.	PROPN
ihlr-20834	743	21	current	current	ADJ
ihlr-20834	743	22	regulatory	regulatory	ADJ
ihlr-20834	743	23	laws	law	NOUN
ihlr-20834	743	24	affecting	affect	VERB
ihlr-20834	743	25	pharmaceutical	pharmaceutical	ADJ
ihlr-20834	743	26	drugs	drug	NOUN
ihlr-20834	743	27	iii	iii	PROPN
ihlr-20834	743	28	.	.	PROPN
ihlr-20834	743	29	preemption	preemption	PROPN
ihlr-20834	743	30	doctrine	doctrine	VERB
ihlr-20834	743	31	analysis	analysis	NOUN
ihlr-20834	743	32	a.	a.	NOUN
ihlr-20834	743	33	preemption	preemption	PROPN
ihlr-20834	743	34	doctrine	doctrine	NOUN
ihlr-20834	743	35	iv	iv	PROPN
ihlr-20834	743	36	.	.	PUNCT
ihlr-20834	743	37	case	case	NOUN
ihlr-20834	743	38	law	law	NOUN
ihlr-20834	743	39	,	,	PUNCT
ihlr-20834	743	40	indiana	indiana	PROPN
ihlr-20834	743	41	statutory	statutory	ADJ
ihlr-20834	743	42	dissemination	dissemination	NOUN
ihlr-20834	743	43	,	,	PUNCT
ihlr-20834	743	44	and	and	CCONJ
ihlr-20834	743	45	recourse	recourse	VERB
ihlr-20834	743	46	available	available	ADJ
ihlr-20834	743	47	for	for	ADP
ihlr-20834	743	48	generic	generic	ADJ
ihlr-20834	743	49	drug	drug	NOUN
ihlr-20834	743	50	consumers	consumer	NOUN
ihlr-20834	743	51	a.	a.	PROPN
ihlr-20834	743	52	wyeth	wyeth	PROPN
ihlr-20834	743	53	,	,	PUNCT
ihlr-20834	743	54	pliva	pliva	NOUN
ihlr-20834	743	55	and	and	CCONJ
ihlr-20834	743	56	bartlett	bartlett	PROPN
ihlr-20834	743	57	1	1	NUM
ihlr-20834	743	58	.	.	PUNCT
ihlr-20834	743	59	wyeth	wyeth	PROPN
ihlr-20834	743	60	–	–	PUNCT
ihlr-20834	743	61	no	no	DET
ihlr-20834	743	62	state	state	NOUN
ihlr-20834	743	63	tort	tort	NOUN
ihlr-20834	743	64	law	law	NOUN
ihlr-20834	743	65	preemption	preemption	NOUN
ihlr-20834	743	66	from	from	ADP
ihlr-20834	743	67	fda	fda	PROPN
ihlr-20834	743	68	’s	’s	PART
ihlr-20834	743	69	brand	brand	NOUN
ihlr-20834	743	70	-	-	PUNCT
ihlr-20834	743	71	name	name	NOUN
ihlr-20834	743	72	drug	drug	NOUN
ihlr-20834	743	73	regulations	regulation	NOUN
ihlr-20834	743	74	2	2	NUM
ihlr-20834	743	75	.	.	X
ihlr-20834	744	1	pliva	pliva	NOUN
ihlr-20834	744	2	–	–	PUNCT
ihlr-20834	744	3	state	state	NOUN
ihlr-20834	744	4	tort	tort	NOUN
ihlr-20834	744	5	law	law	NOUN
ihlr-20834	744	6	preemption	preemption	NOUN
ihlr-20834	744	7	for	for	ADP
ihlr-20834	744	8	failure	failure	NOUN
ihlr-20834	744	9	-	-	PUNCT
ihlr-20834	744	10	to	to	PART
ihlr-20834	744	11	-	-	PUNCT
ihlr-20834	744	12	warn	warn	VERB
ihlr-20834	744	13	claims	claim	NOUN
ihlr-20834	744	14	against	against	ADP
ihlr-20834	744	15	generic	generic	ADJ
ihlr-20834	744	16	manufacturers	manufacturer	NOUN
ihlr-20834	744	17	3	3	NUM
ihlr-20834	744	18	.	.	PUNCT
ihlr-20834	744	19	bartlett	bartlett	PROPN
ihlr-20834	744	20	state	state	PROPN
ihlr-20834	744	21	tort	tort	PROPN
ihlr-20834	744	22	law	law	NOUN
ihlr-20834	744	23	preemption	preemption	NOUN
ihlr-20834	744	24	for	for	ADP
ihlr-20834	744	25	design	design	NOUN
ihlr-20834	744	26	defect	defect	NOUN
ihlr-20834	744	27	claims	claim	NOUN
ihlr-20834	744	28	against	against	ADP
ihlr-20834	744	29	generic	generic	PROPN
ihlr-20834	744	30	manufacturers	manufacturers	PROPN
ihlr-20834	744	31	b.	b.	PROPN
ihlr-20834	744	32	indiana	indiana	PROPN
ihlr-20834	744	33	’s	’s	PART
ihlr-20834	744	34	statutory	statutory	ADJ
ihlr-20834	744	35	analysis	analysis	NOUN
ihlr-20834	744	36	and	and	CCONJ
ihlr-20834	744	37	the	the	DET
ihlr-20834	744	38	importance	importance	NOUN
ihlr-20834	744	39	of	of	ADP
ihlr-20834	744	40	state	state	NOUN
ihlr-20834	744	41	law	law	NOUN
ihlr-20834	744	42	c.	c.	NOUN
ihlr-20834	744	43	recourse	recourse	NOUN
ihlr-20834	744	44	available	available	ADJ
ihlr-20834	744	45	to	to	ADP
ihlr-20834	744	46	generic	generic	ADJ
ihlr-20834	744	47	drug	drug	NOUN
ihlr-20834	744	48	consumers	consumer	NOUN
ihlr-20834	744	49	1	1	NUM
ihlr-20834	744	50	.	.	PUNCT
ihlr-20834	745	1	option	option	NOUN
ihlr-20834	745	2	one	one	NUM
ihlr-20834	745	3	suing	sue	VERB
ihlr-20834	745	4	the	the	DET
ihlr-20834	745	5	name	name	NOUN
ihlr-20834	745	6	brand	brand	NOUN
ihlr-20834	745	7	manufacturer	manufacturer	NOUN
ihlr-20834	745	8	2	2	NUM
ihlr-20834	745	9	.	.	PUNCT
ihlr-20834	745	10	option	option	NOUN
ihlr-20834	745	11	two	two	NUM
ihlr-20834	745	12	–	–	PUNCT
ihlr-20834	745	13	suing	sue	VERB
ihlr-20834	745	14	the	the	DET
ihlr-20834	745	15	generic	generic	ADJ
ihlr-20834	745	16	drug	drug	NOUN
ihlr-20834	745	17	manufacturer	manufacturer	NOUN
ihlr-20834	745	18	for	for	ADP
ihlr-20834	745	19	misbranding	misbrande	VERB
ihlr-20834	745	20	3	3	NUM
ihlr-20834	745	21	.	.	PUNCT
ihlr-20834	745	22	option	option	NOUN
ihlr-20834	745	23	three	three	NUM
ihlr-20834	745	24	–	–	PUNCT
ihlr-20834	745	25	paying	pay	VERB
ihlr-20834	745	26	for	for	ADP
ihlr-20834	745	27	protection	protection	NOUN
ihlr-20834	745	28	through	through	ADP
ihlr-20834	745	29	brand	brand	NOUN
ihlr-20834	745	30	name	name	NOUN
ihlr-20834	745	31	drugs	drug	NOUN
ihlr-20834	745	32	4	4	NUM
ihlr-20834	745	33	.	.	PUNCT
ihlr-20834	745	34	option	option	NOUN
ihlr-20834	745	35	four	four	NUM
ihlr-20834	745	36	legislative	legislative	ADJ
ihlr-20834	745	37	amendment	amendment	NOUN
ihlr-20834	745	38	v.	v.	ADP
ihlr-20834	745	39	conclusion	conclusion	NOUN